


在一个实施方案中，本发明提供由式 XX 的结构表示的化合物：



XX

其中

X_4 是 O、S、SO、C(O)、S(O)[=CHCH$_2$N(CH$_3$)$_2$]、SO$_2$、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[CH$_2$CH$_2$N(CH$_3$)$_2$]、C[=CHCH$_2$N(CH$_3$)$_2$]、PO(C_{1-4} 烷基)、N[CH$_2$CH$_2$N(CH$_3$)$_2$]、NO[CH$_2$CH$_2$N(CH$_3$)$_2$]或键；

A 是 H、OH、SH、NH_2、C_{1-4}烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4} 烷基)、CH_2O(C_{1-4} 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4}烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4}烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、NHC(O)CH_3、C_{1-4}烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、C(O)NH(C_{1-4} 烷基)、C(O)N(C_{1-4} 烷基)$_2$、$C(O)NH_2$、NH(C_{1-4} 烷基)、NHC(O)NH(C_{1-4} 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、NHCO(C_{1-4} 烷基)、$NHSO_2$(C_{1-4} 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[CH_2CH_2(C_{4-8} 环烷基)]、O-[CH_2CH_2(C_{4-8}杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R'是 NH_2、OH 或 CH_3；并且


R_6 是 CN、NO_2、NHC(O)CH_3 或卤化物。

SPRUCE – EXHIBIT 2010 1960
Neurocrine Biosciences, Inc. v. Spruce Biosciences, Inc. PGR2026-00060


在另一个实施方案中，式 I 的化合物由以下结构表示：



或在另一个实施方案中，




在一个实施方案中，本发明提供由式 XXI 的结构表示的化合物：




XXI

其中 A、Z、Y、X_4、Q、R_1 和 R_2 如在化合物 XX 中所述。


在另一个实施方案中，式 XXI 的化合物由以下结构表示：



或在另一个实施方案中，




在一个实施方案中，本发明提供由式 XXII 的结构表示的化合物：




XXII

其中 A、Z、Y、X_4、Q、R_1 和 R_2 如在化合物 XX 中所述，R_7 是 H 或氧代，R_8 是 H 或=CH_2。


在另一个实施方案中，式 XXII 的化合物由以下结构表示：



或在另一个实施方案中，



在一个实施方案中，本发明提供由式 XXIII 的结构表示的化合物：



XXIII

其中

X 是 C 或 N；W 是 C 或 N；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$ 环烷基)]、$O-[CH_2CH_2(C_{4-8}$ 杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；

R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。


在一个实施方案中，本发明提供由式 XXXIII 的结构表示的化合物：



XXXIII

其中 Z、Y、X_4、Q、R_1、R_2 和 R_3 如在化合物 XXIII 中所述。

在一个实施方案中，本发明提供由式 XXXIV 的结构表示的化合物：



XXXIV

其中

X 是 C 或 N；W 是 C 或 N；

X_2 是 C_{1-4} 亚烷基、SO_2、C(O)、$CH-[CH_2-(C_{4-8}$ 环)]、$CH(C_{1-4}$ 烷基)、$CH(NH_2)$、CH(OH)、$CH(C_{1-4}$ 卤代烷基)、键；

X_4 是 O、S、SO、C(O)、$S(O)[=CHCH_2N(CH_3)_2]$、SO_2、NH、NHR'、

NO、C_{1-4}亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4}烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z是H、CN、NO_2、$NHC(O)CH_3$、C_{1-4}烷基、F、Cl、I或Br；

Y是H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I或Br；

Q是H、CN、OH、NO_2、CF_3、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$烷基)、$C(O)N(C_{1-4}$烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$烷基)、$NHC(O)NH(C_{1-4}$烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$烷基)、$NHSO_2(C_{1-4}$烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[$CH_2CH_2(C_{4-8}$环烷基)]、O-[$CH_2CH_2(C_{4-8}$杂环烷基)]或O-[$CH_2CH_2N(CH_3)_2$]；


R_1是H、OH、F、Cl、Br或I；

R_2是H、由R_6取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或CH=CH-O-对氰基苯基；

R_3是H、C_{1-4}烷基、卤化物、CN或NO_2；

R_6是CN、NO_2、$NHC(O)CH_3$或卤化物。

在一个实施方案中，本发明提供由式XXXVII的结构表示的化合物：




XXXVII

其中

X、X_2、X_4、Z、Y、Q、R1和R_3如以上在化合物XXXIV中所述。


在一个实施方案中，本发明提供由式XXXVIII的结构表示的化合物：




XXXVIII

其中X、X_2、X_4、Z、Y、Q、R1和R_3如以上在化合物XXXIV中所述。


在另一个实施方案中，式XXXVIII的化合物由以下结构表示：



或在另一个实施方案中，



在一个实施方案中，本发明提供由式 XXXIX 的结构表示的化合物：



XXXIX

其中：

X 是 C 或 N；W 是 C 或 N；

G 是 O、NH、NC_{1-4}烷基、NC_{1-4}酰基、S、CHC_{1-4}烷基、CHC_{1-4}酰基、$C(C_{1-4}$酰基$)_2$、$C(C_{1-4}$烷基$)_2$或$(CH_2)_n$，其中 n 是 1-3；

T 是 S 或 O；

X_4是 O、S、SO、C(O)、S(O)[$=CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4}亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[$=CHCH_2N(CH_3)_2$]、PO(C_{1-4}烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4}烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、CF_3、NO_2、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$烷基)、$C(O)N(C_{1-4}$烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$烷基)、

NHC(O)NH(C_{1-4} 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[$CH_2CH_2(C_{4-8}$ 环烷基)]、O-[$CH_2CH_2(C_{4-8}$ 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R 是 H、OH、C_{1-4} 烷基、CF_3、CH_2OH、$O(C_{1-4}$ 烷基)或 $O(C_{1-4}$ 酰基)；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；

R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。


在一个实施方案中，本发明提供式 XLII 的化合物：



XLII

其中 X、X_4、Z、Y、Q、R1、R_2 和 R_3 如以上在化合物 XXXIX 中所述。

在一个实施方案中，本发明提供式 XLIV 的化合物：



XLIV


其中：

X、X_4、R、R_1、R_2、R_3、Z、Y 和 Q 如以上在化合物 XXXIX 中所述；


其中

如果 X 是 C，X_4 是 O、NH 或 S，R_1、R_2 和 R_3 是 H 并且 R 是 H，那么 Q 不是卤素、H 或 CN。

在另一个实施方案中，式 XLIV 的化合物由以下结构表示：



在一个实施方案中，本发明提供由式 XLVII 的结构表示的化合物：



XLVII

在一个实施方案中，本发明提供组合物，其包含式(I)的化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合。

在一个实施方案中，所述化合物是选择性雄激素受体调节剂（SARM）。在一个实施方案中，所述 SARM 是部分激动剂。在一个实施方案中，所述 SARM 是组织选择性激动剂，或在一些实施方案中，是组织选择性拮抗剂。

在一个实施方案中，本发明提供一种在雄性个体中避孕的方法，所述方法包括向所述个体给药有效抑制所述个体中精子产生的量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合、或者含有它们的组合物的步骤，由此实现在所述个体中的避孕。

在一个实施方案中，本发明提供激素治疗方法，所述方法包括使个体的雄激素受体与有效实现改变雄激素依赖性病症的量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合、或者含有它们的组合物接触的步骤。

在一个实施方案中，本发明提供治疗罹患前列腺癌的个体的方法，所述方法包括向所述个体给药有效治疗所述个体中的前列腺癌的量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物

或它们的任意组合、或者含有它们的组合物的步骤。

在一个实施方案中，本发明提供延缓罹患前列腺癌的个体的前列腺癌的进展的方法，所述方法包括向所述个体给药有效延缓所述个体中前列腺癌的进展的量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合、或者含有它们的组合物的步骤。

在一个实施方案中，本发明提供治疗个体的骨相关的病症、或增加个体的骨量、促进个体的骨形成的方法，以有效治疗所述骨相关的病症的量给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合、或者含有它们的组合物。

根据这一方面，在一个实施方案中，所述个体罹患骨质疏松症、骨质减少、骨吸收增加、骨折、骨脆弱、骨矿物质密度（BMD）丢失或它们的任意组合。在一个实施方案中，所述方法增加所述个体的骨强度。在一个实施方案中，所述化合物促进或加强成骨细胞分化，或者在另一个实施方案中，所述化合物抑制破骨细胞增殖。

在一个实施方案中，本发明提供治疗个体的肌萎缩症、降低其发病率、延缓其进展、减轻其严重性或减轻与其相关症状的方法，所述方法包括向所述个体给药有效治疗所述个体的所述肌萎缩症的量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合、或者含有它们的组合物的步骤。

根据这一方面，在一个实施方案中，所述肌萎缩症归因于病状、疾患、疾病或病症。在一个实施方案中，所述病状、疾患、疾病或病症是神经性的、感染性的、慢性的或遗传性的。在一个实施方案中，所述病状、疾患、疾病或病症是肌肉营养不良症、肌萎缩、伴 X 染色体的（X-linked）脊延髓肌萎缩症（SBMA）、恶病质、营养不良、麻风病、糖尿病、肾脏病、慢性阻塞性肺疾病（COPD）、癌症、终末期肾功能衰竭、少肌症、肺气肿、骨软化症、HIV 感染、AIDS 或心肌病。

在一个实施方案中，所述肌萎缩症是年龄相关的肌萎缩症，废用性失调相关的肌萎缩症；或者所述肌萎缩症归因于慢性下腰痛、烧伤、中枢神经系统（CNS）损伤或损害、周围神经损伤或损害、脊髓损伤、化学性损伤或损害、或者酒精中毒。

在一个实施方案中，本发明提供治疗人类个体的糖尿病、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的葡萄糖耐受不良、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的高胰岛素血症、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的胰岛素抵抗、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗与糖尿病相关的疾病、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的脂肪肝症、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的心血管疾病、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗个体的恶病质、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个

体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗个体的眼疾病或病症的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。在一个实施方案中，所述眼疾病或病症包括干燥综合征或干眼病。

在一个实施方案中，本发明提供减少个体脂肪量的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，本发明提供增加个体瘦体重的方法，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在另一个实施方案中，本发明提供治疗个体的恶病质、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在一个实施方案中，所述恶病质与所述个体的癌症相关。

在另一个实施方案中，本发明提供治疗个体的类风湿性关节炎、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在另一个实施方案中，本发明提供治疗个体的慢性肾病、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在另一个实施方案中，本发明提供治疗个体的终末期肾病、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在另一个实施方案中，本发明提供治疗个体的脆弱（frailty）、减轻其严

重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在另一个实施方案中，本发明提供治疗个体的性腺功能减退症、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在另一个实施方案中，本发明提供一种治疗个体的年龄相关的功能减退、减轻其严重性、降低其发病率、延缓其发作或减少其发病的方法，所述方法包括向所述个体给药式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤。

在另一个实施方案中，本发明提供以下的方法：抑制精子发生；雄性避孕；激素治疗；治疗前列腺癌；延缓前列腺癌的进展；治疗个体的骨相关的疾病或增加个体的骨量和/或促进个体的骨形成；治疗肌萎缩症、降低其发病率、延缓其进程、减轻其严重性或减轻与其相关的症状；治疗糖尿病、减轻其严重性、降低其发病率、延缓其发作或减少其发病；治疗葡萄糖耐受不良、减轻其严重性、降低其发病率、延缓其发作或减少其发病；治疗高胰岛素血症、减轻其严重性、降低其发病率、延缓其发作或减少其发病；治疗胰岛素抵抗、减轻其严重性、降低其发病率、延缓其发作或减少其发病；治疗与糖尿病相关的疾病、减轻其严重性、降低其发病率、延缓其发作或减少其发病；治疗脂肪肝症、减轻其严重性、降低其发病率、延缓其发作或减少其发病；治疗心血管疾病、减轻其严重性、降低其发病率、延缓其发作或减少其发病；治疗恶病质、减轻其严重性、降低其发病率、延缓其发作或减少其发病；治疗眼疾病或病症；减少脂肪量；或增加个体瘦体重，所述方法包括向所述个体给药有效量的式(I)化合物和/或其异构体、药学上可接受的盐、药品、晶体、*N*-氧化物、水合物或它们的任意组合的步骤，如本文所述。

附图简要说明

在说明书的结论部分特别指出并清楚地要求保护作为本发明的主题。但

是，通过在阅读附图时参照以下的具体描述可以最好地理解关于本发明的组织和操作方法及其目标、特征和优点，其中：

图 1 描绘了各种选择性雄激素受体调节剂类似物的结构（图 1A）和它们的合成路线，例如化合物 XIII（图 1B）、化合物 V（图 1C）、式 XI 的化合物（图 1D）、化合物 XXXV（图 1E）、化合物 XXXVI（图 1F）、化合物 XLVI（图 1G）、化合物 X（图 1H）、化合物 XXIV-XXVIII（图 1I）、化合物 XL（图 1J）、化合物 XLI（图 1K）。

图 2 描绘了制备式 XLIII（oxatidyldione）化合物的合成路线。

图 3 描绘了制备式 XLVIII 化合物的合成路线。

图 4 描绘了制备式 XLIX 化合物的合成路线。

图 5 描绘了制备式 LII 化合物的合成路线。

图 6 描绘了制备式 L 化合物的合成路线。

图 7 描绘了制备式 LI 化合物的合成路线。

图 8 描绘了比卡鲁胺类似物通过野生型雄激素受体的转录激活。在用所示配体处理之前，用 hAR 和雄激素依赖性萤光素酶报告基因构建体短暂转染 CV-1 细胞。报告相对载体处理的对照的增加倍数（n=6）。

图 9 描绘了表 1 中所示的 S-4（图 9A）和睾酮（图 9B）在去势的大鼠中的雄激素活性和合成代谢活性。去势的雄性大鼠在 14 天内接受剂量增加的睾酮（上图）或 S-4（下图）。在处死时测定器官重量，表示为完整对照的百分数。

图 10 描绘了如表 1 中所示的 S-4、S-1、X-2、X-3、X-5 和 X-4（X 分别为 O、O、S、SO_2、CH_2 和 NH）的原子以颜色区分的叠加的碳键合氢隐藏的球-棍模型。激动剂 S-4 和 X-2 以及 S-1 显示出以前未对芳基丙酰胺假定过的六元环状 NH-X 氢键构型。

图 11 描绘 DHT、羟基氟他胺（HF）、比卡鲁胺（bical）和 S-4 通过野生型或突变型雄激素受体的转录激活。用野生型或突变型 AR 和雄激素依赖性报告基因构建体的表达载体短暂转染 CV-1 细胞。报告每一种药物（100 nM）AR-介导的诱导，表示为相对萤光素酶单位除以 β-半乳糖苷酶活性（标准化对照）。

图 12 描绘了雄激素受体配体结合域（AR LBD）的晶体结构。图 12A 显

示与*R*-比卡鲁胺结合的突变型AR LBD(W741L)的总体结构的主视图。图12B显示省略了*R*-比卡鲁胺的Fo-Fc模拟退火省略图中的W741L-*R*-比卡鲁胺和*R*-比卡鲁胺的电子密度图。

图13描绘野生型DHT、T877A-HF和W741L-R-比卡鲁胺的立体重叠，显示类固醇结合平面的概观（图13A）和类固醇结合平面的侧视图（图13B）。


图14描绘了与*R*-比卡鲁胺结合的突变型W741L雄激素受体配体结合域。图14A显示与*R*-比卡鲁胺结合的AR LBD(W741L)的总体结构的侧视图。AF2区（螺旋3、4和12）以绿色突出显示。保守的电荷-发夹（charge-clamp）残基是H3中的K720和H12中的E897。图14B显示与DHT结合的野生型AR LBD的AF2区的结构细节。W741侧链显示在充满原子的空间中。

应理解，为了说明的简单清楚，所述图中所示的元件不一定是按比例绘制的。例如，为了清楚，一些元件的尺寸可能相对于其它元件放大。而且，在认为合适的地方，在所述图中可能重复参考数字以指示相应或类似的元件。

发明详述

在以下的具体说明中，叙述了大量的具体细节以提供透彻地理解本发明。然而，本领域的技术人员会理解，没有这些具体细节也可以实施本发明。在其它一些情况下，对众所周知的方法、过程和组分不作详细描述以便不致使本发明变得含混不清。

在一个实施方案中，本发明提供由式I的结构表示的化合物：



I


其中

X是C或N；W是C或N；

X_1是N、NH、N(C_{1-4}烷基)、NAc、NCOOH或键；或者X_1和X_3与X_1和X_3所连接的X_2和X_5一起形成饱和的或不饱和的、取代的或未取代的

5-或 6-元环；或者 X_1 和 X_5 与 X_1 和 X_5 所连接的 X_2 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；

P 是 H 或式 II：



II；

X_2 是 C_{1-4} 亚烷基、SO_2、C(O)、CH-[CH_2-(C_{4-8} 环)]、CH(C_{1-4} 烷基)、CH(NH_2)、CH(OH)、CH(C_{1-4} 卤代烷基)、键；或者 X_2 和 R_3 与 X_2 所连接的 X_1 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；或者 X_2 和 X_5 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；


X_3 是 C_{1-4} 亚烷基、NH、N、CH(OH)、键；或者 X_1 和 X_3 与 X_1 和 X_3 所连接的 X_2 和 X_5 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；或者 X_3 和 X_5 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_3 和 X_4 一起形成双键或一起形成饱和的或不饱和的、取代的或未取代的 3-6 元环；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；或者 X_4 和 X_5 以及与 X_4 和 X_5 所连接的 X_3 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_3 和 X_4 一起形成双键或一起形成饱和的或不饱和的、取代的或未取代的 3-6 元环；

X_5 是碳或者 X_5 和 X_1 与 X_1 和 X_5 所连接的 X_2 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_5 和 X_2 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_5 和 X_3 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_5 和 X_4 与 X_5 和 X_4 所连接的 X_3 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；

A 不存在，或是 H、OH、SH、NH_2、C_{1-4} 烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4} 烷基)、CH_2O(C_{1-4} 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4} 烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4} 烷基)、C(O)R'、

CH_2CF_3、CF_2CF_3、CH_2OR' $CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；或者 A 和 R 形成式 III 所表示的双键：



III

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、卤化物、CF_3、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、$O\text{-}[CH_2CH_2CH(CH_3)_2]$、$O\text{-}[CH_2CH_2(C_{4-8}$ 环烷基)]、$O\text{-}[CH_2CH_2(C_{4-8}$ 杂环烷基)]或 $O\text{-}[CH_2CH_2N(CH_3)_2]$；

R 是 H、OH、C_{1-4} 烷基、CF_3、CH_2OH、$O(C_{1-4}$ 烷基)或 $O(C_{1-4}$ 酰基)；

R_1 是 H、OH、NH_2、F、Cl、Br 或 I；

R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN、NO_2；或者 R_3 和 X_2 与 R_3 所连接的苯环和 X_2 所连接的 X_1 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；

R'是 NH_2、OH 或 CH_3；

R_4 和 R_5 独立地是 H、CH_3、卤化物、OH、C_{1-4} 烷基、C_{1-6} 环烷基、卤代(C_{1-4} 烷基)、苯基、芳基、C_{4-8} 杂环烷基或羟基(C_{1-4} 烷基)；

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物；

其中

如果 P 是式 II，X 是 C，X_1 是 NH，X_2 是 C(O)，X_3 是 CH_2，R 是 OH 并且 A 是烷基或卤代烷基，那么 X_4 是 $S(O)[=CHCH_2N(CH_3)_2]$、$C(OH)[CH_2CH_2N(CH_3)_2]$、$C[=CHCH_2N(CH_3)_2]$、$N[CH_2CH_2N(CH_3)_2]$、$P(O)(C_{1-4}$ 烷基)或 $N(O)[CH_2CH_2N(CH_3)_2]$；

或者

如果 P 是式 II，X 是 C，X_1 是 NH，X_2 是 C(O)，X_3 是 CH_2，R 是 OH 或 OAlk 并且 X_4 是 O、S、NH、S、SO、SO_2 或烯基，那么 A 是 CN、CH_2OH、

$CH_2O(C_{1-4}$ 烷基)、$CH_2O(C_{1-4}$ 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、$C(O)O(C_{1-4}$ 烷基)、CONHR'、$C(O)N(R')_2$、$C(O)O(C_{1-4}$ 烷基)、C(O)R'、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

或者

如果 P 是苯基，X 是 C，X_1 是 NH，X_2 是 C(O)，R 是 OH 且 A 是 COOH，X_3 是键，X_4 是 CH_2，R_1、R_2 是 H，那么 Q 不是 H；

或者

如果 P 是式 II，X 是 C，X_3 是 CH_2，X_4 是 O 或 NH，R_1、R_2 和 R_3 是 H，并且 X_5 和 X_1 形成 5 元环噁唑烷-2-酮，那么 Q 不是卤素或 H；


或者

如果 P 是 H，X 是 C，X_1 是 NH，X_2 是 C(O)，R 是 OH，A 是烷基，X_3 是键或 CH_2，并且 X_4 是键或 CH_2，R_1 和 R_2 是 H，那么 Q 不是 H 或卤素；


或者

如果 P 是式 II，R_3 是 H，X 和 W 是 C，X_1 和 X_5 与 X_1 和 X_5 所连接的 X_2 形成噁唑烷二酮，R 是烷基，X_3 是 CH_2，并且 X_4 是 O、NH、S、SO_2 或 CH_2，那么 Q 不是卤化物。


在另一个实施方案中，式 I 的化合物由以下结构表示：



在另一个实施方案中，式 I 的化合物由以下结构表示：



在一个实施方案中，本发明提供由式 IV 的结构表示的化合物：



IV

其中

X 是 C 或 N；W 是 C 或 N；

X_2 是 C_{1-4} 亚烷基、SO_2、CH-[CH_2-(C_{4-8} 环)]、CH(C_{1-4} 烷基)、CH(NH_2)、CH(OH)、CH(C_{1-4} 卤代烷基)、键；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 H、OH、SH、NH_2、C_{1-4} 烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4} 烷基)、CH_2O(C_{1-4} 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4} 烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4} 烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、CN、NO_2、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、C(O)NH(C_{1-4} 烷基)、C(O)N(C_{1-4} 烷基)$_2$、$C(O)NH_2$、NH(C_{1-4} 烷基)、NHC(O)NH(C_{1-4} 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、NHCO(C_{1-4} 烷基)、$NHSO_2$(C_{1-4} 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[CH_2CH_2(C_{4-8} 环烷基)]、O-[CH_2CH_2(C_{4-8} 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R 是 H、OH、C_{1-4} 烷基、CF_3、CH_2OH、O(C_{1-4} 烷基)或 O(C_{1-4} 酰基)；

R_1 是 H、OH、NH_2、F、Cl、Br 或 I；


R_2 是 H、R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；


R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。


在另一个实施方案中，式 IV 的化合物由以下结构表示：



在另一个实施方案中，式 IV 的化合物由以下结构表示：



在一个实施方案中，本发明提供由式 VI 的结构表示的化合物：



VI

其中

X 是 C 或 N； W 是 C 或 N；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 H、OH、SH、NH_2、C_{1-4} 烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4} 烷基)、CH_2O(C_{1-4} 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4} 烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4} 烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、CN、NO_2、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、C(O)NH(C_{1-4} 烷基)、C(O)N(C_{1-4} 烷基)$_2$、$C(O)NH_2$、NH(C_{1-4} 烷基)、NHC(O)NH(C_{1-4} 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、NHCO(C_{1-4} 烷基)、

$NHSO_2(C_{1-4}$ 烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$ 环烷基)]、$O-[CH_2CH_2(C_{4-8}$ 杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

R 是 H、OH、C_{1-4} 烷基、CF_3、CH_2OH、$O(C_{1-4}$ 烷基)或 $O(C_{1-4}$ 酰基)；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；


R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。


在另一个实施方案中，式 VI 的化合物由以下结构表示：



在一个实施方案中，式 VI 的化合物由以下结构表示：



在一个实施方案中，本发明提供由式 XII 的结构表示的化合物：



XII

其中

X 是 C 或 N；W 是 C 或 N；

X_4 是 O、S、SO、$S(O)[=CHCH_2N(CH_3)_2]$、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、$C(OH)[CH_2CH_2N(CH_3)_2]$、$C[=CHCH_2N(CH_3)_2]$、$PO(C_{1-4}$ 烷基)、

N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 CN、CH_2OH、$CH_2O(C_{1-4}$烷基)、$CH_2O(C_{1-4}$酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、$C(O)O(C_{1-4}$烷基)、CONHR'、$C(O)N(R')_2$、$C(O)O(C_{1-4}$烷基)、C(O)R'、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4}烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4}烷基、CF_3、CN、NO_2、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$烷基)、$C(O)N(C_{1-4}$烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$烷基)、$NHC(O)NH(C_{1-4}$烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$烷基)、$NHSO_2(C_{1-4}$烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$环烷基)]、$O-[CH_2CH_2(C_{4-8}$杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4}烷基、卤化物、CN 或 NO_2；


R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。


在另一个实施方案中，式 XII 的化合物由以下结构表示：



在另一个实施方案中，式 XII 的化合物由以下结构表示：




在一个实施方案中，本发明提供由式 XIII 的结构表示的化合物：




XIII

其中 A 如以上在化合物 XII 中所述。

在一个实施方案中，本发明提供由式 XIII 的结构表示的化合物：



在一个实施方案中，本发明提供由式 XVII 的结构表示的化合物：



XVII

其中


X_4 是 $S(O)[=CHCH_2N(CH_3)_2]$、$C(OH)[CH_2CH_2N(CH_3)_2]$、$C[=CHCH_2N(CH_3)_2]$、$PO(C_{1-4}$ 烷基)、$N[CH_2CH_2N(CH_3)_2]$、$NO[CH_2CH_2N(CH_3)_2]$；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$ 环烷基)]、$O-[CH_2CH_2(C_{4-8}$ 杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；并且


Y 是 H、C_{1-4} 烷基、CF_3、CN、NO_2、F、Cl、I 或 Br。

在另一个实施方案中，式 XVII 的化合物由以下结构表示：




XVII

在另一个实施方案中，式 XVII 的化合物如以下结构表示：



在一个实施方案中，本发明提供由式 XIX 的结构表示的化合物：



XIX

其中

X 是 C 或 N；W 是 C 或 N；

X_2 是 C_{1-4} 亚烷基、SO_2、C(O)、CH-[CH_2-(C_{4-8} 环)]、CH(C_{1-4} 烷基)、CH(NH_2)、CH(OH)、CH(C_{1-4} 卤代烷基)、键；

X_3 是 C_{1-4} 亚烷基、NH、N、CH(OH)或键；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 H、OH、SH、NH_2、C_{1-4} 烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4} 烷基)、CH_2O(C_{1-4} 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4} 烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4} 烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$ 环烷基)]、$O-[CH_2CH_2(C_{4-8}$ 杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

R_1 是 H、OH、F、Cl、Br 或 I；

R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；


R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物；


其中

如果 X 是 C，X_1 是 NH，X_2 是 C(O)，R 是 OH，A 是烷基，X_3 是键或 CH_2，并且 X_4 是键或 CH_2，R1 和 R_2 是 H，那么 Q 不是 H 或卤素。


在另一个实施方案中，式 XIX 的化合物由以下结构表示：



在另一个实施方案中，式 XIX 的化合物由以下结构表示：



在一个实施方案中，本发明提供由式 XX 的结构表示的化合物：



XX

其中

X_4是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4}亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4}烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 H、OH、SH、NH_2、C_{1-4}烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4}烷基)、CH_2O(C_{1-4}酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4}烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4}烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、$CH_2OR'CH_2C(O)CH=CH_2$或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4}烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$烷基)、$C(O)N(C_{1-4}$烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$烷基)、$NHC(O)NH(C_{1-4}$烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$烷基)、$NHSO_2(C_{1-4}$烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[$CH_2CH_2(C_{4-8}$环烷基)]、O-[$CH_2CH_2(C_{4-8}$杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；


R_1是 H、OH、F、Cl、Br 或 I；

R_2是 H、由 R_6取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；


R'是 NH_2、OH 或 CH_3；并且

R_6是 CN、NO_2、$NHC(O)CH_3$或卤化物。


在另一个实施方案中，式 I 的化合物由以下结构表示：



或在另一个实施方案中，




在一个实施方案中，本发明提供由式 XXI 的结构表示的化合物：




XXI

其中 A、Z、Y、X_4、Q、R_1 和 R_2 如在化合物 XX 中所述。


在另一个实施方案中，式 XXI 的化合物由以下结构表示：



或在另一个实施方案中，




在一个实施方案中，本发明提供由式 XXII 的结构表示的化合物：




XXII

其中 A、Z、Y、X_4、Q、R_1 和 R_2 如在化合物 XX 中所述，R_7 是 H 或氧代，R_8 是 H 或=CH_2。


在另一个实施方案中，式 XXII 的化合物由以下结构表示：



或在另一个实施方案中，



在一个实施方案中，本发明提供由式 XXIII 的结构表示的化合物：



XXIII

其中

X 是 C 或 N；W 是 C 或 N；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、CF_3、NO_2、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[$CH_2CH_2(C_{4-8}$ 环烷基)]、O-[$CH_2CH_2(C_{4-8}$ 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R_1 是 H、OH、F、Cl、Br 或 I；

R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基


或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；

R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。


在一个实施方案中，本发明提供由式 XXXIII 的结构表示的化合物：



XXXIII

其中 Z、Y、X_4、Q、R1 和 R_3 如在化合物 XXIII 中所述。

在一个实施方案中，本发明提供由式 XXXIV 的结构表示的化合物：



XXXIV

其中

X 是 C 或 N；W 是 C 或 N；

X_2 是 C_{1-4} 亚烷基、SO_2、C(O)、CH-[CH_2-(C_{4-8} 环)]、CH(C_{1-4} 烷基)、CH(NH_2)、CH(OH)、CH(C_{1-4} 卤代烷基)、键；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[$CH_2CH_2(C_{4-8}$ 环烷基)]、

O-[CH_2CH_2(C_{4-8}杂环烷基)]或O-[$CH_2CH_2N(CH_3)_2$]；


R_1是H、OH、F、Cl、Br或I；

R_2是H、由R_6取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或CH=CH-O-对氰基苯基；

R_3是H、C_{1-4}烷基、卤化物、CN或NO_2；

R_6是CN、NO_2、$NHC(O)CH_3$或卤化物。

在一个实施方案中，本发明提供由式XXXVII的结构表示的化合物：




XXXVII

其中

X、X_2、X_4、Z、Y、Q、R_1和R_3如以上在化合物XXXIV中所述。


在一个实施方案中，本发明提供由式XXXVIII的结构表示的化合物：




XXXVIII

其中X、X_2、X_4、Z、Y、Q、R1和R_3如以上在化合物XXXIV中所述。

在另一个实施方案中，式XXXVIII的化合物由以下结构表示：



或在另一个实施方案中，



在另一个实施方案中，化合物 XXXVIII 的 X_4 是 O。在另一个实施方案中，化合物 XXXVIII 的 X_2 是 C(O)。在另一个实施方案中，化合物 XXXVIII 的 X_2 是 CH_2。在另一个实施方案中，化合物 XXXVIII 的 Q 是 CN。在另一个实施方案中，化合物 XXXVIII 的 Z 是 CN，并且 Y 是 CF_3。

在一个实施方案中，本发明提供式 I 的化合物，其中 P 是式 II，X_1 和 X_5 与 X_1 和 X_5 所连接的 X_2 一起形成饱和的或未饱和的、取代的或未取代的 5-或 6-元环；

其中


如果 P 是式 II，X 是 C，X_3 是 CH_2，X_4 是 O 或 NH，R_1、R_2 和 R_3 是 H，并且 X_5 和 X_1 形成 5 元环噁唑烷-2-酮，那么 Q 不是卤素或 H；

或者

如果 P 是式 II，R_3 是 H，X 和 W 是 C，X_1 和 X_5 与 X_1 和 X_5 所连接的 X_2 一起形成噁唑烷二酮，R 是烷基，X_3 是 CH_2，并且 X_4 是 O、NH、S、SO_2 或 CH_2，那么 Q 不是卤化物。

在另一个实施方案中，所述饱和的或不饱和的、取代的或未取代的 5-或 6-元环是吡咯烷、哌啶、吗啉、琥珀酰亚胺、噁唑烷、噁唑烷二酮或噁唑烷酮。

在一个实施方案中，本发明提供由式 XXXIX 的结构表示的化合物：



XXXIX

其中：

X 是 C 或 N；W 是 C 或 N；

G 是 O、NH、NC_{1-4} 烷基、NC_{1-4} 酰基、S、CHC_{1-4} 烷基、CHC_{1-4} 酰基、$C(C_{1-4}$ 酰基$)_2$、$C(C_{1-4}$ 烷基$)_2$ 或$(CH_2)_n$，其中 n 是 1-3；

T 是 S 或 O；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、$PO(C_{1-4}$ 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、CF_3、NO_2、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[$CH_2CH_2(C_{4-8}$ 环烷基)]、O-[$CH_2CH_2(C_{4-8}$ 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R 是 H、OH、C_{1-4} 烷基、CF_3、CH_2OH、$O(C_{1-4}$ 烷基)或 $O(C_{1-4}$ 酰基)；

R_1 是 H、OH、F、Cl、Br 或 I；

R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；


R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。

其中

如果 R_3 是 H，X 和 W 是 C，G 是 O，T 是 O，R 是烷基，X_3 是 CH_2，并且 X_4 是 O、NH、S、SO_2 或 CH_2，那么 Q 不是卤化物。


在一个实施方案中，本发明提供式 XLII 的化合物：



XLII

其中 X、X_4、Z、Y、Q、R1、R_2 和 R_3 如以上在化合物 XXXIX 中所述。

在一个实施方案中，本发明提供式 XLIV 的化合物：



XLIV


其中：

X、X_4、R、R_1、R_2、R_3、Z、Y 和 Q 如以上在化合物 XXXIX 中所述；


其中

如果 X 是 C，X_4 是 O、NH 或 S，R_1、R_2 和 R_3 是 H 并且 R 是 H，那么 Q 不是卤素、H 或 CN。

在另一个实施方案中，式 XLIV 的化合物由以下结构表示：




在一个实施方案中，本发明提供由式 XLVII 的结构表示的化合物：



XLVII

在一个实施方案中，本发明提供由式 I 的结构表示的化合物：




I

其中

X 是 C 或 N；W 是 C 或 N；

X_1 是 N、NH、N(C_{1-4} 烷基)、NAc、NCOOH 或键；或者 X_1 和 X_3 与 X_1 和 X_3 所连接的 X_2 和 X_5 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；或者 X_1 和 X_5 与 X_1 和 X_5 所连接的 X_2 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；

P 是 H 或式 II：



II；

X_2 是 C_{1-4} 亚烷基、SO_2、C(O)、CH-[CH_2-(C_{4-8} 环)]、CH(C_{1-4} 烷基)、CH(NH_2)、CH(OH)、CH(C_{1-4} 卤代烷基)、键；或者 X_2 和 R_3 与 X_2 所连接的 X_1 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；或者 X_2 和 X_5 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；


X_3 是 C_{1-4} 亚烷基、NH、N、CH(OH)、键；或者 X_1 和 X_3 与 X_1 和 X_3 所连接的 X_2 和 X_5 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；或者 X_3 和 X_5 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_3 和 X_4 一起形成双键或一起形成饱和的或不饱和的、取代的或未取代的 3-6 元环；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；或者 X_4 和 X_5 与 X_4 和 X_5 所连接的 X_3 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_3 和 X_4 一起形成双键或形成饱和的或不饱和的、取代的或未取代的 3 至 6 元环；

X_5 是碳或 X_5 和 X_1 与 X_1 和 X_5 所连接的 X_2 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_5 和 X_2 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或者 X_5 和 X_3 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；或

X_5和 X_4与 X_5和 X_4所连接的 X_3一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环，且 A 不存在；

A 不存在，或是 H、OH、SH、NH_2、C_{1-4}烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、$CH_2O(C_{1-4}$烷基)、$CH_2O(C_{1-4}$酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、$C(O)O(C_{1-4}$烷基)、CONHR'、$C(O)N(R')_2$、$C(O)O(C_{1-4}$烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、CH_2OR' $CH_2C(O)CH=CH_2$或 $C(O)CH=CH_2$；或者 A 和 R 形成式 III 所表示的双键：



III

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4}烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、卤化物、CF_3、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$烷基)、$C(O)N(C_{1-4}$烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$烷基)、$NHC(O)NH(C_{1-4}$烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$烷基)、$NHSO_2(C_{1-4}$烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$环烷基)]、$O-[CH_2CH_2(C_{4-8}$杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

R 是 H、OH、C_{1-4}烷基、CF_3、CH_2OH、$O(C_{1-4}$烷基)或 $O(C_{1-4}$酰基)；

R_1是 H、OH、F、Cl、Br 或 I；

R_2是 H、由 R_6取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3是 H、C_{1-4}烷基、卤化物、CN、NO_2；或 R_3和 X_2以及与 R_3相连的苯环和与 X_2相连的 X_1形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；

R'是 NH_2、OH 或 CH_3；

R_4和 R_5独立地是 H、CH_3、卤化物、OH、C_{1-4}烷基、C_{1-6}环烷基、卤代(C_{1-4}烷基)、苯基、芳基、C_{4-8}杂环烷基或羟基(C_{1-4}烷基)；

R_6是 CN、NO_2、$NHC(O)CH_3$或卤化物；

其中

如果 P 是式 II，X 是 C，X_1是 NH，X_2是 C(O)，X_3是 CH_2，R 是 OH 并且 A 是烷基或卤代烷基，那么 X_4是 $S(O)[=CHCH_2N(CH_3)_2]$、

C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、N[$CH_2CH_2N(CH_3)_2$]、P(O)(C_{1-4}烷基)或N(O)[$CH_2CH_2N(CH_3)_2$]；

或者

如果P是式II，X是C，X_1是NH，X_2是C(O)，X_3是CH_2，R是OH或OAlk并且X_4是O、S、NH、S、SO、SO_2或亚烷基，那么A是CN、CH_2OH、$CH_2O(C_{1-4}$烷基)、$CH_2O(C_{1-4}$酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4}烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4}烷基)、C(O)R'、$CH_2OR'CH_2C(O)CH=CH_2$或$C(O)CH=CH_2$；

或者

如果P是苯基，X是C，X_1是NH，X_2是C(O)，R是OH并且A是COOH，X_3是键，X_4是CH_2，R_1、R_2是H，那么Q不是H。

或者

如果P是式II，X是C，X_3是CH_2，X_4是O或NH，R_1、R_2和R_3是H，并且X_5和X_1形成5元环噁唑烷-2-酮，那么Q不是卤素或H；


或者

如果P是H，X是C，X_1是NH，X_2是C(O), R是OH，A是烷基，X_3是键或CH_2，并且X_4是键或CH_2，R1和R_2是H，那么Q不是H或卤素；

或者

如果P是式II，R_3是H，X和W是C，X_1和X_5与X_1和X_5所连接的X_2一起形成噁唑烷二酮，R是烷基，X_3是CH_2，并且X_4是O、NH、S、SO_2或CH_2，那么Q不是卤化物。

在一个实施方案中，本发明提供由式IV的结构表示的化合物：



IV

其中

X是C或N；W是C或N；

X_2是C_{1-4}亚烷基、SO_2、CH-[CH_2-(C_{4-8}环)]、CH(C_{1-4}烷基)、CH(NH_2)、CH(OH)、CH(C_{1-4}卤代烷基)、键；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 H、OH、SH、NH_2、C_{1-4} 烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4} 烷基)、CH_2O(C_{1-4} 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4} 烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4} 烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、CN、NO_2、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、C(O)NH(C_{1-4} 烷基)、C(O)N(C_{1-4} 烷基)$_2$、$C(O)NH_2$、NH(C_{1-4} 烷基)、NHC(O)NH(C_{1-4} 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、NHCO(C_{1-4} 烷基)、$NHSO_2$(C_{1-4} 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[CH_2CH_2(C_{4-8} 环烷基)]、O-[CH_2CH_2(C_{4-8} 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R 是 H、OH、C_{1-4} 烷基、CF_3、CH_2OH、O(C_{1-4} 烷基)或 O(C_{1-4} 酰基)；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；

R'是 NH_2、OH 或 CH_3；并且


R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。

在一个实施方案中，本发明提供由式 V 的结构表示的化合物：



V

在一个实施方案中，本发明提供由式 VI 的结构表示的化合物：



VI

其中

X 是 C 或 N；W 是 C 或 N；

X_4 是 O、S、SO、C(O)、S(O)[=CHCH$_2$N(CH$_3$)$_2$]、SO$_2$、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[CH$_2$CH$_2$N(CH$_3$)$_2$]、C[=CHCH$_2$N(CH$_3$)$_2$]、PO(C_{1-4} 烷基)、N[CH$_2$CH$_2$N(CH$_3$)$_2$]、NO[CH$_2$CH$_2$N(CH$_3$)$_2$]或键；

A 是 H、OH、SH、NH$_2$、C_{1-4} 烷基、CHF$_2$、CH$_2$F、CF$_3$、CN、CH$_2$OH、CH$_2$O(C_{1-4} 烷基)、CH$_2$O(C_{1-4} 酰基)、CH$_2$CN、CH$_2$N$_3$、CH$_2$NCS、CHO、C(O)O(C_{1-4} 烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4} 烷基)、C(O)R'、CH$_2$CF$_3$、CF$_2$CF$_3$、CH$_2$OR'CH$_2$C(O)CH=CH$_2$ 或 C(O)CH=CH$_2$；

Z 是 H、CN、NO$_2$、NHC(O)CH$_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF$_3$、CN、NO$_2$、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO$_2$、CF$_3$、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、C(O)CH$_2$NH$_2$、C(O)NH(C_{1-4} 烷基)、C(O)N(C_{1-4} 烷基)$_2$、C(O)NH$_2$、NH(C_{1-4} 烷基)、NHC(O)NH(C_{1-4} 烷基)、CH$_2$C(O)NH$_2$、NHC(O)NH$_2$、NHCO(C_{1-4} 烷基)、NHSO$_2$(C_{1-4} 烷基)、O-[CH$_2$CH$_2$CH(CH$_3$)$_2$]、O-[CH$_2$CH$_2$(C_{4-8} 环烷基)]、O-[CH$_2$CH$_2$(C_{4-8} 杂环烷基)]或 O-[CH$_2$CH$_2$N(CH$_3$)$_2$]；

R 是 H、OH、C_{1-4} 烷基、CF$_3$、CH$_2$OH、O(C_{1-4} 烷基)或 O(C_{1-4} 酰基)；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、(CH$_2$)$_2$-O-对氰基苯基、CH$_2$-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO$_2$；

R'是 NH$_2$、OH 或 CH$_3$；并且

R_6 是 CN、NO$_2$、NHC(O)CH$_3$ 或卤化物。


在一个实施方案中，本发明提供由式 VII 的结构表示的化合物：



VII

其中 Z、Y、R_1、R_2、R_3、Q 和 X_4 如以上在化合物 VI 中所述。


在另一个实施方案中，本发明提供由式 VIII 的结构表示的化合物：



VIII


其中 R_1、R_2、Q 和 X_4 如以上在化合物 VI 中所述。

在一个实施方案中，本发明提供由式 IX 的结构表示的化合物：




IX 8

在一个实施方案中，本发明提供由式 X 的结构表示的化合物：



X

在一个实施方案中，本发明提供由式 XI 的结构表示的化合物：




XI

其中 A 如以上在化合物 VI 中所述。

在另一个实施方案中，化合物 XI 的 A 是 CH_2OH。在另一个实施方案中，化合物 XI 的 A 是 CH_2OMe。在另一个实施方案中，化合物 XI 的 A 是

CF_3。在另一个实施方案中，化合物 XI 的 A 是 CH_3。在另一个实施方案中，化合物 XI 的 A 是 CN。

在一个实施方案中，本发明提供由式 XII 的结构表示的化合物：



XII

其中

X 是 C 或 N；W 是 C 或 N；

X_4 是 O、S、SO、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 CN、CH_2OH、$CH_2O(C_{1-4}$ 烷基)、$CH_2O(C_{1-4}$ 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4} 烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4} 烷基)、C(O)R'、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、CN、NO_2、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、C(O)NH(C_{1-4} 烷基)、C(O)N(C_{1-4} 烷基)$_2$、$C(O)NH_2$、NH(C_{1-4} 烷基)、NHC(O)NH(C_{1-4} 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、NHCO(C_{1-4} 烷基)、$NHSO_2$(C_{1-4} 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[CH_2CH_2(C_{4-8} 环烷基)]、O-[CH_2CH_2(C_{4-8} 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R_1 是 H、OH、F、Cl、Br 或 I；

R_2 是 H、R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；


R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。

在另一个实施方案中，化合物 XII 的 X_4 是 O。在另一个实施方案中，化合物 XII 的 Q 是 CN，并且 R_1 和 R_2 是 H。在另一个实施方案中，化合物

XII 的 Q 是 CN，Z 是 CN，Y 是 CF_3，并且 R_1、R_2 和 R_3 是 H。在另一个实施方案中，化合物 XII 的 A 是 CH_2OH。在另一个实施方案中，化合物 XII 的 A 是 CN。


在一个实施方案中，本发明提供由式 XIII 的结构表示的化合物：



XIII


其中 A 如以上在化合物 XII 中所述。

在一个实施方案中，本发明提供由式 XIV 的结构表示的化合物：




XIV

或在另一个实施方案中，




在一个实施方案中，本发明提供由式 XV 的结构表示的化合物：




XV

在一个实施方案中，本发明提供由式 XVI 的结构表示的化合物：



XVI

在一个实施方案中，本发明提供由式 XVII 的结构表示的化合物：



XVII

其中

X_4 是 $S(O)[=CHCH_2N(CH_3)_2]$、$C(OH)[CH_2CH_2N(CH_3)_2]$、$C[=CHCH_2N(CH_3)_2]$、$PO(C_{1-4}$ 烷基)、$N[CH_2CH_2N(CH_3)_2]$、$NO[CH_2CH_2N(CH_3)_2]$；


Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$ 环烷基)]、$O-[CH_2CH_2(C_{4-8}$ 杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；并且

Y 是 H、C_{1-4} 烷基、CF_3、CN、NO_2、F、Cl、I 或 Br。

在另一个实施方案中，化合物 XVII 的 Q 是 F。在另一个实施方案中，化合物 XVII 的 Q 是 CN。在另一个实施方案中，化合物 XVII 的 Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XVII 的 Q 是 CN，Z 是 CN，并且 Y 是 CF_3。

在一个实施方案中，本发明提供由式 XVIII 的结构表示的化合物：




XVIII

在一个实施方案中，本发明提供由式 XIX 的结构表示的化合物：

在一个实施方案中，本发明提供式 I 的化合物，其中 X_3 和 X_4 一起形成双键或一起形成饱和的或不饱和的、取代的或未取代的 3-6 元环。在另一个实施方案中，所述 3-6 元环是环丙基、环丁基、环戊基、环已基、环丁烯基、环戊烯基、环已烯基、苯、哌啶、吡咯、四氢呋喃、吡咯烷、琥珀

酰亚胺、噁唑烷、噁唑烷二酮或噁唑烷酮。


在另一个实施方案中，本发明提供由式 LIII 的结构表示的化合物：



或


LIII-反式 LIII-顺式

在另一个实施方案中，本发明提供由式 LIV 的结构表示的化合物：



或

LIV LIV



XIX

其中

X 是 C 或 N；W 是 C 或 N；

X_2 是 C_{1-4} 亚烷基、SO_2、C(O)、CH-[CH_2-(C_{4-8} 环)]、CH(C_{1-4} 烷基)、CH(NH_2)、CH(OH)、CH(C_{1-4} 卤代烷基)、键；

X_3 是 C_{1-4} 亚烷基、NH、N、CH(OH)或键；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 H、OH、SH、NH_2、C_{1-4} 烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4} 烷基)、CH_2O(C_{1-4} 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、

C(O)O(C_{1-4}烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4}烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、$CH_2OR'CH_2C(O)CH=CH_2$或C(O)CH=CH_2；

Z是H、CN、NO_2、$NHC(O)CH_3$、C_{1-4}烷基、F、Cl、I或Br；

Y是H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I或Br；

Q是H、CN、OH、NO_2、CF_3、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$烷基)、$C(O)N(C_{1-4}$烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$烷基)、$NHC(O)NH(C_{1-4}$烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$烷基)、$NHSO_2(C_{1-4}$烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[$CH_2CH_2(C_{4-8}$环烷基)]、O-[$CH_2CH_2(C_{4-8}$杂环烷基)]或O-[$CH_2CH_2N(CH_3)_2$]；

R_1是H、OH、F、Cl、Br或I；

R_2是H、由R_6取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或CH=CH-O-对氰基苯基；

R'是NH_2、OH或CH_3；并且

R_6是CN、NO_2、$NHC(O)CH_3$或卤化物；


其中

如果X是C，X_1是NH，X_2是C(O)，R是OH，A是烷基，X_3是键或CH_2，并且X_4是键或CH_2，R_1和R_2是H，那么Q不是H或卤素。

在另一个实施方案中，化合物XIX的X_2是CH_2。在另一个实施方案中，化合物XIX的X_2是C(O)。在另一个实施方案中，化合物XIX的X_3是CH2。在另一个实施方案中，化合物XIX的X_4是O。

在一个实施方案中，本发明提供式I的化合物，其中P是式II，X_2和X_3与X_1一起形成饱和的或不饱和的、取代的或未取代的5-或6-元环。在另一个实施方案中，所述饱和的或不饱和的、取代的或未取代的5-或6-元环是吡咯烷、吡咯、吗啉、哌啶-4-酮或哌啶。

在一个实施方案中，本发明提供由式XX的结构表示的化合物：



XX

I

其中

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

A 是 H、OH、SH、NH_2、C_{1-4} 烷基、CHF_2、CH_2F、CF_3、CN、CH_2OH、CH_2O(C_{1-4} 烷基)、CH_2O(C_{1-4} 酰基)、CH_2CN、CH_2N_3、CH_2NCS、CHO、C(O)O(C_{1-4} 烷基)、CONHR'、C(O)N(R')$_2$、C(O)O(C_{1-4} 烷基)、C(O)R'、CH_2CF_3、CF_2CF_3、$CH_2OR'CH_2C(O)CH=CH_2$ 或 $C(O)CH=CH_2$；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、C(O)NH(C_{1-4} 烷基)、C(O)N(C_{1-4} 烷基)$_2$、$C(O)NH_2$、NH(C_{1-4} 烷基)、NHC(O)NH(C_{1-4} 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、NHCO(C_{1-4} 烷基)、$NHSO_2$(C_{1-4} 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[CH_2CH_2(C_{4-8} 环烷基)]、O-[CH_2CH_2(C_{4-8} 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。

在另一个实施方案中，化合物 XX 的 A 是 CH_3。在另一个实施方案中，化合物 XX 的 X_4 是 O。在另一个实施方案中，化合物 XX 的 Q 是 CN。在另一个实施方案中，化合物 XX 的 Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XX 的 Q 是 CN，Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XX 的 A 是 CH_3，X_4 是 O，Q 是 CN，Z 是 CN，R_1 和 R_2 是 H，并且 Y 是 CF_3。

在一个实施方案中，本发明提供由式 XXI 的结构表示的化合物：




XXI

其中 A、Z、Y、X_4、Q、R_1 和 R_2 如在化合物 XXI 中所述。

在另一个实施方案中，化合物 XXI 的 A 是 CH_3。在另一个实施方案中，化合物 XXI 的 X_4 是 O。在另一个实施方案中，化合物 XXI 的 Q 是 CN。在另一个实施方案中，化合物 XXI 的 Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XXI 的 Q 是 CN，Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XXI 的 A 是 CH_3，X_4 是 O，Q 是 CN，Z 是 CN，R_1 和 R_2 是 H，并且 Y 是 CF_3。

在一个实施方案中，本发明提供由式 XXII 的结构表示的化合物：



XXII


其中 A、Z、Y、X_4、Q、R_1 和 R_2 如在化合物 XX 中所述，R_7 是 H 或氧代，R_8 是 H 或=CH_2。

在另一个实施方案中，化合物 XXII 的 A 是 CH_3。在另一个实施方案中，化合物 XXII 的 X_4 是 O。在另一个实施方案中，化合物 XXI 的 R_7 和 R_8 是 H。在另一个实施方案中，化合物 XXII 的 R_7 是=CH_2，并且 R_8 是氧代。在另一个实施方案中，化合物 XXII 的 Q 是 CN。在另一个实施方案中，化合物 XXII 的 Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XXII 的 A 是 CH_3，X_4 是 O，Z 是 CN，Q 是 CN，R_1 和 R_2 是 H，并且 Y 是 CF_3。

在一个实施方案中，本发明提供式 I 的化合物，其中 P 是式 II，X_3 和 X_1 与 X_1 和 X_3 所连接的 X_2 和 X_5 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环。在另一个实施方案中，所述饱和的或不饱和的、取代的或未取代的 5-或 6-元环是哌嗪、哌嗪-2,6-二酮、哌啶、吡咯烷、环己酮、

环己烷、环己烯、环戊酮、环戊烷、环戊烯、琥珀酰亚胺、噁唑烷、噁唑烷二酮或噁唑烷酮。

在一个实施方案中，本发明提供由式 XXIII 的结构表示的化合物：



XXIII

其中

X 是 C 或 N；W 是 C 或 N；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4} 烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、CF_3、NO_2、卤化物、C_{2-6} 烯基、C_{2-6} 炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[$CH_2CH_2(C_{4-8}$ 环烷基)]、O-[$CH_2CH_2(C_{4-8}$ 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$]；

R_1 是 H、OH、F、Cl、Br 或 I；

R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；


R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2；

R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。


在另一个实施方案中，化合物 XXIII 的 X_4 是 O。在另一个实施方案中，化合物 XXIII 的 Q 是 CN。在另一个实施方案中，化合物 XXIII 的 Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XXIII 的 X_4 是 O，Z 是 CN，Q 是 CN，R_1、R_2 和 R_3 是 H，并且 Y 是 CF_3。

在另一个实施方案中，本发明提供由式 XXIV 的结构表示的化合物：




XXIV

在另一个实施方案中，本发明提供由式 XXV 的结构表示的化合物：




XXV

在另一个实施方案中，本发明提供由式 XXVI 的结构表示的化合物：




XXVI

在另一个实施方案中，本发明提供由式 XXVII 的结构表示的化合物：




XXVII

在另一个实施方案中，本发明提供由式 XXVIII 的结构表示的化合物：




XXVIII

在另一个实施方案中，本发明提供由式 XXIX 的结构表示的化合物：




XXIX

在另一个实施方案中，本发明提供由式 XXX 的结构表示的化合物：




XXX

在另一个实施方案中，本发明提供由式 XXXI 的结构表示的化合物：




XXXI

在另一个实施方案中，本发明提供由式 XXXII 的结构表示的化合物：



XXXII

在一个实施方案中，本发明提供由式 XXXIII 的结构表示的化合物：




XXXIII

其中 Z、Y、X_4、Q、R_1、R_2 和 R_3 如在化合物 XXIII 中所述。

在另一个实施方案中，化合物 XXXIII 的 X_4 是 O。在另一个实施方案中，化合物 XXXIII 的 Q 是 CN。在另一个实施方案中，化合物 XXXIII 的 Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XXXIII 的 X_4 是 O，Z 是 CN，Q 是 CN，R_1、R_2 和 R_3 是 H，并且 Y 是 CF_3。

在一个实施方案中，本发明提供式 I 的化合物，其中 P 是式 II，X_3 和 X_5 形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环。在另一个实施方案中，所述饱和的或不饱和的、取代的或未取代的 5-或 6-元环是四氢呋喃、吡咯烷、哌啶、环己酮、环己烷、环己烯、环己烯酮、环戊酮、环戊烯酮、环戊烷、环戊烯、琥珀酰亚胺、噁唑烷、噁唑烷二酮或噁唑烷酮。

在一个实施方案中，本发明提供由式 XXXIV 的结构表示的化合物：



XXXIV

XXXIV

其中

X 是 C 或 N；W 是 C 或 N；

X_2 是 C_{1-4} 亚烷基、SO_2、C(O)、CH-[CH_2-(C_{4-8} 环)]、CH(C_{1-4} 烷基)、CH(NH_2)、CH(OH)、CH(C_{1-4} 卤代烷基)、键；

X_4 是 O、S、SO、C(O)、S(O)[=$CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[=$CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、NO_2、CF_3、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$ 烷基)、$C(O)N(C_{1-4}$ 烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$ 烷基)、$NHC(O)NH(C_{1-4}$ 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$ 烷基)、$NHSO_2(C_{1-4}$ 烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$ 环烷基)]、$O-[CH_2CH_2(C_{4-8}$杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

R_1 是 H、OH、F、Cl、Br 或 I；

R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；


R_3 是 H、C_{1-4}烷基、卤化物、CN 或 NO_2；

R'是 NH_2、OH 或 CH_3；和

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。


在另一个实施方案中，化合物 XXXIV 的 X_4 是 O。在另一个实施方案中，化合物 XXXIV 的 Q 是 CN。在另一个实施方案中，化合物 XXXIV 的 X_2 是 CH_2。在另一个实施方案中，化合物 XXXIV 的 X_2 是 C(O)。在另一个实施方案中，化合物 XXXIV 的 Z 是 CN，并且 Y 是 CF_3。在另一个实施方案中，化合物 XXXIV 的 X_4 是 O，Z 是 CN，Q 是 CN，R_1、R_2 和 R_3 是 H，并且 Y 是 CF_3。

在另一个实施方案中，本发明提供式 XXXV 的化合物：




XXXV

在另一个实施方案中，本发明提供式 XXXVI 的化合物：



XXXVI

在一个实施方案中，本发明提供由式 XXXVII 的结构表示的化合物：



XXXVII


XXXVII

其中

X、X_2、X_4、Z、Y、Q、R_1、R_2和R_3如以上在化合物 XXXIV 中所述。

在另一个实施方案中，化合物 XXXVII 的X_4是 O。在另一个实施方案中，化合物 XXXVII 的X_2是 C(O)。在另一个实施方案中，化合物 XXXVII 的X_2是CH_2。在另一个实施方案中，化合物 XXXVII 的 Q 是 CN。在另一个实施方案中，化合物 XXXVII 的 Z 是 CN，并且 Y 是CF_3。

在一个实施方案中，本发明提供由式 XXXVIII 的结构表示的化合物：



XXXVIII

其中 X、X_2、X_4、Z、Y、Q、R_1、R_2和R_3如以上在化合物 XXXIV 中所述。

在另一个实施方案中，化合物 XXXVIII 的X_4是 O。在另一个实施方案中，化合物 XXXVIII 的X_2是 C(O)。在另一个实施方案中，化合物 XXXVIII 的X_2是CH_2。在另一个实施方案中，化合物 XXXVIII 的 Q 是 CN。在另一个实施方案中，化合物 XXXVIII 的 Z 是 CN，并且 Y 是CF_3。

在一个实施方案中，本发明提供式 I 的化合物，其中 P 是式 II，X_1和X_5与X_1和X_5所连接的X_2一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；

其中

如果 P 是式 II，X 是 C，X_3 是 CH_2，X_4 是 O 或 NH，R_1、R_2 和 R_3 是 H，并且 X_5 和 X_1 形成 5 元环噁唑烷-2-酮，那么 Q 不是卤素或 H。

在一个实施方案中，本发明提供式 I 的化合物，其中 P 是式 II，X_1 和 X_5 与 X_1 和 X_5 所连接的 X_2 一起形成饱和的或不饱和的、取代的或未取代的 5-或 6-元环；

其中


如果 P 是式 II，X 是 C，X_3 是 CH_2，X_4 是 O 或 NH，R_1、R_2 和 R_3 是 H，并且 X_5 和 X_1 形成 5 元环噁唑烷-2-酮，那么 Q 不是卤素或 H；

或者

如果 P 是式 II，R_3 是 H，X 和 W 是 C，X_1 和 X_5 与 X_1 和 X_5 所连接的 X_2 一起形成噁唑烷二酮，R 是烷基，X_3 是 CH_2，并且 X_4 是 O、NH、S、SO_2 或 CH_2，那么 Q 不是卤化物。

在另一个实施方案中，所述饱和的或不饱和的、取代的或未取代的 5-或 6-元环是吡咯烷、哌啶、吗啉、琥珀酰亚胺、噁唑烷、噁唑烷二酮或噁唑烷酮。

在一个实施方案中，本发明提供由式 XXXIX 的结构表示的化合物：



XXXIX

其中：

X 是 C 或 N；W 是 C 或 N；

G 是 O、NH、NC_{1-4} 烷基、NC_{1-4} 酰基、S、CHC_{1-4} 烷基、CHC_{1-4} 酰基、$C(C_{1-4}$ 酰基$)_2$、$C(C_{1-4}$ 烷基$)_2$ 或$(CH_2)_n$，其中 n 是 1-3；

T 是 S 或 O；

X_4 是 O、S、SO、C(O)、S(O)[$=CHCH_2N(CH_3)_2$]、SO_2、NH、NHR'、NO、C_{1-4} 亚烷基、C(OH)[$CH_2CH_2N(CH_3)_2$]、C[$=CHCH_2N(CH_3)_2$]、PO(C_{1-4} 烷基)、N[$CH_2CH_2N(CH_3)_2$]、NO[$CH_2CH_2N(CH_3)_2$]或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4} 烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、CF_3、NO_2、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、$C(O)NH(C_{1-4}$烷基)、$C(O)N(C_{1-4}$烷基$)_2$、$C(O)NH_2$、$NH(C_{1-4}$烷基)、$NHC(O)NH(C_{1-4}$烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、$NHCO(C_{1-4}$烷基)、$NHSO_2(C_{1-4}$烷基)、$O-[CH_2CH_2CH(CH_3)_2]$、$O-[CH_2CH_2(C_{4-8}$环烷基)]、$O-[CH_2CH_2(C_{4-8}$杂环烷基)]或 $O-[CH_2CH_2N(CH_3)_2]$；

R 是 H、OH、C_{1-4}烷基、CF_3、CH_2OH、$O(C_{1-4}$烷基)或 $O(C_{1-4}$酰基)；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、C_{1-4}烷基、卤化物、CN 或 NO_2；

R'是 NH_2、OH 或 CH_3；并且

R_6 是 CN、NO_2、$NHC(O)CH_3$或卤化物。

在一个实施方案中，本发明提供由式 XXXIX 的结构表示的化合物：



XXXIX

其中：

X 是 C 或 N；W 是 C 或 N；

G 是 O、NH、NC_{1-4}烷基、NC_{1-4}酰基、S、CHC_{1-4}烷基、CHC_{1-4}酰基、$C(C_{1-4}$酰基$)_2$、$C(C_{1-4}$烷基$)_2$或$(CH_2)_n$，其中 n 是 1-3；

T 是 S 或 O；

X_4 是 O、S、SO、C(O)、$S(O)[=CHCH_2N(CH_3)_2]$、SO_2、NH、NHR'、NO、C_{1-4}亚烷基、$C(OH)[CH_2CH_2N(CH_3)_2]$、$C[=CHCH_2N(CH_3)_2]$、$PO(C_{1-4}$烷基)、$N[CH_2CH_2N(CH_3)_2]$、$NO[CH_2CH_2N(CH_3)_2]$或键；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、C_{1-4}烷基、F、Cl、I 或 Br；

Y 是 H、C_{1-4}烷基、CF_3、NO_2、CN、F、Cl、I 或 Br；

Q 是 H、CN、OH、CF_3、NO_2、卤化物、C_{2-6}烯基、C_{2-6}炔基、$C(O)CH_2NH_2$、

C(O)NH(C_{1-4} 烷基)、C(O)N(C_{1-4} 烷基)$_2$、C(O)NH_2、NH(C_{1-4} 烷基)、NHC(O)NH(C_{1-4} 烷基)、$CH_2C(O)NH_2$、$NHC(O)NH_2$、NHCO(C_{1-4} 烷基)、$NHSO_2$(C_{1-4} 烷基)、O-[$CH_2CH_2CH(CH_3)_2$]、O-[CH_2CH_2(C_{4-8} 环烷基)]、O-[CH_2CH_2(C_{4-8} 杂环烷基)]或 O-[$CH_2CH_2N(CH_3)_2$];

R 是 H、OH、C_{1-4} 烷基、CF_3、CH_2OH、O(C_{1-4} 烷基)或 O(C_{1-4} 酰基);

R_1 是 H、OH、F、Cl、Br 或 I;

R_2 是 H、由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基;


R_3 是 H、C_{1-4} 烷基、卤化物、CN 或 NO_2;

R'是 NH_2、OH 或 CH_3;并且

R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物;其中


如果 R_3 是 H,X 和 W 是 C,G 是 O,T 是 O,R 是烷基,X_3 是 CH_2,并且 X_4 是 O、NH、S、SO_2 或 CH_2,那么 Q 不是卤化物。

在一个实施方案中,本发明提供式 XL 的化合物:




XL

在一个实施方案中,本发明提供式 XLI 的化合物:



XLI


在一个实施方案中,本发明提供式 XLII 的化合物:



XLII


其中 X、X_4、Z、Y、Q、R_1、R_2 和 R_3 如以上在化合物 XXXIX 中所述。

在一个实施方案中，本发明提供式 XLIII 的化合物：



XLIII

在一个实施方案中，本发明提供式 XLIV 的化合物：



XLIV


其中：

X、X_4、R、R_1、R_2、R_3、Z、Y 和 Q 如以上在化合物 XXXIXV 中所述；

其中

如果 X 是 C，X_4 是 O、NH 或 S，R_1、R_2 和 R_3 是 H 并且 R 是 H，那么 Q 不是卤素、H 或 CN。


在一个实施方案中，本发明提供由式 XLV 的结构表示的化合物：



XLV


其中 X_4 如以上在化合物 XXXIX 中所述。

在一个实施方案中，本发明提供由式 XLVI 的结构表示的化合物：



XLVI

在一个实施方案中，本发明提供由式 XLVII 的结构表示的化合物：



XLVII

I

其中

X 是 N 或 CH；

Z 是 H、CN、NO_2、$NHC(O)CH_3$、CH_3、F、Cl、I 或 Br；

Y 是 H、CH_3、CF_3、CN、F、Cl、I 或 Br；

Q 是 H、$O\text{-}(CH_2)_2CH(CH_3)_2$ 或 $O\text{-}(CH_2)_2N(CH_3)_2$；

R_1 是 H、OH、F、Cl、Br 或 I；


R_2 是由 R_6 取代的苄基、$(CH_2)_2$-O-对氰基苯基、CH_2-O-对氰基苯基或 CH=CH-O-对氰基苯基；

R_3 是 H、CH_3、卤化物、CN 或 NO_2；

R_4 和 R_5 独立地是 H、CH_3、卤化物、OH、$C_{1\text{-}4}$烷基、$C_{1\text{-}6}$环烷基、卤代($C_{1\text{-}4}$烷基)、苯基、芳基、杂环或羟基-$C_{1\text{-}4}$烷基；并且


R_6 是 CN、NO_2、$NHC(O)CH_3$ 或卤化物。

在一个实施方案中，本发明提供由式 XLVIII 的结构表示的化合物：




XLVIII

在一个实施方案中，本发明提供由式 XLIX 的结构表示的化合物：




XLIX

在一个实施方案中，本发明提供由式 L 的结构表示的化合物：




L

在一个实施方案中，本发明提供由式 LI 的结构表示的化合物：



LI

在一个实施方案中，本发明提供由式 LII 的结构表示的化合物：



LII

在另一个实施方案中，本发明提供式 (I)化合物的药学上可接受的盐。在另一个实施方案中，本发明提供式 (I)化合物的药品。在另一个实施方案中，本发明提供式 (I)化合物的水合物。在另一个实施方案中，本发明提供式 (I)化合物的 *N*-氧化物。在另一个实施方案中，本发明提供式 (I)化合物的多晶形物。在另一个实施方案中，本发明提供式 (I)化合物的晶体。在另一个实施方案中，本发明提供式(I)化合物的任意的代谢产物、异构体、药学上可接受的盐、药品、多晶形物、晶体、不纯物（impurity）、水合物、*N*-氧化物的组合。

在一些实施方案中，术语“异构体”包括但不限于光学异构体和类似物、结构异构体和类似物、构象异构体和类似物等。在一个实施方案中，术语“异构体”是指包括所述化合物的光学异构体。本领域的技术人员会理解，本发明的化合物含有至少一个手性中心。因此，在本发明的方法中所使用的化合物可以以光学活性形式或外消旋形式存在或被分离。一些化合物也可以

表现为同质多晶。应该理解，本发明包括任意的外消旋形式、光学活性形式、多晶型形式或立体异构形式、或者它们的混合物，这些形式具有用于治疗本文所述的雄激素相关病症的性质。在一个实施方案中，所述化合物是纯(*R*)-异构体。在另一个实施方案中，所述化合物是纯(*S*)-异构体。在另一个实施方案中，所述 SARM 是所述(*R*)-异构体和(*S*)-异构体的混合物。在另一个实施方案中，所述 SARM 是包含等量的所述(*R*)-异构体和(*S*)-异构体外消旋混合物。如何制备光学活性形式是本领域公知的（例如，通过重结晶技术拆分所述外消旋形式、通过由光学活性原料合成、通过手性合成或通过使用手性固定相进行色谱分离）。

在另一个实施方案中，本发明的化合物是所述(*R*)-异构体和所述(*S*)-异构体的混合物。在另一个实施方案中，所述混合物包含 60%的所述(*R*)-异构体和 40%的所述(*S*)-异构体。在另一个实施方案中，所述混合物包含 40%的所述(*R*)-异构体和 60%的所述(*S*)-异构体。在另一个实施方案中，所述混合物包含 70%的所述(*R*)-异构体和 30%的所述(*S*)-异构体。在另一个实施方案中，所述混合物包含 30%的所述(*R*)-异构体和 70%的所述(*S*)-异构体。在另一个实施方案中，所述混合物包含 80%的所述(*R*)-异构体和 20%的所述(*S*)-异构体。在另一个实施方案中，所述混合物包含 20%的所述(*R*)-异构体和 80%的所述(*S*)-异构体。在另一个实施方案中，所述混合物包含 90%的所述(*R*)-异构体和 10%的所述(*S*)-异构体。在另一个实施方案中，所述混合物包含 10%的所述(*R*)-异构体和 90%的所述(*S*)-异构体。

在一个实施方案中，本发明的化合物是 SARM。在一个实施方案中，本发明的化合物与细胞核激素受体例如雌激素受体、孕酮受体或糖皮质激素受体结合。

本发明包括本发明化合物的“药学上可接受的盐”，其可以通过本发明的化合物与酸或碱反应产生。

合适的式 I 的胺的药学上可接受的盐可以由无机酸或有机酸制备。在一个实施方案中，胺的无机盐的例子是硫酸氢盐、硼酸盐、溴化物、氯化物、半硫酸盐（hemisulfates）、氢溴酸盐、盐酸盐、2-羟乙基磺酸盐（羟乙基磺酸盐（hydroxyethanesulfonates））、碘酸盐、碘化物、异硫代硫酸盐（isothionates）、硝酸盐、过硫酸盐、磷酸盐、硫酸盐、氨基磺酸盐、

磺胺酸盐、磺酸（烷基磺酸盐、芳基磺酸盐、卤代烷基磺酸盐、卤代芳基磺酸盐）、磺酸盐和硫氰酸盐。

在一个实施方案中，胺的有机盐的例子包括脂肪族类、脂环族类、芳香族类、芳香脂肪族（araliphatic）类、杂环族类、羧酸类和磺酸类有机酸，它们的例子是乙酸盐、精氨酸、天冬氨酸盐、抗坏血酸盐、己二酸盐、邻氨基苯甲酸盐、链烷羧酸盐、取代链烷羧酸盐、藻酸盐、苯磺酸盐、苯甲酸盐、硫酸氢盐、丁酸盐，碳酸氢盐、酒石酸氢盐、羧酸盐、柠檬酸盐、樟脑酸盐（camphorates）、樟脑磺酸盐、环己基氨基磺酸盐、环戊烷丙酸盐、依地酸钙盐、右旋樟脑磺酸（camsylates）、碳酸盐、克拉微酸钾、肉桂酸盐、二羧酸盐、二葡糖酸盐、十二烷基磺酸盐、二氢氯化物、癸酸盐、庚酸盐（enanthuates）、乙磺酸盐、乙二胺四乙酸盐、乙二磺酸盐、丙酸酯十二烷基硫酸盐（estolates）、乙磺酸盐、富马酸盐、甲酸盐、氟化物、半乳糖醛酸盐、葡糖酸盐、谷氨酸盐、乙醇酸盐（glycolates）、葡糖酸盐、葡糖庚酸盐（glucoheptanoates）、甘油磷酸盐、葡庚糖酸盐、对羟乙酰氨基苯砷酸盐（glycollylarsanilates）、戊二酸盐、谷氨酸盐、庚酸盐、己酸盐、羟基马来酸盐、羟基羧酸、己基间苯二酚盐（hexylresorcinates）、羟苯酸盐、羟基萘甲酸盐、氢氟酸盐（hydrofluorate）、乳酸盐、乳糖酸盐（lactobionates）、月桂酸盐、苹果酸盐、马来酸盐、亚甲基双（β-萘酚酸盐）(methylenebis(beta-oxynaphthoate))、丙二酸盐、扁桃酸盐、甲磺酸盐（mesylates）、甲磺酸盐（methane sulfonates）、甲基溴化物、甲基硝酸盐、甲基磺酸盐、马来酸单钾盐、粘酸盐、单羧酸盐、萘磺酸盐、2-萘磺酸盐、烟酸盐、萘磺酸盐、*N*-甲基葡糖胺、草酸酯、辛酸盐、油酸盐、双羟萘酸盐、苯乙酸盐、苦味酸盐、苯基苯甲酸盐、新戊酸盐、丙酸盐、邻苯二甲酸盐、果胶酸盐（pectinates）、苯丙酸盐、棕榈酸盐、泛酸盐、多半乳糖醛酸盐（polygalacturates）、丙酮酸盐、奎尼酸盐、水杨酸、琥珀酸盐、硬脂酸盐、磺胺酸盐、碱式醋酸盐、酒石酸、茶碱乙酸盐（theophyllineacetates）、对甲苯磺酸盐、三氟乙酸盐、对苯二酸盐、单宁酸盐、8-氯茶碱盐、三卤代乙酸盐、三乙基碘、三羧酸盐、十一酸盐或者戊酸盐。

在一个实施方案中，羧酸或酚的无机盐的例子包括铵；碱金属，包括

2019

锂、钠、钾、铯；碱土金属，包括钙、镁、铝；锌、钡、氯或季铵。

在另一个实施方案中，羧酸或酚的有机盐的例子包括精氨酸；有机胺，包括脂肪族有机胺、脂环族有机胺、芳香族有机胺、苄星青霉素、叔丁胺、苯乙苄胺(*N*-苄基苯乙胺)、二环己基胺、二甲胺、二乙醇胺、乙醇胺、乙二胺、海巴胺（hydrabamine）、咪唑、赖氨酸、甲胺、三聚氰胺（meglamines）、*N*-甲基-D-葡糖胺、*N*,*N*'-二苄基乙二胺、烟酰胺、有机胺、鸟氨酸、吡啶、甲基吡啶（picolies）、哌嗪、普鲁卡因、三（羟甲基）甲胺、三乙胺、三乙醇胺、三甲胺、氨基丁三醇或尿素。

在一个实施方案中，所述盐可以通过常规方法形成，例如在其中所述盐不溶解的溶剂或介质或者例如水的溶剂中，使产物的游离碱或游离酸形式与一或多当量合适的酸或碱反应来形成，在真空中、通过冷冻干燥或通过将存在的盐的离子交换为另一种离子或合适的离子交换树脂来除去所述盐。

在一个实施方案中，本发明还包括本文所述化合物的氨基取代物的 *N*-氧化物。同样地，可以用脂肪族和芳香族的羧酸制备酚类化合物的酯，例如乙酸酯和苯甲酸酯。

本发明提供所述化合物的衍生物。在一个实施方案中，“衍生物”包括但不限于醚类衍生物、酸类衍生物、酰胺类衍生物、酯类衍生物等。在另一个实施方案中，本发明还包括所述化合物的水合物。

在一个实施方案中，“水合物”包括但不限于半水化合物、一水合物、二水合物、三水合物等。

在另一些实施方案中，本发明提供所述化合物的代谢产物。在一个实施方案中，“代谢产物”指通过代谢或代谢过程由另一种物质产生的任何物质。

在另一些实施方案中，本发明提供所述化合物的药品。在另一些实施方案中，术语“药品”指例如如本文所述的适合制药用途的组合物（药物组合物）。

在一个实施方案中，“烷基”指饱和脂肪族烃，包括直链、支链和环状烷基。在一个实施方案中，所述烷基具有 1-12 个碳原子。在另一个实施方案中，所述烷基具有 1-7 个碳原子。在另一个实施方案中，所述烷基具有

2020

1-6 个碳原子。在另一个实施方案中，所述烷基具有 1-4 个碳原子。所述烷基可以是未取代的或由一个或多个选自以下的基团取代：卤素、羟基、烷氧羰基、酰胺基、烷基酰胺基、二烷基酰胺基、硝基、氨基、烷氨基、二烷基氨基、羧基、硫代(thio)和硫烷基。在一个实施方案中，所述烷基是 CH_3。

在另一个实施方案中，“烯基”指不饱和的烃，包括具有一个或多个双键的直链、支链和环状基团。所述烯基可以具有一个双键、两个双键、三个双键等。烯基的例子是乙烯基、丙烯基、丁烯基、环己烯基等。在一个实施方案中，所述烯基具有 1-12 个碳原子。在另一个实施方案中，所述烯基具有 1-7 个碳原子。在另一个实施方案中，所述烯基具有 1-6 个碳原子。在另一个实施方案中，所述烯基具有 1-4 个碳原子。所述烯基可以是未取代的或由一个或多个选自以下的基团取代：卤素、羟基、烷氧羰基、酰胺基、烷基酰胺基、二烷基酰胺基、硝基、氨基、烷氨基、二烷基氨基、羧基、硫代和硫烷基。

“卤代烷基”指被一个或多个卤素原子取代的如上定义的烷基，在一个实施方案中被 F 取代，在另一个实施方案中被 Cl 取代，在另一个实施方案中被 Br 取代，在另一个实施方案中被 I 取代。

“芳基”指具有至少一个碳环芳族基团或杂环芳族基团的芳族基团，所述芳基可以是未取代的或由一个或多个选自以下的基团取代：卤素、羟基、烷氧羰基、酰胺基、烷基酰胺基、二烷基酰胺基、硝基、氨基、烷氨基、二烷基氨基、羧基、硫代和硫烷基。芳环的非限制性的例子是苯基、萘基、吡喃基、吡咯基、吡嗪基、嘧啶基、吡唑基、吡啶基、呋喃基、苯硫基、噻唑基、咪唑基、异噁唑基等。在一个实施方案中，所述芳基是 4-8 元环。在另一个实施方案中，所述芳基是 4-12 元环。在另一个实施方案中，所述芳基是 6 元环。在另一个实施方案中，所述芳基是 5 元环。在另一个实施方案中，所述芳基是 2-4 个环的稠环体系。

“羟基”指 OH 基。本领域的技术人员应该理解，当 T 是 OR 时，R 不是 OH。

在一个实施方案中，术语“卤素”在一个实施方案中指 F，在另一个实施方案中指 Cl，在另一个实施方案中指 Br，在另一个实施方案中指 I。在

2021

一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明的外消旋化合物的分离包括结晶技术。在另一个实施方案中，所述结晶技术包括对映异构体的分异结晶（differential crystallization）。在另一个实施方案中，所述结晶技术包括非对映的盐（酒石酸盐或奎宁盐）的分异结晶。在另一个实施方案中，所述结晶技术包括手性辅助衍生物（薄荷醇酯等）的分异结晶。在另一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明的外消旋化合物的分离包括使所述外消旋混合物与另一种手性基团反应，形成非对映的混合物，然后分离非对映异构体并除去其它手性基团以得到纯的对映异构体。在另一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明化合物的外消旋混合物的分离包括手性合成。在另一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明化合物的外消旋混合物的分离包括生物拆分。在另一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明化合物的外消旋混合物的分离包括酶法拆分。在另一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明化合物的外消旋混合物的分离包括使用手性固定相的色谱分离。在另一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明化合物的外消旋混合物的分离包括亲和色谱法。在另一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明化合物的外消旋混合物的分离包括毛细管电泳。在另一个实施方案中，所述光学活性的(*R*)异构体或(*S*)对映异构体从本发明化合物的外消旋混合物的分离包括形成手性碳原子的羟基与光学活性的酸（例如(-)-樟脑酸）的酯基，通过分级结晶或优选通过快速色谱法（flash-chromatography）分离由此获得的非对映异构体的酯，然后将各单独的酯水解为醇。

在另一个实施方案中，通过本发明的方法或通过本发明的外消旋混合物的手性分离所获得的对映异构体的纯度和选择性可以通过 HPLC 分析来测定。

在另一个实施方案中，所述方法还包含将式(I)的化合物转化为其异构体、代谢产物、药学上可接受的盐、药品、*N*-氧化物、水合物或它们的任意组合的步骤。

应该理解，所述方法可以包括本文所述的任何实施方案，本领域的技

2022

术人员会理解，所述实施方案会适于制备对应式的化合物。

在一些实施方案中，本文所述的化合物用于预防和治疗肌萎缩症、骨相关的病症和与糖尿病相关的病症。

在一些实施方案中，本文所述的化合物可单独地或作为组合物用于治疗雄性和雌性的各种激素相关的病症，例如性腺功能减退症、少肌症、勃起障碍、缺乏性欲、骨质疏松症和能育性（fertility）。在一些实施方案中，本文所述的化合物用于刺激或促进或恢复对多种过程的功能，这继而导致治疗本文所述的病症，尤其包括促进红细胞生成、骨发生、肌肉生长、葡萄糖摄取、胰岛素分泌，和/或预防脂质生成、凝血、胰岛素抵抗、动脉粥样硬化、破骨细胞活性等。

在一个实施方案中，本发明的方法利用所述化合物与受体接触或结合，并由此介导所述的效应。在一些实施方案中，所述受体是核受体，在一个实施方案中，所述核受体是雄激素受体，或者在另一个实施方案中是雌激素受体，或者在另一个实施方案中是孕酮受体，或者在另一个实施方案中是糖皮质激素受体。在一些实施方案中，所述多种效应可以作为与个体的多种受体结合的功能而同时发生。在一些实施方案中，本文所述的化合物的组织选择性效应提供对不同靶器官的同时作用。

药物组合物

在一些实施方案中，本发明提供使用的方法，所述方法包括给药含有所述化合物的组合物。如本文使用的，“药物组合物”指“治疗有效量”的活性成分（即式I的化合物），与药学上可接受的载体或稀释剂。如本文使用的，“治疗有效量”指对于给定的病症和给药方案提供疗效的量。

如本文使用的，术语“给药”指使个体与本发明的化合物接触。如本文使用的，给药可以在体外（即试管内）或体内（即活的有机体例如人类的细胞或组织）中进行。在一个实施方案中，本发明包括向个体给药本发明的化合物。

含有本发明化合物的药物组合物可以通过本领域技术人员已知的任何方法向个体给药，例如口服、肠胃外、血管内、癌旁、经粘膜、经皮、肌内、鼻内、静脉内、皮内、皮下、舌下、腹膜内、心室内、颅内、阴道内给药，通过吸入、经直肠、瘤内给药，或者通过其中重组病毒/组合物能被

2023

递送至组织的任何方法（例如穿刺针（needle）或导管）给药。或者，对于向粘膜细胞施用、皮肤或眼睛施用，可能需要局部施用。另一种给药的方法是经吸入剂或气雾剂。

在一个实施方案中，所述药物组合物口服给药，因此它被配制成适合口服给药的形式，即作为固体或液体制剂。合适的固体口服制剂包括片剂、胶囊、丸剂、颗粒剂、小丸（pellets）、散剂等。合适的液体口服制剂包括溶液剂、混悬剂、分散剂、乳剂、油剂等。在本发明的一个实施方案中，所述 SARM 化合物被配制在胶囊中。根据该实施方案，本发明的组合物除含有本发明的化合物和惰性载体或稀释剂之外，还含有硬胶囊。

在一个实施方案中，所述微粒化的胶囊包含含有本发明化合物的颗粒，其中，本文使用的术语"微粒化"指粒径小于 100 微米的颗粒，或者在另一个实施方案中，指粒径小于 60 微米的颗粒，或者在另一个实施方案中，指粒径小于 36 微米的颗粒，或者在另一个实施方案中，指粒径小于 16 微米的颗粒，或者在另一个实施方案中，指粒径小于 10 微米的颗粒，或者在另一个实施方案中，指粒径小于 6 微米的颗粒。

而且，在另一个实施方案中，所述药物组合物通过静脉内、动脉内或肌内注射液体制剂来给药。合适的液体制剂包括溶液剂、混悬剂、分散剂、乳剂、油剂等。在一个实施方案中，所述药物组合物经静脉内给药，因此被配制成适合静脉内给药的形式。在另一个实施方案中，所述药物组合物经动脉内给药，因此被配制成适合动脉内给药的形式。在另一个实施方案中，所述药物组合物肌内给药，因此被配制成适合肌内给药的形式。

而且，在另一个实施方案中，所述药物组合物局部施用于身体表面，因此被配制成适合局部施用的形式。合适的局部制剂包括凝胶剂、软膏、乳剂、洗剂、滴剂等。对于局部施用，本发明的化合物或其生理上耐受的衍生物（例如盐、酯、*N*-氧化物等）被制成在具有或不具有药用载体的生理上可接受的稀释剂中的溶液剂、混悬剂或乳剂，并以这些形式施用。

而且，在另一个实施方案中，所述药物组合物作为栓剂（例如直肠栓剂或尿道栓剂）来给药。而且，在另一个实施方案中，所述药物组合物通过皮下埋植小丸来给药。在另一个实施方案中，所述小丸在一段时间内提供本文所述化合物的控制释放。在另一个实施方案中，所述药物组合物经

2024

阴道给药。

在另一个实施方案中，活性化合物可以在小囊泡、特别是脂质体中递送(参见Langer, Science 249:1627-1633 (1990); Treat等人,于Liposomes in the Therapy of Infectious Disease and Cancer, Lopez- Berestein和Fidler (著者), Liss, New York, pp. 363-366 (1989); Lopez-Berestein, 出处同上, pp. 317-327; 一般地参见出处同上)。

如本文使用的，“药学上可接受的载体或稀释剂”是本领域技术人员熟知的。所述载体或稀释剂可以是用于固体制剂的固体载体或稀释剂、用于液体制剂的液体载体或稀释剂、或它们的混合物。

固体载体/稀释剂包括但不限于胶质、淀粉（例如玉米淀粉、预糊化淀粉（pregeletanized starch））、糖（例如乳糖、甘露醇、蔗糖、葡萄糖）、纤维素材料（例如微晶纤维素）、丙烯酸酯（例如聚甲基丙烯酸酯）、碳酸钙、氧化镁、滑石或它们的混合物。

在一个实施方案中，本发明的组合物可以包括本发明的化合物或其与一种或多种药学上可接受的赋形剂任意组合。

应该理解，本发明包括本文所述化合物（在一些实施方案中被称为“本发明的化合物”）的任何实施方案。

根据本发明的实施方案，合适的赋形剂和载体可以是固体或液体，其类型一般根据使用的给药类型来选择。脂质体也可以用于递送所述组合物。合适的固体载体的例子包括乳糖、蔗糖、明胶和琼脂。口服剂型可以含有合适的粘合剂、润滑剂、稀释剂、崩解剂、着色剂、调味剂、流动诱导剂（flow-inducing agent）和熔解剂。液体剂型可以含有例如合适的溶剂、防腐剂、乳化剂、助悬剂、稀释剂、甜味剂、增稠剂和熔解剂。肠胃外和静脉内形式还应该包含矿物质和其它材料以便使得它们与所选的注射或递药系统的类型相容。当然，也可以使用其它赋形剂。

对于液体制剂，药学上可接受的载体可以是含水的或非水溶液、悬浮液、乳液或油。非水性溶剂的例子是丙二醇、聚乙二醇和可注射的有机酯类例如油酸乙酯。含水载体包括水、醇/水溶液、环糊精、乳液或悬浮液，包括盐水和缓冲介质。油的例子是石油、动物油、植物油或合成来源的油，例如，花生油、大豆油、矿物油、橄榄油、向日葵油和鱼肝油。

2025

肠胃外载体（用于皮下、静脉内、动脉内或肌内注射）包括氯化钠溶液、林格氏葡萄糖、葡萄糖和氯化钠、乳酸林格和固定油。静脉内载体包括流体和营养补充剂、电解质补充剂（例如基于林格氏葡萄糖的电解质补充剂）等。其例子是无菌液体，例如加入和未加入表面活性剂和其它药学上可接受的助剂的水和油。通常，水、盐水、葡萄糖水溶液和相关的糖溶液以及二醇例如丙二醇或聚乙二醇是优选的液体载体，特别是对于可注射溶液剂。油的例子是石油、动物油、植物油或合成来源的油，例如，花生油、大豆油、矿物油、橄榄油、向日葵油和鱼肝油。

而且，所述组合物还可以包含粘合剂（例如阿拉伯胶、玉米淀粉、明胶、卡波姆、乙基纤维素、瓜尔胶、羟丙基纤维素、羟丙基甲基纤维素、聚维酮），崩解剂(例如玉米淀粉、马铃薯淀粉、藻酸、二氧化硅、交联羧甲基纤维素钠（croscarmelose sodium）、交聚维酮、瓜尔胶、羟基乙酸淀粉钠)，各种 pH 和离子强度的缓冲剂(例如 Tris-HCl、醋酸盐、磷酸盐)，防止吸附到表面的添加剂例如白蛋白或明胶，洗涤剂(例如 Tween 20、Tween 80、Pluronic F68、胆汁酸盐)，蛋白酶抑制剂，表面活性剂（例如十二烷基硫酸钠），渗透促进剂，增溶剂(例如克列莫佛(cremophor)、甘油、聚乙烯甘油(polyethylene glycerol)、苯扎氯铵、苯甲酸苄酯、环糊精、失水山梨糖醇(sobitan)酯、硬脂酸)，抗氧化剂(即抗坏血酸、偏亚硫酸氢钠、丁基化羟基苯甲醚（butylated hydroxyanisole）），稳定剂(例如羟丙基纤维素、羟丙基甲基纤维素)，增黏剂(例如卡波姆、胶体二氧化硅、乙基纤维素、瓜尔胶)，甜味剂(例如天冬甜素、柠檬酸)，防腐剂(例如 Thimerosal、苄醇、对羟苯甲酸酯)，着色剂，润滑剂(例如硬脂酸、硬脂酸镁、聚乙二醇、十二烷基硫酸钠)，助流剂(例如胶体二氧化硅)，增塑剂(例如邻苯二甲酸二乙酯、柠檬酸三乙酯)，乳化剂(例如卡波姆、羟丙基纤维素、十二烷基硫酸钠)，聚合物包衣（例如泊洛沙姆或泊洛沙胺（poloxamines））、包衣剂和成膜剂(例如乙基纤维素、丙烯酸酯、聚甲基丙烯酸酯)和/或辅剂。

在一个实施方案中，本文提供的药物组合物是控释组合物，即在该组合物中，本发明的化合物在给药后的一段时间内释放。控释或缓释组合物包括亲脂性贮库（depots）（例如脂肪酸、蜡、油）中的制剂。在另一个实施方案中，所述药物组合物是速释组合物，即在该组合物中全部量的化合

2026

物在给药后立即释放。

在另一个实施方案中，所述药物组合物可以在控释系统中递送。例如，所述药剂可以使用静脉输注、可植入渗透泵、透皮贴剂、脂质体或其它给药方式给药。在一个实施方案中，可以使用泵(参见 Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald 等人, Surgery 88:607 (1980); Saudek 等人, N. Engl. J. Med. 321:674 (1989))。在另一个实施方案中，可以使用聚合物材料。在另一个实施方案中，可以将控释系统置于治疗靶（即脑）附近，因此仅需要全身剂量的一部分(参见例如 Goodson, 于 Medical Applications of Controlled Release, supra, vol. 2, pp. 116-138 (1984))。在 Langer 的一篇综述 (Science 249:1627-1633 (1990))中讨论了其它控释系统。

所述组合物也可以包括在聚合的化合物，例如聚乳酸、聚乙醇酸、水凝胶等的粉粒制剂之中或之上，或在脂质体、微乳、微胶粒、单层或多层小囊泡、血影或原生质球之上引入活性材料。这种组合物会影响物理状态、溶解性、稳定性、体内释放率和体内清除率。

本发明还包括包被聚合物(例如泊洛沙姆或泊洛沙胺)和与直接抗组织特异性受体、配体或抗原的抗体偶联或与组织特异性受体的配体偶联的化合物的微颗组合物。

本发明还包括通过水溶性聚合物，例如聚乙二醇、聚乙二醇和聚丙二醇的共聚物、羧甲基纤维素、葡聚糖、聚乙烯醇、聚乙烯吡咯烷酮或聚脯氨酸的共价连接而修饰的化合物。已知所述修饰的化合物在静脉注射后显示出比相应的未修饰化合物长得多的血液半衰期（Abuchowski 等人, 1981; Newmark 等人, 1982;和 Katre 等人, 1987）。这种修饰也可以增加所述化合物在水溶液中的溶解度、消除聚集、提高所述化合物的物理和化学稳定性，并大大降低所述化合物的免疫原性和反应性。因此，与未修饰的化合物相比，通过更低频率地或更小剂量地给药这种聚合物-化合物衍生物，可以实现期望的体内生物活性。

含有活性组分的药物组合物的制备在本领域中很好理解，例如通过混合、造粒或压片的方法。活性治疗成分经常与药学上可接受的并与所述活性成分相容的赋形剂混合。对于口服给药，本发明的化合物或它们的生理上耐受的衍生物例如盐、酯、*N*-氧化物等与为此目的惯用添加剂例如载体、

稳定剂或惰性稀释剂混合，并以常规方法转化为适合给药的形式，例如片剂、包衣片剂、硬或软胶囊、水溶液、醇溶液或油溶液剂。对于肠胃外给药，本发明的化合物或它们生理上耐受的衍生物例如盐、酯、*N*-氧化物等被转化为溶液剂、混悬剂或乳剂（如果需要，用为此目的的惯用的、合适的物质，例如增溶剂等）。

活性组分可以作为中性的药学上可接受的盐的形式被配制成组合物。药学上可接受的盐包括酸加成盐（由多肽或抗体分子的自由氨基形成），其由无机酸例如盐酸或磷酸、或有机酸例如乙酸、草酸、酒石酸、扁桃酸等形成。由自由羧基形成的盐也可以得自无机碱，例如氢氧化钠、氢氧化钾、氢氧化铵、氢氧化钙或氢氧化铁，以及有机碱，例如异丙胺、三甲胺、2-乙胺基乙醇、组氨酸、普鲁卡因等。

为了用于药物，所述化合物的盐是药学上可接受的盐。但是，其它盐也可用于本发明化合物或其药学上可接受的盐的制备中。合适的本发明化合物的药学上可接受的盐包括酸加成盐，其可以通过例如将本发明化合物的溶液与药学上可接受的酸的溶液混合来形成，所述酸例如盐酸、硫酸、甲磺酸、富马酸、马来酸、琥珀酸、乙酸、苯甲酸、草酸、柠檬酸、酒石酸、碳酸或磷酸。

在一个实施方案中，本发明提供包含本发明的化合物的药物组合物。在一个实施方案中，这种组合物用于口服睾酮替代疗法。

在一个实施方案中，本发明还提供包含两种或多种本发明的化合物或它们的多晶型物、异构体、水合物、盐、*N*-氧化物等的组合物。本发明还涉及组合物和药物组合物，所述药物组合物单独包含本发明的化合物，或者包含本发明的化合物与孕激素或雌激素的组合，或者在另一个实施方案中，包含本发明的化合物与化疗化合物、成骨化合物或生肌化合物、或其它适合本文所述的应用的药剂的组合。在一个实施方案中，本发明的组合物包含合适的载体、稀释剂或盐。

在一个实施方案中，本发明的方法可以包括以各种剂量给药本发明的式 I 化合物。在一个实施方案中，以 0.1-200 mg/天的剂量给药本发明的化合物。在一个实施方案中以 0.1-10 mg 的剂量、或在另一个实施方案中以 0.1-26 mg 的剂量、或在另一个实施方案中以 0.1-60 mg 的剂量、或在另一

个实施方案中以 0.3-16 mg 的剂量，或在另一个实施方案中以 0.3-30 mg 的剂量、或在另一个实施方案中以 0.6-26 mg 的剂量、或在另一个实施方案中以 0.6-60 mg 的剂量、或在另一个实施方案中以 0.76-16 mg 的剂量、或在另一个实施方案中以 0.76-60 mg 的剂量、或在另一个实施方案中以 1-6 mg 的剂量、或在另一个实施方案中 1-20 mg 的剂量、或在另一个实施方案中以 3-16 mg 的剂量、或在另一个实施方案中以 30-60 mg 的剂量、或在另一个实施方案中以 30-76 mg 的剂量、或在另一个实施方案中以 100-2000 mg 的剂量给药本发明的化合物。

在一个实施方案中，本发明的方法可以包括以各种剂量给药本发明的式 I 化合物。在一个实施方案中，以 1 mg 的剂量给药本发明的化合物。在另一个实施方案中，以 3 mg、6 mg、10 mg、16 mg、20 mg、26 mg、30 mg、36 mg、40 mg、46 mg、50 mg、56 mg、60 mg、66 mg、70 mg、76 mg、80 mg、86 mg、90 mg、96 mg 或 100 mg 的剂量给药本发明的化合物。

在一个实施方案中，本发明提供使用方法，该方法包括给药包含以下各项的药物组合物：a) 本文所述的任何实施方案的化合物；和 b) 药学上可接受的载体或稀释剂；所述组合物应理解为包含本文所述化合物的类似物、异构体、代谢产物、衍生物、药学上可接受的盐、*N*-氧化物、水合物或它们的任意组合，并且可以包含式 I 的化合物。

在一些实施方案中，本发明提供药物组合物的使用方法，该药物组合物包含：a) 本文所述的任何实施方案的化合物，包括其类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、*N*-氧化物、水合物或它们的任意组合；b) 药学上可接受的载体或稀释剂；c) 助流剂；和 d) 润滑剂。

在另一个实施方案中，本发明提供药物组合物的使用方法，该药物组合物包含：a) 本文所述的任何实施方案的化合物，包括其类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、*N*-氧化物、水合物或它们的任意组合；b) 乳糖一水合物；c) 微晶纤维素；d) 硬脂酸镁；和 e) 胶体二氧化硅。

在一些实施方案中，本发明的方法利用包含本发明的化合物的组合物，所述方法的优点是所述化合物是雄激素受体的非类固醇类配体并在体内显示出合成代谢活性。根据这个方面，这种化合物不伴有严重的副作用，提

供方便的给药方式和较低的生产成本，并且口服可生物利用，与其它不希望的类固醇受体没有显著的交叉反应性，并且可能具有很长的生物半衰期。

当施用于哺乳动物，特别是人时，预计医师会确定最适合个体的实际剂量和治疗时间，并且可以根据具体个体的年龄、体重和应答而变化。

在一个实施方案中，用于给药的组合物可以是无菌溶液剂，或者在其它实施方案中，可以是含水或非水溶液、混悬剂或乳剂。在一个实施方案中，所述组合物可以包含丙二醇、聚乙二醇、可注射的有机酯例如油酸乙酯、或环糊精。在另一个实施方案中，组合物也可以包含湿润剂、乳化剂和/或分散剂。在另一个实施方案中，所述组合物也可以包含无菌水或任何其它无菌可注射介质。

在一个实施方案中，本发明提供用于如本文所述的本发明的任何方法的化合物和组合物（包括本文所述的任意实施方案）。在一个实施方案中，使用本发明的化合物或含有它的组合物会有利于抑制、压制、增强或促进个体体内所期望的应答，这一点本领域的技术人员会理解。在另一个实施方案中，所述组合物还可以含有其它活性成分，其活性对给药本发明的化合物所针对的具体应用是有用的。

在一些实施方案中，本发明的方法利用含有本发明的化合物的组合物，所述方法的优点是所述化合物是雄激素受体的非类固醇类配体并在体内显示出合成代谢活性。根据这个方面，这种化合物不伴有严重的副作用，提供方便的给药方式和较低的生产成本，并且口服可生物利用，与其它不希望的类固醇受体没有显著的交叉反应性，并且可能具有很长的生物半衰期。

当施用于哺乳动物，特别是人时，预计医师会确定最适合个体的实际剂量和治疗时间，并且可以根据具体个体的年龄、体重和应答而变化。

在一个实施方案中，用于给药的组合物可以是无菌溶液剂，或者在其它实施方案中，可以是水性或非水性的溶剂、悬混剂或乳剂。在一个实施方案中，所述组合物可以包含丙二醇、聚乙二醇、可注射的有机酯例如油酸乙酯、或环糊精。在另一个实施方案中，组合物也可以包含湿润剂、乳化剂和/或分散剂。在另一个实施方案中，所述组合物也可以包含无菌水或任何其它无菌可注射介质。

在一个实施方案中，本发明提供用于如本文所述的本发明的任何方法

的化合物和组合物（包括本文所述的任意实施方案）。在一个实施方案中，使用本发明的化合物或含有它的组合物会有利于抑制、压制除、增强或促进个体体内所期望的应答，这一点本领域的技术人员会理解。在另一个实施方案中，所述组合物还可以含有其它活性成分，其活性对给药本发明的化合物所针对的具体应用是有用的。

在一些实施方案中，所述组合物还含有 5α-还原酶抑制剂（5ARI）、一种或多种 SARM、选择性雌激素受体调节剂（SERM）、芳香酶抑制剂（例如但不局限于阿那曲唑（anastrazole）、依西美坦或来曲唑）、GnRH 激动剂或拮抗剂、类固醇或非类固醇 GR 配体、类固醇或非类固醇 PR 配体、类固醇或非类固醇 AR 配体、17-醛酮还原酶抑制剂或 17β-羟基类固醇脱氢酶抑制剂。在一些实施方案中，这种组合物可以用于治疗激素依赖性病症，例如不育、激素反应性癌例如生殖腺癌或泌尿生殖器癌的瘤形成。

在一些实施方案中，所述组合物包含本文所述的化合物和另一种治疗性化合物，尤其包括 5ARI，例如非那雄胺、度他雄胺、艾宗特来；其他 SARM，例如，RU-58642、RU-56279、WS9761 A 和 B、RU-59063、RU-58841、贝氯特来、LG-2293、L-245976、LG-121071、LG-121091、LG-121104 、 LGD-2226 、 LGD-2941 、 LGD-3305 、 YM-92088 、 YM-175735 、 LGD-1331 、 BMS-357597 、 BMS-391197 、 S-40503 、 BMS-482404 、 EM-4283 、 EM-4977 、 BMS-564929 、 BMS-391197 、 BMS-434588 、 BMS-487745 、 BMS-501949 、 SA-766 、 YM-92088 、 YM-580、LG-123303、LG-123129、PMCol、YM-175735、BMS-591305、BMS-591309 、 BMS-665139 、 BMS-665539 、 CE-590 、 116BG33 、 154BG31、arcarine、ACP-105；SERM，例如，三苯氧胺（tamoxifene）、4-羟三苯氧胺、艾多昔芬、托瑞米芬、奥培米芬（ospemifene）、屈洛昔芬、雷诺昔芬、阿佐昔芬，巴多昔芬（bazedoxifene）、PPT (1,3,5-三(4-羟基苯基)-4-丙基-1*H*-吡唑)、DPN (二芳基丙腈)、拉索昔芬、哌喷昔芬(pipendoxifene)、EM-800、EM-652、萘福昔定、秦哚昔芬、替米利芬、磷酸米泼昔芬、RU 58,688、EM 139、ICI 164,384、ICI 182,780、氯米芬、MER-25 、 二乙基己烯雌酚 、 香豆雌酚 、 染料木黄酮 、 GW5638 、 LY353581、珠氯米芬、恩氯米芬（enclomiphene）、地马孕酮醋酸盐、

DPPE、(*N,N*-二乙基-2-{4-(苯基甲基)-苯氧基}乙胺)、TSE-424、WAY-070、WAY-292、WAY-818、cyclocommunol、普林贝瑞(prinaberel)、ERB-041、WAY-397、WAY-244、ERB-196、WAY-169122、MF-101、ERb-002、ERB-037、ERB-017、BE-1060、BE-380、BE-381、WAY-358、[18F]FEDNP、LSN-500307、AA-102、半枝莲(Ban zhi lian)、CT-101、CT-102、VG-101；GnRH 激动剂或拮抗剂，例如，亮丙瑞林、戈舍瑞林、曲普瑞林、阿法前列醇、组氨瑞林、地肽瑞里、加尼瑞克、安肽伊妥瑞克、西曲瑞克、雷莫瑞克、加尼瑞克、安雷利克斯、替维瑞克、阿巴瑞克、奥扎瑞克(ozarelix)、舒伐格瑞克(sufugolix)、普拉瑞克、地加瑞克(degarelix)、NBI-56418、TAK-810、脂酰基碱(acyline)；FSH 激动剂或拮抗剂、LH 激动剂/拮抗剂、芳香酶抑制剂，例如来曲唑、阿那曲唑、阿他美坦、法倔唑、米那美坦、依西美坦、普洛美坦、利阿唑、NKS-01、伏氯唑、YM-51、芬罗唑、4-羟雄烯二酮、氨基苯乙哌啶酮(aminogluethimide)、罗谷亚胺；类固醇或非类固醇糖皮质激素受体配体，例如，ZK-216348、ZK-243149、ZK-243185、LGD-5552、米非司酮、RPR-106541、ORG-34517、GW-215864X、Sesquicillin、CP-472555、CP-394531、A-222977、AL-438、A-216054、A-276575、CP-394531、CP-409069、UGR-07；类固醇或非类固醇孕酮受体配体；类固醇或非类固醇 AR 拮抗剂，例如氟他胺、羟基氟他胺、比卡鲁胺、尼鲁米特，羟基类固醇脱氢酶抑制剂，PPARα配体例如苯扎贝特、非诺贝特、吉非贝齐；PPARγ配体，例如，达格列酮、吡格列酮、罗格列酮、伊格列酮(isaglitazone)、利格列酮(rivoglitazone)、萘格列酮(netoglitazone)；双重作用的 PPAR 配体，例如，naveglitazar、法格立他扎、替格列扎(tesaglitazar)、拉格列扎(ragaglitazar)、奥格列扎(oxeglitazar)、PN-2034、PPAR δ；17-酮还原酶抑制剂，3β-DHΔ4,6-异构酶抑制剂，3β-DHΔ4,5-异构酶抑制剂，17,20 碳链酶抑制剂，p450c17 抑制剂，p450ssc 抑制剂，17,20 裂合酶抑制剂，或它们的组合。

应该理解，以上给药两种或多种药剂的任何方法、计时、途径或它们的组合应被认为由本文所述的短语“联合给药”所包含。

在一个实施方案中，本发明提供患癌个体的骨骼相关事件(SRE)的治

疗、预防、压制或抑制、或降低罹患它的风险，其包括给药本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合，所述骨骼相关事件(SRE)例如骨折、骨手术、骨辐射、脊髓压迫症、新生骨转移、骨丢失或它们的组合。本发明特别涉及用式(I)的化合物治疗正在进行或已经进行雄激素剥夺治疗(ADT)的罹患前列腺癌个体的 SRE。

在一个实施方案中，用本文提供的方法和/或利用本文提供的组合物治疗的骨骼相关事件是骨折，在一个实施方案中，所述骨折是病理性骨折、非创伤性骨折、脊椎骨折、非脊椎骨折、形态测定骨折（morphometric fractures）或它们的组合。在一些实施方案中，骨折可以是闭合骨折、复合骨折、横骨折、青枝骨折或粉碎性骨折。在一个实施方案中，发生骨折的可以是身体的任何骨，在一个实施方案中，所述骨折是臂、腕、手、指、腿、踝、足、趾、髋、锁骨的任意一块或多块骨中的骨折或它们的组合。

在另一个实施方案中，本文提供的方法和/或组合物有效地治疗、预防、压制、抑制骨骼相关事件、或降低其风险，所述骨骼相关事件例如病理性骨折、脊髓压迫症、高钙血症多、骨相关的疼痛或它们的组合。

在另一个实施方案中，力求用本文提供的方法和/或利用本文提供的组合物治疗的骨骼相关事件包括必要的骨手术和/或骨辐射，其在一些实施方案中，用于治疗在一个实施方案中由骨损害或神经压迫引起的疼痛。在另一个实施方案中，力求用本文提供的方法和/或利用本文提供的组合物治疗的骨骼相关事件包括个体的脊髓压迫症，或有必要改变抗肿瘤疗法，包括改变激素疗法。在一些实施方案中，力求用本文提供的方法和/或利用本文提供的组合物治疗的骨骼相关事件包括治疗、压制、预防骨转移或骨丢失、降低其发病率或延缓其进展或严重性。在一个实施方案中，骨丢失可以包括骨质疏松症、骨质减少或它们的组合。在一个实施方案中，骨骼相关事件可以包括本文所列的实施方案的任意组合。

在一个实施方案中，本文提供的方法和/或利用本文提供的组合物有效地减少骨转移，例如在病灶数量、病灶大小或它们的组合方面。根据本发明的这一方面，在一个实施方案中，本文提供一种预防或抑制个体癌症向骨转移的方法，所述包括向所述个体给药包含托瑞米芬、雷洛昔芬、他莫

昔芬或其类似物、功能衍生物、代谢产物或它们的组合、或它们的药学上可接受的盐的组合物的步骤。在一个实施方案中，所述代谢产物可以包括奥培米芬、非培米芬（fispemifene）或它们的组合。在一个实施方案中，所述癌症是前列腺癌。

在一个实施方案中，所述骨骼相关事件是癌症治疗的结果。在一个实施方案中，所述骨骼相关事件是激素剥夺治疗的结果，而在另一个实施方案中，它们是雄激素剥夺治疗(ADT)的结果。

在一个实施方案中，本发明的化合物用于预防或逆转雄激素剥夺治疗(ADT)引起的副作用，例如肌肉量减少、肌肉强度降低、脆弱、性腺功能减退症、骨质疏松症、骨质减少、BMD 降低和/或骨量减少。

在雄性，尽管成熟期性激素的自然下降（雄激素直接减少以及由雄激素的外周芳构化产生的雌激素的低水平）与骨脆弱有关，但是这种效应在已接受雄激素剥夺治疗的雄性更明显。

在一些实施方案中，本发明的任意组合物包含任意形式的或本文所述的任意实施方案中的式 I 化合物。在一些实施方案中，本发明的任意组合物由任意形式的或在本文所述的任意实施方案中的式 I 化合物组成。在一些实施方案中，本发明的任意组合物主要由任意形式的或在本文所述的任意实施方案中的式 I 的化合物组成。在一些实施方案中，术语“包含”指包含所指的活性剂（例如式 I 的化合物）以及包含制药产业中已知的其它活性剂和药学上可接受的载体、赋形剂、润滑剂、稳定剂等。在一些实施方案中，术语“主要由...组成”指这样的组合物，其唯一的活性成分是所指的活性成分，但是，可以包括用于制剂的稳定、保存等的其它化合物，但是所述其它化合物不直接参与所指的活性成分的疗效。在一些实施方案中，术语“主要由...组成”可以指促进所述活性成分的释放的组分。在一些实施方案中，术语“由...组成”指含有所述活性成分和药学上可接受的载体或赋形剂的组合物。

在一个实施方案中，本发明提供联合制剂。在一个实施方案中，术语“联合制剂”特别地定义为“药盒(kit of parts)”，其意思是如以上定义的组合搭档可以独立地给药，或者通过使用具有不同量的组合搭档的不同的固定组合物给药，即同时地、并发地、分别地或依次地给药。那么，在一些实施方

案中，所述药盒的部件例如可以同时给药，或者按时间先后交替（即对于药盒任何部件在不同的时间点，以相同或不同的时间间隔）给药。在一些实施方案中，可以控制所述联合制剂中的组合搭档的总量的比率。在一个实施方案中，例如为了应对部分待治疗患者亚群的需要或单个患者的需要，所述组合制剂可以变化，所述不同的需要可能归因于具体疾病、所述疾病的严重性、年龄、性别或体重，这可以由本领域的技术人员容易地确定。

应该理解，本发明涉及用于任何适当的疾病、障碍或病症的本文所述的组合物和联合疗法，本领域的技术人员会意识到这一点。上文叙述了所述组合物和联合疗法对特定疾病、障碍和病症的某些应用，它们代表本发明的实施方案，而通过单独或作为所述联合疗法的部分来给药本文所述的化合物或使用本发明的组合物来治疗个体的所述疾病、障碍和病症的方法代表本发明其他的实施方案。

选择性雄激素调节剂化合物的生物活性

在一些实施方案中，本发明的化合物可以用于口服睾酮替代疗法。在其它实施方案中，适当取代的化合物用于：a) 男性避孕；b) 治疗各种激素相关的病症，例如与 ADAM 相关的病症，例如疲劳、抑郁、性欲降低、性功能障碍、勃起功能障碍、性腺功能减退症、骨质疏松症、脱发、肥胖症、少肌症、骨质减少、良性前列腺增生以及情绪和认知改变；c) 治疗与 ADIF 有关的病症，例如性功能障碍、性欲降低、性腺功能减退症、少肌症、骨质减少、骨质疏松症、认知和情绪变化、抑郁、贫血、脱发、肥胖症、子宫内膜异位症、乳腺癌、子宫癌和卵巢癌；d) 治疗和/或预防慢性肌萎缩；e) 治疗前列腺癌、前列腺癌成像、降低前列腺癌的发病率、使其中止或导致其消退；f) 治疗 I 型糖尿病；g) 治疗 II 型糖尿病；h) 压制或抑制糖尿病或降低其发病率；i) 治疗葡萄糖耐受不良；j) 治疗高胰岛素血症；k) 治疗胰岛素抵抗；l) 治疗糖尿病肾病；m) 治疗糖尿病神经病变；n) 治疗糖尿病视网膜病变；o) 治疗脂肪肝症；p) 治疗恶病质；q) 口服雄激素替代和/或其它临床治疗和/或诊断领域，包括本文所述的术语“治疗”所包括的任何实施方案。

在一些实施方案中，本发明的化合物在体内具有组织选择性雄激素活性和合成代谢活性，因此，可用于具体应用，本领域的技术人员会所意识

到这一点。

在一个实施方案中，本发明提供：a) 治疗罹患肌萎缩症的个体的方法；b) 治疗罹患营养不良的个体的方法；c) 治疗个体的骨相关病症的方法；d) 增加个体骨量的方法；e) 改善个体脂质分布的方法；f) 治疗动脉粥样硬化及其相关疾病的方法；g) 改善个体的灵活性和运动的方法；h) 治疗罹患侏儒症的个体的方法；i) 治疗罹患痛经的个体的方法；j) 治疗罹患精神性性交困难的个体的方法；k) 治疗罹患精子生成障碍性不育的个体的方法；这些方法包括向所述个体给药式 I 的化合物和/或所述化合物的类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、不纯物或晶体或它们的任意组合。

在一些实施方案中，本文所述的化合物和/或包含它们的组合物可以用于各种应用和治疗其中需要改善认知、减少或治疗抑郁或其它神经保护作用的疾病。

在一个实施方案中，“认知”指认识的过程，特别是保持清醒、认识、思维、学习和判断的过程。认知涉及心理学、语言学、计算机科学、神经科学、数学、习性学和哲学领域。在一个实施方案中，“情绪”指脾气或精神状态。如本文所指的，变化指认知和/或情绪的任何积极或消极变化。

在一个实施方案中，“抑郁”指涉及身体、情绪和思维的疾病，其影响人吃饭、睡觉的方式、自我感知的方式和考虑事物的方式。抑郁的体征和症状包括缺乏活动兴趣、食欲缺乏或进食过量、缺乏表情、空虚、感觉绝望、悲观、内疚或无助、社交退缩（social withdrawal）、疲劳、睡眠障碍、集中、记忆或作决定困难、躁动、易怒、头痛、消化障碍或慢性疼痛。

在一个实施方案中，本发明的方法用于个体，其为人类。在另一个实施方案中，所述个体是哺乳动物。在另一个实施方案中，所述个体是动物。在另一个实施方案中，所述个体是无脊椎动物。在另一个实施方案中，所述个体是脊椎动物。

在一个实施方案中，所述个体是雄性。在另一个实施方案中，所述个体是雄性。在一些实施方案中，尽管本文所述的方法可以用于治疗雄性和雌性，但是，如本文所述和所举例的，对于某些方法，雌性更有利地应答某些化合物的给药。

在一些实施方案中，尽管本文所述的方法可以用于治疗雄性和雌性，但是，如本文所述的，对于某些方法，雄性更有利地应答某些化合物的给药。

在一些实施方案中，本文所述的化合物和/或包含它们的组合物可以用于以下各项的应用或治疗：脱发（hair loss）、脱发（alopecia）、雄激素性脱发、斑秃、继发化学疗法的脱发、继发放射疗法的脱发、由瘢痕形成诱导的脱发或由应激诱导的脱发。在一个实施方案中，“脱发（hair loss）”或“脱发（alopecia）”指如极普遍类型的男人型脱发的脱发。脱发通常由头皮的斑块脱发开始，有时发展至全秃，甚至体毛脱落。脱发既影响男性也影响女性。

在一些实施方案中，本文所述的化合物和/或包含它们的组合物可以用于与罹患贫血的个体相关的疾病或病症的应用和治疗。在一个实施方案中，“贫血”指具有小于血液中红血细胞的正常数量或小于血液中血红蛋白的正常量、血细胞比容降低、或平均血细胞体积减小或血细胞尺寸减小的病症。在贫血时，血液的携氧能力下降。在一些实施方案中，治疗贫血在本文中也可以指治疗导致贫血的潜在因素，例如：a) 出血；b) 溶血（红血细胞过度破坏）；c) 红血细胞产生不足；和 d) 正常血红蛋白不足。在一些实施方案中，本发明的治疗贫血指治疗贫血的任何形式，包括再生障碍性贫血、苯中毒、范科尼贫血、新生儿溶血病、遗传性球形红细胞增多症、缺铁性贫血、骨质疏松症、恶性贫血、再生障碍性贫血、溶血性贫血、镰状细胞贫血、肾性贫血、地中海贫血、骨髓增生异常综合征和各种骨髓疾病。

在一些实施方案中，本文所述的化合物和/或包含它们的组合物可以用于与个体的性欲问题或个体的勃起功能障碍有关的疾病和/或病症的应用和/或治疗。在一个实施方案中，“性欲”可以指性本能。

在一个实施方案中，术语“勃起”指竖立或直立的能力。勃起组织是能够通过其含有的大量血管的膨胀而极大地膨胀并变硬的组织。

在本发明的另一个实施方案中，提供用于个体（即罹患雄激素依赖性病症的个体）的激素治疗的方法，所述方法包括使患者的雄激素受体与本发明的化合物和/或非类固醇激动剂和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、水合物、*N*-氧化物或它们的任意组合接触的步骤，上述化合物的量有效地使其与所述雄激素受体结合并实现改变雄激素依赖性病症。

在本发明的一个实施方案中，提供用于患者（即罹患雄激素依赖性病症的个体）激素替代治疗的方法，所述方法包括向个体给药足以实现改变所述个体的激素依赖性病症的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、水合物、*N*-氧化物或它们的任意组合的步骤。

可以用本文所述的化合物和/或组合物，包括本发明的方法治疗的雄激素依赖性病症包括与衰老、性腺功能减退症、少肌症、红细胞生成减少、骨质疏松症和与低雄激素（例如睾酮）或雌激素水平相关的任意的其它病症相关的病症。

可以用本文所述的化合物和/或组合物，包括本发明的方法治疗的雄激素依赖性病症可以包括以雄激素或雌激素水平升高为特征的病症，包括多毛症、不育、多囊卵巢综合征、子宫内膜癌、乳腺癌、男人型脱发、前列腺癌、睾丸癌等，本领域的技术人员会知道这一点。对于这些病症，可以向所述个体单独地或联合其它治疗剂给药本文所述的化合物，本领域的技术人员会理解这一点。

在一个实施方案中，本发明提供治疗个体的癌症、降低其发病率、严重性或发病、延缓其进展、延长缓解期或延缓其发作的方法，所述方法包括向所述个体给药本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、水合物、*N*-氧化物或它们的任意组合的步骤。在一些实施方案中，这些癌症是与雄性或雌性的生殖组织相关的激素依赖性或雄激素受体依赖性肿瘤（恶性或良性的），例如前列腺癌、卵巢癌、乳腺癌、子宫癌或睾丸癌等。

在一些实施方案中，本发明提供治疗个体癌前前兆或病变、降低其发病率的方法，所述方法包括向所述个体给药本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、水合物、*N*-氧化物或它们的任意组合的步骤。在一些实施方案中，这些癌前前兆是见于激素应答组织中的雄激素受体依赖性肿瘤或是与雄性或雌性的生殖组织例如前列腺、卵巢、乳腺、子宫或睾丸等相关。在一些实施方案中，这些癌前前兆包括例如前列腺、子宫颈等的任何局部的上皮内瘤样病变。在一些实施方案中，这种方法用于治疗在例如雄性或雌性生殖组织

的组织中的瘤或肿瘤前期、发育异常或增生。

在一个实施方案中，本发明提供化合物、组合物和/或它们在治疗良性前列腺增生(BPH)中的使用方法。“BPH（良性前列腺增生）”是前列腺的良性增大，它是在任何内脏器官中发现的最普通的良性增生性异常，并且是成年男性发病的主要病因。超过 75%的大于 50 岁的男性患 BPH，在九十岁的男性中，其患病率达到 88%。BPH 经常导致逐渐挤压穿过前列腺的尿道部分（前列腺尿道）。因为膀胱的不完全排空和尿急，这造成患者尿频急。尿流的梗阻也能导致一般的排尿失控，包括当希望排尿时排尿启动困难以及因为不能从膀胱排空尿而造成阻止尿流困难（一种称为充溢性尿失禁（overflow urinary incontinence）的病症，它可以导致尿路梗阻和泌尿衰竭（urinary failure））。

在本发明的一个实施方案中，治疗个体的良性前列腺增生(BPH)的方法包括向所述个体给药有效治疗所述个体的 BPH 的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、水合物、*N*-氧化物或它们的任意组合的步骤。

在一些实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合用于治疗个体的恶病质和/或与癌症有关的恶病质、减轻其严重性、降低其发病率或减少其发病的使用方法。在另一个实施方案中，所述癌症包括肾上腺皮质癌、直肠癌、膀胱癌、脑瘤、脑干胶质瘤、脑瘤、小脑星形细胞瘤、大脑星形细胞瘤（cerebral astrocytoma）、室管膜瘤、髓母细胞瘤、幕上原始神经外胚叶瘤（supratentorial primitive neuroectodermal）、松果体瘤、下丘脑胶质瘤、乳腺癌、类癌瘤、癌、子宫颈癌、结肠癌、结直肠癌、子宫内膜癌、食管癌、肝外胆管癌、尤文家族肿瘤（ewings family of tumors）(Pnet)、颅外胚细胞肿瘤、眼癌、眼内黑色素瘤、胆囊癌、胃癌、胚细胞瘤、性腺外肿瘤、妊娠滋养细胞肿瘤、头颈癌、下咽癌、胰岛细胞癌、喉癌、白血病、急性淋巴细胞性白血病、口腔癌、肝癌、肺癌、非小细胞肺癌、小细胞肺癌、AIDS 相关的淋巴瘤、中枢神经系统（原发性）淋巴瘤、皮肤 T 细胞淋巴瘤、淋巴瘤（霍奇金病和非霍奇金病）、恶性间皮瘤、黑色素瘤、Merkel 细胞癌、转移性鳞癌、多发性骨髓瘤、浆细胞瘤、蕈样肉芽肿病、骨髓增生异常综合征、骨髓增殖性疾病、鼻咽癌、神经

母细胞瘤、口咽癌、骨肉瘤、卵巢上皮样癌、卵巢生殖细胞肿瘤、卵巢低恶性潜在肿瘤、胰腺外分泌癌（exocrine pancreatic cancer）、胰岛细胞癌、胰腺癌、鼻旁窦和鼻腔癌、甲状旁腺癌、阴茎癌、嗜铬细胞瘤癌、垂体癌、浆细胞瘤、前列腺癌、横纹肌肉瘤、直肠癌、肾细胞癌、涎腺癌、塞扎里综合征、皮肤癌、皮肤T细胞淋巴瘤、卡波西肉瘤、黑色素瘤、小肠癌、软组织肉瘤、软组织肉瘤、睾丸癌、恶性胸腺瘤、甲状腺癌、尿道癌、子宫癌、肉瘤、童年期异常癌、阴道癌、外阴癌、肾母细胞瘤或它们的任意组合。

在另一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合用于治疗肺癌、减轻其严重性、降低其发病率或延缓其发作的用途。

在另一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合用于治疗非小细胞肺癌、减轻其严重性、降低其发病率或延缓其发作的用途。

在另一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合用于治疗霍奇金病（或者在另一个实施方案中，非霍奇金病）、减轻其严重性、降低其发病率或延缓其发作的用途。

在另一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合用于治疗结直肠癌、减轻其严重性、降低其发病率或延缓其发作的用途。

在一些实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合用于治疗癌症、减轻其严重性、降低其发病率或减少其发病的用途。在另一个实施方案中，所述癌症包括雄激素AR依赖性肿瘤（恶性或良性的），例如前列腺癌、乳腺癌（男性或女性、可行手术或不能手术的）。在另一个实施方案中，所述SARM化合物是

ADT 的辅药（adjunct），所述 ADT 用于治疗前列腺癌、膀胱癌、脑癌、骨肿瘤、结肠癌、子宫内膜癌、肝癌、肺癌、淋巴癌、肾癌、骨肉瘤癌、卵巢癌、胰腺癌、阴茎癌、皮肤癌、甲状腺癌和/或激素依赖性癌。

在一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合的以下用途：a) 治疗骨相关的病症；b) 预防骨相关的病症；c) 压制骨相关的病症；d) 抑制骨相关的病症；e) 增加个体的骨强度；f) 增加个体的骨量；g) 抑制破骨细胞形成的用途。

在一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合的以下用途：a) 加速骨修复；b) 治疗骨病症；c) 治疗骨密度降低；d) 治疗低骨矿物质密度(BMD)；e) 治疗骨量减少；f) 治疗代谢骨病；g) 促进骨生长或再生；h) 促进骨恢复；i) 促进骨折修复；j) 促进骨重建；k) 治疗成形外科（包括脸部、髋部或关节的）后的骨损害；l) 提高骨强度和功能；m) 增加骨皮质量；n) 增加小梁连接性。

在一个实施方案中，所述骨相关的病症是遗传性病症，在另一个实施方案中，是由特定疾病的治疗方案诱导的结果。例如，在一个实施方案中，本文所述的化合物用于治疗由癌症向骨转移而引起的骨相关的病症，或在另一个实施方案中，治疗例如由给予雄激素剥夺治疗应答个体的前列腺致癌作用而引起的骨相关的病症。

在一个实施方案中，所述骨相关的病症是骨质疏松症。在另一个实施方案中，所述骨相关的病症是骨质减少。在另一个实施方案中，所述骨相关的病症是骨吸收增加。在另一个实施方案中，所述骨相关的病症是骨折。在另一个实施方案中，所述骨相关的病症是骨脆弱。

在另一个实施方案中，所述骨相关的病症是骨矿物质密度(BMD)丢失。在另一个实施方案中，所述骨相关的病症是骨质疏松症、骨质减少、骨吸收增加、骨折、骨脆弱和 BMD 丢失的任意组合。每种病症代表本发明独立的实施方案。

在一个实施方案中，“骨质疏松”指由于钙和骨蛋白的消耗造成的骨变薄和骨量减少。在另一个实施方案中，骨质疏松症是全身性的骨骼疾病，其特

征是骨量低、骨组织退化，并由此导致骨脆弱和骨折易感性增加。在骨质疏松症患者，骨强度是异常的，在一个实施方案中，伴随由此引起的骨折风险增加。在另一个实施方案中，骨质疏松症使通常在见于骨中的钙和蛋白质胶原流失，在一个实施方案中，这导致骨性质异常或骨密度下降。在另一个实施方案中，受骨质疏松症影响的骨可仅仅由于通常不会造成骨折的轻微跌倒或损伤而骨折。在一个实施方案中，骨折可以是裂纹骨折的形式（如在髋骨折中）或压缩性骨折的形式（如在脊椎压迫性骨折中）。脊柱、髋和腕是骨质疏松诱发骨折的通常部位，但是，骨折也可以发生于其它骨骼部位。在另一个实施方案中，未加抑制的骨质疏松能够导致体位的改变、身体异常和灵活性下降。

在一个实施方案中，所述骨质疏松症由雄激素剥夺引起。在另一个实施方案中，所述骨质疏松症在雄激素剥夺后发生。在另一个实施方案中，所述骨质疏松症是原发性骨质疏松症。在另一个实施方案中，所述骨质疏松症是继发性骨质疏松症。在另一个实施方案中，所述骨质疏松症是绝经后骨质疏松症。在另一个实施方案中，所述骨质疏松症是幼年骨质疏松症。在另一个实施方案中，所述骨质疏松症是特发性骨质疏松症。在另一个实施方案中，所述骨质疏松症是老年性骨质疏松症。

在另一个实施方案中，所述原发性骨质疏松症是 I 型原发性骨质疏松症。在另一个实施方案中，所述原发性骨质疏松症是 II 型原发性骨质疏松症。每种类型的骨质疏松症代表本发明的独立的实施方案。

根据本发明的这一方面，在一个实施方案中，用本文所述的化合物或其组合治疗所述骨相关的病症。在另一个实施方案中，在给药本文所述的一种或多种化合物之前、同时或之后，可以提供给个体其它骨促进性化合物。在一个实施方案中，所述骨促进性化合物可以包括天然的或合成的物质。

在一个实施方案中，所述骨促进性化合物可以包括骨形态生成蛋白(BMP)；生长因子，例如表皮生长因子(EGF)、成纤维细胞生长因子(FGF)、转化生长因子(TGF)、胰岛素生长因子(IGF)、血小板源性生长因子(PDGF)；Hedgehog 蛋白（例如 *sonic* hedgehog、*indian* hedgehog 和 *desert* hedgehog）；激素，例如促卵泡激素、甲状旁腺素、甲状旁腺激素相关肽、激活素、抑制素、滤泡抑素、*frizzled* 蛋白、*frzb* 蛋白或 *frazzled* 蛋白；BMP 结合蛋白，例

如脊索蛋白和胎球蛋白；细胞因子，例如 IL-3、IL-7、GM-CSF；趋化因子，例如嗜酸细胞活化趋化因子；胶原；骨钙蛋白；骨黏连蛋白等；本领域的技术人员会理解这一点。

在另一个实施方案中，本发明用于治疗骨病的组合物可以包含本文所述的一种或多种化合物、额外的一种或多种骨促进性化合物和骨原细胞。在一个实施方案中，骨原细胞可以是可以被诱导分化为成骨细胞的干细胞或祖细胞。在另一个实施方案中，所述细胞可以是成骨细胞。在另一个实施方案中，可以向个体给药编码骨促进性化合物的核酸，这应该被认为是本发明的部分。

在一个实施方案中，本发明的方法包括含给药用于治疗骨质疏松症的化合物。在另一个实施方案中，本发明的方法包括给药化合物（与 SERM 联合），用于治疗骨质疏松症。在另一个实施方案中，所述 SERM 是三苯氧胺、4-羟三苯氧胺、艾多昔芬、托瑞米芬、奥培米芬、屈洛昔酚、雷诺昔芬、阿佐昔芬、巴多昔芬、PPT (1,3,5-三(4-羟基苯基)-4-丙基-1*H*-吡唑)、DPN (二芳基丙腈)、拉索昔芬、哌喷昔芬、EM-800、EM-652、萘福昔定、秦哚昔芬、替米利芬、磷酸米泼昔芬、RU 58,688、EM 139、ICI 164,384、ICI 182,780、氯米芬、MER-25、二乙基己烯雌酚、香豆雌酚、染料木黄酮、GW5638、LY353581、珠氯米芬、恩氯米芬、地马孕酮醋酸盐、DPPE、(*N,N*-二乙基-2- {4-(苯基甲基)- 苯氧基}乙胺)、TSE-424、WAY-070、WAY-292、WAY-818、cyclocommunol、普林贝瑞、ERB-041、WAY-397、WAY-244 ERB-196、WAY-169122、MF-101、ERb-002、ERB-037、ERB-017、BE-1060、BE-380、BE-381、WAY-358、[18F] FEDNP、LSN-500307、AA-102、半枝莲、CT-101、CT-102、VG-101。

在另一个实施方案中，本发明的方法包括与二膦酸盐联合给药所述 SARM 化合物用于治疗骨质疏松症，所述二膦酸盐例如阿屈膦酸盐、替鲁膦酸（tiludroate）、氯屈膦酸钠（clodroniate）、帕米磷酸钠、羟乙膦酸盐、阿屈膦酸盐、唑屈膦酸盐（zolendronate）、英卡膦酸二钠（cimadronate）、奈立膦酸钠（neridronate）、米诺膦酸（minodronic acid）、依班膦酸盐、利塞膦酸盐或 homoresidronate。

在另一个实施方案中，本发明的方法包括与降钙素例如鲑精组蛋白

（salmon）、依降钙素、SUN-8577 或 TJN-135 联合给药所述化合物用于治疗骨质疏松症。

在另一个实施方案中，本发明的治疗骨质疏松症的方法包括联合以下物质给药所述 SARM 化合物：a) 维生素 D 或衍生物，例如 ZK-156979；b) 维生素 D 受体配体和类似物，例如骨化三醇、钙三醇(topitriol)、ZK-150123、TEI-9647、BXL-628、Ro-26-9228、BAL-2299、Ro-65-2299 或 DP-035；c) 雌激素、雌激素衍生物或结合型雌激素；d) 抗雌激素药、孕激素或合成雌激素/孕激素；e) RANK 配体单克隆抗体，例如 denosumab(以前称为 AMG162 (Amgen))；f) αvβ3 整合素受体拮抗剂；g) 破骨细胞空泡型 ATP 酶抑制剂；h) 结合 VEGF 的破骨细胞受体拮抗剂；i) 钙受体拮抗剂；j) PTh（甲状旁腺素）和类似物、PTHrP 类似物（甲状旁腺素相关肽）；k) 组织蛋白酶 K 抑制剂（AAE581 等）；l) 雷尼酸锶；m) 替勃龙；n) HCT-1026、PSK3471；o) 麦芽糖镓（gallium maltolate）；p) Nutropin AQ；q) 前列腺素（用于骨）；r) p38 蛋白激酶抑制剂；s) 骨形态生成蛋白；t) BMP 拮抗抑制剂；u) HMG-CoA 还原酶抑制剂；v) 维生素 K 或衍生物；w) 依普黄铜；x) 氟化盐；y 饮食钙补充剂和 z) 骨保护素。

在一个实施方案中，本发明的方法用于治疗由激素紊乱、破坏或不平衡引起的或与之相关的疾病或病症。在一个实施方案中，所述激素紊乱、破坏或不平衡包括激素过量。在另一个实施方案中，所述激素紊乱、破坏或不平衡包括激素缺乏。在一个实施方案中，所述激素是类固醇激素。在另一个实施方案中，所述激素是雌激素。在另一个实施方案中，所述激素是雄激素。在另一个实施方案中，所述激素是糖皮质激素。在另一个实施方案中，所述激素是皮质类固醇。在另一个实施方案中，所述激素是黄体生成素（LH）。在另一个实施方案中，所述激素是促卵泡激素（FSH）。在另一个实施方案中，所述激素是本领域已知的任何其它激素。在另一个实施方案中，所述激素紊乱、破坏或不平衡与绝经有关。在另一个实施方案中，所述激素紊乱、破坏或不平衡与男性更年期、男性更年期血管舒缩综合征、男性更年期乳腺发育、肌肉强度和/或功能下降、骨强度和/或功能下降和发怒有关。在另一个实施方案中，激素缺乏是特定处理的结果，如治疗个体疾病或病症的副产物。例如，所述激素缺乏可以是作为个体前列腺癌疗法的雄激素消耗的结果。

每种可能性代表本发明的独立的实施方案。

在另一个实施方案中，本发明涉及治疗少肌症或恶病质和与其相关的病症（例如骨疾病或病症）。

在一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合的以下用途：1) 治疗肌萎缩症；2)预防肌萎缩症；3) 治疗、预防、压制、抑制或减少归因于肌萎缩症引起的肌肉损失；4) 治疗、预防、抑制、减少或压制归因于肌萎缩症的肌萎缩；和/或 5) 治疗、预防、抑制、减少或压制归因于肌萎缩症的肌肉蛋白分解代谢；和/或治疗、预防、抑制、减少或压制归因于终末期肾脏疾病或 CKD 的肌萎缩；和/或 6) 治疗、预防、抑制、减少或压制脆弱。

在另一个实施方案中，用于治疗罹患肌萎缩症或本文所述的任何病症的个体的化合物的用途包括给药包含本文所述的化合物的药物组合物。在另一个实施方案中，所述给药步骤包括将液体形式的所述药物组合物经静脉内、动脉内或肌内注射给所述个体；在所述个体体内皮下埋植含有所述药物组合物的小丸；口服向所述个体给药液体或固体形式的所述药物组合物；或向所述个体的皮肤表面局部施用所述药物组合物。

肌肉是主要用作动力源的身体组织。身体的肌肉有三种类型：a) 骨骼肌——负责身体的四肢和外部区域运动的肌肉；b) 心肌——心脏肌肉；和 c) 平滑肌——位于动脉和肠壁中的肌肉。

在本文中，消耗性（wasting）病症或障碍定义为至少部分地以体重、器官质量或组织质量的异常的进行性损失为特征的病症或障碍。消耗性病症可以作为疾病例如癌症或感染的结果而发生，或可归因于生理或代谢状态，例如因长期卧床休息或当肢体被固定（例如在铸型中）时发生的废用性失调。消耗性病症也可以是年龄相关的。在消耗性病症过程中发生的体重减少的特征可以是总体重的减少或器官重量的减少，例如归因于组织蛋白减少的骨量或肌肉量的减少。

在一个实施方案中，如本文交替使用的，“肌萎缩（muscle wasting）”或“肌萎缩（muscular wasting）”指肌肉量的进行性损失和/或肌肉的进行性衰减和退化，包括控制运动的骨骼肌或随意肌和控制心脏的心肌和平滑肌。在一

个实施方案中，所述肌萎缩病症或障碍是慢性肌萎缩病症或障碍。“慢性肌萎缩”在本文中定义为肌肉量的慢性（即持续很长一段时间的）进行性损失和/或肌肉的慢性进行性衰减和退化。

肌萎缩过程中发生的肌肉量损失可以是以由于肌肉蛋白分解代谢造成的肌肉蛋白分解或降解为特征。蛋白质分解代谢因为异常高速的蛋白质降解、异常低速的蛋白质合成或这两种的结合而发生。无论是由高度的蛋白质降解还是低度的蛋白质合成引起的肌肉蛋白分解代谢或消耗都会导致肌肉量的减少和肌萎缩。术语“分解代谢”具有本领域中普遍知晓的含义，特别是指能量燃烧形式的新陈代谢。

肌萎缩可以作为病状、疾病、病症或障碍的结果而发生。在一个实施方案中，所述病状、疾患、疾病或病症是慢性的。在另一个实施方案中，所述病状、疾患、疾病或病症是遗传性的。在另一个实施方案中，所述病状、疾患、疾病或病症是神经的。在另一个实施方案中，所述病状、疾患、疾病或病症是感染性的。如本文所述的，为之给药本发明的化合物和组合物的病状、疾病、病症或障碍是直接或间接产生肌肉量的消耗（即损失），即肌萎缩症的疾病。

在一个实施方案中，个体的肌萎缩由所述个体的肌营养不良症、肌萎缩、伴 X 染色体的脊延髓肌萎缩症（SBMA）引起。

所述肌营养不良症是遗传性疾病，其特征是控制运动的骨骼肌或随意肌的进行性衰减和退化。心脏肌肉和一些其它不随意肌也受到某些形式的肌营养不良的影响。肌营养不良（MD）的主要形式是：迪谢内肌肉营养不良、强直性肌营养不良、迪谢内肌肉营养不良、贝克肌营养不良、肢肌营养不良、面肩胛臂肌营养不良、先天性营养不良症、眼咽肌营养不良、远侧肌营养不良和埃-德二氏肌营养不良。

肌营养不良症可以影响所有年龄的人群。尽管某些形式首先在婴儿或儿童中出现，其它可能直到中年或更晚才出现。迪谢内 MD 是最普通的形式，一般影响儿童。强直性肌营养不良是这些疾病中在成人中的最通常的疾病。

肌萎缩（MA）以肌肉的消耗或减少和肌肉量的减少为特征。例如，小儿麻痹症后期 MA 是作为小儿麻痹小儿麻痹症后期综合征（PPS）的一部分而发生的肌肉萎缩。所述萎缩包括虚弱、肌疲劳和疼痛。

其它类型的MA是伴X染色体的脊延髓肌萎缩症(SBMA,也称为Kennedy病)。该病由X染色体上的雄激素受体基因的缺陷引起,仅影响男性,其在成年期发作。因为主要病因是雄激素受体突变,所以雄激素替代不是流行的治疗策略。有一些调查研究,其中给予外源性丙酸睾酮以提高雄激素的水平,这有希望克服雄激素不敏感性并可能提供合成代谢效应。然而,使用超生理水平的睾酮用于补充会有局限性和其它潜在的严重并发症。

少肌症是折磨老人和慢性病患者的使人衰弱的疾病,其特征是肌肉量和功能的损失。而且,瘦体重的增加与某些肌萎缩症的发病率和死亡率降低有关。而且,其它情况和病症也与肌萎缩症有联系并能导致肌萎缩。例如,有研究显示,在慢性下腰痛的严重病例中,出现椎旁肌萎缩。

肌萎缩和其它组织消耗也与高龄有关。相信,在老年人中,全身虚弱归因于肌萎缩。随着身体的老化,更多比例的骨骼肌被纤维组织代替。结果,肌肉的力量、性能和耐力显著下降。

由于疾病或损伤而长期住院或例如当肢体被固定时发生的废用性失调也能导致肌肉萎缩或其它组织消耗。研究显示,在长期住院的罹患损伤、慢性病、烧伤、创伤或癌症的患者中,出现长期单侧肌萎缩和体重减少。

中枢神经系统(CNS)损伤或损害也与肌肉萎缩和其它消耗性病症有关。CNS损伤或损害可由例如疾病、创伤或化学药品引起。其例子有中枢神经损伤或损害、周围神经损伤或损害和脊髓损伤或损害。在一个实施方案中,CNS损害或损伤包括阿尔茨海默氏病(AD)、发怒(情绪)、厌食症、神经性厌食症、与衰老有关的厌食症和/或自信(情绪)。

在另一个实施方案中,肌萎缩和其它组织消耗可能由酒精中毒引起,可以用本发明的化合物和组合物来治疗,这代表它们的实施方案。

在一个实施方案中,本发明提供本文所述的化合物或其类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合用于治疗个体的消耗性疾病、障碍或病症的用途。

在一个实施方案中,所述被治疗的消耗性疾病、障碍或病症与慢性病有关。

在一些实施方案中,本发明涉及治疗可能在肌萎缩、体重减少、营养不

良、饥饿中表现出的任何消耗性病症、或任何归因于组织量减少的功能消耗或缺失。

在一些实施方案中，消耗性疾病或病症，例如恶病质、营养不良、结核病、麻风病、糖尿病、肾脏病、慢性障碍性肺病（COPD）、癌症、终末期肾衰竭、少肌症、肺气肿、骨软化症或心肌病，可以通过本发明的方法，经给药本文所述的 SARM 化合物、包含它的组合物、附加或不附加为所治疗的病症提供疗效的药物、化合物或药剂来治疗。

在一些实施方案中，消耗是由于感染肠道病毒、Epstein-Barr 病毒、带状疱疹、HIV、锥虫、流感（influenze）、柯萨奇病毒、立克次氏体、旋毛虫、血吸虫或分枝杆菌，在一些实施方案中，本发明提供其治疗方法。

恶病质是由疾病引起的或作为疾病副反应的虚弱和体重减少。心原性恶病质，即心肌和骨骼肌的肌肉蛋白消耗，是充血性心力衰竭的特征。癌症恶病质是发生在患有实体瘤和恶性血液病的患者的综合征，其表现为因脂肪组织和瘦肌肉量的大量消耗而导致的体重减少。

恶病质也见于获得性免疫缺陷综合征（AIDS），人类免疫缺陷病毒（HIV）相关肌病和/或肌无力/肌萎缩是 AIDS 比较通变的临床表现。患有 HIV 相关肌病或肌无力/肌萎缩的个体通常经受严重的体重下降、全身的或近端的肌无力、压痛和肌萎缩。

在一些实施方案中，本发明提供用于治疗个体感染、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药包含化合物和免疫调节剂、抗感染剂、基因治疗剂或它们的组合的组合物免疫调节剂。在一个实施方案中，所述抗感染剂可以是抗真菌剂、抗细菌剂、抗病毒剂、或抗寄生虫剂或它们的组合。在一些实施方案中，感染包括放射菌病、边虫病、炭疽、曲霉病、菌血症、细菌真菌病、巴尔通体感染、肉毒中毒、布氏菌病、伯霍尔德杆菌感染、弯曲杆菌传染、念珠菌病、猫抓病、衣原体传染、霍乱、梭菌感染、球孢子菌病、交叉感染、隐球菌病、皮肤真菌病、白喉病、埃里希体病、大肠杆菌感染、坏死性筋膜炎、梭杆菌感染、气性坏疽、革兰氏阴性细菌感染、革兰氏阳性细菌感染、组织胞浆菌病、脓疱病、克雷伯菌感染、军团杆菌病、麻风病、钩端螺旋体病、利斯特菌感染、莱姆病、马杜拉分支菌病、类鼻疽、分枝杆

菌感染、支原体感染、真菌病、诺卡尔菌感染、甲癣、瘟疫、肺炎球菌感染、假单胞菌感染、鹦鹉热、Q热、鼠咬热、回归热、风湿热、立克次体感染、洛基山斑点热、沙门菌感染、猩红热、恙虫热斑疹伤寒、败血症、性传播疾病、葡萄球菌感染、链球菌感染、破伤风、蜱传播性疾病(tick-borne diseases)、结核病、土拉菌病、伤寒、虱传斑疹伤寒、弧菌感染、雅司病、耶尔森菌感染、人兽互通病、接合菌病、获得性免疫缺陷综合征、腺病毒科感染、甲病毒感染、虫媒病毒传染、Borna 病、布尼亚病毒科感染、嵌杯病毒科感染、水痘、冠状病毒科感染、柯萨奇病毒感染、巨细胞病毒感染、登革热、DNA病毒感染、触染性痘疮、脑炎、虫媒病毒、Epstein-barr 病毒感染、传染性红斑、汉坦病毒感染、出血热、病毒性肝炎、病毒性人单纯疱疹、带状疱疹、耳部带状疱疹、疱疹病毒科感染、传染性单核细胞增多症、人拉沙热、麻疹、传染性软疣、流行性腮腺炎、副粘病毒科感染、白蛉热、多瘤病毒感染、狂犬病、呼吸合胞体病毒感染、裂谷热、RNA 病毒感染、风疹、慢病毒疾病、天花、亚急性硬化性全脑炎、肿瘤病毒感染、疣、西尼罗热、病毒性疾病、黄热病、阿米巴病、异尖线虫病、蛔虫病、巴贝虫病、人芽囊原虫感染、臭虫叮咬、绦虫感染、美洲锥虫病、隐孢子虫病、环孢子虫感染、囊虫病、双核阿米巴病、裂头绦虫病、龙线虫病、包虫病、体外寄生虫感染、丝虫病、贾第虫病、蠕虫病、钩虫感染、幼虫移行症、利什曼病、虱寄生、罗阿丝虫病、疟疾、感染、蝇蛆病、盘尾丝虫病、原虫感染、疥疮、血吸虫病、(寄生虫性)皮肤病、类圆线虫病、绦虫病、弓蛔虫病、弓形体病、旋毛虫病、滴虫感染、锥虫病、非洲锥虫病或者鞭虫感染。

在一些实施方案中，本发明提供用于治疗个体肌骨疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗中枢神经系统的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药或它们的组合。在一些实施方案中，肌骨疾病包括软骨发育不全、获得性骨肥大综合征、尖头并指（趾）畸形、关节炎、关节挛缩、关节病、神经原性滑囊炎、软骨疾病、锁骨颅骨发育不良、畸形足、筋膜间隔综合征、颅面骨发育不全、颅缝早闭、皮肌炎、杜普伊特伦氏挛缩、侏儒症、埃-范二氏综合征、内生软骨瘤病、酸

细胞增多性肌痛综合征、外生骨疣、筋膜炎、疲劳综合征、纤维肌痛、骨纤维性结构不良、多骨纤维性结构不良、扁平足、足畸形、弗莱尔伯格二蹠骨远端缺血坏死、漏斗胸、Goldenhar 综合征、痛风、拇外翻、髋脱位、骨肥厚、椎间盘移位、歌舞伎化妆综合征(kabuki make-up syndrome)、克-费二氏综合征、兰-吉综合征、莱-佩二氏病、脊柱前凸、下颌骨颜面发育不全、肢骨纹状肥大、线粒体肌病、肌痛性痉挛、肌痉挛状态、肌营养不良、肌肉骨骼畸形、肌骨疾病、肌炎、骨化性肌炎、肌管性肌病、畸形性骨炎、骨性关节炎、骨软骨炎、成骨不全、骨髓炎、骨坏死、骨硬化症、骨质疏松症、波伦综合征、复发性多软骨炎、风湿性多肌痛、多肌炎、横纹肌溶解、风湿性疾病、鲁-辛二氏综合征、绍伊尔曼氏病、脊柱侧凸、塞佛氏病/跟骨骨突炎、脊柱疾病、脊髓骨赘病、椎管狭窄、强直性脊柱炎、脊椎前移、施普伦格耳畸形、滑膜炎、肌腱病变、网球肘、腱鞘炎、致死性发育不全或 Tietze 综合征。

在一些实施方案中，本发明提供用于治疗个体的消化系统疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗中枢神经系统的药、治疗胃肠系统的药、抗感染药、治疗代谢病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，胃肠疾病包括腺瘤结肠息肉、Alagille综合征、肛门疾病、阑尾炎、巴雷特食管、胆道闭锁、胆道疾病、卡罗利病、乳糜泻、胆管炎、胆囊炎、胆石症、溃疡性结肠炎、克罗恩病、吞咽障碍、十二指肠的溃疡、痢疾、假膜性小肠结肠炎、食管失弛症、食管闭锁、食管炎、胰腺外分泌功能不全、脂肪肝、大便失禁、胃炎、肥厚性胃炎、胃肠炎、胃食管反流、胃肌轻瘫、痔疮、肝静脉血栓形成、肝炎、慢性肝炎、膈疝、食管裂孔疝、希尔施普龙病、高血压(HTN)、门静脉高压、炎性肠疾病、肠疾病、肠肿瘤、肠神经元发育异常、肠梗阻、肠易激综合征、乳糖不耐受、肝硬化、肝病、梅克尔憩室、胰腺疾病、胰腺肿瘤、胰腺炎、消化性溃疡、杰格斯综合征、直肠炎、直肠疾病、直肠脱垂、短肠综合征、气管食管瘘、惠普尔病或卓林格-艾丽逊综合征。

在一些实施方案中，本发明提供用于治疗个体口颚病、降低其发病率、

延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，本发明包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、抗感染药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，口颚病包括舌系带过短、夜磨牙症、口灼伤综合征、唇炎、巨颌症、唇裂、含牙囊肿、龈炎、良性迁移性舌炎、唇疱疹、路德维希咽峡炎、巨舌、迈-罗二氏综合征、牙周疾病、皮埃尔·罗班综合征、下颌前突、涎腺疾病、流涎、口疮性口炎、颞下颌关节障碍、颞下颌关节功能紊乱综合征或者口干燥症。

在一些实施方案中，本发明提供用于治疗个体的呼吸道疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗中枢神经系统的药、治疗心血管系统的药、抗感染药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，呼吸道疾病包括气道阻塞、呼吸暂停、石棉沉着病、哮喘、哮喘诱导的肌无力或者骨虚弱、肺膨胀不全、铍中毒、支气管疾病、支气管扩张、细支气管炎、闭塞性细支气管炎机化性肺炎、支气管炎、支气管肺发育不良、慢性阻塞性肺病(COPD)、感冒、咳嗽、胸腔积脓、会厌炎、糖皮质激素(GC)引起的肌病或骨质减少、咯血、肺动脉高压、通气过度、卡塔格内综合征、肺脓肿、肺病、胎便吸入综合征、胸腔积液、胸膜炎、肺炎、气胸、肺泡蛋白质沉着症、慢性阻塞性肺病、肺水肿、肺栓塞、肺气肿、肺纤维化、呼吸窘迫综合征、新生儿呼吸过敏症、呼吸道感染、鼻硬结病、弯刀综合征、严重急性呼吸器官综合病、矽肺、睡眠呼吸暂停、中央喘鸣、气管狭窄、归因于哮喘的肌肉量或骨量减少、慢性阻塞性肺病(COPD)中的消耗、韦格纳氏肉芽肿或者百日咳。

在一些实施方案中，本发明提供用于治疗个体耳鼻喉疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、抗感染药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，耳鼻喉疾病包括中耳胆脂瘤、哮吼、耳聋、鼻出血、听力损失、听觉过敏、迷路炎、喉炎、喉

软化、喉狭窄、乳突炎、梅尼埃病、鼻塞、鼻息肉、耳炎、耳鼻喉病、耳硬化、咽炎、老年性耳聋、咽后脓肿、鼻炎、鼻窦炎、耳鸣、扁桃体炎、鼓膜穿孔、前庭神经元炎、声带麻痹或者语音障碍。

在一些实施方案中，本发明提供用于治疗个体神经系统疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、治疗中枢神经系统的药、抗感染药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，神经系统疾病包括自主神经系统疾病、中枢神经系统疾病、颅神经疾病、脱髓鞘疾病、神经系统畸形、神经病学表现或神经肌肉疾病。

在一些实施方案中，自主神经系统疾病包括灼性神经痛或反射性交感神经营养障碍。

在一些实施方案中，中枢神经系统疾病包括阿尔茨海默氏病、蛛网膜炎、脑脓肿、脑缺血、中枢神经系统感染、大脑性瘫痪、脑血管障碍、皮质基底节变性(corticobasal ganglionic degeneration, CBGD)、Creutzfeldt-Jakob 综合征、丹-沃二氏综合征、痴呆、脑炎、脑脊髓炎、癫痫症、癫痫症诱导的性腺机能减退和/或代谢增进状态、特发性震颤、弗里德赖希共济失调、杰茨曼-斯脱司勒-史茵克病、哈-斯二氏综合征、亨廷顿病、脑积水、缺氧、失眠、脑缺血发作（ischemic attack）、库鲁病、Landau-Kleffner 综合征、Lewy 体病、马-约病、Meige 综合征、脑膜炎、细菌性脑膜炎、病毒性脑膜炎、偏头痛、运动障碍、多系统萎缩、脊髓炎、橄榄体脑桥小脑萎缩、帕金森病、帕金森障碍、脊髓灰质炎、脊髓灰质炎后综合征、朊病毒病、假脑瘤、希-德二氏综合征、婴儿痉挛、脊髓疾病、核上性麻痹、脊髓空洞症、丘脑疾病、抽搐性运动障碍、多动秽语综合征或葡萄膜脑膜脑炎综合征。在一些实施方案中，所述中枢神经系统疾病是囊性纤维化病诱导的性腺机能减退状态。

在一些实施方案中，颅神经疾病包括 Bell 麻痹、颅神经疾病、面部半侧萎缩、面神经痛、舌咽神经疾病、莫比乌斯综合征或者三叉神经痛。

在一些实施方案中，中枢神经系统疾病包括对中枢神经系统（CNS）的损伤或损害。在一些实施方案中，对 CNS 的损伤或损害可能与肌萎缩症有关。

对 CNS 的损伤或损害可以由例如疾病、创伤或化学试剂引起。其例子是中枢神经损伤或损害、周围神经损伤或损害和脊髓损伤或损害。

涉及脊髓损伤（SCI）患者的研究已经显示，在 SCI 后，中枢神经递质可能会改变，造成下丘脑-垂体-肾上腺轴功能障碍，它的破坏导致睾酮和其它激素水平的严重下降。SCI 或其它急性疾病或创伤特征性地包括分解代谢增强和合成代谢活动减低，导致易于损失瘦身体组织的病症，并经常伴随紊乱的营养利用。瘦体重的损失的影响包括伤口扩展和愈合机制受损，使问题进一步复杂化。由于营养不良和蛋白分解代谢加上固定，脊髓损伤的患者处于高度的患褥疮的风险中。

在一个实施方案中，本发明的方法可以治疗各种 CNS 损伤。在一个实施方案中，CNS 损伤可以指神经细胞膜的分解，或者在另一个实施方案中，指神经不能产生或传播神经冲动，或者在另一个实施方案中，指神经细胞的死亡。损伤包括直接或间接影响 CNS 的正常功机能的损害。所述损伤可能是结构性、物理性或机械性损伤，并可能在挤压、压缩或拉伸神经纤维的情况下由身体冲击造成。或者，所述细胞膜可能因疾病、化合失调或生理功能障碍，例如缺氧（例如卒中）、动脉瘤或再灌注而被破坏或降解。CNS 损伤非限制性地包括例如对视网膜神经节细胞损害、外伤性脑损伤、卒中相关的损伤、脑动脉瘤相关的损伤、脊髓损伤（包括单瘫、双侧瘫痪、截瘫、偏瘫和四肢瘫痪）、神经增殖性病症或神经性疼痛综合征。

由于对哺乳动物脊髓的损伤，脊髓中神经之间的连接断裂。这种损伤阻断受该损伤影响的神经束的神经冲动的流动，结果损害感觉功能和运动功能。对脊髓的损伤可能缘于脊髓的压缩或其它挫伤、脊髓挤压或切断。脊髓切断（本文中也称为“横切”），可能是脊髓的完全切断或可能是不完全切断。

在一些实施方案中，治疗罹患 CNS 损伤（或在另一个实施方案中为罹患脊髓损伤）的个体的方法可能伴随用损伤部位的电刺激和给药嘌呤核苷或其类似物（例如美国专利申请公开 20040214790A1 中所述）治疗所述个体。

在一些实施方案中，脱髓鞘疾病包括肾上腺脑白质营养不良、亚历山大病、卡纳万病、脱髓鞘病、Schilder 弥漫性脑硬化、球形细胞脑白质营养不良、异染性脑白质营养不良、多发性硬化或视神经脊髓炎。

在一些实施方案中，神经系统畸形包括阿-蔡二氏畸形、夏-马-图三氏病、

脑膨出、遗传性运动和感觉性神经病、透明隔-视神经发育不良、隐性脊柱裂或椎管闭合不全。

在一些实施方案中，神经病学表现包括失认症、遗忘症、命名不能症、失语症、失用症、背痛、布朗-塞卡尔综合征、小脑性共济失调、舞蹈症、交流障碍、意识错乱、头晕、诵读困难、张力失常、面神经麻痹、肌束震颤、步态障碍、神经性头痛、偏瘫、记忆障碍、智力低下、缄默症、肌阵挛、颈痛、非语言学习障碍、嗅觉障碍、疼痛、麻痹、幻肢、面容失认症、四肢瘫痪、癫痫发作、痉挛、言语障碍、共同感觉迟发性运动障碍、味觉障碍、斜颈、震颤、牙关紧闭、意识丧失或眩晕。

在一些实施方案中，神经肌肉疾病包括肌萎缩侧索硬化、臂丛神经炎、臂丛神经病、延髓性麻痹、腕管综合征、肘管综合征、糖尿病神经病变、家族性自主神经异常、格-巴二氏综合征、遗传性感觉和自主神经系统神经病、米勒·费希尔综合征、运动神经元病、脊髓性肌萎缩、重症肌无力、先天性结构性肌病、神经卡压综合征、神经痛、神经肌肉疾病、家族周期性麻痹、周围神经系统疾病、POEMS 综合征、多神经病、多发性神经根病、雷夫叙姆病、坐骨神经痛、儿童脊髓性肌萎缩、僵人综合征（stiff-person syndrome）、胸廓出口综合征或尺神经压缩综合征。

在一个实施方案中，治疗罹患神经系统疾病的个体的方法包括治疗所述个体的任何继发性病症，所述病症由所述个体患有神经系统疾病而引起，其中的一些在本文中有叙述。

在一些实施方案中，本发明提供用于治疗个体的眼睛疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、治疗心血管系统的药、抗感染药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，眼睛疾病包括急性区域性隐匿性外层视网膜病变(acute zonal occult outer retinopathy)、埃迪综合征、白化病、眼睛黑蒙（ocular-amaurosis）、弱视（fugax）、弱视（amblyopia）、无虹膜、瞳孔不等、无眼畸形、无晶状体、散光、睑缘炎、眼睑下垂、睑痉挛、盲、白内障、睑板腺囊肿、脉络膜视网膜炎、无脉络膜、眼缺损、色觉缺陷、结膜炎、角膜疾病、角膜营养不良、角膜水肿、

角膜溃疡、糖尿病视网膜病变、复视、双行睫、干眼综合征、Duane 眼球后退综合征、睑外翻、睑内翻、内斜视、虹膜色素剥脱综合征、外斜视、眼出血、眼睛瘤、眼睑疾病、悬浮物、广泛纤维化综合征(general fibrosis syndrome)、青光眼、环状萎缩、偏盲、血小板病-白化病综合征、睑腺炎、霍纳综合征、远视、前房出血、虹膜炎、Kearns-Sayer 综合征、角膜炎、圆锥角膜、泪器疾病、泪管阻塞、晶体疾病、黄斑变性、小眼、近视、病理性眼震、Kearns-Sayer、动眼神经疾病、眼肌麻痹、视神经萎缩、视神经疾病、视神经炎、视神经病变、眶蜂窝织炎、视神经乳头水肿、Peter 异常、老视、翼状胬肉、瞳孔失调、屈光不正、视网膜脱离、视网膜疾病、视网膜静脉闭塞、视网膜色素变性、早产儿视网膜病、视网膜劈裂症、巩膜炎、暗点、斜视、Thygeson 表层点状角膜炎、沙眼、葡萄膜炎、白点综合征、视觉障碍或者玻璃体病症。

在一些实施方案中，本发明提供治疗个体的泌尿道和/或男性生殖器疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗胃肠系统的药、抗感染药、治疗肾脏的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，泌尿系疾病和/或男性生殖器疾病包括抗肾小球基底膜疾病、阴茎头炎、膀胱外翻、膀胱肿瘤、隐睾症、间质性膀胱炎、肾性尿崩症、附睾炎、富尼埃坏疽、肾小球肾炎、古德帕斯丘综合征、血性精液、血尿、溶血尿毒症综合征、肾盂积水、尿道下裂、阳痿、不育、肾结石、急性肾功能衰竭、慢性肾功能衰竭、急性肾小管坏死、海绵肾、多囊性肾发育不良、遗传性肾炎、肾病、肾病综合征、夜尿、少尿、阴茎疾病、阴茎硬结、阴茎肿瘤、包茎、阴茎异常勃起、前列腺疾病、良性前列腺增生、前列腺肿瘤、蛋白尿、肾盂肾炎、赖特病、肾动脉梗阻、精索扭转、睾丸疾病、尿道狭窄、尿道炎、尿潴留、泌尿道感染、排尿障碍、泌尿道和男性生殖器疾病、泌尿系疾病、精索静脉曲张、膀胱或尿道回流。

在一些实施方案中，本发明提供治疗个体的皮肤病症、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，本发明包含给予个体组合物，所述组合物包含化合物和抗癌药、免疫

调节剂、治疗皮肤病症的药、抗感染药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，皮肤病症包括痤疮、光线性角化病、脱发、雄激素性脱发、斑秃、继发化学疗法的脱发、继发放射疗法的脱发、由瘢痕形成诱导的脱发、应激诱导的脱发、血管瘤、足癣、水源性瘙痒症、特应性皮炎、脱发、早年脱发、男人性脱发、雄激素性脱发、基底细胞癌、烧伤、褥疮、白塞氏病、睑缘炎、疖、Bowen 病、大疱性类天疱疮、复发性口溃疡、痈、组织蜂窝炎、氯痤疮、手脚慢性皮炎、出汗不良症、感冒疮、接触性皮炎、匍行疹、头皮屑、皮炎、疱疹样皮炎、皮肤纤维瘤、尿布疹、湿疹、大疱性表皮松解症、丹毒、红皮病、擦伤水泡、生殖器疣、化脓性汗腺炎、荨麻疹、多汗症、鱼鳞病、脓疱病、边缘性皮霉病、卡波西肉瘤、瘢痕疙瘩、角化棘皮瘤、毛发角化病、虱感染、扁平苔癣、慢性单纯性苔癣、脂肪瘤、淋巴结炎、恶性黑色素瘤、黑斑病、痱、传染性软疣、钱币状皮炎、佩吉特乳头病、虱病、天疱疮、口周皮炎、光变态反应、光过敏、玫瑰糠疹、毛发红糠疹、银屑病、雷诺病、钱癣（ring worm）、酒渣鼻、疥疮、硬皮病、皮脂腺囊肿、脂溢性角化症、脂溢性皮炎、带状疱疹、皮肤癌、皮赘、蜘蛛状血管病、鳞状细胞癌、淤滞性皮炎、蜱叮咬、须癣、头癣、体癣、股癣、脚癣、甲癣、花斑癣、癣、潜蚤病、癜风病或疣。

在一个实施方案中，所述皮肤病症是伤口或烧伤。在一些实施方案中，发现伤口和/或溃疡从皮肤突出或在粘膜表面上或是器官梗死形成的结果。伤口可能是软组织缺损或损害或者潜在疾病的结果。在一个实施方案中，术语“伤口”指具有正常的组织结构完整性的破坏的身体损伤。该术语也包括术语“疮”、“损害”、“坏死”和“溃疡”。在一个实施方案中，术语“疮”指皮肤或粘膜的任何损害，术语“溃疡”指器官或组织表面的局部缺损或陷凹，其由坏死组织的腐离产生。损害一般与任意的组织缺损有关。坏死与由感染、损伤、发炎或梗死形成引起的死亡组织有关。所有这些都由术语“伤口”包括，所述“伤口”指愈合过程中的任意特定阶段的任何伤口，所述阶段包括任何愈合开始前的阶段，或甚至在产生特定伤口（像外科切口）（预防治疗）之前的阶段。

待根据本发明预防和/或治疗的伤口的例子是，例如无菌伤口、挫伤、切伤、撕裂伤、非穿透伤（即其中无皮肤破坏但损伤下面的结构的伤口）、开放性创伤、贯通伤、穿透伤、刺伤、脓毒性伤口、皮下创伤等。疮的例子有

褥疮、口疮、铬毒性溃疡、感冒疮、受压溃疡等。溃疡的例子是消化性溃疡、十二指肠溃疡、胃溃疡、痛风性溃疡、糖尿病性溃疡、高血压缺血性溃疡、淤积性溃疡、小腿溃疡 (静脉溃疡)、舌下溃疡、粘膜下溃疡、症状性溃疡、营养不良性溃疡、热带溃疡、软下疳（例如由淋病（包括尿道炎、宫颈内膜炎和直肠炎）引起的）。与伤口或疮有关的可以能根据本发明成功治疗的病症是烧伤、炭疽、破伤风、气性坏疽、猩红热（scalatina）、丹毒、寻常须疮、毛囊炎、传染性脓胞病或大疱性脓胞病等。术语“伤口”和“溃疡”以及“伤口”和“疮”的使用经常有一定的重叠，而且这些术语常常随机使用。因此，如上所述，在本文中，术语“伤口”包括术语“溃疡”、“损害”、“疮”和“梗死形成”，这些术语是不加区别地使用的，除非另外指出。

待根据本发明治疗的伤口种类还包括：i)一般的伤口，例如外科伤口、外伤、传染性伤口、缺血性伤口、烫伤伤口、化学伤口、大疱伤口；ii)特别针对口腔的伤口，例如拔牙后伤口、特别是与治疗囊肿和脓肿有关的牙髓伤口、细菌、病毒性或自免疫原性溃疡和损害、机械伤口、化学伤口、烫伤伤口、感染性伤口和苔癣样伤口；具体例子是疱疹溃疡、疱疹性口炎、急性坏死性牙疳和口灼伤综合征；和 iii)皮肤上的伤口，例如肿疡、烧伤（例如化学烧伤、烫伤）、损害（细菌性、病毒性、自免疫性）、咬伤和外科切口。其他的伤口分类方法是：i)归因于外科切口、轻微擦伤和轻微咬伤的小的组织损失，或 ii)严重的组织损失。后面的类别包括缺血性溃疡、受压溃疡、瘘、撕裂、严重咬伤、热烧伤和供区伤(在软组织和硬组织中)和梗死形成。

在本发明的其他方面，待预防和/或治疗的伤口选自无菌伤口、梗死形成、挫伤、切伤、撕裂伤、非穿透伤、开放性创伤、贯通伤、穿透伤、刺伤、脓毒性伤口和皮下创伤。

与本发明有关的其它重要伤口是如缺血性溃疡、受压溃疡、瘘、严重咬伤、热烧伤和供区伤的伤口。

在一个实施方案中，本文所述的化合物作为物理治疗/康复的辅药或作为同化剂用于伤口愈合。在另一个实施方案中，本文所述的化合物用于促进前交叉韧带（ACL）或内侧交叉韧带（MCL）损伤的愈合或加速 ACL 或 MCL 术后恢复。在另一个实施方案中，本文所述的化合物用于提高运动能力。在另一个实施方案中，本文所述的化合物用于治疗烧伤。在另一个实施方案中，

本文所述的化合物用于促进软骨再生。在另一个实施方案中，本文所述的化合物用于预防、治疗或逆转与长期的危重病、肺功能障碍、呼吸机依赖、衰老、AIDS、创伤、外科手术、充血性心力衰竭、心肌病、烧伤、癌症、COPD相关的分解代谢。在另一个实施方案中，本文所述的化合物用于预防或逆转由创伤引起的蛋白质分解代谢。在另一个实施方案中，本文所述的化合物用作：a) 在外科手术中使用的灼烙疗法（cauterization therapy）（激光或辐射）的辅药以促进伤口愈合，b) 冷冻疗法的辅药以促进伤口愈合，c) 化学疗法的辅药以预防副作用，例如脱发、性腺功能减退症、肌萎缩，骨质减少、骨质疏松症、少肌症、LDL、甘油三酯(TG)或总胆固醇增加、HDL 减少。在另一个实施方案中，本文所述的化合物用于慢性分解代谢状态（昏迷、消耗性病症、饥饿、进食障碍）；并发性骨折和肌肉损害；其中有明显的肌肉或骨消耗的危重病；和/或结缔组织疾病和病症。

缺血性溃疡和压迫溃疡是通常愈合得极慢的伤口，特别在这种情况下，改善而快速的愈合当然对病人很重要。而且，当愈合改善且发生得更快时，治疗罹患这种伤口的患者所涉及的费用显著减少。

供区伤的发生与例如硬组织从身体的一个部位移动至身体的另一个部位（例如移植）有关。由这种手术引起的伤口十分疼痛，因此，改善愈合十分有价值。

术语“皮肤”以非常广泛的意义使用，包括皮肤的表皮层，在皮肤或多或少地损伤的情况下，也包括皮肤的真皮层。除了角质层以外，皮肤的表皮层是外（上皮）层，而较深的皮肤结缔组织层称为真皮。

在一些实施方案中，烧伤与睾酮水平降低相关，而性腺功能减退症与伤口愈合延迟相关。在一个实施方案中，本发明的方法提供治疗罹患伤口或烧伤的个体。

在一些实施方案中，本发明提供用于促进前交叉韧带（ACL）或内侧交叉韧带（MCL）损伤愈合或加速 ACL 或 MCL 术后恢复的方法。

在一些实施方案中，本发明提供用于治疗个体的内分泌病症、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统药、治疗胃肠系统的药、

治疗皮肤病症的药、治疗中枢神经系统的药、抗感染药、治疗肝的药、治疗肾脏的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，内分泌病症包括肢端肥大症、艾迪生病、肾上腺疾病、先天性肾上腺增生、雄激素不敏感综合征、先天甲状腺功能减退症、库欣综合征、尿崩症、糖尿病、1 型糖尿病、2 型糖尿病、糖尿病酮症酸中毒、空蝶鞍综合征、内分泌腺肿瘤、内分泌系统疾病、巨人症、性腺障碍、格雷夫斯病、两性同体、醛固酮增多症、高血糖高渗性非酮性昏迷、垂体功能亢进、高催乳素血症、甲状腺功能亢进症、性腺功能减退症、垂体功能减退症、甲状腺功能减退症、卡尔曼综合征、纳尔逊综合征、甲状旁腺疾病、垂体疾病、自身免疫性多内分泌腺病、青春期延迟、早熟青春期、肾性骨营养不良、甲状腺疾病、甲状腺激素抵抗综合征、甲状腺肿瘤、甲状腺结节、甲状腺炎、自身免疫性甲状腺炎、亚急性甲状腺炎或者 Wolfram 综合征。

在一个实施方案中，“性腺功能减退症”是由生殖腺功能性活动异常降低导致的或以其为特征的病症，并伴有生长和性发育延迟。

在一些实施方案中，本发明提供用于治疗个体的泌尿生殖器疾病和/或能育性、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，本发明包含给予个体组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗感染药、治疗肾脏的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，泌尿生殖器疾病和/或能育性疾病包括流产、自发性骨盆粘连、外阴阴道念珠菌病、产后抑郁、妊娠糖尿病、精神性性交困难、难产、子痫、子宫内膜异位症、死胎、胎儿生长迟缓、胎盘破裂过早、女性生殖器疾病、女性生殖器肿瘤、葡萄胎、妊娠剧吐、不孕、卵巢囊肿、卵巢扭转、盆腔炎性疾病、胎盘疾病、胎盘功能不全、多囊卵巢综合征、羊水过多、产后出血、妊娠并发症、异位妊娠、外阴瘙痒、产褥期疾病、产褥感染、输卵管炎、滋养层肿瘤、子宫颈功能不全、子宫内翻、子宫脱垂、阴道疾病、外阴疾病、外阴硬化性苔癣（vulvar lichen sclerosis）。

在一些实施方案中，本发明提供用于治疗个体的血液和/或淋巴疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。

在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统的药、抗感染药、治疗肝脏的药、治疗肾脏的药、治疗代谢病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，血液和/或淋巴疾病包括纤维蛋白原缺乏血症、贫血、再生障碍性贫血、溶血性贫血、先天非球形红细胞性贫血（congenital nonspherocytic anemia）、巨幼细胞贫血、恶性贫血、镰状细胞贫血、肾性贫血、血管淋巴样增生伴嗜酸细胞增多、抗凝血酶 III 缺乏、Bernard-Soulier 综合征、血液凝固障碍、血小板疾病、蓝色橡皮疱样痣综合征、切东二氏综合征、冷球蛋白血症、弥漫性血管内凝血、嗜酸粒细胞增多、Erdheim-Chester 病、胎儿幼红细胞增多症、伊万思综合征、因子 V 缺乏、因子 VII 缺乏、因子 X 缺乏、因子 XI 缺乏、因子 XII 缺乏、范科尼贫血、巨淋巴结增生、血液病、血红蛋白病、阵发性血红蛋白尿、血友病 A、血友病 B、新生儿出血病、组织细胞增多病、朗格汉斯细胞组织细胞增生症、非朗格汉斯细胞组织细胞增生症、乔布综合征、白血球减少症、淋巴结炎、淋巴管平滑肌增多症、淋巴水肿、高铁血红蛋白血症、骨髓增生异常综合征、骨髓纤维化、髓样化生、骨髓增殖性疾病、嗜中性白血球减少症、副蛋白血症、血小板存贮池缺如、真性红细胞增多症、蛋白质 C 缺乏、蛋白质 S 缺乏、紫癜、血小板减少性紫癜症、血栓性血小板减少、RH-同种免疫、结节病、结节病、球形红细胞增多症、脾破裂、地中海贫血、血小板无力症、血小板减少、Waldenstrom 巨球蛋白血症或血管性血友病。

在一些实施方案中，本发明提供用于治疗个体的先天性、遗传性或新生儿疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统药物、治疗胃肠系统的药、治疗皮肤病症的药、治疗中枢神经系统的药、抗感染药、治疗肝脏的药、治疗肾脏的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，先天性、遗传性或新生儿疾病包括艾卡迪综合征、羊膜带综合征、无脑畸形、Angelman 综合征、运动失调性毛细血管扩张症、Bannayan-Zonana 综合征、Barth 综合征、基底细胞痣综合征、贝-威二氏综

合征、布卢姆综合征、腮-耳-肾综合征、猫眼综合征、大脑性巨人症联合畸形综合征（cerebral gigantism-charge syndrome）、染色体 16 异常、染色体 18 异常、染色体 20 异常、染色体 22 异常、Costello 综合征、猫叫综合征、Currarino syndrome 综合征、囊性纤维化病、De Lange 综合征、10q 远侧三体性（distal trisomy 10q）、唐氏综合征、外胚层发育不良症、胎儿酒精综合征、胎儿疾病、胎儿-胎儿输血、脆 X 综合征、弗-谢二氏综合征、腹裂、先天性遗传性疾病、脐疝、前脑无裂畸形、色素失调症、伊维马克综合征、雅各布斯综合征、黄疸、克兰费尔特综合征、拉尔森综合征、劳-穆二氏综合征、无脑回、小头畸形、9p 单体性、指甲膝盖综合征、神经纤维瘤病、神经元蜡样质脂褐质沉积病、努南综合征、Ochoa 综合征(尿路面容综合征（urofacial syndrome），具有古怪面部表情的肾盂积水)、眼脑肾综合征、Pallister-Killian 综合征、帕-魏二氏综合征、Proteus 综合征、梨状腹综合征、Rett 综合征、罗比挠综合征、鲁-塔二氏综合征、脑裂、左右转位、史-伦-奥三氏综合征、Smith-Magenis 综合征、斯特季-韦伯二氏综合征、先天性梅毒、毛发低硫营养不良、三 X 女性、13 三体性(帕塔综合征)、9 三体性、特纳综合征、联体儿、乌谢尔综合征、瓦尔登布尔氏综合征、维尔纳综合征或 Wolf-Hirschhorn 综合征。

在一些实施方案中，本发明提供用于治疗个体的结缔组织疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药物、免疫调节剂、治疗皮肤病症的药、抗感染药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，结缔组织疾病包括强直性脊柱炎、Ehlers-Danlos 综合征、亨诺-许兰氏紫癜、川崎病、马方综合征、结节性多动脉炎、多肌炎、银屑病关节炎、反应性关节炎、类风湿性关节炎、硬皮病、干燥综合征、干眼病、斯蒂尔病、系统性红斑狼疮、塔卡亚萨病或韦格纳肉芽肿病。

在一些实施方案中，本发明提供用于治疗个体的代谢病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗糖尿病药、治疗胃肠系统的药、治疗皮肤病症的药、治疗中枢神经系统的

药、抗感染药、治疗肝脏的药、治疗肾脏的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，代谢病包括酸碱平衡失调、酸中毒、碱中毒、尿黑酸尿症、α-甘露糖苷贮积症、先天性氨基酸代谢障碍、淀粉样变、缺铁性贫血、抗坏血酸缺乏、维生素缺乏症、脚气病、生物素酰胺酶缺乏、碳水化合物缺乏糖蛋白综合征、毒碱病症（carnitine disorders）、胱氨酸贮积症、胱氨酸尿、脱水、法布里病、脂肪酸氧化障碍、岩藻糖苷贮积症、半乳糖血症、戈谢病、吉尔伯特病、葡糖磷酸脱氢酶缺乏、戊二酸血症、糖原贮积病、Hartnup 病、血色素沉着病、血铁质、肝豆状核变性、组氨酸血症、同型胱氨酸尿症、高胆红素血症、高钙血症、高胰岛素血症症、高钾血症、高脂血症、高草酸尿、维生素 A 过多症、低钙血症、低血糖症、低钾血症、低钠血症、低磷酸酯酶血症、胰岛素抵抗、碘缺乏、铁超负荷、慢性特发性黄疸、利氏病、莱-奈二氏综合征、亮氨酸代谢障碍、溶酶体贮积病、镁缺乏、枫糖尿病、Melas 综合征、门凯氏卷发综合征、代谢疾病、代谢综合征 X、先天性代谢缺陷、线粒体疾病、粘脂质累积病、粘脂质累积病、尼曼匹克病、肥胖症、鸟氨酸氨甲酰转移酶缺乏症、骨软化症、糙皮病、过氧化物酶体失调、苯丙酮尿、红血球生成性卟啉病、卟啉症、假性早衰、戈谢病、雷夫叙姆病、Reye 综合征、佝偻病、桑德霍夫病、饥饿、丹吉尔病、泰-萨克斯病、四氢生物蝶呤缺乏、三甲胺尿症(trimethylaminuria)、酪氨酸血症、尿素循环障碍、水电解质平衡失调、韦尼克脑病、维生素 A 缺乏病、维生素 B12 缺乏病、维生素 B 缺乏、沃尔曼病或 Zellweger 综合征。

在一些实施方案中，本发明提供用于治疗个体的环境因素诱发疾病（disorder of environmental origin）、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统药物、治疗胃肠系统的药、治疗皮肤病症的药、治疗中枢神经系统的药、抗感染药、治疗肝脏的药、治疗肾脏的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，环境因素诱发疾病包括耳气压伤、咬伤和蜇伤、脑震荡、烧伤、中心核综合征、颅脑损伤、电击伤、骨折、冻伤、

热应激障碍、晕动病、职业病、中毒、惊吓婴儿综合征、肩损伤、太空运动病、脊髓损伤、蜱性麻痹或伤口(贯通性和非贯通性) 。

在一些实施方案中，本发明提供用于治疗个体的行为机制病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和治疗心血管系统的药物、治疗中枢神经系统的药物、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一个实施方案中，行为机制病包括攻击、对死亡的态度、共同依赖、自伤行为、性行为或社会行为。

在一些实施方案中，本发明提供用于治疗个体精神障碍、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和治疗中枢神经系统的药物、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，精神障碍包括阿斯佩格综合征、注意力缺陷障碍伴多动、注意力缺陷障碍伴多动、双相型障碍、边缘型人格障碍、替身综合征、儿童行为障碍、战时神经症、循环性情感障碍、依赖性人格障碍、抑郁症、分离型精神障碍、心境恶劣障碍、进食障碍、纵火行为、疑病症、冲动控制障碍、克-列二氏综合征、精神障碍、儿童期诊断的精神障碍、多重人格障碍、米肖森综合征、芒氏综合征、代理明肖森综合征（Munchhausen by proxy）、自恋型人格障碍、发作性睡眠、强迫性障碍、性变态、恐怖症、精神病、不宁腿综合征、精神分裂症、季节性情感障碍、性欲和性表现障碍、心理性性功能障碍、睡眠障碍、躯体型障碍、创伤后应激障碍、物质相关性障碍、自杀行为或者拔毛狂。

在一个实施方案中，“抑郁”指涉及身体、情绪和思维的疾病，其影响人吃饭、睡觉的方式、自我感知和考虑事物的方式的想法。抑郁的体征和症状包括缺乏活动兴趣、食欲缺乏或进食过量、缺乏表情、空虚、感觉绝望、悲观、内疚或无助、社交退缩、疲劳、睡眠障碍、集中、记忆或作决定困难、躁动、易怒、头痛、消化障碍或慢性疼痛。

在一个实施方案中，“认知”指认识的过程，特别是保持清醒、认识、思维、学习和判断的过程。认知涉及心理学、语言学、计算机科学、神经科学、数学、习性学和哲学领域。在一个实施方案中，“情绪”指脾气或精神状态。

如本文所指的，变化指认知和/或情绪的任何积极或消极变化。

在一些实施方案中，本发明提供治疗个体的肝病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、治疗胃肠系统的药、抗感染药、治疗肝脏的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一个实施方案中，肝病包括肝癌、原发性胆汁性肝硬变、自身免疫性肝炎、慢性肝病、肝硬化、肝炎、病毒性肝炎(甲型肝炎、乙型肝炎、慢性乙型肝炎、丙型肝炎、慢性丙型肝炎、丁型肝炎、戊型肝炎、肝炎X)、肝功能衰竭、黄疸、新生儿黄疸、肝细胞瘤、肝癌、肝脓肿、酒精性肝病、血色素沉着病、肝豆状核变性病、门静脉高压、原发性硬化性胆管炎、结节病、绦虫、泡状棘球蚴病、片形吸虫病、血吸虫病、戈谢病、Zellweger综合征、酒精中毒、食物中毒、肺炎球菌性肺炎或者嗜盐弧菌。

在一些实施方案中，本发明提供用于治疗个体的肾疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗胃肠道系统的药、抗感染药、治疗肾脏的药、治疗代谢病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，肾病包括肢端肥大症、急性肾衰竭(ARF)(淀粉样变)、常染色体显性多囊肾病、肾结石、肾脏囊肿、常染色体隐性多囊肾病、慢性肾衰竭(CRF)、慢性肾病、科-勒二氏综合征、肺源性心脏病、冷球蛋白血症、糖尿病肾病、血脂异常、戈谢病、肾小球肾炎、肺出血肾炎综合征、溶血尿毒症综合征、肝炎、肾癌、肾结石、白血病、脂蛋白血症、狼疮、多发性骨髓瘤、肾炎、多动脉性肾囊肿（polyartekidney cysts）、链球菌感染后肾小球肾炎、肾小球肾炎、肾痛、先兆子痫、肾结核、肾盂肾炎、肾小管性酸中毒肾病、链球菌所导致的中毒性休克综合征、血栓栓塞、弓形体病、泌尿道感染、膀胱输尿管反流或者威廉斯综合征。

在一个实施方案中，所述肾疾病或病症是急性的，或者在另一个实施方案中是慢性的。在一个实施方案中，其中可以使用所述治疗方法的肾脏疾病或病症的临床适应症包括管型尿、测量的肾小球滤过率或其它肾功能指标。

在一个实施方案中，本发明的方法用于易患肾疾病或病症的个体。在一个实施方案中，关于个体的短语“易患肾疾病或病症”与短语“处于风险的个体”的同义，其包括处于患急性或慢性肾功能衰竭的风险，或如果合理地预计所述个体将罹患与功能性肾单位进行性损失相关的肾功能进行性损失，则所述个体处于需要肾替代疗法的风险。具体的个体是否处于风险是可以由相关医学或兽医学领域的普通技术人员按常规作出的决定。

在一个实施方案中，患有肾病的个体，特别是患有终末期肾脏疾病（ESRD）的男性个体罹患性腺功能减退症，其中一些患有伴发的中度至重度蛋白质能量营养不良（PEM），其造成更高的促红细胞生成素（EPO）需要量，更低的生活质量(QOL)分数和更高的死亡率。许多人具有与性腺功能减退症有关的其它症状，包括疲劳、缺乏食欲、肌无力等。在一些实施方案中，本发明的治疗方法用于治疗与性腺功能减退症有关的症状，所述性腺功能减退症在所述个体中由女性雄激素缺乏（ADIF）引起；由老年男性雄激素缺乏（ADAM）（包括疲劳、抑郁、性欲降低、勃起功能障碍、认知下降、情绪下降）引起；由雄激素不足（男性或女性）、雄激素缺乏（男性或女性）引起。

在一个实施方案中，糖尿病肾病是糖尿病的并发症，其进展得很早，通常在做出糖尿病的临床诊断之前。肾病变最早的临床证据是尿中出现低（但异常）水平(>30 mg/天或 20 μg/min)的白蛋白（微量蛋白尿），接着是持续10-15 年的蛋白尿（>300 mg/24 h 或 200 μg/min）。在 1 型糖尿病患者，糖尿病性高血压通常在病人罹患微量蛋白尿之前或直到病人罹患微量蛋白尿时就十分明显。一旦出现明显的肾病变，肾小球滤过率（GFR）在一段时间（可能是几年）内下降，造成糖尿病个体的终末期肾脏疾病（ESRD）。

高血压是肾脏病的另一种共病因素。在一些实施方案中，根据本发明治疗肾脏病可以包括用本发明的化合物和治疗高血压的药剂进行同步治疗。

在一些实施方案中，本发明提供用于治疗个体的消耗性疾病、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统的药、治疗胃肠道系统的药、治疗中枢神经系统的药、治疗代谢病的药、治疗消耗性疾病的

药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。在一些实施方案中，消耗性疾病包括肌损伤、卧床休养、固定、神经损伤、神经病、糖尿病神经病变、酒精性神经病、脊髓亚急性联合变性、糖尿病、类风湿性关节炎、运动神经元疾病、迪谢内肌营养不良、腕管综合征、慢性感染、结核病、艾迪生病、成人脊髓性肌萎缩（sma）、肢体肌萎缩、酒精性神经病、厌食、神经性厌食、与恶病质相关的厌食、与衰老相关的厌食、后纵隔肿瘤（back tumour）、皮肌炎、髋关节癌、包涵体肌炎、色素失调症、肋间神经痛、幼年型类风湿关节炎、累-卡-佩三氏病、肌萎缩、多灶性运动神经病变、肾病综合征、成骨不全、小儿麻痹症后期综合征、肋骨肿瘤、脊髓性肌萎缩、反射性交感神经营养不良综合征或泰-萨克斯病。

在本文中，消耗性病症或障碍定义为至少部分地以体重、器官质量或组织质量的异常的进行性损失为特征的病症或障碍。消耗性病症可以作为疾病例如癌症的结果而发生，或可归因于生理或代谢状态，例如废用性失调，所述废用性失调可以因长期卧床或当四肢被固定（例如在铸型中）时而发生，或因出现多个伤口（包括例如在糖尿病中出现的截肢、和其它病症）而发生，本领域的技术人员会理解这一点。消耗性病症也可以是年龄相关的。在消耗性病症过程中发生的体重减少的特征可以是总体重的减少或器官重量的减少，例如归因于组织蛋白减少的骨量或肌肉量的减少。

在一个实施方案中，术语“肌萎缩（muscle wasting）”或“肌萎缩（muscular wasting）”指肌肉量的进行性损失和/或肌肉的进行性衰减和退化，包括控制运动的骨骼肌或随意肌和控制心脏的心肌和平滑肌。在一个实施方案中，所述肌萎缩病症或障碍是慢性肌萎缩病症或障碍。“慢性肌萎缩”在本文中定义为肌肉量的慢性（即持续很长一段时间的）进行性损失和/或肌肉量的慢性进行性衰减和退化。

肌萎缩过程中发生的肌肉量损失可以是以由于肌肉蛋白分解代谢造成的肌肉蛋白分解或降解为特征。蛋白质分解代谢因为异常高速的蛋白质降解、异常低速的蛋白质合成或这两种的结合而发生。无论是由高度的蛋白质降解还是低度的蛋白质合成引起的肌肉蛋白分解代谢或消耗都会导致肌肉量的减少和肌萎缩。术语“分解代谢”具有本领域中普遍知晓的含义，特别是指能量燃烧形式的新陈代谢。

肌萎缩可以作为病状、疾病、病症或障碍（包括通过本发明的方法治疗的疾病，例如终末期肾功能衰竭）的结果而发生。

在一些实施方案中，本发明提供用于预防抑制素诱导的横纹肌溶解的方法。在一些实施方案中，本发明提供用于预防抑制素诱导的横纹肌溶解、器官衰竭或功能不全的方法。在一些实施方案中，本发明提供用于预防抑制素诱导的肾功能衰竭或肝功能衰竭或不全的方法。在一个实施方案中，所述方法包括向个体给药包含本发明的化合物和抑制素的组合物。

在一个实施方案中，所述消耗性疾病是个体的恶病质或非意愿体重减轻。在另一个实施方案中，本发明提供用于治疗、预防、抑制、减少或压制罹患肾脏病的个体的肌萎缩的方法。在另一个实施方案中，本发明提供用于治疗、预防、抑制、减少或压制罹患肾脏疾病或病症的个体的蛋白质分解代谢的方法。

恶病质是由疾病引起的或作为疾病副反应的虚弱和体重减少。由于疾病或损伤而长期住院或例如当肢体被固定时发生的废用性失调也能导致肌萎缩。研究显示，长期住院的罹患损伤、慢性病、烧伤、创伤或癌症的患者中，出现长期单侧肌萎缩和由此引起的体重减少。神经系统损伤，例如本文进一步叙述的脊髓损伤，也可能是致病因素。

在一些实施方案中，本发明提供用于治疗个体的消耗性疾病或病症、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在另一个实施方案中，所述消耗性疾病和病症尤其包括：a) 获得性免疫缺陷综合征（AIDS）消耗；b) 与卧床休息有关的消耗；c) 贪食症和/或与贪食症有关的消耗；d) 恶病质；e) 癌症恶病质；f) HIV 消耗；g) 由以下因素引起的减轻体重的恶病质和蛋白质损失：长期的危重病、肺功能障碍、呼吸机依赖、衰老、AIDS、创伤、充血性心脏衰竭、心肌病、烧伤、癌症、慢性阻塞性肺疾病（COPD）、进食障碍例如贪食病、神经性厌食、食欲缺乏、饥饿和/或抑郁。

在一些实施方案中，本发明提供用于治疗个体的无效状态、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述无效状态是小儿麻痹症后期综合征。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和免疫调节

剂、抗糖尿病药、治疗心血管系统的药、治疗胃肠道系统的药、治疗中枢神经系统的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、维生素或它们的组合。

在一些实施方案中，本发明用本发明的化合物提供辅助治疗。例如，在一个实施方案中，在疾病、障碍或病症的治疗（其中使用锻炼和限制饮食）中，给药本发明的化合物包括在这种治疗方案中。例如，在一个实施方案中，如本领域的技术人员将认识的，用本发明的化合物进行的辅助疗法或治疗，结合限制饮食和/或锻炼的，可能是用于治疗胰岛素抵抗、葡萄糖耐受不良、体重减轻、糖尿病、心血管疾病、代谢综合征、癌症、肌萎缩等的疗法。

在一些实施方案中，本发明提供用于治疗个体的性腺功能减退状态、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，本发明提供用于治疗个体的药物治疗诱导的性腺功能减退状态、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一些实施方案中，性腺功能减退症是由治疗引起的，所述治疗改变激素自女性和男性性腺的分泌。在一些实施方案中，性腺功能减退症可能是“原发性的”或“中枢性的”。在原发性性腺功能减退症症中，卵巢或睾丸本身不正常地发挥作用。在一些实施方案中，性腺功能减退症可能是由外科手术、辐射、遗传性病症和发育障碍、肝病和肾病、感染或某些自免疫疾病诱导的。在一些实施方案中，绝经是性腺功能减退症的形式。在一些实施方案中，绝经可能导致闭经、热潮红、阴道干燥或归因于女性雌激素水平下降的易激惹。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统的药、治疗胃肠系统的药、治疗中枢神经系统的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、治疗皮肤病症的药、抗感染药、治疗肝脏的药、治疗肾脏的药、维生素或它们的组合。

在一些实施方案中，本发明提供用于治疗个体的骨质减少状态、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，本发明提供用于治疗个体的药物治疗诱导的骨质减少状态、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一些实施方案中，骨质减少是骨量的轻微减少。在一些实施方案中，骨质

减少是骨质疏松症的前兆。在一些实施方案中，骨质减少定义为比正常年青成人的骨密度低 1-2.5 个标准偏差（SD）的骨密度。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统的药、治疗胃肠系统的药、治疗中枢神经系统的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、治疗皮肤病症的药、抗感染药、治疗肝脏的药、治疗肾脏的药、维生素或它们的组合。

在一些实施方案中，本发明提供用于治疗个体的少肌状态、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，本发明提供用于治疗个体的药物治疗诱导的少肌状态、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一些实施方案中少肌症是严重的肌肉量减少。在一个实施方案中，少肌症的定义是具有比低于正常年青成人的平均值 2 个标准偏差更低的瘦体重。在一些实施方案中，少肌症由以下原因引起：遗传因素、循环系统改变、毛细管:肌纤维比率降低、运动神经元改变、去神经支配、运动神经末梢板衰退、I 型纤维选择性神经移植术、造成肌肉损害的炎症应答、运动减少、营养不良、低膳食蛋白摄入量、维生素 D 缺乏、年龄相关的维生素 D 减少、氧化性应激、肌肉线粒体突变、特定类型肌纤维的改变、肌肉蛋白减少、致残疾病、卒中、阿尔茨海默氏病、帕金森病、骨质疏松症、动脉粥样硬化、糖尿病、高胰岛素血症、肾功能衰竭或性腺功能减退症。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含 SARM 化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统的药、治疗胃肠系统的药、治疗中枢神经系统的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、治疗皮肤病症的药、抗感染药、治疗肝脏的药、治疗肾脏的药、维生素或它们的组合。

在一些实施方案中，本发明提供用于治疗个体的如上文所述的疾病和/或病症的组合、降低其发病率、延缓其发作或进展、或减轻和/或消除与其相关的症状的方法。在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统的药、治疗胃肠系统的药、治疗中枢神经系统的药、治疗代谢病的

药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、治疗皮肤病症的药、抗感染药、治疗肝脏的药、治疗肾脏的药、维生素或它们的组合。

应该理解，如本文所述的本发明的任何方法都包括向个体给药本文所述的化合物或包含它的组合物，以治疗所指的疾病、障碍或病症。每一种本文所述的方法和/或其全部还可能包括给药本文所述的其它治疗剂，本领域的技术人员会理解这一点。

在一些实施方案中，本发明提供用于促进例如乳、精子或卵细胞的产生的方法。在一些实施方案中，本发明提供用于促进瘦肉或卵细胞的产生的方法。在一些实施方案中，本发明提供用于提高饲喂或配种牲畜的生产力的方法，例如增加精子计数、改善精子形态等。在一些实施方案中，本发明提供用于延长农场动物（例如产蛋母鸡、产奶奶牛等）的生产期和/或提高兽群健康（例如改善免疫清除、强壮动物）的方法。

在一个实施方案中，所述方法包括向个体给药组合物，所述组合物包含本发明的化合物和抗癌药、免疫调节剂、抗糖尿病药、治疗心血管系统的药、治疗胃肠系统的药、治疗中枢神经系统的药、治疗代谢病的药、治疗消耗性疾病的药、基因治疗剂、治疗内分泌系统的药、治疗皮肤病症的药、抗感染药、治疗肝脏的药、治疗肾脏的药、维生素、营养添加剂、激素（每一种和/或全部均如本文所述）、或如本文所述的任何其它治疗剂、或它们的组合。

在另一个实施方案中，本发明提供用于治疗个体的以下疾病的方法：囊性纤维化病及由其引起的诱导性性腺功能减退状态、癫痫及由其引起的诱导性性腺功能减退状和/或代谢亢进状态、遗传性血管性水肿、红斑狼疮及由其引起的 BMD 下降、饮酒和抽烟诱导的骨质疏松症，所述方法包括向所述个体给药本文所述的 SARM。

在另一个实施方案中，本发明提供用于治疗个体的以下疾病的方法：小儿麻痹症和小儿麻痹后综合征及其它无效状态、抑制素诱导的横纹肌溶解症、抑制素诱导的肌无力、抑制素诱导的器官衰竭或功能不全，所述方法包括给药本文所述的化合物和任选适当的抑制素（本本领域的技术人员会理解这一点），和/或任何治疗剂。

在另一个实施方案中，本发明提供用于治疗阿片样物质诱导的雄激素缺乏（OPIAD）的方法，所述方法包括向个体给药本文所述的化合物和任选地

阿片剂、阿片样物质、麻醉药等、美沙酮、长效阿片剂/阿片样物质例如 Kadian、缓释吗啡（所有阿片剂/阿片样物质/麻醉药均获得 FDA 批准）、用于治疗海洛因成瘾的阿片剂/阿片样物质、用于治疗恶性肿瘤慢性疼痛的阿片剂/阿片样物质、用于治疗非恶性肿瘤的慢性疼痛综合征的阿片剂/阿片样物质。

在另一个实施方案中，本发明提供用于治疗神经系统疾病、障碍或病症的方法，所述方法包括向所述个体给药本文所述的化合物和任选的抗精神病药（例如佐替平、氟哌啶醇、氨磺必利、利培酮、其它多巴胺 D2 受体拮抗剂）、抗癫痫病药物（例如丙戊酸、卡马西平、奥卡西平（oxcarbamazepine）等）或它们的组合物。

在另一个实施方案中，本发明提供用于治疗激素依赖性疾病、障碍或病症的方法，所述方法包括向所述个体给药本文所述的化合物和任选地化疗剂和治疗（甲氨蝶呤、环磷酰胺、异环磷酰胺、阿霉素、多柔比星、糖皮质激素、环孢菌素、L-甲状腺素、SERM、抗炎药、氟维司群、GnRH 剂、ADT、中止激素替代疗法、颅脑照射、周边照射（peripheral irradiation）等；诱导高催乳素血症（prolactinemia）的药物治疗（通过 5HT2 受体作用的血清素能性的抗抑郁剂、选择性血清素再摄取抑制剂、单胺氧化酶抑制剂、三环抗抑郁剂、抗高血压药例如甲基多巴、利血平、可乐定和维拉帕米；抗多巴胺能的止吐药例如甲氧氯普胺，H2 受体拮抗剂例如西咪替丁和雷尼替丁，雌激素，苯丙胺，AR 部分拮抗剂（酮康唑、螺内酯、依普利酮）

在另一个实施方案中，如本文所述的本发明的化合物和组合物用于促进或加速手术操作后恢复。

在一个实施方案中，本发明提供本文所述的化合物用于减少个体的脂肪量的用途。在另一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合或者含有它们的组合物的这种使用方法。

在另一个实施方案中，本发明提供本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合或者含有它们的组合物的以下用途：治疗腹部脂肪累积；治疗肥胖性少肌症；改善身体成分；减少体脂含

量；减少脂肪量；改善血脂谱（profile），增加肌肉量/肌肉强度/肌肉功能；增加骨量/BMD/骨强度/骨功能；减少体脂；先天性高胰岛素血症；库欣病（高皮质醇血症（hypercortisolemia））；个体的与代谢综合征相关的肥胖症或糖尿病。

在另一个实施方案中，所述个体患有激素失调、激素病症或激素疾病。在另一个实施方案中，所述个体处于绝经。

在一个实施方案中，本发明提供本文所述的化合物用于增加个体的瘦体重的用途。在另一个实施方案中，这种用途包括给药本文所述的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合。

在一个实施方案中，所述个体患有激素失调、激素病症或激素疾病。在另一个实施方案中，所述个体处于绝经。

实施例 15 显示，式(I)的化合物是合成代谢性的，但是其雄激素性最低，因此，这种化合物可以用于治疗过去雄激素是禁忌的患者群。无论睾酮是否存在，式(I)的化合物都显示促进肌肉生长，同时对前列腺施加抗增殖作用，因此，在一个实施方案中，本发明的方法用于恢复患有少肌症或恶病质的个体损失的肌肉量。

在一个实施方案中，本文所述的化合物改变个体的瘦素水平。在另一个实施方案中，本文所述的化合物降低瘦素的水平。在另一个实施方案中，本文所述的化合物增加个体的瘦素水平。已知瘦素对肥胖症小鼠的食欲、体重减轻有影响，因此其已与肥胖症有关。

在一个实施方案中，本文所述的化合物影响瘦素的循环水平，在另一个实施方案中，影响瘦素的组织水平。在一个实施方案中，术语“瘦素的水平”指瘦素的血清水平。如本文所指的，本发明的化合物对体外和体内的瘦素有影响。瘦素的水平可以用本领域的技术人员已知的方法来测定，例如通过可商购的 ELISA 试剂盒来测定。而且，可以通过本领域技术人员已知的任何方法在体外测定或体内测定中测定瘦素的水平。

由于瘦素与控制食欲、减轻体重、摄取食物和能量消耗有关，所以，调节和/或控制瘦素的水平是治疗、预防、抑制罹患肥胖症个体的肥胖症、降低其发病率的有用的治疗方法。调节瘦素的水平可以导致缺乏食欲、减少食物

摄取、增加瘦素个体的能量消耗，因此，可能有利于控制和治疗肥胖症。

在一个实施方案中，术语"肥胖症"定义为由脂肪在身体内过度累积导致体重增加超过骨骼的限制和身体的需要

在一个实施方案中，术语"肥胖症相关的代谢失调"指由肥胖症引起的、作为肥胖症的后果的、因肥胖症而加重的或继发于肥胖症的病症。这种病症的非限制性的例子是骨关节炎、II 型糖尿病、血压增加、卒中和心脏病。

胆固醇、甘油三脂和其它脂质通过脂蛋白在体液中运输，所述脂蛋白可以根据它们的密度划分为例如极低密度脂蛋白（VLDL）、中密度脂蛋白（IDL）、低密度脂蛋白（LDL）和高密度脂蛋白（HDL）。

已显示，LDL-胆固醇在血液中的高水平与动脉粥样硬化有关，动脉粥样硬化是部分地以脂质在动脉特别是冠状动脉的内壁中沉积为特征的进行性疾病。而且已经显示，也 LDL-胆固醇的高血液水平与冠心病有关。而且，HDL 胆固醇的血液水平与冠心病之间存在负相关。

血液中的总胆固醇水平（其为 HDL-胆固醇、LDL-胆固醇、VLDL-胆固醇和乳糜微粒-胆固醇的总和）不一定是冠心病和动脉粥样硬化风险的预兆。

但是，动脉粥样硬化和 LDL 胆固醇水平之间的关联比动脉粥样硬化和总血清胆固醇水平之间的类似关联高得多。

在一个实施方案中，本发明提供将本文所述的化合物用于改善个体的脂质谱和/或减少循环脂质水平的使用方法。在一些实施方案中，根据本发明的这一方面，所述个体罹患选自以下的一种或多种病症：动脉粥样硬化症及其相关疾病、过早衰老、阿尔茨海默氏病、卒中、中毒性肝炎、病毒性肝炎、周围血管功能不全、肾病和高血糖症，而且本发明用于给药本文所述的化合物或含有它的组合物，在一些实施方案中，所述化合物或组合物积极地影响所述个体的脂质谱，这是所述方法用于治疗所指的疾病、障碍和病症的一种手段。

在一个实施方案中，本发明提供治疗动脉硬化症及其相关疾病，例如心血管病症、脑血管障碍、周围血管病症、肠血管病症或它们的组合。

在一个实施方案中，心血管病症包括高血压（HTN）、冠脉疾病（CAD）或心肌灌注。在另一个实施方案中，本发明提供本文所述的 SARM 化合物用于促进主动脉平滑肌细胞增殖的使用方法。在另一个实施方案中，本发明提

供本文所述的化合物用于治疗动脉粥样硬化的使用方法。在另一个实施方案中，本发明提供本文所述的化合物用于降低血压的使用方法。在另一个实施方案中，本发明提供本文所述的化合物用于治疗心脏疾病和病症（包括心肌病、心功能不全例如心肌梗死、心脏肥大和充血性心力衰竭（cognitive heart failure））的使用方法。在另一个实施方案中，本发明提供本文所述的化合物用于保护心脏（包括在胰岛素抵抗中的保护心脏）的使用方；治疗 I 型和 II 型糖尿病、代谢综合征、X 综合征和/或高血压的使用方法。

在一个实施方案中，本发明提供用于治疗、预防个体的心血管和/或脑血管疾病、降低其死亡风险的方法，所述方法包括给药式(I)的化合物或其前药、类似物、异构体、代谢产物、衍生物、药学上可接受的盐、药品、多晶型物、晶体、不纯物、*N*-氧化物、水合物或它们的任意组合、或者含有它们的药物组合物。在一个实施方案中，所述化合物以式(I) 的结构为特征。

在一个实施方案中，式 I 的化合物降低 LDL 和总胆固醇的水平。在另一个实施方案中，式(I)的化合物降低个体的 LDL 和总胆固醇的水平。

在另一个实施方案中，式 I 的化合物与升高 HDL 的药剂联合给药。在另一个实施方案中，式(I)的化合物与升高 HDL 的药剂联合给药。在另一个实施方案中，升高 HDL 的药剂包括烟酸。在另一个实施方案中，所述升高 HDL 的药剂包括贝特类，所述贝特类包括吉非贝齐（Lopid）、硫脲系吉非贝齐类似物和非诺贝特（TriCor）。在另一个实施方案中，升高 HDL 的药剂包括他汀类药物。在另一个实施方案中，升高 HDL 的药剂包括 1-羟基烷基-3-苯硫脲及其类似物。

在一个实施方案中，本发明提供用于降低个体的循环脂质水平的方法，所述方法包括给药式 I 的化合物或其药学上可接受的盐、水合物、*N*-氧化物或它们的任意组合、或者含有它们的组合物。在一个实施方案中，所述个体罹患动脉粥样硬化及其相关疾病、过早衰老、阿尔茨海默氏病、卒中、中毒性肝炎、病毒性肝炎、周围血管功能不全、肾病、高血糖或它们的任意组合。

在一个实施方案中，本发明提供用于治疗个体的动脉粥样硬化及其相关疾病（例如心血管病症、脑血管障碍、周围血管病症或肠血管病症）的方法，所述方法包括向所述个体给药式 I 的化合物或其药学上可接受的盐、水合物、*N*-氧化物或它们的任意组合、或者含有它们的组合物的步骤。所述方法还可

以包括同时、随后或在先给药已知可用于治疗心血管疾病、脑血管障碍、周围血管病症或肠血管病症的一种或多种药剂。

在一个实施方案中，本发明提供改善个体的灵活性和运动的方法，例如通过治疗所述个体的关节炎。

在另一个实施方案中，术语"关节炎"指主要发生在老年人中的非炎性退行性关节病，它以关节软骨变性、骨头及边缘肥大、滑膜改变等为特征。在另一个实施方案中，它还伴有疼痛和僵硬，特别是在长期活动之后。

在一个实施方案中，术语"糖尿病"指胰岛素的相对或绝对缺乏，导致不受控制的糖代谢。大多数患者在临床上可被划分为患胰岛素依赖型糖尿病（IDDM 或 I 型糖尿病）或非胰岛素依赖型糖尿病（NIDDM 或 II 型糖尿病）。

在其它实施方案中，术语"血压增加"或"高血压"指在超过 90/140 mmHg 的重复性高血压。慢性高血压可以造成眼底血管改变、心肌增厚、肾功能衰竭和脑损害。

在其它实施方案中，术语"卒中"指由于供血不足引起脑神经细胞损害，所述供血不足经常由血管破裂或血凝块造成。在其它实施方案中，术语"心脏病"指心脏正常功能和活动发生障碍，包括心力衰竭。

而且，最近显示，雄激素涉及多能间质细胞定型为肌源性谱系并阻止分化为成脂谱系（Singh 等人, Endocrinology, 2003，7 月 24 日）。因此，所述化合物可用于本文所述的阻止脂肪生成和/或改变干细胞分化的方法。

在另一个实施方案中，本发明涉及加速、增加或促进个体减轻体重的方法，所述方法包括向所述个体给药有效加速、增加或促进所述个体减轻体重的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体、或它们的任意组合的步骤。

在另一个实施方案中，本发明涉及降低、压制、抑制或减少个体的食欲的方法，所述方法包括向所述个体给药有效降低、压制、抑制或减少所述个体的食欲的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体、或它们的任意组合的步骤。

在另一个实施方案中，本发明涉及改变个体的身体成分的方法，所述方

法包括向所述个体给药有效改变所述个体的身体成分的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体、或它们的任意组合的步骤。在一个实施方案中，改变所述身体成分包括改变所述个体的瘦体重、去脂体重或它们的组合。

在另一个实施方案中，本发明涉及改变个体的瘦体重或去脂体重的方法，所述方法包括向所述个体给药有效改变所述个体的瘦体重或去肪体重的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体、或它们的任意组合的步骤。

在另一个实施方案中，本发明涉及将个体的脂肪转化为瘦肌肉的方法，所述方法包括向所述个体给药有效将所述个体的脂肪转化为瘦肌肉的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体、或它们的任意组合的步骤。

在另一个实施方案中，本发明涉及治疗个体的肥胖症相关的代谢失调的方法，所述方法包括向所述个体给药有效治疗所述个体的肥胖症相关的代谢失调的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体、或它们的任意组合的步骤。

在另一个实施方案中，本发明涉及预防、压制、抑制或减轻个体的肥胖症相关的代谢失调的方法，所述方法包括向所述个体给药有效预防、压制、抑制或减轻个体的肥胖症相关的代谢失调的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体或它们的任意组合的步骤。

在一个实施方案中，所述肥胖症相关的代谢失调是高血压。在另一个实施方案中，所述病症是骨关节炎。在另一个实施方案中，所述病症是II型糖尿病。在另一个实施方案中，所述病症是血压增加。在另一个实施方案中，所述病症是卒中。在另一个实施方案中，所述病症是心脏病。

在另一个实施方案中，本发明涉及降低、压制、抑制或减少个体脂肪形

成的方法，所述方法包括向所述个体给药本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体、或它们的任意组合的步骤。

在另一个实施方案中，本发明涉及改变个体的干细胞分化的方法，所述方法包括向所述个体给药有效改变所述个体的干细胞分化的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体、或它们的任意组合的步骤。

在一个实施方案中，本文所述的化合物用于：a) 治疗、预防、压制、抑制或减轻肥胖症；b) 加速、增加或促进减轻体重；c) 降低、压制、抑制或减少食欲；d) 改变身体成分；e) 改变瘦体重或去脂体重；f) 将脂肪转化为瘦肌肉；g) 治疗、预防、压制、抑制或减轻肥胖症相关的代谢失调，例如高血压、骨关节炎、糖尿病、青春晚期糖尿病（MODY）、血压增加、卒中或心脏病；h) 降低、压制、抑制或减少脂肪形成；i) 改变干细胞分化；和/或j) 改变瘦素水平。

在一个实施方案中，本文所述的化合物用于治疗或中止糖尿病的进展或治疗糖尿病症状。在另一个实施方案中，本文所述的化合物用于治疗与糖尿病相关的并发症。这些病症包括：高血压（HNT）、脑血管病、冠状动脉粥样硬化性心脏病、黄斑变性、糖尿病视网膜病（眼病）和失明、白内障一全身性炎症（以炎症指标例如红细胞沉降率或C反应蛋白的增加为特征）、出生缺陷、与妊娠有关的糖尿病、先兆子痫和妊娠高血压、肾病（肾功能不全、肾功能衰竭等）、神经疾病（糖尿病神经病变）、浅表和全身性真菌感染、充血性心力衰竭、痛风/高尿酸血症、肥胖症、高甘油三酯血症、高胆固醇血症、脂肪肝症（非酒精性脂肪性肝炎或NASH）、以及糖尿病相关的皮肤病例如糖尿病脂性渐进环死（NLD）、糖尿病大水疱（糖尿病性大疱症）、发疹性黄瘤、Digital Sclerosis、播散性环状肉芽肿和黑棘皮病。

在一个实施方案中，本发明提供治疗、压制、抑制以下人类个体的疾病、或降低其发病率的方法：(a) I型糖尿病；(b) II型糖尿病；(c) 葡萄糖耐受不良；(d) 高胰岛素血症；(e) 胰岛素抵抗；(f) 肾病；(g) 糖尿病神经病变；(h) 糖尿病视网膜病；(i) 脂肪肝症；(j) MODY 和(k) 心血管疾病，所述方法包

括向所述个体给药式(I)的化合物的步骤。

在一些实施方案中，本文所述的化合物和/或包含它们的组合物可以用于与患糖尿病的个体相关的疾病或病症的应用或治疗。在一个实施方案中，寻求通过本发明的方法治疗的个体是患有 I 型糖尿病的个体。I 型糖尿病以胰腺 β 细胞的自身免疫破坏为特征。90%的个体在诊断时出现所述 β 细胞的免疫破坏标志，所述标志包括胰岛细胞（ICA）抗体、谷氨酸脱羧酶（GAD）抗体和胰岛素(IAA)抗体。尽管这种形式的糖尿病通常发生于儿童和青少年中，但是它可以发生于任何年龄。年轻个体的通常具有快速的 β 细胞破坏并与同时存在酮症酸中毒，而成年人经常保持充足的胰岛素分泌以防止酮症酸中毒达许多年。最终，所有 I 型糖尿患者需要胰岛素疗法以保持血糖量正常。

在一个实施方案中，本发明提供治疗 II 型糖尿病的方法。II 型糖尿病以胰岛素抵抗为特征，而且在该疾病发病的某个阶段以胰岛素分泌相对不足为特征。血浆胰岛素浓度（禁食和膳食刺激的）的绝对值通常增加，但是“相对于”胰岛素抵抗的严重性，血浆胰岛素浓度不足以维持正常的葡萄糖稳态。然而，随着时间推移，出现进行性 β 细胞衰竭，接着发生胰岛素绝对值不足。大多数患有 II 型糖尿病的个体表现出腹内性（内脏性）肥胖症、与胰岛素抵抗的存在密切相关的脂肪肝。所述患者的肝脏变成胰岛素抵抗性，糖原分解不受控制，结果是增加的、非生理性的葡萄糖被输送至血液中。肝脏产生的胆固醇和 VLDL 颗粒也不受控制。而且，这些个体通常存在高血压、血脂异常（高甘油三酯水平和低 HDL-胆固醇水平；餐后高脂血症）和 PAI-1 水平升高。这一连串异常被称为“胰岛素抵抗综合征”或“代谢综合征”或肥胖症相关的病症。由于这些异常，II 型糖尿病的患者罹患大血管并发症例如心肌梗死和卒中的风险增大。

在一个实施方案中，本发明提供治疗糖尿病肾病的方法。糖尿病肾病是糖尿病的并发症，其进展得很早，通常在做出糖尿病的临床诊断之前。肾病变最早的临床证据是尿中出现低（但异常）水平（>30 mg/天或 20 μg/min）的白蛋白（微量蛋白尿），接着是持续 10-15 年的蛋白尿（>300 mg/24 h 或 200 μg/min）。在 1 型糖尿病患者，糖尿病性高血压通常在病人罹患微量蛋白尿之前或直到病人罹患微量蛋白尿时就十分明显。一旦出现明显的

肾病变，肾小球滤过率（GFR）在一段时间（可能是几年）内下降，造成糖尿病个体的终末期肾脏疾病（ESRD）。

在一个实施方案中，本发明提供治疗糖尿病神经病变的方法。糖尿病神经病变是由糖尿病引起的神经病症家族。糖尿病神经病变造成手、臂、足和腿麻木，有时造成它们疼痛和无力。糖尿病中的神经病学问题可能发生于每一个器官系统，包括消化道、心脏和生殖器。糖尿病神经病变划分为周围神经病变、自主神经病变、近端神经病变的和局灶性神经病变。周围神经病变造成趾、足、腿、手和臂的疼痛或感觉缺失。自主性神经病变造成消化、肠和膀胱功能、性反应和出汗的变化，也可影响服务心脏和控制血压的神经。近端神经病变造成股、髋或臀疼痛并导致腿无力。局灶性神经病变导致一条神经或一组神经的突然衰弱，造成肌无力或肌痛。身体内的任何神经都可能受影响。

在一个实施方案中，本发明提供治疗糖尿病视网膜病的方法。糖尿病对眼的影响称为糖尿病视网膜病。糖尿病患者更可能罹患眼疾，例如白内障和青光眼。糖尿病视网膜病对视觉的影响变化很广，取决于该疾病的阶段。糖尿病视网膜病的一些共有症状是视力模糊（这经常与血糖水平有关）、漂浮物（floaters）和闪烁（flashes）以及视力突然丧失。

在一个实施方案中，寻求通过本发明的方法治疗的个体是患有葡萄糖耐受不良的个体。葡萄糖耐受不良是糖尿病前期，其中，血糖高于正常水平，但没有高到确保诊断为糖尿病。

在一个实施方案中，寻求通过本发明的方法治疗的个体是患有高胰岛素血症的个体。高胰岛素血症是导致胰腺分泌过量胰岛素的潜在问题的征兆。高胰岛素血症的最普遍的原因是胰岛素抵抗，在这种病症中，你的身体对抗胰岛素的效应，而胰腺试图通过产生更多胰岛素来补偿。高胰岛素血症与II性糖尿病有关。

在一个实施方案中，寻求通过本发明的方法治疗的个体是患有胰岛素抵抗的个体。胰岛素抵抗是其中正常量的胰岛素不足以使脂肪细胞、肌细胞和肝细胞产生正常的胰岛素反应的病症。脂肪细胞中的胰岛素抵抗造成储存的甘油三酯水解，这提高血浆中游离脂肪酸的水平。肌肉中的胰岛素抵抗减少葡萄糖的摄入，而肝脏中的胰岛素抵抗减少葡萄糖储存，这两种效应帮助提

高血糖。归因于胰岛素抵抗的高水平的血浆胰岛素是葡萄糖经常导致代谢综合征和 II 型糖尿病。

糖尿病和肝肥胖症一般与游离脂肪酸（FFA）水平升高有关，游离脂肪酸促进靶组织中的脂质蓄积和胰岛素抵抗，即主要减弱胰岛素在骨骼肌和肝脏中的作用。胰岛素的突出作用是减少自肝脏的葡萄糖输出。FFA 刺激肝脏糖异生，只要糖异生与肝糖原分解降低平行进行（被称为"肝自身调节"的补偿过程），糖异生本身不会导致肝脏葡萄糖输出增加。FFA 刺激胰岛素分泌，而胰岛素通过抑制胰高血糖素（糖原分解的诱导物）的分泌部分地阻止糖原分解。然而，长期高水平的 FFA 导致肝脏胰岛素抵抗，并因此破坏肝自身调节，导致肝葡萄糖产生增加和罹患 II 型糖尿病。脂肪肝和肝脏胰岛素抵抗是高血糖和 II 型糖尿病的主要驱动力。

在一个实施方案中，本发明提供抑制（改善）脂肪肝的方法，所述方法肝中的胰岛素抵抗被抑制（改善），由此解决 II 型胰岛素的基本问题。

在另一个实施方案中，所述糖尿病是 I 型糖尿病。在另一个实施方案中，所述糖尿病是 II 型糖尿病。

在一个实施方案中，本发明提供治疗、压制、抑制人类个体的糖尿病、降低其发病率的方法，所述方法包括向所述个体给药式 I 的化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在另一个实施方案中，所述糖尿病是 I 型糖尿病。在另一个实施方案中，所述糖尿病是 II 型糖尿病。

在一个实施方案中，本发明提供治疗患有葡萄糖耐受不良的人类个体的方法，所述方法包括向所述个体给药式 I 的化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的高胰岛素血症的方法，所述方法包括向所述个体给药式 I 的化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的胰岛素抵抗的方法，所述方法包括向所述个体给药式 I 的化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的糖尿病肾病的方法，所

述方法包括向所述个体给药式 I 的选择性雄激素受体调节剂化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的糖尿病神经病变的方法，所述方法包括向所述个体给药式 I 的化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的糖尿病视网膜病的方法，所述方法包括向所述个体给药式 I 的化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的脂肪肝症的方法，所述方法包括所述个体给药式 I 的选择性雄激素受体调节剂化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在一个实施方案中，本发明提供治疗人类个体的血管疾病的方法，所述方法包括向所述个体给药式 I 的化合物或其异构体、药学上可接受的盐、药品、水合物、*N*-氧化物或它们的任意组合的步骤。

在一个实施方案中，本发明提供用于 a) 治疗、预防、压制、抑制动脉粥样硬化，b) 治疗、预防、压制、抑制归因于脂肪沉积的肝损害的方法，所述方法包括向所述个体给药有效治疗、预防或抑制动脉粥样硬化和归因于脂肪沉积的肝损害的量的本文所述的化合物和/或其类似物、衍生物、异构体、代谢产物、药学上可接受的盐、药品、水合物、*N*-氧化物、前药、多晶型物、晶体或它们的任意组合、或者含有它们的组合物的步骤。

在一个实施方案中，本文所述的化合物用于：a) 治疗、预防、压制、抑制或减轻动脉粥样硬化；b) 治疗、预防、压制、抑制归因于脂肪沉积的肝损害。

在一个实施方案中，动脉粥样硬化指可能从损害动脉最内层开始的慢性复杂疾病。在另一个实施方案中，损害动脉壁的原因可能包括：a) 血液胆固醇水平提高；b) 高血压；c) 烟草烟雾；d) 糖尿病。在另一个实施方案中，吸烟者的这一病症是可治疗的，尽管烟草烟雾可能会使动脉粥样硬化严重恶化并加速其在冠状动脉、大动脉和腿部动脉中的发展。类似地，在另一个实施方案中，本发明的方法可以用于治疗具有早年心血管疾病家族史的个体（其患动脉粥样硬化的风险增加）。

在一个实施方案中，归因于脂肪沉积的肝损害指脂肪在肝细胞中累积形成脂肪肝，脂肪肝可能与肝脏的炎症有关或可能导致肝脏炎症。这可以导致肝的瘢痕形成和硬化。当结瘢痕形成变为广泛性时，其称为肝硬化。

在另一个实施方案中，脂肪在肝脏中蓄积成为肥胖症。在另一个实施方案中，脂肪肝也与糖尿病、高血甘油三酯和大量饮酒有关。在另一个实施方案中，脂肪肝可能伴随某些疾病例如结核病和营养不良、治疗肥胖症的肠分流术、体内维生素 A 过量或使用某些药物比如丙戊酸（商品名：Depakene/Depakote）和皮质类固醇（可的松、泼尼松）而发生。有时脂肪肝作为妊娠并发症发生。

在一个实施方案中，患有肾病的个体，特别是患有终末期肾脏疾病（ESRD）的男性个体罹患性腺功能减退症，其中一些患有伴发的中度至重度的蛋白质-能量营养不良（PEM），其造成更高的促红细胞生成素（EPO）需要量，更低的 QOL 分数和更高的死亡率。许多人具有与性腺功能减退症有关的其它症状，包括疲劳、缺乏食欲、肌无力等。在一些实施方案中，本发明的治疗方法用于治疗与由所述个体的肾脏疾病或病症引起的性腺功能减退症有关的症状。

在一个实施方案中，糖尿病肾病是糖尿病的并发症，其进展得很早，通常在做出糖尿病的临床诊断之前。肾病变最早的临床证据是尿中出现低（但异常）水平（>30 mg/天或 20 μg/min）的白蛋白（微量蛋白尿），接着是持续 10-15 年的蛋白尿（>300 mg/24 h 或 200 μg/min）。在 1 型糖尿病个体，糖尿病性高血压通常在病人罹患微量蛋白尿之前或直到病人罹患微量蛋白尿时就十分明显。一旦出现明显的肾病变，肾小球滤过率（GFR）在一段时间（可能是几年）内下降，造成糖尿病个体的终末期肾脏疾病（ESRD）。

高血压是肾脏病的另一种共病因素。在一些实施方案中，根据本发明治疗肾脏病可以包括用本发明的化合物和治疗高血压的药剂进行同步治疗。

可以用本文所述的化合物和/或组合物，包括本发明的方法治疗的雄激素依赖性病症包括与衰老相关的病症。在一个实施方案中，本文所述的化合物用于：a) 年龄相关的功能下降（ARFD）；b) 逆转或预防 ARFD；c) 逆转或预防老年人 ARFD；d) 逆转或预防 ARFD 引发的少肌症或骨质减少；e) 男性更年期、男性更年期血管舒缩综合征；f) 男性更年期乳腺发育、肌肉强度

/功能；g) 骨强度/功能；h) 愤怒；i) 无力；j) 慢性疲劳综合征；k) 认知损害；和/或 l) 改善认知功能。

在一个实施方案中，本文所述的化合物用于治疗炎症和相关病症，例如：a) 预防、治疗或逆转关节炎；b) 预防、治疗或逆转关节炎性病症，例如贝切特氏病(自动免疫性血管炎)、滑囊炎、二羟焦磷酸钙晶体沉积症(或假性痛风) (CPPD)、腕管综合征、结缔组织病症、克罗恩病、埃-当二氏综合征(EDS)，纤维肌痛、痛风、感染性关节炎、炎症性肠病(IBD)、少年关节炎，系统性红斑狼疮(SLE)、莱姆病、马方综合征、肌炎、骨关节炎、结节性多动脉炎、风湿性多肌痛、银屑病、银屑病关节炎、雷诺现象、反射性交感神经营养不良综合征、莱特综合征、类风湿性关节炎、硬皮病、干燥综合征、肌腱炎或溃疡性结肠炎；c) 预防、治疗或逆转自身免疫性疾病。

在一个实施方案中，本文所述的化合物用于预防医源性作用，包括急性疲劳综合征（手术后）或雄激素剥夺治疗（ADT）诱导的副反应，例如肌肉量减少、肌肉强度降低、脆弱、性腺功能减退症、骨质疏松症、骨质减少、BMD 降低和/或骨量减少。

在一个实施方案中，所述化合物和/或组合物和/或它们的使用方法用于治疗人类个体，其中，在一个实施方案中，所述个体是男性，或在另一个实施方案中，所述个体是女性。

在一个实施方案中，本发明的方法包括给药作为唯一活性成分的本发明的化合物。然而，用于以下的方法也包含在本发明的范围内：糖尿病和相关病症、激素疗法、干眼病、肥胖症、治疗前列腺癌、延缓前列腺的进展、以及预防和/或治疗前列腺癌的复发、男性避孕；治疗骨质疏松症、治疗与 AIDF 相关的病症以及治疗和/或预防慢性肌萎缩，所述方法包括联合一种或多种治疗剂给药所述化合物。这些药剂包括但不局限于：LHRH 类似物、可逆的抗雄激素、抗雌激素药、抗肿瘤药、5-α 还原酶抑制剂、芳香酶抑制剂、孕激素、通过其它细胞核激素受体作用的药剂、选择性雌激素受体调节剂（SERM）、孕激素、雌激素、PDE5 抑制剂、阿扑吗啡、二碳磷酸盐化合物和一种或多种其它的 SARM。

因此，在一个实施方案中，本发明的方法包括联合糖尿病药物（例如曲格列酮、罗格列酮和吡格列酮）给药本发明的化合物。在另一个实施方案中，

本发明的方法包括联合 LHRH 类似物给药所述的化合物。在另一个实施方案中，本发明的方法包括联合可逆的抗雄激素给药所述的化合物。在另一个实施方案中，本发明的方法包括联合抗雌激素药给药所述的化合物。在另一个实施方案中，本发明的方法包括联合抗癌药给药所述的化合物。在另一个实施方案中，本发明的方法包括联合 5-α 还原酶抑制剂给药所述的化合物。在另一个实施方案中，本发明的方法包括联合芳香酶抑制剂给药所述的化合物。在另一个实施方案中，本发明的方法包括联合孕激素给药所述的化合物。在另一个实施方案中，本发明的方法包括联合通过其它细胞核激素受体作用的药剂给药所述的化合物。在另一个实施方案中，本发明的方法包括联合选择性雌激素受体调节剂（SERM）给药所述的化合物。在另一个实施方案中，本发明的方法包括联合孕酮给药所述的化合物。在另一个实施方案中，本发明的方法包括联合雌激素给药所述的化合物。在另一个实施方案中，本发明的方法包括联合 PDE5 抑制剂给药所述的化合物。在另一个实施方案中，本发明的方法包括联合阿扑吗啡给药所述的化合物。在另一个实施方案中，本发明的方法包括联合二碳磷酸盐化合物给药所述的化合物。在另一个实施方案中，本发明的方法包括联合一种或多种其它 SARM 给药所述的化合物。在一些实施方案中，本发明的方法包括联合制剂，所述制剂包含所述的化合物和上文所述的药剂。在一些实施方案中，例如为了应对部分待治疗患者亚群的需要或单个患者的需要，所述联合制剂可以变化，所述不同的需要可能归因于具体疾病、所述疾病的严重性、年龄、性别或体重，这可以由本领域的技术人员容易地确定。在一些实施方案中，本发明的方法包括处理单个患者的需要的个性化用药方法。在一个实施方案中，不同的需要可归因于具体疾病、所述疾病的严重性、患者的整体医学状态或所述患者的年龄。在一些实施方案中，个性化用药是应用基因组数据以更好地定向医学干预的递送。在一些实施方案中，个性化用药方法用作发现和临床测试本发明的新产品的工具。在一个实施方案中，个性化用药包括应用临床上有用的诊断工具，所述工具可能帮助确定病人对具体疾病或病症的易感性。在一些实施方案中，个性化用药是综合性的方法，其在药物和诊断的发现和发展的所有阶段利用患者和健康个体的分子分析来指导决定；通过改善的预防、诊断、治疗和监控方法将这种临床实践的知识应用于更有效地提供准确而高质量的医疗保健。

在一些实施方案中，可以以在动物或人类的雌性升值周期中有效调节能育性的量给药式(I)的化合物，或者在一些实施方案中，以有效控制人类月经周期不规律或有效同步或抑制商品化动物（例如鱼、牛、绵羊、猪、山羊或鸡）、实验室动物（例如猿、黑猩猩、大鼠、小鼠或豚鼠）或家养动物（狗、猫、雪貂、兔或马）的生育期的量给药式(I)的化合物。在一些实施方案中，可以以有效减少月经的量给药式(I)的化合物，由此用于治疗或预防贫血和痛经。在一些实施方案中，可以以有效预防或治疗经前期综合征、子宫内膜异位症、平滑肌瘤（子宫肌瘤）和/或卵巢囊肿的量给药式(I)的化合物。而且，对于患有或以前患有盆腔炎性疾病的个体（其中可能已发生输卵管瘢痕形成），可以使用式(I)的化合物以减少可能发生输卵管妊娠的几率。

在一些实施方案中，可以以有效预防妊娠的量给药式(I)的化合物。在一些实施方案中，这种给药可以在排卵前或性交前、或者在排卵后或性交后。在一些实施方案中，这种给药抑制个体的胚胎植入，或在一些实施方案中抑制个体排卵。

在一些实施方案中，可以以有效诱导雌性宫颈成熟的量给药式(I)的化合物。所述宫颈成熟可以是阵痛和分娩后代的准备、或是刮宫术的准备。在另一个实施方案中，实施这种给药以诱导胚胎或胎儿从个体娩出。

应理解，任何本文所述的化合物的任何用途都可以用于治疗本文所述任何疾病、障碍或病症，而且代表本发明的实施方案。

以下所示的实施例是为了更全面地说明本发明的优选实施方案。但是，它们无论如何都不应该被解释为限制本发明的广泛范围。

实施例

实施例 1

I

化合物 XIII 的合成

2-取代丙烯酸（化合物 46）与 4-氰基-3-三氟甲基苯胺反应，然后进行环氧化。在碳酸钾存在下用对-CN-苯酚使环氧化物开环，产生化合物 XIII，如图 1B 中所示。

实施例 2

化合物 V 的合成

4-氰基-3-三氟甲基苯胺与丙烯-2-磺酰氯（51）反应，进行环氧化，然后在碳酸钾存在下用 p-CN-苯酚使环氧化物开环，产生化合物 V，如图 1C 中所示。

实施例 3

化合物 XI 的合成

用 p-CN-苯酚使环氧乙烷基甲基氨基甲酸叔丁酯（54）开环，得到化合物 55 ，然后用 TFA 脱保护，得到氨基醇 56。将化合物 56 引入与 4-氟-2-三氟甲基苄腈的亲电取代反应中，形成化合物 58。将 58 氧化成相应的羰基衍生物 59，将 59 用于进一步的加成反应，得到化合物 XI，其如图 1D 中所示。

实施例 4

化合物 XXXV 的合成

由起始化合物 3,6-二氧杂-双环[3.1.0]己烷（60）制备 4-亚甲基-四氢呋喃-3-醇（61），如图 1E 显示。该化合物用于与 p-CN-苯酚（50）进行 Mitsunobu 型反应，形成化合物 62。用 OsO_4 进行二羟基化，然后在 TEMPO 基(2,2,6,6-四甲基哌啶哌啶基氧)的存在下用 $NaClO_4$ 进行氧化，形成酸 64。使用亚硫酰二氯和 4-氰基-3-三氟甲基苯胺由化合物 64 产生化合物 XXI，如图 1E 中所示。

实施例 5

化合物 XXXVI 的合成

如实施例 4 中所述制备化合物 62，然后进行环氧化，得到化合物 65，如图 1F 中所示。用 4-CN-3-三氟甲基苯胺使环氧化物开环，产生化合物 XXXVI，如图 1F 中所示。

实施例 6

化合物 XLVI 的合成

4-氰基-3-三氟甲基苯胺与衣康酸酐（66）反应，得到中间体 67。进一步环氧化并用对-CN-苯酚使环氧化物开环，产生化合物 XLVI，如图 1G 中所示。

实施例 7

化合物 XLIII 的合成（图 2）

通过肖登-包曼二氏反应使吡咯烷-2-羧酸（56）酰化，得到异丁烯酰基吡咯烷-2-羧酸（57），随后在 *N*-溴丁二酰亚胺的存在下，将其内酯化，得到溴内酯（58）。在回流条件下，用 24% HBr 溶液将所述溴内酯（58）水解 1 h，随后进行后处理并在乙酸乙酯-己烷混合物中重结晶，得到高收率的 3-溴-2-羟基-2-甲基丙酸（59）[59：白色固体（收率：85%）Mp. 108°C $[\alpha]_D^{25}$ = +10.5 (c=2.5,10 MeOH) NMR (^{1}H, 300MHz, DMSO): 1.35 (s, 3H, CH_3), 3.5 (s, 1H, CH), 3.6 (s, 1H, CH), 4.0 (br, 1H, OH) MS: 205 ($M + Na^+$) $C_4H_7BrO_3$ 已计算出: C, 26.25; H, 3.86 发现: C, 26.28; H, 3.75]。

然后，通过在氩气氛下冷却至 0℃，用三溴乙醛保护化合物 59 的羟基和羧基，在搅拌下滴加浓硫酸。2h 后溶液变暗；移去冰浴，反应混合物在室温下搅拌过夜。溶液用冰稀释并用乙酸乙酯萃取，无水硫酸钠干燥并浓缩，得到化合物 60，从乙酸乙酯-己烷中重结晶后，该化合物的外观为白色晶体。[60: 白色固体（收率：89%） Mp. 97°C NMR (^{1}H, 300MHz, $CDCl_3$): 1.8 (s, 3H, CH_3), 3.7 (s, 2H, CH_2), 5.8 (s, 1H, CH) $C_6H_6Br_4O_3$ 已计算出: C, 16.17; H, 1.36;发现: C, 16.08; H, 1.25]。

将化合物 60 溶解在 1:1 的 2-丙醇与 1M NaOH 的混合物中并在室温下搅拌。3h 后，当通过 TLC 检测不到原料时，加入 4'-氟苯硫酚，反应混合物搅拌过夜。然后，用浓 HCl 将反应混合物调节至 pH 1，用乙酸乙酯萃取并用无水硫酸钠干燥。浓缩有机层，得到油。在己烷-乙酸乙酯-乙酸混合物中对反应混合物进行快速柱层析，然后在乙酸乙酯-己烷中进行重结晶，得到无色针状晶体。通过用浓 HCl 酸化反应混合物使该化合物水解以除去保护基，得到图 2 中所示的手性羟酸（55）[55：白色固体（收率：65%） M.p. 54℃; $[\alpha]_D^{25}$ = +24.85 (c=1.0, MeOH) NMR (^{1}H, 300MHz, $CDCl_3$):1.5 (s, 3H,

CH_3), 3.2 (d, 1H, CH), 3.4 (d, H, CH), 7.0 (m, 2H, Ar, J = 2.0 Hz, 8.9 Hz), 7.5 (m, 2H, Ar, J = 2.0 Hz, 8.9 Hz) MS: 无母离子峰 $C_{10}H_{11}FO_3S$，已计算出：C, 52.16; H, 4.82; 发现: C, 52.05.59; H, 4.76]。

通过于 0℃在氯仿介质中加入硫光气和碳酸氢钠，然后在室温下搅拌过夜，将 4-硝基-3-三氟甲基苯胺转化为相应的异硫氰酸盐（66）。浓缩反应混合物，将其萃取至乙酸乙酯中，干燥，蒸发，通过使用已烷-乙酸乙酯混合物的快速柱层析进行纯化，得到外观为黄色固体的 66。在搅拌下加入羟酸 55 和 4-硝基-3-三氟甲基苯基异硫氰酸盐（66）、三氟乙酸银乙腈溶液和三乙胺，反应混合物加热至回流，保持 1h。通过过滤除去硫化银，减压蒸去溶剂，所得剩余物用水洗涤，萃取至乙酸乙酯中，干燥、过滤并浓缩。通过使用已烷-乙酸乙酯混合物的快速柱层析进行分离，所期望的产物呈现为黄色油。鉴定该化合物是噁唑烷二酮（65），如图 2 中所示。[65: 黄色油(收率：52%)$[\alpha]_D^{25}$ = +39.7 (c=2.5,10 甲醇) NMR (^{1}H, 500MHz, DMSO): 1.8 (s, 3H, CH_3), 3.2 (s, 1H, 20 CH), 3.3 (s, 1H, CH), 6.9 (m, 2H, Ar, J = 2.0 Hz, 8.9 Hz), 7.2 (m, 2H, Ar, J = 2.0 Hz, 8.9 Hz), 7.9 (m, 1H, Ar, J = 2.1 Hz, 9.0Hz), 8.0 (m, 1H, Ar, J = 0.5Hz, 2.1 Hz) 8.1 (m, 1H, Ar, J = 0.5Hz, 9.0Hz) NMR (^{13}C, 500MHz, CDCl3): 22.8, 43.4, 86.7, 117.0, 117.3, 124.4, 124.5, 124.6, 125.0, 126.8, 129.3, 134.2, 134.3, 135.3, 164.9, 172.8 MS: 无母离子峰 $C_{10}H_{11}FO_3S$，已计算出：C, 48.65; H, 2.72; N, 6.30 发现: C, 48.59; H, 2.70; N, 6.31]。

该产物（65）在π受体/供体(R,R)-Whelk-O1 手性柱上的 HPLC 分析显示比率为 70:30 两个峰，对应两个对映异构体，对映异构体过量值为 40%。噁唑烷二酮形成的发生必定经过羟基从亚胺碳上亲核置换硫化银及随后的协同环重排，这可由中间结构（67a）和（67b）得到证实；与 Shibuya 等人建立的机制相同的机制。本文考虑，在上述分析型手性柱中获得的对映异构体的良好分离情况可以扩展至相应的制备柱，以便获得所述对映异构体的定量收率，由此用激子偶联振动圆二色性（exciton coupled vibrational circular dichroism）测定它们的绝对构型，并用以高斯经验计算法辅助测定红外光谱。本文还考虑，杂环体系的氧原子可以用氨基代换以得到对映性的比卡鲁胺的乙内酰脲类似物，然后所述类似物会为与受体的氢键合相互

作用提供额外的位点。

实施例 8

化合物 XLVIII 的合成（图 3）

通过重氮化由 4-氰基-3-三氟甲基苯胺制备 4-溴-2-三氟甲基苄腈（74）。使 4-溴-2-三氟甲基苄腈（74）与 BuLi 反应生成 Li 的衍生物（75）。使 3-溴苄腈与 BuLi 反应生成 Li 的衍生物（77）。用(2-溴乙氧基）-叔丁基二甲基硅烷（78）将 Li 衍生物（77）烷基化，得到衍生物（79），79 用 MeMgI 转化为苯乙酮（80）。随后，脱保护并与对-CN-苯酚发生 Mitsunobu 反应，形成苯乙酮（82）。加入 Li 衍生物（75），然后脱水，得到化合物 XLVIII，如图 3 中所示。

实施例 9

化合物 XLIX 的合成（图 4）

将 4-(2-羟基乙基)-吡啶-2-腈（83）用叔丁基二甲基硅烷保护，并用 MeMgI 将其转化为相应的苯乙酮（85），然后脱保护，制备醚（87）。加入 Li 衍生物（75），然后脱水，得到化合物 XLIX，如图 4 中所示。

实施例 10

化合物 L 的合成（图 6）

通过 4-氯甲氧基苄腈（97）由对-CN-苯酚（50）制备正膦（98），在维蒂希反应中 98 与 3-乙酰基苯甲醛（99）生成衍生物（100）。随后，加入如实施例 8 中所述的 Li 衍生物（75），然后脱水，得到化合物 L，如图 6 中所示。

实施例 11

化合物 LI 的合成（图 7）

用叔丁基二甲基硅烷保护 3-羟甲基苄腈（101），得到化合物（102），随后用 MeMgI 得到相应的苯乙酮（85）。除去保护基，进一步与对-CN-苯酚反应以得到（105）。向（105）中加入 Li 衍生物（75）（如实施例 8 中所

制备），然后脱水，得到化合物 LI，如图 7 中所示。

实施例 12

化合物 LII 的合成（图 5）

用叔丁基二甲基硅烷保护 5-溴-2-羟基苄腈（88），得到化合物（89）。化合物（89）与 BuLi 反应，得到 Li 衍生物（90），其进一步由(2-溴乙氧基)-叔丁基二甲基硅烷烷基化，得到（91）。化合物（91）与 MeMgI 反应成相应的苯乙酮（92），然后脱保护并选择性地保护酚基，得到衍生物（94）。衍生物（94）与对-CN-苯酚反应，得到化合物（95），然后加入 Li 衍生物（75）并脱水（如实施例 8 中所述），得到化合物（96）。随后脱保护，得到化合物 LII，如图 5 中所示。

实施例 13

化合物 XXIV 的一般合成（图 1I）

根据图 1I 制备 4-(4-芳基磺酰-2,5-二甲基哌嗪-1-基)-2-三氟甲基苄腈。于 DMSO-水混合物中在碳酸钾存在下，用 2,5-二甲基哌嗪亲核取代 4-氟-2-三氟甲基苄腈中的氟原子。在三乙胺存在下，通过与芳基磺酰氯的反应制备相应的芳基磺酰衍生物。

实施例 14







雄激素受体（AR）与 SARM 的结合以及 AR-SARM 晶体结构方法





亲合力测定

由斯普拉-道来(氏)大鼠的腹部前列腺得到细胞溶胶 AR。切除前列腺并立即浸没在冰冷的匀浆缓冲液中（10 mM Tris、1.5 m MEDTA 二钠、0.25 M 蔗糖、10 mM 钼酸钠和 1 mM PMSF）。用剪刀将前列腺切碎，匀浆并离心（Model L8-M，Beckman Instruments Inc）。收集上清液（细胞溶胶）并储存在-80℃下直到使用。在存在或不存在浓度增加的感兴趣的化合物（10^{-1} nM-10^{4} nM）的情况下，于 4℃下用饱和浓度的 ^{3}H-MIB (1 nM)和 1 μM 的曲安奈德培养等份（50 μL）的 AR 细胞溶质 18 h。

通过向培养液中加入 1000 nM MIB，测定 ^{3}H-MIB 的非特异性结合。使用羟基磷灰石分离结合的和游离的放射性配体并测定结合的 ^{3}H-MIB 的浓度。使用非线性回归测定 IC_{50}，即抑制 50% ^{3}H-MIB 的特异性结合的供试化合物的浓度。

测定本发明的化合物的亲合力并显示在下表中：

化合物	抑制常数（nM）
	633.5
	528.9 nM
	195.81 nM
	412.24 nM
	396.8 nM
	微摩尔范围

	微摩尔范围
	70.7 nM
	2785 nM
	2632 nM

共转染测定

使 CV-1 细胞（绿猴肾细胞）在补充了 10% FBS、2mM 谷氨酰胺和 1% 链霉素和青霉素的达尔伯克氏改良伊格尔氏培养基（DMEM）上生长到在 T175 组织培养烧瓶中融合。无血清 DMEM 中，将细胞用 3 μg CMVhAR 表达载体、30 μg 雄激素依赖型萤光素酶报道基因构建体(pMMTV-luc)和 30 μg β-半乳糖苷酶表达构建体（pSV-β-半乳糖苷酶；Promega, 5 Madison, WI）经 30 mLPlus 试剂（Invitrogen）和 40 mL LipofectAMINE（Invitrogen）转染。4 小时后，将培养基换成补充 0.2 % FBS 和 2 mM 谷氨酰胺的 DMEM。12 小时后，将细胞转移至 24 孔组织培养板，再过 6 小时后，用 0.1 nM-1000 nM 的药物或不加药物（对照）处理。另外 24 小时后，细胞用冷 PBS 洗涤两次，通过用 100 ML 的被动性溶胞解缓冲液（Promega）培养 30 分钟后收集细胞。

将等份（50 mL）溶胞产物加到不透明的 96 孔板，在自动注入 50 mL 萤光素酶底物（Promega）后，用 MicroLumatPlus LB96V 发光计（Berthold Technologies, Oak Ridge, TN）使用 WinGlow 软件包监测萤光素酶的活性。另将等份（50 mL）的溶胞产物和 50 mL β-半乳糖苷酶测定缓冲液一起加到

透明的96孔板。在37℃下培养2小时后，在Dynex MRX读板器上于420 nm测定吸收值。使萤光素酶活性与 β-半乳糖苷酶活性标准化，以便计算细胞数量和/或转染率损失的差异。

克隆、表达和纯化

由全长AR表达构建体（pCMVhAR）通过用含有侧翼限制酶切位点的引物进行PCR扩增获得AR-LBD（663-919），然后将其插入到pGEX6P-1质粒载体（Amersham）中。通过用30μM IPTG诱导，所述AR LBD于15℃下在大肠杆菌BL21 DE3中表达16小时，为谷胱甘肽-S-转移酶（GST）融合蛋白。在含有150 mM NaCl、50 mM Tris pH 8.0、5 mM EDTA、10% 甘油、1 mg/mL 溶菌酶、10 U/mLDNA酶I、10 mM $MgCl_2$、10 mM DTT、0.5% CHAPS、100 μM配体和100 μM PMSF的缓冲液中，通过三次冻融循环，将细胞溶解。由超速离心得到的上清液与谷胱甘肽琼脂糖凝胶（Amersham）在4℃下培养1 h，并用150 mM NaCl、50 mM Tris pH 8.0、5 mM EDTA、10%甘油、10 mM ATP、10 DM配体、0.1% *n*-辛基-β-葡糖苷和1 mM DTT洗涤。

于4℃下在含有150 mM NaCl、50 mM Tris pH 7.0、10%甘油、0.1% *n*-辛基-β-葡糖苷、1 mM DTT和5 U/mg蛋白质PreScission蛋白酶（Amersham）的缓冲液中过夜切割GST-LBD融合蛋白以从谷胱甘肽琼脂糖凝胶中释放AR LBD。上清液在10 mM pH 7.2的羟乙基哌嗪乙磺酸、10%甘油、10 μM配体、0.1% *n*-辛基-β-葡糖苷、1 mM DTT中稀释3倍，然后装载至HP SP阳离子交换柱（Amersham）上。在相同的稀释缓冲液中用50 mM-500 mM的 NaCl梯度洗脱蛋白。在Millipore 10 kD截留浓缩器中将缓冲液换成含有150 mM Li_2SO_4, 50 mM pH 7.2的羟乙基哌嗪乙磺酸、10%甘油、100 μM配体、0.1% *n*-辛基-β-葡糖苷和10 mM DTT的缓冲液，将蛋白质浓缩至大于4 mg/mL。

结晶、收集数据和结构测定

在一至两天内，利用悬滴蒸发扩散法于0.1 M pH 7.5羟乙基哌嗪乙磺酸和0.5 M-0.8 M的柠檬酸钠中形成 AR LBD晶体。在液氮中快速冷冻之前，将AR LBD晶体转移至由0.1 M pH 7.5的羟乙基哌嗪乙磺酸、0.7 M柠檬酸钠和20%乙二醇组成的溶液中。使用Rigaku RU300旋转阳极发生器

和 R-轴 IV++成像板（Rigaku）收集衍射数据，并用 Crystal Clear 软件进行处理（Molecular Structure Corporation）。AR LBD-DHT 复合物（PDB 编码 1I37）用作使用 Crystallography & NMR System（CNS）进行精制的起始结构。在第一轮精制后，电子密度图使配体准确拟合（fitting）。使用程序 O 加入模型构建物和水分子，使用刚性体、扭转角模拟重结晶法和 CNS 的单个温度因子模块进行更多轮的精制。

SARM 的 X 射线研究

将显示 AR 结合低于 100 nM 的 SARM 在萤光素酶测定中进一步分析，以确定它们是否具有 AR 功能性激动剂活性。随后，使具有最高活性的 SARM 与 AR 受体共结晶并进行 X 射线分析。


实施例 15

SARM 的功能活性

表 1 描述了所示醚连接化合物（比卡鲁胺类似物）的结构和亲合性。所有化合物都使用手性合成方法合成，包括使用 D-脯氨酸作为手性助剂，如美国专利 6,995,284 中所公开地，该专利通过引用结合于此。使用元素分析和波谱数据，即 ^{1}H NMR、^{13}C NMR、MS 和 IRE 确定合成的化合物的结构。

在本发明的一些方面，这些化合物的设计充分理解被鉴定为涉及比卡鲁胺类似物的 AR 亲合力的结构元素，例如：(i) 缺电子的芳香性 A 环，(ii) 在手性中心的 *R*-构型，和(iii) 在 B 环的对位的亲电子基团。重要的是要注意，在这类分子中，当用醚键代替硫醚或磺酰基连接时，活性化合物的手性指示从*(R)*变为*(S)*。除了这些对高 AR 结合亲合力所需的结构特征外，B 环取代和连接基 X 的性质是比卡鲁胺类似物的功能活性的关键性决定因素。

表 1：



编号	R1	R2	X	R3	R4	R5	R6	R7	K_i (nM)
比卡鲁胺	CN	CF_3	SO_2	H	H	F	H	H	11±2
R-20	NO_2	CF_3	SO_2	H	H	COCH3	H	H	9.3±0.8
S-1	NO_2	CF_3	O	H	H	F	H	H	6.1±0.19
S-2	NO_2	CF_3	O	H	H	COCH3	H	H	36.6±2.3
S-3	NO_2	CF_3	O	H	H	$COCH_2CH_3$	H	H	6.1±0.14
S-4	NO_2	CF_3	O	H	H	NHCOCH3	H	H	4.0±0.70
S-5	NO_2	CF_3	O	H	H	CH_3	H	H	34.8±3.5
S-6	NO_2	CF_3	O	H	H	OCH3	H	H	13.7±0.68
S-7	NO_2	CF_3	O	H	H	$NHCO_2C(CH_3)3$	H	H	336.0±71.1
S-9	NO_2	CF_3	O	H	H	H	H	H	4.6±0.26
S-10	NO_2	CF_3	O	F	H	F	H	H	3.4±0.34
S-11	NO_2	CF_3	O	H	F	F	H	H	3.4±0.56
S-12	NO_2	CF_3	O	F	H	F	H	H	3.2±0.30
S-13	NO_2	CF_3	O	CH3	H	F	H	H	6.0±0.70
S-14	NO_2	CF_3	O	H	Cl	F	H	H	10.3±2.0
S-15	NO_2	CF_3	O	H	F	Cl	H	H	4.9±0.3
S-16	NO_2	CF_3	O	H	Cl	Cl	H	H	1.0±0.088
S-17	NO_2	CF_3	O	F	F	F	H	H	11.3±1.1
S-18	NO_2	CF_3	O	F	H	F	H	F	10.3±2.0
S-19	NO_2	CF_3	O	F	F	H	F	H	9.1±0.6
S-20	NO_2	CF_3	O	F	F	F	F	F	1.4±0.34

S-21	NO_2	CF_3	O	H	H	Cl	H	H	8.6±1.2
S-22	NO_2	CF_3	O	H	H	Br	H	H	12.6±1.8
S-23	NO_2	CF_3	O	H	H	I	H	H	22.6±1.6
S-24	NO_2	CF_3	O	H	H	$NHCSNH_2$	H	H	10.2±1.4
S-25	NO_2	CF_3	O	H	H	$NHCSNHCH_3$	H	H	271.2±37.2
S-26	CN	I	O	H	H	F	H	H	3.3±0.10
S-27	CN	CF_3	O	H	H	Cl	H	H	3.4±0.08
S-28	CN	CF_3	O	H	H	$NHCOCH_3$	H	H	12.7±0.02
S-29	CN	Cl	O	H	H	F	H	H	4.5±0.11
S-30	CN	CF_3	O	H	H	F	H	H	3.3±0.08
S-31	F	CF_3	O	H	H	F	H	H	32.6±0.10
S-32	Cl	CF_3	O	H	H	F	H	H	14.5±0.18
S-33	I	CF_3	O	H	H	F	H	H	15.6±0.19
S-34	Br	CF_3	O	H	H	Cl	H	H	52.0±0.13
S-35	Br	CF_3	O	H	H	Br	H	H	25.9±0.04
S-36	H	CF_3	O	H	H	F	H	H	62.0±0.05


对 AR 介导的转录激活的体外研究（图 8）显示，将 X 连接由砜变为氧或将 B 环对位取代由氟变为乙酰胺基都将纯粹的 AR 拮抗剂转化为激动剂，例如在化合物 S-5 和 R-20 中。在体内试验中，先导化合物 S-1 和 S-4 在体内用作 AR 激动剂并显示出组织选择性（图 9A-9B)。S-1 和 S-4 在前列腺中都是部分激动剂，但是在肛提肌、骨和垂体中是完全激动剂，这些是对理想的选择性雄激素受体调节剂提出的特征。

S-4 的口服生物利用度和安全性已经被证实（数据未显示），确证了这些化合物可能有效治疗雄激素缺乏性疾病或病症的观点。先前已经证明，S-1 和 S-4 不是 5α-还原酶的底物。本文考虑，这些配体的组织选择性是因

为它们在前列腺中的激动剂活性没有完全被 5α-还原酶放大，5α-还原酶是在前列腺中而不是肌肉中表达的、将睾酮转化为 DHT 的酶。

表2显示最大疗效百分数对表1的各种化合物的X-和Y-位置的依赖性。如实施例 13 中所述，使用大鼠腹部细胞溶胶作为 AR 源，利用竞争性结合测定来测定完整 AR 的亲合力。如实施例 13 中所述，使用共转染测定，检测完整 AR 的体外功能活性。在 10 nM 配体下分析疗力（即转录激活），将活性表示为对 1 nM 双氢睾酮（DHT）观察到的最大转录激活的百分数。

表 2



ID	X	Y	亲合力 (nM)	疗效 (%最大)
S-1	O	F	6.11 ± 0.19	43.40 ± 2.60
X-2	S	F	11 ± 2	77.4 ± 5.6
X-3	SO_2	F	28 ± 10	18.8 ± 9.3
X-4	NH	F	7.96 ± 0.43	21.33 ± 2.22
X-5	CH_2	F	9 ± 0.2	28.9 ± 2.4
S-4	O	$NH(CO)CH_3$	3.98 ± 0.70	92.92 ± 7.00
S-23	O	I	23 ± 1.6	47.2 ± 1.8

实施例 16

非类固醇配体结合的结构表征

对一系列 4"-氟苯基-2-羟基-2-甲基-*N*-(4'-硝基-3'-三氟甲基苯基)丙酰苯胺化合物进行构象分析，这些化合物仅 X 位置的杂原子不同。该分析检

测了 X 位置取代基对溶液中化合物构象的影响以开发构象化合物。将配体溶液（DMSO-d_6）NMR 构象与它们的来自新近解析的 *R*-比卡鲁胺-W74L-LBD 晶体结构（本文中称为比卡鲁胺-W741L；C. E. Bohl, W. Gao, D. D. Miller, C. E. Bell, J. T. Dalton. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. *Proc Natl Acad Sci U S A* **2005**, *102(17)*, 6201-6. ）的结合构象作比较。已经预料在连接部位中的分子内氢的键合（NH-OH），这在溶液构象中观察到了。然而，对于一些被分析的化合物，这种分子内 NH 氢键供予在 OH 和 X 位置间共享。NH-X 氢键导致所述配体在溶液中的总体形状获得意想不到的弯曲，这种弯曲与在 AR 的同源建模过程中得到的假设性的结合构象明显不同。过去，对丙酰苯胺没有六元 5 环状 NH-X 氢键合构象的假设。激动剂 S-4(X=O,Y=N-乙酰基)和 X-2(X=S,Y=F)和部分激动剂 S-23(X=O,Y=I)和 S-1(X=O,Y=F)最清楚地显示出这种溶液中苯环的 NH 至-X 加-OH 构象（图 10），但是，对于该系列的拮抗剂 X-3(X=SO_2, Y=F)和 X-4(X=NH, Y=F)和 X-5(X=CH_2 ,Y= F)没有观察到这种构象。这表明，所述配体采取这种构象的能力可能对 AR 激活很重要，这一点通过与非类固醇配体的构象的比较得到确证，所述非类固醇配体的构象是在随后解析的 *R*-比卡鲁胺-W741L-LBD（AR 突变体，其中比卡鲁胺用作激动剂）的 X 射线晶体结构中观察到的。

表 3 提供表 1 所中所鉴定的各种化合物的溶液中分子内氢键分析的结果。如表 3 中使用的，氢键的定义是<3.1Å 的原子间距离，该距离是在 SYBYL 6.8 中使用分析->距离命令测得的。

溶液构象使用 NOESY 谱测定。NH-OH 指连接部位酰胺的质子和连接部位羟基的氧之间的原子间距离，NH-X 指连接部位酰胺的质子和连接部位 X 位置的原子之间的原子间距离。S-1 在体外用作部分激动剂，S-4 和 X-2 在体外是激动剂，X-3、X-4 和 X-5 在体外是拮抗剂。

表 3：

ID	NH-OH	NH-X
S-1	2.4	2.3
S-4	2.7	1.9

X-2	2.1	3.0
X-3	2.0	3.6
X-4	2.3	4.4
X-5	2.0	3.9

构建 AR 的位点特异性突变体，检测 DHT 和三种非类固醇配体即羟基氟他胺（HF）、比卡鲁胺和 S-4 刺激 AR 介导的转录的能力（图 11）。在该突变体中，比卡鲁胺表现为激动剂并刺激 AR 介导的转录激活，表明结合比卡鲁胺的 W741L 突变体 AR-LBD 采取类似于用结合激动剂的野生型 AR 观察到的构象的活性构象。考虑到纯化结合拮抗剂的野生型 LBD 的困难，结合比卡鲁胺的 W741L 突变体和结合羟基氟他胺的 T877A 突变体的激动剂构象证明是有用的。本文考虑，这些突变体复合物会采取更紧凑的构象，这样会促进在 LBD 的纯化和结晶过程中伴侣蛋白质的解离，并为我们提供对非类固醇 AR 配体结合机制的首次了解。

使用类似于首先解析与类固醇配体结合的 AR-LBD 晶体结构的科学家所述的方法，将结合 R1881 和 DHT、DHT-5 的野生型 LBD 和结合比卡鲁胺的 W741L LBD 纯化并结晶。而且，使用亲合力更高的比卡鲁胺 *R*-异构体。在大肠杆菌中，GST-LBD 与配体共同表达。在亲和层析和裂解融合蛋白后，LBD 的高 pI（等电点）使杂质蛋白和伴侣蛋白质通过中性 pH 阳离子交换色谱除去。

这两种复合物均采取与结合类固醇的 LBD 非常类似的整体构象（图 12A）。如由溶液构象的 NMR 研究所预示的，比卡鲁胺在磺酰基氧和胺类质子之间形成分子内氢键（图 12B），这与计算机预测的模型（图 10）不同，指示这是不同于醚连接类似物的构象，并表明对配体溶液构象的 NMR 研究可能用于预测与 LBD 结合时的配体构象。这种结象说明，这些突变为非类固醇配体提供更多的空间以嵌入（fit into）LBD，并形成由野生型 DHT 复合物观察到的激动剂构象。

大多数 LBD 残基在野生型 DHT 复合物中的位置类似于非类固醇复合物，尽管配体结构的变化程度惊人（图 13A）。羟基氟他胺（HF）和 *R*-比卡鲁胺具有类似的 A 环和酰胺键结构，这使类固醇平面完全重叠（图 13B）。

在 R752 和 A 环的硝基/氰基之间观察到氢键，这模拟了 DHT 中的 3-酮基，而且在 L704 和 N705 和羟基之间也观察到氢键，这模拟了 DHT 中的 17β-OH。然而，与 DHT 不同的是，在非类固醇配体和 T877 侧链之间没有观察到氢键。

在 R-比卡鲁胺的砜连接基和 B 环区域也观察到残基的位置有很大区别（图 13B），该区域折叠离开类固醇平面并指向口袋（pocket）的顶部，可能占用 W741 吲哚环(在突变体中不存在)的空间。在 T877A-HF 和 WT-DHT 复合物中，W741 吲哚环的位置也区别很大。在 DHT 复合物中，Trp741 侧链与配体接触，而在 T877A-HF 复合物中，该吲哚环距离结合口袋(binding pocket）更远。M745 由 DHT 的 19-甲基置换似乎能解释这些区别。在图 13B 中也看到，与野生型 DHT 和 T877A-HF 相比，*R*-比卡鲁胺磺酰基造成螺旋 12 残基 M895 的置换。然而，该 M895 侧链被容纳在 T877A-HF 复合物的 W741 吲哚环的位置中。在野生型 LBD 中，W741 和 M895 侧链都可能与比卡鲁胺具有不利的阻止激动剂构象形成的相互作用。另一方面，R-比卡鲁胺的 B 环对位上的氟在 AR 的亲水区域结合，所述区域也提供形成氢键的机会。AR 的这一区域位于螺旋 4 和 5 之间的扭转处并与 H874 咪唑十分接近。在该位置被乙酰胺基 S-4、异硫氰酸盐、氰基或硝基取代的化合物证明对 AR 具有改善的亲合力，表明在该区域它们可能形成有利的氢键。

实施例 17

结合激动剂和拮抗剂的 AR LBD 的结构特征

HSP 的解离是由激动剂诱导的 AR LBD 构象变化引起的初始过程之一。在哺乳动物细胞中，HSP 复合物主要包含 HSP90、HSP70、p60 和 p23。HSP90 直接与受体结合成为同型二聚体，而其它蛋白质主要通过 HSP90 与该复合物结合。AR LBD 中的 HSP90 结合位点还没有被很好地表征。包括环 3-4、H4 和 H5 的残基 720-774 正好形成大部分的 AF2 疏水性凹槽（图 14A-14B），它们被鉴定为可能负责使用截短的结合 HSP90 的区域。

重要地，本文考虑，异常的曝露于溶剂的 HSP90 的 α-螺旋与细胞核受体家族的 H12 非常类似，并可能置换这些受体上的 H12 以促进配体结合。

这个观点尤其可能与 AR 有关，因为 AR 的功能与其它细胞核受体相比似乎有重要的不同。放射标记的 AR 的 IP 和蔗糖梯度离心分析显示，激动剂 R1881（而不是拮抗剂羟基氟他胺和比卡鲁胺）诱导 HSP90 解离，这说明伴侣蛋白质复合物的存在而不是 H12 的 MAEII 模体阻止接近 AF2 区。因此，HSP90 的解离似乎直接与 AR 配体的活性有关。

虽然羟基氟他胺用作野生型 AR 的拮抗剂，但是它对 T877A AR 突变体起激动剂作用。其对突变的 AR 的激动剂活性直接与 HSP90 的解离有关。这与 ER 完全不同，其中 ER 激动剂和拮抗剂都启动 HSP 的解离。与 ER 的情况相比，HSP90 的解离对 AR LBD 似乎是能影响受体的构象的更关键的因素。这说明 AR 拮抗剂活性可能涉及另一种机制。

不同 AR 复合物的限制性蛋白水解分析表明，AR 的配体诱导的激活需要 LBD 的两次连续的构象变化。AR 激动剂，即 T、DHT 和 R1881，稳定了 AR 的 29-KD 片段对抗限制性胰蛋白酶消化，而抗雄激素，即醋酸环丙孕酮、羟基氟他胺、尼鲁米特和比卡鲁胺稳定 35-KD 片段。29-KDa 和 35-KDa 片段都含有完整的 LBD（氨基酸 671-919），35-KDa 片段延伸进入铰链区（氨基酸 621-671）。35-KDa 片段也参与激动剂结合的初始步骤，但是在长时间的消化作用下其不稳定。

这种时间依赖性构象变化被钼酸盐的加入而延迟，这说明 HSP 的解离可能导致铰链区暴露于胰蛋白酶消化。因此，已经提出，激动剂结合启动 AR 的第一次构象变化，这触发 HSP 的解离，然后开始第二次构象变化。然而，尽管拮抗剂能启动第一次构象变化，但是它不能促进 HSP 的解离，这稳定了 LBD 和铰链区并保护铰链区不受进一步的胰蛋白酶消化。

实施例 18

对 SARM 进行基于结构的药物设计（SBDD）的全新方法

在基于激动剂与 AR 的结合构象来设计激动剂方面，与拮抗剂比卡鲁胺结合的 AR 突变体 W741L（bicW741L）使我们洞悉本文提供的化合物的结合模式。这也为区分激动剂和拮抗剂的结合模式特征提供了原理。最近解析的结合激动剂 S-1 的野生型 AR（S1-野生型）的晶体结构确证了在 W741L 突变体中观察到的结合模式。在 1.8 Å 的清晰度下，这些结构都被

解析，而且这些结构证明了新型的结合模式，该模式根本上不同于在共晶结构出现之前提出的、由同源模型所表明的模式。

与上述共晶相反，同源模型沿所对接的（docked）类固醇的 α-面具有独特的未被占据的空腔，所述空穴大到足够能容纳丙酰苯胺的 B 环。

确认全新 SBDD 模型

通过 Spearman 相关系数分析对这些 AR 结构模型进行的经验分析提供了每一种模型预测配体亲合力的等级次序的能力的统计学手段。当使用基于分子对接的方法例如全新设计或虚拟筛选以评价该模型是否能用于按优先次序确定应该沿着哪些经计算机模拟（*in silico*）的指导进行时，这种等级顺序统计量是适当的。将为比较分子场分析（CoMFA）模型而编辑的 AR 配体数据库用于以下 AR 模型的 Spearman 分析：CoMFA、结合 S-1 的野生型晶体（简称为 S1-野生型），结合比卡鲁胺的 W741L 晶体（简称为比卡鲁胺 c-W741L）和同源模型。CoMFA (C. E. Bohl, C. Chang, M. L. Mohler, J. Chen, D. D. Miller, P. W. Swaan, J. T. Dalton. A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem 2004, 47(15), 3765-76.)、S1-野生型(C. E. Bohl, D. D. Miller, J. Chen, C. E. Bell, J. T. Dalton. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005, 280(45), 37747-54.)、比卡鲁胺-W741L (C. E. Bohl, W. Gao, D. D. Miller, C. E. Bell, J. T. Dalton. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 2005, 102(17), 6201-6.)和 G1 同源模型((C. A. Marhefka, B. M. Moore, 2nd, T. C. Bishop, L. Kirkovsky, A. Mukherjee, J. T. Dalton, D. D. Miller. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands.*J Med Chem* **2001**, *44(11)*, 1729-40.)的 R_s 值分别为 0.93、0.55、0.29 和-0.28，这说明，S1-野生型模型显著的预测值和比卡鲁胺-W741L 模型有限的预测值表明与以前的基于结构的药物设计模型相比有进步。因此，可以预测这些晶体结构能改善确定由计算机模拟的指导的优先次序的能力，由此促进药物设计。

实施例 19


AR 配体结合的计算预测的确认

对实施例 16 中的扭应变参数和氢键相互作用的检验显示，化合物 XVII 的芳基丙酰胺衍生化合物采取类似于化合物 XLII 的构象。羟基 α 以这样的方式定位到羰基，它参与和受体的天冬酰胺 705 的氢键相互作用。该氨基酸与亮氨酸 704 的主链氧形成弱的氢键。所做的计算预测与结合测定得出的结果一致。然而，为了令人信服地建立上述相互作用和分子采取的构象，建立了合适的分子模型，该模型没有自由羟基和酰胺质子，而且最重要的是，该模型在构象上局限于类似于化合物 XLII 的结构。因此，酰胺氮和羟基氧通过羰基官能团连结，这形成如化合物 XXXIX 中所描绘的噁唑烷二酮衍生物结构。实施芳基丙酰胺衍生的化合物的合成和这些噁唑烷二酮衍生物的立体选择性合成。

实施例 20


化合物 LIV 的合成

通过化合物 LIII 合成化合物 LIV，所考虑的第一组化合物是通过西蒙斯-史密斯反应合成的环丙烷系列，如以下路线所示。



实施例 21

化合物 XVI 的合成



R-3 (XVI)

根据上述路线合成化合物 XVI。根据 US 06995284 合成 R-3，该专利通过引用结合于此。得到 XVI，为黄色油：计算出的质量 415.08, [M-H] 414.0; ^{1}H NMR ($CDCl_3$) 9.13 (bs, 1H, NH), 7.96 (d, J = 9.0 Hz, 2H, ArH), 7.88 (dd, J = 9.0, 2.1 Hz, 1H, ArH), 7.43 (dd, J = 7.6, 1.5 Hz, 1H, ArH), 7.11 (m, 1H, ArH), 6.72 (m, 2H, ArH), 4.15 (bs, 3H, OH & NH2), 3.59 (d, J = 14.1 Hz, 1H, CH2), 3.02 (d, J = 14.1 Hz, 1H, CH2), 1.56 (s, 3H, CH3)。

实施例 22

化合物 XL 的合成

如图 1J 中所描绘地合成化合物 XL。向乙醇中的 L-丙氨酸钠盐中加入异硫氰酸苯酯，温热 30 分钟。蒸去溶剂，并向油状剩余物中加入浓 HCl。收集形成的白色固体，在水中洗涤，得到化合物 2。加入乙酸酐，得到化合物 3，在六甲基二硅氮烷钾盐的存在下加入 1-溴-4-溴甲基苯，得到化合物 XL。

化合物 2 的 ^{1}H NMR ($CDCl_3$)：7.65, 7.63, 7.61, 7.38, 7.35, 7.25, 4.40, 1.62

化合物 3 的 ^{1}H NMR ($CDCl_3$)：7.59, 7.57, 7.56, 7.39, 7.33, 4.92, 2.90, 1.74

化合物 XL 的 ^{1}H NMR ($CDCl_3$)：7.53, 7.52, 7.51, 7.50, 7.49, 7.40, 7.39, 7.37, 7.34, 4,38, 1.67, 1.66；化合物 XL 的熔点：99℃。

实施例 23

化合物 XLI 的合成

如图 1K 中所描绘地合成化合物 XLI。向乙醇中的 L-丙氨酸钠盐中加入 4-异硫氰基-1-硝基-2-三氟甲基苯，温热 30 分钟。蒸去溶剂并向油状剩余物中加入浓 HCl。收集形成的白色固体，在水中洗涤，得到化合物 2。加入乙酸酐，得到化合物 3，在六甲基二硅氮烷钾的存在下加入 1-溴-4-溴甲基苯，得到化合物 XLI。

化合物 3 的 ^{1}H NMR ($CDCl_3$)：10.80, 8.35, 8.18, 7.99, 4.49, 1.43。

化合物 XLI 的 ^{1}H NMR ($CDCl_3$)：7.97, 7.47, 7.43, 7.42, 7.19, 7.15, 6.97,

6.92, 3.93, 3.15, 2.88, 1.98。

虽然本文已经说明和描述了本发明的某些特征，但是本领域的普通技术人员现在会得出许多修改、替换、改变和等同形式。因此，应该理解，所附的权利要求书意在覆盖所有落在本发明的真正精神范围内的这种修改和变化。




图1A




图1B



NC
F3C
NH2
Cl
O
S
O
51
52
[O]
53
HO
CN
K2CO3
NH
OH
(V)

图1C



BocNH
54
50
K2CO3
55
TFA
H2N
56
F
57
58
[O]
59
1.
2. HCl
1. MeOCH2Li
2. HCl
1. MeLi
2. HCl
1. Me3SiCN
2. HCl
1. CF3SiMe3
2. HCl
CH2OH
CH2OMe
CF3
CH3
HO

图1D




图1E




图1F




图1G





图1H



Q=CN, Y=CF_3(化合物XXIV)
Q=CN, Y=Cl(化合物XXV)
Q=Cl, Y=CN(化合物XXVI)
Q=CF_3, Y=Cl(化合物XXVII)
Q=CF_3, Y=CF_3(化合物XXVIII)

图1I






图1J




4-异硫氰基-1-硝基-2-三氟甲基苯

图1K



试剂： a-异丁烯酰氯、NaOH、丙酮； b-NBS、DMF； c-24%HBr；
d-三溴乙醛、浓硫酸； e- (1) NaOH、4-氟苯硫酚、2-丙醇， (2)浓HCl。



试剂：h-硫光气、氯仿、NaCO3， i-三氟乙酸银、三乙胺、乙腈。

图2



NC
F3C
NH2
47
1. NaNO2
2. CuBr
Br
74
BuLi
Li
75
76
77
78
OTBDMS
79
MeMgI
80
81
OH
HO
CN
PPh3, EtO2CN=NCO2Et
KHSO4
(XLVIII)

图3



NC
OH
N
83
NC
OTBDMS
N
84
MeMgI
O
OTBDMS
N
85
O
OH
N
86
HO
CN
PPh3
EtO2CN=NCO2Et
O
O
N
CN
87
NC
F3C
75
Li
KHSO4
CN
O
NC
F3C
N
(XLIX)

图4



NC
Br
HO
88
TBDMSO
89
BuLi
Li
90
OTBDMS
91
MeMgI
92
OH
93
94
CN
PPh3
EtO2CN=NCO2Et
95
F3C
75
KHSO4
96
LII

图5



CN
HO
50
1. NaH
2. MeSCH2Cl
3. MCPBA
4. SOCl2
Cl
O
97
Ph3P
Ph3P
Cl
98
99
100
NC
F3C
Li
75
KHSO4
(L)

图6



NC
OH
101
NC
OTBDMS
102
MeMgI
O
OTBDMS
103
O
OH
104
HO
CN
PPh3
EtO2CN=NCO2Et
O
CN
O
NC
F3C
Li
75
KHSO4
CN
O
NC
F3C
(LI)

图7



野生型AR
0.1 nM
1 nM
10 nM
100 nM
增加倍数（萤光素酶活性）
80
60
40
20
0
S-4
S-1
R-20
比卡鲁胺

图8



140
120
100
80
60
40
20
0
完整对照的百分率
前列腺
E_{max} = 121 +/- 13
ED_{50} = 0.13 +/- 0.03
肛提肌
E_{max} = 104 +/- 10
ED_{50} = 0.15 +/- 0.03
精囊
E_{max} = 70 +/- 19
ED_{50} = 0.12 +/- 0.02
0.10
0.30
0.50
0.75
1.00
剂量率(mg/天)

图9A



100
80
60
40
20
0
完整对照的百分率
肛提肌
Emax = 101.0 +/- 1.0
ED50 = 0.14 +/- 0.01
前列腺
Emax = 35.2 +/- 0.39
ED50 = 0.43 +/- 0.01
精囊
Emax = 28.5 +/- 0.8
ED50 = 0.55 +/- 0.02
0.10
0.30
0.50
0.75
1.00
剂量率(mg/天)

图9B




图10




图11



H9
H10
H8
H1
β2
H4
H3
H5
H7
β1
H6

图12A



Met742
Arg752
Thr877
Leu704
Asn705

图12B




图13A




图13B



H9
H1
H6
H10
β2
H4
H7
H8
H5
H12
H11
β1

图14A



V730
Q733
R726
H4
H3
K720
M734
I737
V716
K717
H12
Q738
W741
L713
I696
M694
E709
E693

图14B

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 3 984 523 A1

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication:
20.04.2022 Bulletin 2022/16

(21) Application number: **21213854.9**

(22) Date of filing: **06.12.2019**

(51) International Patent Classification (IPC):
A61K 9/00 *(2006.01)* ***A61K 31/395*** *(2006.01)*
A61K 31/426 *(2006.01)* ***A61K 31/573*** *(2006.01)*
A61P 5/00 *(2006.01)*

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
A61K 9/0095; A61K 31/426; A61K 31/573; A61P 5/00; C07C 209/52; C07C 249/02; C07C 259/06; C07D 277/42 (Cont.)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: **07.12.2018 US 201862776763 P**
11.03.2019 US 201962816674 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
19848938.7 / 3 890 706

(71) Applicants:
- **Neurocrine Biosciences, Inc.**
  San Diego, California 92130 (US)
- **Sanofi**
  75008 Paris (FR)

(72) Inventors:
- **FARBER, Robert H.**
  San Diego, 92130 (US)
- **LOEWEN, Gordon Raphael**
  San Diego, 92130 (US)
- **ZHANG, Xiaoping**
  San Diego, 92130 (US)
- **GIRI, Nagdeep**
  San Diego, 92130 (US)
- **CHAN, Jean L.**
  San Diego, 92130 (US)
- **STIRN, Scott**
  San Diego, 92130 (US)
- **SAYERS, Brian**
  San Diego, 92130 (US)
- **TAYLOR, Graeme**
  San Diego, 92130 (US)
- **COSTA, Christina Marie**
  San Diego, 92130 (US)
- **PARKS, Stacy**
  Oregon, 97701 (US)
- **VICKERY, Anthony D.**
  Oregon, 97701 (US)
- **DOWNING, Kristie M.**
  Oregon, 97701 (US)
- **IYOHA, Kingsley**
  Nottingham, NG11 6JS (GB)
- **NGWENYA-JONES, Ayanda**
  Nottingham, NG11 6JS (GB)
- **CHARLIER, Anne**
  75008 Paris (FR)
- **MEHTON, Gurvinder Singh**
  Nottingham, NG11 6JS (GB)

(74) Representative: **Mewburn Ellis LLP**
Aurora Building
Counterslip
Bristol BS1 6BX (GB)

Remarks:
This application was filed on 10-12-2021 as a divisional application to the application mentioned under INID code 62.

(54) CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS THEREOF FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA

(57) Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Formula I), or a pharmaceutically acceptable salt thereof. Further provided are pharmaceutical formulations and solid forms of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, and their use in the treatment of congenital adrenal hyperplasia (CAH).

EP 3 984 523 A1

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets
A61K 31/426;
A61K 31/573;
C07C 209/52;
C07C 249/02

Description

TECHNICAL FIELD

[0001] The present disclosure relates to 4-(2-chloro-4-methoxy5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for the treatment of congenital adrenal hyperplasia (CAH). The present disclosure further relates to pharmaceutical formulations and solid forms of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, and their use in the treatment of congenital adrenal hyperplasia (CAH).

BACKGROUND


[0002] Classic congenital adrenal hyperplasia (CAH) is a disease that includes a group of autosomal recessive disorders that result in an enzyme deficiency that alters the production of adrenal steroids due to 21-hydroxylase deficiency, a condition that results in little or no cortisol biosynthesis. One clinical manifestation of the absence of cortisol is the lack of feedback inhibition of pituitary adrenocorticotropic hormone (ACTH) secretion. Increased ACTH levels cause adrenal hyperplasia and the enzyme mutation causes a shunting of cortisol precursor steroids to alternate pathways. Most notably, the shunting of androgens leads to virilization and other developmental complications in females and the overaccumulation of ACTH is associated with the formation of testicular adrenal rest tumors in males. In addition, since the same enzyme (21-hydroxylase) is used in the pathway for the biosynthesis of the mineralocorticoids, a number of these patients suffer from aldosterone deficiency which can result in dehydration and death due to salt-wasting. The prevalence of classic 21-hydroxylase deficiency CAH in the US general population, based on newborn screening, has been documented as 1:10,000 to 1:20,800 (Trakakis et al., "An update to 21-hydroxylase deficient congenital adrenal hyperplasia," Gynecol. Endocrinol. (2010) 26(1):63-71; Hertzberg et al., "Birth prevalence rates of newborn screening disorders in relation to screening practices in the United States," J. Pediatr. (2011) 159(4):555-560).

[0003] Pediatric patients from birth through adolescence, and females in particular, appear to be the most vulnerable population of CAH sufferers and represent the subgroup of patients with the greatest unmet medical need (Cheng and Speiser, "Treatment outcomes in congenital adrenal hyperplasia," Adv. Pediatr. (2012) 59(1):269-281; Merke and Poppas, "Management of adolescents with congenital adrenal hyperplasia," Lancet Diabetes Endocrinol. (2013) 1(4):341-352). Excessive androgen production in these younger patients results in early onset puberty and adrenarche, changes in skeletal maturation patterns, short stature caused by premature growth plate fusion, as well as significant hirsutism and acne problems. While survival is properly ensured through steroid replacement strategies based on physiologic dosing of glucocorticoids (e.g., hydrocortisone) and mineralocorticoids (e.g., fludrocortisone), these doses are often inadequate to suppress the accumulating ACTH and overproduction of progestogens and androgens (e.g., 17-hydroxyprogesterone [17-OHP], androstenedione, and testosterone). The uncontrolled symptoms of androgen excess, indeed, have a substantial impact on the day-to-day functioning and development of these patients.

[0004] Currently, exogenous corticosteroids are the standard of care for treating patients with classic CAH. This treatment is used to correct the cortisol deficiency and reduce the excessive ACTH levels and androgen excess. However, the dose and duration of steroid use required to suppress ACTH are typically well above the normal physiological level used for cortisol replacement alone (as in patients with Addison's disease). This increased exposure to glucocorticoids can lead to iatrogenic Cushing's syndrome, increased cardiovascular risk factors, glucose intolerance, reduced growth velocity, and decreased bone mineral density in CAH patients (Elnecave et al., "Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency," J. Pediatr. Endocrinol. Metab. (2008) 21(12):1155-1162; King et al., "Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia," J. Clin. Endocrinol. Metab. (2006) 91(3):865-869; Migeon and Wisniewski, "Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations," Endocrinol. Metab. Clin. North Am. (2001) 30(1):193-206).

[0005] Corticotropin releasing factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature and acts on specific corticotropin releasing factor 1 (CRF1) receptors on corticotropes in the anterior pituitary to stimulate the release of ACTH. Blockade of these receptors has been shown to decrease the release of ACTH in both animals and humans. Therefore, compounds that block CRF1 receptors have the potential to directly inhibit the excessive ACTH release that occurs in CAH and thereby allow for normalization of androgen production while using lower, more physiologic doses of hydrocortisone.

[0006] The compound of Formula (I)



(I)


4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, is a selective CRF1 receptor antagonist. The compound of Formula (I) can be prepared according to the methods described in U.S. Patent Nos. 6,586,456 and 8,314,249, each of which is hereby incorporated by reference in its entirety. The compound of Formula (I) is a low solubility compound with low bioavailability. Partially due to its low solubility, attempts at formulating the compound of Formula (I) have proven to be difficult, particularly for formulations suitable for pediatric administration.

[0007] Thus, there is a need for a treatment for CAH that avoids the severe complications associated with corticosteroid therapy. There is also a need for a formulation of the compound of Formula (I) with increased bioavailability and a need for a formulation of the compound of Formula (I) that is suitable for pediatric administration. The formulations and methods of the present invention help address these and other needs.

SUMMARY

[0008] Provided herein is a pharmaceutical composition comprising:

(a) a compound of Formula (I):




(I)

or a pharmaceutically acceptable salt thereof; and
(b) one or more of an oily phase vehicle, an emulsifying agent, a nonionic surfactant, and a solubilizing agent.

[0009] Provided herein is a pharmaceutical composition in oral solution dosage form comprising:

(a) a compound of Formula (I):




(I)

or a pharmaceutically acceptable salt thereof;
(b) one or more of a sweetener, an anti-oxidant, and a flavor; and
(c) a liquid vehicle.

[0010] Also provided herein is a pharmaceutical composition of the present disclosure (e.g., a pharmaceutical composition in oral solution dosage form of the present disclosure) for use in therapy, for example, for use in any of the methods disclosed herein.

[0011] Provided herein is a method for treating congenital adrenal hyperplasia (CAH) comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine having the Formula (I):



(I)

or a pharmaceutically acceptable salt thereof.

[0012] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of treating congenital adrenal hyperplasia in a subject.

[0013] Also provided herein is use of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3- fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of treating congenital adrenal hyperplasia in a subject.

[0014] Provided herein is a method of treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in the subject.

[0015] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of treating congenital adrenal hyperplasia in a subject, wherein the compound, or pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in the subject.

[0016] Also provided herein is use of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of treating congenital adrenal hyperplasia in a subject, wherein the compound, or pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic

hormone (ACTH); and (c) androstenedione in the subject.

[0017] In some embodiments, the reduction in level of any of biomarkers is determined by comparing the level of the biomarker as measured during the circadian release on a day prior to administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof and the level of the biomarker as measured during the circadian release on the day after administering the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof. In some embodiments, the circadian release occurs between the hours of 2 a.m. and 10 a.m.

[0018] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered three to eight hours prior to the circadian release of the biomarker.

[0019] In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least 25%. In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least 50%.

[0020] In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 25%. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 40%. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 50%.

[0021] In some embodiments, the level of androstenedione is reduced by at least 25%. In some embodiments, the level of androstenedione is reduced by at least 30%. In some embodiments, the level of androstenedione is reduced by at least 50%.

[0022] In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least 50% and the level of androstenedione is reduced by at least 50%.

[0023] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

[0024] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

[0025] Provided herein is a method for reducing the severity of one or more symptoms selected from hirsutism, precocious puberty, fertility problems, acne, and growth impairment in a subject having classic congenital adrenal hyperplasia, comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce the level of androstenedione in the subject. In some embodiments, the growth impairment is selected from one or more of accelerated height velocity, accelerated weight velocity, or accelerated bone age.

[0026] Also provided herein is a compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing the severity of one or more symptoms selected from hirsutism, precocious puberty, fertility problems, acne, and growth impairment in a subject having classic congenital adrenal hyperplasia, wherein the compound, or pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce the level of androstenedione in the subject.

[0027] Also provided herein is use of a compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of reducing the severity of one or more symptoms selected from hirsutism, precocious puberty, fertility problems, acne, and growth impairment in a subject having classic congenital adrenal hyperplasia, wherein the compound, or pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce the level of androstenedione in the subject.

[0028] In some embodiments, the level of androstenedione is reduced by at least 25%. In some embodiments, the level of androstenedione is reduced by at least 30%. In some embodiments, the level of androstenedione is reduced by at least 50%.

[0029] Provided herein is a method of reducing the level of one or more biomarkers of congenital adrenal hyperplasia in a subject having congenital adrenal hyperplasia comprising administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

[0030] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing the level of one or more biomarkers of congenital adrenal hyperplasia in a subject having congenital adrenal hyperplasia.

[0031] Also provided herein is use of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable

salt thereof, in the manufacture of a medicament for use in a method of reducing the level of one or more biomarkers of congenital adrenal hyperplasia in a subject having congenital adrenal hyperplasia.

[0032] In some embodiments, the one or more biomarkers of congenital adrenal hyperplasia are selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

[0033] Provided herein is a method of reducing the dosage of corticosteroid administered to a subject having congenital adrenal hyperplasia for controlling congenital adrenal hyperplasia comprising administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof. In some embodiments, the corticosteroid is a glucocorticoid.

[0034] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing the dosage of corticosteroid administered to a subject having congenital adrenal hyperplasia.

[0035] Also provided herein is use of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3- fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of reducing the dosage of corticosteroid administered to a subject having congenital adrenal hyperplasia.

[0036] Provided herein is a method of reducing the severity of one or more side effects of glucocorticoid treatment in a subject having congenital adrenal hyperplasia comprising administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, wherein the side effect is selected from osteoporosis, avascular necrosis of bone, myopathy, hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, Cushing syndrome, Cushingoid features, growth suppression, adrenal suppression, gastritis, peptic ulcer, gastrointestinal bleeding, visceral perforation, hepatic steatosis, pancreatitis, hypertension, coronary heart disease, ischemic heart disease, heart failure, dermatoprosis, skin atrophy, ecchymosis, purpura, erosions, striae, delayed wound healing, easy bruising, acne, hirsutism, hair loss, mood changes, depression, euphoria, mood lability, irritability, akathisia, anxiety, cognitive impairment, psychosis, dementia, delirium, cataract, glaucoma, ptosis, mydriasis, opportunistic ocular infections, central serous chorioretinopathy, suppression of cell-mediated immunity, predisposition to infections, and reactivation of latent infections.

[0037] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing the severity of one or more side effects of glucocorticoid treatment in a subject having congenital adrenal hyperplasia, wherein the side effect is selected from osteoporosis, avascular necrosis of bone, myopathy, hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, Cushing syndrome, Cushingoid features, growth suppression, adrenal suppression, gastritis, peptic ulcer, gastrointestinal bleeding, visceral perforation, hepatic steatosis, pancreatitis, hypertension, coronary heart disease, ischemic heart disease, heart failure, dermatoprosis, skin atrophy, ecchymosis, purpura, erosions, striae, delayed wound healing, easy bruising, acne, hirsutism, hair loss, mood changes, depression, euphoria, mood lability, irritability, akathisia, anxiety, cognitive impairment, psychosis, dementia, delirium, cataract, glaucoma, ptosis, mydriasis, opportunistic ocular infections, central serous chorioretinopathy, suppression of cell-mediated immunity, predisposition to infections, and reactivation of latent infections.

[0038] Also provided herein is use of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of reducing the severity of one or more side effects of glucocorticoid treatment in a subject having congenital adrenal hyperplasia, wherein the side effect is selected from osteoporosis, avascular necrosis of bone, myopathy, hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, Cushing syndrome, Cushingoid features, growth suppression, adrenal suppression, gastritis, peptic ulcer, gastrointestinal bleeding, visceral perforation, hepatic steatosis, pancreatitis, hypertension, coronary heart disease, ischemic heart disease, heart failure, dermatoprosis, skin atrophy, ecchymosis, purpura, erosions, striae, delayed wound healing, easy bruising, acne, hirsutism, hair loss, mood changes, depression, euphoria, mood lability, irritability, akathisia, anxiety, cognitive impairment, psychosis, dementia, delirium, cataract, glaucoma, ptosis, mydriasis, opportunistic ocular infections, central serous chorioretinopathy, suppression of cell-mediated immunity, predisposition to infections, and reactivation of latent infections.

[0039] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to reduce the level of 17-hydroxyprogesterone (17-OHP) by at least 50% as compared to the level prior to administration.

[0040] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to reduce the level of androstenedione by at least 30% as compared to the level prior to administration.

[0041] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to (a) reduce the level of 17-hydroxyprogesterone (17-OHP) by at least 50% as compared to the level prior to administration; and (b) reduce the level of androstenedione by at least 30% as compared to the level prior to administration.

[0042] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to from about 25 mg to about 150 mg 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

[0043] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

[0044] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

[0045] Provided herein is a method of treating congenital adrenal hyperplasia in a subject comprising

(i) measuring the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in a biological sample obtained from the subject;
(ii) analyzing the level of the one or more biomarkers to determine if the level of the one or more biomarkers is elevated compared to a healthy subject not having congenital adrenal hyperplasia; and
(iii) administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof if the subject is determined to have elevated levels of the one or more biomarkers.

[0046] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of treating congenital adrenal hyperplasia in a subject comprising

(i) measuring the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in a biological sample obtained from the subject;
(ii) analyzing the level of the one or more biomarkers to determine if the level of the one or more biomarkers is elevated compared to a healthy subject not having congenital adrenal hyperplasia; and
(iii) administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(lS)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof if the subject is determined to have elevated levels of the one or more biomarkers.

[0047] Also provided herein is use of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of treating congenital adrenal hyperplasia in a subject, wherein the method comprises:

(i) measuring the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in a biological sample obtained from the subject;
(ii) analyzing the level of the one or more biomarkers to determine if the level of the one or more biomarkers is elevated compared to a healthy subject not having congenital adrenal hyperplasia; and
(iii) administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(lS)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof if the subject is determined to have elevated levels of the one or more biomarkers.

[0048] In some embodiments, the method further comprises (iv) measuring the level of the one or more biomarkers after administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in a biological sample obtained from the subject to determine whether the subject has reduced levels of the one or more biomarkers as compared with the measurement of step (i). In some embodiments, the method further comprises (v) continuing the administration of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof if the subject has reduced levels of the one or more biomarkers.

[0049] In some embodiments, steps (i) and (iv) are performed on biological samples taken from the subject in a similar manner and within a same time of day window. In some embodiments, steps (i) and (iv) are performed on biological samples taken from the subject within the time of day window from 2 a.m. to 10 a.m. In some embodiments, steps (i) and (iv) are performed on biological samples taken from the subject within the time of day window from 6 a.m. to 10 a.m.

[0050] In some embodiments, steps (i) and (iv) comprise measuring the levels of at least two biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

[0051] In some embodiments, steps (i) and (iv) comprise measuring the levels of (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

[0052] In some embodiments, step (i) comprises measuring the level of 17-hydroxyprogesterone (17-OHP), wherein the level of 17-hydroxyprogesterone (17-OHP) is elevated when it is greater than or equal to 1,000 ng/dL.

[0053] In some embodiments, step (i) comprises measuring the level of androstenedione, wherein the level of androstenedione is elevated when it is greater than 200 ng/dL.

[0054] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cycloptopyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to from about 25 mg to about 150 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base. In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base. In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

[0055] Provided herein is a method of treating congenital adrenal hyperplasia (CAH), in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, where in the subject is in a fed state.

[0056] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject, wherein the subject is in a fed state.

[0057] Also provided herein is use of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject, wherein the subject is in a fed state.

[0058] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered to the subject with a nutritional composition. In some embodiments, the nutritional composition is a liquid dietary supplement comprising about 1500 calories per liter with a caloric distribution of about 14.7% protein, about 32% fat and about 53.3% carbohydrate. In some embodiments, the nutritional composition is administered in an amount of about 8 fluid ounces. In some embodiments, the nutritional composition is administered within 30 minutes of administration of the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

[0059] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered to the subject with a nutritional composition. In some embodiments, the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate. In some embodiments, the nutritional composition is administered in an amount of about 8 fluid ounces. In some embodiments, the nutritional composition is administered within 30 minutes of administration of the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

[0060] In some embodiments, administering the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, exhibits a positive food effect. In some embodiments, the positive food effect is measured in terms of C_{max}, AUC, or combinations thereof when comparing oral administration of the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the fed and fasting states.

[0061] In some embodiments, the ratio of the AUC in the fed state to the AUC in the fasted state is about 5 to about 10. In some embodiments, the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is about 5 to about 10.

[0062] Provided herein is a method of reducing glucocorticoid burden in a subject as measured after a time period of administration of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, wherein the decrease in glucocorticoid burden is relative to the glucocorticoid burden prior to administration of the compound, or pharmaceutically acceptable salt thereof.

[0063] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing glucocorticoid burden in a subject, wherein the decrease in glucocorticoid burden is relative to the glucocorticoid burden prior to administration of the compound, or pharmaceutically acceptable salt thereof.

[0064] Also provided herein is use of a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of reducing glucocorticoid burden in a subject, wherein the decrease in glucocorticoid burden is relative to the glucocorticoid burden prior to administration of the compound, or pharmaceutically acceptable salt thereof.

[0065] Provided herein is a method of improving one or more symptoms selected from quality of life, fatigue, sleep, insulin resistance, glucose tolerance, glucose control, dyslipidemia, hyperlipidemia, bone mineral density, bone turnover, fat mass, weight, central obesity, blood pressure, hirsutism severity, menstrual cyclicity, control of testicular adrenal rest tumor and fertility in a subject having classic congenital adrenal hyperplasia, comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, wherein the symptom is improved after a time period of administration of the compound, or pharmaceutically acceptable salt thereof, wherein the improvement in the one or more symptoms is relative to the status of the one or more symptoms prior to administration of the compound, or pharmaceutically acceptable salt thereof.


[0066] Also provided herein is a compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of improving one or more symptoms selected from quality of life, fatigue, sleep, insulin resistance, glucose tolerance, glucose control, dyslipidemia, hyperlipidemia, bone mineral density, bone turnover, fat mass, weight, central obesity, blood pressure, hirsutism severity, menstrual cyclicity, control of testicular adrenal rest tumor and fertility in a subject having classic congenital adrenal hyperplasia, wherein the symptom is improved after a time period of administration of the compound, or pharmaceutically acceptable salt thereof, wherein the improvement in the one or more symptoms is relative to the status of the one or more symptoms prior to administration of the compound, or pharmaceutically acceptable salt thereof.

[0067] Also provided herein is use of a compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of improving one or more symptoms selected from quality of life, fatigue, sleep, insulin resistance, glucose tolerance, glucose control, dyslipidemia, hyperlipidemia, bone mineral density, bone turnover, fat mass, weight, central obesity, blood pressure, hirsutism severity, menstrual cyclicity, control of testicular adrenal rest tumor and fertility in a subject having classic congenital adrenal hyperplasia, wherein the symptom is improved after a time period of administration of the compound, or pharmaceutically acceptable salt thereof, wherein the improvement in the one or more symptoms is relative to the status of the one or more symptoms prior to administration of the compound, or pharmaceutically acceptable salt thereof.

[0068] Also provided herein is a compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof for use in therapy, for example, for use in any of the methods disclosed herein.

[0069] Also provided herein is use of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(lS)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for manufacture of a medicament for use in any of the methods disclosed herein.

[0070] Also provided herein is a spray-dried dispersion containing 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine having the Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, and a polymer. In some embodiments, the polymer is selected from a neutral polymer, an enteric polymer, and a pyrrolidone polymer. In some embodiments, the weight ratio of the compound of Formula (I) to the polymer is from about 1:9 to about 1:1.

[0071] In some embodiments, the polymer is a neutral polymer. In some embodiment, the neutral polymer is selected from hydroxypropyl methylcellulose (HPMC) and hydroxyethyl cellulose (HEC).


[0072] In some embodiments, the polymer is an enteric polymer. In some embodiments, the enteric polymer is selected from hydroxypropyl methyl cellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), hydroxypropyl methyl cellulose phthalate (HPMCP), an amino methacrylate copolymer, an ammonioalkyl methacrylate copolymer, and a methacrylic copolymer.

[0073] In some embodiments, the polymer is a pyrrolidone polymer. In some embodiments, the pyrrolidone polymer is selected from polyvinyl pyrrolidone (PVP) and a polyvinyl pyrrolidone vinyl acetate (PVP/VA). In some embodiments, the pyrrolidone polymer is PVP/VA. In some embodiments, the copolymer comprises 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 40:60 to about 60:40 by weight. In some embodiments, the copolymer comprises 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 60:40 by weight. In some embodiments, the copolymer has the structure:




wherein the value of n is about 1 to about 2 times the value of m. In some embodiments, the copolymer is copovidone, wherein the value of n is about 1.16 times the value of m. In some embodiments, the copolymer is copovidone having an average molecular weight of about 45,000 to about 70,000.

[0074] Provided herein is a spray-dried dispersion comprising 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine having the Formula (I):



(I)

or a pharmaceutically acceptable salt thereof; and a polymer that is a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate having the structure:



wherein the value of n is about 1 to about 2 times the value of m and the copolymer comprises 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 60:40 by weight; and wherein the weight ratio of the compound of Formula (I) to the copolymer is from about 1:1 to about 1:9.

[0075] In some embodiments of the spray-dried dispersions of the present disclosure, the compound of Formula (I) and the polymer together form homogeneous particles. In some embodiments, the particles have a particle size distribution D_{50} of about 5 μm to about 100 μm. In some embodiments, the particles have a particle size distribution D_{50} of about 10 μm to about 50 μm. In some embodiments, the particles have a particle size distribution D_{50} of about 15 μm to about 30 μm.

[0076] In some embodiments, the weight ratio of the compound of Formula (I) to the polymer is from about 1:1.5 to about 1:9. In some embodiments, the weight ratio of the compound of Formula (I) to the polymer is from about 1:2.5 to about 1:4. In some embodiments, the weight ratio of the compound of Formula (I) to the polymer is about 1:3.

[0077] In some embodiments, the particles have a residual solvent content less than about 2 wt %. In some embodiments, the particles have a residual solvent content less than about 1 wt %. In some embodiments, the particles have a residual solvent content of about 0.5 wt % or less.

[0078] In some embodiments, the compound of Formula (I) in the dispersion is substantially amorphous.

[0079] Also provided herein is a method for preparing a spray-dried dispersion of the present disclosure, comprising: dissolving the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the polymer in an organic solvent to form a solution; and spray-drying the solution to produce the spray-dried dispersion, wherein the spray-drying forms homogeneous particles of the compound of Formula (I) and the polymer.

[0080] In some embodiments, the method comprises removing the organic solvent after formation of the spray-dried dispersion by drying the spray-dried dispersion. In some embodiments, the spray-dried dispersion is dried with a convection tray dryer. In some embodiments, the organic solvent is acetone.

[0081] In some embodiments, the spray dryer inlet temperature is about 60°C to about 80°C. In some embodiments, the spray dryer inlet temperature is about 72°C.

[0082] In some embodiments, the spray dryer outlet temperature is about 25°C to about 45°C. In some embodiments, the spray dryer outlet temperature is about 35°C.

[0083] In some embodiments, the homogeneous particles comprise a bulk density of less than about 0.2 g/mL. In some embodiments, the homogeneous particles comprise a bulk density of less than about 0.15 g/mL.

[0084] In some embodiments, the homogeneous particles comprise a tapped density of less than about 0.3 g/mL. In some embodiments, the homogeneous particles comprise a tapped density of less than about 0.25 g/mL.

[0085] Also provided herein is a pharmaceutical composition comprising the spray-dried dispersion of the present disclosure and one or more pharmaceutically acceptable excipients. In some embodiments, the spray-dried dispersion is present in an amount of about 20% to about 90% w/w of the composition. In some embodiments, the spray-dried dispersion is present in an amount of about 40% to 80% w/w of the composition.

[0086] In some embodiments, the pharmaceutical excipients are selected from the group consisting of a filler, a lubricant, and combinations thereof. In some embodiments, the filler is selected from the group consisting of a binder, a diluent, a disintegrant, a glidant, a surfactant, and combinations thereof.

[0087] In some embodiments, the pharmaceutical composition is formulated in unit dosage form, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg to about 200 mg. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 75 mg to about 150 mg. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 50 mg. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 100 mg.

[0088] In some embodiments, the pharmaceutical composition is formulated as a tablet, capsule, sachet, powder, granules, coated particle, coated tablet, enterocoated tablet, enterocoated capsule, melting strip, or melting film. In some

embodiments, the pharmaceutical composition is in tablet form. In some embodiments, the pharmaceutical composition is in capsule form. In some embodiments, the pharmaceutical composition is coated.

[0089] In some embodiments, the spray-dried dispersion is formulated for oral administration and exhibits a positive food effect when administered orally. In some embodiments, the spray-dried dispersion has a ratio of the AUC in the fed state to the AUC in the fasted state of about 5 to about 10. In some embodiments, wherein the spray-dried dispersion has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 5 to about 10.

[0090] Also provided herein is a method for preparing a pharmaceutical composition, comprising combining the spray-dried dispersion of the present disclosure with one or more pharmaceutically acceptable excipients.

[0091] Also provided herein is a method of treating congenital adrenal hyperplasia (CAH), in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a spray-dried dispersion of the present disclosure or a pharmaceutical composition comprising a spray-dried dispersion of the present disclosure.

[0092] Also provided herein is a spray-dried dispersion of the present disclosure or a pharmaceutical composition comprising a spray-dried dispersion of the present disclosure for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject.

[0093] Also provided herein is use of a spray-dried dispersion of the present disclosure in the manufacture of a medicament for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject.

[0094] In some embodiments, the spray-dried dispersion or the pharmaceutical composition is administered to the subject in a fed state. In some embodiments, the spray-dried dispersion or the pharmaceutical composition is administered to the subject with a nutritional composition. In some embodiments, the nutritional composition is a liquid dietary supplement comprising about 1000 to about 2000 calories per liter with a fat content greater than 30%. In some embodiments, the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate. In some embodiments, the nutritional composition is administered in an amount of about 8 fluid ounces. In some embodiments, the nutritional composition is administered within 30 minutes of administration of the spray-dried dispersion or the pharmaceutical composition.

[0095] In some embodiments, administering the spray-dried dispersion or the pharmaceutical composition exhibits a positive food effect. In some embodiments, the positive food effect is measured in terms of C_{max}, AUC, or combinations thereof when comparing oral administration of the spray-dried dispersion or pharmaceutical composition in the fed and fasting states. In some embodiments, the ratio of the AUC in the fed state to the AUC in the fasted state is about 5 to about 10. In some embodiments, the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is about 5 to about 10. In some embodiments, the ratio of the AUC in the fed state to the AUC in the fasted state is about 10 to about 20. In some embodiments, the ratio of the Cmax in the fed state to the C_{max} in the fasted state is about 10 to about 20.

[0096] In some embodiments of the disclosed methods, the subject is a pediatric subject.

[0097] Also provided herein is a spray-dried dispersion of the present disclosure or a pharmaceutical composition comprising a spray-dried dispersion of the present disclosure, for use in therapy, for example, for use in any of the methods disclosed herein.

[0098] Also provided herein is use of a spray-dried dispersion of the present disclosure for manufacture of a medicament for use in any of the methods disclosed herein.

[0099] Also provided herein is a method of treating congenital adrenal hyperplasia (CAH), in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the present disclosure, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0100] Also provided herein is a pharmaceutical composition of the present disclosure, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject.

[0101] Also provided herein is use of pharmaceutical composition of the present disclosure, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject.

[0102] Also provided herein is pharmaceutical composition of the present disclosure, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy, for example, for use in any of the methods disclosed herein.

[0103] Also provided herein is use of pharmaceutical composition of the present disclosure, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, for manufacture of a medicament for use in any of the methods disclosed herein.

[0104] Also provided herein is a method of improving gastrointestinal absorption of a compound of Formula (I) in a subject, comprising orally administering to the subject a therapeutically effective amount of a spray-dried dispersion of the present disclosure or a pharmaceutical composition comprising a spray-dried dispersion of the present disclosure, wherein the improvement is relative to oral administration of the compound of Formula (I) which has not been prepared

as a spray-dried dispersion.

[0105] Also provided herein is a spray-dried dispersion of the present disclosure or a pharmaceutical composition comprising a spray-dried dispersion of the present disclosure, for use in a method of improving gastrointestinal absorption of a compound of Formula (I) in a subject, wherein the improvement is relative to oral administration of the compound of Formula (I) which has not been prepared as a spray-dried dispersion.

[0106] Also provided herein is use of a spray-dried dispersion of the present disclosure in the manufacture of a medicament for use in a method of improving gastrointestinal absorption of a compound of Formula (I) in a subject, wherein the improvement is relative to oral administration of the compound of Formula (I) which has not been prepared as a spray-dried dispersion.

[0107] In some embodiments, the subject is a pediatric subject.

[0108] Also provided herein is a method of improving oral bioavailability of a compound of Formula (I) in a subject, comprising orally administering to the subject a therapeutically effective amount of a spray-dried dispersion of the present disclosure or a pharmaceutical composition comprising a spray-dried dispersion of the present disclosure, wherein the improvement is relative to oral administration of the compound of Formula (I) which has not been prepared as a spray-dried dispersion.

[0109] Also provided herein is a spray-dried dispersion of the present disclosure or a pharmaceutical composition comprising a spray-dried dispersion of the present disclosure, for use in a method of improving oral bioavailability of a compound of Formula (I) in a subject, wherein the improvement is relative to oral administration of the compound of Formula (I) which has not been prepared as a spray-dried dispersion.

[0110] Also provided herein is use of a spray-dried dispersion of the present disclosure in the manufacture of a medicament for use in a method of improving oral bioavailability of a compound of Formula (I) in a subject, wherein the improvement is relative to oral administration of the compound of Formula (I) which has not been prepared as a spray-dried dispersion.

[0111] In some embodiments, the subject is a pediatric subject.

[0112] Also provided herein is a crystalline salt, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, p-toluenesulfonic acid salt.

[0113] Also provided herein is a crystalline salt, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, p-toluenesulfonic acid salt, for use in therapy, for example, for use in any of the methods disclosed herein.

[0114] Also provided herein is use of a crystalline salt, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, p-toluenesulfonic acid salt, for manufacture of a medicament for use in any of the methods disclosed herein.

[0115] Other features and advantages of the methods, processes, formulations, and uses provided herein will be apparent from the following detailed description and figures, and from the claims.

DESCRIPTION OF DRAWINGS

[0116]

FIG. 1 shows the dissolution performance of several spray-dried dispersion formulations in 0.5 wt% simulated intestinal fluid (SIF) in phosphate buffered saline (PBS), pH 6.5.

FIG. 2 shows the vertical membrane flux cell integrated in the μDiss Profiler™ used for the membrane flux assay.

FIG. 3 shows non-sink dissolution data for several spray-dried dispersion formulations and the compound of Formula (I) in 0.5 wt% SIF in PBS, pH 6.5.

FIG. 4 is a graph showing membrane flux of 1 mg/mL GB/IB 0.5 wt% SIF doses of the compound of Formula (I) and various spray-dried dispersion formulations over time. The solid lines indicate flux (μg min^{-1} cm^{-2}) and the broken lines indicate concentration (μg/mL) in 0.5% SIF.

FIG. 5 is a flow diagram of the spray drying manufacturing process used to prepare a 1000 g batch of a SDD containing 25% of the compound of Formula (I) and 75% PVP/VA 64.

FIGS. 6A and 6B are line graphs showing the pharmacokinetic results of a bioavailability and food effect study in dogs. FIG. 6A shows the results from Cohort 1 and FIG. 6B shows the results from Cohort 2.

FIG. 7 is a flow chart showing the study design of a Phase 1 study of the pharmacokinetics and food effect of the compound of Formula (I) in healthy adult subjects.

FIGS. 8A and 8B are line graphs showing the mean plasma concentration versus time profiles for the compound of Formula (I) under fasted and fed conditions, respectively, in healthy adult subjects.

FIGS. 9A-9C are spaghetti plots of the pharmacokinetics of the compound of Formula (I) in healthy adult subjects under fasted and fed conditions. FIG. 9A shows the $AUC_{0\text{-tlast}}$ values. FIG. 9B shows the $AUC_{0\text{-}\infty}$ values. FIG. 9C shows the C_{max} values.

FIG. 10 is a flow chart showing the study design of a Phase 1 study of the bioavailability, pharmacokinetics and food effect of the compound of Formula (I) in healthy adult subjects.

FIG. 11 shows the study design of a Phase 2 study of the compound of Formula (I) in adult subjects with congenital adrenal hyperplasia.

FIGs. 12A and 12B show the arithmetic mean values for adrenocorticotropic hormone (ACTH) (FIG. 12A) and 17-hydroxyprogesterone (17-OHP) (FIG. 12B) for all 8 Cohort 1 subjects plotted at each time point for pre-treatment baseline (circles), day 1 (squares), and day 14 (triangles).

FIGs. 13A and 13B show arithmetic mean values for androstenedione (FIG. 13A) and testosterone (FIG. 13B) for all 8 Cohort 1 subjects were plotted at each timepoint for pre-treatment baseline (circles), day 1 (squares), and day 14 (triangles).

FIGs. 14A and 14B show the reduction of ACTH at timepoints 8-, 10-, and 12-hours postdose. FIG 14A shows the values for each time point as compared to baseline. FIG. 14B shows the mean values across all three timepoints.

FIGs. 15A and 15B show the reduction of 17-OHP at timepoints 8-, 10-, and 12-hours postdose. FIG 15A shows the values for each time point as compared to baseline. FIG. 15B shows the mean values across all three timepoints.

FIGs. 16A and 16B show the reduction of androstenedione at timepoints 8-, 10-, and 12-hours postdose. FIG 16A shows the values for each time point as compared to baseline. FIG. 16B shows the mean values across all three timepoints.

FIG. 17A shows the plasma ACTH Mean Blood Concentrations following the compound of Formula (I) 50 mg Dose qhs (Cohort 1; n=8). Error bars represent the standard error of the mean for each morning window timepoint. ACTH normal ranges: Female 6 to 58 pg/mL; Male 7 to 69 pg/mL.

FIG. 17B shows the serum 17-OHP Mean Blood Concentrations following the compound of Formula (I) 50 mg Dose qhs (Cohort 1; n=8). Error bars represent the standard error of the mean for each morning window timepoint. 17-OHP normal ranges: Female < 207 ng/dL; Male < 139 ng/dL.

FIG. 17C: shows the serum Androstenedione Mean Blood Concentrations following the compound of Formula (I) 50 mg Dose qhs (Cohort 1; n=8). Error bars represent the standard error of the mean for each morning window timepoint. Androstenedione normal ranges: Female 26 to 214 ng/mL; Male 33 to 134 ng/mL.

FIG. 18A shows the plasma ACTH Mean Blood Concentrations following the compound of Formula (I) 100 mg Dose qhs (Cohort 2; n=4). Error bars represent the standard error of the mean for each morning window timepoint. ACTH normal ranges: Female 6 to 58 pg/mL; Male 7 to 69 pg/mL.

FIG. 18B shows the serum 17-OHP Mean Blood Concentrations following the compound of Formula (I) 100 mg Dose qhs (Cohort 2; n=4). Error bars represent the standard error of the mean for each morning window timepoint. 17-OHP normal ranges: Female < 207 ng/dL; Male < 139 ng/dL.

FIG. 18C shows the serum Androstenedione Mean Blood Concentrations following the compound of Formula (I) 100 mg Dose qhs (Cohort 2; n=4). Error bars represent the standard error of the mean for each morning window timepoint. Androstenedione normal ranges: Female 26 to 214 ng/mL; Male 33 to 134 ng/mL.

FIG. 19A shows the plasma ACTH Mean Blood Concentrations following the compound of Formula (I) 100 mg Dose with Evening Meal (Cohort 3). Error bars represent the standard error of the mean for each morning window timepoint. ACTH normal ranges: Female 6 to 58 pg/mL; Male 7 to 69 pg/mL.

FIG. 19B shows the serum 17-OHP Mean Blood Concentrations following the compound of Formula (I) 100 mg Dose with Evening Meal (Cohort 3). Error bars represent the standard error of the mean for each morning window timepoint. 17-OHP normal ranges: Female < 207 ng/dL; Male < 139 ng/dL.

FIG. 19C shows the serum Androstenedione Mean Blood Concentrations following the compound of Formula (I) 100 mg Dose with Evening Meal (Cohort 3). Error bars represent the standard error of the mean for each morning window timepoint. Androstenedione normal ranges: Female 26 to 214 ng/mL; Male 33 to 134 ng/mL.

FIG. 20 is a scheme showing the manufacturing process for forming 50 mg capsules of the compound of Formula (I).

FIG. 21 is an alternative scheme showing the manufacturing process for forming 50 mg capsules of the compound of Formula (I).

FIGs. 22A and 22B show a scheme showing the manufacturing process for forming SDD granules of the compound of Formula (I).

FIG. 23 is a scheme showing the manufacturing process for forming 50 mg/nL liquid formulation 1 of the compound of Formula (I).

FIG. 24 is a scheme showing the manufacturing process for forming 50 mg/nL liquid formulation 2 of the compound of Formula (I).

FIG. 25 is an XRPD spectrum of the compound of Formula (I) free base crystalline form I.


FIG. 26 is a DSC spectrum of the compound of Formula (I) free base crystalline form I.

FIG. 27 is an XRPD spectrum of the compound of Formula (1) tosylate crystalline form 1.

FIG. 28 is a DSC and TGA spectrum of the compound of Formula (I) tosylate crystalline form 1.

DETAILED DESCRIPTION

[0117] As described herein, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine having the Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, is a selective CRF1 receptor antagonist that has been found to be effective treating congenital adrenal hyperplasia. Specifically, the compound of Formula (I) has been found to effectively reduce several biomarkers associated with congenital adrenal hyperplasia.

[0118] Newborn screening for CAH is performed by immunoassay to measure 17-OHP levels in heel-stick capillary blood specimens obtained within the first 72 hours of life. The blood sample is analyzed for 17-OHP by commercially available dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA; PerkinElmer, Waltham Massachusetts) (White et al., J. Pediatr. 163:10-12 (2013)). Second-tier screening tests utilizing biochemical and molecular genetic testing methods, performed between 8 and 14 days of life, are employed by nine states in the United States and strongly recommended by an additional 5 states. The biochemical method includes immunoassay with organic solvent extraction or liquid chromatography followed by tandem mass spectrometry to measure steroid ratios of 17-OHP, androstenedione, and 21-deoxycortisol to cortisol *(see, e.g.,* Speiser et al., Int. J. Pediatr. Endocrinol. 2010:494173, 2010). The genetic screen looks for *CYP21A2* mutations that are associated with CAH. While not widely employed in the U.S., the addition of a second screening could potentially improve the sensitivity of the overall screening process, where sensitivity of the first screen alone is approximately 72%.

[0119] In absence of results from the newborn screening, female infants with classical CAH are typically identified due to the presence of ambiguous genitalia. Males have normal genitalia at birth and therefore are not diagnosed unless newborn screening is conducted or other medical complications come to attention. Infants who are not initially diagnosed with CAH and suffer from the salt-wasting form of the disease are later diagnosed in the setting of poor weight gain, vomiting, hyperkalemia and hyponatremia within the first few weeks of life.

[0120] Treatment of CAH is based on normalization of hormone and steroid levels using a variety of medications from diagnosis in infancy through adulthood. Glucocorticoids are the current standard treatment in CAH and are used both to correct the endogenous cortisol deficiency and for reducing the elevated ACTH levels from the pituitary, which drives increased androgen production. Unlike the treatment of Addison's disease (adrenal insufficiency), in which cortisol replacement is sufficient, the treatment of CAH must also reduce ACTH production, to control the subsequent androgen excess as well. Thus, the goals of glucocorticoid treatment include cortisol replacement and suppression of ACTH to prevent virilization and menstrual disturbances in women and to inhibit testicular adrenal rest tumors in men. Mineralocorticoid replacement is needed to achieve normal plasma renin activity for maintenance of regular blood pressure, electrolyte balance, and volume status in those patients with the salt-wasting form of CAH.

[0121] The regimen of glucocorticoid treatment must support normal physiology and also ensure that sufficient cortisol is available during events that may elicit a strong stress response (e.g., intercurrent illness, exercise, hypotension). Careful monitoring is also necessary to avoid the development of iatrogenic Cushing's syndrome due to glucocorticoid overtreatment in an effort to adequately suppress androgen production, or Addisonian syndrome due to under-treatment.

[0122] Overtreatment with mineralocorticoids may cause hypertension while under-treatment may lead to low blood pressure, salt loss, fatigue and increased requirements for glucocorticoids. Typical laboratory tests for monitoring treatment efficacy include measurement of plasma concentrations of 17-OHP, androstenedione, testosterone, renin activity, and electrolytes. Adult patients with CAH have an increased prevalence of risk factors for cardiovascular disease including obesity, hypertension, and insulin resistance *(see, e.g.,* Kim et al., Semin. Reprod. Med. 27(4):316-21 (2009)). A study of a large cohort of pediatric and adult CAH patients (n=244) demonstrated that patients are prescribed a variety of glucocorticoid treatment regimens yet frequently suffer from poor hormonal control and the aforementioned adverse outcomes *(see, e.g.,* Finkielstain et al., J. Clin. Endocrinol Metab. 97(12):4429-38 (2012)).

[0123] Treatment of CAH includes efforts to normalize the cortisol deficiency with glucocorticoids (usually hydrocor-

tisone in children but often more potent agents with narrow therapeutic indices, such as dexamethasone, in adults) and, if necessary for salt-wasting, mineralocorticoids (usually fludrocortisone). The glucocorticoid doses required to achieve sufficient suppression of excess androgens, however, are usually well above the normal physiologic dose used for cortisol replacement alone as in patients with Addison's disease. This increased exposure to glucocorticoids can lead to iatrogenic Cushing's syndrome, increased cardiovascular risk factors, glucose intolerance, and decreased bone mineral density in CAH patients *(see, e.g.,* Elnecave et al., J. Pediatr. Endocrinol. Metab. 21:1155-62 (2008); King et al., J. Clin. Endocrinol. Metab. 91(3):8656-59 (2006); Migeon et al., Endocrinol. Metab. Clin. North Am. 30:193-206 (2001)). Recently, best practices for the clinical management of congenital adrenal hyperplasia were published in the *Journal of Clinical Endocrinology and Metabolism* (Speiser, P.W., et al. J. Clin. Endocrinol Metab. November 2018, 103(11): 1-46). This article is incorporated by reference in its entirety.

[0124] Corticotropin-releasing factor (CRF) was isolated from ovine hypothalami and identified as a 41-amino acid peptide. CRF has been found to produce profound alterations in endocrine, nervous, and immune system function. CRF is believed to be the major physiological regulator of the basal and stress-induced release of adrenocorticotropic hormone ("ACTH"), β-endorphin, and other pro-opiomelanocortin ("POMC")-derived peptides from the anterior pituitary (see, *e.g.,* Vale et al., Science 213:1394-1397,1981). Secretion of CRF causes release of ACTH from corticotrophs in the anterior pituitary via binding to the CRF_1 receptor, a member of the class B family of G-protein coupled receptors.

[0125] Due to the physiological significance of CRF, the development of biologically-active small molecules having significant CRF_1 receptor binding activity and which are capable of antagonizing the CRF_1 receptor remains a desirable goal and has been the subject of ongoing research and development for the treatment of anxiety, depression, irritable bowel syndrome, post-traumatic stress disorder, and substance abuse.

[0126] The pituitary hormone ACTH, under the control of hypothalamic corticotropin-releasing factor (CRF), stimulates uptake of cholesterol and drives the synthesis of pregnenolone initiating steroidogenesis in the adrenal gland. The adrenal cortex is comprised of three zones, which produce distinct classes of hormones many of which are driven by ACTH mobilizing cholesterol through this pathway. Deficiencies in these enzymes as a result of mutation or deletion cause the substrate concentrations to increase. In the most common form of CAH resulting from mutations or deletions in the 21-hydroxylase gene (CYP21A2), potent androgens are produced by the adrenal because of the accumulation of the steroid precursors, progesterone and 17-hydroxyprogesterone (17-OHP). Plasma levels of 17-OHP can reach 10-1000 times the normal concentration in these cases. These increases result in the overproduction of androgens, specifically androstenedione, testosterone, and dihydroxytestosterone causing virilization in females. In addition, 21-hydroxylase deficiency in CAH causes insufficient biosynthesis of glucocorticoids and mineralocorticoids, specifically cortisol and aldosterone. Cortisol is a critical negative feedback regulator of hypothalamic CRF secretion and pituitary ACTH release. The lack of glucocorticoid synthesis and release eliminates the restraint on the hypothalamus and pituitary, which causes ACTH levels to increase. The excessive ACTH stimulation causes hypertrophy of the zona fasciculata and zona reticularis resulting in adrenal hyperplasia.

Definitions

[0127] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Methods and materials are described herein for use in the present disclosure; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

[0128] The term "about" preceding a value for DSC, TGA, or T_g, which are reported as degrees Celsius, have an allowable variability of ±5°C. In all other instances, unless otherwise specified, the term "about" preceding a stated value includes the stated value and also includes ±20% of the stated value, and includes more specifically values of ±10%, ±5%, ±2%, and ±1% of the stated value.

[0129] To provide a more concise description, some of the quantitative expressions herein are recited as a range from about amount X to about amount Y. It is understood that when a range is recited, the range is not limited to the recited upper and lower bounds, but rather includes the full range from about amount X through about amount Y, or any range therein.

[0130] "Room temperature" or "RT" refers to the ambient temperature of a typical laboratory, which is typically around 25°C.

[0131] "Spray-drying" refers to the method of producing a dry powder from a solution or slurry. The solution or slurry is atomized or rapidly dried with a hot gas, e.g., air or nitrogen, that causes the solvent to evaporate quickly and uniformly. A "spray-dried dispersion" refers to the powder obtained from the spray-drying process.

[0132] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, antibacterial and antifungal agents, isotonic

and absorption delaying agents, and the like, which are not biologically or otherwise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic formulations is contemplated. Supplementary active ingredients can also be incorporated into the fonnulations. In addition, various excipients, such as are commonly used in the art, can be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, NJ. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (2010); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 12th Ed., The McGraw-Hill Companies.

[0133] "Subject," as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. In some embodiments, the subject is a human.

[0134] In some embodiments, the subject has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented. In some embodiments, the subject has been identified or diagnosed as having congenital adrenal hyperplasia (CAH). In some embodiments, the subject is suspected of having CAH. In some embodiments, the subject has a clinical record indicating that the subject has CAH (and optionally the clinical record indicates that the subject should be treated with any of the compositions provided herein). In some embodiments, the subject is a pediatric subject.

[0135] The term "pediatric subject" as used herein refers to a subject under the age of 21 years at the time of diagnosis or treatment. The term "pediatric" can be further divided into various subpopulations including: neonates (from birth through the first month of life); infants (1 month up to two years of age); children (two years of age up to 12 years of age); and adolescents (12 years of age through 21 years of age (up to, but not including, the twenty-second birthday)). Berhman et al., Textbook of Pediatrics, 15th Ed. Philadelphia: W.B. Saunders Company, 1996; Rudolph et al., Rudolph's Pediatrics, 21st Ed. New York: McGraw-Hill, 2002; and Avery et al., Pediatric Medicine, 2nd Ed. Baltimore: Williams & Wilkins; 1994. In some embodiments, a pediatric subject is from birth through the first 28 days of life, from 29 days of age to less than two years of age, from two years of age to less than 12 years of age, or 12 years of age through 21 years of age (up to, but not including, the twenty-second birthday). In some embodiments, a pediatric subject is from birth through the first 28 days of life, from 29 days of age to less than 1 year of age, from one month of age to less than four months of age, from three months of age to less than seven months of age, from six months of age to less than 1 year of age, from 1 year of age to less than 2 years of age, from 2 years of age to less than 3 years of age, from 2 years of age to less than seven years of age, from 3 years of age to less than 5 years of age, from 5 years of age to less than 10 years of age, from 6 years of age to less than 13 years of age, from 10 years of age to less than 15 years of age, or from 15 years of age to less than 22 years of age.

[0136] As used herein, the terms "treat" or "treatment" refer to therapeutic or palliative measures. Beneficial or desired clinical results include, but are not limited to, alleviation, in whole or in part, of symptoms associated with a disease or disorder or condition, diminishment of the extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state (e.g., one or more symptoms of the disease), and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment.

[0137] The term "preventing," as used herein, means the prevention of the onset, recurrence or spread, in whole or in part, of the disease or condition as described herein, or a symptom thereof.

[0138] The term "administration" or "administering" refers to a method of giving a dosage of a compound or pharmaceutical formulation to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian. The preferred method of administration can vary depending on various factors, e.g., the components of the pharmaceutical formulation, the site of the disease, and the severity of the disease.

[0139] As used herein, "therapeutically effective amount" is an amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, or an amount of a pharmaceutical composition comprising the compound of Formula (I), which is sufficient to achieve the desired effect and can vary according to the nature and severity of the disease condition, and the potency of the compound. A therapeutic effect is the relief, to some extent, of one or more of the symptoms of the disease, and can include curing a disease. "Curing" means that the symptoms of active disease are eliminated. However, certain long-term or permanent effects of the disease can exist even after a cure is obtained (such as, e.g., extensive tissue damage).

[0140] The term "amorphous" means a solid in a solid state that is a non-crystalline state. Amorphous solids are disordered arrangements of molecules and therefore possess no distinguishable crystal lattice or unit cell and consequently have no definable long range ordering. The solid state form of a solid may be determined by polarized light microscopy, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), or other standard techniques known to those of skill in the art.

[0141] As used herein, "time of day window" refers to a period of time defined by a window start time and a window stop time. These times all refer to local times where a sample was taken. The phrase "same time of day window" when

referring to samples taken from the subject mean, e.g., that a sample taken at 8:15 a.m. and a sample taken at 9:15 a.m. are considered to be taken in the same time of day window of, e.g., 2 a.m. to 10 a.m. or 6 a.m. to 10 a.m.

Methods

[0142] The present disclosure relates to methods of treating congenital adrenal hyperplasia (CAH). The methods include administering to a subject a therapeutically effective amount of a compound of Formula (I), or pharmaceutically acceptable salt thereof. In some embodiments, the method includes administering to a subject a therapeutically effective amount of a SDD of the present disclosure that includes a polymer and a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the method includes administering to a subject a therapeutically effective amount of pharmaceutical composition of the present disclosure that contains a SDD that includes a polymer and a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0143] Provided herein is a method of treating congenital adrenal hyperplasia (CAH) comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof to normalize or partially normalize levels of biomarkers associated with congenital adrenal hyperplasia. In some embodiments, normalizing or partially normalizing levels of biomarkers comprises reducing levels of elevated biomarkers or increasing levels of depressed biomarkers as compared to subject without CAH.

[0144] Provided herein is a method of treating congenital adrenal hyperplasia in a subject in need thereof comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce the level of one or more biomarkers associated with congenital adrenal hyperplasia. In some embodiments, the biomarkers are selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in the subject.

[0145] In some embodiments, the reduction in level of any of the biomarkers (e.g., any of 17-OHP, ACTH, and androstenedione) is determined by comparing the level of the biomarker as measured during the circadian release on a day prior to administering the compound of Formula (I), or a pharmaceutically acceptable salt thereof and the level of the biomarker as measured during the circadian release on the day after administering the compound of Formula (I), or a pharmaceutically acceptable salt thereof. A day prior to administering the compound of Formula (I) applies to a subject that has not previously been administered the compound of Formula (I) within at least the past 24 hours.

[0146] In some embodiments, the circadian release of biomarkers associated with CAH occurs between the hours of 2 a.m. and 10 a.m. In other embodiments, the circadian release of biomarkers associated with CAH occurs between the hours of 6 a.m. and 10 a.m.

[0147] In some embodiments of any of the methods disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, is administered to the subject at nighttime or administration prior to sleep (i.e., bedtime administration). In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered three to eight hours prior to the circadian release of the biomarker. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered six to eight hours prior to the circadian release of the biomarker. Administration prior to the circadian release may be adapted for shift workers (*e.g.,* those who work at night and sleep during the day), in which case administration will not necessarily occur at nighttime. Administration is therefore dependent upon the expected circadian release of the biomarker, and can vary depending upon the individual's (*i.e.*, subject, patient) particular work and sleep patterns.

[0148] In some embodiments of the methods provided herein, the level of 17-hydroxyprogesterone is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at lease 35%, at least 40%, at least 50%, at least 55% or at least 60% from pre-administration levels. In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least 25%. In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least 50%. In some embodiments of the methods provided herein, the level of 17-hydroxyprogesterone is reduced by an amount of from about 10% to about 90%, about 15% to about 90%, about 20% to about 90%, about 25% to about 90%, about 30% to about 90%, about 35% to about 90%, about 40% to about 90%, about 50% to about 90%, about 55% to about 90%, or about 60% to about 90% from pre-administration levels.

[0149] In some embodiments, the level of 17-hydroxyprogesterone is reduced to a level within the range of 17-hydroxyprogesterone expected for a subject without CAH, i.e., less than 1,000 ng/dL or less than 200 ng/dL.

[0150] In some embodiments of the methods provided herein, the level of adrenocorticotropic hormone is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at lease 35%, at least 40%, at least 50%, at least 55% or at least 60% from pre-administration levels. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 25%. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 40%. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 50%.

[0151] In some embodiments of the methods provided herein, the level of adrenocorticotropic hormone is reduced by an amount of from about 10% to about 90%, about 15% to about 90%, about 20% to about 90%, about 25% to about 90%, about 30% to about 90%, about 35% to about 90%, about 40% to about 90%, about 50% to about 90%, about

55% to about 90%, or about 60% to about 90% from pre-administration levels.

[0152] In some embodiments, the level of adrenocorticotropic hormone is reduced to a level within the range of adrenocorticotropic hormone expected for a subject without CAH.

[0153] In some embodiments of the methods provided herein, the level of androstenedione is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at lease 35%, at least 40%, at least 50%, at least 55% or at least 60% from pre-administration levels. In some embodiments, the level of androstenedione is reduced by at least 25%. In some embodiments, the level of androstenedione is reduced by at least 30%. In some embodiments, the level of androstenedione is reduced by at least 50%.

[0154] In some embodiments of the methods provided herein, the level of androstenedione is reduced by an amount of from about 10% to about 90%, about 15% to about 90%, about 20% to about 90%, about 25% to about 90%, about 30% to about 90%, about 35% to about 90%, about 40% to about 90%, about 50% to about 90%, about 55% to about 90%, or about 60% to about 90% from pre-administration levels.

[0155] In some embodiments, the level of androstenedione is reduced to a level within the range of androstenedione expected for a subject without CAH, i.e., less than 200 ng/dL.

[0156] Also provided herein is a method for reducing the severity of one or more symptoms selected from hirsutism, precocious puberty, fertility problems, acne, and growth impairment in a subject having classic congenital adrenal hyperplasia, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce one or more biomarker of CAH in a subject, e.g. reduce the androstenedione in the subject. Growth impairment can refer to, e.g., accelerated height velocity, accelerated weight velocity, and/or accelerated bone age.

[0157] Provided herein is a method for reducing the level of one or more biomarkers of congenital adrenal hyperplasia in a subject having congenital adrenal hyperplasia comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the one or more biomarkers of congenital adrenal hyperplasia are selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

[0158] Provided herein is a method for reducing the dosage of corticosteroid administered to a subject having congenital adrenal hyperplasia for controlling congenital adrenal hyperplasia comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the corticosteroid is a glucocorticoid.

[0159] Also provided herein is a method of reducing the severity of one or more side effects of glucocorticoid treatment in a subject having congenital adrenal hyperplasia comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The long-term effects of glucocorticoid treatment are well documented in the art (see, e.g., Oray, M. et al. (2016): Long-term effect of glucocorticoids, Expert Opinion on Drug Safety. DOI: 10.1517/14740338.2016.1140743). Such side effects are associated with every biological system, e.g., musculoskeletal (e.g., osteoporosis, avascular necrosis of bone, and myopathy), endocrine and metabolic (e.g., hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, Cushing syndrome, Cushingoid features, growth suppression, adrenal suppression), gastrointestinal (e.g., gastritis, peptic ulcer, gastrointestinal bleeding, visceral perforation, hepatic steatosis, pancreatitis), cardiovascular (e.g., hypertension, coronary heart disease, ischemic heart disease, heart failure), dermatologic (e.g., dermatoprosis, skin atrophy, ecchymosis, purpura, erosions, striae, delayed wound healing, easy bruising, acne, hirsutism, and hair loss), neuropsychiatric (e.g., mood changes, depression, euphoria, mood lability, irritability, akathisia, anxiety, cognitive impairment, psychosis, dementia, and delirium), ophthalmologic (e.g., cataract, glaucoma, ptosis, mydriasis, opportunistic ocular infections, and central serous chorioretinopathy), and immunologic (e.g., suppression of cell-mediated immunity, predisposition to infections, and reactivation of latent infections).

[0160] Accordingly, in some embodiments, the side effects of glucocorticoid treatment are selected from osteoporosis, avascular necrosis of bone, myopathy, hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, Cushing syndrome, Cushingoid features, growth suppression, adrenal suppression, gastritis, peptic ulcer, gastrointestinal bleeding, visceral perforation, hepatic steatosis, pancreatitis, hypertension, coronary heart disease, ischemic heart disease, heart failure, dermatoprosis, skin atrophy, ecchymosis, purpura, erosions, striae, delayed wound healing, easy bruising, acne, hirsutism, hair loss, mood changes, depression, euphoria, mood lability, irritability, akathisia, anxiety, cognitive impairment, psychosis, dementia, delirium, cataract, glaucoma, ptosis, mydriasis, opportunistic ocular infections, central serous chorioretinopathy, suppression of cell-mediated immunity, predisposition to infections, reactivation of latent infections, and any combination thereof.

[0161] Provided herein is a method of treating congenital adrenal hyperplasia in a subject comprising

(i)measuring the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in a biological sample obtained from the subject;
(ii)analyzing the level of the one or more biomarkers to determine if the level of the one or more biomarkers is elevated compared to a healthy subject not having congenital adrenal hyperplasia; and
(iii)administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof if the subject

is determined to have elevated levels of the one or more biomarkers.

[0162] In some embodiments, the method further comprises (iv) measuring the level of the one or more biomarkers after administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in a biological sample obtained from the subject to determine whether the subject has reduced levels of the one or more biomarkers as compared with the measurement of step (i). In some embodiments, the method further comprises (v) continuing the administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof if the subject has reduced levels of the one or more biomarkers.

[0163] In some embodiments, steps (i) and (iv) are performed on biological samples taken from the subject in a similar manner and within a same time of day window. In some embodiments, steps (i) and (iv) are performed on biological samples taken from the subject within the time of day window from 2 a.m. to 10 a.m. In some embodiments, steps (i) and (iv) are performed on biological samples taken from the subject within the time of day window from 6 a.m. to 10 a.m.

[0164] In some embodiments, steps (i) and (iv) comprise measuring the levels of at least two biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

[0165] In some embodiments, steps (i) and (iv) comprise measuring the levels of (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

[0166] In some embodiments, step (i) comprises measuring the level of 17-hydroxyprogesterone (17-OHP), wherein the level of 17-hydroxyprogesterone (17-OHP) is elevated when it is greater than or equal to 1,000 ng/dL.

[0167] In some embodiments, step (i) comprises measuring the level of androstenedione, wherein the level of androstenedione is elevated when it is greater than 200 ng/dL.

[0168] In some embodiments of the methods of the present disclosure, the compound of Formula (I) is administered at an amount equivalent to from about 25 mg to about 150 mg of the compound of Formula (I) free base. In some embodiments, compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at an amount equivalent to about 50 mg or about 100 mg of the compound of Formula (I) free base.

[0169] In some embodiments of the methods disclosed herein, compound of Formula (I) is administered in the free base form.

[0170] In some embodiments of the methods disclosed herein, the compound of Formula (I) is administered once daily.

[0171] Also provided herein is a method of treating CAH in a pediatric subject. The methods include administering to a pediatric subject a therapeutically effective amount of a compound of Formula (I), or pharmaceutically acceptable salt thereof. In some embodiments, the method includes administering to a pediatric subject a therapeutically effective amount of a SDD of the present disclosure that includes a polymer and a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the method includes administering to a pediatric subject a therapeutically effective amount of pharmaceutical composition of the present disclosure that contains a SDD that includes a polymer and a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pediatric subject is a neonate. In some embodiments, the pediatric subject is an infant. In some embodiments, the pediatric subject is a child. In some embodiments, the pediatric subject is an adolescent.

[0172] In some embodiments of the methods of the present disclosure, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject in a fed state. The term "fed state," as used herein, refers to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof from about 1 hour before consumption of food or a nutritional composition to about 1 hour after consumption of food or a nutritional composition. The term "fasted state," as used herein, refers to a gap of at least two hours between consumption of food or a nutritional composition and administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to the subject with food or a nutritional composition, such as a nutritional supplement or formula, a meal replacement beverage, a liquid dietary supplement, or a high caloric liquid meal. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to the subject within about 1 hour before the subject has consumed food or a nutritional composition. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to the subject within about 1 hour after the subject has consumed food or a nutritional composition. Examples of suitable nutritional compositions include, but are not limited to, infant formulas, dietary supplements, dietary substitutes, and rehydration compositions. In some embodiments, the food is a product containing concentrated calories and protein. In some embodiments, the nutritional composition is a composition utilized for enteral and parenteral supplementation for infants, specialty infant formulas, supplements for the elderly, and supplements for those with gastrointestinal difficulties and/or malabsorption. Adult and pediatric nutritional formulas are well known in the art and are commercially available (e.g., Similac®, Ensure®, Jevity® and Alimentum® from Ross Products Division, Abbott Laboratories, Columbus, Ohio).

[0173] In some embodiments, the nutritional composition is in liquid form. The energy density of the nutritional compositions, when in liquid form, can range from about 0.6 Kcal to about 3 Kcal per mL. In some embodiments, the nutritional composition is in solid or powdered form. When in solid or powdered form, the nutritional supplements can contain from

about 1.2 to more than 9 Kcals per gram, such as about 3 to 7 Kcals per gram.

[0174] In some embodiments, the nutritional composition is a meal replacement bar. Examples include PowerBar®, Glucerna® bars, Choice DM® bars, Ensure® bars, and Boost® bars. In some embodiments, the nutritional composition is a nutrition shake or meal replacement beverage. Commercially available examples include the Ensure® branded adult products (such as Ensure® Original, Ensure® Plus, Ensure® Enlive, Ensure® High Protein, Ensure® Clear, and Ensure® Light), Glucerna®, Choice DM®, Slim Fast®, Pediasure®, Glytrol®, and Resource®. In some embodiments, the nutritional composition is Ensure® Plus. In some embodiments, the nutritional composition is vanilla-flavored Ensure® Plus. Ensure Plus® is a high calorie liquid dietary supplement that contains 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate.

[0175] In some embodiments of the disclosed methods, the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to the subject with 8 fluid ounces (237 mL) of Ensure® Plus. In some embodiments, the Ensure® Plus is vanilla-flavored.

[0176] In some embodiments of the methods, the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to the subject after administration of the nutritional composition. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to the subject before administration of the nutritional composition. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject at the same time as administration of the nutritional composition.

[0177] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to the subject, followed by administration of the nutritional composition. In some embodiments, the nutritional composition is administered about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, or about 60 minutes, or within a range defined by any of the preceding values after administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the nutritional composition is administered 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, or 60 minutes, or within a range defined by any of the preceding values after administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the nutritional composition is administered within 30 minutes of administering the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments of the disclosed methods, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject with 8 fluid ounces (237 mL) of Ensure® Plus. In some embodiments, the Ensure® Plus is vanilla-flavored.

[0178] In some embodiments, the nutritional composition is administered to the subject, followed by administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, or about 60 minutes, or within a range defined by any of the preceding values after administration of the nutritional composition. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, or 60 minutes, or within a range defined by any of the preceding values after administration of the nutritional composition. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered within 30 minutes of administering the nutritional composition. In some embodiments of the disclosed methods, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject with 8 fluid ounces (237 mL) of Ensure® Plus. In some embodiments, the Ensure® Plus is vanilla-flavored.

[0179] In some embodiments of the methods, a food effect is observed between administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof in a fed state versus a fasted state. The term "food effect," as used herein, refers to the relative difference in AUC (area under the curve AUC(0-t) and/or $AUC_{(0-\infty)}$) or C_{max} (maximum plasma concentration or peak plasma concentration) of an active substance, when the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally to a subject, concomitantly with food or in a fed state as compared to the same values when the same compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered in a fasted state. The food effect (F) is calculated as:

$$F\% = [(X_{fasted} - X_{fed}) / X_{fasted}] \times 100$$

where X_{fed} and X_{fasted} are the values of AUC ($AUC_{(0-t)}$ and/or $AUC_{(0-\infty)}$) or C_{max} in the fed and fasted state, respectively. In some embodiments, an increased, or positive, food effect is observed when the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to a subject in a fed state. In some embodiments, administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, results in an increased, or positive, food effect, whereby an increased C_{max} and/or AUC are observed when administered orally in the fed state as compared to the fasting state.

[0180] In some embodiments of the methods, the ratio of the AUC in the fed state to the AUC in the fasted state is about 5 to about 10, such as about 5 to about 9, about 5 to about 8, about 5 to about 7, about 5 to about 6, about 6 to about 10, about 6 to about 9, about 6 to about 8, about 6 to about 7, about 7 to about 10, about 7 to about 9, about 7 to about 8, about 8 to about 10, about 8 to about 9, or about 8 to about 10. In some embodiments, the ratio of the AUC in the fed state to the AUC in the fasted state is about 5, about 6, about 7, about 8, about 9, or about 10, or within a range defined by any of the preceding values. In some embodiments of the methods, the ratio of the AUC in the fed state to the AUC in the fasted state is about 10 to about 20.

[0181] In some embodiments of the methods, the ratio of the AUC in the fed state to the AUC in the fasted state is 5 to 10, such as 5 to 9, 5 to 8, 5 to 7, 5 to 6, 6 to 10, 6 to 9, 6 to 8, 6 to 7, 7 to 10, 7 to 9, 7 to 8, 8 to 10, 8 to 9, or 8 to 10. In some embodiments, the ratio of the AUC in the fed state to the AUC in the fasted state is 5, 6, 7, 8, 9, or 10, or within a range defined by any of the preceding values.

[0182] In some embodiments of the methods, the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is about 5 to about 10, such as about 5 to about 9, about 5 to about 8, about 5 to about 7, about 5 to about 6, about 6 to about 10, about 6 to about 9, about 6 to about 8, about 6 to about 7, about 7 to about 10, about 7 to about 9, about 7 to about 8, about 8 to about 10, about 8 to about 9, or about 8 to about 10. In some embodiments, the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is about 5, about 6, about 7, about 8, about 9, or about 10, or within a range defined by any of the preceding values. In some embodiments, the mean C_{max} of the compound of Formula (I), or pharmaceutically acceptable salt thereof, is about 1.5 to about 3 times higher in the fed stated compared to the fasted state. In some embodiments of the methods, the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is 5 to 10, such as 5 to 9, 5 to 8, 5 to 7, 5 to 6, 6 to 10,6 to 9, 6 to 8, 6 to 7, 7 to 10, 7 to 9, 7 to 8, 8 to 10, 8 to 9, or 8 to 10. In some embodiments, the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is 5, 6, 7, 8, 9, or 10, or within a range defined by any of the preceding values. In some embodiments, the mean C_{max} of the compound of Formula (I), or pharmaceutically acceptable salt thereof, is 1.5 to 3 times higher in the fed stated compared to the fasted state. In some embodiments, the mean C_{max} of the compound of Formula (I), or pharmaceutically acceptable salt thereof, is about 2 times higher in the fed stated compared to the fasted state. In some embodiments of the methods, the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is about 10 to about 20.

[0183] In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered to the subject with a meal. In some embodiments, the meal is a high fat, high caloric meal. In some embodiments, the meal is a low fat, low caloric meal. In some embodiments, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered within approximately 5 minutes after the start of the meal. In some embodiments, the meal is an evening meal. In some embodiments, the meal is a morning meal.

[0184] In some embodiments, the fed state is with a high fat meal. In some embodiments, the fed state is with a low fat meal. The FDA has provided draft guidelines regarding high fat and low fat meals ("Assessing the Effects of Food on Drugs in INDs and NDAs - Clinical Pharmacology Considerations Guidance for Industry," U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), February 2019, Clinical Pharmacology). Table 1 shows test meal definitions provided by the FDA guidance.

Table 1

Meal Type	Total Kcal	Fat		
		Kcal	Grams	Percent
High-Fat	800-1000	500-600	55-65	50
Low-Fat	400-500	100-125	11-14	25

[0185] The composition of a high fat meal provided by the FDA guidance is depicted in Table 2.

Table 2. Composition of a High Fat Meal*

Total Calories	800-1000
Calories from Protein	150
Calories from Carbohydrates	250
Calories from Fat	500-600

(continued)

An Example of a High Fat Breakfast	• Two eggs fried in butter • Two strips of bacon • Two slices of toast with butter • Four ounces of hash brown potatoes • Eight ounces of whole milk
*50 percent of calories are derived from fat. Substitutions can be made to this meal, if the content, volume, and viscosity are maintained.	

[0186] The composition of a low fat meal provided by the FDA guidance is depicted in Table 3.

Table 3. Composition of a Low Fat Meal

Total Calories	400-500
Fat (g)	250
Percent Calories from Fat	25
An Example of a Low Fat Breakfast*	• Eight ounces milk (1 percent fat) • One boiled egg • One packet flavored instant oatmeal made with water
*This low-fat breakfast contains 387 calories and has 10 grams of fat.	

[0187] In some embodiments, a high fat meal contains 800-1000 total Kcal and 500-600 fat Kcal. In some embodiments, a low fat meal contains 400-500 total Kcal and 100-125 fat Kcal.

[0188] Also provided herein is a method of improving gastrointestinal absorption of a compound of Formula (I), or pharmaceutically acceptable salt thereof, in a subject. The method includes orally administering to the subject a pharmaceutical composition of the present disclosure, wherein the improvement is relative to oral administration of the compound of Formula (I), or pharmaceutically acceptable salt thereof, which has not been prepared as a spray-dried dispersion. In some embodiments, the subject is a pediatric subject.

[0189] Also provided herein is a method of improving oral bioavailability of a compound of Formula (I), or pharmaceutically acceptable salt thereof, in a subject. The method includes orally administering to the subject a pharmaceutical composition of the present disclosure, wherein the improvement is relative to oral administration of the compound of Formula (I), or pharmaceutically acceptable salt thereof, which has not been prepared as a spray-dried dispersion.

[0190] In some embodiments of the methods provided herein, the subject is a pediatric subject.

[0191] Also provided herein is a method of treating congenital adrenal hyperplasia (CAH), in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the present disclosure, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition is a lipidic semi-solid formulation. In some embodiments, the pharmaceutical composition is a liquid formulation. In some embodiments, the pharmaceutical composition is administered to the subject in a fed state.

[0192] Also provided herein is a pharmaceutical composition of the present disclosure for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject. In some embodiments, the subject is in a fed state.

[0193] In some embodiments, the pharmaceutical composition is administered to the subject with a nutritional composition. In some embodiments, the nutritional composition is a liquid dietary supplement comprising about 1000 to about 2000 calories per liter with a fat content greater than about 30%. In some embodiments, the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate. In some embodiments, the nutritional composition is administered in an amount of about 6 to about 12 fluid ounces. In some embodiments, the nutritional composition is administered in an amount of about 8 fluid ounces. In some embodiments, the nutritional composition is administered within 30 minutes of administration of the pharmaceutical composition.

[0194] In some embodiments, the pharmaceutical composition exhibits a positive food effect. In some embodiments, the positive food effect is measured in terms of C_{max}, AUC, or a combination thereof of a compound of Formula (I) when comparing oral administration of the pharmaceutical composition in the fed and fasting states. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 5 to about 10. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the

fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 5 to about 10. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 10 to about 20. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 10 to about 20. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1.5 to about 3. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1.5 to about 3. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is 1 to 4 or 5 to 10. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is 1 to 4 or 5 to 10. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is 1 to 4. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is 1 to 4. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is 1.5 to 3. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is 1.5 to 3.

[0195] In some embodiments, the subject is a pediatric subject.

[0196] In some embodiments, the pharmaceutical composition is formulated for oral administration and exhibits a positive food effect when administered orally. In some embodiments, the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 5 to about 10. In some embodiments, the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 5 to about 10. In some embodiments, the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 10 to about 20. In some embodiments, the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 10 to about 20. In some embodiments, the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1 to about 4 or about 5 to about 10. In some embodiments, the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1 to about 4 or about 5 to about 10. In some embodiments, the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1 to about 4. In some embodiments, the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1 to about 4. In some embodiments, the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1.5 to about 3. In some embodiments, the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1.5 to about 3. In some embodiments, the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of 1 to 4 or 5 to 10. In some embodiments, the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of 1 to 4 or 5 to 10. In some embodiments, the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of 1 to 4. In some embodiments, the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of 1 to 4. In some embodiments, the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of 1.5 to 3. In some embodiments, the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of 1.5 to 3.

[0197] In some embodiments, the pharmaceutical composition is administered to the subject with a meal. In some embodiments, the meal is a high fat meal. In some embodiments, the meal is a low fat meal. In some embodiments, the pharmaceutical composition is administered within about 5 minutes after the start of the meal. In some embodiments, the meal is an evening meal. In some embodiments, the meal is a morning meal.

[0198] In some embodiments, administering the pharmaceutical composition exhibits a positive food effect. In some embodiments, the positive food effect is measured in terms of C_{max}, AUC, or combinations thereof of the compound of Formula (I) when comparing oral administration of the pharmaceutical composition in the fed and fasting states. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 5 to about 10. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 5 to about 10. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 10 to about 20. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 10 to about 20. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound

of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1.5 to about 3. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1.5 to about 3. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is 1 to 4 or 5 to 10. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is 1 to 4 or 5 to 10. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is 1 to 4. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is 1 to 4. In some embodiments, the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is 1.5 to 3. In some embodiments, the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is 1.5 to 3.

[0199] For the avoidance of doubt, also provided herein is the corresponding compound of Formula (I), or a pharmaceutically acceptable salt thereof, or corresponding pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the corresponding methods, as described herein.

[0200] For the avoidance of doubt, also provided herein is use of the corresponding compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the corresponding methods, as described herein.

[0201] For the avoidance of doubt, also provided herein is use of the corresponding pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the corresponding methods, as described herein.

Reduction in glucocorticoid burden, adrenal androgens and precursors

[0202] Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones. Glucocorticoids are corticosteroids that bind to the glucocorticoid receptor that is present in almost every vertebrate animal cell. In some embodiments, the subject is concurrently receiving a dose of a glucocorticoid. In some embodiments, the glucocorticoid is selected from cortisol (hydrocortisone), cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, fludrocortisone acetate, and deoxycorticosterone acetate. In some embodiments, the glucocorticoid is cortisol (hydrocortisone). In some embodiments, the glucocorticoid is cortisone. In some embodiments, the glucocorticoid is prednisone. In some embodiments, the glucocorticoid is dexamethasone.

[0203] In some embodiments, the glucocorticoid dose is measured in hydrocortisone equivalents. In some embodiments, the glucocorticoid dose is measured as a multiple of the upper limit of normal of physiologic dosing in hydrocortisone equivalents. Any glucocorticoid can be given in a dose that provides approximately the same glucocorticoid effects as normal cortisol production; this is referred to as physiologic, replacement, or maintenance dosing.

[0204] In some embodiments, the glucocorticoid dose is a physiologic dose as measured after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose is a physiologic dose of about 4 to about 12 mg/m^2/day as measured after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose is a physiologic dose of about 4 to about 9 mg/m^2/day as measured after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose is a physiologic dose that is less than about 8 mg/m^2/day as measured after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0205] In some embodiments, the glucocorticoid dose is a physiologic dose as measured after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose is a physiologic dose of about 4 to about 12 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose is a physiologic dose of about 4 to about 9 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose is a physiologic dose that is less than about 8 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0206] In some embodiments, the glucocorticoid dose concurrently given to the subject is a normal physiological dose of hydrocortisone equivalents. In some embodiments, the glucocorticoid dose concurrently given to the subject is determined after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose concurrently given to the subject is determined after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 2 to about 16 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 4 to about 12 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 5 to about 11 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 6 to about 10 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 7 to about 9 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 4 to about 9 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 8 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 12 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is less than about 8 mg/m^2/day. In some embodiments, a normal physiological dose of hydrocortisone equivalents is about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15 or about 16 mg/m^2/day, or within a range defined by any of the preceding values.

[0207] In some embodiments, the glucocorticoid dose concurrently given to the subject is at the upper limit of normal of a normal physiological dose of hydrocortisone equivalents. In some embodiments, the glucocorticoid dose concurrently given to the subject is determined after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose concurrently given to the subject is determined after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the upper limit of normal is 1.5 times the normal physiological dose. In some embodiments, the upper limit of normal is about 1.5 times the normal physiological dose. In some embodiments, the upper limit of normal is about 1.5 times the normal physiological dose. In some embodiments, the upper limit of normal is about 2 times the normal physiological dose. In some embodiments, the upper limit of normal is about 2.5 times the normal physiological dose. In some embodiments, the upper limit of normal is about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, or about 3.0 times the normal physiological dose, or within a range defined by any of the preceding values.

[0208] In some embodiments, the glucocorticoid dose of the subject is reduced by about 10% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 20% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 30% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 40% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 50% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 60% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 70% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by less than about 20% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 20% to about 50% after a time period of administration of the compound of Formula (I), or a

pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by greater than about 50% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0209] In some embodiments, the glucocorticoid dose of the subject is reduced by about 10% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 20% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 30% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 40% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 50% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 60% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 70% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by less than about 20% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by about 20% to about 50% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid dose of the subject is reduced by greater than about 50% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0210] In some embodiments, the glucocorticoid dose of the subject is reduced within a range defined by any of the preceding values.

[0211] In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least 25% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least 50% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is less than 1.5 times the upper limit of normal after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In

some embodiments, the level of 17-hydroxyprogesterone is within normal limits after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0212] In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is within normal limits after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0213] In some embodiments, the level of 17-hydroxyprogesterone of the subject is reduced within a range defined by any of the preceding values.

[0214] In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 25% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 40% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least 50% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of adrenocorticotropic hormone is less than 1.5 times the upper limit of normal after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of adrenocorticotropic hormone is within normal limits after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0215] In some embodiments, the level of adrenocorticotropic hormone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least about 40% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of adrenocorticotropic hormone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of adrenocorticotropic hormone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of adrenocorticotropic hormone is within normal limits after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0216] In some embodiments, the level of adrenocorticotropic hormone of the subject is reduced within a range defined by any of the preceding values.

[0217] In some embodiments, the level of androstenedione is reduced by at least 25% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of androstenedione is reduced by at least 30% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration

of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of androstenedione is reduced by at least 50% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of androstenedione is less than 1.5 times the upper limit of normal after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of androstenedione is within normal limits after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0218] In some embodiments, the level of androstenedione is reduced by at least about 25% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of androstenedione is reduced by at least about 30% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of androstenedione is reduced by at least about 50% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of androstenedione is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of androstenedione is within normal limits after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0219] In some embodiments, the level of androstenedione of the subject is reduced within a range defined by any of the preceding values.

[0220] In some embodiments, the level of testosterone is reduced by at least 25% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of testosterone is reduced by at least 30% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of testosterone is reduced by at least 50% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of testosterone is less than 1.5 times the upper limit of normal after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of testosterone is within normal limits after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0221] In some embodiments, the level of testosterone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of testosterone is reduced by at least about 30% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of testosterone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of testosterone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of testosterone is within normal limits after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0222] In some embodiments, the level of testosterone of the subject is reduced within a range defined by any of the preceding values.

[0223] In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least 50% and the level of androstenedione is reduced by at least 50% after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of 17-hydroxyprogesterone and the level of androstenedione is relative to the level of 17-hydroxyprogesterone and the level of androstenedione prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is less than 1.5 times the upper limit of normal and the level of androstenedione is less than 1.5 times the upper limit of normal after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is within normal limits and the level of androstenedione is within normal limits after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0224] In some embodiments, the level of 17-hydroxyprogesterone is reduced by at least about 50% and the level of androstenedione is reduced by at least about 50% after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of the level of 17-hydroxyprogesterone and the level of androstenedione is relative to the level of 17-hydroxyprogesterone and the level of androstenedione prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is less than about 1.5 times the upper limit of normal and the level of androstenedione is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the level of 17-hydroxyprogesterone is within normal limits and the level of androstenedione is within normal limits after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0225] In some embodiments, the level of 17-hydroxyprogesterone and androstenedione of the subject is reduced within a range defined by any of the preceding values.

[0226] In some embodiments, the subject exhibits a decrease in glucocorticoid burden after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the decrease in glucocorticoid burden is relative to the glucocorticoid burden prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, one or more symptoms selected from quality of life, fatigue, sleep, insulin resistance, glucose tolerance, glucose control, dyslipidemia, hyperlipidemia, bone mineral density, bone turnover, fat mass, weight, central obesity, blood pressure, hirsutism severity, menstrual cyclicity, control of testicular adrenal rest tumor and fertility, is improved after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the improvement in the one or more symptoms is relative to the status of the one or more symptoms prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0227] In some embodiments, the subject exhibits a decrease in glucocorticoid burden after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the decrease in glucocorticoid burden is relative to the glucocorticoid burden prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, one or more symptoms of glucocorticoid burden selected from quality of life, fatigue, sleep, insulin resistance, glucose tolerance, glucose control, dyslipidemia, hyperlipidemia, bone mineral density, bone turnover, fat mass, weight, central obesity, blood pressure, hirsutism severity, menstrual cyclicity, control of testicular adrenal rest tumor and fertility, is improved after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the improvement in the one or more symptoms is relative to the status of the one or more symptoms prior to administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0228] In some embodiments, the quality of life as measured by the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) in the subject is improved after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the improvement in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) is relative to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) results prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0229] In some embodiments, fatigue is reduced in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction in fatigue is relative to the fatigue prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0230] In some embodiments, sleep is increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in sleep is relative to the sleep prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0231] In some embodiments, insulin resistance is reduced in the subject after a time period of administration of the

compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction of insulin resistance is relative to the insulin resistance prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0232] In some embodiments, glucose tolerance is reduced in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction in glucose tolerance is relative to the glucose tolerance prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0233] In some embodiments, glucose control is increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in glucose control is relative to the glucose control prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0234] In some embodiments, lipid levels reflecting dyslipidemia are reduced in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction in lipid levels is relative to the lipid levels prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0235] In some embodiments, lipid levels reflecting hyperlipidemia are reduced in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the reduction in lipid levels is relative to the lipid levels prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0236] In some embodiments, bone mineral density is increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in bone mineral density is relative to the bone mineral density prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0237] In some embodiments, bone turnover is increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in bone turnover is relative to the bone turnover prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0238] In some embodiments, fat mass is decreased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the decrease in fat mass is relative to the fat mass prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0239] In some embodiments, body weight is decreased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the decrease in body weight is relative to the body weight prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0240] In some embodiments, central obesity is decreased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the decrease in central obesity is relative to the central obesity prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0241] In some embodiments, blood pressure is increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in blood pressure is relative to the blood pressure prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0242] In some embodiments, the severity of hirsutism is decreased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the decrease in the severity of hirsutism is relative to the severity of hirsutism prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0243] In some embodiments, menstrual cyclicity is increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in menstrual cyclicity is relative to the menstrual cyclicity prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0244] In some embodiments, control of testicular adrenal rest tumor is increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in control of testicular adrenal rest tumor is relative to the control of testicular adrenal rest tumor prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0245] In some embodiments, fertility is increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in fertility is relative to the fertility prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0246] In some embodiments, gonadotropin levels are increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in gonadotropin levels is relative to the gonadotropin levels prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0247] In some embodiments, progesterone levels are increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in progesterone

levels is relative to the progesterone levels prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0248] In some embodiments, semen levels are increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in semen levels is relative to the semen levels prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0249] In some embodiments, LH (luteinizing hormone) levels are increased in the subject after a time period of administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the increase in LH levels are relative to the LH levels prior to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0250] In some embodiments, the time period of administration is at least about 4 weeks. In some embodiments, the time period of administration is at least about 24 weeks. In some embodiments, the time period of administration is at least about one year. In some embodiments, the time period of administration is at least 4 weeks. In some embodiments, the time period of administration is at least 24 weeks. In some embodiments, the time period of administration is at least one year. In some embodiments, the time period of administration is less than about 1 day. In some embodiments, the time period of administration is about 1, 2, 3, 4, 5, 6 or 7 days, or within a range of any of the preceding values. In some embodiments, the time period of administration is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 weeks, or within a range of any of the preceding values. In some embodiments, the time period of administration is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months, or within a range of any of the preceding values. It is understood that comparative measurements occur preferably during the morning.

[0251] In some embodiments, the subject is a pediatric subject. In some embodiments, the pediatric subject is less than or equal to six years old. In some embodiments, the pediatric subject is greater than six years old and less than eleven years old. In some embodiments, the pediatric subject is greater than ten years old and less than fifteen years old. In some embodiments, the pediatric subject is greater than fourteen years old and less than nineteen years old.

[0252] In some embodiments, the subject is an adult subject. In some embodiments, the subject is over eighteen years old. In some embodiments, the subject is female. In some embodiments, the subject is male.

[0253] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition described herein. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition described in Example 9. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition described in Example 11. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition described in Example 12. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition described in Example 13. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a hydrochloric acid salt or p-toluenesulfonic acid salt.

[0254] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a p-toluenesulfonic acid salt described herein.

[0255] For the avoidance of doubt, also provided herein is the corresponding compound of Formula (I), or a pharmaceutically acceptable salt thereof, or corresponding pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the corresponding methods, as described herein.

[0256] For the avoidance of doubt, also provided herein is use of the corresponding compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the corresponding methods, as described herein.

[0257] For the avoidance of doubt, also provided herein is use of the corresponding pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the corresponding methods, as described herein.

p-Toluenesulfonic Acid Salt

[0258] In some embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is 4-(2-chloro-4-methoxy -5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, p-toluenesulfonic acid salt.

[0259] In some embodiments, the 4-(2-chloro-4-methoxy -5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, p-toluenesulfonic acid salt is a crystalline salt. In some embodiments, the p-toluenesulfonic acid crystalline salt has Form 1.


[0260] In some embodiments, the p-toluenesulfonic acid crystalline salt has an X-ray powder diffraction pattern as substantially shown in Figure 27. In some embodiments, the p-toluenesulfonic acid crystalline salt has a DSC thermogram substantially as depicted in Figure 28. In some embodiments, the p-toluenesulfonic acid crystalline salt has a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 28.

[0261] In some embodiments, the p-toluenesulfonic acid crystalline salt has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected 9.1, 11.3, 13.2, 16.3 and 21.1 degrees. In some embodiments, the p-toluenesulfonic acid crystalline salt has at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.1, 11.3, 13.2, 16.3 and 21.1 degrees. In some embodiments, the p-toluenesulfonic acid crystalline salt has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.1, 11.3, 13.2, 16.3 and 21.1 degrees. In some embodiments, the p-toluenesulfonic acid crystalline salt has at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.1, 11.3, 13.2, 16.3 and 21.1 degrees. In some embodiments, the p-toluenesulfonic acid crystalline salt has characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 9.1, 11.3, 13.2, 16.3 and 21.1 degrees. In some embodiments, the p-toluenesulfonic acid crystalline salt has an endothermic peak having an onset of melt at about 156 °C (22.2 J/g) in a differential scanning calorimetry (DSC) thermogram.

Lipidic Semi-Solid Formulation

[0262] Provided herein is a lipidic semi-solid formulation, which is a pharmaceutical composition comprising:

(a) a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof; and
(b) one or more of an oily phase vehicle, an emulsifying agent, a nonionic surfactant, and a solubilizing agent.

[0263] In some embodiments, the pharmaceutical composition comprises about 1 wt% to about 20 wt% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 5 wt% to about 15 wt% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 10 wt% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 wt% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base, or within a range of any of the preceding values.

[0264] In some embodiments, the pharmaceutical composition comprises an oily phase vehicle. An oily phase vehicle is a solvent that is poorly miscible with water. In some embodiments, the pharmaceutical composition comprises about 1 wt% to about 50 wt% of the oily phase vehicle. In some embodiments, the pharmaceutical composition comprises about 20 wt% to about 50 wt% of the oily phase vehicle. In some embodiments, the pharmaceutical composition comprises about 35 wt% to about 45 wt% of the oily phase vehicle. In some embodiments, the pharmaceutical composition comprises about 39 wt% of the oily phase vehicle. In some embodiments, the pharmaceutical composition comprises about 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 wt% of the oily phase vehicle, or within a range of any of the preceding values.

[0265] In some embodiments, the oily phase vehicle is selected from medium-chain triglycerides, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol. In some embodiments, the oily phase vehicle is medium-chain triglycerides. In some embodiments, the medium-chain triglycerides are Labrafac TM Lipophile WL1349. In some embodiments, the medium-chain triglycerides are Miglyol 812N.

[0266] In some embodiments, the pharmaceutical composition comprises an emulsifying agent. An emulsifying agent is a compound or substance that acts as a stabilizer for emulsions. In some embodiments, the pharmaceutical composition comprises about 5 wt% to about 50 wt% of the emulsifying agent. In some embodiments, the pharmaceutical composition comprises about 10 wt% to about 30 wt% of the emulsifying agent. In some embodiments, the pharmaceutical composition comprises about 15 wt% to about 25 wt% of the emulsifying agent. In some embodiments, the pharmaceutical composition comprises about 20 wt% of the emulsifying agent. In some embodiments, the pharmaceutical composition comprises

about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 wt% of the emulsifying agent, or within a range of any of the preceding values.

[0267] In some embodiments, the emulsifying agent is selected from medium-chain triglycerides, propylene glycol dicaprylate/dicaprate, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol. In some embodiments, the emulsifying agent is propylene glycol dicaprylate/dicaprate. In some embodiments, the propylene glycol dicaprylate/dicaprate is Labrafac TM PG.

[0268] In some embodiments, the pharmaceutical composition comprises a nonionic surfactant. A nonionic surfactant is a substance with a hydrophilic head and a hydrophobic tail that has no charge that is a formulation component added to improve solubility or emulsion properties. In some embodiments, the pharmaceutical composition comprises about 5 wt% to about 50 wt% of the nonionic surfactant. In some embodiments, the pharmaceutical composition comprises about 10 wt% to about 30 wt% of the nonionic surfactant. In some embodiments, the pharmaceutical composition comprises about 15 wt% to about 25 wt% of the nonionic surfactant. In some embodiments, the pharmaceutical composition comprises about 19 wt% of the nonionic surfactant. In some embodiments, the pharmaceutical composition comprises about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 wt% of the nonionic surfactant, or within a range of any of the preceding values.

[0269] In some embodiments, the nonionic surfactant is selected from oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, Polysorbate 80, Polysorbate 20, Gelucire, lauroyl polyoxyl-32 glycerides, Poloxamer, PEG-32 stearate, and PEG-32 hydrogenated palm glycerides. In some embodiments, the nonionic surfactant is lauroyl polyoxyl-32 glycerides. In some embodiments, the lauroyl polyoxyl-32 glycerides are Gelucire® 44/14.

[0270] In some embodiments, the pharmaceutical composition comprises a solubilizing agent. A solubilizing agent is a solvent that assists with solubilizing the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises about 1 wt% to about 50 wt% of the solubilizing agent. In some embodiments, the pharmaceutical composition comprises about 1 wt% to about 20 wt% of the solubilizing agent. In some embodiments, the pharmaceutical composition comprises about 5 wt% to about 15 wt% of the solubilizing agent. In some embodiments, the pharmaceutical composition comprises about 11 wt% of the solubilizing agent. In some embodiments, the pharmaceutical composition comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 wt% of the solubilizing agent, or within a range of any of the preceding values.

[0271] In some embodiments, the solubilizing agent is selected from oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, Polysorbate 80, Polysorbate 20, vitamin E polyethylene glycol succinate, Gelucire, lauroyl polyoxyl-32 glycerides, and Poloxamer. In some embodiments, the solubilizing agent is vitamin E polyethylene glycol succinate. In some embodiments, the vitamin E polyethylene glycol succinate is Kolliphor® TPGS. In some embodiments, the vitamin E polyethylene glycol succinate is Vitamin E/TPGS 260.

[0272] In some embodiments, the pharmaceutical composition comprises:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;
(b) an oily phase vehicle;
(c) an emulsifying agent;
(d) a nonionic surfactant; and
(e) a solubilizing agent.

[0273] In some embodiments, the pharmaceutical composition comprises:

(a) about 5 wt% to about 15 wt% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 35 wt% to about 45 wt% of an oily phase vehicle;
(c) about 15 wt% to about 25 wt% of an emulsifying agent;
(d) about 15 wt% to about 25 wt% of a nonionic surfactant; and
(e) about 5 wt% to about 15 wt% of a solubilizing agent.

[0274] In some embodiments, the pharmaceutical composition comprises:

(a) about 10 wt% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 39 wt% of an oily phase vehicle;
(c) about 20 wt% of an emulsifying agent;

(d) about 19 wt% of a nonionic surfactant; and
(e) about 11 wt% of a solubilizing agent.

[0275] In some embodiments, the pharmaceutical composition comprises:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine;
(b) a medium-chain triglycerides component;
(c) a propylene glycol dicaprylate/dicaprate component;
(d) a lauroyl polyoxyl-32 glycerides component; and
(e) a vitamin E polyethylene glycol succinate component.

[0276] In some embodiments, the pharmaceutical composition comprises:

(a) about 5 wt% to about 15 wt% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine;
(b) about 35 wt% to about 45 wt% of medium-chain triglycerides;
(c) about 15 wt% to about 25 wt% of propylene glycol dicaprylate/dicaprate;
(d) about 15 wt% to about 25 wt% of lauroyl polyoxyl-32 glycerides; and
(e) about 5 wt% to about 15 wt% of vitamin E polyethylene glycol succinate.

[0277] In some embodiments, the pharmaceutical composition comprises:

(a) about 10 wt% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine;
(b) about 39 wt% of medium-chain triglycerides;
(c) about 20 wt% of propylene glycol dicaprylate/dicaprate;
(d) about 19 wt% of lauroyl polyoxyl-32 glycerides; and
(e) about 11 wt% of vitamin E polyethylene glycol succinate.

[0278] In some embodiments, the lipidic semi-solid pharmaceutical composition has a viscosity between about 15 to about 40 centipoise at about 45 °C. In some embodiments, the lipidic semi-solid pharmaceutical composition has a viscosity between about 26 to about 30 centipoise at about 45 °C. In some embodiments, the lipidic semi-solid pharmaceutical composition has a viscosity between about 5 to about 25 centipoise at about 60 °C. In some embodiments, the lipidic semi-solid pharmaceutical composition has a viscosity between about 14 to about 18 centipoise at about 60 °C.

[0279] In some embodiments, the pharmaceutical composition does not comprise a combination of mannitol, croscarmellose sodium, maize starch, hydroxypropyl methylcellulose, and magnesium stearate.

[0280] In some embodiments, the pharmaceutical composition does not comprise at least one of mannitol, croscarmellose sodium, maize starch, hydroxypropyl methylcellulose, and magnesium stearate.

[0281] In some embodiments, the pharmaceutical composition comprises a compound of Formula (I), or pharmaceutically acceptable salt thereof, in crystalline form. In some embodiments, the pharmaceutical composition comprises a compound of Formula (I), or pharmaceutically acceptable salt thereof, in amorphous form. In some embodiments, the pharmaceutical composition comprises a compound of Formula (I) as a free base. In some embodiments, the crystalline form of the compound of Formula (I) is of Form I.

[0282] In some embodiments, the pharmaceutical composition is formulated in unit dosage form, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg to about 200 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in the unit dosage form in an amount of about 75 mg to about 150 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in the unit dosage form in an amount of about 50 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in the unit dosage form in an amount of about 100 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in the unit dosage form in an amount of about 25 mg, based on the weight of the free base.

[0283] In some embodiments, the pharmaceutical composition is in the form of a tablet, capsule, sachet, powder, granules, coated particle, coated tablet, enterocoated tablet, enterocoated capsule, melting strip, or melting film. In some embodiments, the pharmaceutical composition is in tablet form. In some embodiments, the pharmaceutical composition is in capsule form. In some embodiments, the dosage form is coated.

[0284] Some embodiments provide a method for preparing the pharmaceutical composition, comprising:

(a) heating a mixture of an oily phase vehicle, an emulsifying agent, a nonionic surfactant, and a solubilizing agent;
(b) mixing the mixture of step (a) until a homogeneous mixture is achieved; and
(c) mixing the compound of Formula (I), or a pharmaceutically acceptable salt thereof, with the homogeneous mixture of step (b) until the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is dissolved, forming a composition.


[0285] In some embodiments, the method further comprises:

(d) encapsulating the composition of step (c) in a capsule shell to form a capsule; and
(e) banding the capsule of step (d) in a mixture of banding agent and banding solvent.

Liquid Formulations

[0286] Provided herein is a pharmaceutical composition in oral solution dosage form comprising:

(a) a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof;
(b) one or more of a sweetener, an anti-oxidant, and a flavor; and
(c) a liquid vehicle.

[0287] In some embodiments, the pharmaceutical composition comprises about 1 w/v% to about 50 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 1 w/v% to about 10 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 5 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base, or within a range of any of the preceding values.

[0288] In some embodiments, the pharmaceutical composition comprises a sweetener. A sweetener is a formulation component added to improve taste. In some embodiments, the pharmaceutical composition comprises about 0.01 w/v% to about 1.5 w/v% of the sweetener. In some embodiments, the pharmaceutical composition comprises about 0.1 w/v% to about 0.5 w/v% of the sweetener. In some embodiments, the pharmaceutical composition comprises about 0.15 w/v% of the sweetener. In some embodiments, the pharmaceutical composition comprises about 0.1, 0.2, 0.3, 0.4, or 0.5 w/v% of the sweetener, or within a range of any of the preceding values.

[0289] In some embodiments, the sweetener is selected from saccharin, sucrose, sucralose, aspartame, dextrose, fructose, maltitol, mannitol, sorbitol, and avantame. In some embodiments, the sweetener is saccharin.

[0290] In some embodiments, the pharmaceutical composition comprises an anti-oxidant. An anti-oxidant is a formulation component included to improve stability by preventing oxidation. In some embodiments, the pharmaceutical composition comprises about 0.01 w/v% to about 1.5 w/v% of the anti-oxidant. In some embodiments, the pharmaceutical composition comprises about 0.1 w/v% to about 0.5 w/v% of the anti-oxidant. In some embodiments, the pharmaceutical composition comprises about 0.17 w/v% of the anti-oxidant. In some embodiments, the pharmaceutical composition comprises about 0.1, 0.2, 0.3, 0.4, or 0.5 w/v% of the anti-oxidant, or within a range of any of the preceding values.

[0291] In some embodiments, the anti-oxidant is selected from butylated hydroxytoluene, vitamin E TPGS, butylated

hydroxyanisole, ascorbic acid, lecithin, tert-butylhydroquinone, and citric acid. In some embodiments, the anti-oxidant is butylated hydroxytoluene.

[0292] In some embodiments, the pharmaceutical composition comprises a flavor. A flavor is a formulation component added to mask taste through aromatics. In some embodiments, the pharmaceutical composition comprises about 0.01 w/v% to about 0.5 w/v% of the flavor. In some embodiments, the pharmaceutical composition comprises about 0.05 w/v% to about 0.2 w/v% of the flavor. In some embodiments, the pharmaceutical composition comprises about 0.10 w/v% of the flavor. In some embodiments, the pharmaceutical composition comprises about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19 or 0.2 w/v% of the flavor, or within a range of any of the preceding values.

[0293] In some embodiments, the flavor is selected from FONA orange flavor, FONA Juicy Flavor, FONA Grape Flavor, Firmenich SA Lemon Flavor, Firmenich Tetrarome Orange Flavor, IFF Cherry Flavor, and IFF Grape Flavor. In some embodiments, the flavor is FONA orange flavor.

[0294] A liquid vehicle is a solvent capable of dissolving or partially dissolving the compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the purposes of delivery as an oral dosing solution. In some embodiments, the pharmaceutical composition comprises about 50 w/v% to about 99.9 w/v% of the liquid vehicle. In some embodiments, the pharmaceutical composition comprises about 90 w/v% to about 99 w/v% of the liquid vehicle. In some embodiments, the pharmaceutical composition comprises about 92 w/v% to about 97 w/v% of the liquid vehicle. In some embodiments, the pharmaceutical composition comprises about 94.6 w/v% of the liquid vehicle. In some embodiments, the pharmaceutical composition comprises about 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99 w/v% of the liquid vehicle, or within a range of any of the preceding values.

[0295] In some embodiments, the liquid vehicle is selected from medium-chain triglycerides, propylene glycol dicaprylate/dicaprate, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol. In some embodiments, the liquid vehicle is medium-chain triglycerides. In some embodiments, the medium-chain triglycerides is Labrafac Lipophile WL1349.

[0296] In some embodiments, the pharmaceutical composition further comprises a surfactant. A surfactant is a formulation component added to improve solubility or emulsion properties. In some embodiments, the pharmaceutical composition comprises about 1 w/v% to about 50 w/v% of the surfactant. In some embodiments, the pharmaceutical composition comprises about 10 w/v% to about 30 w/v% of the surfactant. In some embodiments, the pharmaceutical composition comprises about 20 w/v% of the surfactant. In some embodiments, the pharmaceutical composition comprises about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 w/v% of the surfactant, or within a range of any of the preceding values.

[0297] In some embodiments, the surfactant is selected from oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, Polysorbate 80, Polysorbate 20, vitamin E polyethylene glycol succinate, Gelucire, lauroyl polyoxyl-32 glycerides, sodium lauryl sulfate, Poloxamer, corn oil PEG-6 esters, and hydrogenated palm/palm kernel oil PEG-6 esters. In some embodiments, the surfactant is oleoyl polyoxyl-6 glycerides. In some embodiments, the oleoyl polyoxyl-6 glycerides is LABRAFIL M 1944 CS.

[0298] In some embodiments, the pharmaceutical composition comprises about 50 w/v% to about 90 w/v% of the liquid vehicle. In some embodiments, the pharmaceutical composition comprises about 70 w/v% to about 80 w/v% of the liquid vehicle. In some embodiments, the pharmaceutical composition comprises about 75 w/v% of the liquid vehicle. In some embodiments, the pharmaceutical composition comprises about 74.6 w/v% of the liquid vehicle. In some embodiments, the pharmaceutical composition comprises about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 w/v% of the liquid vehicle, or within a range of any of the preceding values.

[0299] In some embodiments, the liquid vehicle is selected from medium-chain triglycerides, propylene glycol dicaprylate/dicaprate, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol. In some embodiments, the liquid vehicle is medium-chain triglycerides. In some embodiments, the medium-chain triglycerides is Labrafac Lipophile WL1349.

[0300] In some embodiments, the pharmaceutical composition comprises:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;
(b) a sweetener;
(c) an anti-oxidant;
(d) a flavor; and
(e) a liquid vehicle.

[0301] In some embodiments, the pharmaceutical composition further comprises a surfactant.

[0302] In some embodiments, the pharmaceutical composition comprises:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of a sweetener;
(c) about 0.1 w/v% to about 0.2 w/v% of an anti-oxidant;
(d) about 0.05 w/v% to about 0.2 w/v% of a flavor; and
(e) about 92 w/v% to about 97 w/v% of a liquid vehicle.

[0303] In some embodiments, the pharmaceutical composition comprises:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of a sweetener;
(c) about 0.17 w/v% of an anti-oxidant;
(d) about 0.1 w/v% of a flavor; and
(e) about 94.6 w/v% of a liquid vehicle.

[0304] In some embodiments, the pharmaceutical composition comprises:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of a sweetener;
(c) about 0.1 w/v% to about 0.2 w/v% of an anti-oxidant;
(d) about 0.05 w/v% to about 0.2 w/v% of a flavor;
(e) about 15 w/v% to about 25 w/v% of a surfactant; and
(f) about 70 w/v% to about 80 w/v% of a liquid vehicle.

[0305] In some embodiments, the pharmaceutical composition comprises:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of a sweetener;
(c) about 0.17 w/v% of an anti-oxidant;
(d) about 0.1 w/v% of a flavor;
(e) about 20 w/v% of a surfactant; and
(f) about 75 w/v% of a liquid vehicle.

[0306] In some embodiments, the pharmaceutical composition comprises:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;
(b) saccharin;
(c) butylated hydroxytoluene;
(d) FONA orange flavor; and
(e) medium-chain triglycerides.

[0307] In some embodiments, the pharmaceutical composition further comprises oleoyl polyoxyl-6 glycerides.

[0308] In some embodiments, the pharmaceutical composition comprises:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of saccharin;
(c) about 0.1 w/v% to about 0.2 w/v% of butylated hydroxytoluene;
(d) about 0.05 w/v% to about 0.2 w/v% of FONA orange flavor; and

(e) about 92 w/v% to about 97 w/v% of medium-chain triglycerides.

[0309] In some embodiments, the pharmaceutical composition comprises:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of saccharin;
(c) about 0.17 w/v% of butylated hydroxytoluene;
(d) about 0.1 w/v% of FONA orange flavor; and
(e) about 94.6 w/v% of medium-chain triglycerides.

[0310] In some embodiments, the pharmaceutical composition comprises:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of saccharin;
(c) about 0.1 w/v% to about 0.2 w/v% of butylated hydroxytoluene;
(d) about 0.05 w/v% to about 0.2 w/v% of FONA orange flavor;
(e) about 15 w/v% to about 25 w/v% of oleoyl polyoxyl-6 glycerides; and
(f) about 70 w/v% to about 80 w/v% of medium-chain triglycerides.

[0311] In some embodiments, the pharmaceutical composition comprises:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of saccharin;
(c) about 0.17 w/v% of butylated hydroxytoluene;
(d) about 0.1 w/v% of FONA orange flavor;
(e) about 20 w/v% of oleoyl polyoxyl-6 glycerides; and
(f) about 75 w/v% of medium-chain triglycerides.

[0312] In some embodiments, the pharmaceutical composition comprises the compound of Formula (I) as a free base.

[0313] In some embodiments, the pharmaceutical composition is formulated in unit dosage form, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg/mL to about 200 mg/mL, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in the unit dosage form in an amount of about 75 mg/mL to about 150 mg/mL, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in the unit dosage form in an amount of about 50 mg/mL, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in the unit dosage form in an amount of about 100 mg/mL, based on the weight of the free base.

[0314] In some embodiments, the liquid pharmaceutical composition has a viscosity between about 1 to about 50 centipoise at about 25 °C.

[0315] Some embodiments provide a method for preparing a pharmaceutical composition comprising:

(a) mixing a liquid vehicle with a sweetener;
(b) mixing the mixture of step (a) with an anti-oxidant and a flavor;
(c) mixing the compound of Formula (I), or a pharmaceutically acceptable salt thereof, with the mixture of step (b); and
(d) mixing the mixture of step (c) with an additional portion of the liquid vehicle.

[0316] In some embodiments, step (a) of the method comprises mixing a liquid vehicle with a sweetener and a surfactant.


Spray-dried dispersions

[0317] The methods and uses of the present disclosure may comprise administering a spray-dried dispersion (SDDs) of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-

ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, and to the use of the SDDs in the treatment of congenital adrenal hyperplasia (CAH).

[0318] In some embodiments, concentration and bioavailability enhancement in an aqueous environment of a low-solubility drug in a spray-dried dispersion is achieved if the SDD exhibits one or more properties, including, for example: (1) the solid dispersion is substantially homogeneous; (2) the drug is substantially amorphous; (3) the SDD has a relatively high drug loading; and (4) the SDD has a low residual solvent content. In some embodiments, the dispersion, when administered to an aqueous environment, provides at least a temporary dissolved drug concentration in the aqueous environment that is greater than the solubility of the crystalline form of the drug in the same environment. The aqueous environment can be, for example, an *in vitro* environment, such as a dissolution test media (e.g., phosphate buffered saline (PBS) solution), or an *in vivo* environment, such as the gastrointestinal (GI) tract of an animal, for example, a human. In some embodiments, the aqueous environment is the lower GI tract, such as the small intestine and large intestine.

[0319] Provided in the present disclosure is a spray-dried dispersion that contains a polymer and a compound having the structure of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof. In some embodiments, the SDD includes a polymer selected from a neutral polymer, an enteric polymer, and a pyrrolidone polymer. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is from about 1:1 to about 1:9.


[0320] In some embodiments, the polymer is a neutral polymer. For example, the polymer does not contain any charged functional groups. In some embodiments, the neutral polymer is a cellulosic polymer. For example, the cellulosic polymer can be a polymer with at least one ester- and/or ether-linked substituent in which the polymer has a degree of substitution of at least 0.05 for each substituent. Examples of suitable neutral polymers include, but are not limited to, hydroxypropyl methylcellulose (HPMC) and hydroxyethyl cellulose (HEC).

[0321] In some embodiments, the polymer is an enteric polymer. An "enteric polymer," as used herein, is a polymeric substance that is substantially insoluble and/or substantially stable under acidic conditions exhibiting a pH of less than about 7 and which is substantially soluble or can decompose under conditions exhibiting a pH of about 7 or more. Examples of suitable enteric polymers include, but are not limited to, carboxymethyl ethyl cellulose (CMEC), cellulose acetate phthalate (CAP), cellulose acetate succinate (CAS), methylcellulose phthalate, hydroxymethyl ethyl cellulose phthalate, hydroxypropyl methyl cellulose phthalate (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), polyvinyl alcohol phthalate, polyvinyl butyrate phthalate, polyvinyl acetal phthalate, a copolymer of vinyl acetate/maleic anhydride, a copolymer of vinylbutylether/maleic anhydride, a copolymer of styrene/maleic acid monoester, a copolymer of methyl acrylate/methacrylic acid, a copolymer of styrene/acrylic acid, a copolymer of methyl acrylate/methacrylic acid/octyl acrylate, a copolymer of methacrylic acid/methyl methacrylate, an amino methacrylate copolymer, an ammonioalkyl methacrylate copolymer, a methacrylic copolymer, and mixtures thereof. In some embodiments, the enteric polymer is selected from hydroxypropyl methyl cellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), hydroxypropyl methyl cellulose phthalate (HPMCP), an amino methacrylate copolymer, an ammonioalkyl methacrylate copolymer, and a methacrylic copolymer. In some embodiments, the enteric polymer is a Eudragit® polymer sold by Evonik Industries (Essen, Germany). In some embodiments, the enteric polymer is an amino methacrylate copolymer. In some embodiments, the amino methacrylate copolymer is Eudragit® E PO/100. In some embodiments, the enteric polymer is an ammonioalkyl methacrylate copolymer. In some embodiments, the ammonioalkyl methacrylate copolymer is Eudragit® RLPO. In some embodiments, the enteric polymer is a methacrylic copolymer. In some embodiments, the methacrylic copolymer is Eudragit® L100 or Eudragit® S100.

[0322] In some embodiments, the polymer is a pyrrolidone polymer. For example, the pyrrolidone polymer can be a vinyl pyrrolidone polymer, such as polyvinyl pyrrolidone (PVP) or polyvinyl pyrrolidone vinyl acetate (PVP/VA), including


homopolymers and copolymers of PVP and homopolymers and copolymers of N-vinyl pyrrolidone. In some embodiments, the pyrrolidone polymer is PVP/VA. In some embodiments, the PVP/VA is a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate. In some embodiments, the copolymer contains 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 30:70 to about 70:30 by weight, such as about 40:60 to about 60:40 by weight, or about 45:55 to about 55:45 by weight. In some embodiments, the copolymer contains 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 30:70, about 35:65, about 40:60, about 45:55, about 50:50, about 55:45, about 60:40, about 65:35, or about 70:30 by weight. In some embodiments, the copolymer contains 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 60:40 by weight.

[0323] In some embodiments, the pyrrolidone polymer has the structure:



where the value of n is about 1 to about 2 times the value of m. For example, the value of n can be about 1, about 1.05, about 1.1, about 1.15, about 1.16, about 1.2, about 1.25, about 1.3, about 1.35, about 1.4, about 1.45, about 1.5, about 1.55, about 1.6, about 1.65, about 1.7, about 1.75, about 1.8, about 1.85, about 1.9, about 1.95, or about 2 times the value of m, or a value within a range defined by any of the preceding values. In some embodiments, the value of n is about 1.16 times the value of m. In some embodiments, the copolymer is copovidone, and the value of n is about 1.16 times the value of m.

[0324] In some embodiments, the pyrrolidone polymer has the structure:



where the value of n is 1 to 2 times the value of m. For example, the value of n can be 1, 1.05, 1.1, 1.15, 1.16, 1.2, 1.25, 1.3, 1.35, 1.4, 1.45, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95, or 2 times the value of m, or a value within a range defined by any of the preceding values. In some embodiments, the value of n is 1.16 times the value of m. In some embodiments, the copolymer is copovidone, and the value of n is 1.16 times the value of m.


[0325] In some embodiments, the polymer used in the disclosed SDDs is present in an amount sufficient to increase the maximum drug concentration of the amorphous form of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the environment of use (e.g., aqueous environment) relative to a control composition that contains an equivalent amount of a crystalline form of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, but without polymer. In some embodiments, once the SDD is introduced into an environment of use (e.g., aqueous environment), the polymer increases the aqueous concentration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, relative to the control composition. It is to be understood that the control composition is free from solubilizers or other components that would materially affect the solubility of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and that the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is in solid form in the control composition.

[0326] In some embodiments of the SDDs, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is from about 1:1 to about 1:9. For example, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer can be about 1:1 to about 1:8, about 1:1 to about 1:7, about 1:1 to about 1:6, about 1:1 to about 1:5, about 1:1 to about 1:4, about 1:1 to about 1:3, about 1:1 to about 1:2, about 1:1 to about 1:1.5, about 1:1.5 to about 1:9, or about 1:2.5 to about 1:4. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is about 1:9, about 1:8, about 1:7.5, about 1:7, about 1:6, about 1:5, about 1:4, about 1:3, about 1:2.5, about 1:2, about 1:1.5, or about

1:1, or a weight ratio within a range defined by any of the preceding values. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is about 1:9. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is about 1:1.5. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is about 1:1.


[0327] In some embodiments of the SDDs, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is from 1:1 to 1:9. For example, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer can be 1:1 to 1:8, 1:1 to 1:7, 1:1 to 1:6, 1:1 to 1:5, 1:1 to 1:4, 1:1 to 1:3, 1:1 to 1:2, 1:1 to 1:1.5, 1:1.5 to 1:9, or 1:2.5 to 1:4. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is 1:9, 1:8,1:7.5,1:7,1:6,1:5,1:4,1:3,1:2.5, 1:2, 1:1.5, or 1:1, or a weight ratio within a range defined by any of the preceding values. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is 1:9. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is 1:1.5. In some embodiments, the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the polymer is 1:1.

[0328] In some embodiments, the spray dried dispersion includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a polymer that is a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate having the structure:



where the value of n is about 1 to about 2 times the value of m and the copolymer contains 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 60:40 by weight, and the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the copolymer is from about 1:1 to about 1:9.

[0329] In some embodiments, the spray dried dispersion includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a polymer that is a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate having the structure:



where the value of n is 1 to 2 times the value of m and the copolymer contains 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of 60:40 by weight, and the weight ratio of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the copolymer is from 1:1 to 1:9.

[0330] In some embodiments of the SDDs, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the polymer together form homogeneous particles. In some embodiments, the particles are a substantially homogeneous composition that includes the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the polymer. As used herein, "substantially homogeneous" means that the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is dispersed as homogeneously as possible throughout the polymer and can be thought of as a solid solution of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, dispersed in the polymer. While the dispersion can have some concentrated domains of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, the dispersion itself has a single glass transition temperature (T_g) which demonstrates that the dispersion is substantially homogeneous. This contrasts with a simple physical mixture of pure amorphous particles of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and pure amorphous polymer particles, which generally displays two distinct T_gS, one of the compound of Formula (I), or a pharmaceutically acceptable salt

thereof, and one of the polymer. "T_g," as used herein, is the characteristic temperature where a glassy material, upon gradual heating, undergoes a relatively rapid (e.g., 10 to 100 seconds) physical change from a glass state to a rubber state.

[0331] In some embodiments, the particles have a particle size distribution (D-value, D_{50}), of about 5 μm to about 100 μm, such as about 5 μm to about 95 μm, about 5 μm to about 90 μm, about 5 μm to about 85 μm, about 5 μm to about 80 μm, about 5 μm to about 75 μm, about 5 μm to about 70 μm, about 5 μm to about 65 μm, about 5 μm to about 60 μm, about 5 μm to about 55 μm, about 5 μm to about 50 μm, about 5 μm to about 45 μm, about 5 μm to about 40 μm, about 5 μm to about 35 μm, about 5 μm to about 30 μm, about 5 μm to about 25 μm, about 5 μm to about 20 μm, about 5 μm to about 15 μm, about 5 μm to about 10 μm, about 10 μm to about 100 μm, about 10 μm to about 95 μm, about 10 μm to about 90 μm, about 10 μm to about 85 μm, about 10 μm to about 80 μm, about 10 μm to about 75 μm, about 10 μm to about 70 μm, about 10 μm to about 65 μm, about 10 μm to about 60 μm, about 10 μm to about 55 μm, about 10 μm to about 50 μm, about 10 μm to about 45 μm, about 10 μm to about 40 μm, about 10 μm to about 35 μm, about 10 μm to about 30 μm, about 10 μm to about 25 μm, about 10 μm to about 20 μm, about 10 μm to about 15 μm, about 15 μm to about 100 μm, about 15 μm to about 95 μm, about 15 μm to about 90 μm, about 15 μm to about 85 μm, about 15 μm to about 80 μm, about 15 μm to about 75 μm, about 15 μm to about 70 μm, about 15 μm to about 65 μm, about 15 μm to about 60 μm, about 15 μm to about 55 μm, about 15 μm to about 50 μm, about 15 μm to about 45 μm, about 15 μm to about 40 μm, about 15 μm to about 35 μm, about 15 μm to about 30 μm, about 15 μm to about 25 μm, about 15 μm to about 20 μm, about 20 μm to about 100 μm, about 20 μm to about 95 μm, about 20 μm to about 90 μm, about 20 μm to about 85 μm, about 20 μm to about 80 μm, about 20 μm to about 75 μm, about 20 μm to about 70 μm, about 20 μm to about 65 μm, about 20 μm to about 60 μm, about 20 μm to about 55 μm, about 20 μm to about 50 μm, about 20 μm to about 45 μm, about 20 μm to about 40 μm, about 20 μm to about 35 μm, about 20 μm to about 30 μm, about 20 μm to about 25 μm, about 25 μm to about 100 μm, about 25 μm to about 95 μm, about 25 μm to about 90 μm, about 25 μm to about 85 μm, about 25 μm to about 80 μm, about 25 μm to about 75 μm, about 25 μm to about 70 μm, about 25 μm to about 65 μm, about 25 μm to about 60 μm, about 25 μm to about 55 μm, about 25 μm to about 50 μm, about 25 μm to about 45 μm, about 25 μm to about 40 μm, about 25 μm to about 35 μm, about 25 μm to about 30 μm, about 30 μm to about 100 μm, about 30 μm to about 95 μm, about 30 μm to about 90 μm, about 30 μm to about 85 μm, about 30 μm to about 80 μm, about 30 μm to about 75 μm, about 30 μm to about 70 μm, about 30 μm to about 65 μm, about 30 μm to about 60 μm, about 30 μm to about 55 μm, about 30 μm to about 50 μm, about 30 μm to about 45 μm, about 30 μm to about 40 μm, about 30 μm to about 35 μm, about 35 μm to about 100 μm, about 35 μm to about 95 μm, about 35 μm to about 90 μm, about 35 μm to about 85 μm, about 35 μm to about 80 μm, about 35 μm to about 75 μm, about 35 μm to about 70 μm, about 35 μm to about 65 μm, about 35 μm to about 60 μm, about 35 μm to about 55 μm, about 35 μm to about 50 μm, about 35 μm to about 45 μm, about 35 μm to about 40 μm, about 40 μm to about 100 μm, about 40 μm to about 95 μm, about 40 μm to about 90 μm, about 40 μm to about 85 μm, about 40 μm to about 80 μm, about 40 μm to about 75 μm, about 40 μm to about 70 μm, about 40 μm to about 65 μm, about 40 μm to about 60 μm, about 40 μm to about 55 μm, about 40 μm to about 50 μm, about 40 μm to about 45 μm, about 45 μm to about 100 μm, about 45 μm to about 95 μm, about 45 μm to about 90 μm, about 45 μm to about 85 μm, about 45 μm to about 80 μm, about 45 μm to about 75 μm, about 45 μm to about 70 μm, about 45 μm to about 65 μm, about 45 μm to about 60 μm, about 45 μm to about 55 μm, about 45 μm to about 50 μm, about 50 μm to about 100 μm, about 50 μm to about 95 μm, about 50 μm to about 90 μm, about 50 μm to about 85 μm, about 50 μm to about 80 μm, about 50 μm to about 75 μm, about 50 μm to about 70 μm, about 50 μm to about 65 μm, about 50 μm to about 60 μm, about 50 μm to about 55 μm, about 55 μm to about 100 μm, about 55 μm to about 95 μm, about 55 μm to about 90 μm, about 55 μm to about 85 μm, about 55 μm to about 80 μm, about 55 μm to about 75 μm, about 55 μm to about 70 μm, about 55 μm to about 65 μm, about 55 μm to about 60 μm, about 60 μm to about 100 μm, about 60 μm to about 95 μm, about 60 μm to about 90 μm, about 60 μm to about 85 μm, about 60 μm to about 80 μm, about 60 μm to about 75 μm, about 60 μm to about 70 μm, about 60 μm to about 65 μm, about 65 μm to about 100 μm, about 65 μm to about 95 μm, about 65 μm to about 90 μm, about 65 μm to about 85 μm, about 65 μm to about 80 μm, about 65 μm to about 75 μm, about 65 μm to about 70 μm, about 70 μm to about 100 μm, about 70 μm to about 95 μm, about 70 μm to about 90 μm, about 70 μm to about 85 μm, about 70 μm to about 80 μm, about 70 μm to about 75 μm, about 75 μm to about 100 μm, about 75 μm to about 95 μm, about 75 μm to about 90 μm, about 75 μm to about 85 μm, about 75 μm to about 80 μm, about 80 μm to about 100 μm, about 80 μm to about 95 μm, about 80 μm to about 90 μm, about 80 μm to about 85 μm, about 85 μm to about 100 μm, about 85 μm to about 95 μm, about 85 μm to about 90 μm, about 90 μm to about 100 μm, about 90 μm to about 95 μm, or about 95 μm to about 100 μm. In some embodiments, the D_{50} is about 5 μm, about 10 μm, about 15 μm, about 16 μm, about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, about 55 μm, about 60 μm, about 65 μm, about 70 μm, about 75 μm, about 80 μm, about 85 μm, about 90 μm, about 95 μm, or about 100 μm. In some embodiments, the D_{50} is about 10 μm, about 11 μm, about 12 μm, about 13 μm, about 14 μm, about 15 μm, about 16 μm, about 17 μm, about 18 μm, about 19 μm, or about 20 μm, or a value within a range defined by any of the preceding values. In some embodiments, the Dso value is about 16 μm. The Dso value can be measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, laser diffraction and

disc centrifugation.

[0332] In some embodiments, the particles have a particle size distribution (D-value, D_{50}), of 5 μm to 100 μm, such as 5 μm to 95 μm, 5 μm to 90 μm, 5 μm to 85 μm, 5 μm to 80 μm, 5 μm to 75 μm, 5 μm to 70 μm, 5 μm to 65 μm, 5 μm to 60 μm, 5 μm to 55 μm, 5 μm to 50 μm, 5 μm to 45 μm, 5 μm to 40 μm, 5 μm to 35 μm, 5 μm to 30 μm, 5 μm to 25 μm, 5 μm to 20 μm, 5 μm to 15 μm, 5 μm to 10 μm, 10 μm to 100 μm, 10 μm to 95 μm, 10 μm to 90 μm, 10 μm to 85 μm, 10 μm to 80 μm, 10 μm to 75 μm, 10 μm to 70 μm, 10 μm to 65 μm, 10 μm to 60 μm, 10 μm to 55 μm, 10 μm to 50 μm, 10 μm to 45 μm, 10 μm to 40 μm, 10 μm to 35 μm, 10 μm to 30 μm, 10 μm to 25 μm, 10 μm to 20 μm, 10 μm to 15 μm, 15 μm to 100 μm, 15 μm to 95 μm, 15 μm to 90 μm, 15 μm to 85 μm, 15 μm to 80 μm, 15 μm to 75 μm, 15 μm to 70 μm, 15 μm to 65 μm, 15 μm to 60 μm, 15 μm to 55 μm, 15 μm to 50 μm, 15 μm to 45 μm, 15 μm to 40 μm, 15 μm to 35 μm, 15 μm to 30 μm, 15 μm to 25 μm, 15 μm to 20 μm, 20 μm to 100 μm, 20 μm to 95 μm, 20 μm to 90 μm, 20 μm to 85 μm, 20 μm to 80 μm, 20 μm to 75 μm, 20 μm to 70 μm, 20 μm to 65 μm, 20 μm to 60 μm, 20 μm to 55 μm, 20 μm to 50 μm, 20 μm to 45 μm, 20 μm to 40 μm, 20 μm to 35 μm, 20 μm to 30 μm, 20 μm to 25 μm, 25 μm to 100 μm, 25 μm to 95 μm, 25 μm to 90 μm, 25 μm to 85 μm, 25 μm to 80 μm, 25 μm to 75 μm, 25 μm to 70 μm, 25 μm to 65 μm, 25 μm to 60 μm, 25 μm to 55 μm, 25 μm to 50 μm, 25 μm to 45 μm, 25 μm to 40 μm, 25 μm to 35 μm, 25 μm to 30 μm, 30 μm to 100 μm, 30 μm to 95 μm, 30 μm to 90 μm, 30 μm to 85 μm, 30 μm to 80 μm, 30 μm to 75 μm, 30 μm to 70 μm, 30 μm to 65 μm, 30 μm to 60 μm, 30 μm to 55 μm, 30 μm to 50 μm, 30 μm to 45 μm, 30 μm to 40 μm, 30 μm to 35 μm, 35 μm to 100 μm, 35 μm to 95 μm, 35 μm to 90 μm, 35 μm to 85 μm, 35 μm to 80 μm, 35 μm to 75 μm, 35 μm to 70 μm, 35 μm to 65 μm, 35 μm to 60 μm, 35 μm to 55 μm, 35 μm to 50 μm, 35 μm to 45 μm, 35 μm to 40 μm, 40 μm to 100 μm, 40 μm to 95 μm, 40 μm to 90 μm, 40 μm to 85 μm, 40 μm to 80 μm, 40 μm to 75 μm, 40 μm to 70 μm, 40 μm to 65 μm, 40 μm to 60 μm, 40 μm to 55 μm, 40 μm to 50 μm, 40 μm to 45 μm, 45 μm to 100 μm, 45 μm to 95 μm, 45 μm to 90 μm, 45 μm to 85 μm, 45 μm to 80 μm, 45 μm to 75 μm, 45 μm to 70 μm, 45 μm to 65 μm, 45 μm to 60 μm, 45 μm to 55 μm, 45 μm to 50 μm, 50 μm to 100 μm, 50 μm to 95 μm, 50 μm to 90 μm, 50 μm to 85 μm, 50 μm to 80 μm, 50 μm to 75 μm, 50 μm to 70 μm, 50 μm to 65 μm, 50 μm to 60 μm, 50 μm to 55 μm, 55 μm to 100 μm, 55 μm to 95 μm, 55 μm to 90 μm, 55 μm to 85 μm, 55 μm to 80 μm, 55 μm to 75 μm, 55 μm to 70 μm, 55 μm to 65 μm, 55 μm to 60 μm, 60 μm to 100 μm, 60 μm to 95 μm, 60 μm to 90 μm, 60 μm to 85 μm, 60 μm to 80 μm, 60 μm to 75 μm, 60 μm to 70 μm, 60 μm to 65 μm, 65 μm to 100 μm, 65 μm to 95 μm, 65 μm to 90 μm, 65 μm to 85 μm, 65 μm to 80 μm, 65 μm to 75 μm, 65 μm to 70 μm, 70 μm to 100 μm, 70 μm to 95 μm, 70 μm to 90 μm, 70 μm to 85 μm, 70 μm to 80 μm, 70 μm to 75 μm, 75 μm to 100 μm, 75 μm to 95 μm, 75 μm to 90 μm, 75 μm to 85 μm, 75 μm to 80 μm, 80 μm to 100 μm, 80 μm to 95 μm, 80 μm to 90 μm, 80 μm to 85 μm, 85 μm to 100 μm, 85 μm to 95 μm, 85 μm to 90 μm, 90 μm to 100 μm, 90 μm to 95 μm, or 95 μm to 100 μm. In some embodiments, the D_{50} is 5 μm, 10 μm, 15 μm, 16 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 80 μm, 85 μm, 90 μm, 95 μm, or 100 μm. In some embodiments, the Dso is 10 μm, 11 μm, 12 μm, 13 μm, 14 μm, 15 μm, 16 μm, 17 μm, 18 μm, 19 μm, or 20 μm, or a value within a range defined by any of the preceding values. In some embodiments, the D_{50} value is 16 μm. The Dso value can be measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, laser diffraction and disc centrifugation.

[0333] The SDDs of the present disclosure have a low residual solvent content. "Residual solvent content," as used herein, refers to the amount of solvent present in the SDD following spray drying, immediately upon exit from the spray dryer. The presence of solvent in the SDD lowers the glass transition temperature (T_g) of the dispersion. In some embodiments, mobility of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the SDD and its propensity to phase separate and crystallize decreases as the amount of residual solvent in the SDD decreases. In some embodiments, the SDDs have a residual solvent content of not more than about 10 wt%, such as not more than about 5 wt%, or not more than about 1 wt%. For example, the SDDs have a residual solvent content of about 2 wt%, about 1.9 wt%, about 1.8 wt%, about 1.7 wt%, about 1.6 wt%, about 1.5 wt%, about 1.4 wt%, about 1.3 wt%, about 1.2 wt%, about 1.1 wt%, about 1 wt%, about 0.9 wt%, about 0.8 wt%, about 0.7 wt%, about 0.6 wt%, about 0.5 wt%, or less. In some embodiments, the SDDs have a residual solvent content of less than about 2 wt%. In some embodiments, the SDDs have a residual solvent content of less than about 1 wt%. In some embodiments, the SDDs have a residual solvent content of about 0.5 wt% or less. In some embodiments, the SDDs have a residual solvent content of not more than 10 wt%, such as not more than 5 wt%, or not more than 1 wt%. For example, the SDDs may have a residual solvent content of 2 wt%, 1.9 wt%, 1.8 wt%, 1.7 wt%, 1.6 wt%, 1.5 wt%, 1.4 wt%, 1.3 wt%, 1.2 wt%, 1.1 wt%, 1 wt%, 0.9 wt%, 0.8 wt%, 0.7 wt%, 0.6 wt%, 0.5 wt%, or less. In some embodiments, the SDDs have a residual solvent content of less than 2 wt%. In some embodiments, the SDDs have a residual solvent content of less than 1 wt%. In some embodiments, the SDDs have a residual solvent content of 0.5 wt% or less.

[0334] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the spray-dried dispersion is substantially amorphous. As used herein, "substantially amorphous" means that the amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, in amorphous form is at least 60 wt% and that the amount of crystalline form present does not exceed 20 wt%. In some embodiments, the compound of Formula (I),

or a pharmaceutically acceptable salt thereof, in the dispersion is "almost completely amorphous," meaning that at least 90 wt% of the drug is amorphous, or that the amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the crystalline form does not exceed 10 wt%. Amounts of crystalline drug can be measured by powder X-ray diffraction (PXRD), scanning electron microscope (SEM) analysis, differential scanning calorimetry (DSC), polarized light microscopy (PLM), or any other standard quantitative or qualitative measurement used to detect crystalline material. Without wishing to be bound by any theory, it is believed that the amorphous, or non-crystalline form, in combination with the polymer, leads to greater ease of dissolution and absorption in the desired location, for example, the intestines, resulting in enhanced bioavailability as compared to a crystalline form of the compound of Formula (I) without polymer.

Process for preparing spray-dried dispersions

[0335] Provided in the present disclosure are methods for preparing a spray-dried dispersion containing a polymer and the compound of Formula (I), or a pharmaceutically acceptable salt thereof, such as the SDDs described herein. In some embodiments, the method includes dissolving the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the polymer in an organic solvent to form a solution; and spray-drying the solution to produce the spray-dried dispersion, wherein the spray-drying forms homogeneous particles of the compound of Formula (I) and the polymer. In some embodiments, the product obtained by spray-drying is dried to remove the solvent or solvent mixture. In some embodiments, the organic solvent is acetone.

[0336] The SDDs disclosed herein can be obtained by spray-drying a mixture comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, one or more polymer(s), and an appropriate solvent or solvent mixture. Spray-drying involves atomization of a liquid mixture containing, for example, a solid and a solvent or solvent mixture, and removal of the solvent or solvent mixture. Atomization can be done, for example, through a two-fluid or pressure or electrosonic nozzle, or on a rotating disk.

[0337] Spray-drying converts a liquid feed to a dried particulate form. In some embodiments, spray-drying involves the atomization of a liquid feed solution into a spray of droplets and contacting the droplets with hot air or gas in a drying chamber. The composition to be spray-dried can be any solution, coarse suspension, slurry, colloidal dispersion, or paste that can be atomized using the selected spray-drying apparatus. In some embodiments, the composition is a solution that is clear and free of undissolved solids. In some embodiments, the sprays are produced by either rotary (wheel) or nozzle atomizers. Evaporation of moisture from the droplets and formation of dry particles proceed under controlled temperature and airflow conditions. Commercially available types of apparatus can be used to conduct the spray-drying. For example, commercial spray dryers are manufactured by Buchi Ltd. and Niro (e.g., the PSD line of spray driers manufactured by Niro). Techniques and methods for spray-drying can also be found in Perry's Chemical Engineering Handbook, 6th Ed., R. H. Perry, D. W. Green & J. O. Maloney, eds., McGraw-Hill Book Co. (1984); and Marshall, "Atomization and Spray-Drying" 50, Chem. Eng. Prog. Monogr. Series 2 (1954).

[0338] In some embodiments, the spray-drying is conducted with an inlet temperature of from about 40°C to about 100°C, for example, from about 60°C to about 80°C, or from about 70°C to about 75°C. In some embodiments, the spray-drying is conducted with an inlet temperature of about 40°C, about 45°C, about 50°C, about 55°C, about 60°C, about 70°C, about 72°C, about 75°C, about 80°C, about 85°C, about 90°C, about 95°C, or about 100°C, or within a range defined by any of the preceding values. In some embodiments, the inlet temperature is about 60°C to about 80°C. In some embodiments, the spray-drying is conducted with an inlet temperature of about 61°C, about 63°C, about 65°C, about 67°C, about 69°C, about 71°C, about 73°C, about 75°C, about 77°C, about 79°C, about 81°C, about 83°C, or about 85°C, or within a range defined by any of the preceding values. In some embodiments, the inlet temperature is about 72°C.

[0339] In some embodiments, the spray-drying is conducted with an inlet temperature of from 40°C to 100°C, for example, from 60°C to 80°C, or from 70°C to 75°C. In some embodiments, the spray-drying is conducted with an inlet temperature of 40°C, 45°C, 50°C, 55°C, 60°C, 70°C, 72°C, 75°C, 80°C, 85°C, 90°C, 95°C, or 100°C, or within a range defined by any of the preceding values. In some embodiments, the inlet temperature is 60°C to 80°C. In some embodiments, the spray-drying is conducted with an inlet temperature of 61°C, 63°C, 65°C, 67°C, 69°C, 71°C, 73°C, 75°C, 77°C, 79°C, 81°C, 83°C, or 85°C, or within a range defined by any of the preceding values. In some embodiments, the inlet temperature is 72°C.

[0340] In some embodiments, the spray-drying is conducted with an outlet temperature of from about 20°C to about 75°C, for example, from about 25°C to about 50°C, or from about 30°C to about 40°C. In some embodiments, the spray-drying is conducted with an outlet temperature of about 20°C, about 25°C, about 30°C, about 35°C, about 40°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, about 70°C, or about 75°C, or within a range defined by any of the preceding values. In some embodiments, the outlet temperature is about 25°C to about 45°C. In some embodiments, the spray-drying is conducted with an outlet temperature of about 24°C, about 26°C, about 28°C, about 30°C, about 32°C, about 34°C, about 36°C, about 38°C, about 40°C, about 42°C, about 44°C, or about 46°C, or within a range

defined by any of the preceding values. In some embodiments, the outlet temperature is about 35°C.

[0341] In some embodiments, the spray-drying is conducted with an outlet temperature of from 20°C to 75°C, for example, from 25°C to 50°C, or from 30°C to 40°C. In some embodiments, the spray-drying is conducted with an outlet temperature of 20°C, 25°C, 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, or 75°C, or within a range defined by any of the preceding values. In some embodiments, the outlet temperature is 25°C to 45°C. In some embodiments, the spray-drying is conducted with an outlet temperature of 24°C, 26°C, 28°C, 30°C, 32°C, 34°C, 36°C, 38°C, 40°C, 42°C, 44°C, or 46°C, or within a range defined by any of the preceding values. In some embodiments, the outlet temperature is 35°C.


[0342] In some embodiments, the method involves removing the organic solvent after formation of the spray-dried dispersion. In some embodiments, the organic solvent is removed by drying the SDD. In some embodiments, a secondary drying process, such as fluidized bed drying, vacuum drying, tray drying, microwave drying, rotary drum drying or biconical vacuum drying is used to remove or reduce residual solvents, such as the organic solvent, to pharmaceutically acceptable levels. In some embodiments, the SDD is dried with a convection tray dryer.

[0343] In some embodiments, the homogeneous particles produced by the methods of the present disclosure have a bulk density of less than about 0.2 g/mL, or less than about 0.15 g/mL. In some embodiments, the homogeneous particles produced by the methods of the present disclosure have a bulk density of about 0.19 g/mL, about 0.18 g/mL, about 0.17 g/mL, about 0.16 g/mL, about 0.15 g/mL, about 0.14 g/mL, about 0.13 g/mL, about 0.12 g/mL, about 0.11 g/mL, about 0.1 g/mL, about 0.09 g/mL, about 0.08 g/mL, about 0.07 g/mL, about 0.06 g/mL or about 0.05 g/mL, or within a range defined by any of the preceding values. In some embodiments, the homogeneous particles produced by the methods of the present disclosure have a bulk density of less than 0.2 g/mL, or less than 0.15 g/mL. In some embodiments, the homogeneous particles produced by the methods of the present disclosure have a bulk density of 0.19 g/mL, 0.18 g/mL, 0.17 g/mL, 0.16 g/mL, 0.15 g/mL, 0.14 g/mL, 0.13 g/mL, 0.12 g/mL, 0.11 g/mL, 0.1 g/mL, 0.09 g/mL, 0.08 g/mL, 0.07 g/mL, 0.06 g/mL or 0.05 g/mL, or within a range defined by any of the preceding values. The term "bulk density," as used herein, refers to a property of powders and is defined as the mass of many particles of the material divided by the total volume they occupy. The total volume includes particle volume, inter-particle void volume and internal pore volume.

[0344] In some embodiments, the homogeneous particles produced by the methods of the present disclosure have a tapped density of less than about 0.3 g/mL, or less than about 0.25 g/mL. In some embodiments, the homogeneous particles produced by the methods of the present disclosure have a tapped density of about 0.29 g/mL, about 0.28 g/mL, about 0.27 g/mL, about 0.26 g/mL, about 0.25 g/mL, about 0.24 g/mL, about 0.23 g/mL, about 0.22 g/mL, about 0.21 g/mL, about 0.2 g/mL, or about 0.19 g/mL, or within a range defined by any of the preceding values. In some embodiments, the homogeneous particles produced by the methods of the present disclosure have a tapped density of less than 0.3 g/mL, or less than 0.25 g/mL. In some embodiments, the homogeneous particles produced by the methods of the present disclosure have a tapped density of 0.29 g/mL, 0.28 g/mL, 0.27 g/mL, 0.26 g/mL, 0.25 g/mL, 0.24 g/mL, 0.23 g/mL, 0.22 g/mL, 0.21 g/mL, 0.2 g/mL, or 0.19 g/mL, or within a range defined by any of the preceding values. The term "tap density" or "tapped density," as used herein, refers to a measure of the density of a powder. The tapped density of a pharmaceutical powder is determined using a tapped density tester, which is set to tap the powder at a fixed impact force and frequency. Tapped density by the USP method is determined by a linear progression of the number of taps.

Deuterated Compounds

[0345] Also disclosed herein are compounds having the structure of the following formula (II):




(II)

or a pharmaceutically acceptable salt thereof, wherein:

each R^1 is independently $C(R^A)_3$;
each R^A is independently hydrogen or deuterium;
each R^2 is independently hydrogen or deuterium;


each R^3 is independently hydrogen or deuterium;
R^4 is




R^5 is hydrogen or deuterium;
R^6 is $C(R^A)_3$; and
R^7 is $C(R^B)_3$, wherein at least one of R^A, R^B, R^2, R^3 and R^5 is deuterium.

[0346] With regard to the compounds provided herein, when a particular atomic position is designated as having deuterium or "D" or "d", it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015%. A position designated as having deuterium typically has a minimum isotopic enrichment factor of, in certain embodiments, at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation) at each designated deuterium position.


[0347] In some embodiments, the compound of Formula (II) may be one of the following, or a pharmaceutically acceptable salt thereof:




1




2



3



4



5

Pharmaceutical compositions

[0348] The methods and uses disclosed herein can comprise administering the compound of Formula (I) as a pharmaceutical composition.

[0349] In some embodiments of the methods described herein, the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered in a pharmaceutical composition further comprising one or more pharmaceutically acceptable excipients.

[0350] Also provided herein is a pharmaceutical composition comprising 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein.

[0351] In some embodiments, the methods and uses described herein comprise administering a pharmaceutical composition that does not comprise a spray-dried dispersion of the compound of Formula (I), as specified, e.g., in Example 1. Accordingly, in some embodiments, the pharmaceutical composition does not comprise any of the following polymers: hydroxypropylmethylcellulose acetate succinate-L (HPMCAS-L); polyvinyl pyrrolidone vinyl acetate 64 (PVP/VA 64); HPMCAS-M; and methyl methacrylate copolymer (1:1) (Eudragit® L100).

[0352] In some embodiments, the methods and uses described herein comprise administering a pharmaceutical composition that is not the reference formulation described in Example 9. Accordingly, in some embodiments, the pharmaceutical composition does not comprise at least three of the excipients selected from caprylic/capric triglyceride (Labrafac® Lipophile, Gattefossé, France); propylene glycol dicrapolate/dicaprate (Labrafac® PG, Gattefossé, France); oleoyl polyoxyl-6 glycerides (Labrafil® M 1944 CS, Gattefossé, France); polysorbate 20; polyoxyl castor oil (Kolliphor® RH 40, BASF, Germany); polyoxyl 15 hydroxystearate (Kolliphor® HS 15, BASF, Germany); lauroyl polyoxyl-32 glycerides (Gelucire® 44/14, Gattefossé, France); d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS); and diethylene glycol monoethyl ether (Transcutol®, Gattefossé, France).

[0353] In some embodiments, the methods and uses described herein comprise administering a pharmaceutical composition that is the formulation described in Example 9. In some embodiments, the methods and uses described herein comprise administering a pharmaceutical composition that is the formulation described in Example 11. In some embodiments, the methods and uses described herein comprise administering a pharmaceutical composition that is the formulation described in Example 12. In some embodiments, the methods and uses described herein comprise administering a pharmaceutical composition that is the formulation described in Example 13.

[0354] In some embodiments, the pharmaceutical compositions include a spray-dried dispersion containing a polymer and the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0355] In some embodiments, the pharmaceutical composition includes the SDD comprising a compound of Formula (I) and one or more pharmaceutically acceptable excipients. In some embodiments, the SDD is present in the pharmaceutical composition in an amount of about 20% to about 90% w/w of the composition, such as about 20% to about 85%,

about 20% to about 80%, about 20% to about 75%, about 20% to about 70%, about 20% to about 65%, about 20% to about 60%, about 20% to about 55%, about 20% to about 50%, about 20% to about 45%, about 20% to about 40%, about 20% to about 35%, about 20% to about 30%, about 20% to about 25%, about 25% to about 90%, about 25% to about 85%, about 25% to about 80%, about 25% to about 75%, about 25% to about 70%, about 25% to about 65%, about 25% to about 60%, about 25% to about 55%, about 25% to about 50%, about 25% to about 45%, about 25% to about 40%, about 25% to about 35%, about 25% to about 30%, about 30% to about 90%, about 30% to about 85%, about 30% to about 80%, about 30% to about 75%, about 30% to about 70%, about 30% to about 65%, about 30% to about 60%, about 30% to about 55%, about 30% to about 50%, about 30% to about 45%, about 30% to about 40%, about 30% to about 35%, about 35% to about 90%, about 35% to about 85%, about 35% to about 80%, about 35% to about 75%, about 35% to about 70%, about 35% to about 65%, about 35% to about 60%, about 35% to about 55%, about 35% to about 50%, about 35% to about 45%, about 35% to about 40%, about 40% to about 90%, about 40% to about 85%, about 40% to about 80%, about 40% to about 75%, about 40% to about 70%, about 40% to about 65%, about 40% to about 60%, about 40% to about 55%, about 40% to about 50%, about 40% to about 45%, about 45% to about 90%, about 45% to about 85%, about 45% to about 80%, about 45% to about 75%, about 45% to about 70%, about 45% to about 65%, about 45% to about 60%, about 45% to about 55%, about 45% to about 50%, about 50% to about 90%, about 50% to about 85%, about 50% to about 80%, about 50% to about 75%, about 50% to about 70%, about 50% to about 65%, about 50% to about 60%, about 50% to about 55%, about 55% to about 90%, about 55% to about 85%, about 55% to about 80%, about 55% to about 75%, about 55% to about 70%, about 55% to about 65%, about 55% to about 60%, about 60% to about 90%, about 60% to about 85%, about 60% to about 80%, about 60% to about 75%, about 60% to about 70%, about 60% to about 65%, about 65% to about 90%, about 65% to about 85%, about 65% to about 80%, about 65% to about 75%, about 65% to about 70%, about 70% to about 90%, about 70% to about 85%, about 70% to about 80%, about 70% to about 75%, about 75% to about 90%, about 75% to about 85%, about 75% to about 80%, about 80% to about 90%, about 80% to about 85%, or about 85% to about 90% w/w of the composition. In some embodiments, the SDD is present in an amount of about 40% to about 90% w/w of the composition. In some embodiments, the SDD is present in an amount of about 40% to about 80% w/w of the composition. In some embodiments, the SDD is present in the pharmaceutical composition in an amount of about 60% to about 80% w/w of the composition. In some embodiments, the SDD is present in an amount of about 80% w/w of the composition. In some embodiments, the SDD is present in the pharmaceutical composition in an amount of about 1% to about 20% w/w of the composition, such as about 13% w/w of the composition.

[0356] In some embodiments, the pharmaceutical composition includes the SDD comprising a compound of Formula (I) and one or more pharmaceutically acceptable excipients. In some embodiments, the SDD is present in the pharmaceutical composition in an amount of 20% to 90% w/w of the composition, such as 20% to 85%, 20% to 80%, 20% to 75%, 20% to 70%, 20% to 65%, 20% to 60%, 20% to 55%, 20% to 50%, 20% to 45%, 20% to 40%, 20% to 35%, 20% to 30%, 20% to 25%, 25% to 90%, 25% to 85%, 25% to 80%, 25% to 75%, 25% to 70%, 25% to 65%, 25% to 60%, 25% to 55%, 25% to 50%, 25% to 45%, 25% to 40%, 25% to 35%, 25% to 30%, 30% to 90%, 30% to 85%, 30% to 80%, 30% to 75%, 30% to 70%, 30% to 65%, 30% to 60%, 30% to 55%, 30% to 50%, 30% to 45%, 30% to 40%, 30% to 35%, 35% to 90%, 35% to 85%, 35% to 80%, 35% to 75%, 35% to 70%, 35% to 65%, 35% to about 60%, 35% to 55%, 35% to 50%, 35% to 45%, 35% to 40%, 40% to 90%, 40% to 85%, 40% to 80%, 40% to 75%, 40% to 70%, 40% to 65%, 40% to 60%, 40% to 55%, 40% to 50%, 40% to 45%, 45% to 90%, 45% to 85%, 45% to 80%, 45% to 75%, 45% to 70%, 45% to 65%, 45% to 60%, 45% to 55%, 45% to 50%, 50% to 90%, 50% to 85%, 50% to 80%, 50% to 75%, 50% to 70%, 50% to 65%, 50% to 60%, 50% to 55%, 55% to 90%, 55% to 85%, 55% to 80%, 55% to 75%, 55% to 70%, 55% to 65%, 55% to 60%, 60% to 90%, 60% to 85%, 60% to 80%, 60% to 75%, 60% to 70%, 60% to 65%, 65% to 90%, 65% to 85%, 65% to 80%, 65% to 75%, 65% to 70%, 70% to 90%, 70% to 85%, 70% to 80%, 70% to 75%, 75% to 90%, 75% to 85%, 75% to 80%, 80% to 90%, 80% to 85%, or about 85% to 90% w/w of the composition. In some embodiments, the SDD is present in an amount of 40% to 90% w/w of the composition. In some embodiments, the SDD is present in an amount of 40% to 80% w/w of the composition. In some embodiments, the SDD is present in the pharmaceutical composition in an amount of 60% to 80% w/w of the composition. In some embodiments, the SDD is present in an amount of 80% w/w of the composition. In some embodiments, the SDD is present in the pharmaceutical composition in an amount of about 1% to about 20% w/w of the composition, such as about 13% w/w of the composition.

[0357] In some embodiments of the pharmaceutical compositions disclosed herein (e.g., a composition including an SDD), the pharmaceutically acceptable excipient is selected from the group consisting of a filler, a lubricant, and combinations thereof. In some embodiments, the pharmaceutical excipients are selected from the group consisting of a glidant, a filler, a disintegrant, a lubricant, and a combination thereof.

[0358] In some embodiments, the pharmaceutical composition includes a filler. In some embodiments, the filler is selected from among binders, diluents, disintegrants, glidants, surfactants, and combinations thereof.

[0359] In some embodiments, the filler include saccharides (e.g., sugars, starch, and cellulose), gelatin, calcium carbonate, and synthetic polymers (e.g., polyvinylpyrrolidone, polyethylene glycol, and poloxamers (e.g., Poloxamer 188, a copolymer of polyoxyethylene and polyoxypropylene)). Exemplary fillers include, but are not limited to, glucose,

sucrose, lactose, a starch, including modified starches such as sodium starch glycolate (e.g., Explotab®), xylitol, dextrin, saccharose, sorbitol, mannitol (e.g., Parteck® M 200 (mannitol with an average particle size of about 50 μm to about 500 μm) or Parteck® M 100 (mannitol with an average particle size of less than 212 μm)), a cellulose, a polyvinylpyrrolidone, a polyethylene glycol, a polyvinyl alcohol, a polymethacrylate, dibasic calcium phosphate, magnesium stearate, calcium stearate, sodium stearate, stearic acid, hydrogenated vegetable oils, a mineral oil, sodium lauryl sulfate, magnesium lauryl sulfate, glyceryl palmitostearate, sodium benzoate, sodium stearyl fumarate, colloidal silicon dioxide, sodium benzoate, sodium oleate, sodium acetate, aliginic acid, alginates (e.g., sodium alginate), calcium silicate, and ion exchange resins. Exemplary cellulose fillers include microcrystalline cellulose (e.g., Avicel® PH-101 (microcrystalline cellulose with an average particle size of approximately 50 μm) or Avicel® PH 200 (microcrystalline cellulose with an average particle size of approximately 180 μm)), methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, and hydroxypropylmethylcellulose. Exemplary fillers include cross-linked polyvinylpyrrolidone such as with an average particle size of 90 μm to 130 μm) or with an average particle size of 10 μm to 30 μm). Other fillers known to those of skill in the art are also contemplated as being useful when formulated in the pharmaceutical compositions described herein.

[0360] In some embodiments, the filler is a binder. Binders include agents that hold the active pharmaceutical ingredient (e.g., spray-dried dispersion containing a polymer and the compound of Formula (I), or a pharmaceutically acceptable salt thereof) and inactive ingredients together in a cohesive mix. Exemplary binders include, but are not limited to, glucose, sucrose, lactose, a starch, including modified starches such as sodium starch glycolate (Explotab®), xylitol, dextrin, saccharose, sorbitol, mannitol (e.g., Parteck® M 200 (mannitol with an average particle size of about 50 μm to about 500 μm), Parteck® M 100 (mannitol with an average particle size of less than 212 μm)), gelatin, gum tragacanth, acacia mucilage, a cellulose, a polyvinylpyrrolidone, a polyethylene glycol, a polyvinyl alcohol, a polymethacrylate, and sodium starch glycolate. Exemplary cellulose fillers include microcrystalline cellulose (e.g., Avicel® PH-101 (microcrystalline cellulose with an average particle size of approximately 50 μm) or Avicel® PH 200 (microcrystalline cellulose with an average particle size of approximately 180 μm)), cellulose ethers, methyl cellulose, ethyl cellulose, croscarmellose sodium, sodium carboxy methyl cellulose starches, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose. Exemplary polyvinylpyrrolidone fillers include cross-linked polyvinylpyrrolidone such as Kollidon® CL (crospovidone with an average particle size of 90 μm to 130 μm) or Kollidon® CL-SF (crospovidone with an average particle size of 10 μm to 30 μm). Other binders known to those of skill in the art are also contemplated as being useful when formulated in the compositions described herein.

[0361] In some embodiments, the filler is a diluent. Suitable diluents include, but are not limited to, lactose, mannitol, isomalt, sucrose, dextrose, and sorbitol.

[0362] In some embodiments, the filler is a disintegrant. Disintegrants include any agent that promotes breakup of the formulation in an aqueous environment, for example, to promote more rapid release of the active pharmaceutical ingredient (e.g., the compound of Formula (I), or a pharmaceutically acceptable salt thereof). Exemplary disintegrants include, but are not limited to, starch and modified starches, such as corn starch, potato starch, sodium starch glycolate or croscarmellose sodium, alginic acid, alginates, such as sodium alginate, polyvinylpyrrolidone, bentonite, methylcellulose, agar, carboxymethylcellulose, crospovidone, acid-carbonate effervescent systems, such as citric acid with bicarbonate salts, and ion exchange resins. Other disintegrants known to those of skill in the art are also contemplated as being useful when formulated in the compositions described herein.

[0363] In some embodiments, the pharmaceutical composition comprises a disintegrant. In some embodiments, the pharmaceutical composition comprises about 1 w/w% to about 30 w/w% of the disintegrant. In some embodiments, the pharmaceutical composition comprises about 5 w/w% to about 15 w/w% of the disintegrant. In some embodiments, the pharmaceutical composition comprises about 10 w/w% of the disintegrant. In some embodiments, the disintegrant is selected from croscarmellose sodium, sodium starch glycolate, crospovidone, and sodium bicarbonate. In some embodiments, the disintegrant is croscarmellose sodium.

[0364] In some embodiments, the filler is a glidant. Glidants can be used to improve the flowability of a powder or granules or both. Glidants include, but are not limited to, silicone dioxide, such as colloidal silicon dioxide or hydrated silicon dioxide, magnesium silicate, magnesium aluminometasilicate, talc, starch, calcium silicate, light anhydrous silicic acid, and silicon dioxide aerogels.

[0365] In some embodiments, the pharmaceutical composition comprises a glidant. In some embodiments, the pharmaceutical composition comprises about 0.1 w/w% to about 5 w/w% of the glidant. In some embodiments, the pharmaceutical composition comprises about 0.1 w/w% to about 1 w/w% of the glidant. In some embodiments, the pharmaceutical composition comprises about 0.67 w/w% of the glidant. In some embodiments, the glidant is selected from calcium silicate, silicon dioxide, and talc. In some embodiments, the glidant is calcium silicate.

[0366] In some embodiments, the filler is a surfactant, wetting agent, solubilizer, or combination thereof. Examples include, but are not limited to, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., Tween®), polyoxyethylene stearates, sodium dodecylsulfate, tyloxapol (a nonionic liquid polymer of the alkyl aryl polyether alcohol type, also known as superinone or triton). Other examples

include, but are not limited to, poloxamers such as Pluronic® F68, F127, and F108, which are block copolymers of ethylene oxide and propylene oxide, and polyxamines such as Tetronic® 908 (also known as Poloxamine® 908), which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (available from BASF), dextran, lecithin, dialkylesters of sodium sulfosuccinic acid, such as Aerosol® OT, which is a dioctyl ester of sodium sulfosuccinic acid (available from American Cyanimid), Duponol® P, which is a sodium lauryl sulfate (available from DuPont), Triton® X-200, which is an alkyl aryl polyether sulfonate (available from Rohm and Haas), Tween® 20 and Tween® 80, which are polyoxyethylene sorbitan fatty acid esters (available from ICI Specialty Chemicals), Carbowax™ 3550 and 934, which are polyethylene glycols (available from Union Carbide), Crodesta™ F-110, which is a mixture of sucrose stearate and sucrose distearate, and Crodesta™ SL-40 (both available from Croda Inc.), and SA90HCO, which has the chemical formula $C_{18}H_{37}$-$CH_2(CON(CH_3)CH_2(CHOH)_4CH_2OH)_2$.

[0367] In some embodiments, the pharmaceutical composition comprises a filler. In some embodiments, the pharmaceutical composition comprises about 30 w/w% to about 99 w/w% of the filler. In some embodiments, the pharmaceutical composition comprises about 50 w/w% to about 90 w/w% of the filler. In some embodiments, the pharmaceutical composition comprises about 75.5 w/w% of the filler. In some embodiments, the filler is selected from mannitol, microcrystalline cellulose, lactose, starch, isomalt, silicified microcrystalline cellulose, Dicalcium Phosphate, maltodextrin, and a combination thereof. In some embodiments, the filler is a combination of mannitol and microcrystalline cellulose. In some embodiments, the pharmaceutical composition comprises about 30 w/w% to about 80 w/w% of mannitol. In some embodiments, the pharmaceutical composition comprises about 50 w/w% to about 60 w/w% of mannitol. In some embodiments, the pharmaceutical composition comprises about 56 w/w% of mannitol. In some embodiments, the pharmaceutical composition comprises about 1 w/w% to about 50 w/w% of microcrystalline cellulose. In some embodiments, the pharmaceutical composition comprises about 10 w/w% to about 30 w/w% of microcrystalline cellulose. In some embodiments, the pharmaceutical composition comprises about 20 w/w% of microcrystalline cellulose. In some embodiments, the pharmaceutical composition comprises about 56 w/w% of mannitol and about 20 w/w% of microcrystalline cellulose.

[0368] In some embodiments, the pharmaceutical composition includes a lubricant. Lubricants are agents added to pharmaceutical formulations to reduce friction during processing and prevent ingredients from clumping together. Exemplary lubricants include, but are not limited to, talc, starch, magnesium stearate, calcium stearate, sodium stearate, zinc stearate, stearic acid, vegetable stearin, adipic acid, waxy fatty acids, such as glyceryl behenate, a hydrogenated vegetable oil, a mineral oil, a polyethylene glycol, lycopodium, sodium lauryl sulfate, magnesium lauryl sulfate, glyceryl palmitostearate, sodium benzoate, sodium chloride, sterotex, glycerol monostearate, sodium stearyl fumarate, colloidal silicon dioxide, sodium benzoate, sodium oleate, and sodium acetate. Other lubricants known to those of skill in the art are also contemplated as being useful when formulated in the compositions described herein.

[0369] In some embodiments, the pharmaceutical composition comprises a lubricant. In some embodiments, the pharmaceutical composition comprises about 0.1 w/w% to about 10 w/w% of the lubricant. In some embodiments, the pharmaceutical composition comprises about 0.1 w/w% to about 1 w/w% of the lubricant. In some embodiments, the pharmaceutical composition comprises about 0.5 w/w% of the lubricant. In some embodiments, the pharmaceutical lubricant is selected from sodium stearyl fumarate, magnesium stearate, stearic acid sodium lauryl sulfate, sodium oleate, glyceryl behenate, and talc. In some embodiments, the lubricant is sodium stearyl fumarate.

[0370] In some embodiments, the pharmaceutical composition comprises:

(a) the spray-dried dispersion comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a polymer;
(b) a glidant;
(c) a filler; and
(d) a disintegrant.

[0371] In some embodiments, the pharmaceutical composition comprises:

(a) about 1 w/w% to about 20 w/w% of the spray-dried dispersion comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a polymer;
(b) about 0.1 w/w% to about 1 w/w% of a glidant;
(c) about 50 w/w% to about 90 w/w% of a filler; and
(d) about 5 w/w% to about 0.2 w/w% of a disintegrant.

[0372] In some embodiments, the pharmaceutical composition comprises:

(a) about 13 w/w% of the spray-dried dispersion comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a polymer;

(b) about 0.67 w/w% of a glidant;
(c) about 75.5 w/w% of a filler; and
(d) about 10 w/w% of a disintegrant.

[0373] In some embodiments, the pharmaceutical composition comprises:

(a) the spray-dried dispersion of Example 3;
(b) calcium silicate;
(c) a combination of mannitol and microcrystalline cellulose; and
(d) croscarmellose sodium.

[0374] In some embodiments, the pharmaceutical composition comprises:

(a) about 1 w/w% to about 20 w/w% of the spray-dried dispersion of Example 3;
(b) about 0.1 w/w% to about 1 w/w% of calcium silicate;
(c) about 50 w/w% to about 60 w/w% of mannitol and about 10 w/w% to about 30 w/w% of microcrystalline cellulose; and
(d) about 5 w/w% to about 0.2 w/w% of croscarmellose sodium.

[0375] In some embodiments, the pharmaceutical composition comprises:

(a) about 13 w/w% of the spray-dried dispersion of Example 3;
(b) about 0.67 w/w% of calcium silicate;
(c) about 56 w/w% of mannitol and about 20 w/w% of microcrystalline cellulose; and
(d) about 10 w/w% of croscarmellose sodium.

[0376] Additional excipients can be included in the pharmaceutical formulations of the present disclosure. Further examples of excipients include, but are not limited to, pigments, colorants, flavoring agents, preservatives, and sweeteners. Flavors and colors can be added to improve the taste or appearance of a formulation. Examples of preservatives used in pharmaceutical compositions are aromatic alcohols, such as benzyl or phenol alcohol, antioxidants such as vitamin A, vitamin E, vitamin C, and selenium, amino acids such as cysteine and methionine, citric acid and sodium citrate, or synthetic preservatives such as methyl paraben and propyl paraben. Sweeteners can be added to make the ingredients more palatable, especially in chewable tablets or liquids like syrups.

[0377] Also provided are methods for preparing a pharmaceutical composition, such as a pharmaceutical composition of the present disclosure. In some embodiments, the method includes combining the spray-dried dispersion described herein with one or more pharmaceutically acceptable excipients, e.g., a pharmaceutically acceptable excipient described herein.

[0378] In some embodiments, the method for preparing the pharmaceutical composition comprises:

(a) blending the spray-dried dispersion described herein, with a glidant;
(b) further blending the blend of step (a) with a filler and a disintegrant;
(c) screening the blend of step (b) to break up aggregates and assist with blend uniformity;
(d) further blending the intragranular blend of step (c);
(e) compaction of the intragranular blend of step (d) via roller compaction to form granules; and
(f) milling of ribbon from roller compaction into granules of step (e).

[0379] In some embodiments, the spray-dried dispersion is the spray-dried dispersion described in Example 3.

[0380] The pharmaceutical compositions of the present disclosure are formulated for oral administration. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media can be employed. For solid oral preparations such as, for example, powders, capsules, caplets, gelcaps, and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

[0381] Oral pharmaceutical dosage forms can be solid, gel, or liquid. In some embodiments, the dosage form is a solid dosage form. In some embodiments, the solid dosage form is a pill, tablet, capsule, caplet, gelcaps, granules, powder, sachet, melting strip, or melting film. In some embodiments, the solid dosage form is coated. In some embodiments, the

coating is an enteric coating, a sugar coating, or a film coating. In some embodiments, the solid dosage form is a coated particle, coated tablet, enterocoated tablet, or enterocoated capsule. In some embodiments, the solid dosage form is a pill or tablet. Types of oral tablets include compressed, chewable lozenges and tablets which may be enteric coated, sugar coated or film coated. In some embodiments, the pharmaceutical composition is formulated as a capsule. In some embodiments, the pharmaceutical composition is formulated as a powder, solution, or suspension (e.g., in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides), or is encapsulated in a capsule (gelatin or cellulose base capsule). Capsules can be hard or soft gelatin capsules, while granules and powders can be provided in non-effervescent or effervescent form with a combination of other ingredients known to those skilled in the art.

[0382] The pharmaceutical compositions of the present disclosure can contain, per dosage unit, e.g., tablet, capsule, powder, and the like, an amount of the active ingredient necessary to deliver an effective dose as described above.

[0383] In some embodiments, the pharmaceutical compositions of the present disclosure are formulated in unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg to about 200 mg in the unit dosage form. For example, about 5 mg to about 175 mg, about 5 mg to about 150 mg, about 5 mg to about 125 mg, about 5 mg to about 100 mg, about 5 mg to about 75 mg, about 5 mg to about 50 mg, about 5 mg to about 25 mg, about 25 mg to about 200 mg, about 25 mg to about 175 mg, about 25 mg to about 150 mg, about 25 mg to about 125 mg, about 25 mg to about 100 mg, about 25 mg to about 75 mg, about 25 mg to about 50 mg, about 50 mg to about 200 mg, about 50 mg to about 175 mg, about 50 mg to about 150 mg, about 50 mg to about 125 mg, about 50 mg to about 100 mg, about 50 mg to about 75 mg, about 75 mg to about 200 mg, about 75 mg to about 175 mg, about 75 mg to about 150 mg, about 75 mg to about 125 mg, about 75 mg to about 100 mg, about 100 mg to about 200 mg, about 100 mg to about 175 mg, about 100 mg to about 150 mg, about 100 mg to about 125 mg, about 125 mg to about 200 mg, about 125 mg to about 175 mg, about 125 mg to about 150 mg, about 150 mg to about 200 mg, about 150 mg to about 175 mg, or about 175 mg to about 200 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of about 25 mg to about 125 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of about 75 mg to about 150 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg, about 10 mg, about 25 mg, about 35 mg, about 50 mg, about 65 mg, about 75 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, or about 200 mg in the unit dosage form, or within a range defined by any of the preceding values. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of about 50 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of about 100 mg in the unit dosage form.. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of about 25 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of 5 mg to 250 mg in the unit dosage form. For example, 5 mg to 175 mg, 5 mg to 150 mg, 5 mg to 125 mg, 5 mg to 100 mg, 5 mg to 75 mg, 5 mg to 50 mg, 5 mg to 25 mg, 25 mg to 200 mg, 25 mg to 175 mg, 25 mg to 150 mg, 25 mg to 125 mg, 25 mg to 100 mg, 25 mg to 75 mg, 25 mg to 50 mg, 50 mg to 200 mg, 50 mg to 175 mg, 50 mg to 150 mg, 50 mg to 125 mg, 50 mg to 100 mg, 50 mg to 75 mg, 75 mg to 200 mg, 75 mg to 175 mg, 75 mg to 150 mg, 75 mg to 125 mg, 75 mg to 100 mg, 100 mg to 200 mg, 100 mg to 175 mg, 100 mg to 150 mg, 100 mg to 125 mg, 125 mg to 200 mg, 125 mg to 175 mg, 125 mg to 150 mg, 150 mg to 200 mg, 150 mg to 175 mg, or 175 mg to 200 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of 25 mg to 125 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of 75 mg to 150 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of 5 mg, 10 mg, 25 mg, 35 mg, 50 mg, 65 mg, 75 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, or 200 mg in the unit dosage form, or within a range defined by any of the preceding values. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of 50 mg in the unit dosage form. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is present in an amount of 100 mg in the unit dosage form. In some embodiments, the pharmaceutical compositions of the present disclosure are formulated as a tablet. In some embodiments, the tablet is coated. In some embodiments, the pharmaceutical compositions of the present disclosure are formulated as capsules. In some embodiments, the pharmaceutical compositions are in sachet form. In some embodiments, the pharmaceutical compositions are in granule form.

[0384] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in a dose of about 25 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in a dose of about 50 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in a dose of about 75 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in a dose of about 100 mg, based on the weight of the

free base.

[0385] In some embodiments, the pharmaceutical composition is administered in a dose of about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition is administered in a dose of about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition is administered in a dose of about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition is administered in a dose of about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

[0386] In some embodiments, the pharmaceutical composition comprises about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition comprises about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

[0387] The daily dosage of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition as described in the present disclosure can be varied over a wide range from about 1.0 mg to about 10,000 mg per adult human per day, or higher, or any range therein. For oral administration, the compositions can be provided in the form of tablets containing, for example, about 0.01 mg, about 0.05 mg, about 0.1 mg, about 0.5 mg, about 1.0 mg, about 2.5 mg, about 5.0 mg, about 10.0 mg, about 15.0 mg, about 25.0 mg, about 50.0 mg, about 75.0 mg, about 100 mg, about 150 mg, about 200 mg, about 250 or about 500 milligrams of the compound of Formula (I), or pharmaceutically acceptable salt thereof, for the symptomatic adjustment of the dosage to the subject to be treated. In some embodiments, an effective amount of the compound of Formula (I), or pharmaceutically acceptable salt thereof, can be supplied at a dosage level of from about 0.1 mg/kg to about 1000 mg/kg of body weight per day, or any range therein, for example, the range can be from about 0.5 mg/kg to about 500 mg/kg, about 1.0 mg/kg to about 250 mg/kg, about 0.1 mg/kg to about 100 mg/kg, about 0.1 mg/kg to about 50.0 mg/kg of body weight per day, about 0.1 mg/kg to about 15.0 mg/kg of body weight per day, about 0.5 mg/kg to about 7.5 mg/kg of body weight per day, or any amount to range therein. In some embodiments, an effective amount of the compound of Formula (I), or pharmaceutically acceptable salt thereof, can be supplied at a dosage level of from 0.1 mg/kg to 1000 mg/kg of body weight per day, or any range therein, for example, the range can be from 0.5 mg/kg to 500 mg/kg, 1.0 mg/kg to 250 mg/kg, 0.1 mg/kg to 100 mg/kg, 0.1 mg/kg to 50.0 mg/kg of body weight per day, 0.1 mg/kg to 15.0 mg/kg of body weight per day, 0.5 mg/kg to 7.5 mg/kg of body weight per day, or any amount to range therein. A pharmaceutical composition as provided herein can be administered on a regimen of 1 to 4 times per day or in a single daily dose.

[0388] In some embodiments, the daily dose of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is about 25 mg, based on the weight of the free base. In some embodiments, the daily dose of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is about 50 mg, based on the weight of the free base. In some embodiments, the daily dose of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is about 75 mg, based on the weight of the free base. In some embodiments, the daily dose of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is about 100 mg, based on the weight of the free base. In some embodiments, the daily dose of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is about 150 mg, based on the weight of the free base. In some embodiments, the daily dose of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is about 200 mg, based on the weight of the free base.

[0389] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered twice daily in a dose of about 25 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered twice daily in a dose of about 50 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered twice daily in a dose of about 75 mg, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered twice daily in a dose of about 100 mg, based on the weight of the free base.

[0390] In some embodiments, the daily dose of the pharmaceutical composition is about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the daily dose of the pharmaceutical composition is about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the daily dose of the pharmaceutical composition is about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the daily dose of the pharmaceutical composition is about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the daily dose of the pharmaceutical composition is about 150 mg of the compound of Formula (I),

or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the daily dose of the pharmaceutical composition is about 200 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

[0391] In some embodiments, the pharmaceutical composition is administered twice daily in a dose of about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition is administered twice daily in a dose of about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered twice daily in a dose of about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the pharmaceutical composition is administered twice daily in a dose of about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

[0392] In some embodiments, the method comprises administering a daily dose of the pharmaceutical composition comprising about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the method comprises administering a daily dose of the pharmaceutical composition comprising about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the method comprises administering a daily dose of the pharmaceutical composition comprising about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the method comprises administering a daily dose of the pharmaceutical composition comprising about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the method comprises administering a daily dose of the pharmaceutical composition comprising about 150 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the method comprises administering a daily dose of the pharmaceutical composition comprising about 200 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

[0393] In some embodiments, the method comprises administering the pharmaceutical composition twice daily in a dose of about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the method comprises administering the pharmaceutical composition twice daily in a dose of about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the method comprises administering the compound of Formula (I), or a pharmaceutically acceptable salt thereof, twice daily in a dose of about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base. In some embodiments, the method comprises administering the pharmaceutical composition twice daily in a dose of about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

[0394] Factors associated with the particular subject being treated, including subject age, weight, diet, and time of administration, can result in the need to adjust dosages. In some embodiments, the subject is a human adult. In some embodiments, the subject is a pediatric subject.

[0395] One skilled in the art will recognize that both *in vivo* and *in vitro* trials using suitable, known, and generally accepted cell and/or animal models are predictive of the ability of a test compound to treat or prevent a given disorder. One skilled in the art will further recognize that human clinical trials including first-in-human, dose ranging and efficacy trials, in healthy subjects and/or those suffering from a given disorder, can be completed according to methods well known in the clinical and medical arts. For example, determining proper dosages for pediatric subjects can be determined using known methods, including weight, age, and models such as Simcyp® Pediatric Simulation modeling (CERTARA, Princeton, N.J.) which can be used to establish a pharmacokinetic approach for dosing that takes into account subject age, ontogeny of the clearance pathways that a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and body surface area (BSA).

[0396] In some embodiments, the pharmaceutical compositions of the present disclosure are stable for at least 3 months. In some embodiments, the pharmaceutical compositions are stable for at least 6 months. In some embodiments, the pharmaceutical compositions are stable for at least 9 months. In some embodiments, the pharmaceutical compositions are stable for at least 12 months. For example, the compositions do not exhibit a change (e.g., greater than 5%) in appearance, pH, percent impurities, activity (as measured by in vitro assays), or osmolarity over time, e.g., at least 3 months, 6 months, 9 months, or at least 12 months as compared to the original composition after manufacturing. In some embodiments, the pharmaceutical compositions do not exhibit a significant change, as defined by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), in one or more of appearance, pH, percent impurities, activity (as measured by *in vitro* assays), or osmolarity over time, e.g., at least 12 months as compared to the original pharmaceutical composition after manufacturing.

Kits

[0397] Also provided are kits. Typically, a kit includes one or more pharmaceutical compositions as described herein, e.g., a pharmaceutical composition containing, e.g., a spray-dried dispersion as described in Examples 1-4, or the formulation described in Example 9. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering the pharmaceutical composition as provided herein, and directions for use of the kit (e.g., instructions for treating a subject). In some embodiments, the kit can include a pharmaceutical composition as described herein and a label that indicates that the contents are to be administered to a subject with congenital adrenal hyperplasia. The actual dose of the compound of Formula (I), or pharmaceutically acceptable salt thereof, provided herein depends on the specific formulation, the weight of the patient, and on the condition to be treated.

EXAMPLES

Example 1: Spray-dried dispersion formulations containing the compound of Formula (I) and various polymers

Spray-dried** dispersion **formulations

[0398] A series of spray-dried dispersion (SDD) formulations containing the compound of Formula (I) and a polymer were prepared. The SDD formulations included: (1) 10% compound of Formula (I)/90% hydroxypropylmethylcellulose acetate succinate-L (HPMCAS-L); (2) 25% compound of Formula (I)/75% HPMCAS-L; (3) 40% compound of Formula (I)/60% HPMCAS-L; (4) 25% compound of Formula (I)/75% polyvinyl pyrrolidone vinyl acetate 64 (PVP/VA 64); (5) 25% compound of Formula (I)/60% Cabosil (fumed silica)/15% HPMCAS-L; (6) 25% compound of Formula (I)/75% HPMCAS-M; and (7) 25% compound of Formula (I)/75% methyl methacrylate copolymer (1:1) (Eudragit® L100).

[0399] The PVP/VA polymer was a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate with a ratio of 60:40 by weight 1-vinyl-2-pyrrolidone:vinyl acetate with an average molecular weight of 45,000-70,000 (copovidone, sold as Kollidon® VA 64, BASF, Florham Park, NJ). The HPMCAS was a mixture of acetic acid and monosuccinic acid esters of hydroxypropylmethyl cellulose that was either grade L (HPMCAS-L), with an acetyl content of 5-9%, a succinoyl content of 14-18%, a methoxyl content of 20-24%, and a hydroxypropoxy content of 5-9% (sold by Shin-Etsu, Japan); or grade M (HPMCAS-M), with an acetyl content of 7-11%, a succinoyl content of 10-14%, a methoxyl content of 21-25%, and a hydroxypropoxy content of 5-9% (sold by Shin-Etsu, Japan).

Dissolution performance

[0400] Dissolution performance of several of the SDD formulations described above was tested (see FIG. 1). 1000 μgA/mL of each SDD was tested in 0.5 wt% simulated intestinal fluid (SIF) in PBS, pH 6.5. Samples were tested at 5, 10, 20, 45, 90, and 1200 minutes. A lipid formulation containing 10% of the compound of Formula (I) was used as a control. The results are shown in Table 4, below.

Table 4. Dissolution data of various SDDs

Sample	C_{max90} (μg/mL)	AUC_{90} (min*μg/mL)	C_{mix90} (μg/mL)	$Ultra_{90}$ (μg/mL)	C_{1200} (μg/mL)	$Ultra_{1200}$ (μg/mL)
2	762	66,080	743	210	671	166
4	322	27,330	306	109*	268	199
6	718	62,240	708	202	632	217
7	742	60,600	742	113*	674	194
Control	802	69,580	800	253	799	270
*Large variability between replicates, high value discarded						

Non-sink dissolution

[0401] A membrane flux assay was performed (see, e.g., Stewart et al., Mol. Pharm. (2017) 14:2032-2046) and non-sink dissolution data was collected for several of the SDD formulations described above and compared to the compound

of Formula (I) and several reference formulations, including a semi-solid lipidic formulation (Reference Formulation 1) and two self-emulsifying drug delivery system (SEDDS) formulations (Reference Formulations 2 and 3). The components of the Reference Formulations are shown in Table 5, below, and include, in addition to the compound of Formula (I), caprylic/capric triglyceride (Labrafac® Lipophile, Gattefossé, France); propylene glycol dicrapolate/dicaprate (Labrafac® PG, Gattefossé, France); oleoyl polyoxyl-6 glycerides (Labrafil® M 1944 CS, Gattefossé, France); polysorbate 20; polyoxyl castor oil (Kolliphor® RH 40, BASF, Germany); polyoxyl 15 hydroxystearate (Kolliphor® HS 15, BASF, Germany); lauroyl polyoxyl-32 glycerides (Gelucire® 44/14, Gattefossé, France); d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS); and diethylene glycol monoethyl ether (Transcutol®, Gattefossé, France).

Table 5. Reference formulations (capsules)

Formulation (mg/caps)	Ref. Formulation 1	Ref. Formulation 2	Ref. Formulation 3
Formula (I)	50.0	50.0	50.0
Labrafac® Lipophile	196.0	100.0	100.0
Labrafac® PG	102.0	-	-
Labrafil® M 1944 CS	-	135.0	46.0
Polysorbate 20	-	-	89.9
Kolliphor® RH 40	-	-	100.0
Kolliphor® HS 15	-	165.0	-
Gelucire® 44/14	95.0	-	-
TPGS	57.0	-	65.0
Transcutol®	-	50.0	50.0
Total	500.0	500.0	500.0

[0402] The assay measured the flux across simulated gastric and intestinal walls via UV spectroscopy (μDiss ProfilerTM, Pion Inc., Billerica, MA). Briefly, the assay was performed as follows. A vertical membrane flux cell consisting of a donor compartment and a receiver compartment, and separated by an Accurel PP 1E (55% porous, 100 μm thickness) polypropylene membrane (3M, Maplewood, MN) (FIG. 2), was impregnated with 50 μL of Pion GIT-0 lipid solution consisting of 20% w/w phospholipid dissolved into dodecane (Pion Inc., Billerica, MA) and attached to the receiver vessel. Both the donor and receiver compartments were agitated by magnetic stirring. The receiver compartment contained a plastic spacer and grating to elevate the stir bar above the membrane. Samples were introduced to the donor vessel by pre-weighing directly into the donor vessel and subsequently adding dissolution medium. Once the dissolution medium was added to the donor vessel, the receiver vessel was inserted into the donor vessel and suspended vertically 5 mm above the donor compartment by a plastic sleeve. For this assay, the simulated gastric (feed) media was 0.1 N HCl, pH 2 and included 200 μgA/mL of each SDD, and the simulated intestinal (receiver) media was 0.5 wt% SIF in PBS, pH 6.5 and included 100 μgA/mL of each SDD. The temperature for the assay was maintained at 44.5°C. UV probes (10 mm path length) connected to a Rainbow UV spectrometer (Pion Inc.) system were used to determine the apparent drug concentration in the receiver vessels. Samples of the donor compartment were removed with a disposable pipet for centrifugation followed by HPLC and DLS analysis of the supernatant. The results are shown in FIG. 3 and Table 6, below.

Table 6. Non-sink dissolution data

Sample	C_{maxGB} (μg/mL)	$C_{max90\ IB}$ (μg/mL)	$AUC_{4\text{-}90IB}$ (min*μg/mL)	C_{90} (μg/mL)	$Ultra_{90}$ (μg/mL)	C_{1200} (μg/ML)
Formula (I)	0	1	10	0	0	3
1	6	80	6,800	80	79	90
2	17	74	6,240	73	73	86
4	6	4	200	4	5	36
5	23	55	3,180	55	54	83
6	35	71	6,070	71	77	83

(continued)

Sample	C_{maxGB} (μg/mL)	$C_{max90\ IB}$ (μg/mL)	$AUC_{4\text{-}90IB}$ (min*μg/mL)	C_{90} (μg/mL)	$Ultra_{90}$ (μg/mL)	C_{1200} (μg/ML)
Ref. Formulation 1	205	109	9,050	109	-	-
Ref. Formulation 2	249	120	10,160	120	-	-
Ref. Formulation 3	218	107	9,100	107	-	-

[0403] The membrane flux of 1 mg/mL gastric barrier/intestinal barrier (GB/IB) 0.5 wt% SIF doses of the compound of Formula (I) and spray-dried dispersions (2) 25% compound of Formula (I)/75% HPMCAS-L and (4) 25% compound of Formula (I)/75% PVP/VA 64 were also determined. The results are shown in FIG. 4 as receiver concentration vs. time and flux vs. time (smoothed derivative of receiver concentration x volume/surface area).

Example 2: Characterization of a spray-dried dispersion containing 25% of the compound of Formula (I) and 75% of a polyvinyl pyrrolidone vinyl acetate (PVP/VA) polymer

SDD stability screening

[0404] Several of the SDDs described in Example 1 were tested for chemical and physical stability. Wet SDD stability studies were performed, with samples stored at both 5°C and 25°C. Measurements were taken after 1 week and 2 weeks of storage. The results are shown in Table 7 below. The column with a retention time of 32.36 min correlates with the compound of Formula (I).

Table 7. Wet SDD stability data

Retention time (min)			11.04	16.79	17.26	30.94	32.26			
Relative retention time			0.34	0.52	0.53	0.96	1.00			
	Storage temp	**Timepoint**						**Total impurities**	**Potency (mgA/g)**	**Std Dev**
Ref. Std.						0.37	99.63	0.37		
Formula (I)						0.26	99.74	0.26		
Sample 1		initial		0.13	0.16	0.25	99.46	0.54	100	1.3
	5°C	1 week		0.03	0.03	0.26	99.69	0.31	99	0.0
		2 weeks		0.12	0.16	0.28	99.45	0.55	99	0.5
	25°C	1 week		0.03	0.04	0.26	99.67	0.33	99	0.3
		2 weeks		0.21	0.27	0.28	99.24	0.76	98	0.8
Sample 2		initial	<LOQ	0.07	0.08	0.26	99.59	0.41	247	0.3
	5°C	1 week	<LOQ	0.02	0.03	0.26	99.70	0.30	248	1.3
		2 weeks	<LOQ	0.22	0.27	0.27	99.24	0.76	246	0.3
	25°C	1 week	<LOQ	0.02	0.03	0.26	99.69	0.31	248	0.9
		2 weeks	<LOQ	0.23	0.28	0.26	99.23	0.77	246	1.4

LOQ = limit of quantification

[0405] Solution stability studies were also performed, with samples stored at both 5°C and 25°C. Measurements were taken after 1 week and 2 weeks of storage. The results are shown in Table 8 below. The column with a retention time of 32.36 min correlates with the compound of Formula (I).

Table 8. SDD solution stability data

Retention time (min)			31.51	32.26	
Relative retention time			0.97	1.00	
	Storage temp	**Timepoint**			**Total impurities**
Ref. Std.			0.74	99.26	0.74
Formula (I)			0.26	99.74	0.26
Sample 1		initial	0.33	99.67	0.33
	5°C	2 weeks	0.29	99.71	0.29
	25°C	2 weeks	0.38	99.62	0.38
Sample 2		initial	0.25	99.75	0.25
	5°C	2 weeks	0.26	99.74	0.26
	25°C	2 weeks	0.33	99.67	0.33

[0406] Stability studies were also performed for the SDD containing 25% of the compound of Formula (I) and 75% PVP/VA 64, with samples stored at both 5°C (closed with desiccant), 25°C (60% RH, closed with desiccant), and 30°C (65% RH, closed with desiccant). Measurements were taken after storage for 1 month, 2 months, 3 months, 6 months, and 12 months. No change in purity was observed after 12 months of storage. The results are shown in Table 9 below. The column with a retention time of 30.2 min correlates with the compound of Formula (I).

Table 9. SDD stability data

Retention time (min)			28.7	30.2		
Relative retention time			0.95	1.00		
	Storage conditions	**Timepoint**			**Total impurities**	**Potency (mgA/g)**
Crystalline Formula (I)			0.26	99.74	0.26	1001

(continued)

	Storage conditions	Timepoint			Total impurities	Potency (mgA/g)
Sample 4 (25% Formula (I):75% PVP/VA 64)		initial	0.26	99.74	0.26	245
	5°C (closed w/ desiccant)	1 month	0.25	99.75	0.25	247
		2 months	0.25	99.75	0.25	244
		3 months	0.26	99.74	0.26	246
		6 months	0.25	99.75	0.25	245
		12 months	0.25	99.75	0.25	248
	25°C/60% RH (closed with desiccant)	1 month	0.25	99.75	0.25	245
		2 months	0.25	99.75	0.25	247
		3 months	0.25	99.75	0.25	246
		6 months	0.25	99.75	0.25	242
		12 months	0.25	99.75	0.25	245
	30°C/65% RH (closed with desiccant)	1 month	0.25	99.75	0.25	249
		2 months	0.25	99.75	0.25	242
		3 months	0.25	99.75	0.25	246
		6 months	0.25	99.73	0.25	243
		12 months	0.25	99.75	0.25	242

[0407] While Samples 1 and 2 showed degradation after about 2 weeks of storage, the SDD containing 25% of the compound of Formula (I) and 75% PVP/VA 64 (Sample 4) was found to be both chemically and physically stable and was further screened and characterized as described below.

25% Formula (I)/75% PVP/VA 64 SDD process parameter screening manufacture Round 1

[0408] The 25% Formula (I)/75% PVP/VA 64 SDD was prepared on a Pharmaceutical Spray Dryer with 100 kg/hr drying gas capacity (PSD-1). The manufacturing summary is shown in Table 10, below.

Table 10. Manufacturing summary of process parameters

Formulation	25% Formula (I):75% PVP/VA 64
Solids Loading (wt%)	10
Batch Size (kg)	1.5
Solvent	Acetone
Atomizer (Pressure Swirl)	SK 80-16
Solution Flow-rate (g/min)	160
Atomization Pressure (psig)	480
Inlet Temperature (°C)	94
Outlet Temperature (°C)	40
Calculated Outlet Acetone Saturation (% RS)	6.2
Dry Yield (%)	73

[0409] Based on the 73% yield observed in the first round of process screening, three sprays were performed to investigate the effect of reducing solution throughput and outlet temperature on product yield. All sprays were conducted

at a reduced flow-rate of 110 g/min. The outlet temperature was varied at 40°C (Lot A), 35°C (Lot B), and 30°C (Lot C). The outlet temperature was decreased while maintaining a low outlet acetone saturation to increase the difference between the chamber outlet temperature and the wet SDD T_g, thus improving product yields. The spray dryer chamber and outlet ductwork were cleaned between all manufactures. A manufacturing summary is shown in Table 11.

Table 11. Manufacturing summary for process parameters (1.5 kg batch size)

Description	Low Flow-Rate	Low Flow-Rate/Low Outlet Temperature	Low Flow-Rate/Lower Outlet Temperature
Lot	A	B	C
Solids Loading (wt%)	10	10	10
Batch Size (kg)	1.5	1.5	1.5
Solvent	Acetone	Acetone	Acetone
Atomizer (Pressure Swirl)	Steinen A75	Steinen A75	Steinen A75
Solution Flow-Rate (g/min)	110	110	110
Atomization Pressure (psig)	275	285	285
Inlet Temperature (°C)	79	72	63
Outlet Temperature (°C)	40	35	30
Calculated Outlet Acetone Saturation (% RS)	4.3	5.2	6.4
Calculated wet SDD T_g (°C)	72	71	69
Dry Yield (%)	55	80	43

[0410] The conditions used for Lot B were found to give the highest yield. One additional spray was then performed at the same processing conditions as Lot B while increasing the batch size from 1.5 kg to 3.5 kg to evaluate process consistency and to determine if product yield would continue to improve over time. The averaged process conditions for this lot are shown in Table 12.

Table 12. Manufacturing summary of process parameters (1.5 kg and 3.5 kg batch sizes)

Description	Low Flow-Rate/Low Outlet Temperature	Low Flow-Rate/Low Outlet Temperature/Larger Batch Size
Lot	B	D
Solids Loading (wt%)	10	10
Batch Size (kg)	1.5	3.5
Solvent	Acetone	Acetone
Atomizer (Pressure Swirl)	Steinen A75	Steinen A75
Solution Flow-Rate (g/min)	110	110
Atomization Pressure (psig)	285	285
Inlet Temperature (°C)	72	72
Outlet Temperature (°C)	35	35
Calculated Outlet Acetone Saturation (% RS)	5.2	5.2
Calculated wet SDD T_g (°C)	71	71
Dry Yield (%)	80	84

[0411] The 1.5 kg batch size (Lot D) was sprayed with an 84% yield compared to the 80% yield of the 3.5 kg batch (Lot B).

25% Formula (I)/75% PVP/VA 64 SDD process parameter screening characterisation

[0412] The 25% Formula (I)/75% PVP/VA 64 SDDs manufactured to evaluate processing parameters were characterized for powder properties, performance, and physical and chemical properties. Testing included particle size distribution by Malvern, determination of bulk and tapped density, microcentrifuge dissolution, modulated differential scanning calorimetry (mDSC), powder x-ray diffraction (PXRD), scanning electron microscope (SEM), and assay and related substances. The results did not show any significant differences between the lots.

[0413] The particle size distribution (PSD) and tabulated powder properties data of the 25% Formula (I)/75% PVP/VA 64 SDDs are shown in Table 13. All 25% Formula (I)/75% PVP/VA 64 SDDs were observed to have a very similar PSD with a D_{50} of approximately 16 μm. All 25% Formula (I)/75% PVP/VA 64 SDDs were observed to have low bulk and tapped densities.

Table 13. Powder properties of process parameter screening PVP/VA-64 SDDs

Sample	Lot	D_{10} (μm)	D_{50} (μm)	D_{90} (μm)	$D_{(3,2)}$ (μm)	$D_{(4,3)}$ (μm)	Span	Bulk density (g/mL)	Tapped density (g/mL)
40°C Outlet	**A**	**5**	**15**	**34**	**8**	**17**	**1.93**	**0.12**	**0.25**
35°C Outlet	**B**	**5**	**16**	**36**	**9**	**19**	**1.97**	**0.11**	**0.23**
30°C Outlet	**C**	**5**	**15**	**32**	**7**	**17**	**1.86**	**0.12**	**0.27**
35°C Outlet, 3.5 kg batch	**D**	**5**	**16**	**38**	**9**	**19**	**1.98**	**0.12**	**0.24**

[0414] The 3.5 kg batch size lot was analyzed and compared to process parameter Lot A. Dissolution performance was similar for each of these lots. Dissolution was rapid to C_{max} and high free drug was sustained through 90 minutes. These data are shown in Table 14.

Table 14. Dissolution performance of Lot A (1.5 kg batch size) vs. Lot D (3.5 kg batch size)

Sample	C_{max90} (μg/mL)	AUC_{90} (min*μg/mL)	C_{90} (μg/mL)	$Ultra_{90}$ (μg/mL)
Lot A	447	37,740	437	319
Lot D	437	37,120	433	301

[0415] The 25% Formula (I)/75% PVP/VA 64 SDDs were also evaluated by DSC, PXRD, and SEM. The DSC thermograms showed a single T_g at 84°C, indicating homogeneous dispersions. PXRD diffractograms showed no evidence of crystals in the SDDs. SEM images showed inflated sphere morphology with some broken particles and some very small particles.

[0416] Additional testing on Lot B was carried out, which included assessing the chemical/physical stability of both spray solution and SDD prior to secondary drying (wet SDD) to establish maximum in-process hold times. Residual acetone concentration as a function of secondary drying time in a convection tray dryer was also evaluated to nominate tray drying conditions to ensure the SDD is dried below International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines for acetone.

[0417] Residual acetone content as a function of drying time was assessed by drying wet SDD in a tray dryer and collecting samples over a 24-hour period. Wet SDD was dried at 40°C/15% relative humidity (RH) and was observed to dry below ICH acetone guidelines (0.5 wt%, 5000 ppm) by four hours.

[0418] Spray solution hold time was determined by making up a representative solution that contained 2.5 wt% compound of Formula (I), 7.5 wt% PVP/VA 64, and 90 wt% acetone. These solutions were analyzed initially for related substances. and then aged at 5°C and 25°C. Aliquots were taken and analyzed for related substances periodically for 14 days. Results showed no change in impurity profile at either condition through 14 days.

[0419] Wet SDD was analyzed for impurities after storage at 5°C and 25°C for 1 and 2 weeks and compared to the impurity profiles of the ingoing compound of Formula (I) and the SDD that was secondarily dried immediately after spray drying. The impurity profiles were similar to that of the initial dried sample and the ingoing compound of Formula (I) through 2 weeks of storage.

[0420] The wet SDD stability samples were characterized for physical stability by DSC, PXRD, and SEM. DSC thermograms showed a single T_g at 81°C, indicative of a homogeneous dispersion with no phase separation. The PXRD diffractograms did not show any evidence of crystals after storage at either condition. SEM images showed a typical morphology of mostly inflated spheres with some broken particles.

Example 3: Preparation of a 1000 g batch of a spray-dried dispersion containing 25% of the compound of Formula (I) and 75% PVP/VA 64

[0421] A 1000 g batch of the spray-dried dispersion containing 25% of the compound of Formula (I) and 75% PVP/VA 64 was prepared as described in Example 2 for the 1.5 kg and 3.5 kg batches. Briefly, acetone (90% (w/w) of the total mixture) was added to the mixing tank followed by the addition of 250.0 g of the compound of Formula (I) (2.5% (w/w) of the total mixture). The mixture was mixed for 30 minutes in the dark at a temperature range of 15°C to 27°C. At the end of the mixing period, the solution was clear and free of undissolved solids. The PVP/VA 64 (750.0 g, 7.5% (w/w) of the total mixture) was then added and the mixture was stirred for an additional 30 minutes in the dark at a temperature range of 15°C to 27°C. At the end of the mixing period, the solution was clear and free of undissolved solids.

[0422] The solution was pumped and atomized in a drying chamber. The spray-dried dispersions were prepared in a Pharmaceutical Spray Dryer with 100 kg/hr drying gas capacity (PSD-1). The inlet temperature was set at 75°C (varied between 60°C-90°C). The outlet temperature was set at 35°C (varied between 32°C-38°C). The feed pressure was set at 280 psig (varied between 230-330 psig). The feed rate was set at 110 g/min (varied between 90-130 g/min). The spray dried powder was then dried in a convection tray dryer with a bed depth of ≤ 2.5 cm at 40°C (⊥5°C) and 15% relative humidity (⊥10%) for 24 hours under amber light. The residual acetone after drying was < 0.5 wt% (5000 ppm). FIG. 5 is a flow diagram of the manufacturing process.

Example 4: Preparation of spray-dried dispersion formulations of the compound of Formula (I) for clinical use

[0423] The spray-dried dispersion (SDD) containing 25% compound of Formula (I) and 75% PVP/VA 64, prepared as described above, was formulated as a suspension or a capsule for clinical use.

Suspension preparation

[0424] A suspension that contained 50 mg of the SDD was prepared as follows. A 30 mL amber dosing bottle was tared on a balance. 200.0 mg SDD (50 mgA) ± 5% was then weighed into the dosing bottle. Using a 10-mL syringe, 5.0 mL of water (purified, USP) was added to the dosing bottle and the bottle was capped and shaken moderately for 30 seconds. The SDD suspension was stored in an amber vial at 2-8°C prior to use, and dosed within 24 hours of preparation.

Capsule preparation

[0425] An empty hard gelatin capsule, size 0 (Capsugel, Morristown, NJ), was placed on a balance and the weight was recorded. 200.0 mg SDD (50 mgA) ± 5% was then weighed onto weigh paper or an equivalent. All contents were transferred to the capsule using a ProFunnel device for Size 0 capsules. The filled capsule was placed on the balance and the weight was recorded. The weight of the empty capsule was subtracted from the filled weight, ensuring that the weight of the SDD within the capsule was 200.0 mg SDD ± 5%, or from 190.0 mg to 210.0 mg. The capsule was securely closed with the head, assuring it clicked into place. The capsules were stored in an amber vial at 2-8°C prior to use, and were dosed within 24 hours of preparation.

Example 5: Dog relative bioavailability and food effect study

[0426] Four spray-dried dispersions (SDDs), formulated in 0.25% methylcellulose as a suspension, were prepared: (1) 25% compound of Formula (I)/75% HPMCAS-L; (2) 10% compound of Formula (I)/90% HPMCAS-L; (3) 25% compound of Formula (I)/75% methyl methacrylate copolymer (1:1) (Eudragit® L100); and (4) 25% compound of Formula (I)/75% PVP/VA 64. A clinical capsule formulation was prepared as a reference formulation (Reference Formulation 1 from Table 5, above).

[0427] Dogs (two cohorts, six dogs in each) were dosed in six sessions, including fasted state sessions and fed sessions (high fat diet), with 50 mg dose of one of the SDDs or reference per dog in a 3-way crossover design. Each session had a 3-day washout in between. All formulations were well tolerated. The study design is shown in Table 15, below.

Table 15. Study design

Cohort 1	Session 1 (Fasted)	Session 2 (Fed)	Session 3 (Fasted)	Session 4 (Fed)	Session 5 (Fasted)	Session 6 (Fed)
Dog 1001	Reference	Reference	SDD 1	SDD 1	SDD 2	SDD 2
Dog 1002	Reference	Reference	SDD 1	SDD 1	SDD 2	SDD 2
Dog 2001	SDD 1	SDD 1	SDD 2	SDD 2	Reference	Reference
Dog 2002	SDD 1	SDD 1	SDD 2	SDD 2	Reference	Reference
Dog 3001	SDD 2	SDD 2	Reference	Reference	SDD 1	SDD 1
Dog 3002	SDD 2	SDD 2	Reference	Reference	SDD 1	SDD 1
Cohort 2	**Session 1 (Fasted)**	**Session 2 (Fed)**	**Session 3 (Fasted)**	**Session 4 (Fed)**	**Session 5 (Fasted)**	**Session 6 (Fed)**
Dog 4001	Reference	Reference	SDD 3	SDD 3	SDD 4	SDD 4
Dog 4002	Reference	Reference	SDD 3	SDD 3	SDD 4	SDD 4
Dog 5001	SDD 3	SDD 3	SDD 4	SDD 4	Reference	Reference
Dog 5002	SDD 3	SDD 3	SDD 4	SDD 4	Reference	Reference
Dog 6001	SDD 4	SDD 4	Reference	Reference	SDD 3	SDD 3
Dog 6002	SDD 4	SDD 4	Reference	Reference	SDD 3	SDD 3

[0428] The area under the plasma concentration versus time curve from 0 hours extrapolated to infinity ($AUC_{0-\infty}$), maximum plasma concentration (C_{max}), the apparent terminal half-life ($t_{½}$), and the time to achieve maximum plasma concentration (t_{max}) were calculated. Results are shown in Table 16, below, and in FIGS. 6A and 6B.

Table 16. Pharmacokinetic results

Cohort	Form	Fasted [Mean (%CV)]		Fed [Mean (%CV)]		Ratio of Fed/Fasted [Mean (%CV)]	
		C_{max} (ng/mL)	AUC_{inf} (hr*ng/mL)	C_{max} (ng/mL)	AUC_{inf} (hr*ng/mL)	C_{max}	AUC
1 (N=4) *	**Ref**	652 (55.5)	5170 (69.4)	3650 (19.5)	20100 (22)	6.9 (48)	5.5 (69.2)
	SDD 1	524 (62.7)	2870 (62.9)	5760 (25.6)	22800 (14.6)	15.4 (66.9)	8 (89.6)
	SDD 2	487 (45.7)	3950 (26.4)	4220 (27.4)	18100 (26.8)	16.5 (40.7)	6.3 (34.6)

(continued)

Cohort	Form	Fasted [Mean (%CV)]		Fed [Mean (%CV)]		Ratio of Fed/Fasted [Mean (%CV)]	
		C_{max} (ng/mL)	AUC_{inf} (hr*ng/mL)	C_{max} (ng/mL)	AUC_{inf} (hr*ng/mL)	C_{max}	AUC
2 (N=6)	Ref	854 (40.2)	5520 (59.1)	4220 (27.4)	18100 (26.8)	5.8 (46.5)	4.1 (49.2)
	SDD 3	453 (28.3)	2830 (21.6)	5320 (13.5)	23800 (26.1)	12.6 (30.3)	8.6 (22.2)
	SDD 4	353 (20.1)	1840 (21.9)	3060 (20.7)	17200 (20.5)	8.9 (29.3)	8.4 (46.1)
*Animals 2001 and 2002 were excluded from summary statistics due to emesis in all 3 fed sessions, which resulted in notably lower exposures							

[0429] The results showed that $t_{1/2}$ and t_{max} were similar among the formulations, and comparable between the fed and fasted states. Under the fed state with a high fat meal, exposures increased and inter-animal variability decreased. The food effect was more notable with the spray-dried dispersion formulations, especially for peak exposure (C_{max}).

[0430] Compared to the reference form, SDD 4 (25% compound of Formula (I)/75% PVP/VA 64) appeared to have lower inter-animal variability, lower exposures under the fasted state, and slightly lower C_{max} but relatively comparable AUC in the fed state.

Example 6: Phase 1 study to evaluate the pharmacokinetics, effect of food on pharmacokinetics, and safety of the compound of Formula (I) in healthy adult subjects

[0431] The present study was designed to evaluate the pharmacokinetics (PK) of the compound of Formula (I) as well as to evaluate the effect of a fed condition on the PK of the compound of Formula (I). The 50 mg dose was chosen for this study because it was within the tested dose range in completed Phase 1 and Phase 2 trials and was well tolerated in those studies. The objectives of the study were: to evaluate the PK of the compound of Formula (I) 50 mg in healthy adult subjects; to evaluate the effect of food on the PK of the compound of Formula (I) 50 mg; and to evaluate the safety and tolerability of the compound of Formula (I) 50 mg.

Study Design

[0432] This was a Phase 1, open-label, randomized, 2-period crossover study of the PK and the effect of food on the PK of the compound of Formula (I) in 16 healthy male and female adult subjects, 18 to 55 years of age.

[0433] After providing informed consent, subjects were screened for eligibility to participate in the study up to 28 days prior to Day 1 of treatment period 1. Eligible subjects were admitted to the clinical unit on Day -1 and randomized to 1 of the 2 treatment sequences (16 subjects [8 males and 8 females]; see Table 17, below). On Day 1 of each treatment period, subjects received a single dose of the compound of Formula (I) 50 mg under fasted or fed conditions. There were 21 days between doses.

Table 17. Treatment sequences

Treatment sequence	Treatment period I	Treatment period 2
1	Formula (I) - fasted	Formula (I) - fed
2	Formula (I) - fed	Formula (I) - fasted

[0434] Subjects were required to fast for at least 4 hours before check-in on Day -1. In the fasted condition, subjects were required to fast overnight for at least 10 hours prior to dosing and continued to fast for an additional 4 hours after dosing. In the fed condition, subjects were required to fast overnight for at least 10 hours and then ingest a liquid dietary supplement with study drug (liquid dietary supplement was consumed within 30 minutes) and not consume any other food for 4 hours after dosing. During both treatment periods, water was not permitted for 1 hour before dosing until 2 hours after dosing except for the water/liquid dietary supplement provided for study drug dosing. Vanilla-flavored Ensure Plus® was used as the liquid dietary supplement.

[0435] On Day 1 of each treatment period, subjects were dosed with the compound of Formula (I) 50 mg. Blood samples were collected for PK analysis over a period of 36 hours during the in-house stay. Subjects remained in the

unit on the day of dosing and were discharged on Day 2 of each treatment period, following completion of all required procedures. On the mornings of Days 8 and 15 of each treatment period, subjects returned to the clinical unit on an outpatient basis for PK blood sample collection and safety assessments. On Day 21 of treatment period 1, subjects arrived at the site and had Day 21 assessments completed in the evening, and they stayed overnight at the site and began Day 1 of treatment period 2 the following day. A final follow-up study visit was conducted on Day 22 of treatment period 2 (21 ± 2 days after treatment period 2 dosing) or upon early termination.

[0436] During each treatment period, blood samples for PK analysis were collected within 45 minutes before dosing, and at approximately 30 minutes, and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 36, 168, 336, and 504 hours after dosing.

[0437] Safety assessments (including clinical safety laboratory tests, vital sign measurements, physical examinations, and electrocardiograms (ECGs)) were conducted at scheduled times throughout the study. Adverse events (AEs) and the use of concomitant medications were monitored throughout the study. FIG. 7 illustrates the study design.

*Test **product**, dose **and mode of administration***

[0438] The compound of Formula (I) was supplied as an encapsulated, lipidic semi-solid containing 50 mg of the compound of Formula (I) as free base equivalent for oral administration. Subjects swallowed a single capsule with approximately 240 mL of water in the fasted condition. Subjects swallowed a single capsule with a liquid dietary supplement (Ensure Plus® [237 mL container]) with up to an additional 120 mL of water in the fed condition.

Duration of treatment

[0439] The duration of study participation for each adult subject was approximately 10 weeks, including up to 28 days of screening, 2 days of dosing separated by 21 days, and a final follow-up study visit 21 days after receiving the last dose of study drug during treatment period 2.

Criteria for Evaluation

Pharmacokinetics

[0440] The following plasma PK parameters were calculated for the compound of Formula (I):

- Area under the plasma concentration versus time curve from 0 hours to last measurable concentration ($AUC_{0\text{-tlast}}$)
- Area under the plasma concentration versus time curve from 0 to 24 hours ($AUC_{0\text{-}24}$)
- Area under the plasma concentration versus time curve from 0 hours extrapolated to infinity ($AUC_{0\text{-}\infty}$)
- Maximum plasma concentration (C_{max})
- Time to achieve maximum plasma concentration (t_{max})
- Delay time between time of dosing and time of appearance of measurable test article (T_{lag})
- Apparent terminal half-life ($t_{½}$)
- Apparent terminal rate constant (λz)
- Apparent mean residence time (MRT)
- Molar AUC ratio of the hydroxylated metabolite of the compound of Formula (I) to the parent drug the compound of Formula (I)

[0441] The following plasma PK parameters were calculated only for the compound of Formula (I):

- Apparent systemic clearance after oral administration (CL/F)
- Apparent volume of distribution during terminal phase after oral administration (Vz/F)

Safety

[0442] Safety was monitored throughout the study and included the following assessments:

- Adverse events (AEs)
- Clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis)
- Vital sign measurements (including orthostatic blood pressure and pulse rate)
- Physical examinations
- 12-lead electrocardiograms (ECGs)

Statistical Methods

[0443] Pharmacokinetic parameters were calculated using noncompartmental methods and summarized by condition (fed or fasted) using descriptive statistics. Two-sided 90% confidence intervals were calculated for the ratio under the fed condition vs. under the fasted condition for $AUC_{0-\infty}$, $AUC_{0-tlast}$, and C_{max} for the compound of Formula (I) and the hydroxylated metabolite of the compound of Formula (I).

[0444] Safety data were summarized with descriptive statistics.

Pharmacokinetics

***Pharmacokinetic** assessments*

[0445] PK plasma samples for analyses of the compound of Formula (I) and the hydroxylated metabolite of the compound of Formula (I) were collected at the following times during each treatment period:

- Day 1: within 45 minutes before dosing, and at approximately 30 minutes, and 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 12, and 16 hours after dosing.
- Day 2: approximately 24 and 36 hours after dosing.
- Day 8: approximately 168 hours after dosing.
- Day 15: approximately 336 hours after dosing.
- Approximately 504 hours after dosing (for treatment period 1, this sample was collected in the morning at least 30 minutes prior to the predose sample on Day 1 of treatment period 2).
- Final study visit for subjects who terminate early: 1 sample.

[0446] Blood samples on Day 1 were collected within 5 minutes of the scheduled sampling times (other than the predose sample). Blood samples on Days 2, 8, and 15 were collected within 2 hours of the scheduled sampling time. The 504 hour blood sample for treatment period 2 had a $\pm$ 2-day window. A PK sample was to be collected from subjects who terminated early. The exact time of sampling in hour and minutes was recorded.

Bioanalytical methods

[0447] Plasma samples were analyzed for the compound of Formula (I) and for its hydroxylated metabolite by in Ventiv Health, Princeton NJ, in compliance with Good Laboratory Practice (GLP) and relevant Standard Operating Procedures (SOPs).

[0448] The concentrations of the compound of Formula (I) and the hydroxylated metabolite of the compound of Formula (I) were quantified in plasma samples according to validated methods using tandem mass spectrometry in positive ion mode. This method was validated for the analysis of the compound of Formula (I) and the hydroxylated metabolite of the compound of Formula (I) in 25.0 μL dipotassium ethylenediaminetetraacetic acid (K_2-EDTA) human plasma samples over concentration ranges of 5.00 to 2500 ng/mL and 0.500 and 250 ng/mL, respectively. All analytical results were within acceptable limits. Incurred sample reanalysis (ISR) was successfully conducted in this study for both analytes.

Results

Pharmacokinetic results

[0449] Eight male and eight female subjects were enrolled. The mean age was 37.1 years (range, 21 to 55 years). The majority of subjects were White (93.8%) and of Hispanic ethnicity (81.3%). The mean weight at screening was 160.28 lbs (range, 102.0 to 222.2 lbs) and mean BMI was 25.50 kg/m^2 (range, 20.7 to 30.5 kg/m^2). The randomization was well balanced with respect to demographics and baseline characteristics.

[0450] All 16 subjects were included in the safety analysis set. No subjects were excluded from the safety analysis set and no subject had his or her PK data excluded from analysis.

[0451] The mean plasma concentration versus time profiles for the compound of Formula (I) under fasted and fed conditions are presented in FIGS. 8A and 8B, respectively. The compound of Formula (I) was slowly absorbed after oral administration in both fasted and fed conditions. Mean plasma concentrations were lower in the fasted than in the fed condition.

[0452] PK parameters for the compound of Formula (I) after treatment with the compound of Formula (I) under fasted and fed conditions are summarized in Table 18, below, where AUC_{0-24}=area under the plasma concentration vs. time curve from 0 to 24 hours, AUCo-t_{bu}t=AUC from 0 hours to last measurable concentration, $AUC_{0-\infty}$=AUC from 0 hours

extrapolated to infinity, CL/F=apparent systemic clearance after oral administration, CV=coefficient of variation, C_{max}=maximum plasma concentration, CV(%)=coefficient of variation, max=maximum, min=minimum, MRT=apparent mean residence time, PK=pharmacokinetic, SD=standard deviation, $t_{½}$=apparent terminal half-life, T_{lag}=delay time between time of dosing and time of appearance of measurable test article, t_{max}=time to maximum plasma concentration, VZ/F=apparent volume of distribution during the terminal phase after oral administration.

[0453] The PK data for t_{max}, T_{lag}, $t_{½}$, MRT, and Vz/F were rounded to 2 significant figures and all other parameters (AUC_{0-24}, $AUC_{0-tlast}$, $AUC_{0-\infty}$, C_{max}, and CL/F) were rounded to 3 significant figures. The last significant figure was rounded up if the digit to the right of it was ≥5, and was rounded down if the digit to the right of it was ≤4.

Table 18. Summary of Formula (I) PK parameters (safety analysis set)

Parameter Statistic	Fasted Formula (I) (50 mg) (N=16)	Fed Formula (I) (50 mg) (N=15)
AUC_{0-24} (ng×hr/mL) Mean (SD) Geometric CV%	5590 (2230) 32.7	9950 (2540) 26.2
$AUC_{0-tlast}$ (ng×hr/mL) Mean (SD) Geometric CV%	8020 (5110) 53.6	16200 (5450) 39.7
$AUC_{0-\infty}$ (ng×hr/mL) Mean (SD) Geometric CV%	9440 (2990) [n=7] 39.7	17800 (4990) [n=12] 28.1
C_{max} (ng/mL) Mean (SD) Geometric CV%	731 (301) 36.6	1550 (392) 24.2
t_{max} (hours) Median (min, max)	6.0 (3.0, 6.0)	5.0 (3.0, 6.0)
T_{lag} (hours) Mean (SD)	0.63 (0.22)	0.94 (0.37)
$t_{½}$ (hours) Mean (SD) Geometric CV%	33 (17) [n=7] 99	42 (6.8) [n=12] 15
MRT (hours) Mean (SD) Geometric CV%	28 (11) [n=7] 49	30 (5.0) [n=12] 16
CL/F (L/hr) Mean (SD) Geometric CV%	6.0 (2.7) [n=7] 40	3.0 (0.82) [n=12] 28
VZ/F (L) Mean (SD) Geometric CV%	240 (120) [n=7] 67	180 (57) [n=12] 30

[0454] As seen in Table 18, above, administration of the compound of Formula (I) 50 mg under fed compared with fasted conditions resulted in a higher mean C_{max} of the compound of Formula (I) (approximately 2-fold higher; 1550 vs. 731 ng/mL), a longer $t_{½}$ (42 vs. 33 hours), a slightly shorter median t_{max} (5.0 vs. 6.0 hours), and a higher mean $AUC_{0-\infty}$ (approximately 2-fold higher; 17800 vs. 9440 ngxhr/mL). The compound of Formula (I) geometric mean ratios for C_{max} and $AUC_{0-tlast}$ for fed vs. fasted conditions were 218.6% and 215.2%, respectively, indicating that the compound of Formula (I) absorption was approximately 2-fold greater when administered with food. The upper and lower 90% confidence interval (CI) bounds for both C_{max} (187.4% and 255.1%, respectively) and $AUC_{0-tlast}$ (182.9% and 253.1%, respectively) were outside of the "no-effect" range of 80.00% to 125.00%, indicating that there was a food effect on the compound of Formula (I) exposure.

[0455] Frequency distribution of T_{lag} and t_{max} values are presented in Table 19 and Table 20, respectively. Spaghetti plots for the compound of Formula (I) $AUC_{0-tlast}$, $AUC_{0-\infty}$ and C_{max} are shown in FIGS. 9A, 9B, and 9C, respectively.

Table 19. Frequency distribution of plasma Formula (I) T_{lag} values by treatment (safety analysis set)

T_{lag} (hr)	Statistic	Fasted (Formula (I) 50 mg) (N=16)	Fed (Formula (I) 50 mg) (N=15)
0.50	n (%)	11 (68.8%)	3 (20.0%)
0.53	n (%)	1 (6.3%)	0 (0.0%)
0.55	n (%)	0 (0.0%)	1 (6.7%)
1.00	n (%)	4 (25.0%)	8 (53.3%)
1.02	n (%)	0 (0.0%)	1 (6.7%)
1.03	n (%)	0 (0.0%)	1 (6.7%)
2.00	n (%)	0 (0.0%)	1 (6.7%)

Table 20. Frequency distribution of plasma Formula (I) T_{max} values by treatment (safety analysis set)

T_{max} (hr)	Statistic	Fasted (Formula (I) 50 mg) (N=16)	Fed (Formula (I) 50 mg) (N=15)
3.00	n (%)	1 (6.3%)	2 (13.3%)
4.02	n (%)	1 (6.3%)	0 (0.0%)
5.00	n (%)	4 (25.0%)	8 (53.3%)
5.03	n (%)	0 (0.0%)	1 (6.7%)
5.05	n (%)	0 (0.0%)	1 (6.7%)
6.00	n (%)	10 (62.5%)	2 (13.3%)
6.02	n (%)	0 (0.0%)	1 (6.7%)

[0456] The compound of Formula (I) was slowly absorbed after oral administration in the fasted and fed conditions. In the fasted condition, the mean compound of Formula (I) C_{max} was approximately 53% lower than in the fed condition (731 vs. 1550 ng/mL). Due to a prolonged elimination phase, $t_{½}$ values and therefore, $AUC_{0-\infty}$ values could not be determined for some the compound of Formula (I) concentration-time profiles. Mean $AUC_{0-\infty}$ was approximately 47% lower in the fasted condition than in the fed condition (9440 vs. 17800 ngxhr/mL) for those subjects for whom $AUC_{0-\infty}$ could be determined. Mean $AUC_{0-tlast}$ was approximately 50% lower in the fasted condition than in the fed condition (8020 vs. 16200 ngxhr/mL). Median t_{max} was slightly longer in the fasted condition than in the fed condition (6.0 vs. 5.0 hours) and mean $t_{½}$ was shorter in the fasted condition than in the fed condition (33 vs. 42 hours) for those subjects for whom a $t_{½}$ could be determined. Variability in the compound of Formula (I) PK (geometric CV%) for AUC, C_{max}, $t_{½}$, and MRT was lower in the fed condition compared with the fasted condition.

[0457] The geometric mean ratios and associated 90% CIs for $AUC_{0-tlast}$ and C_{max} for the compound of Formula (I) after treatment with the compound of Formula (I) for the fed vs. fasted condition are provided in Table 21, below, where $AUC_{0-tlast}$= AUC from 0 hours to last measurable concentration, C_{max}=maximum plasma concentration, and PK=pharmacokinetic.

Table 21. Formula (I) geometric mean ratios for PK exposure parameters under fed vs. fasted conditions (safety analysis set)

Parameter	Ratio[a] (%) (Fed vs. Fasted Condition)	90% Confidence Interval[b]
$AUC_{0-tlast}$ (ngxhr/mL)	215.2	182.9,253.1
C_{max} (ng/mL)	218.6	187.4,255.1
[a] Ratio of geometric least-squares means was based on a mixed model using log-transformed (base 10) data. [b] The 90% confidence interval for geometric mean ratio was based on least-squares means using log-transformed (base 10) data.		

[0458] The compound of Formula (I) geometric mean ratios for C_{max} and $AUC_{0-tlast}$ for the fed vs. fasted conditions were 218.6% and 215.2%, respectively, indicating that the compound of Formula (I) absorption was approximately 2-fold greater when administered with food. The upper and lower 90% CI bounds for both C_{max} (187.4%, 255.1%) and $AUC_{0-tlast}$ (182.9%, 253.1%) were outside of the "no-effect" range of 80.00% to 125.00%, indicating that there was a food effect on the compound of Formula (I) exposure. Due to the missing $AUC_{0-\infty}$ values, the food effect on overall exposure was not assessed using $AUC_{0-\infty}$ values.

Conclusion

[0459] Administration of the compound of Formula (I) 50 mg under fed compared with fasted conditions resulted in a higher mean C_{max} of the compound of Formula (I) (approximately 2-fold higher; 1550 vs. 731 ng/mL), a longer $t_{½}$ (42 vs. 33 hours), a slightly shorter median t_{max} (5.0 vs. 6.0 hours), and a higher mean $AUC_{0-\infty}$ (approximately 2-fold higher; 17800 vs. 9440 ngxhr/mL). The compound of Formula (I) geometric mean ratios for C_{max} and $AUC_{0-tlast}$ for fed vs. fasted conditions were 218.6% and 215.2%, respectively, indicating that the compound of Formula (I) absorption was approx-

imately 2-fold greater when administered with food. The upper and lower 90% CI bounds for both C_{max} (187.4%, 255.1%) and $AUC_{0\text{-tlast}}$ (182.9%, 253.1%) were outside of the "no-effect" range of 80.00% to 125.00%, indicating that there was a food effect on the compound of Formula (I) exposure. Similar results were observed with the hydroxylated metabolite of the compound of Formula (I). Overall, these results indicate that the compound of Formula (I) 50 mg was well tolerated in healthy subjects when administered under fasted or fed conditions and that the total AUC and C_{max} were increased when the compound of Formula (I) was taken with food.

Example 7: Phase 1 study to evaluate the relative bioavailability, effect of food on pharmacokinetics, and safety of formulations of the compound of Formula (I) in healthy adult subjects

[0460] A Phase 1 study to compare the relative bioavailability of a 50 mg dose of different formulations of the compound of Formula (I) as well as to evaluate the effect of fasting and fed conditions on the pharmacokinetics (PK) of the compound of Formula (I) was designed. The 50 mg dose was chosen for this study because it is within the tested dose range in completed Phase 1 and Phase 2 trials and was well tolerated in those studies. The objectives of the study are: to evaluate the PK and compare the relative bioavailability of the compound of Formula (I) 50 mg formulations in healthy adult subjects; to evaluate the effect of food on the PK of the compound of Formula (I) 50 mg formulations; and to evaluate the safety and tolerability of the compound of Formula (I) 50 mg formulations.

Study Design

[0461] This is a Phase 1, open-label, randomized, three-period crossover study of the relative bioavailability and the effect of food on the PK of the compound of Formula (I) 50 mg in healthy adult subjects. During treatment period 1 and treatment period 2, subjects will receive a single dose of the compound of Formula (I) 50 mg administered as an encapsulated, lipidic semi-solid (reference) and 1 of 2 different spray-dried dispersion (SDD) test formulations (suspension or capsule) under fed conditions, and during treatment period, three subjects will receive the same SDD test formulation under fasted conditions.

[0462] A total of 36 healthy adult subjects will be randomized to 1 of 4 treatment sequences (9 subjects per sequence; approximately equal distribution of males and females per sequence; see Table 22, below). There will be 21 days between each dose.

Table 22. Treatment sequences

Treatment sequence	Treatment period 1 (Fed)	Treatment period 2 (Fed)	Treatment period 3 (Fasted)
1	Reference	SDD suspension	SDD suspension
2	SDD suspension	Reference	SDD suspension
3	Reference	SDD capsule	SDD capsule
4	SDD capsule	Reference	SDD capsule

[0463] After providing informed consent, subjects will be screened for eligibility to participate in the study. Screening will begin up to 28 days prior to Day 1 of treatment period 1. Eligible subjects will be admitted to the clinical unit on Day -1, and randomized to 1 of the 4 treatment sequences on Day 1 of treatment period 1. During treatment periods 1 and 2, subjects will fast overnight for at least 10 hours and then ingest a liquid dietary supplement (vanilla-flavored Ensure Plus®, 237 mL container) with the study drug and not consume any other food for 4 hours after dosing. During treatment period 3, subjects will fast overnight for at least 10 hours prior to dosing and continue to fast for an additional 4 hours after dosing. During all treatment periods, water will not be permitted for 1 hour before dosing until 2 hours after dosing except for the water/liquid dietary supplement provided for study drug dosing.

[0464] On Day 1 of each treatment period, subjects will be dosed with the compound of Formula (I) 50 mg and have blood samples collected for PK analysis. Subjects will complete a taste satisfaction questionnaire after study drug ingestion on Day 1 of treatment period 3 (only for subjects who receive the SDD suspension under the fasted condition). Subjects will remain in the unit on the day of dosing and will be discharged on Day 2 of each treatment period, following completion of all required procedures, including collection of the 36-hour PK sample. On the mornings of Days 8 and 15 of each treatment period, subjects will return to the clinical unit on an outpatient basis for PK blood sample collection and safety assessments. On Day 21 of treatment period 1 and treatment period 2, subjects will arrive at the site and have Day 21 assessments completed, and they will stay overnight at the site and begin Day 1 of treatment period 2 or treatment period 3 the following day. A final follow-up study visit will be conducted on Day 22 of treatment period 3 (21 ± 2 days after treatment period 3 dosing) or upon early termination.

[0465] Blood samples for PK analysis and safety assessments will be collected/conducted at scheduled times throughout the study. The study design schematic is shown in FIG. 10.

Duration of treatment

[0466] The expected duration of study participation for each healthy adult subject will be approximately 13 weeks, including up to 28 days of screening, 3 doses each separated by 21 days, and a final follow-up study visit 21 days after receiving the last dose of study drug during treatment period 3.

Test ***product,*** *dose,* ***and mode*** *of* ***administration***

[0467] The compound of Formula (I) will be supplied as two different test formulations for oral administration: as powder in bottles for constitution into a suspension (20 mL) and as powder-filled capsules. The compound of Formula (I) test formulations will contain 50 mg of the compound of Formula (I) as free base equivalent. Subjects must swallow the study drug with a liquid dietary supplement (Ensure Plus® [237 mL container]) with an additional 100 mL of water (SDD capsule formulation) or with an additional 80 mL of water (SDD suspension formulation) during treatment period 1 or 2. Subjects must swallow the study drug with 330 mL of water (SDD capsule formulation) or 310 mL of water (SDD suspension formulation) during treatment period 3.

Reference therapy, dose, and mode of administration

[0468] The compound of Formula (I) reference formulation (encapsulated, lipidic semi-solid formulation) will be supplied as capsules for oral administration. The compound of Formula (I) reference capsules will contain 50 mg of the compound of Formula (I) as free base equivalent. Subjects must swallow a single capsule with a liquid dietary supplement (Ensure Plus [237 mL container]) with an additional 100 mL of water during treatment period 1 or 2.

Criteria for Evaluation

Pharmacokinetics

[0469] Blood samples for assessment of plasma concentrations of the compound of Formula (I) and metabolites will be collected within 45 minutes before dosing, and at approximately 30 minutes, and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 36, 168, 336, and 504 hours after dosing.

[0470] The following plasma PK parameters will be calculated for the compound of Formula (I) and metabolites:

- Area under the plasma concentration versus time curve from 0 hours to the time of the last measurable concentration ($AUC_{0\text{-}tlast}$)
- Area under the plasma concentration curve extrapolated from 0 hours to infinity ($AUC_{0\text{-}\infty}$)
- Maximum plasma concentration (C_{max})
- Time to achieve maximum plasma concentration (t_{max})
- Delay time between time of dosing and time of appearance of measurable test article (T_{lag})
- Apparent terminal half-life ($t_{½}$)
- Apparent terminal rate constant (λz)
- Apparent mean residence time (MRT)
- Molar AUC ratio of primary metabolite(s) to the parent drug the compound of Formula (I)

[0471] The following plasma PK parameters will be calculated only for the compound of Formula (I):

- Apparent systemic clearance after oral administration (CL/F)
- Apparent volume of distribution during terminal phase after oral administration (Vz/F)

Other assessment

[0472] A taste satisfaction questionnaire will be administered.

Safety ***assessments***

[0473] Safety will be monitored throughout the study and will include the following assessments:

- AEs
- Clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis)
- Vital sign measurements (including orthostatic blood pressure and pulse rate)
- Physical examinations
- 12-lead electrocardiogram (ECG)

Statistical methods

[0474] Pharmacokinetic parameters will be calculated using noncompartmental methods and summarized by formulation using descriptive statistics. Two-sided 90% confidence intervals will be calculated for the ratio of each test formulation (SDD suspension and SDD capsule) vs. the reference formulation for $AUC_{0-\infty}$, $AUC_{0-tlast}$, and C_{max} for the compound of Formula (I) and metabolites under fed conditions. Further, two-sided 90% confidence intervals will be calculated for the ratio of each test formulation under fasted conditions vs. under fed conditions for $AUC_{0-\infty}$, $AUC_{0-tlast}$, and C_{max} for the compound of Formula (I) and metabolites.

[0475] Safety and taste satisfaction questionnaire data will be summarized with descriptive statistics.

Results

Pharmacokinetic results

[0476] Pharmacokinetic results are shown in Tables 23-26, below.

Table 23: Summary of Plasma Pharmacokinetic Parameters (Safety Analysis Set - SDD Suspension Group)

		Compound of Formula (I) Plasma Concentration		
Parameter (units) Statistic		**Reference Capsule (Fed) (N=18)**	**SDD Suspension (Fed) (N=18)**	**SDD Suspension (Fasted) (N=18)**
$AUC_{0-tlast}$ (ng×hr/mL)				
	Mean (SD)	16600 (7880)	5980 (3960)	737 (417)
	Geom CV(%)	46.8	72.8	68.7
$AUC_{0-\infty}$ (ng×hr/mL)				
	Mean	17400 (8010)	6500 (4180)	893 (480)
	Geom CV(%)	45.4	71.7	60.1
C_{max} (ng/mL)				
	Mean (SD)	1480 (506)	672 (323)	72.3 (44.9)
	Geom CV(%)	32.1	57.9	57.5
t_{max} (hr)				
	Median (min, max)	5.0 (3.0, 6.0)	5.0 (5.0, 10)	7.0 (5.0, 12)
T_{lag} (hr)				
	Mean (SD)	1.0 (0.31)	0.85 (0.29)	1.2 (0.65)
$t_{½}$ (hr)				
	Mean (SD)	50 (20)	19 (6.1)	9.0 (0.46)
	Geom CV(%)	140	93	23
MRT (hr)				
	Mean (SD)	36 (43)	23 (24)	17 (2.9)
	Geom CV(%)	84	62	18
CL/F (L/hr)				

(continued)

		Compound of Formula (I) Plasma Concentration	
Parameter (units) Statistic	**Reference Capsule (Fed) (N=18)**	**SDD Suspension (Fed) (N=18)**	**SDD Suspension (Fasted) (N=18)**
Mean (SD)	3.4 (1.4)	11 (8.0)	80 (54)
Geom CV(%)	45	72	63
Vz/F (L)			
Mean (SD)	180 (260)	210 (140)	970 (560)
Geom CV(%)	93	77	53
T_{last} (hr)			
Mean (SD)	170 (140)	77 (110)	31 (7.6)
Geom CV(%)	120	92	30

Table 24: Geometric Mean Ratios for Pharmacokinetic Exposure Parameters by formulation and fed vs fasted (Safety Analysis Set - SDD Suspension Group)

Analyte Parameter (units)	**Treatment Comparison**	**Ratio (%)**	**90% CI**
Compound of Formula (I)			
$AUC_{0\text{-}tlast}$ (ngxhr/mL)	SDD Suspension (Fed) vs. Reference Capsule (Fed)	32.2	(26.4%, 39.4%)
$AUC_{0\text{-}\infty}$	SDD Suspension (Fed) vs. Reference Capsule (Fed)	33.5	(27.7%, 40.6%)
C_{max} (ng/mL)	SDD Suspension (Fed) vs. Reference Capsule (Fed)	42.2	(34.8%, 51.2%)
$AUC_{0\text{-}tlast}$ (ngxhr/mL)	SDD Suspension (Fasted) vs. Reference Capsule (Fed)	4.4	(3.4%, 5.7%)
$AUC_{0\text{-}\infty}$	SDD Suspension (Fasted) vs. Reference Capsule (Fed)	5.0	(3.8%, 6.5%)
C_{max} (ng/mL)	SDD Suspension (Fasted) vs. Reference Capsule (Fed)	4.5	(3.8%, 5.4%)

Table 25: Summary of Plasma Pharmacokinetic Parameters (Safety Analysis Set - SDD Capsule Group)

		Compound of Formula (I) Plasma Concentration	
Parameter (units) Statistic	**Reference Capsule (Fed) (N=18)**	**SDD Capsule (Fed) (N=18)**	**SDD Capsule (Fasted) (N=17)**
$AUC_{0\text{-}tlast}$ (ng×hr/mL)			
Mean (SD)	19500 (7960)	9470 (4670)	1840 (1650)
Geom CV (%)	50.4	48.0	78.7
$AUC_{0\text{-}\infty}$ (ng×hr/mL)			
Mean	20100 (7850)	10000 (4610)	2120 (1830)
Geom CV (%)	47.1	44.9	73.7

(continued)

		Compound of Formula (I) Plasma Concentration	
Parameter (units) Statistic	**Reference Capsule (Fed) (N=18)**	**SDD Capsule (Fed) (N=18)**	**SDD Capsule (Fasted) (N=17)**
C_{max} (ng/mL)			
Mean (SD)	1770 (494)	1110 (449)	143 (110)
Geom CV (%)	25.7	44.5	74.1
t_{max} (hr)			
Median (min,max)	5.0 (5.0, 8.0)	5.0 (3.0, 6.0)	7.0 (6.0, 12)
T_{lag} (hr)			
Mean (SD)	1.0 (0.38)	1.3 (0.49)	1.2 (0.88)
$t_{½}$ (hr)			
Mean (SD)	35 (18)	26 (20)	14 (11)
Geom CV (%)	69	98	49
MRT (hr)			
Mean (SD)	28 (12)	25 (14)	21 (9.2)
Geom CV (%)	45	55	31
CL/F (L/hr)			
Mean (SD)	3.0 (1.5)	5.9 (2.4)	36 (18)
Geom CV (%)	47	45	74
Vz/F (L)			
Mean (SD)	130 (61)	190 (140)	630 (380)
Geom CV (%)	47	75	72
T_{last} (hr)			
Mean (SD)	170 (96)	100 (89) 44 (32)	
Geom CV (%)	91	100	39

Table 26: Geometric Mean Ratios for Pharmacokinetic Exposure Parameters by formulation and fed vs fasted (Safety Analysis Set - SDD Suspension Group)

Analyte Parameter (units)	**Treatment Comparison**	**Ratio (%)**	**90% CI**
Compound of Formula (I)			
$AUC_{0\text{-tlast}}$	SDD Capsule (Fed) vs. Reference Capsule (Fed)	48.2	(41.4%, 56.1%)
$AUC_{0\text{-}\infty}$ (ngxhr/mL)	SDD Capsule (Fed) vs. Reference Capsule (Fed)	49.7	(43.1%, 57.2%)

(continued)

Analyte Parameter (units)	Treatment Comparison	Ratio (%)	90% CI
Compound of Formula (I)			
C_{max} (ng/mL)	SDD Capsule (Fed) vs. Reference Capsule (Fed)	59.8	(51.7%, 69.2%)
$AUC_{0\text{-}tlast}$ (ngxhr/mL)	SDD Capsule (Fasted) vs. Reference Capsule (Fed)	8.0	(5.7%, 11.2%)
$AUC_{0\text{-}\infty}$ (ngxhr/mL)	SDD Capsule (Fasted) vs. Reference Capsule (Fed)	9.0	(6.6%, 12.4%)
C_{max} (ng/mL)	SDD Capsule (Fasted) vs. Reference Capsule (Fed)	6.7	(4.9%, 9.2%)

Example 8: Phase 2 study of the compound of Formula (I) in adult subjects with congenital adrenal hyperplasia

[0477] A Phase 2 study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the compound of Formula (I) in adult subjects with classic congenital adrenal hyperplasia (CAH) was designed. The objectives of the study are: to assess the safety and tolerability of two ascending doses of the compound of Formula (I) in adult subjects with CAH; to evaluate the effect of repeated doses of the compound of Formula (I) on endogenous levels of PD biomarkers in adult subjects with CAH; and to evaluate plasma exposures following repeated doses of the compound of Formula (I) administered nightly.

[0478] The lower dose strength selected for this study, the compound of Formula (I) 50 mg, was well tolerated in both single and repeat-dose safety and PK studies in healthy volunteers. Doses up to 100 mg were also well tolerated in both single-dose and repeat-dose Phase 1 studies in healthy volunteers, and importantly, in a large Phase 2 study in non-elderly female and male subjects with major depressive disorder receiving the compound of Formula (I) during an 8-week, double-blind treatment period. Furthermore, the anticipated steady state exposures with the selected the compound of Formula (I) doses, using the predicted C_{max} and AUC, are within the acceptable safety margins defined by the nonclinical toxicology studies that have been conducted to date.

Study Design

[0479] A Phase 2, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, PK, and PD of the compound of Formula (I) in approximately 30 adult female and male subjects (18 to 50 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency CAH was designed. The study will include a sequential-cohort design with four compound of Formula (I) dose cohorts: 50 mg and 100 mg, with each dose administered for 14 consecutive days:

- Cohort 1: compound of Formula (I) 50 mg once daily with a bottle of vanilla-flavored Ensure Plus® (~237 mL) at approximately 2200 hours.
- Cohort 2: compound of Formula (I) 100 mg once daily with a bottle of vanilla-flavored Ensure Plus® (~237 mL) at approximately 2200 hours.
- Cohort 3: compound of Formula (I) 100 mg once daily with the evening meal at approximately 1900 hours.
- Cohort 4: compound of Formula (I) 100 mg twice daily with breakfast at approximately 0700 hours and with the evening meal at approximately 1900 hours.

[0480] There will be an approximate 2-week period to evaluate safety and tolerability data before proceeding from Cohort 1 to Cohort 2. Subjects who previously completed the current study in Cohort 1 or Cohort 2 may reenroll to participate in Cohorts 3 or 4 (in addition to new subjects). Table 27 below depicts the dose cohorts, doses, and number of subjects per cohort.

Table 27. Dose cohorts, doses, and number of subjects

Cohort	Compound of Formula (I) Dose	Approximate Dosing Time(s)	Number of Subjects
1	50 mg	2200 hours	8-10
2	100 mg	2200 hours	8-10

(continued)

Cohort	Compound of Formula (I) Dose	Approximate Dosing Time(s)	Number of Subjects
3	100 mg	1900 hours	8-10
4	100 mg	0700 and 1900 hours	Up to 8

[0481] Subjects will be screened for eligibility to participate in the study for up to approximately 3 weeks (Days -28 to -8). Subjects who reenroll and have had a stable medication regimen for CAH since their last visit in this study do not have to undergo screening; those who reenroll and have had a change to their medication regimen for CAH must undergo a second screening visit. During screening, subjects will provide a single blood sample in the morning between 0700 and 1000 hours (prior to first morning dose of hydrocortisone) to determine their 17-hydroxyprogesterone (17-OHP) levels for study entry.

[0482] Eligible subjects who have a screening 17-OHP level ≥1,000 ng/dL will be admitted to the study center for 1 night and have baseline serial PD samples collected over a 24-hour period beginning in the evening of Day -7. Baseline serial PD samples will be collected at approximately 2145, 2300, 2400, 0100, 0200, 0400, 0600, 0800, 1000, 1200, 1400, 1600, and 2200 hours. The subjects' usual morning dose of steroidal treatments will be administered after the 1000 hours PD sample is collected on Day -6. Subjects will be discharged on Day -6 after the last PD sample is collected.

[0483] Subjects within each dose cohort will be admitted to the study center on Days 1 and 14 (first and last day of dosing). Subjects will have a blood sample collected on Day 1 for CYP21A2 genotyping. Baseline safety assessments will be collected on Day 1 prior to the first dose of study drug. Study drug (the compound of Formula (I) 50 or 100 mg) will be administered at approximately 2200 hours for Cohorts 1 and 2 and at approximately 1845, 2000, 2100, 2200, 2300, 2400, 0100, 0200, 0400, 0600, 0800, 1000, 1200, 1400, 1800, 1900, and 2200 hours for Cohorts 3 and 4. The subjects' usual morning dose of steroidal treatments will be administered after the 1000 hours PD sample is collected on Day -6. Subjects will be discharged on Day -6 after the last PD sample is collected.

[0484] Subjects in Cohorts 1 and 2 will be admitted to the study center on Days 1 and 14 (first and last day of dosing). Subjects will have a blood sample collected on Day 1 for cytochrome P450 (CYP) 21A2 genotyping. Baseline safety assessments will be collected on Day 1 prior to the first dose of study drug. Study drug (compound of Formula(I) 50 mg or 100 mg) will be administered at approximately 2200 hours. The subjects' usual morning dose of concurrent steroidal treatments will be administered after the 12-hour post-dose PK/PD samples are collected (at approximately 1000 hours) on Day 2 and after the 16-hour post-dose PK/PD samples are collected (at approximately 1400 hours) on Day 15. Subjects will be discharged from the study center the evening on Days 2 and 15 following completion of all study-related procedures for those days. Prior to this discharge on Day 2, study drug will be administered at the study center at approximately 2200 hours. Study drug will then be selfadministered nightly at home at approximately 2200 hours on Days 3 to 13. Subjects will take their usual morning dose of concurrent steroidal treatments at approximately 1000 hours on Days 3 to 14. On Day 7 during the treatment period, PK, PD, and safety assessments will be conducted in an outpatient setting at the study center.

[0485] Subjects in Cohorts 3 and 4 will have a blood sample collected on Day 1 for CYP21A2 genotyping (only for subjects who have not previously participated in Cohorts 1 or 2). Baseline safety assessments will be collected on Day 1 prior to the first dose of study drug. For Cohort 3, study drug (compound of Formula(I) 100 mg) will be administered at home on Days 1 to 13 at approximately 1900 hours with each subject's evening meal. For Cohort 4, study drug compound of Formula(I) 100 mg) will be administered at home on Days 2 to 14 at approximately 0700 hours with each subject's breakfast and on Days 1 to 13 at approximately 1900 hours with each subjects' evening meal. For both cohorts, the Day 14 evening dose will be administered at the study site. Subjects will take their usual morning dose of concurrent steroidal treatments at approximately 1000 hours on Days 1 to 14. On Day 7 during the treatment period, PK, PD, and safety assessments will be conducted in an outpatient setting at the study center. Subjects will be admitted to the study center on Day 14 (last day of dosing). On Day 14, subjects will receive study drug in the study center at approximately 1900 hours with a standard (moderate fat/moderate calorie) evening meal. The subjects' usual morning dose of concurrent steroidal treatments will be administered after PK/PD samples are collected at approximately 1400 hours on Day 15. Subjects will be discharged from the study center the evening on Day 15 following completion of all study-related procedures.

[0486] For all cohorts, follow-up visits on Days 21, 28, and 35 will be conducted at the study center or the subject's home by a qualified home healthcare provider (based on the subject's preference). A final study visit will be conducted at the study site approximately 5 weeks after the last dose of study drug (on Day 49 or early termination). There will be a visit window of - 8 hours for Day 7, -8 hours/+3 days for Days 21, 28, and 35, and +7 days for the final study visit. Safety, tolerability, PK, and PD will be assessed at scheduled times throughout the study. The study design schematic is shown in FIG. 11.

*Dose **escalation procedure***

[0487] Cohort 1 will consist of approximately 8 to 10 subjects who will receive a daily dose of the compound of Formula (I) 50 mg at approximately 2200 hours for 14 days (subjects will receive study drug at the site on Days 1, 2, and 14, and self-administer study drug at home on Days 3 to 13). Following the completion of Day 15 assessments for all subjects in the Cohort 1, a medical monitor will review the accumulated safety and tolerability results to ensure there are no safety concerns with proceeding to the 100 mg dose (Cohorts 2 and 3), and to determine if a maximum tolerated dose (MTD) has been reached. If the MTD is reached, no dose escalation will occur. There will be an approximate 2-week period between Cohorts 1 and 2 to accommodate this safety review. A similar procedure will be used prior to proceeding to the 100 mg twice daily dose (Cohort 4).

[0488] If the medical monitor determines that it is safe to proceed to the compound of Formula (I) 100 mg, subjects in Cohort 2 will be administered the compound of Formula (I) 100 mg daily for 14 days. Dosing for Cohorts 3 and 4 may begin simultaneously with Cohort 2.

[0489] During the 14-day dosing period for any cohort, dosing may be postponed or halted if one or more subjects experience a severe or serious adverse event (AE), or if the type, frequency, or severity of AEs becomes unacceptable. If dosing is postponed, the medical monitor will review all available safety, tolerability, and PK data before allowing any further subjects to receive study drug.

Study Population

[0490] Approximately 30 adult female and male subjects (18 to 50 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency CAH, who meet all protocol eligibility criteria, will be enrolled. Subjects who previously completed the current study in Cohort 1 or Cohort 2 may reenroll to participate in Cohorts 3 or 4 (in addition to new subjects).

Duration** of **treatment

[0491] The expected duration of study participation for each subject is approximately 11 weeks, including up to approximately 3 weeks for screening, a 24-hour PD baseline period (approximately 7 days prior to the first day of dosing), 14 days of dosing, and a follow-up period of approximately 5 weeks. The total duration of the study will be an additional 8 to 11 weeks for subjects who reenroll.

Test product, dose, and mode** of **administration

[0492] The compound of Formula (I) will be supplied as capsules containing 50 mg of the compound of Formula (I) free base for oral administration (see, e.g., Reference 1 formulation as described in Example 9). Doses of the compound of Formula (I) are 50 mg and 100 mg, administered in oral capsule form. Each dose of study drug for Cohorts 1 and 2 is to be administered with a bottle of vanilla-flavored Ensure Plus® (~237 mL). Each dose of study drug for Cohort 3 is to be administered with each subject's evening meal at approximately 1900 hours. Each dose of study drug for Cohort 4 is to be administered with each subject's breakfast at approximately 1900 hours (i.e., a total daily dose of 200 mg).

Criteria for Evaluation

Cohorts 1 and 2

[0493] Blood samples to evaluate 24-hour PD baseline will be collected on Days -7 to -6 at approximately 2145, 2300, 2400, 0100, 0200, 0400, 0600, 0800, 1000, 1200, 1400, 1600, and 2200 hours. Blood samples to evaluate PK and PD parameters of the compound of Formula (I) will be collected on Days 1 to 2 and Days 14 to 15 at: 15 minutes pre-dose and at 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours post-dose; Day 7 (at approximately 24 hours post-dose); Days 21, 28, and 35 (at approximately 168, 336, and 504 hours post-dose); and at the final study visit (Day 49 or early termination).

Cohorts 3 and 4

[0494] Blood samples to evaluate 24-hour PD baseline will be collected on Days -7 to -6 at approximately 1845, 2000, 2100, 2200, 2300, 2400, 0100, 0200, 0400, 0600, 0800, 1000, 1200, 1400, 1800, 1900, and 2200 hours. Blood samples to evaluate PK and PD parameters of the compound of Formula (I) will be collected on Days 14 to 15 at the following times (for Cohort 4, all times are relative to evening dosing unless otherwise indicated): 15 minutes predose and at 1, 2, 3, 4, 5, 6, 7, 9, 11, 13, 15, 17, 19, 23, 24, and 27 hours postdose; Day 7 (at 24 hours postdose for Cohort 3 or at 12

hours post morning dose but prior to the evening dose for Cohort 4); Days 21, 28, and 35 (at approximately 168, 336, and 504 hours postdose); and at the final study visit (Day 49 or early termination).

Pharmacokinetics

[0495] The following plasma PK parameters will be calculated for the compound of Formula (I) and metabolites:

- Area under the plasma concentration versus time curve from 0 hours to last measurable concentration ($AUC_{0\text{-tlast}}$)
- Area under the plasma concentration versus time curve from 0 to 24 hours ($AUC_{0\text{-}24}$)
- Maximum plasma concentration (C_{max})
- Time to maximum plasma concentration (t_{max})
- Delay time between time of dosing and time of appearance of measurable test article (T_{lag})
- Terminal half-life ($t_{½}$)
- Apparent terminal rate constant (λz)
- Apparent mean residence time (MRT)

[0496] Additional PK parameters for Day 14 only:

- Average plasma concentration at steady state (C_{avg})
- Percent fluctuation at steady state (% fluctuation)
- Accumulation index at steady state
- Apparent systemic clearance after oral administration (CL/F) (the compound of Formula (I) only)

Pharmacodynamics

[0497] Primary: Morning 17-OHP (serum; ng/dL) from the 0600, 0800, and 1000 hour samples (8-, 10-, and 12-hour post-dose samples from Cohorts 1 and 2 and 11-, 13-, and 15-hour postdose samples from Cohorts 3 and 4.

[0498] Secondary: 17-OHP at all other times, androstenedione (serum; ng/dL), testosterone (serum; ng/dL), cortisol (serum; μg/dL), and adrenocorticotropic hormone (plasma ACTH; pg/mL).

Safety

[0499] Safety and tolerability will be monitored throughout the study and will include the following assessments:

- Adverse events
- Clinical laboratory tests - clinical chemistry (including creatine kinase, myoglobin, total and conjugated bilirubin), hematology, coagulation (prothrombin time, aPTT, d-dimer, fibrinogen), and urinalysis (including quantitative myoglobin, casts and crystals)
- Vital signs
- Physical examinations (including musculoskeletal exam)
- 12-lead electrocardiograms (ECGs)
- Columbia-Suicide Severity Rating Scale (C-SSRS)
- Brief Psychiatric Rating Scale (BPRS)

Statistical methods

[0500] Safety, PK, and PD variables will be summarized within each dose cohort (the compound of Formula (I) 50 mg and 100 mg) using descriptive statistics. Summaries of PD measures will include both observed values and changes from pre-dose.

Results

Pharmacokinetic results

[0501] Eight subjects (four female and four male) were enrolled in this study and completed Cohort 1. Age, sex, and BMI information for the study participants is shown in Table 28, below.

Table 28. Cohort 1 Subjects

Subject ID	Age (years)	Sex (Male/Female)	BMI (kg/m^2)
001	37	Female	24.9
002	25	Female	32.0
003	49	Male	37.2
004	36	Male	25.0
005	27	Female	25.5
006	19	Male	21.7
007	25	Male	27.5
008	31	Female	34.4

[0502] The subjects received a daily dose of the compound of Formula (I) at 50 mg at approximately 2200 hours (~10 p.m. or bedtime) for 14 days. Arithmetic mean values for ACTH (FIG. 12A) and 17-OHP (FIG. 12B) for all 8 Cohort 1 subjects were plotted at each timepoint for Pre-treatment Baseline, Day 1, and Day 14. Both ACTH and 17OHP concentration profiles at day 1 and day 14 show clear reductions from the baseline mean profiles. Cohort 1 mean PK parameters of T_{max}, C_{max}, and AUC24 for the compound of Formula (I) are shown in Table 29 below. These PK parameters are consistent with observations from Phase 1 studies in healthy volunteers.

Table 29. Cohort 1 Mean PK parameters of T_{max}, C_{max}, and AUC_{24}

	Day 1			Day 14		
	T_{max}	C_{max}	AUC_{24}	T_{max}	C_{max}	AUC_{24}
Mean	**5.4**	**1305**	**10,292**	**4.4**	**1349**	**14,297**
CV%	30	25	24	32	15	24

[0503] Additional measurements of cohort 1 and cohort 2 mean PK parameters of T_{max}, C_{max}, and AUC_{24} for the compound of Formula (I) on Day 1 of dosing are shown in Table 30 below.

Table 30: Mean PK parameters of T_{max}, C_{max}, and AUC_{24} on Day 1 of dosing

	Cohort 1 50 mg- Ensure			Cohort 2 100 mg-Ensure		
Day 1	**T_{max}* (h)**	**C_{max} (ng/ml)**	**AUC_{24} (h*ng/ml)**	**T_{max} (h)**	**C_{max} (ng/ml)**	**AUC_{24} (h*ng/ml)**
G.Mean	6	1,270	10,411	4	2,370	24,725
CV%	-	25	24	-	21	42
N	8	8	8	8	4	4
*Median						

[0504] Additional measurements of cohort 1, cohort 2 and cohort 3 mean PK parameters of T_{max}, C_{max}, and AUC24 for the compound of Formula (I) on Day 14 of dosing are shown in Table 31 below.

Table 31: Mean PK parameters of T_{max}, C_{max}, and AUC24 on Day 14 of dosing

	Cohort 1 50 mg- Ensure			Cohort 2 100 mg-Ensure			Cohort 3 100 mg w/evening Meal		
Day 14	Tmax* (h)	Cmax (ng/ml)	AUC24 (h*ng/ml)	Tmax (h)	Cmax (ng/ml)	AUC24 (h*ng/ml)	Tmax (h)	Cmax (ng/ml)	AUC24 (h*ng/ml)
G. Mean	4	1,335	14,070	4	3,379	35,416	3	3,650	34,706

(continued)

	Cohort 1 50 mg- Ensure			Cohort 2 100 mg-Ensure			Cohort 3 100 mg w/evening Meal		
Day 14	Tmax* (h)	Cmax (ng/ml)	AUC24 (h*ng/ml)	Tmax (h)	Cmax (ng/ml)	AUC24 (h*ng/ml)	Tmax (h)	Cmax (ng/ml)	AUC24 (h*ng/ml)
CV%		15	24		31	7		2	15
N	8	8	8	6	6	6	8	8	8
*Median									

[0505] Arithmetic mean values for androstenedione (FIG. 13A) and testosterone (FIG. 13B) for all 8 Cohort 1 subjects were plotted at each timepoint for Pre-treatment Baseline, day 1, and day 14. The androstenedione concentration profile on Day 1 and Day 14 shows a clear reduction from the baseline mean profile.

[0506] When focusing exclusively on the critical morning window period (timepoints at 8-, 10-, and 12-hours postdose) from 6:00 a.m. to 10:00 a.m., the levels of ACTH show marked reductions from baseline at each of the 3 timepoints on Days 1 and 14 (FIG. 14A). Arithmetic mean values across all three timepoints show >=50% reductions from baseline at Day 1 and Day 14 (FIG. 14B).

[0507] When focusing exclusively on the critical morning window period (timepoints at 8-, 10-, and 12-hours postdose) from 6:00 a.m. to 10:00 a.m., the levels of 17-OHP show marked reductions from baseline at each of the 3 timepoints on Days 1 and 14 (FIG. 15A). Arithmetic mean values across all three timepoints show >=40% reductions from baseline at Day 1 and Day 14 (FIG 15B).

[0508] When focusing exclusively on the critical morning window period (timepoints at 8-, 10-, and 12-hours postdose) from 6:00 a.m. to 10:00 a.m., the levels of androstenedione show marked reductions from baseline at each of the 3 timepoints on Days 1 and 14 (FIG. 16A). Arithmetic mean values across all three timepoints show >=30% reductions from baseline at Day 1 and Day 14 (FIG. 16B).

[0509] A summary of reduction in 17-OHP and androstenedione in cohort 1 is shown in Table 32. Further, the androstenedione levels of three subjects was normalized by the treatment for the three subjects with Subject ID Nos. 001, 002, and 006).

Table 32. Cohort 1 Summary of Reduction in 17-OHP and Androstenedione at each timepoint in the morning window (6 a.m. to 10 a.m.)

Subject ID	Sex/Age	Dosing Day	17-OHP % change from baseline			Androstenedione % change from baseline		
			6 AM	8 AM	10 AM	6 AM	8 AM	10 AM
001	F/37	D1 D14	-61.4 -90.3	14.7 -67.2	-24.1 -37.2	-42.0 -84.6	2.0 -58.6	-19.5 -55.1
002	F/25	D1 D14	-96.0 -37.7	-95.5 -58.6	45.4 -24.9	-68.0 -34.2	-66.7 -47.8	-21.7 -38.7
003	M/49	D1 D14	-11.8 -24.5	-46.6 -5.2	-34.0 -22.9	-13.4 -7.5	-47.1 -10.8	-22.7 -16.0
004	M/36	D1 D14	-13.7 -53.6	17.1 -46.8	10.1 -35.8	4.5 -13.8	15.9 -15.2	3.0 -21.2
005	F/27	D1 D14	-24.4 -78.8	-83.6 -95.1	-52.2 -86.3	-35.6 26.7	-50.3 -13.7	-33.5 -10.9
006	M/19	D1D14 D14	-5.1 -25.4	-1.1 -20.4	-97.8 -98.3	-10.0 -67.8	-18.5 -62.7	-78.9 -92.1
007	M/25	D1 D14	-50.0 14.9	-28.0 4.0	-27.4 -7.1	-24.8 -4.8	-30.0 -36.8	-15.8 -30.2
008	F/31	D1 D14	-64.5 -59.0	-80.7 -65.2	-92.8 -89.1	-12.2 74.5	7.0 99.4	-9.3 59.2

Table 33. Cohort 1 Summary of PK parameters of T_{max}, C_{max}, and AUC_{24} for each subject at days 1 and 14

Day 1	Day 1			Day 14		
Subject ID	T_{max} (h)	AUC_{24} C_{max} (ng/ml) (h*ng/ml)		T_{max} (h)	C_{max} (ng/ml)	AUC_{24} (h*ng/ml)
001	6	1830	14,487	6	1570	20,863
002	6	1210	11,829	4	1610	15,494
003	6	1060	11,068	3	1310	15,599
004	4	1670	9,669	3	1160	10,180
005	8	961	9,266	6	1550	15,130
006	4	1030	6,574	3	1090	10,288
007	6	1550	8,239	6	1170	12,880
008	3	1130	11,209	4	1330	13,944
Mean	**5.4**	**1305**	**10,292**	**4.4**	**1349**	**14,297**
CV%	30	25	24	32	15	24
N	8	8	8	8	8	8

[0510] After 14 days of once-daily compound of Formula (I) administration, a majority of participants in Cohorts 1-3 showed reduced serum concentrations of adrenal androgens and precursors. Mean changes from baseline (±standard deviation) in Cohort 1 were as follows: 17-OHP, -2341.0±1535.0 ng/dL; androstenedione, -98.4±98.7 ng/dL; and ACTH, -157.0±194.9 pg/mL. Mean reductions were larger in Cohort 2 (17-OHP, -4406.0±5516.1; androstenedione, -362.8±354.0; ACTH, -180.9±155.2) and Cohort 3 (17-OHP, -4760.1±4018.2; androstenedione, -210.9±188.6; ACTH, -358.9±177.6), suggesting a possible dose response. FIGs. 17A-17C, 18A-18C, and 19A-19C depict results from Cohorts 1, 2, and 3, respectively.

Summary

[0511] The results from this ongoing Phase II open-label study demonstrated a reduction of at least 50 percent from baseline in 17-hydroxyprogesterone (17-OHP) and adrenocorticotropic hormone (ACTH) levels in more than 50 percent of CAH patients in cohort 1 treated with the compound of Formula (I) for 14 days (i.e., 6 of 8 patients in cohort 1 had a reduction of ≥50% from baseline levels of 17-OHP during at least one morning window timepoint, see, e.g., Table 32). Meaningful reductions were also observed in other biomarkers, including androstenedione (i.e., 4 of these patients also had a reduction of ≥50% from baseline levels of androstenedione during at least one morning window timepoint, see, e.g., Table 32). The greater reductions in biomarkers in cohorts 2 and 3, treated with double the dose of the compound of Formula (I) compared with cohort 1, suggest a possible dose response. Further, the compound of Formula (I) was well-tolerated with a relatively small number of mild adverse events (AEs) reported (e.g., headache, ovulation pain, fatigue, localized infection (toe), dizziness, nausea, URI, contusion with the most common being headache). No clinically significant findings from routine labs, vital signs, or electrocardiograms were found.

Example 9: Reference Formulation 1 of the compound of Formula (I)

[0512] Tables 34A and 34B show Reference formulation 1 of the compound of Formula (I) as used in the clinical studies described in Examples 6 and 8, above. An example manufacturing process is shown in FIG. 20. Another example manufacturing process is shown in FIG. 21.

Table 34A:

Component	Quality Standard	Function	50 mg Capsule	
			Weight mg/unit)	% (w/w)
Compound of Formula (I), free base	In-house	Active Ingredient	50.0	10.0
Medium-Chain Triglycerides Labrafac TM Lipophile WL1349)	NF	Oily Phase Vehicle	196.0	39.2
Propylene Glycol Dicaprylate/Dicaprate, (LabrafacTM PG)	NF	Emulsifying Agent	102.0	20.4
Lauroyl Polyoxyl-32 Glycerides (Gelucire® 44/14)	NF	Nonionic Surfactant & Solubilizing Agent	95.0	19.0
Vitamin E Polyethylene Glycol Succinate (Kolliphor® TPGS)	USP/NF	Solubilizing Agent	57.0	11.4
Total Emulsion Weight			**500.0**	**100.0**
Gelatin Capsule Shell. Size #00, Swedish Orange cap/body; (Coni-Snap®)	Non -Pharmacopoeial	Capsule Shell	--	
Gelatin Powder, 220 Bloom	USP	Capsule shell banding agent	--	--
Purified Water	USP	Capsule shell banding solvent	--	--

Table 34B:

Component	Quality Standard	Function	50 mg Capsule	
			Weight (mg/un it)	% (w/w)
Compound of Formula (I), free base	In-house	Active Ingredient	50.0	10.0
Medium-Chain Triglycerides (caprylic:capric acid 60: 40; Miglyol 812N)	Ph. Eur./NF	Vehicle	195.85	39.2
Propylene Glycol Dicaprylocaprate, (LabrafacTM PG)	Ph. Eur.	Vehicle	102.15	20.4
Lauroyl macrogolglycerides type 1500-Lauroyl polyoxylglycerides type 1500 (Gelucire® 44/14)	Ph. Eur./NF	Surfactant	95.0	19.0
Vitamin E Polyethylene Glycol Succinate, 260 mg/g d-alpha tocopherol (Vitamin E/TPGS 260)	NF	Surfactant	57.0	11.4
Total Emulsion Weight			**500.0**	**100.0**
Orange opaque hard capsule, size 0, composed of gelatin, titanium dioxide and red ferric oxide (Swedish Orange ®)	Non Pharmacopoeial	Capsule Shell	--	--
Ethanol (96%) and Purified Water	USP	Capsule shell banding solvent	--	--

Example 10: Study Evaluating Effect of Ensure Plus, Ensure Pudding, Milk and High Fat Meal on Reference Capsule

Study design

[0513] This is a Phase 1, open-label, randomized, four-period crossover study to evaluate the effect of food with different levels of fat and caloric content on the PK, safety, and tolerability of the compound of Formula (I) in healthy adult subjects.

[0514] A total of 16 healthy adult subjects (8 males and 8 females) will be randomly assigned to 1 of 4 treatment sequences (4 subjects per sequence [2 males and 2 females per sequence]; see Table 35 below). During each treatment period, subjects will receive a single dose of the compound of Formula (I) 100 mg administered with the appropriate meal, according to the randomization scheme. There will be a washout of at least 21 days between each dose.

Table 35:

Treatment Sequence	Treatment Period 1	Treatment Period 2	Treatment Period 3	Treatment Period 4
1	Reference meal	Test meal 1	Test meal 2	Test meal 3
2	Test meal 1	Test meal 3	Reference meal	Test meal 2
3	Test meal 2	Reference meal	Test meal 3	Test meal 1
4	Test meal 3	Test meal 2	Test meal 1	Reference meal
Reference meal: vanilla-flavored Ensure Plus® Test meal 1: Low fat, low caloric content meal 1 Test meal 2: Low fat, low caloric content meal 2 Test meal 3: standard high fat, high caloric content meal				

[0515] After providing informed consent, subjects will be screened for eligibility to participate in the study. Screening will begin up to 28 days before Day 1 of treatment period 1. Eligible subjects will be admitted to the clinical unit on Day -1 and randomized to 1 of the 4 treatment sequences on Day 1 of treatment period 1. During each treatment period, subjects will fast overnight for at least 10 hours until the start of the assigned meal, according to the randomization scheme, and ingest the study drug at approximately 0800 hours. Subjects must complete the entire meal within the specified time period and should not consume any other food for 4 hours after dosing. For all treatment periods, water will not be permitted for 1 hour before dosing until 2 hours after dosing except for the water provided with study drug dosing and planned meals.

[0516] On Day 1 of each treatment period, subjects will be dosed with the compound of Formula (I) 100 mg. Blood samples will be collected for PK analysis over a period of 36 hours during the in-house stay. During each treatment period, subjects will remain in the clinic on the day of dosing and will be discharged on Day 2 after completing all required procedures. On the mornings of Days 8 and 15 of each treatment period, subjects will return for an outpatient visit to the clinic for PK blood sample collection and safety assessments. On Day 21 of treatment periods 1 to 3, subjects will arrive at the site and have Day 21 assessments completed and they will stay overnight at the site and begin Day 1 of the subsequent treatment period the following day. A final follow-up study visit will be conducted on Day 22 of treatment period 4 (21 ± 2 days after treatment period 4 dosing) or upon early termination.

[0517] Blood samples for PK d/conducted at scheduled times throughout the study.

Study population

[0518] Sixteen healthy adult subjects (8 males and 8 females) between 18 and 55 years of age, inclusive, who meet all protocol eligibility criteria, will be enrolled.

Duration of treatment

[0519] The expected duration of study participation for each healthy adult subject will be approximately 16 weeks, including up to 28 days of screening, 4 days of dosing with at least 21 days between consecutive doses, and a final follow-up study visit 21 days (± 2 days) after receiving the last dose of study drug during treatment period 4.

Test product, dose, and mode of administration

[0520] The compound of Formula (I) will be supplied as capsules for oral administration (encapsulated, lipidic semi-solid formulation, e.g., Example 9). The compound of Formula (I) capsules will contain 50 mg of the compound of Formula (I) as free base equivalent. During each treatment period, subjects will receive two 50 mg capsules (100 mg) of the study drug along with a meal and water as defined by the randomization scheme. The food, water, and study drug administration are as follows:

Reference meal: Two capsules of study drug will be administered approximately 5 minutes after the start of a liquid dietary supplement (i.e., Ensure Plus® [237 mL container]) and an additional 120 mL of water for study drug dosing.
Test meal 1: Two capsules of study drug will be administered approximately 5 minutes after the start of a low fat, low caloric meal 1 with 120 mL of water for study drug dosing.
Test meal 2: Two capsules of study drug will be administered approximately 5 minutes after the start of a low fat, low caloric meal 2 with 120 mL of water for study drug dosing.
Test meal 3: Two capsules of study drug will be administered approximately 30 minutes after the start of a high fat, high caloric meal with 120 mL of water for study drug dosing.

CRITERIA FOR EVALUATION

Pharmacokinetics

[0521] Blood samples for assessment of plasma concentrations of the compound of Formula (I) and metabolites will be collected within 45 minutes before dosing, and at approximately 30 minutes, and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 36, 168, 336, and 504 hours after dosing.

[0522] The following plasma PK parameters will be calculated for the compound of Formula (I) and metabolites:

- Area under the plasma concentration versus time curve from 0 hours to last measurable concentration ($AUC_{0\text{-}tlast}$)
- Area under the plasma concentration versus time curve from 0 hours extrapolated to infinity ($AUC_{0\text{-}\infty}$)
- Maximum plasma concentration (C_{max})
- Time to achieve maximum plasma concentration (t_{max})
- Delay time between time of dosing and time of appearance of measurable test article (T_{lag})
- Apparent terminal half-life ($t_{½}$)
- Apparent terminal rate constant (λz)
- Apparent mean residence time (MRT)
- Molar AUC ratio of primary metabolite(s) to the parent drug compound of Formula (I). The following plasma PK parameters will be calculated only for the compound of Formula (I):
- Apparent systemic clearance after oral administration (CL/F)
- Apparent volume of distribution during terminal phase after oral administration (Vz/F)

Safety Assessments

[0523] Safety will be monitored throughout the study and will include the following assessments:

- Adverse events (AEs)
- Clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis)
- Vital sign measurements (including orthostatic blood pressure and pulse rate)
- Physical examinations
- 12-lead electrocardiograms (ECGs)

Statistical methods

[0524] Pharmacokinetic parameters will be calculated using noncompartmental methods and summarized by meal type (test meal/reference meal) using descriptive statistics. Two-sided 90% confidence intervals will be calculated for the ratio of each test meal versus the reference meal for $AUC_{0\text{-}\infty}$, $AUC_{0\text{-}tlast}$, and C_{max} for the compound of Formula (I)

and metabolites.

[0525] Safety data will be summarized with descriptive statistics.

Results

Pharmacokinetic results

[0526] Pharmacokinetic results are shown in Table 36 below.

Table 36: Summary of Plasma Pharmacokinetic Parameters

		Compound of Formula (I) Plasma Concentration			
Parameter (units) Statistic	**Ensure Plus (Fed) (N=18)**	**Ensure Pudding (Fed) (N=18)**	**Whole Milk (Fed) (N=17)**	**High Fat Meal (Fed) (N=17)**	
$AUC_{0\text{-}tlast}$ (ng×hr/mL)					
Mean (SD)	36703 (17400)	34077 (11597)	35561 (15866)	55487 (23242)	
Geom CV(%)	58	39.7	44.6	41.9	
$AUC_{0\text{-}\infty}$ (ng×hr/mL)					
	Mean	45386 (19648)	40037 (9515)	46737 (17395)	63755 (19139)
	Geom CV(%)	43.3	23.8	38.8	31
C_{max} (ng/mL)					
	Mean (SD)	3090 (1070)	3038 (984)	2835 (1005)	4336 (1938)
	Geom CV(%)	39.7	34.9	34.5	53.6
t_{max} (hr)					
	Median (min, max)	5.0 (2.0, 10.0)	5.0 (4.0, 6.0)	5.0 (4.0, 7.0)	5.0 (4.0, 7.0)
T_{lag} (hr)					
	Mean (SD)	0.38 (0.46)	0.20 (0.25)	0.16 (0.31)	0.29 (0.37)
$t_{½}$ (hr)					
	Mean (SD)	361 (263)	373 (196)	373 (143)	326 (120)
	Geom CV(%)	61.1	48.6	37.1	33.8
CL/F (L/hr)					
	Mean (SD)	2.49 (0.956)	2.636 (0.659)	2.427 (0.975)	1.706 (0.526)
	Geom CV(%)	41.2	24.8	38.8	31.1
Vz/F (L)					
	Mean (SD)	1254 (906)	1414 (720)	1308 (627)	816 (378)
	Geom CV(%)	72.7	58.4	61.3	54.9

Example 11: Spray-dried Dispersion Granule Formulation of the Compound of Formula (I) (SDD-G)

[0527] Table 37 shows a granule formulation of the compound of Formula (I) using a SDD prepared according to Example 3, above. An example manufacturing process is shown in FIG. 22A and FIG. 22B.

Table 37:

Component	Quality Standard	Function	50 mg Sachet		Batch Weight (g)
			Weight (mg/ unit)	% (w/w)	
Example 3, SDD	In-house	Drug Substance	200.0	13.33	40
Calcium Silicate (ZEOPHARM 250)	NF	Glidant	10.0	0.67	2
Mannitol (Pearlitol 200SD)	NF / EP / JP	Filler	832.5	55.5	166.5
Microcrystalline Cellulose (Avicel PH-102)	NF / EP / JP	Filler	300.0	20.0	60
Croscarmellose Sodium (Ac-Di-Sol®) SD711	NF / EP / JP	Disintegrant	150.0	10.0	30
Sodium Stearyl Fumarate	NF / EP / JP	Lubricant	7.5	0.5	1.5
Total			1500	100.0	300

Example 12: Liquid Formulation 1 of the Compound of Formula (I)

[0528] Table 38 shows liquid formulation 1 of the Compound of Formula (I) free base. An example manufacturing process is shown in FIG. 23.

Table 38:

Component	Quality Standard	Function	50 mg/mL Oral Solution		Batch Weight (g)
			Weight (mg/mL)	% (w/v)	
Compound of Formula (I) FB	In-house	Drug Substance	50.0	5	20.03
Saccharin	NF / EP	Sweetener	1.5	0.15	0.61
Butylated hydroxytoluene	NF / EP	Anti-oxidant	1.7	0.17	0.69
FONA orange flavor	NF	Flavor	1.0	0.1	0.41
Labrafac Lipophile WL1349	NF / EP	Liquid Vehicle	to 1 mL	94.58	358.87
Total			1 mL	100.0	380.6

Example 13: Liquid Formulation 2 of the Compound of Formula (I)

[0529] Table 39 shows liquid formulation 2 of the Compound of Formula (I) free base. An example manufacturing process is shown in FIG. 24.

Table 39:

Component	Quality Standard	Function	50 mg/mL Oral Solution		Batch Weight (g)
			Weight (mg/mL)	% (w/v)	
Compound of Formula (I) FB	In-house	Drug Substance	50.0	5	20.17
Saccharin	NF / EP	Sweetener	1.5	0.15	0.61

(continued)

Component	Quality Standard	Function	50 mg/mL Oral Solution		Batch Weight (g)
			Weight (mg/mL)	% (w/v)	
Butylated hydroxytoluene	NF / EP	Anti-oxidant	1.7	0.17	0.68
LABRAFIL M 1944 CS	NF / EP	Surfactant	200.0	20	80.16
FONA orange flavor	NF	Flavor	1.0	0.1	0.40
Labrafac Lipophile WL1349	NF / EP	Liquid Vehicle	to 1 mL	74.58	278.68
Total			1 mL	100.0	380.7

Example 14: A Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Relative Bioavailability, Effect of Food, Safety and Tolerability of Different Compound of Formula (I) Prototype Formulations in Healthy Adult Subjects.

Methodology

[0530] This is a single center, open-label, randomized, single dose 4-period crossover study in healthy adult subjects designed to investigate the pharmacokinetic (PK) and safety of up to 4 compound of Formula (I) liquid lipidic prototype formulations (compound of Formula (I) Oral Solution, Prototype Formulations, 50 mg/mL), a compound of Formula (I) spray dried dispersion formulation (compound of Formula (I) Granule for Sprinkle, 25 - 50 mg) and compound of Formula (I), 50 mg Capsules (Reference). It is planned to enroll 36 subjects to be allocated as 3 cohorts of 12 subjects per cohort, with 6 sub-cohorts of 6 subjects per sub-cohort. In each of these 6 sub- cohorts, 6 subjects will be assigned to one of 3 sub-cohorts where a single oral dose of Investigational Medicinal Product (IMP) is administered in 4 dosing periods (Periods 1 to 4) in multiple fed or fasted states or to one of 3 sub-cohorts where a single oral dose of IMP is administered in 2 dosing periods (Periods 1 and 2) only in the fed state. Within each sub-cohort, subjects will also be randomized before administration of the first dose of IMP in Period 1 to one of the following treatment sequences (Table 40):

Table 40:

Sub-Cohort	Sequence	Number of Subjects	Total Number of Periods Dosed	Regimen			
				Period 1	Period 2	Period 3	Period 4
1A	ABEF	3	4	Regimen A	Regimen B	Regimen E	Regimen F
	BAEF	3	4	Regimen B	Regimen A	Regimen E	Regimen F
1B	AB	3	2	Regimen A	Regimen B	N/A	N/A
	BA	3	2	Regimen B	Regimen A	N/A	N/A
2A	ADEF	3	4	Regimen A	Regimen D	Regimen E	Regimen F
	DAEF	3	4	Regimen D	Regimen A	Regimen E	Regimen F
2B	AD	3	2	Regimen A	Regimen D	N/A	N/A
	DA	3	2	Regimen D	Regimen A	N/A	N/A

(continued)

Sub-Cohort	Sequence	Number of Subjects	Total Number of Periods Dosed	Regimen			
				Period 1	Period 2	Period 3	Period 4
3A	ACEF	3	4	Regimen A	Regimen C	Regimen E	Regimen F
	CAEF	3	4	Regimen C	Regimen A	Regimen E	Regimen F
3B	AC	3	2	Regimen A	Regimen C	N/A	N/A
	CA	3	2	Regimen C	Regimen A	N/A	N/A

[0531] At informed consent, subjects will agree either to participate in 2 study periods or 4 study periods. Once placed into a sub-cohort, the order in which subjects receive the study treatments will be randomized based on the schedule above.

[0532] Subjects will receive up to 4 regimens in up to 4 periods in an order according to the randomization schedule within each sub-cohort.

[0533] The effect of different prandial states on the PK of the compound of Formula (I) may be explored in Periods 3 and 4 by administering in the fasted state or after an alternative meal (e.g. high fat, standard or light breakfast, etc.).

[0534] The proposed regimens are presented in Table 41 below:

Table 41:

Regimen	Investigational Medicinal Product	Dose	Route of Administration	Prandial State
A	Compound of Formula (I), 50 mg Capsules (Reference)	50 mg	Oral	Fed (Ensure Plus)
B	Compound of Formula (I) Oral Solution, Prototype Formulation 1,50 mg/mL	50 mg	Oral	Fed (Ensure Plus)
C	Compound of Formula (I) Oral Solution, Prototype Formulation 2, 50 mg/mL	50 mg	Oral	Fed (Ensure Plus)
D	Compound of Formula (I) Granule for Sprinkle, 25 - 50 mg	50 mg	Oral	Fed (Ensure Plus)
E	Compound of Formula (I) Oral Solution, Prototype Formulation 1	100 mg	Oral	Fed (Ensure Plus)
F	Compound of Formula (I) Oral Solution, Granule for Sprinkle	50 mg	Oral	Fed (alternative meal)

Study Design:

[0535] Subjects will be screened for eligibility to participate in the study up to 28 days before the first dose of IMP in Period 1. Each study period will follow the same study design. Subjects will be admitted to the clinical unit on the evening prior to IMP administration (Day -1). For Periods 1 and 2 (Regimen A and one of either Regimens B, C or D), all subjects will receive the compound of Formula (I) formulations in the morning according to the randomization schedule in the fed state with a liquid dietary supplement (Ensure Plus). For Periods 3 and 4 (Regimens E and F), subjects will receive the compound of Formula (I) formulations in the morning according to the randomization schedule in the fed state with a liquid dietary supplement or an alternate prandial state (fasted or alternative meal). IMP administration will be performed on Day 1 with an appropriate interval between subjects based on logistical requirements (approximately 10 min). Meals will be standardized for each treatment regimen across periods.

[0536] Subjects will remain in the clinical unit until 36 h post-dose when they will be discharged. Subjects will return to the clinical unit at 168 h (7 days) and 336 h (14 days) postdose for a PK blood sample and safety assessments. The

minimum washout between IMP dosing occasions will be 14 days between Periods 1 and 2 and 21 days or more to accommodate interim data reviews between Periods 2 and 3 and between Periods 3 and 4.

[0537] There will be a follow-up phone call 18 to 24 days post-final visit to ensure the ongoing wellbeing of subjects.

[0538] Following the completion of Period 2 for all cohorts, there will be an interim data review during which the PK and safety data will be reviewed, plus any relevant emerging Chemistry, Manufacturing and Control (CMC) stability study information, to determine the formulation, dose level and prandial state in which to administer the IMP in Period 3 (Regimen E). There will be a similar interim review following completion of Period 3 (administration of Regimen E) to determine the formulation, dose level and prandial state in which to administer the IMP in Period 4 (Regimen F). The criteria for the interim decisions will be based on available compound of Formula (I) PK data: e.g., C_{max}, T_{max}, AUC(0-36), F_{rel} and safety data.

Number of Subjects Planned:

[0539] It is planned to enroll 36 healthy male and female (non-pregnant, non-lactating) subjects in 6 sub-cohorts of 6 subjects per sub-cohort. These sub-cohorts will be combined in sets of 2 to create 3 cohorts of n = 12 for Periods 1 and 2 to target data in 10 evaluable subjects in each cohort for the primary objectives per formulation variant. A total of 18 subjects, 6 from each of Sub-Cohorts 1A, 2A and 3A participating in Periods 1 and 2, will additionally participate in Periods 3 and 4 with a target of a minimum of 6 evaluable subjects. A subject will be considered evaluable for a particular regimen if they have received an IMP and has completed sufficient planned PK assessments up to 336 h (14 days) after dosing for that regimen to allow for the assessment of study endpoints. A subject will be considered evaluable for a particular comparison (e.g., food effect, relative bioavailability) if they have received both IMPs under comparison and have sufficient PK data up to 14 days after each regimen to allow for assessment of study endpoints.

[0540] Subjects withdrawn due to an IMP-related adverse event (AE) will not be replaced. Subjects who are withdrawn for other reasons may be replaced as required by agreement between the principal investigator (PI) and sponsor to ensure sufficient numbers of evaluable subjects at the end of each study period. Replacement subjects may be required to be dosed with specific formulations from the previous regimens in order to obtain the minimum number of evaluable subjects required for interim decisions and to obtain data in any other regimen that is required to fulfil the study objective comparisons, with the exception that any previously dosed IMP that has been considered sub-optimal will not be dosed. Up to 8 replacement subjects in total may be enrolled into the study. The maximum number of subjects that may be dosed is 44 in total.

[0541] If a subject withdraws from Sub-Cohort 1A, 2A or 3A after Period 2, it is acceptable to replace them with a subject from Sub-Cohort 1B, 2B or 3B provided the subject signs an updated consent form agreeing to participate in four treatment periods. At the discretion of the investigator, such a subject may not be required to undergo repeat screening procedures.

Duration of Study:

[0542] For subjects enrolled to receive single dose administration on 4 separate occasions in Periods 1 to 4 (Sub-Cohorts 1A, 2A and 3A), the estimated time from screening until the follow-up phone call is approximately 15 to 16 weeks.

[0543] For subjects enrolled to receive single dose administration on 2 separate occasions in Periods 1 to 2 only (Sub-Cohorts 1B, 2B and 3B), the estimated time from screening until the follow-up phone call is approximately 8 to 9 weeks.

Pharmacokinetic Assessments:

[0544] The plasma concentration data for a compound of Formula (I) will be analyzed for final reporting by Quotient Sciences and for interim reviews by Neurocrine Biosciences, Inc. (NBI), using Phoenix WinNonlin v8.0 or a more recent version (Certara USA, Inc., USA). NBI will be responsible for PK analysis for interim review.

[0545] PK analysis of the concentration time data obtained will be performed using appropriate non-compartmental techniques to obtain estimates of the following PK parameters (Table 42) where possible and appropriate:

Table 42:

T_{lag}	Time prior to the first measurable (nonzero) concentration
T_{max}	Time to maximum plasma concentration
C_{max}	Maximum plasma concentration
$AUC_{0\text{-}tlast}$	Area under the plasma concentration versus time curve (AUC) from 0 h to last measurable concentration

(continued)

AUC_{0-inf}	AUC from 0 h extrapolated to infinity
AUC_{extrap}	Percentage of AUC_{0-inf} extrapolated beyond the last measurable concentration
Lambda-z	Slope of the apparent terminal phase
$T_{1/2}$	Apparent terminal half-life
CL/F^a	Apparent systemic clearance after oral administration
Vd/F^a	Apparent volume of distribution based on the area after a single oral administration
MRT	Mean residence time
MPR $AUC_{0-tlast}$	Metabolite to parent ratio based on $AUC_{0-tlast}$
MPR AUC_{0-inf}	Metabolite to parent ratio based on AUC_{0-inf}

Taste Assessments:

[0546] Taste will be assessed for each IMP formulation and vehicle (e.g., Ensure Plus, soft food) using a questionnaire designed for this purpose and adapted for this specific study as required.

[0547] The questionnaire will ask subjects to rate the acceptability of smell, sweetness, bitterness, flavor, mouth feel, and aftertaste on a 6-point scale, and overall experience on a 5-point scale for each IMP formulation independently of any previous formulations.

Statistical Methodology:

[0548] Descriptive summaries for all safety data, PK assessments and taste questionnaire data will be provided. No hypothesis testing will be performed for the safety or taste questionnaire data.

Periods 1 and 2 - for Each Cohort Separately

Relative Bioavailability

[0549] Statistical modelling will be performed on the natural log-transformed compound of Formula (I) PK parameters (AUC(0-tlast), AUC(0-inf) and Cmax) to assess relative bioavailability (Frel) using a mixed effects model with terms for regimen, period and sequence as fixed effects and subject within sequence as a random effect. Ratios of geometric means (GMRs) and 90% confidence interval (CI) for the relevant comparison of interest, i.e., between each of the prototype formulations (compound of Formula (I) Oral Solution, Prototype Formulation 1, 50 mg/mL, e.g., Example 12; compound of Formula (I) Oral Solution, Prototype Formulation 2, 50 mg/mL, e.g., Example 13; and compound of Formula (I) Granule for Sprinkle, 25 - 50 mg, e.g. Example 11 [Regimens B, C and D, respectively]) and compound of Formula (I), 50 mg Capsules, e.g., Example 9 (Reference; Regimen A) will be presented.

All Periods (Periods 1 to 4)

Food Effect

[0550] Statistical modelling will be performed on the compound of Formula (I) PK parameters AUC(0-tlast), AUC(0-inf) and Cmax to assess for the effects of food, if relevant. The natural log-transformed PK parameters will be analyzed for bioavailability using a mixed effects model with terms for prandial state (and meal type if applicable) as a fixed effect and subject as a random effect. Ratios of geometric means and 90% CI for the relevant comparisons of interest will be presented where the ratio is defined as fasted/fed or test meal/reference meal (if applicable).

Relative Bioavailability

[0551] Statistical modelling will be performed on the natural log-transformed compound of Formula (I) PK parameters (AUC(0-tlast), AUC(0-inf) and Cmax) to assess relative bioavailability using a mixed effects model with terms for regimen as a fixed effect and subject as a random effect. Ratios of geometric means and 90% CI for the relevant comparison of interest i.e., between each of the prototype formulations (Regimens E and F, IMPs to be determined by interim reviews

following completion of Periods 2 and 3) and compound of Formula (I), 50 mg Capsules (Reference; Regimen A) will be presented.

Results

[0552] Preliminary PK data is summarized in Table 43 below:

Table 43: Preliminary Data from Periods 1 and 2

	A- Reference	B-Oral Solution 1	C-Oral Solution 2	D- SDD Granule
N	35	12	12	12
Tmax * (h)	5 (2,6)	6 (5,7)	5 (5,7)	5 (5,7)
Cmax (ng/ml)	1361 (33)	790 (31)	1082 (46)	1075 (35)
AUC36 (h*ng/ml)	9452 (30)	5556 (34)	7582 (37)	6691 (41)
*Geometric Mean /CV% for AUC and Cmax; Median for Tmax				


Example 15. Compound of Formula (I) Crystalline Free Base Form I

Example 15A

Scheme 1: Preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (Compound of Formula (I), Form I)


[0553]

Scheme 1



Step 1: Preparation of (*S*)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)-N-(1-phenylethyl)ethan-1-imine (Compound 3-A)

[0554]




Compound 3-A

[0555] A mixture of 2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethan-1-one (1-A, 150.7 kg, 1 eq., as a 27.6% w/w solution in toluene, Example 15C), (*S*)-(-)-1-Phenylethylamine (2-A, 112.9 kg, 1.19 eq.), and *p*-toluenesulfonic acid (7.4 kg, 0.05 eq.) is refluxed at 110 - 120 °C for 23 - 25 h in a reactor set up in a Dean-Stark configuration. The solvent is then removed at 125 - 135 °C under atmospheric pressure until distillation halts and a portion of toluene (275 kg, 2.24 w/w) is added to afford a suspension. The suspension is refluxed at 110 - 120 °C for 23 - 25 h. The mixture is cooled to

22 °C and washed twice with aqueous NH_4Cl (10%, 301.2 kg, 0.72 eq.) and once with aqueous $NaHCO_3$ (5%, 301.2 kg, 0.23 eq., check pH 8 - 9). The solvent is removed at 125 - 135 °C and atmospheric pressure to a target volume of 256 L, the mixture is filtered over celite, the cake is washed with toluene (25 kg). The resulting mixture containing compound 3-A is used directly in the next step without isolation. The yield is determined by correcting for the LOD and GC-FID purity of the sample (208.4 kg, 90.0% corrected, 0.89% Compound 2-A). EI-MS: 294.1 $[M-H]^+$, 190.1 $[M-C_6H_5CH(CH_3)]^+$, 105.1 $[C_6H_5CH(CH_3)]^+$.

Step 2: Preparation of (*S*)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)-N-((*S*)-1-phenylethyl)ethan-1-amine hydrochloride (Compound 4-A)

[0556]




Compound 4-A

[0557] Sponge nickel catalyst (144 kg, 0.70 w/w, shipped as a 50% w/w suspension in water) is added to a hydrogenation reactor, equipped with a dip tube capable of removing material from the top of the mass inside, minimizing the amount of water introduced. The supernatant is discarded, ethanol (329.3 kg, 1.58 w/w, anhydrous) is added, the suspension is stirred and then allowed to settle. This process is repeated four more times and the Karl Fisher (KF) of the supernatant is checked (≤ 1% H_2O w/w). Compound 3-A (208.4 kg, 1 eq., as a 62.6% solution in toluene) is added to the mixture in the hydrogenation reactor and ethanol (387.6 kg, 1.86 w/w) is used to rinse the addition flask into the hydrogenation reactor. The hydrogenation reactor is pressurized/depressurized twice with nitrogen (2 bar) and twice with hydrogen (5 bar) then pressurized with hydrogen (9.8 - 10.2 bar) and heated to 33 - 37 °C and stirred for 17 - 19 h. The system is depressurized/pressurized three times with nitrogen (1 bar) and the suspension is filtered and washed with three times with ethanol (493.8 kg, 2.37 w/w). HCl (concentrated, 83.4 kg, 1.07 eq.) is added and the mixture stirred 25 - 35 min at 20

[0558] - 24 °C. The mixture is concentrated by distillation at 78 - 80 °C and atmospheric pressure to remove water with a distillate target volume of 1167 L (5.6 L/kg, Compound 3-A) and the KF of the solution is checked (≤ 1.5% H_2O w/w). The mixture is stirred at 48 - 52 °C for 55 - 65 min, then 68 - 72 °C for 55 - 65 min, then cooled to 20 - 24 °C at a rate of 12 °C/h and stirred for 25 - 35 min, then cooled to 0 - 4 °C at a rate of 10 °C/h and stirred for 55 - 65 min. The suspension is filtered, the cake is washed twice with precooled ethanol (329.2 kg, 1.58 w/w, 0 °C), and the collected solid is dried at 40 °C to afford compound 4-A (156.5 kg, 66.4% uncorrected). ^1H NMR (400 MHz, DMSO-*d*6) δ ppm -0.33 - -0.06 (m, 2 H) 0.11 - 0.31 (m, 3 H) 1.57 (d, *J*=6.57 Hz, 3 H) 1.95 (br t, *J*=7.07 Hz, 2 H) 2.26 (d, *J*=1.26 Hz, 3 H) 3.68 (br d, *J*=7.83 Hz, 1 H) 3.92 (br t, *J*=6.44 Hz, 1H) 6.98 (dd, *J*=7.71, 1.14 Hz, 1H) 7.28 - 7.36 (m, 2 H) 7.37 - 7.50 (m, 5 H). ESI-MS: 298.2 m/z $[M+H]^+$.

Step 3: Preparation of (*S*)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethan-1-amine hydrochloride (Compound 5-A)

[0559]




Compound 5-A

[0560] Compound 4-A (156.5 kg, 1.00 eq.) and Pd/C (7.8 kg, 10% Pd basis) are added to an inerted hydrogenation reactor. The reactor is then pressurized/depressurized twice with nitrogen (2 bar) and then methanol (494.5 kg, 3.16 w/w) is added. The reactor is depressurized/pressurized three times with nitrogen (2 bar) then three times with hydrogen (5 bar), pressurized with hydrogen (9.8 - 10.2 bar), heated to 58 - 62 °C and stirred for 7 - 9 h. The reaction mixture is cooled to 20 - 24 °C. The reactor is depressurized/pressurized three times with nitrogen (1 bar) and the suspension is filtered and washed three times with methanol (492.9 kg, 3.15 w/w). The solution is concentrated at 63 - 67°C and atmospheric pressure to a distillate target volume of 1408 L (9.0 L/kg Compound 4-A). *n*-Heptane (1173.8 kg, 7.5 w/w) is added and the mixture is refluxed at 65 - 80 °C and atmospheric pressure in Dean-Stark configuration to remove methanol. The suspension is cooled to 31 - 35 °C and filtered, the cake washed with n-heptane (147.1 kg, 0.94 w/w), and the solid dried at 40 °C (101.0 kg, 93.8% uncorrected, 99.2% ee). ^{1}H NMR (400 MHz, DMSO-d6) δ ppm -0.12 - 0.14 (m, 2 H) 0.26 - 0.42 (m, 2 H) 0.44 - 0.55 (m, 1 H) 1.70 - 1.83 (m, 2 H) 2.23 (d, *J*=1.52 Hz, 3 H) 4.24 (t, *J*=7.33 Hz, 1 H) 7.22 - 7.29 (m, 1 H) 7.29 - 7.36 (m, 1 H) 7.40 (dd, *J*=10.99, 1.39 Hz, 1 H). ESI-MS: 194.2 $[M+H]^+$, 177.0 $[M\text{-}NH_2]^+$.

Step 4: Preparation of (*S*)-4-(2-chloro-4-methoxy-5-methylphenyl)-*N*-(2-cyclopropyt-1-(3-fluoro-4-methylphenyl)ethyl)-5-methylthiazol-2-amine (Compound 7-A)

[0561]




Compound 7-A

[0562] A mixture of n-heptane (146 kg), water (142 kg), Compound 5-A (57.4 kg), and aqueous sodium hydroxide (30% w/w, 41.0 kg) was stirred together. The layers were partitioned, and the aqueous layer removed. The organic layer was washed with water (170 kg) and the layers partitioned. The organic layer was set aside using n-heptane (40 kg) to rinse and n-heptane (145 kg) and 1-(2-chloro-4-methoxy-5-methylphenyl)-2-thiocyanatopropan-1-one (6-A, 66.1 kg) were added to the reactor and heated to 85 °C. The previously set aside organic layer containing the free base of Compound 5-A was added at 84 - 85 °C to the reactor and rinsed with n-heptane (20 kg). The resulting mixture was stirred for 2 h at 83 °C. Subsequently, the solvent was switched to methanol by four put-and-take additions/vacuum distillations of methanol (180 kg) at 55 °C with the target volume being 287 L remaining in the reactor. The suspension was cooled to 5 °C and water (570 kg) was added over 4 h at 5 - 10 °C, with the first 60 kg added very slowly. The suspension was aged 2 h at °C and then isolated by filtration and washed with a mixture of methanol/water (91/115 kg) and then a mixture of methanol/water (134/57 kg). The yellow solid was dried at 25 °C and 1 mbar for 17 h then 40 °C and 1 mbar for 22 h to afford Compound 7-A (97.4 kg, 87.5% yield). ^{1}H NMR (400 MHz, DMSO-d6) δ ppm -0.01 - 0.14 (m, 2 H) 0.29 - 0.42 (m, 2 H) 0.61 - 0.73 (m, 1 H) 1.47 (dt, *J*=13.83, 6.85 Hz, 1 H) 1.76 (dt, *J*=13.89, 7.20 Hz, 1 H) 2.00 (s, 3 H) 2.11 (s, 3 H) 2.19 (d, *J*=1.01 Hz, 3 H) 3.82 (s, 3 H) 4.54 (q, *J*=7.58 Hz, 1 H) 7.00 (s, 1 H) 7.06 (d, *J*=0.76 Hz,

1H) 7.08 - 7.14 (m, 2 H) 7.18 - 7.23 (m, 1 H) 7.89 (d, *J*=8.08 Hz, 1 H). ESI-MS: 445.3 m/z $[M+H]^+$.

Step 5: Preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1*S*)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (Compound of Formula (I))

[0563]



Compound of Formula (I)

[0564] A mixture of MTBE (279 kg), tetra-n-butylammonium bromide (10.5 kg), and Compound 7-A (95.4 kg) were heated at 60 °C external temperature for 30 min and then cooled to 0 °C. Aqueous potassium hydroxide (52.4% w/w, 364 kg) and propargyl bromide (39.4 kg as an 80% w/w solution in toluene, 1.19 eq.) were added at 0 - 5 °C and the biphasic mixture aged 14.5 h at 4 - 6 °C with vigorous stirring. Subsequently, water (191 kg) was added and the aqueous layer was discharged. The organic layer was washed twice with water (382 kg) and once with aqueous acetic acid (5.26% w/w, 190 kg) at 20 °C. The mixture is polish filtered, rinsed with ethanol (11 kg) and then the solvent switched to ethanol by 3 put-and-take additions/vacuum distillations of ethanol (300 kg) at 25 - 30 °C for the first cycle and then 35 - 40 °C with the target volume of each cycle being 250 L remaining in the reactor. Ethanol (164 kg) was added and the mixture heated at 60 °C external for 0.5 h before it was cooled to 25 °C in 1 h and seeded with authentic compound of Formula (I) (0.340 kg) which may be prepared as described below in Example 15B. The suspension was aged for 5 h, cooled to 0 °C in 2 h, aged 12 h, filtered, and washed twice with ethanol (24 kg each) precooled to 0 °C. The white solid was dried at 40 °C and 1 mbar for 19 h to yield 80.15 kg of the compound of Formula (I), Form I (77.2% yield). ^{1}H NMR (400 MHz, DMSO-*d*6) δ ppm 0.14 (qt, *J*=8.59, 4.42 Hz, 2 H) 0.29 - 0.48 (m, 2 H) 0.61 - 0.82 (m, 1 H) 1.89 (dt, *J*=14.08, 6.98 Hz, 1 H), 2.07 (br d, *J*=7.83 Hz, 1 H) 2.10 (s, 3 H) 2.14 (s, 3 H) 2.20 (d, *J*=1.01 Hz, 3 H) 3.11 (t, *J*=2.27 Hz, 1 H) 3.83 (s, 3 H) 3.94 - 4.22 (m, 2 H) 5.26 (t, *J*=7.58 Hz, 1 H) 7.05 (s, 1 H) 7.10 ~ 7.36 (m, 4 H). ESI-MS: 483.2 m/z $[M+H]^+$.

[0565] The crystallinity of the crystalline free base Compound of Formula (I), Form I was confirmed by XRPD (Figure 25, Table 44) and further supported by DSC (Figure 26), indicating the crystalline compound having an onset of melt at about 84.4 °C (71.9 J/g). TGA of the crystalline free base exhibited about 0.6% of weight loss due to solvent/H_2O.

Table 44. XRPD Peak Data for the Compound of Formula (I) Crystalline Free Base Form I

2-Theta (°)	Height (cps)
5.901(15)	1221(101)
10.367(11)	1280(103)
11.762(13)	1377(107)
12.582(11)	1591(115)
13.802(2)	7326(247)
14.1541(16)	20179(410)
15.173(14)	449(61)
15.854(7)	2906(156)
16.746(5)	5113(206)
18.366(7)	1171(99)

(continued)

2-Theta (°)	Height (cps)
19.586(2)	27789(481)
20.100(4)	10759(299)
20.794(4)	5441(213)
21.730(5)	7125(244)
22.239(7)	10370(294)
23.056(11)	3482(170)
23.714(7)	2300(138)
24.115(7)	8402(265)
25.666(4)	26173(467)
26.296(6)	1505(112)
26.752(4)	9919(288)
27.264(7)	1016(92)
27.874(7)	2092(132)
28.623(3)	10560(297)
29.546(6)	5811(220)
30.025(3)	2248(137)
30.737(10)	1333(105)
31.017(19)	1406(108)
31.588(10)	2292(138)
31.809(8)	2212(136)
32.126(13)	593(70)
33.200(16)	839(84)
	996(158)
33.914(13)	1156(98)
34.276(16)	1008(92
34.564(12)	1056(94
35.397(18)	816(82)
36.073(10)	1928(127)
36.67(3)	562(68)
37.347(9)	1553(114)
37.776(12)	1573(114)
39.070(7)	1890(125)
39.743(15)	1042(93)
40.643(9)	2808(153)
41.106(8)	1107(96)
41.984(11)	2686(150)
42.376(16)	986(91)
42.901(16)	492(64)


(continued)

2-Theta (°)	Height (cps)
43.543(10)	4744(199)
44.419(16)	2810(153)

Example 15B

Preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1*S*)-2-cyclopropy1-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (Compound of Formula (I), seed batch)

[0566]




[0567] A mixture of MTBE, *tetra*-n-butylammonium bromide, and Compound 7-A cooled to 0 °C is treated with aqueous potassium hydroxide and propargyl bromide maintaining the temperature at 0 - 5 °C. The resulting biphasic mixture is aged 23 h at 4 - 6 °C. Subsequently, water and MTBE are added and the aqueous layer is discharged. The organic layer is washed twice with water and once with aqueous acetic acid at 20 °C. Ethanol is added and then the solvent switched to ethanol by 3 put-and-take additions/vacuum distillations of ethanol at 35 - 40 °C with a target volume of each cycle remaining in the vessel, except for the third cycle where the mixture is concentrated to dryness. Ethanol is added to the vessel and the mixture heated at 60 °C external for 0.5 h before it is cooled to 20 °C in 1 h and aged 18 h affording a suspension. The suspension is cooled to 0 °C, aged 6 h, filtered, and washed twice with ethanol pre-cooled to 0 °C to afford a solid. The solid is dried at 40 °C under vacuum to afford the compound of Formula (I).

Example 15C

Scheme 2: Preparation of 2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethan-1-one (Compound 1-A)


[0568]

Scheme 2



Step 1: Preparation of 2-cyclopropyl-*N*-methoxy-*N*-methylacetamide (Compound 2-B)

[0569]




Compound 2-B

[0570] A suspension of 1,1'-Carbonyldiimidazole (152.6 kg, 1.01 eq.) in DCM (682 kg, 513 L, 7.3 w/w relative to 2-cyclopropylacetic acid) was treated with a solution of 2-cyclopropylacetic acid (1-B, 93.6 kg, 1 eq.) in DCM (248 kg, 186 L, 2.65 w/w) over at least 1 h, keeping the temperature ≤ 25 °C and compensating for significant effervescence. The resulting mixture is stirred for 15 min at 22 °C and then *N,O*-dimethylhydroxylamine•HCl (93.3 kg, 1.03 eq.) is added in portions, keeping the temperature ≤30 °C. Subsequently, triethylamine (46.4 kg, 0.49 eq.) is added to the stirring mixture at 20 - 25 °C. The resulting mixture is stirred at 22 °C at least 1 h. The mixture is washed once with $KHSO_4$ solution (0.24 M, 357.1 kg, 0.09 eq.), once with $KHSO_4$ solution (0.40 M, 365.4 kg, 0.15 eq.), once with $KHSO_4$ solution (0.80 M, 384.5 kg, 0.30 eq.), and once with $NaHCO_3$ solution (0.60 M, 393.1 kg, 0.24 eq.). Residual DCM is removed by three put-and-takes of THF (166.6 kg, 1.78 w/w) and vacuum distillation (50 - 60 °C, to minimum volume/until distillation stops). THF (333.2 kg. 3.56 w/w) is added and the yield is determined by correcting for the LOD and GC-FID purity of the sample (131.5 kg, 98.2% corrected). ^{1}H-NMR (400 MHz, DMSO-d6) δ: - 0.01 - 0.03 (m, 2H) 0.32 - 0.36 (m, 2H) 0.81 - 0.90 (br m, 1H) 2.18 (d, *J*=6.80 Hz, 2H) 2.97 (s, 3 H) 3.53 (s, 3H). ESI-MS: 144.0 $[M+H]^+$.

Step 2: Preparation of 2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethan-1-one (Compound 1-A)

[0571]



Compound 1-A

[0572] Mg (turnings, 28.6 kg, 1.37 eq.) are suspended in THF (244.7 kg, 2.0 w/w) and DIBAL-H (1 M in n-heptane, 18.9 kg, 0.03 eq.) is added dropwise at 30 °C, The resulting mixture is stirred at 30 °C for at least 10 min and then 4-bromo-2-fluoro-1-methylbenzene (3-B, neat, 21.1 kg, 0.13 eq.) is added over at least 30 min at 30 - 50 °C. Subsequently, the mixture is treated with a solution of 4-bromo-2-fluoro-1-methylbenzene (3-B, 191.6 kg, 1.18 eq.) in THF (414.5 kg, 3.37 w/w) at 30 - 50 °C over 3 h or less. The mixture is stirred at 30 °C for at least 1 h. Subsequently, the mixture is treated with 2-cyclopropyl-*N*-methoxy-*N*-methylacetamide (2-B, 123.0 kg, 1 eq., 25.9% w/w solution in THF) over at least 1 h at 15 - 25 °C. The resulting mixture is stirred at 20 - 25 °C for at least 1 h. The stirring mixture is then treated with aqueous HCl (3 M, 10.3% w/w, 668.9 kg, 2.24 eq.) at 10 - 25 °C and the resulting mixture is stirred at least 2 h (check pH 3.0 - 3.5). The layers are separated, and the aqueous layer is combined with heptane (290.3 kg, 2.36 w/w). The layers are separated, and the organic layer is washed once with $NaHCO_3$ solution (0.63 M, 211.6 kg, 0.15 eq.) and once with NaCl solution (2.57 M, 213.0 kg, 0.55 eq.). The residual solvents are removed by vacuum distillation at 58 - 62 °C until distillation stops and then one put-and-take of toluene (275.5 kg, 2.24 w/w) at 107 - 117 °C until distillation stops. Toluene (275.5 kg, 2.24 w/w) is added and the yield is determined by correcting for the LOD and GC-FID purity of the sample (150.7 kg, 91.3% corrected). ^{1}H NMR (400 MHz, DMSO-*d*6) δ ppm 0.07 - 0.21 (m, 2 H) 0.40 - 0.54 (m, 2 H) 1.02 (ttt, *J*=8.16, 8.16, 6.68, 6.68, 4.86, 4.86 Hz, 1 H) 2.30 (d, *J*=1.77 Hz, 3 H) 2.91 (d, *J*=6.57 Hz, 2 H) 7.44 (t, *J*=7.83 Hz, 1 H) 7.57 - 7.78 (m, 2 H). ESI-MS: 193.1 $[M+H]^+$.

Example 16: Compound of Formula (I) Crystalline Tosylate Salt Form 1

[0573] Approximately 20 mg of the Compound of Formula (I) was weighed into a vial. Using a positive displacement

pipette, 250 μL of solvent (IPA) was added to the vial along with a stir bar. The vial was placed in an aluminum block on a Reacti-Therm mixer and heated to 60 °C for ~1 hour. A molar equivalent of para-toluenesulfonic acid was added to the vial (20 μL of a 2M solution in water) and allowed to stir. The sample was slow cooled back to room temperature along with mild Nitrogen gas for evaporation. Precipitate was collected, left to dry overnight, and then analyzed by XRPD, DSC, and TGA.

[0574] The crystallinity of the crystalline tosylate form 1 was confirmed by XRPD (Figure 27, Table 45) and further supported by DSC (Figure 28), indicating the crystalline compound having an onset of melt at about 156 °C (22.2 J/g). TGA of the crystalline compound is provided in Figure 28, and exhibited about 0.5% of weight loss due to solvent/H_2O.

Table 45. XRPD Peak Data for the Compound of Formula (I) Crystalline Tosylate Form 1

2-Theta (°)	Height (cps)
8.112(9)	957(89)
9.124(2)	12296(320)
9.471(2)	4519(194)
10.525(3)	8507(266)
11.316(3)	10211(292)
13.182(5)	6158(227)
13.494(6)	1598(115)
14.249(9)	2197(135)
15.208(9)	1746(121)
15.711(7)	1437(109)
16.252(5)	5723(218)
16.692(3)	3848(179)
17.540(4)	1578(115)
19.031(6)	6774(238)
19.265(4)	6491(233)
19.499(10)	3152(162)
20.401(3)	8581(267)
20.656(4)	3040(159)
21.142(3)	11498(310)
21.703(6)	4979(204)
21.870(11)	5331(211)
22.277(5)	3701(176)
22.769(3)	10159(291)
23.297(3)	14954(353)
23.532(4)	3597(173)
23.810(3)	9590(283)
24.73(2)	2325(139)
25.47(4)	1704(119)
26.087(5)	2413(142)
26.71(3)	422(59)
27.210(6)	1648(117)
27.593(5)	2825(153)

(continued)

2-Theta (°)	Height (cps)
28.472(4)	6417(231)
29.51(3)	1423(109)
29.98(3)	849(84)
30.63(6)	1262(103)
30.77(3)	1121(97)
31.577(3)	5563(215)
32.74(4)	874(85)
33.73(4)	1111(96)
34.415(13)	2054(131)
34.799(11)	706(77)
35.139(15)	1320(105)
35.682(16)	1028(93)
38.39(4)	751(79)
39.743(17)	1790(122)
40.219(16)	762(80)
41.23(3)	925(88)
43.16(3)	1540(113)
44.288(12)	1142(98)


OTHER EMBODIMENTS

[0575] It is to be understood that the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

[0576] The following numbered paragraphs set out preferred features and preferred combinations of features of the present invention:

1. A pharmaceutical composition comprising:

(a) a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof; and

(b) one or more of an oily phase vehicle, an emulsifying agent, a nonionic surfactant, and a solubilizing agent.

2. The pharmaceutical composition of paragraph 1, comprising about 1 wt% to about 20 wt% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

3. The pharmaceutical composition of paragraph 1, comprising about 5 wt% to about 15 wt% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

4. The pharmaceutical composition of paragraph 1, comprising about 10 wt% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

5. The pharmaceutical composition of any one of paragraphs 1-4, comprising an oily phase vehicle.

6. The pharmaceutical composition of any one of paragraphs 1-5, comprising about 1 wt% to about 50 wt% of the oily phase vehicle.

7. The pharmaceutical composition of any one of paragraphs 1-5, comprising about 20 wt% to about 50 wt% of the oily phase vehicle.

8. The pharmaceutical composition of any one of paragraphs 1-5, comprising about 35 wt% to about 45 wt% of the oily phase vehicle.

9. The pharmaceutical composition of any one of paragraphs 1-5, comprising about 39 wt% of the oily phase vehicle.

10. The pharmaceutical composition of any one of paragraphs 1-9, wherein the oily phase vehicle is selected from medium-chain triglycerides, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol.

11. The pharmaceutical composition of any one of paragraphs 1-10, wherein the oily phase vehicle is medium-chain triglycerides.

12. The pharmaceutical composition of any one of paragraphs 10-11, wherein the medium-chain triglycerides are Labrafac TM Lipophile WL1349.

13. The pharmaceutical composition of any one of paragraphs 10-11, wherein the medium-chain triglycerides are Miglyol 812N.

14. The pharmaceutical composition of any one of paragraphs 1-13, comprising an emulsifying agent.

15. The pharmaceutical composition of any one of paragraphs 1-14, comprising about 5 wt% to about 50 wt% of the emulsifying agent.

16. The pharmaceutical composition of any one of paragraphs 1-14, comprising about 10 wt% to about 30 wt% of the emulsifying agent.

17. The pharmaceutical composition of any one of paragraphs 1-14, comprising about 15 wt% to about 25 wt% of the emulsifying agent.

18. The pharmaceutical composition of any one of paragraphs 1-14, comprising about 20 wt% of the emulsifying agent.

19. The pharmaceutical composition of any one of paragraphs 1-18, wherein the emulsifying agent is selected from medium-chain triglycerides, propylene glycol dicaprylate/dicaprate, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol.

20. The pharmaceutical composition of any one of paragraphs 1-19, wherein the emulsifying agent is propylene glycol dicaprylate/dicaprate.

21. The pharmaceutical composition of any one of paragraphs 19-20, wherein the propylene glycol dicaprylate/dicaprate is Labrafac TM PG.

22. The pharmaceutical composition of any one of paragraphs 1-21, comprising a nonionic surfactant.

23. The pharmaceutical composition of any one of paragraphs 1-22, comprising about 5 wt% to about 50 wt% of the nonionic surfactant.

24. The pharmaceutical composition of any one of paragraphs 1-22, comprising about 10 wt% to about 30 wt% of the nonionic surfactant.

25. The pharmaceutical composition of any one of paragraphs 1-22, comprising about 15 wt% to about 25 wt% of the nonionic surfactant.

26. The pharmaceutical composition of any one of paragraphs 1-22, comprising about 19 wt% of the nonionic surfactant.

27. The pharmaceutical composition of any one of paragraphs 1-26, wherein the nonionic surfactant is selected from oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, Polysorbate 80, Polysorbate 20, Gelucire, lauroyl polyoxyl-32 glycerides, Poloxamer, PEG-32 stearate, and PEG-32 hydrogenated palm glycerides.

28. The pharmaceutical composition of any one of paragraphs 1-27, wherein the nonionic surfactant is lauroyl polyoxyl-32 glycerides.

29. The pharmaceutical composition of any one of paragraphs 27-28, wherein the lauroyl polyoxyl-32 glycerides are Gelucire® 44/14.

30. The pharmaceutical composition of any one of paragraphs 1-29, comprising a solubilizing agent.

31. The pharmaceutical composition of any one of paragraphs 1-30, comprising about 1 wt% to about 50 wt% of the solubilizing agent.

32. The pharmaceutical composition of any one of paragraphs 1-30, comprising about 1 wt% to about 20 wt% of the solubilizing agent.

33. The pharmaceutical composition of any one of paragraphs 1-30, comprising about 5 wt% to about 15 wt% of the solubilizing agent.

34. The pharmaceutical composition of any one of paragraphs 1-30, comprising about 11 wt% of the solubilizing agent.

35. The pharmaceutical composition of any one of paragraphs 1-34, wherein the solubilizing agent is selected from oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, Polysorbate 80, Polysorbate 20, vitamin E polyethylene glycol succinate, Gelucire, lauroyl polyoxyl-32 glycerides, and Poloxamer.

36. The pharmaceutical composition of any one of paragraphs 1-35, wherein the solubilizing agent is vitamin E polyethylene glycol succinate.

37. The pharmaceutical composition of any one of paragraphs 35-36, wherein the vitamin E polyethylene glycol succinate is Kolliphor® TPGS.

38. The pharmaceutical composition of any one of paragraphs 35-36, wherein the vitamin E polyethylene glycol succinate is Vitamin E/TPGS 260.

39. The pharmaceutical composition of paragraph 1, comprising:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;
(b) an oily phase vehicle;
(c) an emulsifying agent;
(d) a nonionic surfactant; and
(e) a solubilizing agent.

40. The pharmaceutical composition of paragraph 1, comprising:

(a) about 5 wt% to about 15 wt% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 35 wt% to about 45 wt% of an oily phase vehicle;
(c) about 15 wt% to about 25 wt% of an emulsifying agent;
(d) about 15 wt% to about 25 wt% of a nonionic surfactant; and
(e) about 5 wt% to about 15 wt% of a solubilizing agent.

41. The pharmaceutical composition of paragraph 1, comprising:

(a) about 10 wt% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 39 wt% of an oily phase vehicle;
(c) about 20 wt% of an emulsifying agent;
(d) about 19 wt% of a nonionic surfactant; and
(e) about 11 wt% of a solubilizing agent.

42. The pharmaceutical composition of paragraph 1, comprising:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine;
(b) a medium-chain triglycerides component;
(c) a propylene glycol dicaprylate/dicaprate component;
(d) a lauroyl polyoxyl-32 glycerides component; and
(e) a vitamin E polyethylene glycol succinate component.

43. The pharmaceutical composition of paragraph 1, comprising:

(a) about 5 wt% to about 15 wt% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine;
(b) about 35 wt% to about 45 wt% of medium-chain triglycerides;
(c) about 15 wt% to about 25 wt% of propylene glycol dicaprylate/dicaprate;
(d) about 15 wt% to about 25 wt% of lauroyl polyoxyl-32 glycerides; and
(e) about 5 wt% to about 15 wt% of vitamin E polyethylene glycol succinate.

44. The pharmaceutical composition of paragraph 1, comprising:

(a) about 10 wt% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine;
(b) about 39 wt% of medium-chain triglycerides;
(c) about 20 wt% of propylene glycol dicaprylate/dicaprate;
(d) about 19 wt% of lauroyl polyoxyl-32 glycerides; and
(e) about 11 wt% of vitamin E polyethylene glycol succinate.

45. The pharmaceutical composition of any one of paragraphs 1-44, wherein the compound of Formula (I), or pharmaceutically acceptable salt thereof, is in crystalline form.

46. The pharmaceutical composition of any one of paragraphs 1-45, comprising the compound of Formula (I) as a free base.

47. The pharmaceutical composition of paragraph 45, wherein the crystalline form comprises Form I of the compound of Formula (I).

48. The pharmaceutical composition of any one of paragraphs 1-47, formulated in unit dosage form, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg to

about 200 mg, based on the weight of the free base.

49. The pharmaceutical composition of paragraph 48, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 75 mg to about 150 mg, based on the weight of the free base.

50. The pharmaceutical composition of paragraph 48, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 50 mg, based on the weight of the free base.

51. The pharmaceutical composition of paragraph 48, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 100 mg, based on the weight of the free base.

52. The pharmaceutical composition of paragraph 48, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 25 mg, based on the weight of the free base.

53. The pharmaceutical composition of any one of paragraphs 1-52, that is in the form of a tablet, capsule, sachet, powder, granules, coated particle, coated tablet, enterocoated tablet, enterocoated capsule, melting strip, or melting film.

54. The pharmaceutical composition of any one of paragraphs 48-53, wherein the pharmaceutical composition is in tablet form.

55. The pharmaceutical composition of any one of paragraphs 48-53, wherein the pharmaceutical composition is in capsule form.

56. The pharmaceutical composition of any one of paragraphs 48-55, wherein the dosage form is coated.

57. A method for preparing the pharmaceutical composition of any one of paragraphs 1-56, comprising:


(a) heating a mixture of an oily phase vehicle, an emulsifying agent, a nonionic surfactant, and a solubilizing agent;
(b) mixing the mixture of step (a) until a homogeneous mixture is achieved; and
(c) mixing the compound of Formula (I), or a pharmaceutically acceptable salt thereof, with the homogeneous mixture of step (b) until the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is dissolved, forming a composition.

58. The method of paragraph 57, further comprising:

(d) encapsulating the composition of step (c) in a capsule shell to form a capsule; and
(e) banding the capsule of step (d) in a mixture of banding agent and banding solvent.

59. A pharmaceutical composition in oral solution dosage form comprising:

(a) a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof;
(b) one or more of a sweetener, an anti-oxidant, and a flavor; and
(c) a liquid vehicle.

60. The pharmaceutical composition of paragraph 59, comprising about 1 w/v% to about 50 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

61. The pharmaceutical composition of paragraph 59, comprising about 1 w/v% to about 10 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

62. The pharmaceutical composition of paragraph 59, comprising about 5 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

63. The pharmaceutical composition of any one of paragraphs 59-62, comprising a sweetener.

64. The pharmaceutical composition of any one of paragraphs 59-63, comprising about 0.01 w/v% to about 1.5 w/v% of the sweetener.

65. The pharmaceutical composition of any one of paragraphs 59-63, comprising about 0.1 w/v% to about 0.5 w/v% of the sweetener.

66. The pharmaceutical composition of any one of paragraphs 59-63, comprising about 0.15 w/v% of the sweetener.

67. The pharmaceutical composition of any one of paragraphs 59-66, wherein the sweetener is selected from saccharin, sucrose, sucralose, aspartame, dextrose, fructose, maltitol, mannitol, sorbitol, and avantame.

68. The pharmaceutical composition of any one of paragraphs 59-67, wherein the sweetener is saccharin.

69. The pharmaceutical composition of any one of paragraphs 59-68, comprising an anti-oxidant.

70. The pharmaceutical composition of any one of paragraphs 59-69, comprising about 0.01 w/v% to about 1.5 w/v% of the anti-oxidant.

71. The pharmaceutical composition of any one of paragraphs 59-69, comprising about 0.1 w/v% to about 0.5 w/v% of the anti-oxidant.

72. The pharmaceutical composition of any one of paragraphs 59-69, comprising about 0.17 w/v% of the anti-oxidant.

73. The pharmaceutical composition of any one of paragraphs 59-72, wherein the anti-oxidant is selected from butylated hydroxytoluene, vitamin E TPGS, butylated hydroxyanisole, ascorbic acid, lecithin, tert-butylhydroquinone, and citric acid.

74. The pharmaceutical composition of any one of paragraphs 59-73, wherein the anti-oxidant is butylated hydroxytoluene.

75. The pharmaceutical composition of any one of paragraphs 59-74, comprising a flavor.

76. The pharmaceutical composition of any one of paragraphs 59-75, comprising about 0.01 w/v% to about 0.5 w/v% of the flavor.

77. The pharmaceutical composition of any one of paragraphs 59-75, comprising about 0.05 w/v% to about 0.2 w/v% of the flavor.

78. The pharmaceutical composition of any one of paragraphs 59-75, comprising about 0.10 w/v% of the flavor.

79. The pharmaceutical composition of any one of paragraphs 59-78, wherein the flavor is selected from FONA orange flavor, FONA Juicy Flavor, FONA Grape Flavor, Firmenich SA Lemon Flavor, Firmenich Tetrarome Orange Flavor, IFF Cherry Flavor, and IFF Grape Flavor.

80. The pharmaceutical composition of any one of paragraphs 59-79, wherein the flavor is FONA orange flavor.

81. The pharmaceutical composition of any one of paragraphs 59-80, comprising about 50 w/v% to about 99.9 w/v%

of the liquid vehicle.

82. The pharmaceutical composition of any one of paragraphs 59-80, comprising about 92 w/v% to about 97 w/v% of the liquid vehicle.

83. The pharmaceutical composition of any one of paragraphs 59-80, comprising about 94.6 w/v% of the liquid vehicle.

84. The pharmaceutical composition of any one of paragraphs 59-83, wherein the liquid vehicle is selected from medium-chain triglycerides, propylene glycol dicaprylate/dicaprate, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol.

85. The pharmaceutical composition of any one of paragraphs 59-84, wherein the liquid vehicle is medium-chain triglycerides.

86. The pharmaceutical composition of any one of paragraphs 84-85, wherein the medium-chain triglycerides is Labrafac Lipophile WL1349.

87. The pharmaceutical composition of any one of paragraphs 59-86, further comprising a surfactant.

88. The pharmaceutical composition of paragraph 87, comprising about 1 w/v% to about 50 w/v% of the surfactant.

89. The pharmaceutical composition of paragraph 87, comprising about 10 w/v% to about 30 w/v% of the surfactant.

90. The pharmaceutical composition of paragraph 87, comprising about 20 w/v% of the surfactant.

91. The pharmaceutical composition of any one of paragraphs 87-90, wherein the surfactant is selected from oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, Polysorbate 80, Polysorbate 20, vitamin E polyethylene glycol succinate, Gelucire, lauroyl polyoxyl-32 glycerides, sodium lauryl sulfate, Poloxamer, corn oil PEG-6 esters, and hydrogenated palm/palm kernel oil PEG-6 esters.

92. The pharmaceutical composition of any one of paragraphs 87-91, wherein the surfactant is oleoyl polyoxyl-6 glycerides.

93. The pharmaceutical composition of any one of paragraphs 91-92, wherein the oleoyl polyoxyl-6 glycerides is LABRAFIL M 1944 CS.

94. The pharmaceutical composition of any one of paragraphs 59-93, comprising about 70 w/v% to about 80 w/v% of the liquid vehicle.

95. The pharmaceutical composition of any one of paragraphs 59-93, comprising about 75 w/v% of the liquid vehicle.

96. The pharmaceutical composition of any one of paragraphs 59-95, wherein the liquid vehicle is selected from medium-chain triglycerides, propylene glycol dicaprylate/dicaprate, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol.

97. The pharmaceutical composition of any one of paragraphs 59-96, wherein the liquid vehicle is medium-chain triglycerides.

98. The pharmaceutical composition of any one of paragraphs 95-96, wherein the medium-chain triglycerides is Labrafac Lipophile WL1349.

99. The pharmaceutical composition of paragraph 59, comprising:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;
(b) a sweetener;
(c) an anti-oxidant;
(d) a flavor; and

(e) a liquid vehicle.

100. The pharmaceutical composition of paragraph 99, further comprising a surfactant.

101. The pharmaceutical composition of paragraph 59, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of a sweetener;
(c) about 0.1 w/v% to about 0.2 w/v% of an anti-oxidant;
(d) about 0.05 w/v% to about 0.2 w/v% of a flavor; and
(e) about 92 w/v% to about 97 w/v% of a liquid vehicle.

102. The pharmaceutical composition of paragraph 59, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of a sweetener;
(c) about 0.17 w/v% of an anti-oxidant;
(d) about 0.1 w/v% of a flavor; and
(e) about 94.6 w/v% of a liquid vehicle.

103. The pharmaceutical composition of paragraph 59, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of a sweetener;
(c) about 0.1 w/v% to about 0.2 w/v% of an anti-oxidant;
(d) about 0.05 w/v% to about 0.2 w/v% of a flavor;
(e) about 15 w/v% to about 25 w/v% of a surfactant; and
(f) about 70 w/v% to about 80 w/v% of a liquid vehicle.

104. The pharmaceutical composition of paragraph 59, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of a sweetener;
(c) about 0.17 w/v% of an anti-oxidant;
(d) about 0.1 w/v% of a flavor;
(e) about 20 w/v% of a surfactant; and
(f) about 75 w/v% of a liquid vehicle.

105. The pharmaceutical composition of paragraph 59, comprising:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;
(b) saccharin;
(c) butylated hydroxytoluene;
(d) FONA orange flavor; and
(e) medium-chain triglycerides.

106. The pharmaceutical composition of paragraph 105, further comprising oleoyl polyoxyl-6 glycerides.

107. The pharmaceutical composition of paragraph 106, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of saccharin;
(c) about 0.1 w/v% to about 0.2 w/v% of butylated hydroxytoluene;
(d) about 0.05 w/v% to about 0.2 w/v% of FONA orange flavor; and
(e) about 92 w/v% to about 97 w/v% of medium-chain triglycerides.

108. The pharmaceutical composition of paragraph 59, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of saccharin;
(c) about 0.17 w/v% of butylated hydroxytoluene;
(d) about 0.1 w/v% of FONA orange flavor; and
(e) about 94.6 w/v% of medium-chain triglycerides.

109. The pharmaceutical composition of paragraph 59, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1 S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of saccharin;
(c) about 0.1 w/v% to about 0.2 w/v% of butylated hydroxytoluene;
(d) about 0.05 w/v% to about 0.2 w/v% of FONA orange flavor;
(e) about 15 w/v% to about 25 w/v% of oleoyl polyoxyl-6 glycerides; and
(f) about 70 w/v% to about 80 w/v% of medium-chain triglycerides.

110. The pharmaceutical composition of paragraph 59, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of saccharin;
(c) about 0.17 w/v% of butylated hydroxytoluene;
(d) about 0.1 w/v% of FONA orange flavor;
(e) about 20 w/v% of oleoyl polyoxyl-6 glycerides; and
(f) about 75 w/v% of medium-chain triglycerides.

111. The pharmaceutical composition of any one of paragraphs 59-110, comprising the compound of Formula (I) as a free base.

112. The pharmaceutical composition of any one of paragraphs 59-111, formulated in unit dosage form, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg/mL to about 200 mg/mL, based on the weight of the free base.

113. The pharmaceutical composition of paragraph 112, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 75 mg/mL to about 150 mg/mL, based on the weight of the free base.

114. The pharmaceutical composition of paragraph 112, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 50 mg/mL, based on the weight of the free base.

115. The pharmaceutical composition of paragraph 112, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 100 mg/mL, based on the weight of the free base.

116. The pharmaceutical composition of any one of paragraphs 1-56, having a viscosity between about 15 to about

40 centipoise at about 45 °C.


117. A method for preparing the pharmaceutical composition of any one of paragraphs 59-116, comprising:

(a) mixing a liquid vehicle with a sweetener;
(b) mixing the mixture of step (a) with an anti-oxidant and a flavor;
(c) mixing the compound of Formula (I), or a pharmaceutically acceptable salt thereof, with the mixture of step (b); and
(d) mixing the mixture of step (c) with an additional portion of the liquid vehicle.

118. The method of paragraph 117, wherein step (a) comprises mixing a liquid vehicle with a sweetener and a surfactant.

119. A spray-dried dispersion comprising:

a compound having the structure of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof; and
a polymer selected from a neutral polymer, an enteric polymer, and a pyrrolidone polymer;
wherein the weight ratio of the compound of Formula (I) to the polymer is from about 1:1 to about 1:9.

120. The spray-dried dispersion of paragraph 119, wherein the neutral polymer is selected from hydroxypropyl methylcellulose (HPMC) and hydroxyethyl cellulose (HEC).

121. The spray-dried dispersion of paragraph 119, wherein the enteric polymer is selected from hydroxypropyl methyl cellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), hydroxypropyl methyl cellulose phthalate (HPMCP), an amino methacrylate copolymer, an ammonioalkyl methacrylate copolymer, and a methacrylic copolymer.


122. The spray-dried dispersion of paragraph 119, wherein the pyrrolidone polymer is selected from polyvinyl pyrrolidone (PVP) and a polyvinyl pyrrolidone vinyl acetate (PVP/VA).

123. The spray-dried dispersion of paragraph 122, wherein the pyrrolidone polymer is PVP/VA.

124. The spray-dried dispersion of paragraph 123, wherein the copolymer comprises 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 40:60 to about 60:40 by weight.

125. The spray-dried dispersion of paragraph 124, wherein the copolymer comprises 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 60:40 by weight.

126. The spray-dried dispersion of any one of paragraphs 122-125, wherein the copolymer has the structure:




wherein the value of n is about 1 to about 2 times the value of m.

127. The spray-dried dispersion of paragraph 126, wherein the copolymer is copovidone, wherein the value of n is about 1.16 times the value of m.

128. The spray-dried dispersion of paragraph 126, wherein the copolymer is copovidone having an average molecular weight of about 45,000 to about 70,000.


129. A spray-dried dispersion comprising:

a compound having the structure of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof; and
a polymer that is a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate having the structure:



wherein the value of n is about 1 to about 2 times the value of m and the copolymer comprises 1-vinyl-2-pyrrolidone and vinyl acetate at a ratio of about 60:40 by weight; and
wherein the weight ratio of the compound of Formula (I) to the copolymer is from about 1:1 to about 1:9.

130. The spray-dried dispersion of any one of paragraphs 119-129, wherein the compound of Formula (I) and the polymer together form homogeneous particles.

131. The spray-dried dispersion of any one of paragraphs 119-130, wherein the particles have a particle size distribution D_{50} of about 5 μm to about 100 μm.

132. The spray-dried dispersion of any one of paragraphs 119-131, wherein the particles have a particle size distribution D_{50} of about 10 μm to about 50 μm.

133. The spray-dried dispersion of any one of paragraphs 119-132, wherein the particles have a particle size distribution D_{50} of about 15 μm to about 30 μm.

134. The spray-dried dispersion of any one of paragraphs 119-133, wherein the weight ratio of the compound of Formula (I) to the polymer is from about 1:1.5 to about 1:9.

135. The spray-dried dispersion of any one of paragraphs 119-134, wherein the weight ratio of the compound of Formula (I) to the polymer is from about 1:2.5 to about 1:4.

136. The spray-dried dispersion of any one of paragraphs 119-135, wherein the weight ratio of the compound of Formula (I) to the polymer is about 1:3.

137. The spray-dried dispersion of any one of paragraphs 119-136, wherein the particles have a residual solvent content less than about 2 wt %.

138. The spray-dried dispersion of any one of paragraphs 119-137, wherein the particles have a residual solvent content less than about 1 wt %.

139. The spray-dried dispersion of any one of paragraphs 119-138, wherein the particles have a residual solvent content of about 0.5 wt % or less.

140. The spray-dried dispersion of any one of paragraphs 119-139, wherein the compound of Formula (I) in the dispersion is substantially amorphous.

141. A pharmaceutical composition comprising the spray-dried dispersion of any one of paragraphs 119-140 and one or more pharmaceutically acceptable excipients.

142. The pharmaceutical composition of paragraph 141, wherein the spray-dried dispersion is present in an amount of about 20% to about 90% w/w of the composition.

143. The pharmaceutical composition of paragraph 142, wherein the spray-dried dispersion is present in an amount of about 40% to about 80% w/w of the composition.

144. The pharmaceutical composition of paragraph 141, wherein the spray-dried dispersion is present in an amount of about 1% to about 20% w/w of the composition.

145. The pharmaceutical composition of paragraph 144, wherein the spray-dried dispersion is present in an amount of about 13% w/w of the composition.

146. The pharmaceutical composition of any one of paragraphs 141-145, wherein the pharmaceutical excipients are selected from the group consisting of a filler, a lubricant, and combinations thereof.

147. The pharmaceutical composition of paragraph 146, wherein the filler is selected from the group consisting of a binder, a diluent, a disintegrant, a glidant, a surfactant, and combinations thereof.

148. The pharmaceutical composition of any one of paragraphs 141-147 formulated in unit dosage form, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg to about 200 mg.

149. The pharmaceutical composition of paragraph 148, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 75 mg to about 150 mg.

150. The pharmaceutical composition of paragraph 149, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 50 mg.

151. The pharmaceutical composition of paragraph 149, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 100 mg.

152. The pharmaceutical composition of any one of paragraphs 141-151, wherein the pharmaceutical excipients are selected from the group consisting of a glidant, a filler, a disintegrant, a lubricant, and a combination thereof.

153. The pharmaceutical composition of any one of paragraphs 141-152, comprising a glidant.

154. The pharmaceutical composition of any one of paragraphs 152-153, comprising about 0.1 w/w% to about 5 w/w% of the glidant.

155. The pharmaceutical composition of any one of paragraphs 152-153, comprising about 0.1 w/w% to about 1 w/w% of the glidant.

156. The pharmaceutical composition of any one of paragraphs 152-153, comprising about 0.67 w/w% of the glidant.

157. The pharmaceutical composition of any one of paragraphs 152-156, wherein the glidant is selected from calcium silicate, silicon dioxide, and talc.

158. The pharmaceutical composition of any one of paragraphs 152-157, wherein the glidant is calcium silicate.

159. The pharmaceutical composition of any one of paragraphs 141-158, comprising a filler.

160. The pharmaceutical composition of any one of paragraphs 152-159, comprising about 30 w/w% to about 99 w/w% of the filler.

161. The pharmaceutical composition of any one of paragraphs 152-159, comprising about 50 w/w% to about 90 w/w% of the filler.

162. The pharmaceutical composition of any one of paragraphs 152-159, comprising about 75.5 w/w% of the filler.

163. The pharmaceutical composition of any one of paragraphs 152-162, wherein the filler is selected from mannitol, microcrystalline cellulose, lactose, starch, isomalt, silicified microcrystalline cellulose, Dicalcium Phosphate, maltodextrin, and a combination thereof.

164. The pharmaceutical composition of any one of paragraphs 152-163, wherein the filler is a combination of mannitol and microcrystalline cellulose.

165. The pharmaceutical composition of any one of paragraphs 163-164, comprising about 30 w/w% to about 80 w/w% of mannitol.

166. The pharmaceutical composition of any one of paragraphs 163-164, comprising about 50 w/w% to about 60 w/w% of mannitol.

167. The pharmaceutical composition of any one of paragraphs 163-164, comprising about 56 w/w% of mannitol.

168. The pharmaceutical composition of any one of paragraphs 163-167, comprising about 1 w/w% to about 50 w/w% of microcrystalline cellulose.

169. The pharmaceutical composition of any one of paragraphs 163-167, comprising about 10 w/w% to about 30 w/w% of microcrystalline cellulose.

170. The pharmaceutical composition of any one of paragraphs 163-167, comprising about 20 w/w% of microcrystalline cellulose.

171. The pharmaceutical composition of any one of paragraphs 163-167, comprising about 56 w/w% of mannitol and about 20 w/w% of microcrystalline cellulose.

172. The pharmaceutical composition of any one of paragraphs 141-171, comprising a disintegrant.

173. The pharmaceutical composition of any one of paragraphs 152-172, comprising about 1 w/w% to about 30 w/w% of the disintegrant.

174. The pharmaceutical composition of any one of paragraphs 152-172, comprising about 5 w/w% to about 15 w/w% of the disintegrant.

175. The pharmaceutical composition of any one of paragraphs 152-172, comprising about 10 w/w% of the disintegrant.

176. The pharmaceutical composition of any one of paragraphs 152-175, wherein the disintegrant is selected from croscarmellose sodium, sodium starch glycolate, crospovidone, and sodium bicarbonate.

177. The pharmaceutical composition of any one of paragraphs 152-176, wherein the disintegrant is croscarmellose sodium.

178. The pharmaceutical composition of any one of paragraphs 141-177, comprising a lubricant.

179. The pharmaceutical composition of any one of paragraphs 152-178, comprising about 0.1 w/w% to about 10 w/w% of the lubricant.

180. The pharmaceutical composition of any one of paragraphs 152-178, comprising about 0.1 w/w% to about 1 w/w% of the lubricant.

181. The pharmaceutical composition of any one of paragraphs 152-178, comprising about 0.5 w/w% of the lubricant.

182. The pharmaceutical composition of any one of paragraphs 152-181, wherein the lubricant is selected from sodium stearyl fumarate, magnesium stearate, stearic acid, sodium lauryl sulfate, sodium oleate, glyceryl behenate, and talc.

183. The pharmaceutical composition of any one of paragraphs 152-182, wherein the lubricant is sodium stearyl fumarate.

184. The pharmaceutical composition of any one of paragraphs 141-183, comprising:

(a) the spray-dried dispersion of any one of paragraphs 119-140;
(b) a glidant;
(c) a filler; and
(d) a disintegrant.

185. The pharmaceutical composition of any one of paragraphs 141-183, comprising:

(a) about 1 w/w% to about 20 w/w% of the spray-dried dispersion of any one of paragraphs 119-140;
(b) about 0.1 w/w% to about 1 w/w% of a glidant;
(c) about 50 w/w% to about 90 w/w% of a filler; and
(d) about 5 w/w% to about 0.2 w/w% of a disintegrant.

186. The pharmaceutical composition of any one of paragraphs 141-183, comprising:

(a) about 13 w/w% of the spray-dried dispersion of any one of paragraphs 119-140;
(b) about 0.67 w/w% of a glidant;
(c) about 75.5 w/w% of a filler; and
(d) about 10 w/w% of a disintegrant.

187. The pharmaceutical composition of any one of paragraphs 141-183, comprising:

(a) the spray-dried dispersion of Example 3;

(b) calcium silicate;
(c) a combination of mannitol and microcrystalline cellulose; and
(d) croscarmellose sodium.

188. The pharmaceutical composition of paragraph 187, comprising:

(a) about 1 w/w% to about 20 w/w% of the spray-dried dispersion of Example 3;
(b) about 0.1 w/w% to about 1 w/w% of calcium silicate;
(c) about 50 w/w% to about 60 w/w% of mannitol and about 10 w/w% to about 30 w/w% of microcrystalline cellulose; and
(d) about 5 w/w% to about 0.2 w/w% of croscarmellose sodium.

189. The pharmaceutical composition of paragraph 188, comprising:

(a) about 13 w/w% of the spray-dried dispersion of Example 3;
(b) about 0.67 w/w% of calcium silicate;
(c) about 56 w/w% of mannitol and about 20 w/w% of microcrystalline cellulose; and
(d) about 10 w/w% of croscarmellose sodium.

190. The pharmaceutical composition of any one of paragraphs 141-189 that is formulated as a tablet, capsule, sachet, powder, granules, coated particle, coated tablet, enterocoated tablet, enterocoated capsule, melting strip, or melting film.

191. The pharmaceutical composition of paragraph 190, wherein the pharmaceutical composition is in tablet form.

192. The pharmaceutical composition of paragraph 190, wherein the pharmaceutical composition is in capsule form.

193. The pharmaceutical composition of paragraph 190, wherein the pharmaceutical composition is in sachet form.

194. The pharmaceutical composition of paragraph 190, wherein the pharmaceutical composition is in granule form.

195. The pharmaceutical composition of any one of paragraphs 190-192, wherein the pharmaceutical composition is coated.

196. A method for preparing the spray-dried dispersion of any one of paragraphs 119-140, comprising:

dissolving the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the polymer in an organic solvent to form a solution; and
spray-drying the solution to produce the spray-dried dispersion, wherein the spray-drying forms homogeneous particles of the compound of Formula (I) and the polymer.

197. The method of paragraph 196, comprising removing the organic solvent after formation of the spray-dried dispersion by drying the spray-dried dispersion.

198. The method of paragraph 197, wherein the spray-dried dispersion is dried with a convection tray dryer.

199. The method of any one of paragraphs 196-198, wherein the organic solvent is acetone.

200. The method of any one of paragraphs 196-199, wherein the spray dryer inlet temperature is about 60°C to about 80°C.

201. The method of paragraph 200, wherein the spray dryer inlet temperature is about 72°C.

202. The method of any one of paragraphs 196-201, wherein the spray dryer outlet temperature is about 25°C to about 45°C.

203. The method of paragraph 202, wherein the spray dryer outlet temperature is about 35°C.

204. The method of any one of paragraphs 196-203, wherein the homogeneous particles comprise a bulk density of less than about 0.2 g/mL.

205. The method of paragraph 204, wherein the homogeneous particles comprise a bulk density of less than about 0.15 g/mL.

206. The method of any one of paragraphs 196-205, wherein the homogeneous particles comprise a tapped density of less than about 0.3 g/mL.

207. The method of paragraph 206, wherein the homogeneous particles comprise a tapped density of less than about 0.25 g/mL.

208. A method for preparing a pharmaceutical composition, comprising combining the spray-dried dispersion of any one of paragraphs 119-140 with one or more pharmaceutically acceptable excipients.

209. The method of paragraph 208, comprising:

(a) blending the spray-dried dispersion of any one of paragraphs 119-140, with a glidant;
(b) further blending the blend of step (a) with a filler and a disintegrant;
(c) screening the blend of step (b) to break up aggregates and assist with blend uniformity;
(d) further blending the intragranular blend of step (c);
(e) compaction of the intragranular blend of step (d) via roller compaction to form granules; and
(f) milling of ribbon from roller compaction into granules of step (e).

210. A method of treating congenital adrenal hyperplasia (CAH), in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the spray-dried dispersion of any one of paragraphs 119-140 or the pharmaceutical composition of any one of paragraphs 141-195.

211. The method of paragraph 210, wherein the spray-dried dispersion or the pharmaceutical composition is administered to the subject in a fed state.

212. The method of paragraph 210 or paragraph 211, wherein the spray-dried dispersion or the pharmaceutical composition is administered to the subject with a nutritional composition.

213. The method of paragraph 212, wherein the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate.

214. The method of paragraph 212 or paragraph 213, wherein the nutritional composition is administered in an amount of about 8 fluid ounces.

215. The method of any one of paragraphs 212-214, wherein the nutritional composition is administered within 30 minutes of administration of the spray-dried dispersion or the pharmaceutical composition.

216. The method of any one of paragraphs 211-215, wherein administering the spray-dried dispersion or the pharmaceutical composition exhibits a positive food effect.

217. The method of paragraph 216, wherein the positive food effect is measured in terms of C_{max}, AUC, or combinations thereof when comparing oral administration of the spray-dried dispersion or pharmaceutical composition in the fed and fasting states.

218. The method of any one of paragraphs 211-217, wherein the ratio of the AUC in the fed state to the AUC in the fasted state is about 5 to about 10.

219. The method of any one of paragraphs 211-217, wherein the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is about 5 to about 10.

220. The method of any one of paragraphs 210-219, wherein the subject is a pediatric subject.

221. A method of improving gastrointestinal absorption of a compound of Formula (I) in a subject, comprising orally administering to the subject the pharmaceutical composition of any one of paragraphs 141-195, wherein the improvement is relative to oral administration of the compound of Formula (I) which has not been prepared as a spray-dried dispersion.

222. The method of paragraph 221, wherein the subject is a pediatric subject.

223. A method of improving oral bioavailability of a compound of Formula (I) in a subject, comprising orally administering to the subject the pharmaceutical composition of any one of paragraphs 141-195, wherein the improvement is relative to oral administration of the compound of Formula (I) which has not been prepared as a spray-dried dispersion.

224. The method of paragraph 223, wherein the subject is a pediatric subject.

225. The spray-dried dispersion of any one of paragraphs 119-140, wherein the spray-dried dispersion is formulated for oral administration and exhibits a positive food effect when administered orally.

226. The spray-dried dispersion of paragraph 225, wherein the spray-dried dispersion has a ratio of the AUC in the fed state to the AUC in the fasted state of about 5 to about 10.

227. The spray-dried dispersion of paragraph 225, wherein the spray-dried dispersion has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 5 to about 10.

228. A crystalline salt, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, p-toluenesulfonic acid salt.

229. The salt of paragraph 228, having Form 1 of the Compound of Formula (I).

230. The salt of paragraph 228 or paragraph 229, having an X-ray powder diffraction pattern as substantially shown in Figure 27.

231. The salt of any one of paragraphs 228-230, having a DSC thermogram substantially as depicted in Figure 28.

232. The salt of any one of paragraphs 228-231, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 28.

233. The salt of any one of paragraphs 228-232, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected 9.1, 11.3, 13.2, 16.3 and 21.1 degrees.

234. The salt of any one of paragraphs 228-232, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.1, 11.3, 13.2, 16.3 and 21.1 degrees.

235. The salt of any one of paragraphs 228-232, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.1, 11.3, 13.2, 16.3 and 21.1 degrees.

236. The salt of any one of paragraphs 228-232, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.1, 11.3, 13.2, 16.3 and 21.1 degrees.

237. The salt of any one of paragraphs 228-232, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 9.1, 11.3, 13.2, 16.3 and 21.1 degrees.

238. The salt of any one of paragraphs 228-237, having an endothermic peak having an onset of melt at about 156 °C (22.2 J/g) in a differential scanning calorimetry (DSC) thermogram.

239. A method of treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone

(ACTH); and (c) androstenedione in the subject.

240. The method of paragraph 239, wherein the reduction in level of any of biomarkers is determined by comparing the level of the biomarker as measured during the circadian release on a day prior to administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof and the level of the biomarker as measured during the circadian release on the day after administering the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

241. The method of paragraph 240, wherein the circadian release occurs between the hours of 2 a.m. and 10 a.m.

242. The method of any one of paragraphs 239-241, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered three to eight hours prior to the circadian release of the biomarker.

243. The method of any one of paragraphs 239-242, wherein the level of 17-hydroxyprogesterone is reduced by at least 25%.

244. The method of any one of paragraphs 239-242, wherein the level of 17-hydroxyprogesterone is reduced by at least 50%.

245. The method of any one of paragraphs 239-244, wherein the level of adrenocorticotropic hormone is reduced by at least 25%.

246. The method of any one of paragraphs 239-244, wherein the level of adrenocorticotropic hormone is reduced by at least 40%.

247. The method of any one of paragraphs 239-244, wherein the level of adrenocorticotropic hormone is reduced by at least 50%.

248. The method of any one of paragraphs 239-247, wherein the level of androstenedione is reduced by at least 25%.

249. The method of any one of paragraphs 239-247, wherein the level of androstenedione is reduced by at least 30%.

250. The method of any one of paragraphs 239-247, wherein the level of androstenedione is reduced by at least 50%.

251. The method of any one of paragraphs 239-250, wherein the level of 17-hydroxyprogesterone is reduced by at least 50% and the level of androstenedione is reduced by at least 50%.

252. The method of any one of paragraphs 239-251, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

253. The method of any one of paragraphs 239-252, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

254. A method for reducing the severity of one or more symptoms selected from hirsutism, precocious puberty, fertility problems, acne, and growth impairment in a subject having classic congenital adrenal hyperplasia, comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce the level of androstenedione in the subject.

255. The method of paragraph 254, wherein the growth impairment is selected from one or more of accelerated height velocity, accelerated weight velocity, or accelerated bone age.

256. The method of paragraph 254 or 255, wherein the androstenedione is reduced by at least 25%.

257. The method of paragraph 254 or 255, wherein the androstenedione is reduced by at least 30%.

258. The method of paragraph 254 or 255, wherein the androstenedione is reduced by at least 50%.

259. A method of reducing the level of one or more biomarkers of congenital adrenal hyperplasia in a subject having congenital adrenal hyperplasia comprising administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

260. The method of paragraph 259, wherein the one or more biomarkers of congenital adrenal hyperplasia are selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

261. A method of reducing the dosage of corticosteroid administered to a subject having congenital adrenal hyperplasia for controlling congenital adrenal hyperplasia comprising administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

262. The method of paragraph 261, wherein the corticosteroid is a glucocorticoid.

263. A method of reducing the severity of one or more side effects of glucocorticoid treatment in a subject having congenital adrenal hyperplasia comprising administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof,
wherein the side effect is selected from osteoporosis, avascular necrosis of bone, myopathy, hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, Cushing syndrome, Cushingoid features, growth suppression, adrenal suppression, gastritis, peptic ulcer, gastrointestinal bleeding, visceral perforation, hepatic steatosis, pancreatitis, hypertension, coronary heart disease, ischemic heart disease, heart failure, dermatoprosis, skin atrophy, ecchymosis, purpura, erosions, striae, delayed wound healing, easy bruising, acne, hirsutism, hair loss, mood changes, depression, euphoria, mood lability, irritability, akathisia, anxiety, cognitive impairment, psychosis, dementia, delirium, cataract, glaucoma, ptosis, mydriasis, opportunistic ocular infections, central serous chorioretinopathy, suppression of cell-mediated immunity, predisposition to infections, and reactivation of latent infections.

264. The method of any one of paragraphs 259-263, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to reduce the level of 17-hydroxyprogesterone (17-OHP) by at least 50% as compared to the level prior to administration.

265. The method of any one of paragraphs 259-264, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to reduce the level of androstenedione by at least 30% as compared to the level prior to administration.

266. The method of any one of paragraphs 259-264, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to (a) reduce the level of 17-hydroxyprogesterone (17-OHP) by at least 50% as compared to the level prior to administration; and (b) reduce the level of androstenedione by at least 30% as compared to the level prior to administration.

267. The method of any one of paragraphs 259-266, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to from about 25 mg to about 150 mg 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

268. The method of any one of paragraphs 259-267, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-

2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

269. The method of any one of paragraphs 259-268, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

270. A method of treating congenital adrenal hyperplasia in a subject comprising

(i) measuring the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in a biological sample obtained from the subject;
(ii) analyzing the level of the one or more biomarkers to determine if the level of the one or more biomarkers is elevated compared to a healthy subject not having congenital adrenal hyperplasia; and
(iii) administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof if the subject is determined to have elevated levels of the one or more biomarkers.

271. The method of paragraph 270, further comprising (iv) measuring the level of the one or more biomarkers after administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1-S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in a biological sample obtained from the subject to determine whether the subject has reduced levels of the one or more biomarkers as compared with the measurement of step (i).

272. The method of paragraph 271, further comprising (v) continuing the administration of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof if the subject has reduced levels of the one or more biomarkers.

273. The method of paragraph 271 or 272, wherein steps (i) and (iv) are performed on biological samples taken from the subject in a similar manner and within a same time of day window.

274. The method of any one of paragraphs 271-273, wherein steps (i) and (iv) are performed on biological samples taken from the subject within the time of day window from 2 a.m. to 10 a.m.

275. The method of any one of paragraphs 271-273, wherein steps (i) and (iv) are performed on biological samples taken from the subject within the time of day window from 6 a.m. to 10 a.m.

276. The method of any one of paragraphs 271-275, wherein steps (i) and (iv) comprise measuring the levels of at least two biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

277. The method of any one of paragraphs 271-275, wherein steps (i) and (iv) comprise measuring the levels of (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

278. The method of any one of paragraphs 270-277, wherein step (i) comprises measuring the level of 17-hydroxyprogesterone (17-OHP), wherein the level of 17-hydroxyprogesterone (17-OHP) is elevated when it is greater than or equal to 1,000 ng/dL.

279. The method of any one of paragraphs 270-278, wherein step (i) comprises measuring the level of androstenedione, wherein the level of androstenedione is elevated when it is greater than 200 ng/dL.

280. The method of any one of paragraphs 270-279, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to from about 25 mg to about 150 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

281. The method of any one of paragraphs 270-279, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

282. The method of any one of paragraphs 270-281, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

283. A method of treating congenital adrenal hyperplasia (CAH), in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, where in the subject is in a fed state.

284. The method of paragraph 283, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered to the subject with a nutritional composition.

285. The method of paragraph 284, wherein the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate.

286. The method of paragraph 284 or 285, wherein the nutritional composition is administered in an amount of about 8 fluid ounces.

287. The method of any one of paragraphs 284-286, wherein the nutritional composition is administered within 30 minutes of administration of the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

288. A pharmaceutical composition of any one of paragraphs 1-56, 59-116 or 141-195 for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject.

289. The pharmaceutical composition for use according to paragraph 288, wherein the subject is in a fed state.

290. The pharmaceutical composition for use according to paragraph 288 or paragraph 289, wherein the subject is administered the pharmaceutical composition with a nutritional composition.

291. The pharmaceutical composition for use according to paragraph 290, wherein the nutritional composition is a liquid dietary supplement comprising about 1000 to about 2000 calories per liter with a fat content greater than about 30%.

292. The pharmaceutical composition for use according to paragraph 290, wherein the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate.

293. The pharmaceutical composition for use according to any one of paragraphs 290-292, wherein the nutritional composition is administered in an amount of about 6 to about 12 fluid ounces.

294. The pharmaceutical composition for use according to any one of paragraphs 290-293, wherein the nutritional composition is administered in an amount of about 8 fluid ounces.

295. The pharmaceutical composition for use according to any one of paragraphs 290-294, wherein the nutritional composition is administered within 30 minutes of administration of the pharmaceutical composition.

296. The pharmaceutical composition for use according to any one of paragraphs 289-295, wherein administering the pharmaceutical composition exhibits a positive food effect.

297. The pharmaceutical composition for use according to paragraph 296, wherein the positive food effect is meas-

ured in terms of C_{max}, AUC, or a combination thereof of a compound of Formula (I) when comparing oral administration of the pharmaceutical composition in the fed and fasting states.

298. The pharmaceutical composition for use according to any one of paragraphs 289-297, wherein the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

299. The pharmaceutical composition for use according to any one of paragraphs 289-297, wherein the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

300. The pharmaceutical composition for use according to any one of paragraphs 289-297, wherein the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

301. The pharmaceutical composition for use according to any one of paragraphs 289-297, wherein the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

302. The pharmaceutical composition for use according to any one of paragraphs 288-301, wherein the subject is a pediatric subject.

303. The pharmaceutical composition for use according to any one of paragraphs 289-295, wherein the pharmaceutical composition exhibits a positive food effect when administered orally.

304. The pharmaceutical composition for use according to paragraph 303, wherein the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1 to about 4 or about 5 to about 10.

305. The pharmaceutical composition for use according to paragraph 303, wherein the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1 to about 4 or about 5 to about 10.

306. The pharmaceutical composition for use according to paragraph 303, wherein the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1.5 to about 3.

307. The pharmaceutical composition for use according to paragraph 303, wherein the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1.5 to about 3.

308. The pharmaceutical composition for use according to any one of paragraphs 288-307, wherein the pharmaceutical composition is administered to the subject with a meal.

309. The pharmaceutical composition for use according to paragraph 308, wherein the meal is a high fat meal.

310. The pharmaceutical composition for use according to paragraph 308, wherein the meal is a low fat meal.

311. The pharmaceutical composition for use according to any one of paragraphs 308-310, wherein the pharmaceutical composition is administered within about 5 minutes after the start of the meal.

312. The pharmaceutical composition for use according to any one of paragraphs 308-311, wherein the meal is an evening meal.

313. The pharmaceutical composition for use according to any one of paragraphs 308-311, wherein the meal is a morning meal.

314. The pharmaceutical composition for use according to any one of paragraphs 308-313, wherein administering the pharmaceutical composition exhibits a positive food effect.

315. The pharmaceutical composition for use according to paragraph 314, wherein the positive food effect is measured in terms of C_{max}, AUC, or combinations thereof of the compound of Formula (I) when comparing oral admin-

istration of the pharmaceutical composition in the fed and fasting states.

316. The pharmaceutical composition for use according to any one of paragraphs 308-315, wherein the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

317. The pharmaceutical composition for use according to any one of paragraphs 308-316, wherein the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

318. The pharmaceutical composition for use according to any one of paragraphs 308-315, wherein the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

319. The pharmaceutical composition for use according to any one of paragraphs 308-315 or 318, wherein the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

320. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the pharmaceutical composition comprises about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

321. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the pharmaceutical composition comprises about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

322. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the pharmaceutical composition comprises about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

323. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the pharmaceutical composition comprises about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

324. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

325. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

326. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

327. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

328. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 150 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

329. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 200 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

330. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering the pharmaceutical composition twice daily in a dose of about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

331. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering the pharmaceutical composition twice daily in a dose of about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

332. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering the pharmaceutical composition twice daily in a dose of about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

333. The pharmaceutical composition for use according to any one of paragraphs 288-319, wherein the method comprises administering the pharmaceutical composition twice daily in a dose of about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

334. The pharmaceutical composition for use according to any one of paragraphs 288-333, wherein the subject is concurrently receiving a dose of a glucocorticoid.

335. The pharmaceutical composition for use according to paragraph 334, wherein the glucocorticoid is selected from cortisol (hydrocortisone), cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, fludrocortisone acetate, and deoxycorticosterone acetate.

336. The pharmaceutical composition for use according to paragraph 334 or 335, wherein the glucocorticoid is cortisol (hydrocortisone).

337. The pharmaceutical composition for use according to paragraph 334 or 335, wherein the glucocorticoid is cortisone.

338. The pharmaceutical composition for use according to paragraph 334 or 335, wherein the glucocorticoid is prednisone.

339. The pharmaceutical composition for use according to any one of paragraphs 334-338, wherein the glucocorticoid dose is measured in hydrocortisone equivalents.

340. The pharmaceutical composition for use according to any one of paragraphs 334-339, wherein the glucocorticoid dose is measured as a multiple of the upper limit of normal of physiologic dosing in hydrocortisone equivalents.

341. The pharmaceutical composition for use according to any one of paragraphs 334-340, wherein the glucocorticoid dose is a physiologic dose as measured after a time period of administration of the pharmaceutical composition.

342. The pharmaceutical composition for use according to any one of paragraphs 334-340, wherein the glucocorticoid dose is a physiologic dose of about 4 to about 12 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition.

343. The pharmaceutical composition for use according to any one of paragraphs 334-340, wherein the glucocorticoid dose is a physiologic dose of about 4 to about 9 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition.

344. The pharmaceutical composition for use according to any one of paragraphs 334-340, wherein the glucocorticoid dose is a physiologic dose that is less than about 8 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition.

345. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by about 10% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition

346. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by about 20% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

347. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by about 30% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

348. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by about 40% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

349. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

350. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by about 60% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

351. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by about 70% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

352. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by less than about 20% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

353. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by about 20% to about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

354. The pharmaceutical composition for use according to any one of paragraphs 334-344, wherein the glucocorticoid dose of the subject is reduced by greater than about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

355. The pharmaceutical composition for use according to any one of paragraphs 288-354, wherein the level of 17-hydroxyprogesterone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the pharmaceutical composition.

356. The pharmaceutical composition for use according to any one of paragraphs 288-354, wherein the level of 17-hydroxyprogesterone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the pharmaceutical composition.

357. The pharmaceutical composition for use according to any one of paragraphs 288-354, wherein the level of 17-hydroxyprogesterone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

358. The pharmaceutical composition for use according to any one of paragraphs 288-354, wherein the level of 17-hydroxyprogesterone is within normal limits after a time period of administration of the pharmaceutical composition.

359. The pharmaceutical composition for use according to any one of paragraphs 288-358, wherein the level of adrenocorticotropic hormone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

360. The pharmaceutical composition for use according to any one of paragraphs 288-358, wherein the level of adrenocorticotropic hormone is reduced by at least about 40% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

361. The pharmaceutical composition for use according to any one of paragraphs 288-358, wherein the level of adrenocorticotropic hormone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

362. The pharmaceutical composition for use according to any one of paragraphs 288-358, wherein the level of adrenocorticotropic hormone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

363. The pharmaceutical composition for use according to any one of paragraphs 288-354, wherein the level of adrenocorticotropic hormone is within normal limits after a time period of administration of the pharmaceutical composition.

364. The pharmaceutical composition for use according to any one of paragraphs 288-363, wherein the level of androstenedione is reduced by at least about 25% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

365. The pharmaceutical composition for use according to any one of paragraphs 288-363, wherein the level of androstenedione is reduced by at least about 30% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

366. The pharmaceutical composition for use according to any one of paragraphs 288-363, wherein the level of androstenedione is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

367. The pharmaceutical composition for use according to any one of paragraphs 288-363, wherein the level of androstenedione is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

368. The pharmaceutical composition for use according to any one of paragraphs 288-363, wherein the level of androstenedione is within normal limits after a time period of administration of the pharmaceutical composition.

369. The pharmaceutical composition for use according to any one of paragraphs 288-368, wherein the level of testosterone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

370. The pharmaceutical composition for use according to any one of paragraphs 288-368, wherein the level of testosterone is reduced by at least about 30% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

371. The pharmaceutical composition for use according to any one of paragraphs 288-368, wherein the level of testosterone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

372. The pharmaceutical composition for use according to any one of paragraphs 288-368, wherein the level of testosterone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

373. The pharmaceutical composition for use according to any one of paragraphs 288-368, wherein the level of testosterone is within normal limits after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

374. The pharmaceutical composition for use according to any one of paragraphs 288-354, wherein the level of 17-hydroxyprogesterone is reduced by at least about 50% and the level of androstenedione is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone and the level of androstenedione is relative to the level of 17-hydroxyprogesterone and the level of androstenedione prior to administration of the pharmaceutical composition.

375. The pharmaceutical composition for use according to any one of paragraphs 288-354, wherein the level of 17-hydroxyprogesterone is less than about 1.5 times the upper limit of normal and the level of androstenedione is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

376. The pharmaceutical composition for use according to any one of paragraphs 288-354, wherein the level of 17-hydroxyprogesterone is within normal limits and the level of androstenedione is within normal limits after a time period of administration of the pharmaceutical composition.

377. The pharmaceutical composition for use according to any one of paragraphs 334-376, wherein the subject exhibits a decrease in glucocorticoid burden after a time period of administration of the pharmaceutical composition, wherein the decrease in glucocorticoid burden is relative to the glucocorticoid burden prior to administration of the pharmaceutical composition.

378. The pharmaceutical composition for use according to paragraph 377, wherein one or more symptoms of glucocorticoid burden selected from quality of life, fatigue, sleep, insulin resistance, glucose tolerance, glucose control, dyslipidemia, hyperlipidemia, bone mineral density, bone turnover, fat mass, weight, central obesity, blood pressure, hirsutism severity, menstrual cyclicity, control of testicular adrenal rest tumor and fertility, is improved after a time period of administration of the pharmaceutical composition, wherein the improvement in the one or more symptoms is relative to the status of the one or more symptoms prior to administration of the pharmaceutical composition.

379. The pharmaceutical composition for use according to any one of paragraphs 341-378, wherein the time period of administration is at least about 4 weeks.

380. The pharmaceutical composition for use according to any one of paragraphs 341-378, wherein the time period of administration is at least about 24 weeks.

381. The pharmaceutical composition for use according to any one of paragraphs 341-378, wherein the time period of administration is at least about one year.

382. The pharmaceutical composition for use according to any one of paragraphs 288-381, wherein the subject is a pediatric subject.

383. The pharmaceutical composition for use according to paragraph 382, wherein the pediatric subject is less than or equal to six years old.

384. The pharmaceutical composition for use according to paragraph 382, wherein the pediatric subject is greater than six years old and less than eleven years old.

385. The pharmaceutical composition for use according to paragraph 382, wherein the pediatric subject is greater than ten years old and less than fifteen years old.

386. The pharmaceutical composition for use according to paragraph 382, wherein the pediatric subject is greater than fourteen years old and less than nineteen years old.

387. The pharmaceutical composition for use according to any one of paragraphs 288-381, wherein the subject is an adult subject.

388. The pharmaceutical composition for use according to any one of paragraphs 387, wherein the adult subject is over eighteen years old.

389. The pharmaceutical composition for use according to any one of paragraphs 288-388, wherein the subject is female.

390. The pharmaceutical composition for use according to any one of paragraphs 288-388, wherein the subject is male.

391. The pharmaceutical composition for use according to any one of paragraphs 288-390, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a hydrochloric acid salt or p-toluenesulfonic acid salt.

392. The pharmaceutical composition for use according to any one of paragraphs 288-390, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a p-toluenesulfonic acid salt of any one of paragraphs 228-238.

393. A compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of treating congenital adrenal hyperplasia in a subject, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in the subject.

394. The compound of paragraph 393, wherein the reduction in level of any of biomarkers is determined by comparing the level of the biomarker as measured during the circadian release on a day prior to administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof and the level of the biomarker as measured during the circadian release on the day after administering the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

395. The compound of paragraph 394, wherein the circadian release occurs between the hours of 2 a.m. and 10 a.m.

396. The compound of any one of paragraphs 393-395, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered three to eight hours prior to the circadian release of the biomarker.

397. The compound of any one of paragraphs 393-396, wherein the level of 17-hydroxyprogesterone is reduced by at least 25%.

398. The compound of any one of paragraphs 393-396, wherein the level of 17-hydroxyprogesterone is reduced by at least 50%.

399. The compound of any one of paragraphs 393-398, wherein the level of adrenocorticotropic hormone is reduced by at least 25%.

400. The compound of any one of paragraphs 393-398, wherein the level of adrenocorticotropic hormone is reduced by at least 40%.

401. The compound of any one of paragraphs 393-398, wherein the level of adrenocorticotropic hormone is reduced by at least 50%.

402. The compound of any one of paragraphs 393-401, wherein the level of androstenedione is reduced by at least 25%.

403. The compound of any one of paragraphs 393-401, wherein the level of androstenedione is reduced by at least 30%.

404. The compound of any one of paragraphs 393-401, wherein the level of androstenedione is reduced by at least 50%.

405. The compound of any one of paragraphs 393-401, wherein the level of 17-hydroxyprogesterone is reduced by at least 50% and the level of androstenedione is reduced by at least 50%.

406. The compound of any one of paragraphs 393-405, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

407. The compound of any one of paragraphs 393-406, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

408. A compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing the severity of one or more symptoms selected from hirsutism, precocious puberty, fertility problems, acne, and growth impairment in a subject having classic congenital adrenal hyperplasia, wherein the compound is administered in an amount sufficient to reduce the level of androstenedione in the subject.

409. The compound of paragraph 408, wherein the growth impairment is selected from one or more of accelerated height velocity, accelerated weight velocity, or accelerated bone age.

410. The compound of paragraph 408 or 409, wherein the level of androstenedione is reduced by at least 25%.

411. The compound of paragraph 408 or 409, wherein the level of androstenedione is reduced by at least 30%.

412. The compound of paragraph 408 or 409, wherein the level of androstenedione is reduced by at least 50%.

413. A compound, which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing the level of one or more biomarkers of congenital adrenal hyperplasia in a subject having congenital adrenal hyperplasia.

414. The compound of paragraph 413, wherein the one or more biomarkers of congenital adrenal hyperplasia are selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

415. A compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing the dosage of corticosteroid administered to a subject having congenital adrenal hyperplasia.

416. The compound of paragraph 415, wherein the corticosteroid is a glucocorticoid.

417. A compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of reducing the severity of one or more side effects of glucocorticoid treatment in a subject having congenital

adrenal hyperplasia, wherein the side effect is selected from osteoporosis, avascular necrosis of bone, myopathy, hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, Cushing syndrome, Cushingoid features, growth suppression, adrenal suppression, gastritis, peptic ulcer, gastrointestinal bleeding, visceral perforation, hepatic steatosis, pancreatitis, hypertension, coronary heart disease, ischemic heart disease, heart failure, dermatoprosis, skin atrophy, ecchymosis, purpura, erosions, striae, delayed wound healing, easy bruising, acne, hirsutism, hair loss, mood changes, depression, euphoria, mood lability, irritability, akathisia, anxiety, cognitive impairment, psychosis, dementia, delirium, cataract, glaucoma, ptosis, mydriasis, opportunistic ocular infections, central serous chorioretinopathy, suppression of cellmediated immunity, predisposition to infections, and reactivation of latent infections.

418. The compound of any one of paragraphs 413-417, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to reduce the level of 17-hydroxyprogesterone (17-OHP) by at least 50% as compared to the level prior to administration.

419. The compound of any one of paragraphs 413-418, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to reduce the level of androstenedione by at least 30% as compared to the level prior to administration.

420. The compound of any one of paragraphs 413-417, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof is administered at an amount sufficient to (a) reduce the level of 17-hydroxyprogesterone (17-OHP) by at least 50% as compared to the level prior to administration; and (b) reduce the level of androstenedione by at least 30% as compared to the level prior to administration.

421. The compound of any one of paragraphs 413-420, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to from about 25 mg to about 150 mg 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

422. The compound of any one of paragraphs 413-421, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

423. The compound of any one of paragraphs 413-422, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

424. A compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, for use in a method of treating congenital adrenal hyperplasia in a subject comprising

(i) measuring the level of one or more biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione in a biological sample obtained from the subject;
(ii) analyzing the level of the one or more biomarkers to determine if the level of the one or more biomarkers is elevated compared to a healthy subject not having congenital adrenal hyperplasia; and
(iii) administering to the subject 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof if the subject is determined to have elevated levels of the one or more biomarkers.

425. The compound of paragraph 424, further comprising (iv) measuring the level of the one or more biomarkers after administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in a biological sample obtained from the subject to determine whether the subject has reduced levels of the one or more biomarkers as compared with the measurement of step (i).

426. The compound of paragraph 425, further comprising (v) continuing the administration of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof if the subject has reduced levels of the one or more biomarkers.

427. The compound of paragraph 425 or 426, wherein steps (i) and (iv) are performed on biological samples taken from the subject in a similar manner and within a same time of day window.

428. The compound of any one of paragraphs 425-427, wherein steps (i) and (iv) are performed on biological samples taken from the subject within the time of day window from 2 a.m. to 10 a.m.

429. The compound of any one of paragraphs 425-427, wherein steps (i) and (iv) are performed on biological samples taken from the subject within the time of day window from 6 a.m. to 10 a.m.

430. The compound of any one of paragraphs 425-429, wherein steps (i) and (iv) comprise measuring the levels of at least two biomarkers selected from (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

431. The compound of any one of paragraphs 425-429, wherein steps (i) and (iv) comprise measuring the levels of (a) 17-hydroxyprogesterone (17-OHP); (b) adrenocorticotropic hormone (ACTH); and (c) androstenedione.

432. The compound of any one of paragraphs 424-431, wherein step (i) comprises measuring the level of 17-hydroxyprogesterone (17-OHP), wherein the level of 17-hydroxyprogesterone (17-OHP) is elevated when it is greater than or equal to 1,000 ng/dL.

433. The compound of any one of paragraphs 424-432, wherein step (i) comprises measuring the level of androstenedione, wherein the level of androstenedione is elevated when it is greater than 200 ng/dL.

434. The compound of any one of paragraphs 424-433, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to from about 25 mg to about 150 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

435. The compound of any one of paragraphs 424-433, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered once daily at an amount equivalent to about 50 mg or about 100 mg of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine free base.

436. The compound of any one of paragraphs 424-435, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine is administered in the free base form.

437. A compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof for use in a method of treating congenital adrenal hyperplasia (CAH), in a subject, wherein the subject is in a fed state.

438. The compound of paragraph 437, wherein the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, is administered to the subject with a nutritional composition.

439. The compound of paragraph 438, wherein the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate.

440. The compound of paragraph 438 or 439, wherein the nutritional composition is administered in an amount of about 8 fluid ounces.

441. The compound of any one of paragraphs 438-440, wherein the nutritional composition is administered within

30 minutes of administration of the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

442. The compound of any one of paragraphs 437-441, wherein administering the 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, exhibits a positive food effect.

443. The compound of paragraph 442, wherein the positive food effect is measured in terms of C_{max}, AUC, or combinations thereof when comparing oral administration of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in the fed and fasting states.


444. The compound of any one of paragraphs 437-443, wherein the ratio of the AUC in the fed state to the AUC in the fasted state is about 5 to about 10.

445. The compound of any one of paragraphs 437-443, wherein the ratio of the C_{max} in the fed state to the C_{max} in the fasted state is about 5 to about 10.

Claims

1. A pharmaceutical composition in oral solution dosage form comprising:

   (a) a compound of Formula (I):



(I)

   or a pharmaceutically acceptable salt thereof;
   (b) one or more of a sweetener, an anti-oxidant, and a flavor; and
   (c) a liquid vehicle, wherein the liquid vehicle is selected from medium-chain triglycerides, propylene glycol dicaprylate/dicaprate, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol.

2. The pharmaceutical composition of claim 1, comprising about 1 w/v% to about 50 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

3. The pharmaceutical composition of claim 1, comprising about 1 w/v% to about 10 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

4. The pharmaceutical composition of claim 1, comprising about 5 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

5. The pharmaceutical composition of any one of claims 1-4, comprising a sweetener.

6. The pharmaceutical composition of any one of claims 1-5, comprising about 0.01 w/v% to about 1.5 w/v% of the sweetener.

7. The pharmaceutical composition of any one of claims 1-5, comprising about 0.1 w/v% to about 0.5 w/v% of the

sweetener.

8. The pharmaceutical composition of any one of claims 1-5, comprising about 0.15 w/v% of the sweetener.

9. The pharmaceutical composition of any one of claims 1-8, wherein the sweetener is selected from saccharin, sucrose, sucralose, aspartame, dextrose, fructose, maltitol, mannitol, sorbitol, and avantame.

10. The pharmaceutical composition of any one of claims 1-9, wherein the sweetener is saccharin.

11. The pharmaceutical composition of any one of claims 1-10, comprising an anti-oxidant.

12. The pharmaceutical composition of any one of claims 1-11, comprising about 0.01 w/v% to about 1.5 w/v% of the anti-oxidant.

13. The pharmaceutical composition of any one of claims 1-11, comprising about 0.1 w/v% to about 0.5 w/v% of the anti-oxidant.

14. The pharmaceutical composition of any one of claims 1-11, comprising about 0.17 w/v% of the anti-oxidant.

15. The pharmaceutical composition of any one of claims 1-14, wherein the anti-oxidant is selected from butylated hydroxytoluene, vitamin E TPGS, butylated hydroxyanisole, ascorbic acid, lecithin, tert-butylhydroquinone, and citric acid.

16. The pharmaceutical composition of any one of claims 1-15, wherein the anti-oxidant is butylated hydroxytoluene.

17. The pharmaceutical composition of any one of claims 1-16, comprising a flavor.

18. The pharmaceutical composition of any one of claims 1-17, comprising about 0.01 w/v% to about 0.5 w/v% of the flavor.

19. The pharmaceutical composition of any one of claims 1-17, comprising about 0.05 w/v% to about 0.2 w/v% of the flavor.

20. The pharmaceutical composition of any one of claims 1-17, comprising about 0.10 w/v% of the flavor.

21. The pharmaceutical composition of any one of claims 1-20, wherein the flavor is selected from FONA orange flavor, FONA Juicy Flavor, FONA Grape Flavor, Firmenich SA Lemon Flavor, Firmenich Tetrarome Orange Flavor, IFF Cherry Flavor, and IFF Grape Flavor.

22. The pharmaceutical composition of any one of claims 1-21, wherein the flavor is FONA orange flavor.

23. The pharmaceutical composition of any one of claims 1-22, comprising about 50 w/v% to about 99.9 w/v% of the liquid vehicle.

24. The pharmaceutical composition of any one of claims 1-22, comprising about 90 w/v% to about 99 w/v% of the liquid vehicle.

25. The pharmaceutical composition of any one of claims 1-22, comprising about 92 w/v% to about 97 w/v% of the liquid vehicle.

26. The pharmaceutical composition of any one of claims 1-22, comprising about 94.6 w/v% of the liquid vehicle.

27. The pharmaceutical composition of any one of claims 1-22, comprising about 70 w/v% to about 80 w/v% of the liquid vehicle.

28. The pharmaceutical composition of any one of claims 1-22, comprising about 75 w/v% of the liquid vehicle.

29. The pharmaceutical composition of any one of claims 1-28, wherein the liquid vehicle is medium-chain triglycerides.

30. The pharmaceutical composition of claim 29, wherein the medium-chain triglycerides is Labrafac Lipophile WL1349.

31. The pharmaceutical composition of any one of claims 1-30, further comprising a surfactant.

32. The pharmaceutical composition of claim 31, comprising about 1 w/v% to about 50 w/v% of the surfactant.

33. The pharmaceutical composition of claim 31, comprising about 10 w/v% to about 30 w/v% of the surfactant.

34. The pharmaceutical composition of claim 31, comprising about 20 w/v% of the surfactant.

35. The pharmaceutical composition of any one of claims 31-34, wherein the surfactant is selected from oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, Polysorbate 80, Polysorbate 20, vitamin E polyethylene glycol succinate, Gelucire, lauroyl polyoxyl-32 glycerides, sodium lauryl sulfate, Poloxamer, corn oil PEG-6 esters, and hydrogenated palm/palm kernel oil PEG-6 esters.

36. The pharmaceutical composition of any one of claims 31-35, wherein the surfactant is oleoyl polyoxyl-6 glycerides.

37. The pharmaceutical composition of any one of claims 35-36, wherein the oleoyl polyoxyl-6 glycerides is LABRAFIL M 1944 CS.

38. The pharmaceutical composition of any one of claims 1-37, wherein the liquid vehicle is selected from medium-chain triglycerides, propylene glycol dicaprylate/dicaprate, glycerin, propylene glycol, polyethylene glycol, olive oil, soybean oil, corn oil, and transcutol.

39. The pharmaceutical composition of any one of claims 1-38, wherein the liquid vehicle is medium-chain triglycerides.

40. The pharmaceutical composition of any one of claims 1-38, wherein the medium-chain triglycerides is Labrafac Lipophile WL1349.

41. The pharmaceutical composition of claim 1, comprising:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;
(b) a sweetener;
(c) an anti-oxidant;
(d) a flavor; and
(e) a liquid vehicle.

42. The pharmaceutical composition of claim 41, further comprising a surfactant.

43. The pharmaceutical composition of claim 1, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of a sweetener;
(c) about 0.1 w/v% to about 0.2 w/v% of an anti-oxidant;
(d) about 0.05 w/v% to about 0.2 w/v% of a flavor; and
(e) about 92 w/v% to about 97 w/v% of a liquid vehicle.

44. The pharmaceutical composition of claim 1, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of a sweetener;
(c) about 0.17 w/v% of an anti-oxidant;
(d) about 0.1 w/v% of a flavor; and

(e) about 94.6 w/v% of a liquid vehicle.

45. The pharmaceutical composition of claim 1, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of a sweetener;
(c) about 0.1 w/v% to about 0.2 w/v% of an anti-oxidant;
(d) about 0.05 w/v% to about 0.2 w/v% of a flavor;
(e) about 15 w/v% to about 25 w/v% of a surfactant; and
(f) about 70 w/v% to about 80 w/v% of a liquid vehicle.

46. The pharmaceutical composition of claim 1, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of a sweetener;
(c) about 0.17 w/v% of an anti-oxidant;
(d) about 0.1 w/v% of a flavor;
(e) about 20 w/v% of a surfactant; and
(f) about 75 w/v% of a liquid vehicle.

47. The pharmaceutical composition of claim 1, comprising:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;
(b) saccharin;
(c) butylated hydroxytoluene;
(d) FONA orange flavor; and
(e) medium-chain triglycerides.

48. The pharmaceutical composition of claim 47, further comprising oleoyl polyoxyl-6 glycerides.

49. The pharmaceutical composition of claim 48, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of saccharin;
(c) about 0.1 w/v% to about 0.2 w/v% of butylated hydroxytoluene;
(d) about 0.05 w/v% to about 0.2 w/v% of FONA orange flavor; and
(e) about 92 w/v% to about 97 w/v% of medium-chain triglycerides.

50. The pharmaceutical composition of claim 1, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of saccharin;
(c) about 0.17 w/v% of butylated hydroxytoluene;
(d) about 0.1 w/v% of FONA orange flavor; and
(e) about 94.6 w/v% of medium-chain triglycerides.

51. The pharmaceutical composition of claim 1, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-

4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.1 w/v% to about 0.2 w/v% of saccharin;
(c) about 0.1 w/v% to about 0.2 w/v% of butylated hydroxytoluene;
(d) about 0.05 w/v% to about 0.2 w/v% of FONA orange flavor;
(e) about 15 w/v% to about 25 w/v% of oleoyl polyoxyl-6 glycerides; and
(f) about 70 w/v% to about 80 w/v% of medium-chain triglycerides.

52. The pharmaceutical composition of claim 1, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on the weight of the free base;
(b) about 0.15 w/v% of saccharin;
(c) about 0.17 w/v% of butylated hydroxytoluene;
(d) about 0.1 w/v% of FONA orange flavor;
(e) about 20 w/v% of oleoyl polyoxyl-6 glycerides; and
(f) about 75 w/v% of medium-chain triglycerides.

53. The pharmaceutical composition of claim 51 or 52, wherein:

the oleoyl polyoxyl-6 glycerides is LABRAFIL M 1944 CS; and
the medium-chain triglycerides is Labrafac TM Lipophile WL1349.

54. The pharmaceutical composition of any one of claims 1-53, comprising the compound of Formula (I) as a free base.

55. The pharmaceutical composition of any one of claims 1-54, formulated in unit dosage form, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg/mL to about 200 mg/mL, based on the weight of the free base.

56. The pharmaceutical composition of claim 55, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 75 mg/mL to about 150 mg/mL, based on the weight of the free base.

57. The pharmaceutical composition of claim 55, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 50 mg/mL, based on the weight of the free base.

58. The pharmaceutical composition of claim 55, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 100 mg/mL, based on the weight of the free base.

59. The pharmaceutical composition of any one of claims 1-58, having a viscosity between about 1 to about 50 centipoise at about 25 °C.

60. A method for preparing the pharmaceutical composition of any one of claims 1-59, comprising:

(a) mixing a liquid vehicle with a sweetener;
(b) mixing the mixture of step (a) with an anti-oxidant and a flavor;
(c) mixing the compound of Formula (I), or a pharmaceutically acceptable salt thereof, with the mixture of step (b); and
(d) mixing the mixture of step (c) with an additional portion of the liquid vehicle.

61. The method of claim 60, wherein step (a) comprises mixing a liquid vehicle with a sweetener and a surfactant.

62. A pharmaceutical composition of any one of claims 1-59 for use in a method of treating congenital adrenal hyperplasia (CAH) in a subject.

63. The pharmaceutical composition for use according to claim 62, wherein the subject is in a fed state.

64. The pharmaceutical composition for use according to claim 62 or 63, wherein the subject is administered the phar-

maceutical composition with a nutritional composition.

65. The pharmaceutical composition for use according to claim 64, wherein the nutritional composition is a liquid dietary supplement comprising about 1000 to about 2000 calories per liter with a fat content greater than about 30%.

66. The pharmaceutical composition for use according to claim 64, wherein the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter with a caloric distribution of 14.7% protein, 32% fat and 53.3% carbohydrate.

67. The pharmaceutical composition for use according to any one of claims 64-66, wherein the nutritional composition is administered in an amount of about 6 to about 12 fluid ounces.

68. The pharmaceutical composition for use according to any one of claims 64-67, wherein the nutritional composition is administered in an amount of about 8 fluid ounces.

69. The pharmaceutical composition for use according to any one of claims 64-68, wherein the nutritional composition is administered within 30 minutes of administration of the pharmaceutical composition.

70. The pharmaceutical composition for use according to any one of claims 63-69, wherein administering the pharmaceutical composition exhibits a positive food effect.

71. The pharmaceutical composition for use according to claim 70, wherein the positive food effect is measured in terms of C_{max}, AUC, or a combination thereof of a compound of Formula (I) when comparing oral administration of the pharmaceutical composition in the fed and fasting states.

72. The pharmaceutical composition for use according to any one of claims 63-71, wherein the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

73. The pharmaceutical composition for use according to any one of claims 63-71, wherein the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

74. The pharmaceutical composition for use according to any one of claims 63-71, wherein the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

75. The pharmaceutical composition for use according to any one of claims 63-71, wherein the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

76. The pharmaceutical composition for use according to any one of claims 62-75, wherein the subject is a human subject.

77. The pharmaceutical composition for use according to any one of claims 63-69, wherein the pharmaceutical composition exhibits a positive food effect when administered orally.

78. The pharmaceutical composition for use according to claim 77, wherein the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1 to about 4 or about 5 to about 10.

79. The pharmaceutical composition for use according to claim 77, wherein the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1 to about 4 or about 5 to about 10.

80. The pharmaceutical composition for use according to claim 77, wherein the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1.5 to about 3.

81. The pharmaceutical composition for use according to claim 77, wherein the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1.5 to about 3.

82. The pharmaceutical composition for use according to any one of claims 62-81, wherein the pharmaceutical composition is administered to the subject with a meal.

83. The pharmaceutical composition for use according to claim 82, wherein the meal is a high fat meal.

84. The pharmaceutical composition for use according to claim 82, wherein the meal is a low fat meal.

85. The pharmaceutical composition for use according to any one of claims 82-84, wherein the pharmaceutical composition is administered within about 5 minutes after the start of the meal.

86. The pharmaceutical composition for use according to any one of claims 82-85, wherein the meal is an evening meal.

87. The pharmaceutical composition for use according to any one of claims 82-85, wherein the meal is a morning meal.

88. The pharmaceutical composition for use according to any one of claims 82-87, wherein administering the pharmaceutical composition exhibits a positive food effect.

89. The pharmaceutical composition for use according to claim 88, wherein the positive food effect is measured in terms of C_{max}, AUC, or combinations thereof of the compound of Formula (I) when comparing oral administration of the pharmaceutical composition in the fed and fasting states.

90. The pharmaceutical composition for use according to any one of claims 82-89, wherein the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

91. The pharmaceutical composition for use according to any one of claims 82-90, wherein the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

92. The pharmaceutical composition for use according to any one of claims 82-89, wherein the ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

93. The pharmaceutical composition for use according to any one of claims 82-89 and 92, wherein the ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

94. The pharmaceutical composition for use according to any one of claims 62-93, wherein the pharmaceutical composition comprises about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

95. The pharmaceutical composition for use according to any one of claims 62-93, wherein the pharmaceutical composition comprises about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

96. The pharmaceutical composition for use according to any one of claims 62-93, wherein the pharmaceutical composition comprises about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

97. The pharmaceutical composition for use according to any one of claims 62-93, wherein the pharmaceutical composition comprises about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

98. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

99. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises

administering a daily dose of the pharmaceutical composition comprising about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

100. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

101. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

102. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 150 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

103. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering a daily dose of the pharmaceutical composition comprising about 200 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

104. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering the pharmaceutical composition twice daily in a dose of about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

105. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering the pharmaceutical composition twice daily in a dose of about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

106. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering the pharmaceutical composition twice daily in a dose of about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

107. The pharmaceutical composition for use according to any one of claims 62-93, wherein the method comprises administering the pharmaceutical composition twice daily in a dose of about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on the weight of the free base.

108. The pharmaceutical composition for use according to any one of claims 62-107, wherein the subject is concurrently receiving a dose of a glucocorticoid.

109. The pharmaceutical composition for use according to claim 108, wherein the glucocorticoid is selected from cortisol (hydrocortisone), cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, fludrocortisone acetate, and deoxycorticosterone acetate.

110. The pharmaceutical composition for use according to claim 108 or 109, wherein the glucocorticoid is cortisol (hydrocortisone).

111. The pharmaceutical composition for use according to claim 108 or 109, wherein the glucocorticoid is cortisone.

112. The pharmaceutical composition for use according to claim 108 or 109, wherein the glucocorticoid is prednisone.

113. The pharmaceutical composition for use according to any one of claims 108-112, wherein the glucocorticoid dose is measured in hydrocortisone equivalents.

114. The pharmaceutical composition for use according to any one of claims 108-113, wherein the glucocorticoid dose is measured as a multiple of the upper limit of normal of physiologic dosing in hydrocortisone equivalents.

115. The pharmaceutical composition for use according to any one of claims 108-114, wherein the glucocorticoid dose is a physiologic dose as measured after a time period of administration of the pharmaceutical composition.

116. The pharmaceutical composition for use according to any one of claims 108-114, wherein the glucocorticoid dose is a physiologic dose of about 4 to about 12 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition.

117. The pharmaceutical composition for use according to any one of claims 108-114, wherein the glucocorticoid dose is a physiologic dose of about 4 to about 9 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition.

118. The pharmaceutical composition for use according to any one of claims 108-114, wherein the glucocorticoid dose is a physiologic dose that is less than about 8 mg/m^2/day as measured after a time period of administration of the pharmaceutical composition.

119. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by about 10% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition

120. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by about 20% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

121. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by about 30% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

122. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by about 40% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

123. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

124. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by about 60% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

125. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by about 70% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

126. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by less than about 20% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

127. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose of the subject is reduced by about 20% to about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

128. The pharmaceutical composition for use according to any one of claims 108-118, wherein the glucocorticoid dose

SPRUCE – EXHIBIT 2010
Neurocrine Biosciences, Inc. v. Spruce Biosciences, Inc. PGR2026-00059 2265

of the subject is reduced by greater than about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

129. The pharmaceutical composition for use according to any one of claims 62-128, wherein the level of 17-hydroxyprogesterone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the pharmaceutical composition.

130. The pharmaceutical composition for use according to any one of claims 62-128, wherein the level of 17-hydroxyprogesterone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the pharmaceutical composition.

131. The pharmaceutical composition for use according to any one of claims 62-128, wherein the level of 17-hydroxyprogesterone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

132. The pharmaceutical composition for use according to any one of claims 62-128, wherein the level of 17-hydroxyprogesterone is within normal limits after a time period of administration of the pharmaceutical composition.

133. The pharmaceutical composition for use according to any one of claims 62-132, wherein the level of adrenocorticotropic hormone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

134. The pharmaceutical composition for use according to any one of claims 62-132, wherein the level of adrenocorticotropic hormone is reduced by at least about 40% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

135. The pharmaceutical composition for use according to any one of claims 62-132, wherein the level of adrenocorticotropic hormone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

136. The pharmaceutical composition for use according to any one of claims 62-132, wherein the level of adrenocorticotropic hormone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

137. The pharmaceutical composition for use according to any one of claims 62-128, wherein the level of adrenocorticotropic hormone is within normal limits after a time period of administration of the pharmaceutical composition.

138. The pharmaceutical composition for use according to any one of claims 62-137, wherein the level of androstenedione is reduced by at least about 25% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

139. The pharmaceutical composition for use according to any one of claims 62-137, wherein the level of androstenedione is reduced by at least about 30% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

140. The pharmaceutical composition for use according to any one of claims 62-137, wherein the level of androstenedione is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

141. The pharmaceutical composition for use according to any one of claims 62-137, wherein the level of androstenedione is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

142. The pharmaceutical composition for use according to any one of claims 62-137, wherein the level of androstenedione is within normal limits after a time period of administration of the pharmaceutical composition.

143. The pharmaceutical composition for use according to any one of claims 62-142, wherein the level of testosterone is reduced by at least about 25% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

144. The pharmaceutical composition for use according to any one of claims 62-142, wherein the level of testosterone is reduced by at least about 30% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

145. The pharmaceutical composition for use according to any one of claims 62-142, wherein the level of testosterone is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

146. The pharmaceutical composition for use according to any one of claims 62-142, wherein the level of testosterone is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

147. The pharmaceutical composition for use according to any one of claims 62-142, wherein the level of testosterone is within normal limits after a time period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

148. The pharmaceutical composition for use according to any one of claims 62-128, wherein the level of 17-hydroxyprogesterone is reduced by at least about 50% and the level of androstenedione is reduced by at least about 50% after a time period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone and the level of androstenedione is relative to the level of 17-hydroxyprogesterone and the level of androstenedione prior to administration of the pharmaceutical composition.

149. The pharmaceutical composition for use according to any one of claims 62-128, wherein the level of 17-hydroxyprogesterone is less than about 1.5 times the upper limit of normal and the level of androstenedione is less than about 1.5 times the upper limit of normal after a time period of administration of the pharmaceutical composition.

150. The pharmaceutical composition for use according to any one of claims 62-128, wherein the level of 17-hydroxyprogesterone is within normal limits and the level of androstenedione is within normal limits after a time period of administration of the pharmaceutical composition.

151. The pharmaceutical composition for use according to any one of claims 108-150, wherein the subject exhibits a decrease in glucocorticoid burden after a time period of administration of the pharmaceutical composition, wherein the decrease in glucocorticoid burden is relative to the glucocorticoid burden prior to administration of the pharmaceutical composition.

152. The pharmaceutical composition for use according to claim 151, wherein one or more symptoms of glucocorticoid burden selected from quality of life, fatigue, sleep, insulin resistance, glucose tolerance, glucose control, dyslipidemia, hyperlipidemia, bone mineral density, bone turnover, fat mass, weight, central obesity, blood pressure, hirsutism severity, menstrual cyclicity, control of testicular adrenal rest tumor and fertility, is improved after a time period of administration of the pharmaceutical composition, wherein the improvement in the one or more symptoms is relative to the status of the one or more symptoms prior to administration of the pharmaceutical composition.

153. The pharmaceutical composition for use according to any one of claims 115-152, wherein the time period of administration is at least about 4 weeks.

154. The pharmaceutical composition for use according to any one of claims 115-152, wherein the time period of administration is at least about 24 weeks.

155. The pharmaceutical composition for use according to any one of claims 115-152, wherein the time period of administration is at least about one year.

156. The pharmaceutical composition for use according to any one of claims 62-155, wherein the subject is a pediatric subject.

157. The pharmaceutical composition for use according to claim 156, wherein the pediatric subject is less than or equal to six years old.

158. The pharmaceutical composition for use according to claim 156, wherein the pediatric subject is greater than six years old and less than eleven years old.

159. The pharmaceutical composition for use according to claim 156, wherein the pediatric subject is greater than ten years old and less than fifteen years old.

160. The pharmaceutical composition for use according to claim 156, wherein the pediatric subject is greater than fourteen years old and less than nineteen years old.

161. The pharmaceutical composition for use according to any one of claims 62-155, wherein the subject is an adult subject.

162. The pharmaceutical composition for use according to any one of claims 161, wherein the adult subject is over eighteen years old.

163. The pharmaceutical composition for use according to any one of claims 62-162, wherein the subject is female.

164. The pharmaceutical composition for use according to any one of claims 62-162, wherein the subject is male.

165. The pharmaceutical composition for use according to any one of claims 62-164, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a hydrochloric acid salt or p-toluenesulfonic acid salt.

166. The pharmaceutical composition for use according to any one of claims 62-164, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a p-toluenesulfonic acid crystalline salt.



1000μgA/mL in 0.5wt% SIF in PBS, pH 6.5
SAMPLE 2
SAMPLE 6
SAMPLE 4
SAMPLE 7
CONTROL
Formula (I) (μg/mL)
Time (min)
0
100
200
300
400
500
600
700
800
900
0
30
60
90
1200

FIG. 1



Receiver
Holder
Donor
Permeate Tube
Permeate Tube Stir Bar
Screen
Membrane (attached to Permeate Tube)
"Stop" for Permeated Tube
Outer Reservoir

FIG. 2



G: 200μgA/mL in 0.01N HCl
IB: 100μgA/mL in 0.5wt% SIF in PBS, pH 6.5
Formula (I)
Sample 2
Sample 1
Sample 6
Sample 5
Sample 4
Ref. Formulation 2
Ref. Formulation 3
Ref. Formulation 1
Formula (I) (μg/mL)
240
220
200
180
160
140
120
100
80
60
40
20
-30
0
30
60
90
1200
Time (min)

FIG. 3



Dose: 1mg/mL GB/IB 0.5%SIF
Formula (I)
Sample 4
Sample 2
Receiver (µg/mL)
Flux (µg min-1 cm-2)
Time (min)
0
50
100
150
200
250
300
350
400
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
0
100
200
300
400
500
600

FIG. 4



Components
Unit Operations, Equipment Class and Target Process Parameters
In Process Controls and Tests
Acetone
DISPENSING
Solvent addition
Formula (I)
DISPENSING
& ADDITION
Mixing
30 minutes (Before addition of next component)
15° C to 27° C (Solution temperature range
Solution should be clear and free of undissolved solids. Protect from light.
Kollidon VA64
DISPENSING
& ADDITION
Mixing
30 minutes (Before addition of next component)
15° C to 27° C (Solution temperature range
Solution should be clear and free of undissolved solids. Protect from light.

FIG. 5



SPRAY-DRYING
150 kg/hr Drying-Gas Flow-Rate Spray Dryer
PRE-HEATING
System Gas Flow: 1850 g/min (1550-2150 g/min) Dryer Inlet temp.: 75°C (60-90° C)
WARM-UP
System Gas Flow: 1850 g/min (1550-2150 g/min)
Dryer Inlet Temp: 75° C (60-90° C)
Dryer Inlet Temp: 35° C (32-38° C)
Feed Pressure: 250 psig (200-300 psig)
Feed Rate: 100 g/min (80-120 g/min)
SPRAY-DRYING
150 kg/hr Drying-Gas Flow-Rate Spray Dryer
SOLUTION
System Gas Flow: 1850 g/min (1550-2150 g/min)
Dryer Inlet Temp: 75° C (60-90° C)
Dryer Inlet Temp: 35° C (32-38° C)
Feed Pressure: 280 psig (230-330 psig)
Feed Rate: 110 g/min (90-130 g/min)
SHUT DOWN
System Gas Flow: 1850 g/min (1550-2150 g/min)
Dryer Inlet Temp: 75° C (60-90° C)
Dryer Inlet Temp: 35° C (32-38° C)
Feed Pressure: 250 psig (200-300 psig)
Feed Rate: 100 g/min (80-120 g/min)
SECONDARY DRYING
Convection Tray Dryer
CONDITIONS
Temperature: 40° C (±5 °C)
Relative Humidity: 15% (±10%)
Bed Depth: ≤ 2.5 cm
Drying Time: 24 hrs
Target Residual Acetone: <0.5 wt% (5000 ppm) Under amber light

FIG. 5 (cont)



Cohort 1
Ref Form (fasted)
Ref Form (fed)
Test Form 1 (fasted)
Test Form 1 (fed)
Test Form 2 (fasted)
Test Form 2 (fed)
Mean+ SD Conc (ng/mL)
10000
1000
100
10
1
0
6
12
18
24
30
36
42
48
Time (hr)

FIG. 6A



Cohort 2
Ref Form (fasted)
Ref Form (fed)
Test Form 3 (fasted)
Test Form 3 (fed)
Test Form 4 (fasted)
Test Form 4 (fed)
Mean ± SD Conc (ng/mL)
10000
1000
100
10
1
0
6
12
18
24
30
36
42
48
Time (hr)

FIG. 6B



Screening Period
Study Drug Treatment Periods
Follow-Up Period
Days -28 to -1
Treatment Period 1
Fasted or Fed
Days 1 and 2
21 days between doses
Treatment Period 2
Fasted or Fed
Days 1 and 2
21 days
Day 22 (Final Study Visit)

FIG. 7



Plasma Concentration (ng/mL)
2000
1500
1000
500
0
0
4
8
12
16
24
36
Scheduled Time Postdose (Hours)
Treatment Fasted Fed

FIG. 8A



Plasma Concentration (ng/mL)
1000
100
10
1
0
4
8
12
16
24
36
Scheduled Time Postdose (Hours)
Treatment
Fasted
Fed

FIG. 8B



Treatment Sequence Fasted/Fed
Treatment Sequence Fed/Fasted
Plasma AUC (0-last) (ng*hr/mL)
25000
20000
15000
10000
5000
Fasted
Fed
Fed
Fasted
Treatment

FIG. 9A



Treatment Sequence Fasted/Fed
Treatment Sequence Fed/Fasted
Plasma AUC (0-last) (ng*hr/mL)
25000
20000
15000
10000
5000
Fasted
Fed
Fed
Fasted
Treatment

FIG. 9B




Treatment Sequence Fasted/Fed
Treatment Sequence Fed/Fasted
Plasma Cmax (ng/mL)
2000
1500
1000
500
Fasted
Fed
Fed
Fasted
Treatment

FIG. 9C



a SDD=Compound of Formula (I) spray dried dispersion (suspension or capsule formulation).
b Reference formulation=Compound of Formula (I) encapsulated, lipid semi-solid.

FIG. 10




FIG. 11

a Visit on Days 21 (+3 days), 28 (+3 days), and 35 (+3 days); final study visit on Day 49 (+7 days) or early termination.
PD = pharmacodynamic.



ACTH -- Average All Subjects
Baseline
Day 1
Day 14
Concentration (pg/mL)
450
400
350
300
250
200
150
100
50
0
predose
1hr
2hr
3hr
4hr
6hr
8hr
10hr
12hr
14hr
16hr
20hr
24hr
Morning
Window
6 – 10 AM

FIG. 12A



17-OHP -- Average All Subjects
Baseline
Day 1
Day 14
Concentration (pg/mL)
7000
6000
5000
4000
3000
2000
1000
0
predose
1hr
2hr
3hr
4hr
6hr
8hr
10hr
12hr
14hr
16hr
20hr
24hr
Morning
Window
6 – 10 AM

FIG. 12B



Androstenedione -- Average All Subjects
Baseline
Day 1
Day 14
Concentration (pg/mL)
350
300
250
200
150
100
50
0
predose
1hr
2hr
3hr
4hr
6hr
8hr
10hr
12hr
14hr
16hr
20hr
24hr
Morning
Window
6 – 10 AM

FIG. 13A



Testosterone -- Average All Subjects
Baseline
Day 1
Day 14
Concentration (pg/mL)
300
250
200
150
100
50
0
predose
1hr
2hr
3hr
4hr
6hr
8hr
10hr
12hr
14hr
16hr
20hr
24hr
Morning
Window
6 – 10 AM

FIG. 13B



ACTH Morning Window
predose
8hr
10hr
12hr
ACTH (pg/ml)
450
400
350
300
250
200
150
100
50
0
Baseline
Day 1
Day 14

FIG. 14A



ACTH Mean Morning Window
Predose
Mean Morning
ACTH (pg/ml)
350
300
250
200
150
100
50
0
Baseline
Day 1
Day 14

FIG. 14B



17-OHP Morning Window
predose
8hr
10hr
12hr
17-OHP (ng/dl)
7000
6000
5000
4000
3000
2000
1000
0
Baseline
Day 1
Day 14

FIG. 15A



17-OHP Mean Morning Window
Predose
Mean Morning
17-OHP (ng/dl)
6000
5000
4000
3000
2000
1000
0
Baseline
Day 1
Day 14

FIG. 15B



Androstenedione Morning Window
predose
8hr
10hr
12hr
Androstenedione (ng/dl)
350
300
250
200
150
100
50
0
Baseline
Day 1
Day 14

FIG. 16A



Androstenedione Mean Morning Window
Predose
Mean Morning
Androstenedione (ng/dl)
350
300
250
200
150
100
50
0
Baseline
Day 1
Day 14

FIG. 16B



Baseline
Day 14
ACTH (pg/mL)
500
450
400
350
300
250
200
150
100
50
0
Predose
1
2
3
4
6
8
10
12
14
16
18
20
24
Scheduled Time Postdose (Hours)

FIG. 17A



Baseline
Day 14
17-OHP (ng/dL)
9000
7500
6000
4500
3000
1500
0
Predose
1
2
3
4
6
8
10
12
14
16
18
20
24
Scheduled Time Postdose (Hours)

FIG. 17B



Baseline
Day 14
ULN, female
ULN, male
Androstenedione (ng/dL)
450
400
350
300
250
200
150
100
50
0
Predose 1
2
3
4
6
8
10
12
14
16
18
20
24
Scheduled Time Postdose (Hours)

FIG. 17C



Baseline
Day 14
ACTH (pg/mL)
550
500
450
400
350
300
250
200
150
100
50
0
Predose
1
2
3
4
6
8
10
12
14
16
18
20
24
Scheduled Time Postdose (Hours)

FIG. 18A



Baseline
Day 14
17-OHP (ng/dL)
19500
18000
16500
15000
13500
12000
10500
9000
7500
6000
4500
3000
1500
0
Predose
1
2
3
4
6
8
10
12
14
16
18
20
24
Scheduled Time Postdose (Hours)

FIG. 18B



Baseline
Day 14
ULN, female
ULN, male
Androstenedione (ng/dL)
1600
1400
1200
1000
800
600
400
200
0
Predose 1 2 3 4 6 8 10 12 14 16 18 20 24
Scheduled Time Postdose (Hours)

FIG. 18C

2300



Baseline
Day 14
ACTH (pg/mL)
700
650
600
550
500
450
400
350
300
250
200
150
100
50
0
Predose 1 2 3 4 5 6 7 9 11 13 15 17 19 23 24 27
ions: Cohort 3, 100 mg with Evening Meal (N=6)

FIG. 19A



Baseline
Day 14
17-OHP (ng/dL)
9000
7500
6000
4500
3000
1500
0
Predose 1 2 3 4 5 6 7 9 11 13 15 17 19 23 24 27
Scheduled Time Postdose (Hours)

FIG. 19B



Androstenedione (ng/dL)
500
450
400
350
300
250
200
150
100
50
0
Predose 1 2 3 4 5 6 7 9 11 13 15 17 19 23 24 27
Scheduled Time Postdose (Hours)
ULN, female
ULN, male
Baseline
Day 14

FIG. 19C




Manufacturing Process Flow Diagram:
Components
Unit Operations, Equipment Class and Target Process Parameters
In Process Controls and Tests
Labrafac™ Lipophile WL 1349
Labrafac™ PG
Gelucire® 44/14
Kolliphor® TPGS
HEATING
55° C
(hotplate)
MIXING
Mix until visual homogeneity is achieved
(paddle maker)
Visual confirmation of homogeneity
Formula (I) free base
MIXING
Mix until fully dissolved
Visual confirmation of dissolution
ENCAPSULATION
Hibar P/450 Encapsulator
Adjust dosing screw to target fill range
Target Weight: 500 mg
Mean Weight Limits
WL target ±3.0%
Individual Weight Limits
WL target ±5.0%
Manual closing of capsules
Every 30 min
Closed Length
Fill weight (mean and individual)
Gelatin Powder
Purified Water
MIXING
<Paddle mixer>
BANDING
Automated capsule sealing machine
600° C
Visual Inspection
WEIGHT SORTING
Automated weight sorter
Target weight ± 5.0%
Weight
Release Testing

FIG. 20



* Can be contained in hydro-alcoholic solution ready for manufacturing use

FIG. 21



Components
Unit Operations, Equipment Class, and Target Process Parameters
In Process Controls and Tests
25% Compound of Formula (I): Copovidone SDD Calcium Silicate
Microcrystalline Cellulose Mannitol Croscarmellose Sodium
Sodium Stearyl Fumarate
Blending
Bin Blender
900 rotations at 15 RPM
Screening
Sieve screen
25 Mesh Screen
Blending
Bin Blender
300 rotations at 15 RPM
Screening
Comil 197
Screen Size 062G
Blending
Bin Blender
300 rotations at 15 RPM
IPC
Density
Particle Size

FIG. 22A



Components
Unit Operations, Equipment Class, and Target Process Parameters
In Process Controls and Tests
Roller Compaction
Gerteis Mini-Pactor
Roll Design: Knurled/smooth
Roll gap: 2-3 mm
Roll speed: 2-8 RPM
Roll Force: TBD
Milll screen size: 1.0 mm
Blending
Bin Blender
300 rotations at 15 RPM
Sachet Fill
1500 mg of granulation for 50 mg sachet
IPC
Density
Particle Size
Release Testing
Per Specification

FIG. 22B



Components
Unit Operations, Equipment Class, and Target Process Parameters
In Process Controls and Tests
75% of Total Medium Chain Triglycerides Saccharin
Mix with overhead Mixer to create a medium vortex (This step may require temperature control, studies on-going)
Butylated Hydroxytoluene Orange Flavor
Mix with overhead Mixer to create a medium vortex
Compound of Formula (I)
Mix with overhead Mixer to create a medium vortex
Remaining 25% of Medium Chain Triglycerides
Mix with overhead Mixer to create a medium vortex
IPC
Label Claim Check
Bottle Filling
IPC
Fill Weight Checks
Release Testing
See Specification

FIG. 23



Components
Unit Operations, Equipment Class, and Target Process Parameters
In Process Controls and Tests
75% of Total Medium Chain Triglycerides
Saccharin
PEG-5 Oleate
Mix with overhead Mixer to create a medium vortex
(This step may require temperature control, studies on-going)
Butylated Hydroxytoluene
Orange Flavor
Mix with overhead Mixer to create a medium vortex
Compound of Formula (I)
Mix with overhead Mixer to create a medium vortex
Remaining 25% of Medium Chain Triglycerides
Mix with overhead Mixer to create a medium vortex
IPC
Label Claim Check
Bottle Filling
IPC
Fill Weight Checks
Release Testing
See Specification

FIG. 24



Intensity (cps)
4e+004
3e+004
2e+004
1e+004
0e+000
10
20
30
40
2-theta (deg)

FIG. 25



84.41°C
71.94J/g
Heat Flow (W/g)
Temperature (°C)
Exo Up
Universal V4.5A TA Instruments
2
0
-2
-4
-6
0
50
100
150
200
250
300

FIG. 26



Intensity (cps)
2.5e+004
2.0e+004
1.5e+004
1.0e+004
5.0e+003
0.0e+000
10
20
30
40
2-theta (deg)

FIG. 27



_TGA_962018
_DSC_962018
Weight Loss: 0.016 mg
Weight Percent Loss: 0.457%
Enthalpy (normalized): 22.203 J/g
Onset x: 155.71°C
Weight (%)
Heat Flow A° (mW)
Temperature (°C)
110
100
90
80
70
60
2
1
0
-1
-2
0
50
100
150
200
250
300

FIG. 28

Europäisches Patentamt
European Patent Office
Office européen des brevets

EUROPEAN SEARCH REPORT

Application Number
EP 21 21 3854

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2015/112642 A1 (NEUROCRINE BIOSCIENCES INC [US]) 30 July 2015 (2015-07-30) * SSR-125543; page 14 * * claims 1-21 *	1-166	INV. A61K9/00 A61K31/395 A61K31/426 A61K31/573 A61P5/00
A	WO 2010/125414 A1 (SANOFI-AVENTIS [FR]; PARKANYI ZSOLT [HU] ET AL.) 4 November 2010 (2010-11-04) * the whole document *	1-166	
A	WO 2018/219804 A1 (BAYER PHARMA AG [DE]) 6 December 2018 (2018-12-06) * the whole document *	1-166	

TECHNICAL FIELDS SEARCHED (IPC)
A61K

1 The present search report has been drawn up for all claims

Place of search	Date of completion of the search	Examiner
Munich	14 March 2022	Schüle, Stefanie

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO FORM 1503 03.82 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO. EP 21 21 3854

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-03-2022

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015112642 A1	30-07-2015	AU 2015209452 A1	04-08-2016
		AU 2020207774 A1	06-08-2020
		CA 2936974 A1	30-07-2015
		CN 106102740 A	09-11-2016
		CN 111228274 A	05-06-2020
		EP 3096756 A1	30-11-2016
		IL 246783 A	31-10-2021
		JP 6585625 B2	02-10-2019
		JP 6936825 B2	22-09-2021
		JP 2017503030 A	26-01-2017
		JP 2019081814 A	30-05-2019
		JP 2020138978 A	03-09-2020
		JP 2022010260 A	14-01-2022
		KR 20160106176 A	09-09-2016
		KR 20210064407 A	02-06-2021
		NZ 722122 A	26-06-2020
		RU 2016133972 A	05-03-2018
		RU 2020112197 A	21-05-2020
		US 2017020877 A1	26-01-2017
		US 2019231781 A1	01-08-2019
		US 2021137926 A1	13-05-2021
		US 2021361659 A1	25-11-2021
		WO 2015112642 A1	30-07-2015
WO 2010125414 A1	04-11-2010	AR 076478 A1	15-06-2011
		AU 2010243362 A1	17-11-2011
		BR PI1014627 A2	25-08-2015
		CA 2760384 A1	04-11-2010
		CN 102414185 A	11-04-2012
		EP 2424848 A1	07-03-2012
		JP 5608221 B2	15-10-2014
		JP 2012525368 A	22-10-2012
		KR 20120014005 A	15-02-2012
		MY 152269 A	15-09-2014
		RU 2011148584 A	10-06-2013
		SG 175829 A1	29-12-2011
		TW 201105640 A	16-02-2011
		US 2012083608 A1	05-04-2012
		UY 32594 A	30-11-2010
		WO 2010125414 A1	04-11-2010
WO 2018219804 A1	06-12-2018	NONE	

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6586456 B **[0006]**
- US 8314249 B **[0006]**

Non-patent literature cited in the description

- **TRAKAKIS et al.** An update to 21-hydroxylase deficient congenital adrenal hyperplasia. *Gynecol. Endocrinol.,* 2010, vol. 26 (1), 63-71 **[0002]**
- **HERTZBERG et al.** Birth prevalence rates of newborn screening disorders in relation to screening practices in the United States. *J. Pediatr.,* 2011, vol. 159 (4), 555-560 **[0002]**
- **CHENG ; SPEISER.** Treatment outcomes in congenital adrenal hyperplasia. *Adv. Pediatr.,* 2012, vol. 59 (1), 269-281 **[0003]**
- **MERKE ; POPPAS.** Management of adolescents with congenital adrenal hyperplasia. *Lancet Diabetes Endocrinol,* 2013, vol. 1 (4), 341-352 **[0003]**
- **ELNECAVE et al.** Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency. *J. Pediatr. Endocrinol. Metab.,* 2008, vol. 21 (12), 1155-1162 **[0004]**
- **KING et al.** Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. *J. Clin. Endocrinol. Metab.,* 2006, vol. 91 (3), 865-869 **[0004]**
- **MIGEON ; WISNIEWSKI.** Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations. *Endocrinol. Metab. Clin. North Am.,* 2001, vol. 30 (1), 193-206 **[0004]**
- **WHITE et al.** *J. Pediatr.,* 2013, vol. 163, 10-12 **[0118]**
- **SPEISER et al.** *Int. J. Pediatr. Endocrinol.,* 2010, vol. 2010, 494173 **[0118]**
- **KIM et al.** *Semin. Reprod. Med.,* 2009, vol. 27 (4), 316-21 **[0122]**
- **FINKIELSTAIN et al.** *J. Clin. Endocrinol Metab.,* 2012, vol. 97 (12), 4429-38 **[0122]**
- **ELNECAVE et al.** *J. Pediatr. Endocrinol. Metab.,* 2008, vol. 21, 1155-62 **[0123]**
- **KING et al.** *J. Clin. Endocrinol. Metab.,* 2006, vol. 91 (3), 8656-59 **[0123]**
- **MIGEON et al.** *Endocrinol. Metab. Clin. North Am.,* 2001, vol. 30, 193-206 **[0123]**
- **SPEISER, P.W. et al.** *J. Clin. Endocrinol Metab.,* November 2018, vol. 103 (11), 1-46 **[0123]**
- **VALE et al.** *Science,* 1981, vol. 213, 1394-1397 **[0124]**
- Goodman and Gilman's: The Pharmacological Basis of Therapeutics. The McGraw-Hill Companies, 2010 **[0132]**
- **BERHMAN et al.** Textbook of Pediatrics. W.B. Saunders Company, 1996 **[0135]**
- **RUDOLPH et al.** Rudolph's Pediatrics. McGraw-Hill, 2002 **[0135]**
- **AVERY et al.** Pediatric Medicine. Williams & Wilkins, 1994 **[0135]**
- **ORAY, M. et al.** Long-term effect of glucocorticoids. *Expert Opinion on Drug Safety,* 2016 **[0159]**
- Perry's Chemical Engineering Handbook. McGraw-Hill Book Co, 1984 **[0337]**
- **MARSHALL.** Atomization and Spray-Drying. *Chem. Eng. Prog. Monogr. Series 2,* 1954, vol. 50 **[0337]**
- **STEWART et al.** *Mol. Pharm.,* 2017, vol. 14, 2032-2046 **[0401]**

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 487/04, A61K 31/505 // (C07D 487/04, 239:00, 231:00) (C07D 487/04, 251:00, 231:00) (C07D 487/04, 249:00, 239:00) (C07D 487/04, 251:00, 249:00)

A1

(11) International Publication Number: **WO 98/03510**

(43) International Publication Date: 29 January 1998 (29.01.98)

(21) International Application Number: PCT/US97/13072

(22) International Filing Date: 23 July 1997 (23.07.97)

(30) Priority Data:

60/023,290	24 July 1996 (24.07.96)	US
08/686,047	24 July 1996 (24.07.96)	US
Not furnished	23 July 1997 (23.07.97)	US

(71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).


(72) Inventors: ARVANITIS, Argyrios, Georgious; 101 Willow Glen Drive, Kennett Square, PA 19348 (US). CHORVAT, Robert, John; 1193 Killarney Lane, West Chester, PA 19382 (US).

(74) Agent: FERGUSON, Blair, Q.; The du Pont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).


(81) Designated States: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: AZOLO TRIAZINES AND PYRIMIDINES



(I)



(II)

(57) Abstract

Corticotropin releasing factor (CRF) antagonists of formula (I) or (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

TITLE

AZOLO TRIAZINES AND PYRIMIDINES

FIELD OF THE INVENTION

This invention relates a treatment of psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress, by administration of certain [1,5-*a*]-pyrazolo-1,3,5-triazines, [1,5-*a*]-1,2,3-triazolo-1,3,5-triazines, [1,5-*a*]-pyrazolo-pyrimidines and [1,5-*a*]-1,2,3-triazolo-pyrimidines.

BACKGROUND OF THE INVENTION

Corticotropin releasing factor (herein referred to as CRF), a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin(POMC)-derived peptide secretion from the anterior pituitary gland [J. Rivier et al., *Proc. Nat. Acad. Sci. (USA)* 80:4851 (**1983**); W. Vale et al., *Science* 213:1394 (**1981**)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., *Rec. Prog. Horm. Res.* 39:245 (**1983**); G.F. Koob, *Persp. Behav. Med.* 2:39 (**1985**); E.B. De Souza et al., *J.*

Neurosci. 5:3189 (**1985**)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J.E. Blalock, *Physiological Reviews* 69:1 (**1989**); J.E. Morley, *Life Sci.* 41:527 (**1987**)].

Clinical data provide evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E.B. De Souza, *Hosp. Practice* 23:59 (**1988**)].

In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [C.B. Nemeroff et al., *Science* 226:1342 (**1984**); C.M. Banki et al., *Am. J. Psychiatry* 144:873 (**1987**); R.D. France et al., *Biol. Psychiatry* 28:86 (**1988**); M. Arato et al., *Biol Psychiatry* 25:355 (**1989**)]. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [C.B. Nemeroff et al., *Arch. Gen. Psychiatry* 45:577 (**1988**)]. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P.W. Gold et al., *Am J. Psychiatry* 141:619 (**1984**); F. Holsboer et al., *Psychoneuroendocrinology* 9:147 (**1984**); P.W. Gold et al., *New Eng. J. Med.* 314:1129 (**1986**)]. Preclinical studies in rats and non-human primates provide additional support for the

hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R.M. Sapolsky, *Arch. Gen. Psychiatry* 46:1047 (**1989**)]. There is preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain [Grigoriadis et al., *Neuropsychopharmacology* 2:53 (**1989**)].

There has also been a role postulated for CRF in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine / non-benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models [D.R. Britton et al., *Life Sci.* 31:363 (**1982**); C.W. Berridge and A.J. Dunn *Regul. Peptides* 16:83 (**1986**)]. Preliminary studies using the putative CRF receptor antagonist a-helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C.W. Berridge and A.J. Dunn *Horm. Behav.* 21:393 (**1987**), *Brain Research Reviews* 15:71 (**1990**)]. Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test [K.T. Britton et al., *Psychopharmacology* 86:170 (**1985**); K.T. Britton et al., *Psychopharmacology* 94:306 (**1988**)] and in the acoustic startle test [N.R. Swerdlow et al., *Psychopharmacology* 88:147 (**1986**)] in rats. The benzodiazepine receptor antagonist (Ro15-1788), which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-


dependent manner while the benzodiazepine inverse agonist (FG7142) enhanced the actions of CRF [K.T. Britton et al., *Psychopharmacology* 94:306 (**1988**)].

The mechanisms and sites of action through which the standard anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. It has been hypothesized however, that they are involved in the suppression of the CRF hypersecretion that is observed in these disorders. Of particular interest is that preliminary studies examining the effects of a CRF receptor antagonist (α-helical CRF_{9-41}) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for review see G.F. Koob and K.T. Britton, In: *Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide*, E.B. De Souza and C.B. Nemeroff eds., CRC Press p221 (1990)].

Several publications describe corticotropin releasing factor antagonist compounds and their use to treat psychiatric disorders and neurological diseases. Examples of such publications include DuPont Merck PCT application US94/11050 , Pfizer WO 95/33750, Pfizer WO 95/34563, Pfizer WO 95/33727 and Pfizer EP 0778 277 A1.


Insofar as is known, [1,5-*a*]-pyrazolo-1,3,5-triazines, [1,5-*a*]-1,2,3-triazolo-1,3,5-triazines, [1,5-*a*]-pyrazolo-pyrimidines and [1,5-*a*]-1,2,3-triazolo-pyrimidines, have not been previously reported as corticotropin releasing factor antagonist compounds useful in the treatment of psychiatric disorders and neurological diseases. However, there have been publications which teach some of these compounds for other uses.

For instance, EP 0 269 859 (Ostuka, 1988) discloses pyrazolotriazine compounds of the formula




where R^1 is OH or alkanoyl, R^2 is H, OH, or SH, and R^3 is an unsaturated heterocyclic group, naphthyl or substituted phenyl, and states that the compounds have xanthine oxidase inhibitory activity and are useful for treatment of gout.

EP 0 594 149 (Ostuka, 1994) discloses pyrazolotriazine and pyrazolopyrimidine compounds of the formula




where A is CH or N, R^0 and R^3 are H or alkyl, and R^1 and R^2 are H, alkyl, alkoxyl, alkylthio, nitro, etc., and states that the compounds inhibit androgen and are useful in treatment of benign prostatic hypertrophy and prostatic carcinoma.

US 3,910,907 (ICI, 1975) discloses pyrazolotriazines of the formula:




where R1 is CH_3, C_2H_5 or C_6H_5, X is H, C_6H_5, m-$CH_3C_6H_4$, CN, COOEt, Cl, I or Br, Y is H, C_6H_5, o-$CH_3C_6H_4$, or p-$CH_3C_6H_4$, and Z is OH, H, CH_3, C_2H_5, C_6H_5, n-C_3H_7, i-C_3H_7, SH, SCH_3, NHC_4H_9, or $N(C_2H_5)_2$, and states that the compounds are c-AMP phosphodiesterase inhibitors useful as bronchodilators.

US 3,995,039 discloses pyrazolotriazines of the formula:




where R^1 is H or alkyl, R^2 is H or alkyl, R^3 is H, alkyl, alkanoyl, carbamoyl, or lower alkylcarbamoyl, and R is pyridyl, pyrimidinyl, or pyrazinyl, and states that the compounds are useful as bronchodilators.

US 5,137,887 discloses pyrazolotriazines of the formula




where R is lower alkoxy, and teaches that the compounds are xanthine oxidase inhibitors and are useful for treatment of gout.

US 4,892,576 discloses pyrazolotriazines of the formula




where X is O or S, Ar is a phenyl, naphthyl, pyridyl or thienyl group, R_6-R_8 are H, alkyl, etc., and R_9 is H, alkyl, phenyl, etc. The patent states that the compounds are useful as herbicides and plant growth regulants.

US 5,484,760 and WO 92/10098 discloses herbicidal compositions containing, among other things, a herbicidal compound of the formula




where A can be N, B can be CR_3, R_3 can be phenyl or substituted phenyl, etc., R is $-N(R_4)SO_2R_5$ or $-SO_2N(R_6)R_7$ and R_1 and R_2 can be taken together to form




where X, Y and Z are H, alkyl, acyl, etc. and D is O or S.

US 3,910,907 and Senga et al., J. Med. Chem., 1982, 25, 243-249, disclose triazolotriazines cAMP phosphodiesterase inhibitors of the formula




where Z is H, OH, CH_3, C_2H_5, C_6H_5, n-C_3H_7, iso-C_3H_7, SH, SCH_3, NH(n-C_4H_9), or $N(C_2H_5)_2$, R is H or CH_3, and R_1 is CH_3 or C_2H_5. The reference lists eight therapeutic areas where inhibitors of cAMP phosphodiesterase could have utility: asthma, diabetes mellitus, female fertility control, male infertility, psoriasis, thrombosis, anxiety, and hypertension.

WO95/35298 (Otsuka, 1995) discloses pyrazolopyrimidines and states that they are useful as analgesics. The compounds are represented by the formula



where Q is carbonyl or sulfonyl, n is 0 or 1, A is a single bond, alkylene or alkenylene, R^1 is H, alkyl, etc., R^2 is naphthyl, cycloalkyl, heteroaryl, substituted phenyl or phenoxy, R^3 is H, alkyl or phenyl, R^4 is H, alkyl, alkoxycarbonyl, phenylalkyl, optionally phenylthio-substituted phenyl, or halogen, R^5 and R^6 are H or alkyl.


EP 0 591 528 (Otsuka,1991) discloses anti-inflammatory use of pyrazolopyrimidines represented by the formula



where R_1, R_2, R_3 and R_4 are H, carboxyl, alkoxycarbonyl, optionally substituted alkyl, cycloalkyl, or phenyl, R_5


is SR_6 or NR_7R_8, R_6 is pyridyl or optionally substituted phenyl, and R_7 and R_8 are H or optionally substituted phenyl.

Springer et al, J. Med. Chem., 1976, vol. 19, no. 2, 291-296 and Springer U.S. patents 4021,556 and 3,920,652 disclose pyrazolopyrimidines of the formula




where R can be phenyl, substituted phenyl or pyridyl, and their use to treat gout, based on their ability to inhibit xanthine oxidase.

Joshi et al., J. Prakt. Chemie, 321, 2, 1979, 341-344, discloses compounds of the formula




where R^1 is CF_3, C_2F_5, or C_6H_4F, and R^2 is CH_3, C_2H_5, CF_3, or C_6H_4F.

Maquestiau et al., Bull. Soc. Belg., vol.101, no. 2, 1992, pages 131-136 discloses a pyrazolo[1,5-*a*]pyrimidine of the formula



Ibrahim et al., Arch. Pharm. (weinheim) 320, 487-491 (1987) discloses pyrazolo[1,5-*a*]pyrimidines of the formula



where R is NH2 or OH and Ar is 4-phenyl-3-cyano-2-aminopyrid-2-yl.

Other references which disclose azolopyrimidines inclued EP 0 511 528 (Otsuka, 1992), US 4,997,940 (Dow, 1991), EP 0 374 448 (Nissan, 1990), US 4,621,556 (ICN,1997), EP 0 531 901 (Fujisawa, 1993), US 4,567,263 (BASF, 1986), EP 0 662 477 (Isagro, 1995), DE 4 243 279 (Bayer, 1994), US 5,397,774 (Upjohn, 1995), EP 0 521 622 (Upjohn, 1993), WO 94/109017 (Upjohn, 1994), J. Med. Chem., 24, 610-613 (1981), and J. Het. Chem., 22, 601 (1985).

SUMMARY OF THE INVENTION

In accordance with one aspect, the present invention provides novel compounds, pharmaceutical compositions and methods which may be used in the treatment of affective disorder, anxiety, depression, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal disease, anorexia nervosa or other feeding disorder, drug or alcohol withdrawal symptoms, drug addiction, inflammatory disorder, fertility problems, disorders, the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic, phobias, obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer, human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases such as ulcers, irritable bowel syndrome, Crohn's disease, spastic colon, diarrhea, and post operative ilius and colonic hypersensitivity associated by psychopathological disturbances or stress; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress;

stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; cardiovascular and hear related disorders including hypertension, tachycardia and congestive heart failure; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., stress induced fevers, porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; osteoporosis; psychosocial dwarfism and hypoglycemia in a mammal.

The present invention provides novel compounds which bind to corticotropin releasing factor receptors, thereby altering the anxiogenic effects of CRF secretion. The compounds of the present invention are useful for the treatment of psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in a mammal.


According to another aspect, the present invention provides novel compounds of Formulae (1) and (2) (described below) which are useful as antagonists of the corticotropin releasing factor. The compounds of the present invention exhibit activity as corticotropin releasing factor antagonists and appear to suppress CRF hypersecretion. The present invention also includes pharmaceutical compositions containing such compounds of Formulae (1) and (2), and methods of using such compounds for the suppression of CRF hypersecretion, and/or for the treatment of anxiogenic disorders.

According to yet another aspect of the invention, the compounds provided by this invention (and especially labelled compounds of this invention) are also useful as standards and reagents in determining the ability of a potential pharmaceutical to bind to the CRF receptor.


DETAILED DESCRIPTION OF INVENTION

[1] The present invention comprises a method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by

antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of Formulae (1) or (2):



(1)



(2)

and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein:

A is N or CR;

Z is N or CR^2;

Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R^4 groups and each Ar is attached to an unsaturated carbon atom;

R is independently selected at each occurrence from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, halo, CN, C_1-C_4 haloalkyl;

R^1 is independently selected at each occurrence from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, halo, CN, C_1-C_4 haloalkyl, C_1-C_{12} hydroxyalkyl, C_2-C_{12} alkoxyalkyl, C_2-C_{10} cyanoalkyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl, NR^9R^{10}, C_1-C_4 alkyl-NR^9R^{10}, NR^9COR^{10}, OR^{11}, SH or $S(O)_nR^{12}$;

R^2 is selected from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl, C_1-C_4 hydroxyalkyl, halo, CN, $-NR^6R^7$, NR^9COR^{10}, $-NR^6S(O)_nR^7$, $S(O)_nNR^6R^7$, C_1-C_4 haloalkyl, $-OR^7$, SH or $-S(O)_nR^{12}$;

R^3 is selected from:

-H, OR^7, SH, $S(O)_nR^{13}$, COR^7, CO_2R^7, $OC(O)R^{13}$, NR^8COR^7, $N(COR^7)_2$, $NR^8CONR^6R^7$, $NR^8CO_2R^{13}$, NR^6R^7, $NR^{6a}R^{7a}$, $N(OR^7)R^6$, $CONR^6R^7$, aryl, heteroaryl and heterocyclyl, or

-C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_8 cycloalkyl, C_5-C_8 cycloalkenyl, C_4-C_{12} cycloalkylalkyl or C_6-C_{10} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl and heterocyclyl;

R^4 is independently selected at each occurrence from: C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, NO_2, halo, CN, C_1-C_4 haloalkyl, NR^6R^7, NR^8COR^7, $NR^8CO_2R^7$, COR^7, OR^7, $CONR^6R^7$, $CO(NOR^9)R^7$, CO_2R^7, or $S(O)_nR^7$, where each such C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl and C_4-C_{12} cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_4 alkyl, NO_2, halo, CN, NR^6R^7, NR^8COR^7, $NR^8CO_2R^7$, COR^7 OR^7, $CONR^6R^7$, CO_2R^7, $CO(NOR^9)R^7$, or $S(O)_nR^7$;

R^6 and R^7, R^{6a} and R^{7a} are independently selected at each occurrence from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups;

R^8 is independently selected at each occurrence from H or C_1-C_4 alkyl;

R^9 and R^{10} are independently selected at each occurrence from H, C_1-C_4 alkyl, or C_3-C_6 cycloalkyl;

R^{11} is selected from H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_3-C_6 cycloalkyl;

R^{12} is C_1-C_4 alkyl or C_1-C_4 haloalkyl;

R^{13} is selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, aryl, aryl(C_1-C_4 alkyl)-, heteroaryl or heteroaryl(C_1-C_4 alkyl)-;

R^{14} is selected from C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_3-C_8 cycloalkyl, or C_4-C_{12} cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, and C_1-C_6 alkylthio, C_1-C_6 alkylsulfinyl and C_1-C_6 alkylsulfonyl;

R^{15} and R^{16} are independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10}

cycloalkyl, C_4-C_{16} cycloalkylalkyl, except that for $S(O)_nR^{15}$, R^{15} cannot be H;

aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, and $CONR^{16}R^{15}$;

heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, and $CONR^{16}R^{15}$;


heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{15}R^{16}$, and $CONR^{16}R^{15}$;

n is independently at each occurrence 0, 1 or 2,


[2] Preferred methods of the present invention are methods in wherein in the compound of Formulae (1) or (2), Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R^4 substituents.

[3] Further preferred methods of the above invention are methods wherein, in the compound of Formulae (1) or (2), A is N, Z is CR^2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R^1 and R^2 are CH_3, and R^3 is $NR^{6a}R^{7a}$.

[4] The present invention comprises compounds of Formulae (1) or (2):



(1)



(2)

and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein:

A is N or CR;

Z is N or CR^2;

Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R^4 groups and each Ar is attached to an unsaturated carbon atom;

R is independently selected at each occurrence from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, halo, CN, C_1-C_4 haloalkyl;

R^1 is independently selected at each occurrence from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, halo, CN, C_1-C_4 haloalkyl, C_1-C_{12} hydroxyalkyl, C_2-C_{12} alkoxyalkyl, C_2-C_{10} cyanoalkyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl, NR^9R^{10}, C_1-C_4 alkyl-NR^9R^{10}, NR^9COR^{10}, OR^{11}, SH or $S(O)_nR^{12}$;

R^2 is selected from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl, C_1-C_4 hydroxyalkyl, halo, CN, $-NR^6R^7$, NR^9COR^{10}, $-NR^6S(O)_nR^7$, $S(O)_nNR^6R^7$, C_1-C_4 haloalkyl, $-OR^7$, SH or $-S(O)_nR^{12}$;

R^3 is selected from:

-H, OR^7, SH, $S(O)_nR^{13}$, COR^7, CO_2R^7, $OC(O)R^{13}$, NR^8COR^7, $N(COR^7)_2$, $NR^8CONR^6R^7$, $NR^8CO_2R^{13}$, NR^6R^7, $NR^{6a}R^{7a}$, $N(OR^7)R^6$, $CONR^6R^7$, aryl, heteroaryl and heterocyclyl, or

-C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_8 cycloalkyl, C_5-C_8 cycloalkenyl, C_4-C_{12} cycloalkylalkyl or C_6-C_{10} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl and heterocyclyl;

R^4 is independently selected at each occurrence from: C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, NO_2, halo, CN, C_1-C_4 haloalkyl, NR^6R^7, NR^8COR^7, $NR^8CO_2R^7$, COR^7, OR^7, $CONR^6R^7$, $CO(NOR^9)R^7$, CO_2R^7, or $S(O)_nR^7$, where each such C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl and C_4-C_{12} cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_4 alkyl, NO_2, halo, CN, NR^6R^7, NR^8COR^7, $NR^8CO_2R^7$, COR^7 OR^7, $CONR^6R^7$, CO_2R^7, $CO(NOR^9)R^7$, or $S(O)_nR^7$;

R^6 and R7, R^{6a} and R^{7a} are independently selected at each occurrence from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3

substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl, -aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl),

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine; N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups;

R^8 is independently selected at each occurrence from H or C_1-C_4 alkyl;

R^9 and R^{10} are independently selected at each occurrence from H, C_1-C_4 alkyl, or C_3-C_6 cycloalkyl;

R^{11} is selected from H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_3-C_6 cycloalkyl;

R^{12} is C_1-C_4 alkyl or C_1-C_4 haloalkyl;

R^{13} is selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, aryl, aryl(C_1-C_4 alkyl)-, heteroaryl or heteroaryl(C_1-C_4 alkyl)-;

R^{14} is selected from C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_3-C_8 cycloalkyl, or C_4-C_{12} cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected

at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, and C_1-C_6 alkylthio, C_1-C_6 alkylsulfinyl and C_1-C_6 alkylsulfonyl;

R^{15} and R^{16} are independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_4-C_{16} cycloalkylalkyl, except that for $S(O)_nR^{15}$, R^{15} cannot be H;

aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, and $CONR^{16}R^{15}$;

heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, and $CONR^{16}R^{15}$;

heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{15}R^{16}$, and $CONR^{16}R^{15}$;

n is independently at each occurrence 0, 1 or 2,

with the provisos that:

(1) when A is N, Z is CR^2, R^2 is H, R^3 is $-OR^7$ or $-OCOR^{13}$, and R^7 is H, then R^1 is not H, OH or SH;

(2) when A is N, Z is CR^2, R^1 is CH_3 or C_2H_5, R^2 is H, and R^3 is OH, H, CH_3, C_2H_5, C_6H_5, n-C_3H_7, i-C_3H_7, SH, SCH_3, NHC_4H_9, or $N(C_2H_5)_2$, then Ar is not phenyl or m-CH_3-phenyl;

(3) when A is N, Z is CR^2, R^2 is H, and Ar is pyridyl, pyrimidinyl or pyrazinyl, and R^3 is $NR^{6a}R^{7a}$, then R^{6a} and R^{7a} are not H or alkyl;

(4) when A is N, Z is CR^2, and R^2 is $SO_2NR^6R^7$, then R^3 is not OH or SH;

(5) when A is CR and Z is CR^2, then R^2 is not-$NR^6SO_2R^7$ or $-SO_2NR^6R^7$;

(6) when A is N, Z is CR^2 and R^2 is $-NR^6SO_2R^7$ or $-SO_2NR^6R^7$, then R^3 is not OH or SH;

(7) when A is N, Z is CR^2, R^1 is methyl or ethyl, R^2 is H, and R^3 is H, OH, CH_3, C_2H_5, C_6H_5, n-C_3H_7,

iso-C_3H_7, SH, SCH_3, $NH(n\text{-}C_4H_9)$, or $N(C_2H_5)_2$, then Ar is not unsubstituted phenyl or m-methylphenyl;

(8) when A is CR, Z is CR^2, R^2 is H, phenyl or alkyl, R^3 is NR^8COR^7 and Ar is phenyl or phenyl substituted with phenylthio, then R^7 is not aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocycly(C_1-C_4 alkyl);

(9) when A is CR, Z is CR^2, R^2 is H or alkyl, Ar is phenyl, and R^3 is SR^{13} or $NR^{6a}R^{7a}$, then R^{13} is not aryl or heteroaryl and R^{6a} and R^{7a} are not H or aryl; or

(10) when A is CH, Z is CR^2, R^1 is OR^{11}, R^2 is H, R^3 is OR^7, and R^7 and R^{11} are both H, then Ar is not phenyl, p-Br-phenyl, p-Cl-phenyl, p-$NHCOCH_3$-phenyl, p-CH_3-phenyl, pyridyl or naphthyl;

(11) when A is CH, Z is CR^2, R^2 is H, Ar is unsubstituted phenyl, and R^3 is CH_3, C_2H_5, CF_3 or C_6H_4F, then R_1 is not CF_3 or C_2F_5;

(12) when A is CR, R is H, Z is CR^2, R^2 is OH, and R^1 and R^3 are H, then Ar is not phenyl;

(13) when A is CR, R is H, Z is CR^2, R^2 is OH or NH_2, R^1 and R^3 are CH_3, then Ar is not 4-phenyl-3-cyano-2-aminopyrid-2-yl.

[5] Preferred compounds of the above invention are compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof with the additional provisos that: (1) when A is N, R^1 is H, C_1-C_4 alkyl, halo, CN, C_1-C_{12} hydroxyalkyl, C_1-C_4

alkoxyalkyl or $SO_2(C_1-C_4$ alkyl), R^3 is $NR^{6a}R^{7a}$ and R^{6a} is unsubstituted C_1-C_4 alkyl, then R^{7a} is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C_3-C_6 cycloalkyl; and (2) A is N, R^1 is H, C_1-C_4 alkyl, halo, CN, C_1-C_{12} hydroxyalkyl, C_1-C_4 alkoxyalkyl or $SO_2(C_1-C_4$ alkyl), R^3 is $NR^{6a}R^{7a}$ and R^{7a} is unsubstituted C_1-C_4 alkyl, then R^{6a} is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C_3-C_6 cycloalkyl.

[6] Preferred compounds of the above invention also include compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R^4 substituents.

[7]. Preferred compounds of the above invention also include compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is N, Z is CR^2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R^1 and R^2 are CH_3, and R^3 is $NR^{6a}R^{7a}$.

[11] More preferred compounds of the above invention are compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is N.

[12] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[13] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R^4 substituents.

[14] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^3 is $NR^{6a}R^{7a}$ or OR^7.

[15] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents, and R^3 is $NR^{6a}R^{7a}$ or OR^7.

[16] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR^2.

[17] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R^4 substituents.

[18] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^3 is $NR^{6a}R^{7a}$ or OR^7.

[19] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is independently selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl)-, heteroaryl, heteroaryl(C_1-C_4 alkyl)-, heterocyclyl or heterocyclyl(C_1-C_4 alkyl)-; and

R^{7a} is independently selected at each occurrence from:

-H,

-C_5-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups.

[20] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are selected from:

-C_1-C_4 alkyl or C_3-C_6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from

C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl, and

-aryl or heteroaryl.

[21] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is selected from:

-C_1-C_4 alkyl and each such C_1-C_4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15},

CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[22] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R^{6a} and R^{7a} is selected from:

-C_3-C_6 cycloalkyl, each such C_3-C_6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl,

-heteroaryl or

-heterocyclyl,

and the other of R^{6a} and R^{7a} is unsubstituted C_1-C_4 alkyl.

[23] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, each such C_1-C_{10} alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$,

$R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[24] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents, and R^3 is $NR^{6a}R^{7a}$ or OR^7.

[25] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is independently selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl)-, heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is independently selected at each occurrence from:

-H,

-C_5-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl),

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups.

[26] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are selected from:

-C_1-C_4 alkyl or C_3-C_6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, -COR^{15},

CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl, and

-aryl or heteroaryl.

[27] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are

-C_1-C_4 alkyl, each such C_1-C_4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[28] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl,

cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is:

-C_1-C_4 alkyl and each such C_1-C_4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[29] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R^{6a} and R^{7a} is selected from:

-C_3-C_6 cycloalkyl, each such C_3-C_6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl,

-heteroaryl or

-heterocyclyl,

and the other of R^{6a} and R^{7a} is unsubstituted C_1-C_4 alkyl.

[30] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, each such C_1-C_{10} alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[31] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein

-Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents,

-R^3 is $NR^{6a}R^{7a}$ or OR^7 and

-R^1 and R^2 are independently selected from H, C_1-C_4 alkyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl.

[32] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is independently selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl)-, heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is independently selected at each occurrence from:

-H,

-C_5-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl),

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups.

[33] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are selected from:

-C_1-C_4 alkyl or C_3-C_6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl, and

-aryl or heteroaryl.

[34] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are

-C_1-C_4 alkyl, each such C_1-C_4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[35] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is:

-C_1-C_4 alkyl and each such C_1-C_4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[36] More preferred compounds of the above invention also include compounds and isomers thereof,

stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R^{6a} and R^{7a} is selected from:

-C_3-C_6 cycloalkyl, each such C_3-C_6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl,


-heteroaryl or

-heterocyclyl,

and the other of R^{6a} and R^{7a} is unsubstituted C_1-C_4 alkyl.

[37] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, each such C_1-C_{10} alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[38] Specifically preferred compounds of the above invention are compounds of Formula (50)



FORMULA (50)

and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, selected from the group consisting of:

a compound of Formula (50) wherein R^3 is $-NHCH(n\text{-}Pr)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)(n\text{-}Bu)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-(n\text{-}Pr)(CH_2cPr)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(n\text{-}Bu)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OEt)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Me)(Ph)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(n-Pr)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(n-Pr)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-OEt$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CN)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Me)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-OCH(Et)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(n\text{-}Pr)(CH_2cPr)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Me)(CH_2N(Me)_2)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(cPr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(n\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(n\text{-}Bu)(CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OEt)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2CH_2OMe)(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is morpholino, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NH(c\text{-}Pr)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is CN, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)(CH_2CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)(CH_2CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is (*S*)-NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(Et)2, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(CH_2CH_2OMe)2, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NH(CH_2OMe)(CH_2-iPr), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(CH_2CH_2OMe)2, R^{4a} is Me, R^{4b} is H, R^{4c} is H, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(CH_2CH_2OMe)2, R^{4a} is Me, R^{4b} is H, R^{4c} is NMe2, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)(n-Pr), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OEt)(Et), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is NMe2, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(Et)2, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(Et)2, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is NMe2, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is (*S*)-$NHCH(CH_2OMe)(CH_2CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)(CH_2CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is (*S*)-$NHCH(CH_2OMe)(CH_2CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)(CH_2CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NH(Et)(CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is Me, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)(CH_2CH_2OH)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is Me, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is Me, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2c\text{-}Pr)(n\text{-}Pr)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is Me, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is CN, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OH)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H; and

a compound of Formula (50) wherein R^3 is $N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H.

[39] More specifically preferred is 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolo-1,3,5-triazine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[40] More specifically preferred is 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2,5-dimethyl-4-methoxyphenyl)-[1,5-a]-pyrazolo-1,3,5-triazine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[41] More preferred are compounds of the above invention are compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is CR.

[42] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[43] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R^4 substituents.

[44] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^3 is $NR^{6a}R^{7a}$ or OR^7.

[45] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents, and R^3 is $NR^{6a}R^{7a}$ or OR^7.

[46] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR^2.

[47] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is

phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R^4 substituents.

[48] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^3 is $NR^{6a}R^{7a}$ or OR^7.

[49] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents, and R^3 is $NR^{6a}R^{7a}$ or OR^7.

[50] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, and each such C_1-C_{10} alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[51] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of

stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein


-Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents,

-R^3 is $NR^{6a}R^{7a}$ or OR^7 and

-R^1 and R^2 are independently selected from H, C_1-C_4 alkyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl.

[52] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, and each such C_1-C_{10} alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

[53] Specifically preferred compounds of the above invention are compounds of Formula (51)



FORMULA (51)

and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof selected from the group consisting of:

a compound of Formula (51) wherein R^3 is $-NHCH(n\text{-}Pr)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -N(n-Pr)(CH_2CH_2CN), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -N(n-Bu)(CH_2CH_2CN), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -NHCH(n-Pr)(CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is (*S*) $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -NH(Et), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(n\text{-}Pr)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is (*S*) $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(n\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is (*S*) $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(n\text{-}Pr)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(n\text{-}Pr)(CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is OMe and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is OMe and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is OMe and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Pr)(CH_2CH_2CN)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Bu)(Et)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)CH_2OMe$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NEt_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H; and

a compound of Formula (51) wherein R^3 is $-N(Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H.

[54] More specifically preferred is 7-(3-pentylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolopyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[55] More specifically preferred is 7-(Diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-[1,5-a]-pyrazolopyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[56] More specifically preferred is 7-(N-(3-cyanopropyl)-N-propylamino)-2,5-dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and

pharmaceutically acceptable salt or pro-drug forms thereof.

The present invention also provides pharmaceutical compositions comprising compounds of Formulae (1) and (2) and a pharmaceutically acceptable carrier.

Many compounds of this invention have one or more asymmetric centers or planes. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. The compounds may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, (enantiomeric and diastereomeric) and racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

The term "alkyl" includes both branched and straight-chain alkyl having the specified number of carbon atoms. Commonly used abbreviations have the following meanings: Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl. The prefix "n" means a straight chain alkyl. The prefix "c" means a cycloalkyl. The prefix "(*S*)" means the S enantiomer and the prefix "(*R*)" means the R enantiomer. Alkenyl" includes hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the

like. "Alkynyl" includes hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like. "Haloalkyl" is intended to include both branched and straight-chain alkyl having the specified number of carbon atoms, substituted with 1 or more halogen; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-,bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and so forth. "Halo" or "halogen" includes fluoro, chloro, bromo, and iodo.

The term "substituted", as used herein, means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

The term "appropriate amino acid protecting group" means any group known in the art of organic synthesis for the protection of amine or carboxylic acid groups. Such amine protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis" John Wiley & Sons, New York (1991) and "The Peptides: Analysis, Synthesis,

Biology, Vol. 3, Academic Press, New York (1981), the disclosure of which is hereby incorporated by reference. Any amine protecting group known in the art can be used. Examples of amine protecting groups include, but are not limited to, the following: 1) acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate types such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyls, 1-(p-biphenyl)-1-methylethoxycarbonyl, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate types such as tert-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl types such as triphenylmethyl and benzyl; 6) trialkylsilane such as trimethylsilane; and 7) thiol containing types such as phenylthiocarbonyl and dithiasuccinoyl.

The term "pharmaceutically acceptable salts" includes acid or base salts of the compounds of Formulae (1) and (2). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.

Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing

Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.


"Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug of formula (I) or (II) *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of formula (I) and (II) are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compounds. Prodrugs include compounds wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formulas (I) and (II); and the like.

The term "therapeutically effective amount" of a compound of this invention means an amount effective to antagonize abnormal level of CRF or treat the symptoms of affective disorder, anxiety or depression in a host.


Syntheses

Some compounds of Formula (1) may be prepared from intermediate compounds of Formula (7), using the procedures outlined in Scheme 1:

SCHEME 1



(7) Y = O (8)



(1) A = N

Compounds of Formula (7) (where Y is O) may be treated with a halogenating agent or sulfonylating agent in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80°C to 250°C to give products of Formula (8) (where X is halogen, alkanesulfonyloxy, arylsulfonyloxy or haloalkane-sulfonyloxy). Halogenating agents include, but are not limited to, $SOCl_2$, $POCl_3$, PCl_3, PCl_5, $POBr_3$, PBr_3 or PBr_5. Sulfonylating agents include, but are not limited to, alkanesulfonyl halides or anhydrides (such as methanesulfonyl chloride or methanesulfonic acid anhydride), arylsulfonyl halides or anhydrides (such as p-toluenesulfonyl chloride or anhydride) or haloalkylsulfonyl halides or anhydrides (preferably trifluoromethanesulfonic anhydride). Bases may include, but are not limited to, alkali metal


hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from -20°C to 100°C.

Compounds of Formula (8) may be reacted with compounds of Formula R^3H (where R^3 is defined as above except R^3 is not SH, COR^7, CO_2R^7, aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80 to 250°C to generate compounds of Formula (1). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bicarbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably

N,N-di-isopropyl-N-ethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from 0°C to 140°C.

Scheme 2 delineates the procedures for converting intermediate compounds of Formula (7) (where Y is S) to some compounds of Formula (1).

SCHEME 2



Compounds of Formula (7) (where Y is S) may be treated with an alkylating agent $R^{13}X$ (where R^{13} is defined as above, except R^{13} is not aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80°C to 250°C. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal hydroxides, alkali metal bis(trialkylsilyl)amides (preferably sodium


bis(trimethylsilyl)amide), trialkyl amines (prefereably N,N-di-isopropyl-N-ethyl amine or triethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from -80°C to 100°C.

Compounds of Formula (12) (Formula (1) where R^3 is SR^{13}) may then be reacted with compounds of Formula R^3H to give compounds of Formula (1), using the same conditions and reagents as were used for the conversion of compounds of Formula (8) to compounds of Formula (1) as outlined for Scheme 1 above. Alternatively, compounds of Formula (12) (Formula (1) where R^3 is SR^{13}) may be oxidized to compounds of Formula (13) (Formula (1) where R^3 is $S(O)_nR^{13}$, n is 1,2) by treatment with an oxidizing agent in the presence of an inert solvent at temperatures ranging from -80°C to 250°C. Oxidizing agents include, but are not limited to, hydrogen peroxide, alkane or aryl peracids (preferably peracetic acid or m-chloro-perbenzoic acid), dioxirane, oxone, or sodium periodate. Inert solvents may include, but are not limited to, alkanones (3 to 10 carbons, preferably acetone), water, alkyl alcohols (1 to 6 carbons), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens

(preferably dichloromethane) or combinations thereof. The choices of oxidant and solvent are known to those skilled in the art (cf. Uemura, S., Oxidation of Sulfur, Selenium and Tellurium, in Comprehensive Organic Synthesis, Trost, B.M. ed., (Elmsford, NY: Pergamon Press, 1991), 7, 762-769). Preferred reaction temperatures range from -20°C to 100°C. Compounds of Formula (13) (Formula (1) where R^3 is $S(O)_nR^{13}$, n is 1,2) may then be reacted with compounds of Formula R^3H to give compounds of Formula (1), using the same conditions and reagents as were used for the conversion of compounds of Formula (8) to compounds of Formula (1) as outlined for Scheme (1) above.

Compounds of Formula (1), where R^3 may be $-NR^8COR^7$, $-N(COR^7)_2$, $-NR^8CONR^6R^7$, $-NR^8CO_2R^{13}$, $-NR^6R^7$, $-NR^8SO_2R^7$, may be prepared from compounds of Formula (7), where Y is NH, by the procedures depicted in Scheme 3.

SCHEME 3



(7) Y = NH

(1)

A = N;
R_3 = NR^6R^7, NR^8COR^7, $N(COR^7)_2$, $NR_8CONR^6R^7$, $NR_8CO_2R_{13}$


Reaction of compounds of Formula (7), where Y is NH, with alkylating agents, sulfonylating agents or acylating agents or sequential reactions with

combinations thereof, in the presence or absence of a base in an inert solvent at reaction temperatures ranging from -80°C to 250°C may afford compounds of Formula (1), where R^3 may be $-NR^8COR^7$, $-N(COR^7)_2$, $-NR^8CONR^6R^7$, $-NR^8CO_2R^{13}$, $-NR^6R^7$, $-NR^8SO_2R^7$. Alkylating agents may include, but are not limited to, C_1-C_{10} alkyl -halides, -tosylates, -mesylates or -triflates; C_1-C_{10} haloalkyl(1 - 10 halogens)-halides, -tosylates, -mesylates or -triflates; C_2-C_8 alkoxyalkyl-halides, -tosylates, -mesylates or -triflates; C_3-C_6 cycloalkyl-halides, -tosylates, -mesylates or -triflates; C_4-C_{12} cycloalkylalkyl-halides, -tosylates, -mesylates or -triflates; aryl(C_1-C_4 alkyl)-halides, -tosylates, -mesylates or -triflates; heteroaryl(C_1-C_4 alkyl)-halides, -tosylates, -mesylates or -triflates; or heterocyclyl(C_1-C_4 alkyl)-halides, -tosylates, -mesylates or -triflates. Acylating agents may include, but are not limited to, C_1-C_{10} alkanoyl halides or anhydrides, C_1-C_{10} haloalkanoyl halides or anhydrides with 1 - 10 halogens, C_2-C_8 alkoxyalkanoyl halides or anhydrides, C_3-C_6 cycloalkanoyl halides or anhydrides, C_4-C_{12} cycloalkylalkanoyl halides or anhydrides, aroyl halides or anhydrides, aryl(C_1-C_4) alkanoyl halides or anhydrides, heteroaroyl halides or anhydrides, heteroaryl(C_1-C_4) alkanoyl halides or anhydrides, heterocyclylcarboxylic acid halides or anhydrides or heterocyclyl(C_1-C_4) alkanoyl halides or anhydrides. Sulfonylating agents include, but are not limited to, C_1-C_{10} alkylsulfonyl halides or anhydrides, C_1-C_{10} haloalkylsulfonyl halides or anhydrides with 1 - 10 halogens, C_2-C_8 alkoxyalkylsulfonyl halides or anhydrides, C_3-C_6 cycloalkylsulfonyl halides or anhydrides, C_4-C_{12} cycloalkylalkylsulfonyl halides or anhydrides, arylsulfonyl halides or anhydrides, aryl(C_1-C_4 alkyl)-, heteroarylsulfonyl halides or anhydrides, heteroaryl(C_1-C_4 alkyl)sulfonyl halides or anhydrides,

heterocyclylsulfonyl halides or anhydrides or heterocyclyl(C_1-C_4 alkyl)sulfonyl halides or anhydrides. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0°C to 100°C.

Scheme 4 delineates procedures, which may be employed to prepare intermediate compounds of Formula (7), where Y is O, S and Z is CR^2.

SCHEME 4



Compounds of the formula $ArCH_2CN$ are reacted with compounds of the formula R^2COR^b, where R^2 is defined above and R^b is halogen, cyano, lower alkoxy (1 to 6 carbons) or lower alkanoyloxy (1 to 6 carbons), in the presence of a base in an inert solvent at reaction temperatures ranging from -78°C to 200°C to afford compounds of Formula (3). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal

dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal hydroxides, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), water, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0°C to 100°C.

Compounds of Formula (3) may be treated with hydrazine-hydrate in the presence of an inert solvent at temperatures ranging from 0°C to 200°C, preferably 70°C to 150°C, to produce compounds of Formula (4). Inert solvents may include, but are not limited to, water, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Compounds of Formula (4) may be reacted with compounds of Formula (5) (where R^c is alkyl (1-6 carbons)) in the presence or absence of an acid in the presence of an inert solvent at temperatures ranging from 0°C to 200°C to produce compounds of Formula (6). Acids may include, but are


not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), haloalkanoic acids (2 - 10 carbons, 1-10 halogens, such as trifluoroacetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, water, alkanenitriles (1 to 6 carbons, preferably acetonitrile), halocarbons of 1 to 6 carbons and 1 to 6 halogens (preferably dichloromethane or chloroform), alkyl alcohols of 1 to 10 carbons (preferably ethanol), dialkyl ethers (4 to 12 carbons, preferably diethyl ether or di-isopropylether) or cyclic ethers such as dioxan or tetrahydrofuran. Preferred temperatures range from ambient temprature to 100°C.

Compounds of Formula (6) may be converted to intermediate compounds of Formula (7) by treatment with compounds $C=Y(R^d)_2$ (where Y is O or S and R^d is halogen (preferably chlorine), alkoxy (1 to 4 carbons) or alkylthio (1 to 4 carbons)) in the presence or absence of a base in an inert solvent at reaction temperatures from -50°C to 200°C. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkali metal carbonates, alkali metal hydroxides, trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably

dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred temperatures are 0°C to 150°C.

Intermediate compounds of Formula (7), where Z is N, may be synthesized according the methods outlined in Scheme 5.

SCHEME 5



Compounds of $ArCH_2CN$ are reacted with compounds of Formula $R^qCH_2N_3$ (where R^q is a phenyl group optionally substituted by H, alkyl (1 to 6 carbons) or alkoxy (1 to 6 carbons) in the presence or absence of a base in an inert solvent at temperatures ranging from 0°C to 200°C to generate compounds of Formula (9). Bases may include, but are not limited to, alkali metal hydrides


(preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide, sodium ethoxide or potassium t-butoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal hydroxides, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from ambient temperature to 100°C.

Compounds of Formula (9) may be treated with a reducing agent in an inert solvent at -100°C to 100°C to afford products of Formula (10). Reducing agents include, but are not limited to, (a) hydrogen gas in combination with noble metal catalysts such as Pd-on-carbon, PtO_2, Pt-on-carbon, Rh-on-alumina or Raney nickel, (b) alkali metals (preferably sodium) in combination with liquid ammonia or (c) ceric ammonium nitrate. Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), water, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides

(preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). The preferred reaction temperatures are -50°C to 60°C. Compounds of Formula (9) are then converted to compounds of Formula (7) (where Z is N) via intermediates of Formula (11) using the reagents and reaction conditions outlined in Scheme 4 for the conversion of compounds of Formula (4) to compounds of Formula (7) (where Z is CR^2).

Compounds of Formula (1) may also be prepared from compounds of Formula (7) (where Y is O, S and Z is defined above) as outlined in Scheme 6:

SCHEME 6




(7) Y = O, S; Z = N, CR^2 **(1) A = N**

Compounds of Formula (7) may be reacted with compounds of Formula R^3H in the presence of a dehydrating agent in an inert solvent at reaction temperatures ranging from 0°C to 250°C. Dehydrating agents include, but are not limited to, P_2O_5, molecular sieves or inorganic or organic acids. Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Inert solvents may include, but are not limited to,

alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably glyme or diglyme), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or halocarbons of 1 to 10 carbons and 1 to 10 halogens (preferably chloroform). Preferred reaction temperatures range from ambient temperature to 150°C.

Some compounds of Formula (1) (where A is N) may also be prepared by the methods shown in Scheme 7:

SCHEME 7




Intermediate compounds of Formula (14), where Z is defined above, may be reacted with compounds of Formula $R^3C(OR^e)3$, where R^e may be alkyl (1 to 6 carbons) in the presence or absence of an acid in an inert solvent at temperatures ranging from 0°C to 250°C. Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or

catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from 50°C to 150°C.

Intermediate compounds of Formula (7) may also be synthesized by the reactions displayed in Scheme 8.

SCHEME 8



(15) Y = OH, SH NR^6R^7;
Z = N, CR^2,
X = Br, Cl, I, B(OR"")2

(7) A = N


Compounds of Formula (15), (where Y is OH, SH, NR^6R^7; Z is defined above, X is Br, Cl, I, O_3SCF_3 or $B(OR"")_2$ and R"" is H or alkyl (1 to 6 carbons)) may be reacted with a compound of Formula ArM (where M is halogen, alkali metal, ZnCl, ZnBr, ZnI, MgBr, MgCl, MgI, $CeCl_2$, $CeBr_2$ or copper halides) in the presence or absence of an

organometallic catalyst in the presence or absence of a base in an inert solvents at temperatures ranging from -100°C to 200°C. Those skilled in the art will recognize that the reagents ArM may be generated in situ. Organometallic catalysts include, but are not limited to, palladium phosphine complexes (such as $Pd(PPh_3)_4$), palladium halides or alkanoates (such as $PdCl_2(PPh_3)_2$ or $Pd(OAc)_2$) or nickel complexes (such as $NiCl_2(PPh_3)_2$). Bases may include, but are not limited to, alkali metal carbonates or trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine). Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or water. Preferred reaction temperatures range from -80°C to 100°C.

The choices of M and X are known to those skilled in the art (cf. Imamoto, T., Organocerium Reagents in Comprehensive Organic Synthesis, Trost, B.M. ed., (Elmsford, NY: Pergamon Press, 1991), 1, 231-250; Knochel, P., Organozinc, Organocadmium and Organomercury Reagents in Comprehensive Organic Synthesis, Trost, B.M. ed., (Elmsford, NY: Pergamon Press, 1991), 1, 211-230; Knight, D.W., Coupling Reactions between sp^2 Carbon Centers, in Comprehensive Organic Synthesis, Trost, B.M. ed., (Elmsford, NY: Pergamon Press, 1991), 3, 481-520).

Compounds of Formula (1) may also be prepared using the methods shown in Scheme 9.

SCHEME 9



(16) X = Br, Cl, I, $B(OR"")_2$, O_3SCF_3


(1)


Compounds of Formula (16), where A, Z, R^1 and R^3 are defined above and X is Br, Cl, I, O_3SCF_3 or $B(OR"")_2$ and R"" is H or alkyl (1 to 6 carbons)) may be reacted with a compound of Formula ArM (where M is halogen, alkali metal, ZnCl, ZnBr, ZnI, MgBr, MgCl, MgI, $CeCl_2$, $CeBr_2$ or copper halides) in the presence or absence of an organometallic catalyst in the presence or absence of a base in an inert solvents at temperatures ranging from -100°C to 200°C. Those skilled in the art will recognize that the reagents ArM may be generated in situ (see the above references in Comprehensive Organic Synthesis). Organometallic catalysts include, but are not limited to, palladium phosphine complexes (such as $Pd(PPh_3)_4$), palladium halides or alkanoates (such as $PdCl_2(PPh_3)_2$ or $Pd(OAc)_2$) or nickel complexes (such as $NiCl_2(PPh_3)_2$). Bases may include, but are not limited to, alkali metal carbonates or trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine). Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably

benzene or toluene) or water. Preferred reaction temperatures range from -80°C to 100°C.

Intermediate compounds of Formula (7) (where Y is O, S, NH, Z is CR^2 and R^1, R^2 and Ar are defined as above) may be prepared as illustrated in Scheme 10.

SCHEME 10





(7) Y = O, S, NH; Z = CR^2,

Compounds of Formula (3) may be reacted with compounds of Formula $H_2NNH(C=Y)NH_2$, where Y is O, S or NH, in the presence or absence of a base or acid in an inert solvent at temperatures from 0°C to 250°C to produce compounds of Formula (17). Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts


of such acids may be used. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane).

Preferred reaction temperatures range from 0°C to 150°C. Compounds of Formula (17) may then be reacted with compounds of Formula $R^3C(OR^e)3$, where R^e may be alkyl (1 to 6 carbons) in the presence or absence of an acid in an inert solvent at temperatures ranging from 0°C to 250°C. Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably

acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from 50°C to 150°C.

In Scheme 11, the procedures which may be used to convert compounds of Formula (1), where R^3 is COR^7, CO_2R^7, NR^8COR^7 and $CONR^6R^7$, to other compounds of Formula (1), where R^3 is $CH(OH)R^7$, CH_2OH, $NR^8CH_2R^7$ and $CH_2NR^6R^7$ by treatment with a reducing agent in an inert solvent at temperatures ranging from -80°C to 250°C.

SCHEME 11



(1) R^3 = COR^7, CO_2R^7, $CONR^6R^7$


(1) R^3 = $C(OH)R^7$, CH_2OH, $CH_2NR^6R^7$

Reducing agents include, but are not limited to, alkali metal or alkaline earth metal borohydrides (preferably lithium or sodium borohydride), borane, dialkylboranes (such as di-isoamylborane), alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal (trialkoxy)aluminum hydrides, or dialkyl aluminum

hydrides (such as di-isobutylaluminum hydride). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from -80°C to 100°C.

In Scheme 12, the procedures are shown which may be used to convert compounds of Formula (1), where R^3 is COR^7 or CO_2R^7, to other compounds of Formula (1), where R^3 is $C(OH)(R^7)_2$ by treatment with a reagent of Formula R^7M in an inert solvent at temperatures ranging from -80°C to 250°C.

SCHEME 12




(1) $R^3 = COR^7$, CO_2R^7, (1) $R^3 = C(OH)(R^7)_2$

M is halogen, alkali metal, ZnCl, ZnBr, ZnI, MgBr, MgCl, MgI, $CeCl_2$, $CeBr_2$ or copper halides. Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from -80°C to 100°C.

Compounds of Formula (1), where R^3 may be $-NR^8COR^7$, $-N(COR^7)_2$, $-NR^8CONR^6R^7$, $-NR^8CO_2R^{13}$, $-NR^6R^7$, $-NR^8SO_2R^7$, may be synthesized as depicted in Scheme 13.

SCHEME 13



Reaction of compounds of Formula (18), where R and R^1 are defined above, with compounds of Formula (4) or (10) in the presence or absence of base in an inert solvent may produce compounds of Formula (19) at temperatures

ranging from -50°C to 250°C. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0°C to 100°C.


Compounds of Formula (19) may then be reacted with alkylating agents, sulfonylating agents or acylating agents or sequential reactions with combinations thereof, in the presence or absence of a base in an inert solvent at reaction temperatures ranging from -80°C to 250°C may afford compounds of Formula (1), where R^3 may be $-NR^8COR^7$, $-N(COR^7)_2$, $-NR^8CONR^6R^7$, $-NR^8CO_2R^{13}$, $-NR^6R^7$, $-NR^8SO_2R^7$. Alkylating agents may include, but are not limited to, C_1-C_{10} alkyl -halides, -tosylates, -mesylates or -triflates; C_1-C_{10} haloalkyl(1 - 10 halogens)-halides, -tosylates, -mesylates or -triflates; C_2-C_8 alkoxyalkyl-halides, -tosylates, -mesylates or -triflates; C_3-C_6 cycloalkyl-halides, -tosylates, -mesylates or -triflates; C_4-

C_{12} cycloalkylalkyl-halides, -tosylates, -mesylates or -triflates; aryl(C_1-C_4 alkyl)-halides, -tosylates, -mesylates or -triflates; heteroaryl(C_1-C_4 alkyl)-halides, -tosylates, -mesylates or -triflates; or heterocyclyl(C_1-C_4 alkyl)-halides, -tosylates, -mesylates or -triflates. Acylating agents may include, but are not limited to, C_1-C_{10} alkanoyl halides or anhydrides, C_1-C_{10} haloalkanoyl halides or anhydrides with 1 - 10 halogens, C_2-C_8 alkoxyalkanoyl halides or anhydrides, C_3-C_6 cycloalkanoyl halides or anhydrides, C_4-C_{12} cycloalkylalkanoyl halides or anhydrides, aroyl halides or anhydrides, aryl(C_1-C_4) alkanoyl halides or anhydrides, heteroaroyl halides or anhydrides, heteroaryl(C_1-C_4) alkanoyl halides or anhydrides, heterocyclylcarboxylic acid halides or anhydrides or heterocyclyl(C_1-C_4) alkanoyl halides or anhydrides. Sulfonylating agents include, but are not limited to, C_1-C_{10} alkylsulfonyl halides or anhydrides, C_1-C_{10} haloalkylsulfonyl halides or anhydrides with 1 - 10 halogens, C_2-C_8 alkoxyalkylsulfonyl halides or anhydrides, C_3-C_6 cycloalkylsulfonyl halides or anhydrides, C_4-C_{12} cycloalkylalkylsulfonyl halides or anhydrides, arylsulfonyl halides or anhydrides, aryl(C_1-C_4 alkyl)-, heteroarylsulfonyl halides or anhydrides, heteroaryl(C_1-C_4 alkyl)sulfonyl halides or anhydrides, heterocyclylsulfonyl halides or anhydrides or heterocyclyl(C_1-C_4 alkyl)sulfonyl halides or anhydrides. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably

pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0°C to 100°C.

Compounds of Formula (1), where A is CR and R is defined above, may be synthesized by the methods depicted in Scheme 14.

SCHEME 14



Compounds of Formula (4) or (10) may be treated with compounds of Formula (20), where R^1 and R^3 are defined above in the presence or absence of base in an inert solvent at temperatures ranging from 0°C to 250°C to give compounds of Formula (1), where A is CR and R is defined above. Bases may include, but are not limited

to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0°C to 100°C. Alternatively, compounds of Formula (1) where A is CR and R is defined above, may be synthesized through intermediates (22) and (23).

Compounds of Formula (4) or (10) may be treated with compounds of Formula (21), where R^1 is defined above and R^e is alkyl (1 - 6 carbons), in the presence or absence of base in an inert solvent at temperatures ranging from 0°C to 250°C to give compounds of Formula (1), where A is CR and R is defined above. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium

bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0°C to 100°C. Compounds of Formula (22) may be treated with a halogenating agent or sulfonylating agent in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80°C to 250°C to give products of Formula (23) (where X is halogen, alkanesulfonyloxy, arylsulfonyloxy or haloalkane-sulfonyloxy). Halogenating agents include, but are not limited to, $SOCl_2$, $POCl_3$, PCl_3, PCl_5, $POBr_3$, PBr_3 or PBr_5. Sulfonylating agents include, but are not limited to, alkanesulfonyl halides or anhydrides (such as methanesulfonyl chloride or methanesulfonic acid anhydride), arylsulfonyl halides or anhydrides (such as p-toluenesulfonyl chloride or anhydride) or haloalkylsulfonyl halides or anhydrides (preferably trifluoromethanesulfonic anhydride). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably


N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from -20°C to 100°C.

Compounds of Formula (23) may be reacted with compounds of Formula R^3H (where R3 is defined as above except R^3 is not SH, COR^7, CO_2R^7, aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80°C to 250°C to generate compounds of Formula (1). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bicarbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably

tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from 0°C to 140°C.

Some compounds of Formula (1) may also be prepared using the methods shown in Scheme 15.

SCHEME 15



A compound of Formula (24) (R_c is a lower alkyl group and Ar is defined as above) may be reacted with hydrazine in the presence or absence of an inert solvent to afford an intermediate of Formula (25), where Ar is defined as above. The conditions employed are similar to those used for the preparation of intermediate of Formula (4) from compound of Formula (3) in Scheme 4. Compounds of Formula (25), where A is N, may be reacted with reagents of the formula $R^1C(=NH)OR_e$, where R^1 is

defined above and R_e is a lower alkyl group) in the presence or absence of an acid in an inert solvent, followed by reaction with a compound of formula YisC(R_d)2 (where Y is O or S and R^d is halogen (preferably chlorine), alkoxy (1 to 4 carbons) or alkylthio (1 to 4 carbons)) in the presence or absence of a base in an inert solvent to give compounds of Formula (27) (where A is N and Y is O, S). The conditions for these transformations are the same as those employed for the conversions of compound of Formula (4) to compound of Formula (7) in Scheme 4.

Alternatively, compounds of Formula (25), where A is CR, may be reacted with compounds of the formula R^1(C=O)CHR(C=Y)OR_c (where R^1 and R are defined as above and R_c is a lower alkyl group) to give a compound of Formula (27) (where A is CR) using conditions similar to those employed for the conversion of compounds of Formula (21) to compounds of Formula (22) in Scheme 14. Intermediates of Formula (27) (where Y is O) may be treated with halogenating agents or sulfonylating agents in the presence or absence of a base in an inert solvent, followed by reaction with R^3H or R^2H in the presence or absence of a base in an inert solvent to give compounds of Formula (1) (where Z is CR^2).

It will be recognized by those skilled in the art that various combinations of halogenating agents, sulfonylating agents, R^3H or R^2H may be used in different orders of reaction sequences in Scheme 15 to afford compounds of Formula (1). For example, in some cases, it may be desirable to react compounds with stoichiometric amounts of halogenating agents or sulfonylating agents, react with R^2H (or R^3H), then repeat the reaction with halogenating agents or sulfonylating agents and react with R^3H (or R^2H) to give compounds of Formula (1). The reaction conditions and reagents used for these conversions are similar to the


ones employed for the conversion of intermediate compounds of Formulae (22) to (23) to (1) in Scheme 14 (for A is CR) or the conversion of intermediate compounds of Formulae (7) to (8) to (1) in Scheme 1 (where A is N).

Alternatively, compounds of Formula (27) (where Y is S) may be converted to compounds of Formula (1) in Scheme 15. Intermediate compounds of Formula (27) may be alkylated with a compound R^fX (where R^f is lower alkyl and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in an inert solvent, (then optionally oxidized with an oxidizing agent in an inert solvent) and then reacted with R^3H in the presence or absence of a base in an inert solvent to give a compound of Formula (1). The conditions and reagents employed are similar to those used in the conversion of intermediate compounds of Formulae (7) to (12) (or to (13)) to compounds of Formula (1) in Scheme 2.

Compounds of Formula (1) may be prepared from compounds of Formula (24), using an alternate route as depicted in Scheme 15. Compounds of Formula (24) may be converted to compounds of Formula (27) via reaction with compounds of formula $NH_2NH(C=NH)NH_2$ in the presence or absence of an acid in an inert solvent, followed by reaction with compounds $R^1C(OR_c)_3$ (where R_c is lower alkyl and R^1 is defined as above), using the conditions employed for the conversion of compounds of Formulae (3) to (17) to (7) in Scheme 10.

Some compounds of Formula (2) may be prepared by the methods illustrated in Scheme 16.

SCHEME 16



(27b) Y = O, S

(28)Y = O, S

(1) Z = COH

(2)

Compounds of Formula (27b) may be treated with various alkylating agents $R^{14}X$ (where R^{14} is defined above and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in the presence or absence of a base in an inert solvent to afford structures of Formula (28). Compounds of Formula (28) (Y is O) may then be converted to compounds of Formula (2) by treatment with halogenating agents or sulfonylating agents in the presence or absence of a base in an inert solvent, followed by reaction with R^3H in the presence or absence of a base in an inert solvent to give compounds of Formula (2). The reaction conditions used for these conversions are similar to the

ones employed for the conversion of intermediate compounds (22) to (23) to (1) in Scheme 14 (for A is CR) or the conversion of intermediate compounds of Formulae (7) to (8) to (1) in Scheme 1 (where A is N).

Alternatively, compounds of Formula (28) (Y is S) may be alkylated with a compound R^fX (where R^f is lower alkyl and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in an inert solvent, (then optionally oxidized with an oxidizing agent in an inert solvent) and then reacted with R^3H in the presence or absence of a base in an inert solvent to give a compound of Formula (1). The conditions and reagents employed are similar to those used in the conversion of intermediate compounds of Formulae (7) to (12) (or to (13)) to compounds of Formula (1) in Scheme 2.

Compounds of Formula (1), where Z is COH, may be converted to compounds of Formula (2) as illustrated in Scheme 16. Treatment with various alkylating agents $R^{14}X$ (where R^{14} is defined above and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in the presence or absence of a base in an inert solvent to afford structures (2). It will be recognized by one skilled in the art that the methods used in Scheme 16 may also be used to prepare compounds of Formula (1) where Z is COR^7.

For Scheme 16, the terms "base" and " inert solvent" may have the meanings given below. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents

may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from -20°C to 100°C.

EXAMPLES

Analytical data were recorded for the compounds described below using the following general procedures. Proton NMR spectra were recorded on an IBM-Bruker FT-NMR (300 MHz); chemical shifts were recorded in ppm (δ) from an internal tetramethysilane standard in deuterochloroform or deuterodimethylsulfoxide as specified below. Mass spectra (MS) or high resolution mass spectra (HRMS) were recorded on a Finnegan MAT 8230 spectrometer (using chemi-ionization (CI) with NH_3 as the carrier gas or gas chromatography (GC) as specified below) or a Hewlett Packard 5988A model spectrometer. Melting points were recorded on a Buchi Model 510 melting point apparatus and are uncorrected. Boiling points are uncorrected. All pH determinations during workup were made with indicator paper.

Reagents were purchased from commercial sources and, where necessary, purified prior to use according to the general procedures outlined by D. Perrin and W.L.F. Armarego, *Purification of Laboratory Chemicals*, 3rd ed., (New York: Pergamon Press, 1988). Chromatography was

performed on silica gel using the solvent systems indicated below. For mixed solvent systems, the volume ratios are given. Otherwise, parts and percentages are by weight.

The following examples are provided to describe the invention in further detail. These examples, which set forth the best mode presently contemplated for carrying out the invention, are intended to illustrate and not to limit the invention.

EXAMPLE 1

Preparation of
2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]
-pyrazolo-[1,3,5]-triazin-4(3H)-one
(Formula 7, where Y is O, R_1 is CH_3, Z is C-CH_3,
Ar is 2,4-dimethylphenyl)

A. 1-Cyano-1-(2,4-dimethylphenyl)propan-2-one

Sodium pellets (9.8g, 0.43 mol) were added portionwise to a solution of 2,4-dimethylphenylacetonitrile (48 g, 0.33 mol) in ethyl acetate (150 mL) at ambient temperature. The reaction mixture was heated to reflux temperature and stirred for 16 hours. The resulting suspension was cooled to room temperature and filtered. The collected precipitate was washed with copious amounts of ether and then air-dried. The solid was dissolved in water and a 1N HCl solution was added until the pH = 5-6. The mixture was extracted with ethyl acetate (3 X 200 mL); the combined organic layers were dried over $MgSO_4$ and filtered. Solvent was removed *in vacuo* to afford a white solid (45.7g, 74% yield): NMR ($CDCl_3$,300 MHz):; CI-MS: 188 (M + H).

B. 5-Amino-4-(2,4-dimethylphenyl)-3-methylpyrazole

A mixture of 1-cyano-1-(2,4-dimethylphenyl)propan-2-one (43.8g, 0.23 mol), hydrazine-hydrate (22 mL, 0.46 mol), glacial acetic acid (45 mL, 0.78 mol) and toluene (500 mL) were stirred at reflux temperature for 18 hours in an apparatus fitted with a Dean-Stark trap. The reaction mixture was cooled to ambient temperature and solvent was removed in vacuo. The residue was dissolved in 6N HCl and the resulting solution was extracted with ether three times. A concentrated ammonium hydroxide solution was added to the aqueous layer until pH = 11. The resulting semi-solution was extracted three times with ethyl acetate. The combined organic layers were dried over $MgSO_4$ and filtered. Solvent was removed *in vacuo* to give a pale brown viscous oil (34.6g, 75% yield): NMR ($CDCl_3$,300 MHz): 7.10 (s, 1H), 7.05 (d, 2H, J=1), 2.37 (s, 3H), 2.10 (s, 3H); CI-MS: 202 (M + H).

C. 5-Acetamidino-4-(2,4-dimethylphenyl)-3-methylpyrazole, acetic acid salt

Ethyl acetamidate hydrochloride (60g, 0.48 mol) was added quickly to a rapidly stirred mixture of potassium carbonate (69.5g, 0.50 mol), dichloromethane (120 mL) and water (350 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (2 X 120 mL). The combined organic layers were dried over $MgSO_4$ and filtered. Solvent was removed by simple distillation and the pot residue, a clear pale yellow liquid, (35.0 g) was used without further purification.

Glacial aetic acid (9.7 mL, 0.17 mol) was added to a stirred mixture of 5-amino-4-(2,4-dimethylphenyl)-3-methylpyrazole (34g, 0.17 mol), ethyl acetamidate (22g, 0.25 mol) and acetonitrile (500 mL). The resulting reaction mixture was stirred at room temperature for 3 days; at the end of which time, it was concentrated in vacuo to about one-third of its original volume. The resulting suspension was filtered and the collected

solid was washed with copious amounts of ether. The white solid was dried *in vacuo* (31.4g, 61% yield): NMR (DMSO-d_6,300 MHz): 7.00 (s, 1H), 6.90 (dd, 2H, J=7, 1), 2.28 (s, 3H), 2.08 (s, 3H), 2.00 (s, 3H), 1.90 (s, 3H), 1.81 (s, 3H); CI-MS: 243 (M + H).

D. 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-[1,3,5]-triazin-4(3H)-one

Sodium pellets (23g, 1 mol) were added portionwise to ethanol (500 mL) with vigorous stirring. After all the sodium reacted, 5-acetamidino-4-(2,4-dimethylphenyl)-3-methylpyrazole, acetic acid salt (31.2g, 0.1 mol) and diethyl carbonate (97 mL, 0.8 mol) were added. The resulting reaction mixture was heated to reflux temperature and stirred for 18 hours. The mix was cooled to room temperature and solvent was removed in vacuo. The residue was dissolved in water and a 1N HCl solution was added slowly until pH = 5-6. The aqueous layer was extracted with ethyl acetate three times; the combined organic layers were dried over $MgSO_4$ and filtered. Solvent was removed *in vacuo* to give a pale tan solid (26g, 98% yield): NMR ($CDCl_3$,300 MHz): 7.15(s, 1H), 7.09 (s, 2H), 2.45 (s, 3H), 2.39 (s, 3H), 2.30 (s, 3H); CI-MS: 269 (M + H).

EXAMPLE 2

Preparation of
5-methyl-3-(2,4,6-trimethylphenyl)[1,5-a]-[1,2,3]-triazolo-[1,3,5]-triazin-7(6H)-one
(Formula 7, where Y is O, R_1 is CH_3, Z is N, Ar is 2,4,6-trimethylphenyl)

A. 1-Phenylmethyl-4-(2,4,6-trimethylphenyl)-5-aminotriazole

A mixture of 2,4,6-trimethylbenzyl cyanide (1.0g, 6.3 mmol), benzyl azide (0.92g, 6.9 mmol) and potassium

t-butoxide (0.78g, 6.9 mmol) in tetrahydrofuran (10mL) was stirred at ambient temperature for 2.5 days. The resulting suspension was diluted with water and extracted three times with ethyl acetate. The combined organic layers were dried over $MgSO_4$ and filtered. Solvent was removed in vacuo to give a brown oil. Trituration with ether and filtration afforded a yellow solid (1.12g, 61% yield): NMR ($CDCl_3$,300 MHz):7.60-7.30 (m, 5H), 7.30-7.20 (m, 2H), 5.50 (s, 2H), 3.18 (br s, 2H), 2.30 (s, 3H), 2.10 (s, 6H); CI-MS: 293 (M + H).

B. 4-(2,4,6-Trimethylphenyl)-5-aminotriazole

Sodium (500 mg, 22 mmol) was added with stirring to a mixture of liquid ammonia (30 mL) and 1-phenylmethyl-4-(2,4,6-trimethylphenyl)-5-aminotriazole (1.1g, 3.8 mmol). The reaction mixture was stirred until a dark green color persisted. An ammonium chloride solution (mL) was added and the mixture was stirred while warming to ambient temperature over 16 hours. The residue was treated with a 1M HCl solution and filtered. The aqueous layer was basified with a concentrated ammonium hydroxide solution (pH = 9) and then extracted with ethyl acetate three times. The combined organic layers were dried over $MgSO_4$ and filtered. Solvent was removed in vacuo to give a yellow solid (520 mg), which was homogeneous by thin layer chromatography (ethyl acetate):
NMR ($CDCl_3$,300 MHz): 6.97 (s, 2H), 3.68-3.50 (br.s, 2H), 2.32 (s, 3H), 2.10 (s, 6H); CI-MS: 203 (M + H).

C. 4-(2,4,6-Trimethylphenyl)-5-acetamidinotriazole, acetic acid salt

A mixture of 4-(2,4,6-trimethylphenyl)-5-aminotriazole (400 mg, 1.98 mmol), ethyl acetamidate (261 mg, 3 mmol) and glacial acetic acid (0.1 mL, 1.98 mmol) in acetonitrile (6 mL) was stirred at ambient

temperature for 4 hours. The resulting suspension was filtered and the collected solid was washed with copious amounts of ether. Drying *in vacuo* afforded a white solid (490 mg, 82% yield): NMR (DMSO-d_6,300 MHz):7.90-7.70 (br s, 0.5H), 7.50-7.20 (br. s, 0.5H), 6.90 (s, 2H), 6.90 (s, 2H), 3.50-3.10 (br s, 3H), 2.30-2.20 (br s, 3H), 2.05 (d, 1H, J = 7), 1.96 (s, 6H), 1.87 (s, 6H); CI-MS: 244 (M + H).

D. 5-methyl-3-(2,4,6-trimethylphenyl)[1,5-a]-[1,2,3]-triazolo-[1,3,5]-triazin-7(4H)-one

Sodium (368 mg, 16.2 mmol) was added with stirring to ethanol (10 mL) at room temperature. After the sodium had reacted, 4-(2,4,6-trimethylphenyl)-5-acetamidino-triazole, acetic acid salt (490 mg, 1.6 mmol) and diethyl carbonate (1.6 mL, 13 mmol) were added. The reaction mixture was stirred at reflux temperature for 5 hours, then cooled to room temperature. The reaction mixture was diluted with water; a 1N HCl solution was added until pH = 5-6 and three extractions with ethyl acetate were performed. The combined organic layers were dried over $MgSO_4$ and filtered. Solvent was removed *in vacuo* to give a yellow residue. Trituration with ether and filtration afforded a yellow solid (300 mg, 69% yield): NMR ($CDCl_3$,300 MHz): 6.98 (s, 2H), 2.55 (s, 3H), 2.35 (s, 3H), 2.10 (s, 6H); CI-MS: 270 (M + H).

EXAMPLE 3

Preparation of 4-(di(carbomethoxy)methyl)-2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-1,3,5-triazine

(Formula 1, where R^3 is $CH(CHCO_2CH_3)_2$, R_1 is CH_3, Z is C-CH_3, Ar is 2,4-dimethylphenyl)

A. 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]- pyrazolotriazine

A mixture of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-1,3,5-triazin-4-one (Example 1, 1.38g, 4.5 mmol), N,N-dimethylaniline (1 mL, 8 mmol) and phosphorus oxychloride (10 mL) was stirred at reflux temperature for 48 hours. The excess phosphorus oxychloride was removed *in vacuo*. The residue was poured onto ice-water, stirred briefly and extracted quickly with ethyl acetate three times. The combined organic layers were washed with ice water, then dried over $MgSO_4$ and filtered. Solvent was removed *in vacuo* to give a brown oil. Flash column chromatography (ethyl acetate:hexanes::1:4) gave one fraction (Rf = 0.5) Solvent was removed in vacuo to afford a yellow oil (1.0g, 68% yield): NMR ($CDCl_3$,300 MHz): 7.55 (d, 1H, J = 1), 7.38 (dd, 1H, J = 7,1), 7.30 (d, 1H, J = 7), 2.68 (s, 3H), 2.45 (s, 3H); CI-MS: 327 (M + H).

B. 4-(di(carbomethoxy)methyl)-2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-1,3,5-triazine

Sodium hydride (60% in oil, 80 mg, 2 mmol) was washed with hexanes twice, decanted after each washing and taken up in anhydrous tetrahydrofuran (THF, 1 mL). A solution of diethyl malonate (0.32g, 2 mmol) in THF (2 mL) was added dropwise over 5 min, during which time vigorous gas evolution ensued. A solution of 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolotriazine (0.5g, 1.75 mmol) in THF (2 mL) was added and the reaction mixture was then stirred under a nitrogen atmosphere for 48 hours. The resulting suspension was poured onto water and extracted three times with ethyl acetate. The combined organic layers were washed once with brine, dried over $MgSO_4$ and filtered. Solvent was removed *in vacuo* to give a brown

oil. Column chromatography (ethyl acetate:hexanes::1:9) afforded, after removal of solvent *in vacuo*, a pale yellow solid (Rf = 0.2, 250 mg, 35% yield): mp 50-52°C; NMR ($CDCl_3$, 300 MHz): 12.35 (br.s, 1H, 7.15-7.00 (m, 3H), 4.40 (q, 2H, J = 7), 4.30 (q, 2H, J = 7), 2.4, 2.35, 2.3, 2.2, 2.1 (5 s, 12H), 1.4 (t, 3H, J = 7), 1.35-1.25 (m, 3H); CI-HRMS: Calcd: 411.2032, Found: 411.2023.

EXAMPLE 6

Preparation of 4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolo-1,3,5-triazine

(Formula 1, where R^3 is $NHCH(CH_2OCH_3)_2$, R_1 is CH_3, Z is C-CH_3, Ar is 2,4-dichlorophenyl)

A. 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]- pyrazolotriazine

A mixture of 2,7-dimethyl-8-(2,4 dimethylphenyl)[1,5-a]-pyrazolo-1,3,5-triazin-4-one (Example 1, 1.38g, 4.5 mmol), N,N-dimethylaniline (1 mL, 8 mmol) and phosphorus oxychloride (10 mL) was stirred at reflux temperature for 48 hours. The excess phosphorus oxychloride was removed in vacuo. The residue was poured onto ice-water, stirred briefly and extracted quickly with ethyl acetate three times. The combined organic layers were washed with ice water, then dried over $MgSO_4$ and filtered. Solvent was removed *in vacuo* to give a brown oil. Flash column chromatography (ethyl acetate:hexanes::1:4) gave one fraction (Rf = 0.5) Solvent was removed *in vacuo* to afford a yellow oil (1.0g, 68% yield): NMR ($CDCl_3$,300 MHz): 7.55 (d, 1H, J = 1), 7.38 (dd, 1H, J = 7,1), 7.30 (d, 1H, J = 7), 2.68 (s, 3H), 2.45 (s, 3H); CI-MS: 327 (M + H).


B. 4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4- dichlorophenyl)[1,5-a]-pyrazolo-1,3,5-triazine

A mixture of 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolo-1,3,5-triazine (Part A, 570 mg, 1.74 mmol), 1,3-dimethoxypropyl-2-aminopropane (25mg, 2.08 mmol) and ethanol (10 mL) was stirred at ambient temperature for 18 hours. The reaction mixture was poured onto water (25 mL) and extracted three times with ethyl acetate. The combined organic layers were dried over $MgSO_4$ and filtered. Solvent was removed *in vacuo*. Column chromatography (CH_2Cl_2:CH_3OH::50:1) afforded one fraction. Removal of solvent *in vacuo* gave a solid (250 mg, 35% yield): mp 118-120°C; NMR ($CDCl_3$,300 MHz): 7.50 (s, 1H), 7.28 (dd, 2H, J = 8,1), 6.75 (d, 1H, J = 8), 4.70-4.58 (m, 1H), 3.70-3.55 (m, 4H), 3.43 (s, 6H), 2.50 (s, 3H), 2.35 (s, 3H); CI-HRMS: Calcd: 409.1072, Found: 409.1085; Analysis Calcd. for $C_{18}H_{21}Cl_2N_5O_2$: C, 52.69, H, 5.17, N, 17.07, Cl, 17.28; Found: C, 52.82, H, 5.06, N, 16.77, Cl, 17.50.

Using the above procedures and modifications known to one skilled in the art of organic synthesis, the following additional examples of Tables 1-4 may be prepared.

The examples delineated in TABLE 1 may be prepared by the methods outlined in Examples 1, 2, 3 or 6. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example.

TABLE 1



Ex.	Z	R_3	Ar	mp(°C)
6[a]	C-Me	$NHCH(CH_2OMe)_2$	2,4-Cl_2-Ph	118-120
7[b]	C-Me	$NHCHPr_2$	2,4-Cl_2-Ph	114-116
8[c]	C-Me	NEtBu	2,4-Cl_2-Ph	oil
9[d]	C-Me	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4-Cl_2-Ph	oil
10[e]	C-Me	$N(CH_2CH_2OMe)_2$	2,4-Cl_2-Ph	oil
11[f]	C-Me	NH-3-heptyl	2,4-Cl_2-Ph	90-92
12[g]	C-Me	$NHCH(Et)CH_2OMe$	2,4-Cl_2-Ph	179-181
13[h]	C-Me	NEt_2	2,4-Cl_2-Ph	133-134
14[i]	C-Me	$NHCH(CH_2OEt)_2$	2,4-Cl_2-Ph	oil
15[j]	C-Me	NH-3-pentyl	2,4-Cl_2-Ph	139-140
16[k]	C-Me	NMePh	2,4-Cl_2-Ph	60-62
17[l]	C-Me	NPr_2	2,4-Cl_2-Ph	oil
18[m]	C-Me	NH-3-hexyl	2,4-Cl_2-Ph	130-132
19	C-Me	morpholino	2,4-Cl_2-Ph	
20	C-Me	$N(CH_2Ph)CH_2CH_2OMe$	2,4-Cl_2-Ph	
21	C-Me	$NHCH(CH_2Ph)CH_2OMe$	2,4-Cl_2-Ph	
22	C-Me	NH-4-tetrahydropyranyl	2,4-Cl_2-Ph	
23	C-Me	NH-cyclopentyl	2,4-Cl_2-Ph	
24	C-Me	1,2,3,4-tetrahydro-isoquinolinyl	2,4-Cl_2-Ph	
25	C-Me	CH_2-(1,2,3,4-tetrahydro-isoquinolinyl)	2,4-Cl_2-Ph	
26[n]	C-Me	OEt	2,4-Cl_2-Ph	141-143
27	C-Me	$OCH(Et)CH_2OMe$	2,4-Cl_2-Ph	

	28	C-Me	OCH_2Ph	2,4-Cl_2-Ph	
	29	C-Me	O-3-pentyl	2,4-Cl_2-Ph	
	30	C-Me	SEt	2,4-Cl_2-Ph	
	31	C-Me	S(O)Et	2,4-Cl_2-Ph	
5	32	C-Me	SO_2Et	2,4-Cl_2-Ph	
	33	C-Me	$CH(CO_2Et)_2$	2,4-Cl_2-Ph	
	34	C-Me	$C(Et)(CO_2Et)_2$	2,4-Cl_2-Ph	
	35	C-Me	$CH(Et)CH_2OH$	2,4-Cl_2-Ph	
	36	C-Me	$CH(Et)CH_2OMe$	2,4-Cl_2-Ph	
10	37	C-Me	$CONMe_2$	2,4-Cl_2-Ph	
	38	C-Me	$COCH_3$	2,4-Cl_2-Ph	
	39	C-Me	$CH(OH)CH_3$	2,4-Cl_2-Ph	
	40	C-Me	C(OH)Ph-3-pyridyl	2,4-Cl_2-Ph	
	41	C-Me	Ph	2,4-Cl_2-Ph	
15	42	C-Me	2-CF_3-Ph	2,4-Cl_2-Ph	
	43	C-Me	2-Ph-Ph	2,4-Cl_2-Ph	
	44	C-Me	3-pentyl	2,4-Cl_2-Ph	
	45	C-Me	cyclobutyl	2,4-Cl_2-Ph	
	46	C-Me	3-pyridyl	2,4-Cl_2-Ph	
20	47	C-Me	$CH(Et)CH_2CONMe_2$	2,4-Cl_2-Ph	
	48	C-Me	$CH(Et)CH_2CH_2NMe_2$	2,4-Cl_2-Ph	
	49[o]	C-Me	$NHCH(CH_2OMe)_2$	2,4,6-Me_3-Ph	125-127
	50	C-Me	$NHCHPr_2$	2,4,6-Me_3-Ph	
	51	C-Me	NEtBu	2,4,6-Me_3-Ph	
25	52	C-Me	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4,6-Me_3-Ph	
	53[ae]	C-Me	$N(CH_2CH_2OMe)_2$	2,4,6-Me_3-Ph	123-124
	54	C-Me	NH-3-heptyl	2,4,6-Me_3-Ph	
	55[ac]	C-Me	$NHCH(Et)CH_2OMe$	2,4,6-Me_3-Ph	145-146
	56[ah]	C-Me	NEt_2	2,4,6-Me_3-Ph	88-90
30	57[ai]	C-Me	$NHCH(CH_2OEt)_2$	2,4,6-Me_3-Ph	132-134
	58[ad]	C-Me	NH-3-pentyl	2,4,6-Me_3-Ph	134-135
	59	C-Me	NMePh	2,4,6-Me_3-Ph	
	60	C-Me	NPr_2	2,4,6-Me_3-Ph	
	61	C-Me	NH-3-hexyl	2,4,6-Me_3-Ph	
35	62	C-Me	morpholino	2,4,6-Me_3-Ph	
	63	C-Me	$N(CH_2Ph)CH_2CH_2OMe$	2,4,6-Me_3-Ph	

64	C-Me	NHCH(CH_2Ph)CH_2OMe	2,4,6-Me_3-Ph	
65	C-Me	NH-4-tetrahydropyranyl	2,4,6-Me_3-Ph	
66	C-Me	NH-cyclopentyl	2,4,6-Me_3-Ph	
67	C-Me	1,2,3,4-tetrahydro-isoquinolinyl	2,4,6-Me_3-Ph	
68	C-Me	CH_2-(1,2,3,4-tetrahydro-isoquinolinyl)	2,4,6-Me_3-Ph	
69	C-Me	OEt	2,4,6-Me_3-Ph	
70	C-Me	OCH(Et)CH_2OMe	2,4,6-Me_3-Ph	
71	C-Me	OCH_2Ph	2,4,6-Me_3-Ph	
72	C-Me	O-3-pentyl	2,4,6-Me_3-Ph	
73	C-Me	SEt	2,4,6-Me_3-Ph	
74	C-Me	S(O)Et	2,4,6-Me_3-Ph	
75	C-Me	SO_2Et	2,4,6-Me_3-Ph	
76	C-Me	CH(CO_2Et)$_2$	2,4,6-Me_3-Ph	
77	C-Me	C(Et)(CO_2Et)$_2$	2,4,6-Me_3-Ph	
78	C-Me	CH(Et)CH_2OH	2,4,6-Me_3-Ph	
79	C-Me	CH(Et)CH_2OMe	2,4,6-Me_3-Ph	
80	C-Me	$CONMe_2$	2,4,6-Me_3-Ph	
81	C-Me	$COCH_3$	2,4,6-Me_3-Ph	
82	C-Me	CH(OH)CH_3	2,4,6-Me_3-Ph	
83	C-Me	C(OH)Ph-3-pyridyl	2,4,6-Me_3-Ph	
84	C-Me	Ph	2,4,6-Me_3-Ph	
85	C-Me	2-CF_3-Ph	2,4,6-Me_3-Ph	
86	C-Me	2-Ph-Ph	2,4,6-Me_3-Ph	
87	C-Me	3-pentyl	2,4,6-Me_3-Ph	
88	C-Me	cyclobutyl	2,4,6-Me_3-Ph	
89	C-Me	3-pyridyl	2,4,6-Me_3-Ph	
90	C-Me	CH(Et)CH_2CONMe_2	2,4,6-Me_3-Ph	
91	C-Me	CH(Et)$CH_2CH_2NMe_2$	2,4,6-Me_3-Ph	
92[p]	C-Me	NHCH(CH_2OMe)$_2$	2,4-Me_2-Ph	44-45
93[q]	C-Me	N(CH_2CH_2OMe)$_2$	2,4-Me_2-Ph	oil
94[r]	C-Me	NHCH(Et)CH_2OMe	2,4-Me_2-Ph	102-104
95[s]	C-Me	NH-3-pentyl	2,4-Me_2-Ph	102-104
96[t]	C-Me	NEt_2	2,4-Me_2-Ph	oil
97[u]	C-Me	N(CH_2CN)$_2$	2,4-Me_2-Ph	148-150

	98[v]	C-Me	NHCH(Me)CH_2OMe	2,4-Me_2-Ph	102-104
	99[w]	C-Me	OCH(Et)CH_2OMe	2,4-Me_2-Ph	oil
	100[x]	C-Me	NPr-c-C_3H_5	2,4-Me_2-Ph	oil
	101[y]	C-Me	NHCH(Me)CH_2NMe_2	2,4-Me_2-Ph	47-48
5	102[z]	C-Me	N(c-C_3H_5)CH_2CH_2CN	2,4-Me_2-Ph	117-118
	103[aa]	C-Me	N(Pr)CH_2CH_2CN	2,4-Me_2-Ph	oil
	104[ab]	C-Me	N(Bu)CH_2CH_2CN	2,4-Me_2-Ph	oil
	105	C-Me	$NHCHPr_2$	2,4-Me_2-Ph	
	106	C-Me	NEtBu	2,4-Me_2-Ph	
10	107	C-Me	NPr(CH_2-c-C_3H_5)	2,4-Me_2-Ph	
	108	C-Me	NH-3-heptyl	2,4-Me_2-Ph	
	109	C-Me	NEt_2	2,4-Me_2-Ph	
	110	C-Me	NHCH(CH_2OEt)$_2$	2,4-Me_2-Ph	
	111	C-Me	NH-3-pentyl	2,4-Me_2-Ph	
15	112	C-Me	NMePh	2,4-Me_2-Ph	
	113	C-Me	NPr_2	2,4-Me_2-Ph	
	114	C-Me	NH-3-hexyl	2,4-Me_2-Ph	
	115	C-Me	morpholino	2,4-Me_2-Ph	
	116	C-Me	N(CH_2Ph)CH_2CH_2OMe	2,4-Me_2-Ph	
20	117	C-Me	NHCH(CH_2Ph)CH_2OMe	2,4-Me_2-Ph	
	118	C-Me	NH-4-tetrahydropyranyl	2,4-Me_2-Ph	
	119	C-Me	NH-cyclopentyl	2,4-Me_2-Ph	
	120	C-Me	1,2,3,4-tetrahydro-isoquinolinyl	2,4-Me_2-Ph	
25	121	C-Me	CH_2-(1,2,3,4-tetrahydro-isoquinolinyl)	2,4-Me_2-Ph	
	122	C-Me	OEt	2,4-Me_2-Ph	
	123	C-Me	OCH(Et)CH_2OMe	2,4-Me_2-Ph	
	124	C-Me	OCH_2Ph	2,4-Me_2-Ph	
30	125	C-Me	O-3-pentyl	2,4-Me_2-Ph	
	126	C-Me	SEt	2,4-Me_2-Ph	
	127	C-Me	S(O)Et	2,4-Me_2-Ph	
	128	C-Me	SO_2Et	2,4-Me_2-Ph	
	3	C-Me	CH(CO_2Et)$_2$	2,4-Me_2-Ph	50-52
35	129	C-Me	C(Et)(CO_2Et)$_2$	2,4-Me_2-Ph	

	130	C-Me	$CH(Et)CH_2OH$	$2,4\text{-}Me_2\text{-}Ph$	
	131	C-Me	$CH(Et)CH_2OMe$	$2,4\text{-}Me_2\text{-}Ph$	
	132	C-Me	$CH(Et)CH_2OEt$	$2,4\text{-}Me_2\text{-}Ph$	
	133	C-Me	$CONMe_2$	$2,4\text{-}Me_2\text{-}Ph$	
5	134	C-Me	$COCH_3$	$2,4\text{-}Me_2\text{-}Ph$	
	135	C-Me	$CH(OH)CH_3$	$2,4\text{-}Me_2\text{-}Ph$	
	136	C-Me	C(OH)Ph-3-pyridyl	$2,4\text{-}Me_2\text{-}Ph$	
	137	C-Me	Ph	$2,4\text{-}Me_2\text{-}Ph$	
	138	C-Me	$2\text{-}CF_3\text{-}Ph$	$2,4\text{-}Me_2\text{-}Ph$	
10	139	C-Me	2-Ph-Ph	$2,4\text{-}Me_2\text{-}Ph$	
	140	C-Me	3-pentyl	$2,4\text{-}Me_2\text{-}Ph$	
	141	C-Me	cyclobutyl	$2,4\text{-}Me_2\text{-}Ph$	
	142	C-Me	3-pyridyl	$2,4\text{-}Me_2\text{-}Ph$	
	143	C-Me	$CH(Et)CH_2CONMe_2$	$2,4\text{-}Me_2\text{-}Ph$	
15	144	C-Me	$CH(Et)CH_2CH_2NMe_2$	$2,4\text{-}Me_2\text{-}Ph$	
	145[bc]	C-Me	$NHCH(CH_2OMe)_2$	2-Me-4-MeO-Ph	45-46
	146[bd]	C-Me	$N(CH_2CH_2OMe)_2$	2-Me-4-MeO-Ph	oil
	147[be]	C-Me	$NHCH(Et)CH_2OMe$	2-Me-4-MeO-Ph	86-88
	148[bf]	C-Me	$N(Pr)CH_2CH_2CN$	2-Me-4-MeO-Ph	oil
20	149	C-Me	$OCH(Et)CH_2OMe$	2-Me-4-MeO-Ph	
	150[af]	C-Me	$NHCH(CH_2OMe)_2$	2-Br-4-MeO-Ph	88-90
	151[al]	C-Me	$N(CH_2CH_2OMe)_2$	2-Br-4-MeO-Ph	oil
	152[ag]	C-Me	$NHCH(Et)CH_2OMe$	2-Br-4-MeO-Ph	95-97
	153	C-Me	$N(Pr)CH_2CH_2CN$	2-Br-4-MeO-Ph	
25	154	C-Me	$OCH(Et)CH_2OMe$	2-Br-4-MeO-Ph	
	155	C-Me	$NHCH(CH_2OMe)_2$	$2\text{-}Me\text{-}4\text{-}NMe_2\text{-}Ph$	
	156	C-Me	$N(CH_2CH_2OMe)_2$	$2\text{-}Me\text{-}4\text{-}NMe_2\text{-}Ph$	oil
	157	C-Me	$NHCH(Et)CH_2OMe$	$2\text{-}Me\text{-}4\text{-}NMe_2\text{-}Ph$	
	158	C-Me	$N(Pr)CH_2CH_2CN$	$2\text{-}Me\text{-}4\text{-}NMe_2\text{-}Ph$	
30	159	C-Me	$OCH(Et)CH_2OMe$	$2\text{-}Me\text{-}4\text{-}NMe_2\text{-}Ph$	
	160	C-Me	$NHCH(CH_2OMe)_2$	$2\text{-}Br\text{-}4\text{-}NMe_2\text{-}Ph$	
	161	C-Me	$N(CH_2CH_2OMe)_2$	$2\text{-}Br\text{-}4\text{-}NMe_2\text{-}Ph$	
	162	C-Me	$NHCH(Et)CH_2OMe$	$2\text{-}Br\text{-}4\text{-}NMe_2\text{-}Ph$	
	163	C-Me	$N(Pr)CH_2CH_2CN$	$2\text{-}Br\text{-}4\text{-}NMe_2\text{-}Ph$	
35	164	C-Me	$OCH(Et)CH_2OMe$	$2\text{-}Br\text{-}4\text{-}NMe_2\text{-}Ph$	
	165	C-Me	$NHCH(CH_2OMe)_2$	2-Br-4-i-Pr-Ph	

	166	C-Me	$N(CH_2CH_2OMe)_2$	2-Br-4-i-Pr-Ph	
	167	C-Me	$NHCH(Et)CH_2OMe$	2-Br-4-i-Pr-Ph	
	168	C-Me	$N(Pr)CH_2CH_2CN$	2-Br-4-i-Pr-Ph	
	169	C-Me	$OCH(Et)CH_2OMe$	2-Br-4-i-Pr-Ph	
5	170	C-Me	$NHCH(CH_2OMe)_2$	2-Br-4-Me-Ph	
	171	C-Me	$N(CH_2CH_2OMe)_2$	2-Br-4-Me-Ph	
	172	C-Me	$NHCH(Et)CH_2OMe$	2-Br-4-Me-Ph	
	173	C-Me	$N(Pr)CH_2CH_2CN$	2-Br-4-Me-Ph	
	174	C-Me	$OCH(Et)CH_2OMe$	2-Br-4-Me-Ph	
10	175[ar]	C-Me	$NHCH(CH_2OMe)_2$	2-Me-4-Br-Ph	108-109
	176	C-Me	$N(CH_2CH_2OMe)_2$	2-Me-4-Br-Ph	
	177	C-Me	$NHCH(Et)CH_2OMe$	2-Me-4-Br-Ph	
	178	C-Me	$N(Pr)CH_2CH_2CN$	2-Me-4-Br-Ph	
	179	C-Me	$OCH(Et)CH_2OMe$	2-Me-4-Br-Ph	
15	180	C-Me	$NHCH(CH_2OMe)_2$	2-Cl-4,6-Me_2-Ph	
	181	C-Me	$N(CH_2CH_2OMe)_2$	2-Cl-4,6-Me_2-Ph	
	182	C-Me	$NHCH(CH_2OMe)_2$	4-Br-2,6-$(Me)_2$-Ph	
	183	C-Me	$N(CH_2CH_2OMe)_2$	4-Br-2,6-$(Me)_2$-Ph	
	184	C-Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SMe-Ph	
20	185	C-Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SMe-Ph	
	186	C-Me	$NHCH(CH_2OMe)_2$	2-Br-4-CF_3-Ph	
	187	C-Me	$N(CH_2CH_2OMe)_2$	2-Br-4-CF_3-Ph	
	188	C-Me	$NHCH(CH_2OMe)_2$	2-Br-4,6-$(MeO)_2$-Ph	
	189	C-Me	$N(CH_2CH_2OMe)_2$	2-Br-4,6-$(MeO)_2$-Ph	
25	190	C-Me	$NHCH(CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$-Ph	
	191	C-Me	$N(CH_2CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$-Ph	
	192	C-Me	$NHCH(CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph	
	193	C-Me	$N(CH_2CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph	
	194	C-Me	$NHCH(CH_2OMe)_2$	4-(COMe)-2-Br-Ph	
30	195	C-Me	$N(CH_2CH_2OMe)_2$	4-(COMe)-2-Br-Ph	
	196	C-Me	$NHCH(CH_2OMe)_2$	2,4,6-Me_3-pyrid-3-yl	
	197	C-Me	$N(CH_2CH_2OMe)_2$	2,4,6-Me_3-pyrid-3-yl	
	198	C-Me	$NHCH(CH_2OMe)_2$	2,4-$(Br)_2$-Ph	
	199	C-Me	$N(CH_2CH_2OMe)_2$	2,4-$(Br)_2$-Ph	
35	200	C-Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SMe-Ph	
	201	C-Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SMe-Ph	

202	C-Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SO_2Me-Ph
203	C-Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SO_2Me-Ph
204	C-Me	$NHCH(CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
205	C-Me	$N(CH_2CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
206	C-Me	$NHCH(CH_2OMe)_2$	2,6-(Me)2-4-SO_2Me-Ph
207	C-Me	$N(CH_2CH_2OMe)_2$	2,6-(Me)2-4-SO_2Me-Ph
208	C-Me	$NHCH(CH_2OMe)_2$	2-I-4-i-Pr-Ph
209	C-Me	$N(CH_2CH_2OMe)_2$	2-I-4-i-Pr-Ph
210	C-Me	$NHCH(CH_2OMe)_2$	2-Br-4-$N(Me)_2$-6-MeO-Ph
211	C-Me	$N(CH_2CH_2OMe)_2$	2-Br-4-$N(Me)_2$-6-MeO-Ph
212	C-Me	$NHCH(CH_2OMe)_2$	2,4-[SMe]2-Ph
213	C-Me	$N(CH_2CH_2OMe)_2$	2,4-[SMe]2-Ph
214	C-Me	$NHCH(CH_2OMe)_2$	2,4-[SO_2Me]2-Ph
215	C-Me	$N(CH_2CH_2OMe)_2$	2,4-[SO_2Me]2-Ph
216	C-Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
217	C-Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
218	C-Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SO_2Me-Ph
219	C-Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SO_2Me-Ph
220	C-Me	$NHCH(CH_2OMe)_2$	2-$N(Me)_2$-4-Me-Ph
221	C-Me	$N(CH_2CH_2OMe)_2$	2-$N(Me)_2$-4-Me-Ph
222	C-Me	$NHCH(CH_2OMe)_2$	2-MeS-4,6-$(Me)_2$-Ph
223	C-Me	$N(CH_2CH_2OMe)_2$	2-MeS-4,6-$(Me)_2$-Ph
224	C-Me	$NHCH(CH_2OMe)_2$	2-(CH_3CO)-4,6-$(Me)_2$-Ph
225	C-Me	$N(CH_2CH_2OMe)_2$	2-(CH_3CO)-4,6-$(Me)_2$-Ph
226	H	$NHCH(CH_2OMe)_2$	2,4-Me_2-Ph
227	H	$NHCH(CH_2OMe)_2$	2,4-Me_2-Ph
228	CF3	$N(CH_2CH_2OMe)_2$	2,4-Me_2-Ph
229	CF3	$N(CH_2CH_2OMe)_2$	2,4-Me_2-Ph
230	N	$NHCH(CH_2OMe)_2$	2,4,6-Me_3-Ph
231	N	$NHCHPr_2$	2,4,6-Me_3-Ph
232	N	NEtBu	2,4,6-Me_3-Ph
233	N	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4,6-Me_3-Ph
234	N	$N(CH_2CH_2OMe)_2$	2,4,6-Me_3-Ph
235	N	NH-3-heptyl	2,4,6-Me_3-Ph
236	N	NHCH(Et)CH_2OMe	2,4,6-Me_3-Ph
237	N	NEt_2	2,4,6-Me_3-Ph

238	N	$NHCH(CH_2OEt)_2$	2,4,6-Me_3-Ph
239	N	NH-3-pentyl	2,4,6-Me_3-Ph
240	N	NMePh	2,4,6-Me_3-Ph
241	N	NPr_2	2,4,6-Me_3-Ph
242	N	NH-3-hexyl	2,4,6-Me_3-Ph
243	N	morpholino	2,4,6-Me_3-Ph
244	N	$N(CH_2Ph)CH_2CH_2OMe$	2,4,6-Me_3-Ph
245	N	$NHCH(CH_2Ph)CH_2OMe$	2,4,6-Me_3-Ph
246	N	NH-4-tetrahydropyranyl	2,4,6-Me_3-Ph
247	N	NH-cyclopentyl	2,4,6-Me_3-Ph
248	N	1,2,3,4-tetrahydro-isoquinolinyl	2,4,6-Me_3-Ph
249	N	CH_2-(1,2,3,4-tetrahydro-isoquinolinyl)	2,4,6-Me_3-Ph
250	N	OEt	2,4,6-Me_3-Ph
251	N	$OCH(Et)CH_2OMe$	2,4,6-Me_3-Ph
252	N	OCH_2Ph	2,4,6-Me_3-Ph
253	N	O-3-pentyl	2,4,6-Me_3-Ph
254	N	SEt	2,4,6-Me_3-Ph
255	N	S(O)Et	2,4,6-Me_3-Ph
256	N	SO_2Et	2,4,6-Me_3-Ph
257	N	$CH(CO_2Et)_2$	2,4,6-Me_3-Ph
258	N	$C(Et)(CO_2Et)_2$	2,4,6-Me_3-Ph
259	N	$CH(Et)CH_2OH$	2,4,6-Me_3-Ph
260	N	$CH(Et)CH_2OMe$	2,4,6-Me_3-Ph
261	N	$CONMe_2$	2,4,6-Me_3-Ph
262	N	$COCH_3$	2,4,6-Me_3-Ph
263	N	$CH(OH)CH_3$	2,4,6-Me_3-Ph
264	N	C(OH)Ph-3-pyridyl	2,4,6-Me_3-Ph
265	N	Ph	2,4,6-Me_3-Ph
266	N	2-CF_3-Ph	2,4,6-Me_3-Ph
267	N	2-Ph-Ph	2,4,6-Me_3-Ph
268	N	3-pentyl	2,4,6-Me_3-Ph
269	N	cyclobutyl	2,4,6-Me_3-Ph
270	N	3-pyridyl	2,4,6-Me_3-Ph
271	N	$CH(Et)CH_2CONMe_2$	2,4,6-Me_3-Ph

272	N	$CH(Et)CH_2CH_2NMe_2$	2,4,6-Me_3-Ph
273	N	$NHCH(CH_2OMe)_2$	2,4-Me_2-Ph
274	N	$NHCHPr_2$	2,4-Me_2-Ph
275	N	NEtBu	2,4-Me_2-Ph
276	N	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4-Me_2-Ph
277	N	$N(CH_2CH_2OMe)_2$	2,4-Me_2-Ph
278	N	NH-3-heptyl	2,4-Me_2-Ph
279	N	$NHCH(Et)CH_2OMe$	2,4-Me_2-Ph
280	N	NEt_2	2,4-Me_2-Ph
281	N	$NHCH(CH_2OEt)_2$	2,4-Me_2-Ph
282	N	NH-3-pentyl	2,4-Me_2-Ph
283	N	NMePh	2,4-Me_2-Ph
284	N	NPr_2	2,4-Me_2-Ph
285	N	NH-3-hexyl	2,4-Me_2-Ph
286	N	morpholino	2,4-Me_2-Ph
287	N	$N(CH_2Ph)CH_2CH_2OMe$	2,4-Me_2-Ph
288	N	$NHCH(CH_2Ph)CH_2OMe$	2,4-Me_2-Ph
289	N	NH-4-tetrahydropyranyl	2,4-Me_2-Ph
290	N	NH-cyclopentyl	2,4-Me_2-Ph
291	N	1,2,3,4-tetrahydro-isoquinolinyl	2,4-Me_2-Ph
292	N	CH_2-(1,2,3,4-tetrahydro-isoquinolinyl)	2,4-Me_2-Ph
293	N	OEt	2,4-Me_2-Ph
294	N	$OCH(Et)CH_2OMe$	2,4-Me_2-Ph
295	N	OCH_2Ph	2,4-Me_2-Ph
296	N	O-3-pentyl	2,4-Me_2-Ph
297	N	SEt	2,4-Me_2-Ph
298	N	S(O)Et	2,4-Me_2-Ph
299	N	SO_2Et	2,4-Me_2-Ph
300	N	$CH(CO_2Et)_2$	2,4-Me_2-Ph
301	N	$C(Et)(CO_2Et)_2$	2,4-Me_2-Ph
302	N	$CH(Et)CH_2OH$	2,4-Me_2-Ph
303	N	$CH(Et)CH_2OMe$	2,4-Me_2-Ph
304	N	$CONMe_2$	2,4-Me_2-Ph
305	N	$COCH_3$	2,4-Me_2-Ph

306	N	CH(OH)CH_3	2,4-Me_2-Ph	
307	N	C(OH)Ph-3-pyridyl	2,4-Me_2-Ph	
308	N	Ph	2,4-Me_2-Ph	
309	N	2-CF_3-Ph	2,4-Me_2-Ph	
310	N	2-Ph-Ph	2,4-Me_2-Ph	
311	N	3-pentyl	2,4-Me_2-Ph	
312	N	cyclobutyl	2,4-Me_2-Ph	
313	N	3-pyridyl	2,4-Me_2-Ph	
314	N	CH(Et)CH_2CONMe_2	2,4-Me_2-Ph	
315	N	CH(Et)$CH_2CH_2NMe_2$	2,4-Me_2-Ph	
316[an]	C-Me	NEt_2	2-Br-4-MeO-Ph	oil
317[am]	C-Me	NH-3-pentyl	2-Br-4-MeO-Ph	oil
318[aj]	C-Me	NHCH(CH_2CH_2OMe)CH_2OMe	2,4,6-Me_3-Ph	101-103
319[ao]	C-Me	NH(c-C_3H_5)	2,4-Me_2-Ph	oil
320[ak]	C-Me	morpholino	2,4,6-Me_3-Ph	139-141
321[ap]	C-Me	NHCH(CH_2OMe)$_2$	2-CN-4-Me-Ph	152-153
322[aq]	C-Me	N(c-C_3H_5)CH_2CH_2CN	2,4,6-Me_3-Ph	149-151
324[as]	C-Me	NHCH(CH_2CH_2OMe)CH_2OMe	2-Me-4-Br-Ph	115-117
325[at]	C-Me	NHCH(CH_2OMe)$_2$	2,5-Me_2-4-MeO-Ph	55-57
326[au]	C-Me	N(CH_2CH_2OMe)$_2$	2,5-Me_2-4-MeO-Ph	72
327[av]	C-Me	NH-3-pentyl	2,5-Me_2-4-MeO-Ph	45-47
328[aw]	C-Me	NEt_2	2,5-Me_2-4-MeO-Ph	oil
329[ax]	C-Me	NHCH(CH_2OMe)$_2$	2-Cl-4-MePh	80-81
330[ay]	C-Me	NCH(Et)CH_2OMe	2-Cl-4-MePh	77-79
331[az]	C-Me	N(CH_2CH_2OMe)$_2$	2-Cl-4-MePh	oil
332[ba]	C-Me	(S)-NHCH(CH_2CH_2OMe)CH_2OMe	2-Cl-4-MePh	139-140
333[bb]	C-Me	N(c-C_3H_5)CH_2CH_2CN	2,5-Me_2-4-MeOPh	120-122
334[bg]	C-Me	NEt_2	2-Me-4-MeOPh	oil
335[bh]	C-Me	OEt	2-Me-4-MeOPh	oil
336[bi]	C-Me	(S)-NHCH(CH_2CH_2OMe)CH_2OMe	2-Me-4-MeOPh	oil
337[bj]	C-Me	N(c-C_3H_5)CH_2CH_2CN	2-Me-4-MeOPh	129
338[bk]	C-Me	NHCH(CH_2CH_2OEt)$_2$	2-Me-4-MeOPh	amorph.
339	C-Me	N(c-C_3H_5)CH_2CH_2CN	2,4-Cl_2-Ph	109-110
340	C-Me	(S)-NHCH(CH_2CH_2OMe)CH_2OMe	2,4-Cl_2-Ph	93-94
341	C-Me	NH-3-pentyl	2-Me-4-BrPh	118-119
342	C-Me	N(CH_2CH_2OMe)$_2$	2-Me-4-BrPh	oil

	343	C-Me	NHCH(CH_2-iPr)CH_2OMe	2,4-Me_2-Ph	oil
	344	C-Me	NHCH(Pr)CH_2OMe	2,4-Me_2-Ph	94-95
	345	C-Me	NHCH(Et)CH_2OEt	2,4-Me_2-Ph	76-77
	346	C-Me	NHCH(CH_2OMe)CH_2CH_2OMe	2-Me-4-Me_2NPh	oil
5	347	C-Me	NEt_2	2-Me-4-ClPh	oil
	348	C-Me	NH-3-pentyl	2-Me-4-ClPh	122-124
	349	C-Me	N(CH_2CH_2OMe)$_2$	2-Me-4-ClPh	oil
	350	C-Me	NHCH(CH_2OMe)$_2$	2-Me-4-ClPh	122-123
	351	C-Me	NEt_2	2-Me-4-ClPh	oil
10	352	C-Me	NEt_2	2-Cl-4-MePh	oil
	353	C-Me	NH-3-pentyl	2-Cl-4-MePh	120-121
	354	C-Me	NHCH(CH_2OMe)$_2$	2-Cl-4-MeOPh	
	355[bl]	C-Me	N(CH_2CH_2OMe)$_2$	2-Cl-4-MeOPh	oil
	356[bm]	C-Me	NHCH(Et)CH_2OMe	2-Cl-4-MeOPh	108-110
15	357[bn]	C-Me	N(c-Pr)CH_2CH_2CN	2-Cl-4-MeOPh	127-129
	358[bo]	C-Me	NEt_2	2-Cl-4-MeOPh	oil
	359[bp]	C-Me	NH-3-pentyl	2-Cl-4-MeOPh	77-79
	360	C-Me	NHCH(Et)CH_2CH_2OMe	2-Cl-4-MeOPh	
	361	C-Me	NHCH(Me)CH_2CH_2OMe	2-Cl-4-MeOPh	
20	362	C-Me	NHCH(Et)CH_2CH_2OMe	2-Br-4-MeOPh	
	363	C-Me	NHCH(Me)CH_2CH_2OMe	2-Br-4-MeOPh	
	364	C-Me	NHCH(Et)CH_2CH_2OMe	2-Me-4-MeOPh	
	365	C-Me	NHCH(Me)CH_2CH_2OMe	2-Me-4-MeOPh	
	366	C-Me	NHCH(CH_2OMe)$_2$	2-Cl-4,5-(MeO)$_2$Ph	
25	367	C-Me	N(CH_2CH_2OMe)$_2$	2-Cl-4,5-(MeO)$_2$Ph	
	368	C-Me	NHCH(Et)CH_2OMe	2-Cl-4,5-(MeO)$_2$Ph	
	369	C-Me	N(c-Pr)CH_2CH_2CN	2-Cl-4,5-(MeO)$_2$Ph	
	370	C-Me	NEt_2	2-Cl-4,5-(MeO)$_2$Ph	
	371	C-Me	NH-3-pentyl	2-Cl-4,5-(MeO)$_2$Ph	
30	372	C-Me	NHCH(Et)CH_2CH_2OMe	2-Cl-4,5-(MeO)$_2$Ph	
	373	C-Me	NHCH(Me)CH_2CH_2OMe	2-Cl-4,5-(MeO)$_2$Ph	
	374[bq]	C-Me	NHCH(CH_2OMe)$_2$	2-Br-4,5-(MeO)$_2$Ph	137-138
	375	C-Me	N(CH_2CH_2OMe)$_2$	2-Br-4,5-(MeO)$_2$Ph	
	376[br]	C-Me	NHCH(Et)CH_2OMe	2-Br-4,5-(MeO)$_2$Ph	147-148
35	377	C-Me	N(c-Pr)CH_2CH_2CN	2-Br-4,5-(MeO)$_2$Ph	
	378[bs]	C-Me	NEt_2	2-Br-4,5-(MeO)$_2$Ph	52-58

379	C-Me	NH-3-pentyl	2-Br-4,5-$(MeO)_2$Ph
380	C-Me	NHCH(Et)CH_2CH_2OMe	2-Br-4,5-$(MeO)_2$Ph
381	C-Me	NHCH(Me)CH_2CH_2OMe	2-Br-4,5-$(MeO)_2$Ph
382	C-Me	NHCH$(CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$Ph
383	C-Me	N$(CH_2CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$Ph
384	C-Me	NHCH(Et)CH_2OMe	2-Cl-4,6-$(MeO)_2$Ph
385	C-Me	N(c-Pr)CH_2CH_2CN	2-Cl-4,6-$(MeO)_2$Ph
386	C-Me	NEt_2	2-Cl-4,6-$(MeO)_2$Ph
387	C-Me	NH-3-pentyl	2-Cl-4,6-$(MeO)_2$Ph
388	C-Me	NHCH(Et)CH_2CH_2OMe	2-Cl-4,6-$(MeO)_2$Ph
389	C-Me	NHCH(Me)CH_2CH_2OMe	2-Cl-4,6-$(MeO)_2$Ph
390	C-Me	NHCH$(CH_2OMe)_2$	2-Me-4,6-$(MeO)_2$Ph
391	C-Me	N$(CH_2CH_2OMe)_2$	2-Me-4,6-$(MeO)_2$Ph
392	C-Me	NHCH(Et)CH_2OMe	2-Me-4,6-$(MeO)_2$Ph
393	C-Me	N(c-Pr)CH_2CH_2CN	2-Me-4,6-$(MeO)_2$Ph
395	C-Me	NEt_2	2-Me-4,6-$(MeO)_2$Ph
396	C-Me	NH-3-pentyl	2-Me-4,6-$(MeO)_2$Ph
397	C-Me	NHCH(Et)CH_2CH_2OMe	2-Me-4,6-$(MeO)_2$Ph
398	C-Me	NHCH(Me)CH_2CH_2OMe	2-Me-4,6-$(MeO)_2$Ph
399	C-Me	N(c-Pr)CH_2CH_2CN	2-Br-4,6-$(MeO)_2$Ph
400	C-Me	NEt_2	2-Br-4,6-$(MeO)_2$Ph
401	C-Me	NH-3-pentyl	2-Br-4,6-$(MeO)_2$Ph
402	C-Me	NHCH(Et)CH_2CH_2OMe	2-Br-4,6-$(MeO)_2$Ph
403	C-Me	NHCH(Me)CH_2CH_2OMe	2-Br-4,6-$(MeO)_2$Ph
404	C-Me	NHCH(Et)CH_2CH_2OMe	2-Me-4-MeOPh
405	C-Me	NHCH(Me)CH_2CH_2OMe	2-Me-4-MeOPh
406	C-Me	NHCH$(CH_2OMe)_2$	2-MeO-4-MePh
407	C-Me	N$(CH_2CH_2OMe)_2$	2-MeO-4-MePh
408	C-Me	NHCH(Et)CH_2OMe	2-MeO-4-MePh
409	C-Me	N(c-Pr)CH_2CH_2CN	2-MeO-4-MePh
410	C-Me	NEt_2	2-MeO-4-MePh
411	C-Me	NH-3-pentyl	2-MeO-4-MePh
412	C-Me	NHCH(Et)CH_2CH_2OMe	2-MeO-4-MePh
413	C-Me	NHCH(Me)CH_2CH_2OMe	2-MeO-4-MePh
414	C-Me	NHCH$(CH_2OMe)_2$	2-MeO-4-MePh
415	C-Me	N$(CH_2CH_2OMe)_2$	2-MeO-4-MePh

416	C-Me	NHCH(Et)CH_2OMe	2-Me0-4-MePh		
417	C-Me	N(c-Pr)CH_2CH_2CN	2-Me0-4-MePh		
418	C-Me	NEt_2	2-Me0-4-MePh		
419	C-Me	NH-3-pentyl	2-Me0-4-MePh		
420	C-Me	NHCH(Et)CH_2CH_2OMe	2-Me0-4-MePh		
421	C-Me	NHCH(Me)CH_2CH_2OMe	2-Me0-4-MePh		
423[bt]	C-Me	NHCH($CH_2OMe)_2$	2-Me0-4-ClPh	oil	
424	C-Me	N($CH_2CH_2OMe)_2$	2-Me0-4-ClPh		
425	C-Me	NHCH(Et)CH_2OMe	2-Me0-4-ClPh		
426	C-Me	N(c-Pr)CH_2CH_2CN	2-Me0-4-ClPh		
427	C-Me	NEt_2	2-Me0-4-ClPh		
428	C-Me	NH-3-pentyl	2-Me0-4-ClPh		
429	C-Me	NHCH(Et)CH_2CH_2OMe	2-Me0-4-ClPh		
430	C-Me	NHCH(Me)CH_2CH_2OMe	2-Me0-4-ClPh		

NOTES FOR TABLE 1:

a) Analysis Calcd: C, 52.69, H, 5.17, N, 17.07, Cl, 17.28; Found: C, 52.82, H, 5.06, N, 16.77, Cl, 17.50.

b) CI-HRMS: Calcd: 406.1565, Found: 405.1573 (M + H); Analysis Calcd: C: 59.11; H: 6.20; N: 17.23; Cl: 17.45; Found: C: 59.93; H: 6.34; N: 16.50; Cl: 16.95;
NMR ($CDCl_3$, 300 MHz): 0.95 (t, J = 8, 4H), 1.30-1.40 (m, 4H), 1.50-1.75 (m, 4H), 2.35 (s, 3H), 2.48 (s, 3H), 4.30-4.45 (m, 1H), 6.15 (d, J = 8, 1H), 7.30 (s, 2H), 7.50 (s, 1H)

c) CI-HRMS: Calcd: 392.1409, Found: 392.1388 (M + H);
NMR ($CDCl_3$, 300 MHz): 1.00 (t, J =8, 3H), 1.35 (t, J = 8, 3H), 1.41 (q, J = 8, 2H), 1.65-1.85 (m, 2H), 2.30 (s, 3H), 2.40 (s, 3H), 3.85-4.20 (m, 4H), 7.30 (s, 2H), 7.50 (s, 1H).

d) CI-HRMS: Calcd: 404.1409, Found: 404.1408 (M + H);
NMR($CDCl_3$, 300 MHz): 0.35-0.45 (m, 2H), 0.52-0.62 (m, 2H), 0.98 (t, J = 8, 3H), 1.70-1.90 (m, 2H),

2.30 (s, 3H), 2.40 (s, 3H), 3.85-4.02 (m, 2H), 4.02-4.20 (m, 2H), 7.30 (s, 2H), 7.50 (s, 1H).

e) CI-HRMS: Calcd: 424.1307, Found: 424.1307 (M + H): NMR ($CDCl_3$, 300 MHz): 2.28 (s, 3H), 2.40 (s, 3H), 3.40 (s, 6H), 3.75 (t, J = 8, 4H), 4.20-4.45 (m, 4H), 7.30 (s, 2H), 7.50 (s, 1H).

f) CI-HRMS: Calcd: 406.1565, Found: 406.1578 (M + H); NMR ($CDCl_3$, 300 MHz): 0.90 (t, J = 8, 3H), 1.00 (t, J = 8, 3H), 1.28-1.45 (m, 4H), 1.50-1.80 (m, 4H), 2.35 (s, 3H), 2.50 (s, 3H), 4.20-4.35 (m, 1H), 6.10-6.23 (m, 1H), 7.30 (s, 2H), 7.50 (s, 1H).

g) CI-HRMS: Calcd: 394.1201, Found: 394.1209 (M + H); NMR ($CDCl_3$, 300 MHz): 1.02 (t, J = 8, 3H), 1.65-1.90 (m, 2H), 2.35 (s, 3H), 2.48 (s, 3H), 3.40 (s, 3H), 3.50-3.60 (m, 2H), 4.35-4.45 (brs, 1H), 6.50-6.60 (m, 1H), 7.30 (s, 2H), 7.50 (s, 1H).

h) CI-HRMS: Calcd: 364.1096, Found: 364.1093 (M + H); Analysis: Calcd: C: 56.05; H: 5.27; N: 19.23; Cl: 19.46; Found: C: 55.96; H: 5.24; N: 18.93; Cl: 19.25;
NMR ($CDCl_3$, 300 MHz): 1.35 (t, J = 8, 6H), 2.30 (3, 3H), 2.40 (s, 3H), 3.95-4.15 (m, 4H), 7.30 (s, 2H), 7.50 (d, J = 1, 1H).

i) CI-HRMS: Calcd: 438.1464, Found: 438.1454 (M + H); NMR ($CDCl_3$, 300 MHz): 1.22 (t, J = 8, 6H), 2.35 (s, 3H), 2.47 (s, 3H), 3.39 (q, J = 8, 4H), 3.65 (dd, J = 8, 1, 2H), 3.73 (dd, J = 8, 1, 2H), 4.55-4.65 (m, 1H), 6.75 (d, J = 8, 1H), 7.30 (d, J = 1, 2H), 7.50 (s, 1H).

j) CI-HRMS: Calcd: 378.1252, Found: 378.1249 (M + H); Analysis: Calcd: C: 57.15; H: 5.61; N: 18.51; Cl: 18.74; Found: C: 57.56; H: 5.65; N: 18.35; Cl: 18.45;
NMR ($CDCl_3$, 300 MHz): 1.00 (t, J = 8, 6H), 1.55-1.70 (m, 2H), 1.70-1.85 (m, 2H), 2.35 (s, 3H), 2.50

(s, 3H), 4.15-4.25 (m, 1H), 6.18 (d, J = 8, 1H), 7.30 (s, 2H), 7.50 (s, 1H).

k) CI-HRMS: Calcd: 398.0939, Found: 398.0922 (M + H); Analysis: Calcd: C: 60.31; H: 4.30; N: 17.58; Cl: 17.80; Found: C: 60.29; H: 4.59; N: 17.09; Cl: 17.57;
NMR ($CDCl_3$, 300 MHz): 2.05 (s, 3H), 2.50 (s, 3H), 3.78 (s, 3H), 7.20-7.45 (m, 7H), 7.50 (d, J = 1, 1H).

l) CI-HRMS: Calcd: 392.1409, Found: 392.1391 (M + H);
NMR ($CDCl_3$, 300 MHz): 0.98 (t, J = 8, 6H), 1.70-1.85 (m, 4H), 2.30 (s, 3H), 2.40 (s, 3H), 3.80-4.10 (m, 4H), 7.30 (s, 2H), 7.50 (d, J = 1, 1H).

m) CI-HRMS: Calcd: 392.1409, Found: 392.1415 (M + H); Analysis: Calcd: C: 58.17; H: 5.92; N: 17.85; Cl: 18.07; Found: C: 58.41; H: 5.85: N: 18.10; Cl: 17.75;
NMR ($CDCl_3$, 300 MHz): 0.90-1.05 (m, 6H), 1.35-1.55 (m, 2H), 1.55-1.85 (m, 4H), 2.35 (s, 3H), 2.48 (s, 3H), 4.20-4.35 (m, 1H), 6.15 (d, J = 8, 1H), 7.30 (s, 2H), 7.50 (d, J = 1, 1H).

n) CI-HRMS: Calcd: 337.0623, Found: 337.0689 (M + H); Analysis: Calcd: C: 53.43; H: 4.18; N: 16.62; Cl: 21.03, Found: C: 53.56; H: 4.33; N: 16.56; Cl: 20.75;
NMR ($CDCl_3$, 300 MHz): 1.60 (t, J = 8, 3H), 2.40 (s, 3H), 2.55 (s, 3H), 4.80 (q, J = 8, 2H), 7.30 (d, J = 8, 1H), 7.35 (dd, J = 8, 1, 1H), 7.55 (d, J = 1, 1H).

o) CI-HRMS: Calcd: 383.2321, Found: 383.2309 (M + H);
NMR ($CDCl_3$, 300 MHz): 2.00 (s, 6H), 2.20 (s, 3H), 2.30 (s, 3H), 2.45 (s, 3H), 3.45 (s, 6H), 3.61 (dd, J = 8, 8, 2H), 3.70 (dd, J = 8, 8, 2H), 4.60-4.70 (m, 1H), 6.70 (d, J = 8, 1H), 6.94 (s, 2H).

p) CI-HRMS: Calcd: 370.2243, Found: 370.2246 (M + H);

Analysis: Calcd: C: 65.02; H: 7.38; N: 18.96;
Found: C: 65.22; H: 7.39; N: 18.71;
NMR ($CDCl_3$, 300 MHz): 2.18 (s, 3H), 2.30 (s, 3H), 2.45 (s, 3H), 3.45 (s, 6H), 3.60 (dd, J = 8, 8, 2H), 3.69 (dd, J = 8, 8, 2H), 4.60-4.70 (m, 1H), 6.70 (d, J = 8, 1H), 7.05 (d, J = 8, 1H), 7.07 (d, J = 8, 1H), 7.10 (s, 1H).

q) CI-HRMS: Calcd: 384.2400, Found: 384.2393 (M + H);
NMR ($CDCl_3$, 300 MHz): 2.16 (s, 3H), 2.25 (s, 3H), 2.35 (s, 3H), 2.39 (s, 3H), 3.40 (s, 6H), 3.77 (t, J = 8, 4H), 4.20-4.45 (m, 4H), 7.02 (d, J = 8, 1H) 7.05 (s, 1H), 7.10 (d, J = 7, 1H).

r) CI-HRMS: Calcd: 354.2294, Found: 354.2271 (M + H);
Analysis: Calcd: C: 67.96; H: 7.71; N: 19.81;
Found: C: 67.56; H: 7.37; N: 19.60;
NMR ($CDCl_3$, 300 MHz): 1.03 (t, J = 8, 3H), 1.65-1.88 (m, 2H), 2.17 (s, 3H), 2.30 (s, 3H), 2.35 (s, 3H), 2.45 (s, 3H), 3.40 (s, 3H), 3.50-3.62 (m, 2H), 4.30-4.45 (m, 1H), 6.51 (d, J = 8, 1H), 7.04 (d, J = 8, 1H), 7.10 (d, J =8, 1H), 7.12 (s, 1H).

s) CI-HRMS: Calcd: 338.2345, Found: 338.2332 (M + H);
Analysis: Calcd: C: 71.18; H: 8.06; N: 20.75;
Found: C: 71.43; H: 7.80; N: 20.70;
NMR ($CDCl_3$, 300 MHz): 1.00 (t, J = 8, 6H), 1.55-1.70 (m, 2H), 1.70-1.85 (m, 2H), 2.19 (s, 3H), 2.30 (s, 3H), 2.35 (s, 3H), 2.46 (s, 3H), 4.15-4.26 (m, 1H), 6.17 (d, J = 8, 1H), 7.06 (d, J = 8, 1H), 7.10 (d, J = 1, 1H), 7.13 (s, 1H).

t) CI-HRMS: Calcd: 324.2188, Found: 324.2188 (M + H);
NMR ($CDCl_3$, 300 MHz): 1.25 (t, J = 8, 6H), 2.16 (s, 3H), 2.28 (s, 3H), 2.35 (s, 3H), 2.40 (s, 3H), 3.95-4.20 (m, 4H), 7.05 (dd, J = 8, 1, 1H), 7.07 (s, 1H), 7.10 (d, J = 1, 1H)

u) CI-HRMS: Calcd: 346.1780, Found: 346.1785 (M + H);
Analysis: Calcd: C: 66.07; H: 5.54; N: 28.39;
Found: C: 66.07; H: 5.60; N: 27.81;

NMR ($CDCl_3$, 300 MHz): 2.15 (s, 3H), 2.32 (s, 3H) 2.17 (s, 3H), 2.52 (s, 3H), 5.25-5.35 (m, 4H), 7.08 (s, 2H), 7.15 (s, 1H).

v) CI-HRMS: Calcd: 340.2137, Found: 340.2137 (M + H); Analysis: Calcd: C: 67.23; H: 7.42; N: 20.63; Found:C: 67.11; H: 7.39; N: 20.26; NMR ($CDCl_3$, 300 MHz): 1.40 (d, J = 8, 3H), 2.16 (s, 3H), 2.32 (s, 3H), 2.35 (s, 3H), 2.47 (s, 3H), 3.42 (s, 3H), 3.50-3.60 (m, 2H), 4.50-4.15 (m, 1H), 6.56 (d, J = 8, 1H), 7.00-7.15 (m, 3H).

w) CI-HRMS: Calcd: 355.2134, Found: 355.2134 (M + H); NMR ($CDCl_3$, 300 MHz): 1.05 (t, J = 8, 3H), 1.85-2.00 (m, 2H), 2.17 (s, 3H), 2.36 (s, 6H), 2.50 (s, 3H), 3.41 (s, 3H), 3.45 (dd, J = 8, 3, 1H), 3.82 (dd, J = 8, 1, 1H), 5.70-5.80 (m, 1H), 7.00-7.20 (m, 3H).

x) CI-HRMS: Calcd: 364.2501, Found: 364.2501 (M + H); NMR ($CDCl_3$, 300 MHz): 0.35-0.43 (m, 2H), 0.50-0.60 (m, 2H), 0.98 (t, J = 8, 3H), 1.20-1.30 (m, 1H), 1.72-1.90 (m, 2H), 2.18 (s, 3H) 2.28 (s, 3H), 2.35 (s, 3H), 2.40 (s, 3H), 3.88-4.03 (m, 2H), 4.03-4.20 (m, 2H), 7.00-7.15 (m, 3H).

y) CI-HRMS: Calcd: 353.2454, Found: 353.2454 (M + H); Analysis: Calcd: C: 68.15; H: 8.02; N: 23.84; Found: C: 67.43; H: 7.81; N: 23.45; NMR ($CDCl_3$, 300 MHz): 1.38 (d, J = 8, 3H), 2.18 (s, 3H), 2.30-2.40 (m, 12H), 2.47 93, 3H), 2.60-2.75 (m, 2H), 4.30-4.50 (m, 1H), 6.60-6.70 (m, 1H), 7.00-7.15 (m, 3H).

z) CI-HRMS: Calcd: 361.2140, Found: 361.2128 (M + H); NMR ($CDCl_3$, 300 MHz): 0.75-0.83 (m, 2H), 1.00-1.10 (m, 2H), 2.17 (s, 3H), 2.30 (s, 3H), 2.36 (s, 3H), 2.47 (s, 3H), 2.85 (t, J = 8, 2H), 3.30-3.40 (m, 1H), 4.40-4.55 (m, 2H), 7.00-7.18 (m, 3H).

aa) CI-HRMS: Calcd: 363.2297, Found: 363.2311 (M + H);

NMR ($CDCl_3$, 300 MHz): 1.01 (t, 3H, J=8), 1.75-1.90 (m,2H), 2.15 (s,3H), 2.19 (s, 3H), 2.35 (s, 3H), 2.40 (s, 3H), 2.40 (s, 3H), 2.98 (t, 2H, J = 8), 3.97-4.15 (m, 2H), 4.15-4.30 (m, 2H), 7.03(d, 1H, 1H), 7.08 (d, 1H, J = 8), 7.10 (s, 1H).

ab) CI-HRMS: Calcd: 363.2297, Found: 363.2295 (M + H); NMR ($CDCl_3$, 300 MHz): 1.01 (t, 3H, J = 8), 1.35-1.55 (m, 2H), 1.75-1.90 (m, 2H), 2.15 (s, 3H), 2.30 (s, 3H), 2.36 (s, 3H), 2.46 (s, 3H), 4.10-4.30 (m, 2H), 4.95-5.10 (br s, 2H), 7.05 (d, 1H, J = 8), 7.10 (d, 1H, J = 8), 7.15 (s, 1H).

ac) CI-HRMS: Calcd: 368.2450, Found: 368.2436; Analysis: Calcd: C, 68.62, H, 7.95, N, 19.06; Found: C, 68.73, H, 7.97, N, 19.09; NMR ($CDCl_3$, 300 MHz): 1.05 (t, J = 8, 3H), 1.70-1.90 (m, 2H), 2.01 (d, J = 3, 6H), 2.20 (s, 3H), 2.30 (s, 3H), 2.46, 2.465 (s, s, 3H), 3.42, 3.48 (s, s, 3H), 3.53-3.63 (m, 2H), 4.35-4.45 (m, 1H), 6.73 (d, J = 8, 1H), 6.97 (s, 2H).

(ad) CI- HRMS: Calcd: 352.2501, Found: 352.2500 (M + H): Analysis: Calcd: C: 71.76; H: 8.33; N: 19.92, Found: C: 71.55; H: 8.15; N: 19.28; NMR ($CDCl_3$, 300 MHz): 1.01(t, J = 8, 6H), 1.58 -1.70 (m, 2H), 1.70-1.85 (m, 2H), 2.02 (s, 6H), 2.19 (s, 3H), 2.45 (s, 3H), 4.12-4.28 (m, 1H), 6.18 (d, J = 8, 1H), 6.95 (s, 2H).

(ae) CI- HRMS: Calcd: 398.2556, Found: 398.2551 (M + H); Analysis: Calcd: C: 66.47; H: 7.86; N: 17.62, Found: C: 66.74; H: 7.79; N: 17.70; NMR ($CDCl_3$, 300 MHz): 2.00 (s, 6H), 2.12 (s, 3H), 2.30 (s, 3H), 2.37 (s, 3H), 3.40 (s, 6H), 3.78 (t, J = 8, 4H), 4.25-4.40 (m, 4H), 6.93 (s, 2H).

(af) CI-HRMS: Calcd: 450.1141, Found: 450.1133 (M + H); Analysis: Calcd: C: 50.67; H: 5.37; N: 15.55; Br: 17.74; Found: C: 52.36; H: 5.84; N: 14.90; Br: 17.44;

NMR ($CDCl_3$, 300 MHz): 2.32 (s, 3H), 2.57 (s, 3H), 3.42 (s, 6H), 3.60 (q, J = 8, 2H), 3.69 (q, J = 8, 2H), 3.82 (s, 3H), 4.60-4.70 (m, 1H), 6.73 (d, J = 8, 1H), 6.93 (dd, J = 8, 1, 1H), 7.22 (d, J = 8, 1H).

ag) CI-HRMS: Calcd: 434.1192, Found: 434.1169 (M + H); Analysis: Calcd: C: 52.54; H: 5.58; N: 16.12; Br: 18.40; Found: C: 52.57; H: 5.60; N: 15.98; Br: 18.22;
NMR ($CDCl_3$, 300 MHz): 1.00-1.07 (m, 3H), 1.65-1.85 (m, 2H), 2.35 (s, 3H), 2.46, 2.47 (s, s, 3H), 3.40, 3.45 (s, s, 3H), 3.83 (s, 3H), 4.35-4.45 (m, 1H), 6.55 (d, J = 8, 1H), 6.92 (dd, J = 8, 1, 1H), 7.20-7.30 (m, 2H).

ah) CI-HRMS: Calcd: 337.2266, Found: 337.2251 (M + H); Analysis: Calcd: C: 70.18; H: 8.06; N: 20.75; Found: C: 70.69; H: 7.66; N: 20.34;
NMR ($CDCl_3$, 300 MHz): 1.35 (t, J = 8, 6H), 2.01 (s, 6H), 2.15 (s, 3H), 2.30 (s, 3H), 2.38 (s, 3H), 4.07 (q, J = 8, 4H), 6.93 (s, 2H).

ai) CI-HRMS: Calcd: 412.2713, Found: 412.2687 (M + H); Analysis: Calcd: C: 67.13; H: 8.08; N: 17.02; Found : C: 67.22; H: 7.85; N: 17.13;
NMR ($CDCl_3$, 300 MHz):1.24 (t, J = 8, 6H), 2.00 (s, 6H), 2.20 (s, 3H), 2.30 (s, 3H), 2.43 (s, 3H), 3.60 (q, J = 8, 4H), 3.66 (dd, J = 8, 3, 2H), 3.75 (dd, J = 8, 3, 2H), 4.55-4.65 (m, 1H), 6.75 (d, J = 8, 1H), 6.95 (s, 2H).

aj) CI-HRMS: Calcd: 398.2556, Found: 398.2545 (M + H); Analysis: Calcd: C: 66.47; H: 7.86; N: 17.62; Found: C: 66.87; H: 7.62; N: 17.75;
NMR ($CDCl_3$, 300 MHz): 1.95-2.10 (m, 8H), 2.20 (s, 3H), 2.32 (s, 3H), 2.44 (s, 3H), 3.38 (s, 3H), 3.42 (s, 3H), 3.50-3.70 (m, 4H), 4.58-4.70 (m, 1H), 6.87 (d, J = 8, 1H), 6.95 (s, 2H).

ak) CI-HRMS: Calcd: 338.1981, Found: 338.1971 (M + H);

Analysis: Calcd: C: 67.63; H: 6.87; N: 20.06;
Found: C: 67.67; H: 6.82; N: 20.31;
NMR ($CDCl_3$, 300 MHz): 2.15 (s, 3H), 2.29 (s, 3H), 2.35 (s, 3H), 2.43 (s, 3H), 3.90 (t, J = 8, 4H), 4.35-4.45 (m, 4H), 7.00-7.15 (m, 3H).

al) CI-HRMS: Calcd: 464.1297, Found: 464.1297 (M + H);
NMR ($CDCl_3$, 300 MHz): 2.28 (s, 3H), 2.40 (s, 3H), 3.40 (s, 6H), 3.75 (t, J = 8, 4H), 3.83 (s, 3H), 4.20-4.50 (m, 4H), 6.93 (dd, J = 8, 1, 1H), 7.20 (s, 1H), 7.24 (d, J = 1, 1H).

am) CI-HRMS: Calcd: 418.1242, Found: 418.1223 (M + H);
NMR ($CDCl_3$, 300 MHz): 1.00 (t, d, J = 8, 1, 6H), 1.55-1.75 (m, 4H), 2.34 (s, 3H), 2.49 (s, 3H), 2.84 (s, 3H), 4.15-4.27 (m, 1H), 6.19 (d, J = 8, 1H), 6.93 (dd, J = 8, 1, 1H), 7.21-7.30 (m, 2H).

an) CI-HRMS: Calcd: 404.1086, Found: 404.1079(M + H);
NMR ($CDCl_3$, 300 MHz): 1.35 (t, J = 8, 6H), 2.28 (s, 3H), 2.40 (s, 3H), 3.83 (s, 3H), 3.90-4.08 (m, 2H), 4.08-4.20 (m, 2H), 6.92 (dd, J = 8, 1, 1H), 7.20-7.25 (m, 2H).

ao) CI-HRMS: Calcd: 308.1875, Found: 308.1872 (M + H);
NMR ($CDCl_3$, 300 MHz): 0.75-0.80 (m, 2H), 0.93-1.00 (m, 2H), 2.16 (s, 3H), 2.28 (s, 3H), 2.35 (s, 3H), 2.53 (s, 3H), 3.00-3.10 (m, 1H), 6.50-6.55 (m, 1H), 7.00-7.15 (m, 3H).

ap) CI-HRMS: Calcd: 397.1988, Found: 397.1984 (M + H);
NMR ($CDCl_3$, 300 MHz): 2.43 (s, 3H), 2.50 (s, 3H), 3.43 (s, 3H), 3.61 (dd, J = 8, 8, 2H), 3.69 (dd,J = 8, 8, 2H), 3.88 (s, 3H), 4.58-4.70 (m, 1H), 6.75 (d, J = 8, 1H), 7.20 (dd, J = 8, 1, 1H), 7.25 (d, J = 1, 1H), 7.40 (s, 1H).

aq) CI-HRMS: Calcd: 375.2297, Found: 375.2286 (M + H);
Analysis: Calcd: C: 70.56; H: 7.01; N: 22.44;
Found: C: 70.49; H: 6.99; N: 22.45;
NMR ($CDCl_3$, 300 MHz): 0.79-0.85 (m, 2H), 1.00-1.05 (m, 1H), 2.00 (s, 6H), 2.19 (s, 3H), 2.32 (s, 3H),

2.44 (s, 3H), 2.84 (t, J = 8, 2H), 3.30-3.40 (m, 1H), 4.50 (t, J = 8, 2H), 6.95 (s, 2H).

ar) CI-HRMS: Calcd: 434.1192, Found: 434.1189 (M + H); Analysis: Calcd: C: 52.54; H: 5.58; N: 16.12; Br: 18.40; Found: C: 52.75; H: 5.59; N: 16.09; Br: 18.67;
NMR ($CDCl_3$, 300 MHz): 2.19 (s, 3H), 2.30 (s, 3H), 2.47 (s, 3H), 3.43 (s, 6H), 3.60 (dd, J = 8, 8, 2H), 3.70 (dd, J = 8,8, 2H), 4.58-4.70 (m, 1H), 6.71 (d, J = 8, 1H), 7.08 (d, J = 8, 1H), 7.37 (dd, J = 8, 1, 1H), 7.45 (d, J = 1, 1H).

as) CI-HRMS: Calcd: 448.1348, Found: 448.1332 (M + H); Analysis: Calcd: C: 53.58; H: 5.85; N: 16.62; Br: 17.82; Found: C: 53.68; H: 5.74; N: 15.52; Br: 13.03;
NMR ($CDCl_3$, 300 MHz): 1.95-2.10 (m, 2H), 2.20 (s, 3H), 2.30 (s, 3H), 2.47 (s, 3H), 3.38 (s, 3H), 3.41 (s, 3H), 3.50-3.67 (m, 4H), 4.55-4.70 (m, 1H), 6.89 (d, J = 8, 1H), 7.05 (d, J = 8, 1H), 7.35 (dd, J = 8, 1, 1H), 7.47 (d, J = 1, 1H).

at) CI-HRMS: Calcd: 400.2349, Found: 400.2348 (M + H); Analysis: Calcd: C: C: 63.14; H: 7.32; N: 17.53; Found: C:63.40; H: 7.08; N: 17.14;
NMR ($CDCl_3$, 300 MHz): 2.16 (s, 3H), 2.20 (s, 3H), 2.30 (s, 3H), 2.46 (s, 3H), 3.42 (s, 6H), 3.60 (q, J = 8, 2H), 3.70 (q, J = 8, 2H), 3.85 (s, 3H), 4.59-4.70 (m, 1H), 6.70 (d, J = 8, 1H), 6.76 (s, 1H), 6.96 (s, 1H).

au) CI-HRMS: Calcd: 414.2505, Found: 414.2493 (M + H);
NMR ($CDCl_3$, 300 MHz): 2.15 (s, 3H), 2.19 (s, 3H), 2.25 (s, 3H), 2.40 (s, 3H), 3.40 (s, 6H), 3.76 (t, J = 8, 4H), 3.84 (s, 3H), 4.20-4.45 (m, 4H), 6.77 (s, 1H), 6.93 (s, 1H).

av) CI-HRMS: Calcd: 368.2450, Found: 368.2447 (M + H);
NMR ($CDCl_3$, 300 MHz): 1.00 (t, J = 8, 6H), 1.55-1.85 (m, 4H), 2.19 (s, 3H), 2.20 (s, 3H), 2.30 (s,

3H), 2.47 (s, 3H), 3.88 (s, 3H), 4.10-4.30 (m, 1H), 6.15 (d, J = 8, 1H), 6.78 (s, 1H), 6.98 (s, 1H).

aw) CI-HRMS: Calcd: 353.2216, Found: 353.2197 (M + H); NMR ($CDCl_3$, 300 MHz): 1.35 (t, J = 8, 6H), 2.17 (s, 3H), 2.19 (s, 3H), 2.28 (s, 3H), 2.40 (s, 3H), 3.85 (s, 3H), 3.90-4.20 (m, 4H), 6.78 (s, 1H), 6.95 (s, 1H).

ax) CI-HRMS: Calcd: 390.1697, Found: 390.1688 (M + H); Analysis: Calcd: C: 58.53; H: 6.20; N: 17.96; Cl: 9.09; Found: C: 58.95; H: 6.28; N: 17.73; Cl: 9.15; NMR ($CDCl_3$, 300 MHz): 2.35 (s, 3H), 2.37 (s, 3H), 2.48 (s, 3H), 3.42 (s, 6H), 3.60 (dd, J = 8, 8, 2H) 3.68 (dd, J = 8, 8, 2H), 4.59-4.72 (m, 1H), 6.72 (d, J = 8, 1H), 7.12 (d, J = 8, 1H), 7.23 (d, J = 8, 1H), 7.32 (s, 1H).

ay) CI-HRMS: Calcd: 374.1748, Found: 374.1735 (M + H); Analysis: Calcd: C: 61.04; H: 6.47; N: 18.73; Cl: 9.48; Found: C: 61.47; H: 6.54; N: 18.23; Cl: 9.61; NMR ($CDCl_3$,300 MHz): 1.01 (t, J = 8, 3H), 1.62-1.88 (m, 4H), 2.35 (s, 3H), 2.37 (s, 3H), 2.48 (d, J = 1, 3H), 3.40, 3.45 (s, s, 3H), 3.50-3.64 (m, 2H), 4.38-4.47 (m, 1H), 6.53 (d, J = 8, 1H), 7.12 (d, J = 8, 1H), 7.07 (d, J = 8, 1H), 7.12 (s, 1H).

az) CI-HRMS: Calcd: 404.1853, Found: 404.1839 (M + H); NMR ($CDCl_3$, 300 MHz): 2.29 (s, 3H), 2.38 (s, 3H), 2.40 (s, 3H), 3.40 (s, 6H), 3.76 (t, J = 8, 4H), 4.20-4.45 (m, 4H), 7.11 (d, J = 8, 1H), 7.22 (d, J = 8, 1H), 7.31 (s, 1H).

ba) CI-HRMS: Calcd: 404.1853, Found: 404.1859 (M + H); Analysis: C: 59.47; H: 6.50; N: 17.34; Cl: 8.79; Found: C: 59.73; H: 6.46; N: 17.10; Cl: 8.73; NMR ($CDCl_3$, 300 MHz): 1.95-2.08 (m, 2H), 2.35 (s, 3H), 2.38 (s, 3H), 2.46 (s, 3H), 3.38 (s, 3H), 3.41 (s, 3H), 3.50-3.65 (m, 4H), 4.56-4.70 (m, 1H), 6.85 (d, J = 8, 1H), 7.12 (d, J = 8, 1H), 7.45 (d, J = 8, 1H), 7.32 (s, 1H).

bb) CI-HRMS: Calcd: 391.2246, Found: 391.2258 (M + H); Analysis: C: 67.67; H: 6.71; N: 21.52; Found: C: 67.93; H: 6.70; N: 21.48; NMR ($CDCl_3$, 300 MHz): 0.76-0.84 (m, 2H), 0.84-0.91 (m, 2H), 1.00-1.08 (m, 2H), 2.15 (s, 3H), 2.20 (s, 3H), 2.29 (s, 3H), 2.45 (s, 3H), 2.85 (t, J = 8, 2H), 3.28-3.30 (m, 1H), 3.85 (s, 3H), 6.78 (s, 1H), 6.95 (s, 1H).

bc) CI-HRMS: Calcd: 386.2192, Found: 386.2181 (M + H); Analysis: C: 62.32; H: 7.06; N: 18.17; Found: C: 62.48; H: 6.83; N: 18.15; NMR ($CDCl_3$, 300 MHz): 7.1 (d, 1H, J = 8), 6.9 (d, 1H, J = 1), 6.8 (dd, 1H, J = 8,1), 6.7 (br.d, 1H, J = 8), 4.7-4.6 (m, 1H), 3.85 (s, 3H), 3.70-3.55 (m, 4H), 3.45 (s, 6H), 2.5 (s, 3H), 2.3 (s, 3H), 2.15 (s, 3H).

bd) CI-HRMS: Calcd: 400.2349, Found: 400.2336 (M + H); NMR ($CDCl_3$, 300 MHz): 7.1 (d, 1H, J = 7), 6.85 (d, 1H, J = 1), 6.75 (dd, 1H, J = 7,1), 4.45-4.25 (br.s, 4H), 3.75 (t, 4H, J = 7), 3.4 (s, 6H), 2.4 (s, 3H), 2.25 (s, 3H), 2.15 (s, 3H).

be) CI-HRMS: Calcd: 370.2243, Found: 370.2247 (M + H); Analysis: C: 65.02; H: 7.38; N: 18.96; Found: C: 65.28; H: 7.27; N: 18.71; NMR ($CDCl_3$, 300 MHz): 7.1 (d, 1H, J = 8), 6.85 (d, 1H, J = 1), 6.8 (dd, 1H, J = 8,1), 6.5 (br. d, 1H, J = 1), 4.5-4.3 (m, 1H), 3.85 (s, 3H), 3.65-3.5 (m, 2H), 3.4 (s, 2H), 2.5 (s, 3H), 2.3 (s, 3H), 2.2 (s, 3H), 1.9-1.7 (m, 2H), 1.05 (t, 3H, J = 7).

bf) CI-HRMS: Calcd: 379.2246, Found: 379.2248 (M + H); NMR ($CDCl_3$, 300 MHz): 7.1 (d, 1H, J = 8), 6.85 (d, 1H, J = 1), 6.8 (dd, 1H, J = 8,1), 4.3-4.0 (m, 4H), 3.85 (s, 3H), 3.0 (t, 2H, J = 7), 2.45 (s, 3H), 2.3 (s, 3H), 2.2 (s, 3H), 1.9-1.8 (m, 2H), 1.0 (t, 3H, J = 7).

bg) CI-HRMS: Calcd: 340.2137, Found: 340.2122 (M + H);

NMR ($CDCl_3$, 300 MHz): 7.1 (d, 1H, J = 8), 6.85 (d, 1H, J = 1), 6.75 (dd, 1H, J = 8,1), 4.2-4.0 (br.m, 4H), 3.85 (s, 3H, 2.4 (s, 3H), 2.3 (s, 3H), 2.2 (s, 3H), 1.35 (t, 6H, J = 7).

bh) CI-HRMS: Calcd: 313.1665, Found: 313.6664 (M + H).

bi) CI-HRMS: Calcd: 400.2349, Found: 400.2346 (M + H); NMR ($CDCl_3$, 300 MHz): 7.1 (d, 1H, J = 7), 6.9-6.75 (m, 3H), 4.7-4.55 (m, 1H), 3.8 (s, 3H), 3,7-3.5 (m, 4H), 3.45 (s, 3H), 3.35 (s, 3H), 2.5 (s, 3H), 2.3 (s, 3H), 2.2 (s, 3H), 2.1-1.95 (m, 2H).

bj) CI-HRMS: Calcd: 377.2090, Found: 377.2092 (M + H); Analysis: C: 67.00; H: 6.44; N: 22.32; Found: C: 67.35; H: 6.44; N: 22.23; NMR ($CDCl_3$, 300 MHz): 7.1 (d, 1H, J = 8), 6.9 (d, 1H, J = 1), 6.8 (dd, 1H, J = 8,1), 4.55-4.4 (m, 2H), 3.85 (s, 3H), 3.4-3.3 (m, 1H), 2.85 (t, 2H, J = 7), 2.5 (s, 3H), 2.3 (s, 3H), 2.2 (s, 3H), 1.1-1.0 (m, 2H), 0.85-0.75 (m, 2H).

bk) CI-HRMS: Calcd: 413.2427, Found: 413.2416 (M + H); NMR ($CDCl_3$, 300Hz): 7.1 (d, 1H, J = 8), 6.85 (d, 1H, J = 1), 6.75 (dd, 1H, J = 8,1), 4.6 (m, 1H), 3.85 (s, 3H), 3.75-3.6(m, 4H), 3.6 (q, 4H, J = 7), 2.5 (s, 3H), 2.3 s, 3H), 2.2 (s, 3H), 1.25 (t, 6H, J = 7).

bl) CI-HRMS: Calcd: 420.1802, Found: 420.1825(M + H);

bm) CI-HRMS: Calcd: 390.1697, Found: 390.1707(M + H);

bn) CI-HRMS: Calcd: 397.1465, Found: 397.1462(M + H);

bo) CI-HRMS: Calcd: 360.1513, Found: 360.1514(M + H);

bp) CI-HRMS: Calcd: 374.1748, Found: 374.1737(M + H);

bq) CI-HRMS: Calcd: 479.1155, Found: 479.1154(M + H);

br) CI-HRMS: Calcd: 463.1219, Found: 463.1211(M + H); Analysis Calcd: C: 51.96, H: 5.23, N, 15.15, Br: 17.28; Found: C: 52.29, H: 5.62, N: 14.79, Br: 17.47

bs) CI-HRMS: Calcd: 433.1113, Found: 433.1114(M, ^{79}Br);

bt) NH_3-CI MS: Calcd: 406, Found: 406 (M + H)+;

NMR ($CDCl_3$, 300 MHz) : δ 7.28 (d, J=10Hz, 1H), 7.03 (d, J=8Hz, 1H), 6.96 (s, 1H), 6.7 (d, J=9, 1H), 4.63 (m, 1H), 3.79 (s, 3H), 3.6 (m, 4H), 3.42 (s, 6H), 2.47 (s, 3H), 2.32 (s, 3H).

EXAMPLE 431

Preparation of 2,4,7-dimethyl-8-(4-methoxy-2-methylphenyl)[1,5-a]-pyrazolo-1,3,5-triazine (Formula 1, where R^3 is CH_3, R_1 is CH_3, Z is C-CH_3, Ar is 2,4-dimethylphenyl)

5-Acetamidino-4-(4-methoxy-2-methylphenyl)-3-methylpyrazole, acetic acid salt (602 mg, 2 mmol) was mixed with a saturated $NaHCO_3$ solution (10 mL). The aqueous mixture was extracted with EtOAc three times. The combined organic layers were dried over $MgSO_4$, filtered and concentrated in vacuo. The residue was taken up in toluene (10 mL) and trimethyl orthoacetate (0.36 g, 3 mmol) was added to the suspension. The reaction mixture was heated to reflux temperature under a nitrogen atmosphere and stirred for 16 hours. After being cooled to ambient temperature, the reaction mixture was concentrated in vacuo to give an oily solid. Column chromatography ($CHCl_3$:MeOH::9:1) afforded, after removal of solvent in vacuo, a yellow viscous oil (Rf = 0.6, 210 mg, 37% yield): NMR ($CDCl_3$, 300 MHz): 7.15 (d, 1H, J = 8), 6.9 (d, 1H, J = 1), 6.85 (dd, 1H, J = 8,1), 3.85 (s, 3H), 2.95 (s, 3H), 2.65 (s, 3H), 2.4 (s, 3H), 2.15 (s, 3H); CI-HRMS: Calcd: 283.1559, Found: 283.1554 (M + H).

EXAMPLE 432

7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine (Formula 1 where A is CH, R1 is Me, R3 is OH, Z is C-Me, Ar is 2-chloro-4-methylphenyl)

5-Amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole (1.86 g, 8.4 mmol) was dissolved in glacial acetic acid (30 mL) with stirring. Ethyl acetoacetate (1.18 mL, 9.2 mmol) was then added dropwise to the resulting solution. The reaction mixture was then heated to reflux temperature and stirred for 16 hours, then cooled to room temperature. Ether (100 mL) was added and the resulting precipitate was collected by filtration. Drying in vacuo afforded a white solid (1.0 g, 42% yield): NMR ($CDCl_3$, 300Hz): 8.70 (br.s 1H), 7.29 (s, 1H), 7.21-7.09 (m, 2H), 5.62 (s, 1H), 2.35 (s, 6H), 2.29 (s, 3H); CI-MS: 288 (M+H).

EXAMPLE 433

7-chloro-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine (Formula 1 where A is CH, R1 is Me, R3 is Cl, Z is C-Me, Ar is 2-chloro-4-methylphenyl)

A mixture of 7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)-pyrazolo[1,5-a]pyrimidine (1.0 g, 3.5 mmol), phosphorus oxychloride (2.7 g, 1.64 mL, 17.4 mmol), N,N-diethylaniline (0.63 g, 0.7 mL, 4.2 mmol) and toluene (20 mL) was stirred at reflux temperature for 3 hours, then it was cooled to ambient temperature. The volatiles were removed in vacuo. Flash chromatography (EtOAc:hexane::1:2) on the residue gave 7-chloro-5-methyl-3-(2-chloro-4-methylphenyl)-pyrazolo[1,5-a]pyrimidine (900 mg, 84% yield) as a yellow oil: NMR

($CDCl_3$, 300Hz): 7.35 (s, 1H), 7.28-7.26 (m, 1H), 71.6 (d, 1H, J = 7), 6.80 (s, 1H), 2.55 (s, 3H), 2.45 (s, 3H), 2.40 (s, 3H); CI- MS: 306 (M+H).

EXAMPLE 434


7-(pentyl-3-amino)-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine

(Formula 1 where A is CH, R1 is Me, R3 is pentyl-3-amino, Z is C-Me, Ar is 2-chloro-4-methylphenyl)

A solution of 3-pentylamine (394mg, 6.5 mmol) and 7-chloro-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine (200 mg, 0.65 mmol) in dimethylsulfoxide (DMSO, 10 mL) was stirred at 150°C for 2 hours; then it was cooled to ambient temperature. The reaction mixture was then poured onto water (100 mL) and mixed. Three extractions with dichloromethane, washing the combined organic layers with brine, drying over $MgSO_4$, filtration and removal of solvent in vacuo produced a yellow solid. Flash chromatography (EtOAc:hexanes::1:4) afforded a white solid (140 mg, 60% yield): mp 139-141°C; NMR ($CDCl_3$, 300Hz):7.32 (s, 1H), 7.27 (d, 1H, J = 8), 7.12 (d, 1H, J = 7), 6.02 (d, 1H, J = 9), 5.78 (s, 1H), 3.50-3.39 (m, 1H), 2.45 (s, 3H), 2.36 (s, 6H), 1.82-1.60 (m, 4H), 1.01 (t, 6H, J = 8); Analysis Calcd for $C_{20}H_{25}ClN_4$: C, 67.31, H, 7.06, N, 15.70, Cl: 9.93; Found: C, 67.32, H, 6.95, N, 15.50, Cl, 9.93.

The examples delineated in TABLE 2 may be prepared by the methods outlined in Examples 1A, 1B, 432, 433, 434. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example, EtOAc is ethyl acetate.

TABLE 2



Ex.	Z	R3	Ar	mp (°C)
435[b]	C-Me	$N(CH_2CH_2OMe)_2$	2,4-Cl_2-Ph	71-73
436[c]	C-Me	N(Bu)Et	2,4-Cl_2-Ph	86-87
437[d]	C-Me	$NHCH(Et)CH_2OMe$	2,4-Cl_2-Ph	110-111
438[e]	C-Me	$N(Pr)CH_2CH_2CN$	2,4-Cl_2-Ph	83-85
439[f]	C-Me	NH-3-pentyl	2,4-Cl_2-Ph	175-176
440[g]	C-Me	$NHCH(CH_2OMe)_2$	2,4-Cl_2-Ph	107
441[h]	C-Me	$NHCH(Et)_2$	2,4-Me_2-Ph	oil
442[i]	C-Me	$NHCH(CH_2OMe)_2$	2,4-Me_2-Ph	103-105
443[j]	C-Me	$N(CH_2CH_2OMe)_2$	2,4-Me_2-Ph	87-89
444[k]	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	2,4-Me_2-Ph	133(dec)
445[l]	C-Me	$N(CH_2CH_2OMe)_2$	2-Cl,4-MePh	77-78
446[m]	C-Me	$NHCH(CH_2OMe)_2$	2-Cl,4-MePh	131-133
447[n]	C-Me	$NHCH(Et)_2$	2-Cl,4-MePh	139-141
448[o]	C-Me	NEt_2	2,4-Me_2-Ph	92-94
449[p]	C-Me	$N(Pr)CH_2CH_2CN$	2,4-Me_2-Ph	143-144
450[q]	C-Me	$N(Bu)CH_2CH_2CN$	2,4-Me_2-Ph	115-117
451[r]	C-Me	$NHCH(Et)CH_2OMe$	2,4-Me_2-Ph	oil
452[s]	C-Me	$NHCH(Et)_2$	2-Me,4-MeOPh	104-106
453[t]	C-Me	$NHCH(CH_2OMe)_2$	2-Me,4-MeOPh	115-116
454[u]	C-Me	$N(CH_2CH_2OMe)_2$	2-Me,4-MeOPh	oil
455[v]	C-Me	(S)-$NHCH(CH_2CH_2OMe)$-(CH_2OMe)	2-Me,4-MeOPh	oil
456[w]	C-Me	(S)-$NHCH(CH_2CH_2OMe)$-(CH_2OMe)	2,4-Me_2-Ph	oil

	457[x]	C-Me	$N(CH_2CH_2OMe)_2$	2-Me,4-ClPh	oil
	458[y]	C-Me	NHEt	$2,4\text{-}Me_2\text{-}Ph$	oil
	459[z]	C-Me	$NHCH(Et)_2$	2-Me,4-ClPh	94-96
	460[aa]	C-Me	$NHCH(CH_2OMe)_2$	2-Me,4-ClPh	113-114
	461[ab]	C-Me	N(Ac)Et	$2,4\text{-}Me_2\text{-}Ph$	oil
	462[ac]	C-Me	(S)-$NHCH(CH_2CH_2OMe)$-(CH_2OMe)	2-Me,4-ClPh	oil
	463[ad]	C-Me	$N(Pr)CH_2CH_2CN$	2-Me,4-MeOPh	118-119
	464[ae]	C-Me	NEt_2	2-Me,4-MeOPh	97-99
	465[af]	C-Me	(S)-$NHCH(CH_2CH_2OMe)$-(CH_2OMe)	2-Cl,4-MePh	101-103
	466[ag]	C-Me	NEt_2	2-Cl,4-MePh	129-130
	467[ah]	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Me,4-MeOPh	177-178
	468[ai]	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Cl,4-MePh	162-163
	469[aj]	C-Me	$NHCH(Et)CH_2OMe$	2-Me,4-MeOPh	oil
	470[ak]	C-Me	$NHCH(Et)CH_2OMe$	2-Cl,4-MePh	111-113
	471	C-Me	$NHCH(CH_2OMe)_2$	2-Cl-4-MeOPh	
	472	C-Me	$N(CH_2CH_2OMe)_2$	2-Cl-4-MeOPh	
	473	C-Me	$NHCH(Et)CH_2OMe$	2-Cl-4-MeOPh	
	474	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Cl-4-MeOPh	
	475	C-Me	NEt_2	2-Cl-4-MeOPh	
	476	C-Me	NH-3-pentyl	2-Cl-4-MeOPh	
	477	C-Me	$NHCH(Et)CH_2CH_2OMe$	2-Cl-4-MeOPh	
	478	C-Me	$NHCH(Me)CH_2CH_2OMe$	2-Cl-4-MeOPh	
	479	C-Me	$NHCH(Et)CH_2CH_2OMe$	2-Br-4-MeOPh	
	480	C-Me	$NHCH(Me)CH_2CH_2OMe$	2-Br-4-MeOPh	
	481	C-Me	$NHCH(Et)CH_2CH_2OMe$	2-Me-4-MeOPh	
	482	C-Me	$NHCH(Me)CH_2CH_2OMe$	2-Me-4-MeOPh	
	483	C-Me	$NHCH(CH_2OMe)_2$	$2\text{-}Cl\text{-}4,5\text{-}(MeO)_2Ph$	
	484	C-Me	$N(CH_2CH_2OMe)_2$	$2\text{-}Cl\text{-}4,5\text{-}(MeO)_2Ph$	
	485	C-Me	$NHCH(Et)CH_2OMe$	$2\text{-}Cl\text{-}4,5\text{-}(MeO)_2Ph$	
	486	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	$2\text{-}Cl\text{-}4,5\text{-}(MeO)_2Ph$	
	487	C-Me	NEt_2	$2\text{-}Cl\text{-}4,5\text{-}(MeO)_2Ph$	99-101
	488	C-Me	NH-3-pentyl	$2\text{-}Cl\text{-}4,5\text{-}(MeO)_2Ph$	169-170
	489	C-Me	$NHCH(Et)CH_2CH_2OMe$	$2\text{-}Cl\text{-}4,5\text{-}(MeO)_2Ph$	

	490	C-Me	NHCH(Me)CH_2CH_2OMe	2-Cl-4,5-$(MeO)_2$Ph	
	491	C-Me	NHCH$(CH_2OMe)_2$	2-Br-4,5-$(MeO)_2$Ph	90-93
	492	C-Me	N$(CH_2CH_2OMe)_2$	2-Br-4,5-$(MeO)_2$Ph	110
	493	C-Me	NHCH(Et)CH_2OMe	2-Br-4,5-$(MeO)_2$Ph	
5	494	C-Me	N(c-Pr)CH_2CH_2CN	2-Br-4,5-$(MeO)_2$Ph	
	495	C-Me	NEt_2	2-Br-4,5-$(MeO)_2$Ph	
	496	C-Me	NH-3-pentyl	2-Br-4,5-$(MeO)_2$Ph	
	497	C-Me	NHCH(Et)CH_2CH_2OMe	2-Br-4,5-$(MeO)_2$Ph	
	498	C-Me	NHCH(Me)CH_2CH_2OMe	2-Br-4,5-$(MeO)_2$Ph	
10	499	C-Me	NHCH$(CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$Ph	
	500	C-Me	N$(CH_2CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$Ph	
	501	C-Me	NHCH(Et)CH_2OMe	2-Cl-4,6-$(MeO)_2$Ph	
	502	C-Me	N(c-Pr)CH_2CH_2CN	2-Cl-4,6-$(MeO)_2$Ph	
	503	C-Me	NEt_2	2-Cl-4,6-$(MeO)_2$Ph	
15	504	C-Me	NH-3-pentyl	2-Cl-4,6-$(MeO)_2$Ph	
	505	C-Me	NHCH(Et)CH_2CH_2OMe	2-Cl-4,6-$(MeO)_2$Ph	
	506	C-Me	NHCH(Me)CH_2CH_2OMe	2-Cl-4,6-$(MeO)_2$Ph	
	507	C-Me	NHCH$(CH_2OMe)_2$	2-Me-4,6-$(MeO)_2$Ph	
	508	C-Me	N$(CH_2CH_2OMe)_2$	2-Me-4,6-$(MeO)_2$Ph	
20	509	C-Me	NHCH(Et)CH_2OMe	2-Me-4,6-$(MeO)_2$Ph	
	510	C-Me	N(c-Pr)CH_2CH_2CN	2-Me-4,6-$(MeO)_2$Ph	
	511	C-Me	NEt_2	2-Me-4,6-$(MeO)_2$Ph	
	512	C-Me	NH-3-pentyl	2-Me-4,6-$(MeO)_2$Ph	
	513	C-Me	NHCH(Et)CH_2CH_2OMe	2-Me-4,6-$(MeO)_2$Ph	
25	514	C-Me	NHCH(Me)CH_2CH_2OMe	2-Me-4,6-$(MeO)_2$Ph	
	515	C-Me	N(c-Pr)CH_2CH_2CN	2-Br-4,6-$(MeO)_2$Ph	
	516	C-Me	NEt_2	2-Br-4,6-$(MeO)_2$Ph	
	517	C-Me	NH-3-pentyl	2-Br-4,6-$(MeO)_2$Ph	
	518	C-Me	NHCH(Et)CH_2CH_2OMe	2-Br-4,6-$(MeO)_2$Ph	
30	519	C-Me	NHCH(Me)CH_2CH_2OMe	2-Br-4,6-$(MeO)_2$Ph	
	520	C-Me	NHCH(Et)CH_2CH_2OMe	2-Me-4-MeOPh	
	521	C-Me	NHCH(Me)CH_2CH_2OMe	2-Me-4-MeOPh	
	522	C-Me	NHCH$(CH_2OMe)_2$	2-MeO-4-MePh	
	523	C-Me	N$(CH_2CH_2OMe)_2$	2-MeO-4-MePh	
35	524	C-Me	NHCH(Et)CH_2OMe	2-MeO-4-MePh	
	525	C-Me	N(c-Pr)CH_2CH_2CN	2-MeO-4-MePh	

526	C-Me	NEt_2	2-MeO-4-MePh
527	C-Me	NH-3-pentyl	2-MeO-4-MePh
528	C-Me	$NHCH(Et)CH_2CH_2OMe$	2-MeO-4-MePh
529	C-Me	$NHCH(Me)CH_2CH_2OMe$	2-MeO-4-MePh
530	C-Me	$NHCH(CH_2OMe)_2$	2-MeO-4-MePh
531	C-Me	$N(CH_2CH_2OMe)_2$	2-MeO-4-MePh
532	C-Me	$NHCH(Et)CH_2OMe$	2-MeO-4-MePh
533	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-MeO-4-MePh
534	C-Me	NEt_2	2-MeO-4-MePh
535	C-Me	NH-3-pentyl	2-MeO-4-MePh
536	C-Me	$NHCH(Et)CH_2CH_2OMe$	2-MeO-4-MePh
537	C-Me	$NHCH(Me)CH_2CH_2OMe$	2-MeO-4-MePh
538	C-Me	$NHCH(CH_2OMe)_2$	2-MeO-4-ClPh
539	C-Me	$N(CH_2CH_2OMe)_2$	2-MeO-4-ClPh
540	C-Me	$NHCH(Et)CH_2OMe$	2-MeO-4-ClPh
541	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-MeO-4-ClPh
542	C-Me	NEt_2	2-MeO-4-ClPh
543	C-Me	NH-3-pentyl	2-MeO-4-ClPh
544	C-Me	$NHCH(Et)CH_2CH_2OMe$	2-MeO-4-ClPh
545	C-Me	$NHCH(Me)CH_2CH_2OMe$	2-MeO-4-ClPh

NOTES FOR TABLE 2:

b) CI-HRMS: Calcd: 423.1355; Found: 423.1337 (M + H).

c) Analysis: Calcd: C, 61.38, H, 6.18, N, 14.32: Found: C, 61.54, H, 6.12, N, 14.37.

d) Analysis: Calcd: C: 58.02, H, 5.65, N, 14.24; Found: C, 58.11, H, 5.52, N, 14.26.

e) Analysis: Calcd: C, 59.71, H, 5.26, N, 14.85; Found: C, 59.94, H, 5.09, N, 17.23.

f) Analysis: Calcd: C, 60.48, H, 5.89, N, 14.85, Found: C, 60.62, H, 5.88, N, 14.82.

h) CI-HRMS: Calcd: 337.2388; Found: 337.2392 (M + H).

i) Analysis: Calcd: C, 68.45, H, 7.669, N, 15.21, Found: C, 68.35, H, 7.49 N, 14.91.

j) Analysis: Calcd: C, 69.08, H, 7.915, N, 14.65, Found: C, 68.85, H, 7.83, N, 14.54.

k) Analysis: Calcd: C, 73.51, H, 7.01, N, 19.48, Found: C, 71.57, H, 7.15, N, 19.12.

l) CI-HRMS: Calcd: 403.1899; Found: 403.1901 (M + H).

m) Analysis: Calcd: C, 61.77, H, 6.49, N, 14.41, Cl. 9.13; Found: C, 61.90, H, 6.66, N, 13.62, Cl, 9.25.

n) Analysis: Calcd: C, 67.31, H, 7.06, N, 15.70, Cl. 9.93; Found: C, 67.32, H, 6.95, N, 15.50, Cl, 9.93.

o) Analysis: Calcd: C, 74.50, H, 8.14, N, 17.38, Found: C, 74.43, H, 7.59, N, 17.16.

p) Analysis: Calcd: C, 73.10, H, 7.54, N, 19.37, Found: C, 73.18, H, 7.59, N, 18.81.

q) Analysis: Calcd: C, 73.57, H, 7.78, N, 18.65, Found: C, 73.55, H, 7.79, N, 18.64.

r) CI-HRMS: Calcd: 353.2333; Found: 353.2341 (M + H).

s) Analysis: Calcd: C, 71.56, H, 8.02, N, 15.90, Found: C, 71.45, H, 7.99, N, 15.88.

t) Analysis: Calcd: C, 65.60, H, 7.34, N, 14.57, Found: C, 65.42, H, 7.24, N, 14.37.

u) CI-HRMS: Calcd: 399.2398; Found: 399.2396 (M + H).

v) CI-HRMS: Calcd: 399.2398; Found: 399.2396 (M + H).

w) CI-HRMS: Calcd: 383.2450; Found: 383.2447 (M + H).

x) CI-HRMS: Calcd: 403.1887; Found: 403.1901 (M + H).

y) CI-HRMS: Calcd: 295.1919; Found: 295.1923 (M + H).

z) Analysis: Calcd: C, 67.31, H, 7.06, N, 15.70, Found: C, 67.12, H, 6.86, N, 15.53.

aa) Analysis: Calcd: C, 61.77, H, 6.49, N, 14.41, Cl, 9.13; Found: C, 62.06, H, 6.37, N, 14.25, Cl, 9.12.

ab) CI-HRMS: Calcd: 337.2017; Found: 337.2028 (M + H).

ac) CI-HRMS: Calcd: 403.1893; Found: 403.1901 (M + H).

ad) Analysis: Calcd: C, 70.00, H, 7.22, N, 18.55, Found: C, 70.05, H, 7.22, N, 18.36.

ae) Analysis: Calcd: C, 70.98, H, 7.74, N, 16.55, Found: C, 71.15, H, 7.46, N, 16.56.

ag) Analysis: Calcd: C, 66.59, H, 6.76, N, 16.34, Found: C, 66.69, H,6.82, N, 16.20.

ah) Analysis: Calcd: C, 70.38, H, 6.71, N, 18.65, Found: C, 70.35, H,6.82, N, 18.83.


ai) Analysis: Calcd: C, 66.39, H, 5.85, N, 18.44, Cl, 9.33; Found: C, 66.29, H, 5.51, N, 18.36, Cl, 9.31.

aj) CI-HRMS: Calcd: 369.2278; Found: 369.2291 (M + H).

ak) Analysis: Calcd: C, 64.42, H, 6.77, N, 15.02, Found: C, 64.59, H,6.51, N, 14.81.

The examples delineated in TABLE 3 may be prepared by the methods outlined in Examples 1, 2, 3 or 6. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example.

TABLE 3



Ex.	Z	R_3	Ar	mp(°C)
546[a]	C-Me	$NHCH(Et)_2$	2-Me-4-Me_2N-Ph	164-166
547[b]	C-Me	S-$NHCH(CH_2CH_2OMe)$-CH_2OMe	2,4-Me2-Ph	oil
548[c]	C-Me	S-$NHCH(CH_2CH_2OMe)$-CH_2OMe	2-Me-4-Cl-Ph	oil
549[d]	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Me-4-Cl-Ph	115-116

550[e]	C-Me	NHCH(Et)CH_2CN	2-Me-4-Cl-Ph	131-132
551[f]	C-Me	$N(Et)_2$	2,3-Me_2-4-OMe-Ph	oil
552[g]	C-Me	$N(CH_2CH_2OMe)CH_2CH_2OH$	2,4-Cl_2-Ph	oil
553[h]	C-Me	$N(CH_2CH_2OMe)_2$	2,3-Me_2-4-OMe-Ph	oil
554[i]	C-Me	$NHCH(Et)_2$	2,3-Me_2-4-OMePh	123-124
555[j]	C-Me	$N(CH_2$-c-Pr)Pr	2-Me-4-Cl-Ph	oil
556[k]	C-Me	N(c-Pr)CH_2CH_2CN	2,3-Me_2-4-OMePh	158-160
557	C-Me	N(c-Pr)Et	2-Cl-4-OMePh	
558	C-Me	N(c-Pr)Me	2-Cl-4-OMePh	
559	C-Me	N(c-Pr)Pr	2-Cl-4-OMePh	
560	C-Me	N(c-Pr)Bu	2-Cl-4-OMePh	
561[l]	C-Me	$N(Et)_2$	2-Cl-4-CN-Ph	115-117
562	C-Me	$N(c\text{-}Pr)_2$	2-Cl-4-OMe	127-129
563[m]	C-Me	$NHCH(CH_2OH)_2$	2,4-Cl_2-Ph	128-129
564	C-Me	N(c-Pr)Et	2-Br-4,5-(MeO)2Ph	
565	C-Me	N(c-Pr)Me	2-Br-4,5-(MeO)2Ph	
566	C-Me	NH-c-Pr	2-Me-4-MeOPh	126-128
567	C-Me	NHCH(Et)CH2OH	2-Me-4-MeOPh	60-62
568	C-Me	NMe_2	2-Br-4,5-(MeO)2Ph	
569	C-Me	$NHCH(Et)_2$	2-Me-4-MeOPh	103-105
570	C-Me	N(c-Pr)Et	2-Me-4-MeOPh	173-174
571	C-Me	NH-2-pentyl	2,4-Cl_2-Ph	118-120
572	C-Me	NHCH(Et)CH2CN	2,4-Cl_2-Ph	141-142
573	C-Me	NHCH(Pr)CH2OMe	2,4-Cl_2-Ph	87-88
574	C-Me	NHCH(CH2-iPr)CH2OMe	2,4-Cl_2-Ph	amorphous
575	C-Me	NH-2-butyl	2,4-Me_2-Ph	oil
576	C-Me	NH-2-pentyl	2,4-Me_2-Ph	oil
577	C-Me	NH-2-hexyl	2,4-Me_2-Ph	oil
578	C-Me	NHCH(i-Pr)Me	2,4-Me_2-Ph	oil
579	C-Me	NHCH(Me)CH2-iPr	2,4-Me_2-Ph	oil
580	C-Me	NHCH(Me)-c-C6H11	2,4-Me_2-Ph	oil
581	C-Me	NH-2-indanyl	2,4-Me_2-Ph	oil
582	C-Me	NH-1-indanyl	2,4-Me_2-Ph	oil
583	C-Me	NHCH(Me)Ph	2,4-Me_2-Ph	oil
584	C-Me	NHCH(Me)CH_2-(4-ClPh)	2,4-Me_2-Ph	oil

585	C-Me	NHCH(Me)CH_2COCH_3	2,4-Me_2-Ph	oil
586	C-Me	NHCH(Ph)CH_2Ph	2,4-Me_2-Ph	oil
587	C-Me	NHCH(Me)$(CH_2)_3NEt_2$	2,4-Me_2-Ph	oil
588	C-Me	NH-(2-Ph-c-C_3H_4)	2,4-Me_2-Ph	oil
589	C-Me	NHCH(Et)CH_2CN	2,4-Me_2-Ph	119-120
590	C-Me	NH-3-hexyl	2,4-Me_2-Ph	oil
591[n]	C-Me	NEt_2	2-MeO-4-ClPh	oil
592[o]	C-Me	$NHCH(Et)_2$	2-MeO-4-ClPh	oil
593[p]	C-Me	NHCH(Et)CH_2OMe	2-MeO-4-ClPh	oil
594	C-Me	NMe_2	2-MeO-4-ClPh	oil
595[q]	C-Me	$NHCH(Et)_2$	2-OMe-4-MePh	oil
596[r]	C-Me	NEt_2	2-OMe-4-MePh	oil
597[s]	C-c-Pr	$NHCH(CH_2OMe)_2$	2,4-Cl_2-Ph	oil
598	C-Me	N(c-Pr)Et	2,4-Me_2-Ph	
599	C-Me	N(c-Pr)Et	2,4-Cl_2-Ph	
600	C-Me	N(c-Pr)Et	2,4,6-Me_3-Ph	
601	C-Me	N(c-Pr)Et	2-Me-4-Cl-Ph	
602	C-Me	N(c-Rr)Et	2-Cl-4-Me-Ph	
603	C-Me	$NHCH(c\text{-}Pr)_2$	2,4-Cl_2-Ph	
604	C-Me	$NHCH(c\text{-}Pr)_2$	2,4-Me_2-Ph	
605	C-Me	$NHCH(c\text{-}Pr)_2$	2-Me-4-Cl-Ph	
606	C-Me	$NHCH(c\text{-}Pr)_2$	2-Cl-4-Me-Ph	
607	C-Me	$NHCH(c\text{-}Pr)_2$	2-Me-4-OMe-Ph	
608	C-Me	$NHCH(c\text{-}Pr)_2$	2-Cl-4-OMe-Ph	
609	C-Me	$NHCH(CH_2OMe)_2$	2-Cl-5-F-OMePh	
610	C-Me	NEt_2	2-Cl-5-F-OMePh	
611	C-Me	N(c-Pr)CH_2CH_2CN	2-Cl-5-F-OMePh	
612	C-Me	$NHCH(Et)_2$	2-Cl-5-F-OMePh	
613	C-Me	$N(CH_2CH_2OMe)_2$	2-Cl-5-F-OMePh	
614	C-Me	NEt_2	2,6-Me_2-pyrid-3-yl	
615	C-Me	N(c-Pr)CH_2CH_2CN	2,6-Me_2-pyrid-3-yl	
616	C-Me	$NHCH(Et)_2$	2,6-Me_2-pyrid-3-yl	
617	C-Me	$N(CH_2CH_2OMe)_2$	2,6-Me_2-pyrid-3-yl	
618	C-OH	$NHCH(CH_2OMe)_2$	2,4-Me_2-Ph	
619	C-OH	NEt_2	2,4-Me_2-Ph	
620	C-OH	N(c-Pr)CH_2CH_2CN	2,4-Me_2-Ph	

621	C-OH	$NHCH(Et)_2$	$2,4\text{-}Me_2\text{-}Ph$
623	C-OH	$N(CH_2CH_2OMe)_2$	$2,4\text{-}Me_2\text{-}Ph$
624	$C\text{-}NEt_2$	$NHCH(CH_2OMe)_2$	$2,4\text{-}Me_2\text{-}Ph$
625	$C\text{-}NEt_2$	NEt_2	$2,4\text{-}Me_2\text{-}Ph$
626	$C\text{-}NEt_2$	$N(c\text{-}Pr)CH_2CH_2CN$	$2,4\text{-}Me_2\text{-}Ph$
627	$C\text{-}NEt_2$	$NHCH(Et)_2$	$2,4\text{-}Me_2\text{-}Ph$
628	$C\text{-}NEt_2$	$N(CH_2CH_2OMe)_2$	$2,4\text{-}Me_2\text{-}Ph$
629	C-Me	$NHCH(Et)_2$	2-Me-4-CN-Ph
630	C-Me	$N(CH_2CH_2OMe)_2$	2-Me-4-CN-Ph

Notes for Table 3:

a) CI-HRMS: Calcd:367.2610, Found: 367.2607 (M + H);

b) CI-HRMS: Calcd:384.2400, Found: 384.2393 (M + H);

c) CI-HRMS: Calcd:404.1853, Found: 404.1844 (M + H);

d) CI-HRMS: Calcd:381.1594, Found: 381.1596 (M + H);
Analysis: Calcd: C: 63.07, H, 5.57, N, 22.07, Cl, 9.32;
Found: C: 63.40, H, 5.55, N, 21.96, Cl: 9.15

e) CI-HRMS: Calcd:369.1594, Found: 369.1576 (M + H);

f) CI-HRMS: Calcd:354.2216, Found: 354.2211 (M + H);

g) CI-HRMS: Calcd:410.1072, Found: 410.1075 (M + H);

h) CI-HRMS: Calcd:414.2427, Found: 414.2427(M + H);

i) CI-HRMS: Calcd:368.2372, Found: 368.2372(M + H);

j) CI-HRMS: Calcd:384.1955, Found: 384.1947(M + H);

k) CI-HRMS: Calcd:391.2168, Found: 391.2160(M + H);

l) CI-HRMS: Calcd:335.1984, Found: 335.1961(M + H);

m) CI-HRMS: Calcd:382.0759, Found: 382.0765(M + H);

n) NH_3-CI MS: Calcd: 360, Found: 360 (M + H)+

o) NH_3-CI MS: Calcd: 374, Found: 374 (M + H)+;
NMR ($CDCl_3$, 300 MHz) : δ 7.29 (d, J=8.4Hz, 1H), 7.04 (dd, J=1.8,8Hz, 1H), 6.96 (d, J=1.8Hz, 1H), 6.15 (d, J=10, 1H), 4.19 (m, 1H), 3.81 (s, 3H), 2.47 (s, 3H), 2.32 (s, 3H), 1.65 (m, 4H), 0.99 (t, J=7.32Hz, 6H)

p) NH_3-CI MS: Calcd: 390, Found: 390 (M + H)+;

NMR ($CDCl_3$, 300 MHz) : δ 7.28 (d, J=8Hz, 1H), 7.03 (d, J=8Hz, 1H), 6.96 (s, 1H), 6.52 (d, J=9Hz, 1H), 4.36 (m, 1H), 3.8 (s, 3H), 3.55 (m, 2H), 3.39 (s, 3H), 2.47 (s, 3H), 2.32 (s, 3H), 1.76 (m, 2H), 1.01 (t, J=7.32Hz, 3H).


q) CI-HRMS: Calcd: 354.2294, Found: 354.2279 (M + H)+

r) CI-HRMS: Calcd: 340.2137, Found: 340.2138 (M + H)+

s) CI-HRMS: Calcd: 436.1307, Found: 436.1296 (M + H)+

The examples delineated in TABLE 4 may be prepared by the methods outlined in Examples 1A, 1B, 432, 433, 434. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example, EtOAc is ethyl acetate.

TABLE 4




Ex.	Z	R_3	Ar	mp(°C)
631	C-Me	$NHCH(Et)_2$	2-Br-4,5-$(MeO)_2$Ph	160-161
632	C-Me	$NHCH(Et)_2$	2-Br-4-MeOPh	110-111
633	C-Me	$N(CH_2CH_2OMe)_2$	2-Br-4-MeOPh	74-76
634	C-Me	$NHCH(CH_2OMe)_2$	2-Br-4-MeOPh	128-130

	635	C-Me	$N(Et)_2$	2-Me-4-ClPh	113-114
	636	C-Me	N(c-Pr)Et	$2,4\text{-}Cl_2Ph$	
	637	C-Me	N(c-Pr)Et	$2,4\text{-}Me_2Ph$	
	638	C-Me	N(c-Pr)Et	$2,4,6\text{-}Me_3Ph$	
5	639	C-Me	N(c-Pr)Et	2-Me-4-MeOPh	
	640	C-Me	N(c-Pr)Et	2-Cl-4-MeOPh	
	641	C-Me	N(c-Pr)Et	2-Cl-4-MePh	
	642	C-Me	N(c-Pr)Et	2-Me-4-ClPh	
	643	C-Me	$NHCH(c\text{-}Pr)_2$	$2,4\text{-}Cl_2\text{-}Ph$	
10	644	C-Me	$NHCH(c\text{-}Pr)_2$	$2,4\text{-}Me_2\text{-}Ph$	
	645	C-Me	$NHCH(c\text{-}Pr)_2$	2-Me-4-Cl-Ph	
	646	C-Me	$NHCH(c\text{-}Pr)_2$	2-Cl-4-Me-Ph	
	647	C-Me	$NHCH(c\text{-}Pr)_2$	2-Me-4-OMe-Ph	
	648	C-Me	$NHCH(c\text{-}Pr)_2$	2-Cl-4-OMe-Ph	
15	649	C-Me	$NHCH(CH_2OMe)_2$	2-Cl-5-F-OMePh	
	650	C-Me	NEt_2	2-Cl-5-F-OMePh	
	651	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Cl-5-F-OMePh	
	652	C-Me	$NHCH(Et)_2$	2-Cl-5-F-OMePh	
	653	C-Me	$N(CH_2CH_2OMe)_2$	2-Cl-5-F-OMePh	
20	654	C-Me	NEt_2	$2,6\text{-}Me_2\text{-pyrid-3-yl}$	
	655	C-Me	$N(c\text{-}Pr)CH_2CH_2CN$	$2,6\text{-}Me_2\text{-pyrid-3-yl}$	
	656	C-Me	$NHCH(Et)_2$	$2,6\text{-}Me_2\text{-pyrid-3-yl}$	
	657	C-Me	$N(CH_2CH_2OMe)_2$	$2,6\text{-}Me_2\text{-pyrid-3-yl}$	
	658	C-OH	$NHCH(CH_2OMe)_2$	$2,4\text{-}Me_2\text{-Ph}$	
25	659	C-OH	NEt_2	$2,4\text{-}Me_2\text{-Ph}$	
	660	C-OH	$N(c\text{-}Pr)CH_2CH_2CN$	$2,4\text{-}Me_2\text{-Ph}$	
	661	C-OH	$NHCH(Et)_2$	$2,4\text{-}Me_2\text{-Ph}$	
	662	C-OH	$N(CH_2CH_2OMe)_2$	$2,4\text{-}Me_2\text{-Ph}$	
	663	$C\text{-}NEt_2$	$NHCH(CH_2OMe)_2$	$2,4\text{-}Me_2\text{-Ph}$	
30	664	$C\text{-}NEt_2$	NEt_2	$2,4\text{-}Me_2\text{-Ph}$	
	665	$C\text{-}NEt_2$	$N(c\text{-}Pr)CH_2CH_2CN$	$2,4\text{-}Me_2\text{-Ph}$	
	666	$C\text{-}NEt_2$	$NHCH(Et)_2$	$2,4\text{-}Me_2\text{-Ph}$	
	667	$C\text{-}NEt_2$	$N(CH_2CH_2OMe)_2$	$2,4\text{-}Me_2\text{-Ph}$	
	668	C-Me	$NHCH(Et)_2$	2-Me-4-CN-Ph	
35	669	C-Me	$N(CH_2CH_2OMe)_2$	2-Me-4-CN-Ph	

The examples in Tables 5 or 6 may be prepared by the methods illustrated in Examples 1A, 1B, 2, 3, 6, 431, 432, 433, 434 or by appropriate combinations thereof. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example.

Table 5



Ex.	R_{14}	R_3	Ar
670	Me	$NHCH(CH_2OMe)_2$	2,4-Cl_2-Ph
671	Me	$NHCHPr_2$	2,4-Cl_2-Ph
672	Me	NEtBu	2,4-Cl_2-Ph
673	Me	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4-Cl_2-Ph
674	Me	$N(CH_2CH_2OMe)_2$	2,4-Cl_2-Ph
675	Me	NH-3-heptyl	2,4-Cl_2-Ph
676	Me	$NHCH(Et)CH_2OMe$	2,4-Cl_2-Ph
677	Me	NEt_2	2,4-Cl_2-Ph
678	Me	$NHCH(CH_2OEt)_2$	2,4-Cl_2-Ph
679	Me	NH-3-pentyl	2,4-Cl_2-Ph
680	Me	NMePh	2,4-Cl_2-Ph
681	Me	NPr_2	2,4-Cl_2-Ph
682	Me	NH-3-hexyl	2,4-Cl_2-Ph
683	Me	morpholino	2,4-Cl_2-Ph

684	Me	$N(CH_2Ph)CH_2CH_2OMe$	$2,4-Cl_2-Ph$
685	Me	$NHCH(CH_2Ph)CH_2OMe$	$2,4-Cl_2-Ph$
686	Me	NH-4-tetrahydropyranyl	$2,4-Cl_2-Ph$
687	Me	NH-cyclopentyl	$2,4-Cl_2-Ph$
688	Me	OEt	$2,4-Cl_2-Ph$
689	Me	$OCH(Et)CH_2OMe$	$2,4-Cl_2-Ph$
690	Me	OCH_2Ph	$2,4-Cl_2-Ph$
691	Me	O-3-pentyl	$2,4-Cl_2-Ph$
692	Me	SEt	$2,4-Cl_2-Ph$
693	Me	S(O)Et	$2,4-Cl_2-Ph$
694	Me	SO_2Et	$2,4-Cl_2-Ph$
695	Me	Ph	$2,4-Cl_2-Ph$
696	Me	$2-CF_3-Ph$	$2,4-Cl_2-Ph$
697	Me	2-Ph-Ph	$2,4-Cl_2-Ph$
698	Me	3-pentyl	$2,4-Cl_2-Ph$
699	Me	cyclobutyl	$2,4-Cl_2-Ph$
700	Me	3-pyridyl	$2,4-Cl_2-Ph$
701	Me	$CH(Et)CH_2CONMe_2$	$2,4-Cl_2-Ph$
702	Me	$CH(Et)CH_2CH_2NMe_2$	$2,4-Cl_2-Ph$
703	Me	$NHCH(CH_2OMe)_2$	$2,4,6-Me_3-Ph$
704	Me	$NHCHPr_2$	$2,4,6-Me_3-Ph$
705	Me	NEtBu	$2,4,6-Me_3-Ph$
706	Me	$NPr(CH_2-c-C_3H_5)$	$2,4,6-Me_3-Ph$
707	Me	$N(CH_2CH_2OMe)_2$	$2,4,6-Me_3-Ph$
708	Me	NH-3-heptyl	$2,4,6-Me_3-Ph$
709	Me	$NHCH(Et)CH_2OMe$	$2,4,6-Me_3-Ph$
710	Me	NEt_2	$2,4,6-Me_3-Ph$
711	Me	$NHCH(CH_2OEt)_2$	$2,4,6-Me_3-Ph$
712	Me	NH-3-pentyl	$2,4,6-Me_3-Ph$
713	Me	NMePh	$2,4,6-Me_3-Ph$
714	Me	NPr_2	$2,4,6-Me_3-Ph$
715	Me	NH-3-hexyl	$2,4,6-Me_3-Ph$
716	Me	morpholino	$2,4,6-Me_3-Ph$
717	Me	$N(CH_2Ph)CH_2CH_2OMe$	$2,4,6-Me_3-Ph$
718	Me	$NHCH(CH_2Ph)CH_2OMe$	$2,4,6-Me_3-Ph$
719	Me	NH-4-tetrahydropyranyl	$2,4,6-Me_3-Ph$

720	Me	NH-cyclopentyl	2,4,6-Me_3-Ph
721	Me	OEt	2,4,6-Me_3-Ph
722	Me	OCH(Et)CH_2OMe	2,4,6-Me_3-Ph
723	Me	OCH_2Ph	2,4,6-Me_3-Ph
724	Me	O-3-pentyl	2,4,6-Me_3-Ph
725	Me	SEt	2,4,6-Me_3-Ph
726	Me	S(O)Et	2,4,6-Me_3-Ph
727	Me	SO_2Et	2,4,6-Me_3-Ph
728	Me	CH(CO_2Et)$_2$	2,4,6-Me_3-Ph
729	Me	C(Et)(CO_2Et)$_2$	2,4,6-Me_3-Ph
730	Me	CH(Et)CH_2OH	2,4,6-Me_3-Ph
731	Me	CH(Et)CH_2OMe	2,4,6-Me_3-Ph
732	Me	$CONMe_2$	2,4,6-Me_3-Ph
733	Me	$COCH_3$	2,4,6-Me_3-Ph
734	Me	CH(OH)CH_3	2,4,6-Me_3-Ph
735	Me	C(OH)Ph-3-pyridyl	2,4,6-Me_3-Ph
736	Me	Ph	2,4,6-Me_3-Ph
737	Me	2-Ph-Ph	2,4,6-Me_3-Ph
738	Me	3-pentyl	2,4,6-Me_3-Ph
739	Me	cyclobutyl	2,4,6-Me_3-Ph
740	Me	3-pyridyl	2,4,6-Me_3-Ph
741	Me	CH(Et)CH_2CONMe_2	2,4,6-Me_3-Ph
742	Me	CH(Et)$CH_2CH_2NMe_2$	2,4,6-Me_3-Ph
743	Me	NHCH(CH_2OMe)$_2$	2,4-Me_2-Ph
744	Me	N(CH_2CH_2OMe)$_2$	2,4-Me_2-Ph
745	Me	NHCH(Et)CH_2OMe	2,4-Me_2-Ph
746	Me	NH-3-pentyl	2,4-Me_2-Ph
747	Me	NEt_2	2,4-Me_2-Ph
748	Me	N(CH_2CN)$_2$	2,4-Me_2-Ph
749	Me	NHCH(Me)CH_2OMe	2,4-Me_2-Ph
750	Me	OCH(Et)CH_2OMe	2,4-Me_2-Ph
751	Me	NPr-c-C_3H_5	2,4-Me_2-Ph
752	Me	NHCH(Me)CH_2NMe_2	2,4-Me_2-Ph
753	Me	N(c-C_3H_5)CH_2CH_2CN	2,4-Me_2-Ph
754	Me	N(Pr)CH_2CH_2CN	2,4-Me_2-Ph
755	Me	N(Bu)CH_2CH_2CN	2,4-Me_2-Ph

756	Me	$NHCHPr_2$	2,4-Me_2-Ph
757	Me	NEtBu	2,4-Me_2-Ph
758	Me	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4-Me_2-Ph
759	Me	NH-3-heptyl	2,4-Me_2-Ph
760	Me	NEt_2	2,4-Me_2-Ph
761	Me	$NHCH(CH_2OEt)_2$	2,4-Me_2-Ph
762	Me	NH-3-pentyl	2,4-Me_2-Ph
763	Me	NMePh	2,4-Me_2-Ph
764	Me	NPr_2	2,4-Me_2-Ph
765	Me	NH-3-hexyl	2,4-Me_2-Ph
766	Me	morpholino	2,4-Me_2-Ph
767	Me	$N(CH_2Ph)CH_2CH_2OMe$	2,4-Me_2-Ph
768	Me	$NHCH(CH_2Ph)CH_2OMe$	2,4-Me_2-Ph
769	Me	NH-4-tetrahydropyranyl	2,4-Me_2-Ph
770	Me	NH-cyclopentyl	2,4-Me_2-Ph
771	Me	$NHCH(CH_2OMe)_2$	2-Me-4-MeO-Ph
772	Me	$N(CH_2CH_2OMe)_2$	2-Me-4-MeO-Ph
773	Me	$NHCH(Et)CH_2OMe$	2-Me-4-MeO-Ph
774	Me	$N(Pr)CH_2CH_2CN$	2-Me-4-MeO-Ph
775	Me	$OCH(Et)CH_2OMe$	2-Me-4-MeO-Ph
776	Me	$NHCH(CH_2OMe)_2$	2-Br-4-MeO-Ph
777	Me	$N(CH_2CH_2OMe)_2$	2-Br-4-MeO-Ph
778	Me	$NHCH(Et)CH_2OMe$	2-Br-4-MeO-Ph
779	Me	$N(Pr)CH_2CH_2CN$	2-Br-4-MeO-Ph
780	Me	$OCH(Et)CH_2OMe$	2-Br-4-MeO-Ph
781	Me	$NHCH(CH_2OMe)_2$	2-Me-4-NMe_2-Ph
782	Me	$N(CH_2CH_2OMe)_2$	2-Me-4-NMe_2-Ph
783	Me	$NHCH(Et)CH_2OMe$	2-Me-4-NMe_2-Ph
784	Me	$N(Pr)CH_2CH_2CN$	2-Me-4-NMe_2-Ph
785	Me	$OCH(Et)CH_2OMe$	2-Me-4-NMe_2-Ph
786	Me	$NHCH(CH_2OMe)_2$	2-Br-4-NMe_2-Ph
787	Me	$N(CH_2CH_2OMe)_2$	2-Br-4-NMe_2-Ph
788	Me	$NHCH(Et)CH_2OMe$	2-Br-4-NMe_2-Ph
789	Me	$N(Pr)CH_2CH_2CN$	2-Br-4-NMe_2-Ph
790	Me	$OCH(Et)CH_2OMe$	2-Br-4-NMe_2-Ph
791	Me	$NHCH(CH_2OMe)_2$	2-Br-4-i-Pr-Ph


792	Me	$N(CH_2CH_2OMe)_2$	2-Br-4-i-Pr-Ph
793	Me	NHCH(Et)CH_2OMe	2-Br-4-i-Pr-Ph
794	Me	N(Pr)CH_2CH_2CN	2-Br-4-i-Pr-Ph
795	Me	OCH(Et)CH_2OMe	2-Br-4-i-Pr-Ph
796	Me	$NHCH(CH_2OMe)_2$	2-Br-4-Me-Ph
797	Me	$N(CH_2CH_2OMe)_2$	2-Br-4-Me-Ph
798	Me	NHCH(Et)CH_2OMe	2-Br-4-Me-Ph
799	Me	N(Pr)CH_2CH_2CN	2-Br-4-Me-Ph
800	Me	OCH(Et)CH_2OMe	2-Br-4-Me-Ph
801	Me	$NHCH(CH_2OMe)_2$	2-Me-4-Br-Ph
802	Me	$N(CH_2CH_2OMe)_2$	2-Me-4-Br-Ph
803	Me	NHCH(Et)CH_2OMe	2-Me-4-Br-Ph
804	Me	N(Pr)CH_2CH_2CN	2-Me-4-Br-Ph
805	Me	OCH(Et)CH_2OMe	2-Me-4-Br-Ph
806	Me	$NHCH(CH_2OMe)_2$	2-Cl-4,6-Me_2-Ph
807	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4,6-Me_2-Ph
808	Me	$NHCH(CH_2OMe)_2$	4-Br-2,6-$(Me)_2$-Ph
809	Me	$N(CH_2CH_2OMe)_2$	4-Br-2,6-$(Me)_2$-Ph
810	Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
811	Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
812	Me	$NHCH(CH_2OMe)_2$	2-Br-4-CF_3-Ph
813	Me	$N(CH_2CH_2OMe)_2$	2-Br-4-CF_3-Ph
814	Me	$NHCH(CH_2OMe)_2$	2-Br-4,6-$(MeO)_2$-Ph
815	Me	$N(CH_2CH_2OMe)_2$	2-Br-4,6-$(MeO)_2$-Ph
816	Me	$NHCH(CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$-Ph
817	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$-Ph
818	Me	$NHCH(CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
819	Me	$N(CH_2CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
820	Me	$NHCH(CH_2OMe)_2$	4-(COMe)-2-Br-Ph
821	Me	$N(CH_2CH_2OMe)_2$	4-(COMe)-2-Br-Ph
822	Me	$NHCH(CH_2OMe)_2$	2,4,6-Me_3-pyrid-3-yl
823	Me	$N(CH_2CH_2OMe)_2$	2,4,6-Me_3-pyrid-3-yl
824	Me	$NHCH(CH_2OMe)_2$	2,4-$(Br)_2$-Ph
825	Me	$N(CH_2CH_2OMe)_2$	2,4-$(Br)_2$-Ph
826	Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
827	Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SMe-Ph

828	Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SO_2Me-Ph
829	Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SO_2Me-Ph
830	Me	$NHCH(CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
831	Me	$N(CH_2CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
832	Me	$NHCH(CH_2OMe)_2$	2,6-(Me)2-4-SO_2Me-Ph
833	Me	$N(CH_2CH_2OMe)_2$	2,6-(Me)2-4-SO_2Me-Ph
834	Me	$NHCH(CH_2OMe)_2$	2-I-4-i-Pr-Ph
835	Me	$N(CH_2CH_2OMe)_2$	2-I-4-i-Pr-Ph
836	Me	$NHCH(CH_2OMe)_2$	2-Br-4-$N(Me)_2$-6-MeO-Ph
837	Me	$N(CH_2CH_2OMe)_2$	2-Br-4-$N(Me)_2$-6-MeO-Ph
838	Me	NEt_2	2-Br-4-MeO-Ph
839	Me	NH-3-pentyl	2-Br-4-MeO-Ph
840	Me	$NHCH(CH_2OMe)_2$	2-CN-4-Me-Ph
841	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2,4,6-Me_3-Ph
842	Me	$NHCH(CH_2CH_2OMe)CH_2OMe$	2-Me-4-Br-Ph
843	Me	$NHCH(CH_2OMe)_2$	2,5-Me_2-4-MeO-Ph
844	Me	$N(CH_2CH_2OMe)_2$	2,5-Me_2-4-MeO-Ph
845	Me	NH-3-pentyl	2,5-Me_2-4-MeO-Ph
846	Me	NEt_2	2,5-Me_2-4-MeO-Ph
847	Me	$NHCH(CH_2OMe)_2$	2-Cl-4-MePh
848	Me	$NCH(Et)CH_2OMe$	2-Cl-4-MePh
849	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4-MePh
850	Me	(S)-$NHCH(CH_2CH_2OMe)CH_2OMe$	2-Cl-4-MePh
851	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2,5-Me_2-4-MeOPh
852	Me	NEt_2	2-Me-4-MeOPh
853	Me	OEt	2-Me-4-MeOPh
854	Me	(S)-$NHCH(CH_2CH_2OMe)CH_2OMe$	2-Me-4-MeOPh
855	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2-Me-4-MeOPh
856	Me	$NHCH(CH_2CH_2OEt)_2$	2-Me-4-MeOPh
857	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2,4-Cl_2-Ph
858	Me	NEt_2	2-Me-4-ClPh
859	Me	NH-3-pentyl	2-Me-4-ClPh
860	Me	$N(CH_2CH_2OMe)_2$	2-Me-4-ClPh
861	Me	$NHCH(CH_2OMe)_2$	2-Me-4-ClPh
862	Me	NEt_2	2-Me-4-ClPh
863	Me	NEt_2	2-Cl-4-MePh

864	Me	NH-3-pentyl	2-Cl-4-MePh
865	Me	$NHCH(CH_2OMe)_2$	2-Cl-4-MeOPh
866	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4-MeOPh
867	Me	$NHCH(Et)CH_2OMe$	2-Cl-4-MeOPh
868	Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Cl-4-MeOPh
869	Me	NEt_2	2-Cl-4-MeOPh
870	Me	NH-3-pentyl	2-Cl-4-MeOPh
871	Me	$NHCH(Et)CH_2CH_2OMe$	2-Cl-4-MeOPh
872	Me	$NHCH(Me)CH_2CH_2OMe$	2-Cl-4-MeOPh
873	Me	$NHCH(Et)CH_2CH_2OMe$	2-Br-4-MeOPh
874	Me	$NHCH(Me)CH_2CH_2OMe$	2-Br-4-MeOPh
875	Me	$NHCH(Et)CH_2CH_2OMe$	2-Me-4-MeOPh
876	Me	$NHCH(Me)CH_2CH_2OMe$	2-Me-4-MeOPh
877	Me	$NHCH(CH_2OMe)_2$	2-Cl-4,5-$(MeO)_2$Ph
878	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4,5-$(MeO)_2$Ph
879	Me	$NHCH(Et)CH_2OMe$	2-Cl-4,5-$(MeO)_2$Ph
880	Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Cl-4,5-$(MeO)_2$Ph
881	Me	NEt_2	2-Cl-4,5-$(MeO)_2$Ph
882	Me	NH-3-pentyl	2-Cl-4,5-$(MeO)_2$Ph
883	Me	$NHCH(Et)CH_2CH_2OMe$	2-Cl-4,5-$(MeO)_2$Ph
884	Me	$NHCH(Me)CH_2CH_2OMe$	2-Cl-4,5-$(MeO)_2$Ph
885	Me	$NHCH(CH_2OMe)_2$	2-Br-4,5-$(MeO)_2$Ph
886	Me	$N(CH_2CH_2OMe)_2$	2-Br-4,5-$(MeO)_2$Ph
887	Me	$NHCH(Et)CH_2OMe$	2-Br-4,5-$(MeO)_2$Ph
888	Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Br-4,5-$(MeO)_2$Ph
889	Me	NEt_2	2-Br-4,5-$(MeO)_2$Ph
890	Me	NH-3-pentyl	2-Br-4,5-$(MeO)_2$Ph
891	Me	$NHCH(CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$Ph
892	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$Ph
893	Me	NEt_2	2-Cl-4,6-$(MeO)_2$Ph
894	Me	NH-3-pentyl	2-Cl-4,6-$(MeO)_2$Ph
895	Me	$NHCH(CH_2OMe)_2$	2-Me-4,6-$(MeO)_2$Ph
896	Me	$N(CH_2CH_2OMe)_2$	2-Me-4,6-$(MeO)_2$Ph
897	Me	$NHCH(Et)CH_2OMe$	2-Me-4,6-$(MeO)_2$Ph
898	Me	NEt_2	2-Me-4,6-$(MeO)_2$Ph
899	Me	NH-3-pentyl	2-Me-4,6-$(MeO)_2$Ph

	900	Me	NHCH(Et)CH_2CH_2OMe	2-Me-4-MeOPh
	901	Me	NHCH(Me)CH_2CH_2OMe	2-Me-4-MeOPh
	902	Me	NHCH$(CH_2OMe)_2$	2-Me0-4-MePh
	903	Me	N$(CH_2CH_2OMe)_2$	2-Me0-4-MePh
	904	Me	NHCH(Et)CH_2OMe	2-Me0-4-MePh
	905	Me	N(c-Pr)CH_2CH_2CN	2-Me0-4-MePh
	906	Me	NEt_2	2-Me0-4-MePh
	907	Me	NH-3-pentyl	2-Me0-4-MePh
	908	Me	NHCH(Et)CH_2CH_2OMe	2-Me0-4-MePh
	909	Me	NHCH(Me)CH_2CH_2OMe	2-Me0-4-MePh
	910	Me	NHCH$(CH_2OMe)_2$	2-Me0-4-MePh
	911	Me	N$(CH_2CH_2OMe)_2$	2-Me0-4-MePh
	912	Me	NHCH(Et)CH_2OMe	2-Me0-4-MePh
	913	Me	N(c-Pr)CH_2CH_2CN	2-Me0-4-MePh
	914	Me	NEt_2	2-Me0-4-MePh
	915	Me	NH-3-pentyl	2-Me0-4-MePh
	916	Me	NHCH$(CH_2OMe)_2$	2-Me0-4-ClPh
	917	Me	N$(CH_2CH_2OMe)_2$	2-Me0-4-ClPh
	918	Me	NHCH(Et)CH_2OMe	2-Me0-4-ClPh
	919	Me	NEt_2	2-Me0-4-ClPh
	920	Me	NH-3-pentyl	2-Me0-4-ClPh

Table 6



Ex.	R_{14}	R_3	Ar
921	Me	$NHCH(CH_2OMe)_2$	2,4-Cl_2-Ph
922	Me	$NHCHPr_2$	2,4-Cl_2-Ph
923	Me	NEtBu	2,4-Cl_2-Ph
924	Me	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4-Cl_2-Ph
925	Me	$N(CH_2CH_2OMe)_2$	2,4-Cl_2-Ph
926	Me	NH-3-heptyl	2,4-Cl_2-Ph
927	Me	$NHCH(Et)CH_2OMe$	2,4-Cl_2-Ph
928	Me	NEt_2	2,4-Cl_2-Ph
929	Me	$NHCH(CH_2OEt)_2$	2,4-Cl_2-Ph
930	Me	NH-3-pentyl	2,4-Cl_2-Ph
931	Me	NMePh	2,4-Cl_2-Ph
932	Me	NPr_2	2,4-Cl_2-Ph
933	Me	NH-3-hexyl	2,4-Cl_2-Ph
934	Me	morpholino	2,4-Cl_2-Ph
935	Me	$N(CH_2Ph)CH_2CH_2OMe$	2,4-Cl_2-Ph
936	Me	$NHCH(CH_2Ph)CH_2OMe$	2,4-Cl_2-Ph
937	Me	NH-4-tetrahydropyranyl	2,4-Cl_2-Ph
938	Me	NH-cyclopentyl	2,4-Cl_2-Ph
939	Me	OEt	2,4-Cl_2-Ph
940	Me	$OCH(Et)CH_2OMe$	2,4-Cl_2-Ph
941	Me	OCH_2Ph	2,4-Cl_2-Ph
942	Me	O-3-pentyl	2,4-Cl_2-Ph
943	Me	SEt	2,4-Cl_2-Ph

944	Me	S(O)Et	2,4-Cl_2-Ph
945	Me	SO_2Et	2,4-Cl_2-Ph
946	Me	Ph	2,4-Cl_2-Ph
947	Me	2-CF_3-Ph	2,4-Cl_2-Ph
948	Me	2-Ph-Ph	2,4-Cl_2-Ph
949	Me	3-pentyl	2,4-Cl_2-Ph
950	Me	cyclobutyl	2,4-Cl_2-Ph
951	Me	3-pyridyl	2,4-Cl_2-Ph
952	Me	$CH(Et)CH_2CONMe_2$	2,4-Cl_2-Ph
953	Me	$CH(Et)CH_2CH_2NMe_2$	2,4-Cl_2-Ph
954	Me	$NHCH(CH_2OMe)_2$	2,4,6-Me_3-Ph
955	Me	$NHCHPr_2$	2,4,6-Me_3-Ph
956	Me	NEtBu	2,4,6-Me_3-Ph
957	Me	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4,6-Me_3-Ph
958	Me	$N(CH_2CH_2OMe)_2$	2,4,6-Me_3-Ph
959	Me	NH-3-heptyl	2,4,6-Me_3-Ph
960	Me	$NHCH(Et)CH_2OMe$	2,4,6-Me_3-Ph
961	Me	NEt_2	2,4,6-Me_3-Ph
962	Me	$NHCH(CH_2OEt)_2$	2,4,6-Me_3-Ph
963	Me	NH-3-pentyl	2,4,6-Me_3-Ph
964	Me	NMePh	2,4,6-Me_3-Ph
965	Me	NPr_2	2,4,6-Me_3-Ph
966	Me	NH-3-hexyl	2,4,6-Me_3-Ph
967	Me	morpholino	2,4,6-Me_3-Ph
968	Me	$N(CH_2Ph)CH_2CH_2OMe$	2,4,6-Me_3-Ph
969	Me	$NHCH(CH_2Ph)CH_2OMe$	2,4,6-Me_3-Ph
970	Me	NH-4-tetrahydropyranyl	2,4,6-Me_3-Ph
971	Me	NH-cyclopentyl	2,4,6-Me_3-Ph
972	Me	OEt	2,4,6-Me_3-Ph
973	Me	$OCH(Et)CH_2OMe$	2,4,6-Me_3-Ph
974	Me	OCH_2Ph	2,4,6-Me_3-Ph
975	Me	O-3-pentyl	2,4,6-Me_3-Ph
976	Me	SEt	2,4,6-Me_3-Ph
977	Me	S(O)Et	2,4,6-Me_3-Ph
978	Me	SO_2Et	2,4,6-Me_3-Ph
979	Me	$CH(CO_2Et)_2$	2,4,6-Me_3-Ph

	980	Me	$C(Et)(CO_2Et)_2$	2,4,6-Me_3-Ph
	981	Me	$CH(Et)CH_2OH$	2,4,6-Me_3-Ph
	982	Me	$CH(Et)CH_2OMe$	2,4,6-Me_3-Ph
	983	Me	$CONMe_2$	2,4,6-Me_3-Ph
5	984	Me	$COCH_3$	2,4,6-Me_3-Ph
	985	Me	$CH(OH)CH_3$	2,4,6-Me_3-Ph
	986	Me	C(OH)Ph-3-pyridyl	2,4,6-Me_3-Ph
	987	Me	Ph	2,4,6-Me_3-Ph
	988	Me	2-Ph-Ph	2,4,6-Me_3-Ph
10	989	Me	3-pentyl	2,4,6-Me_3-Ph
	990	Me	cyclobutyl	2,4,6-Me_3-Ph
	991	Me	3-pyridyl	2,4,6-Me_3-Ph
	992	Me	$CH(Et)CH_2CONMe_2$	2,4,6-Me_3-Ph
	993	Me	$CH(Et)CH_2CH_2NMe_2$	2,4,6-Me_3-Ph
15	994	Me	$NHCH(CH_2OMe)_2$	2,4-Me_2-Ph
	995	Me	$N(CH_2CH_2OMe)_2$	2,4-Me_2-Ph
	996	Me	$NHCH(Et)CH_2OMe$	2,4-Me_2-Ph
	997	Me	NH-3-pentyl	2,4-Me_2-Ph
	998	Me	NEt_2	2,4-Me_2-Ph
20	999	Me	$N(CH_2CN)_2$	2,4-Me_2-Ph
	1000	Me	$NHCH(Me)CH_2OMe$	2,4-Me_2-Ph
	1001	Me	$OCH(Et)CH_2OMe$	2,4-Me_2-Ph
	1002	Me	NPr-c-C_3H_5	2,4-Me_2-Ph
	1003	Me	$NHCH(Me)CH_2NMe_2$	2,4-Me_2-Ph
25	1004	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2,4-Me_2-Ph
	1005	Me	$N(Pr)CH_2CH_2CN$	2,4-Me_2-Ph
	1006	Me	$N(Bu)CH_2CH_2CN$	2,4-Me_2-Ph
	1007	Me	$NHCHPr_2$	2,4-Me_2-Ph
	1008	Me	NEtBu	2,4-Me_2-Ph
30	1009	Me	$NPr(CH_2\text{-}c\text{-}C_3H_5)$	2,4-Me_2-Ph
	1010	Me	NH-3-heptyl	2,4-Me_2-Ph
	1011	Me	NEt_2	2,4-Me_2-Ph
	1012	Me	$NHCH(CH_2OEt)_2$	2,4-Me_2-Ph
	1013	Me	NH-3-pentyl	2,4-Me_2-Ph
35	1014	Me	NMePh	2,4-Me_2-Ph
	1015	Me	NPr_2	2,4-Me_2-Ph

1016	Me	NH-3-hexyl	2,4-Me_2-Ph
1017	Me	morpholino	2,4-Me_2-Ph
1018	Me	N(CH_2Ph)CH_2CH_2OMe	2,4-Me_2-Ph
1019	Me	NHCH(CH_2Ph)CH_2OMe	2,4-Me_2-Ph
1020	Me	NH-4-tetrahydropyranyl	2,4-Me_2-Ph
1021	Me	NH-cyclopentyl	2,4-Me_2-Ph
1022	Me	NHCH(CH_2OMe)$_2$	2-Me-4-MeO-Ph
1023	Me	N(CH_2CH_2OMe)$_2$	2-Me-4-MeO-Ph
1024	Me	NHCH(Et)CH_2OMe	2-Me-4-MeO-Ph
1025	Me	N(Pr)CH_2CH_2CN	2-Me-4-MeO-Ph
1026	Me	OCH(Et)CH_2OMe	2-Me-4-MeO-Ph
1027	Me	NHCH(CH_2OMe)$_2$	2-Br-4-MeO-Ph
1028	Me	N(CH_2CH_2OMe)$_2$	2-Br-4-MeO-Ph
1029	Me	NHCH(Et)CH_2OMe	2-Br-4-MeO-Ph
1030	Me	N(Pr)CH_2CH_2CN	2-Br-4-MeO-Ph
1031	Me	OCH(Et)CH_2OMe	2-Br-4-MeO-Ph
1032	Me	NHCH(CH_2OMe)$_2$	2-Me-4-NMe_2-Ph
1033	Me	N(CH_2CH_2OMe)$_2$	2-Me-4-NMe_2-Ph
1034	Me	NHCH(Et)CH_2OMe	2-Me-4-NMe_2-Ph
1035	Me	N(Pr)CH_2CH_2CN	2-Me-4-NMe_2-Ph
1036	Me	OCH(Et)CH_2OMe	2-Me-4-NMe_2-Ph
1037	Me	NHCH(CH_2OMe)$_2$	2-Br-4-NMe_2-Ph
1038	Me	N(CH_2CH_2OMe)$_2$	2-Br-4-NMe_2-Ph
1039	Me	NHCH(Et)CH_2OMe	2-Br-4-NMe_2-Ph
1040	Me	N(Pr)CH_2CH_2CN	2-Br-4-NMe_2-Ph
1041	Me	OCH(Et)CH_2OMe	2-Br-4-NMe_2-Ph
1042	Me	NHCH(CH_2OMe)$_2$	2-Br-4-i-Pr-Ph
1043	Me	N(CH_2CH_2OMe)$_2$	2-Br-4-i-Pr-Ph
1044	Me	NHCH(Et)CH_2OMe	2-Br-4-i-Pr-Ph
1045	Me	N(Pr)CH_2CH_2CN	2-Br-4-i-Pr-Ph
1046	Me	OCH(Et)CH_2OMe	2-Br-4-i-Pr-Ph
1047	Me	NHCH(CH_2OMe)$_2$	2-Br-4-Me-Ph
1048	Me	N(CH_2CH_2OMe)$_2$	2-Br-4-Me-Ph
1049	Me	NHCH(Et)CH_2OMe	2-Br-4-Me-Ph
1050	Me	N(Pr)CH_2CH_2CN	2-Br-4-Me-Ph
1051	Me	OCH(Et)CH_2OMe	2-Br-4-Me-Ph

1052	Me	$NHCH(CH_2OMe)_2$	2-Me-4-Br-Ph
1053	Me	$N(CH_2CH_2OMe)_2$	2-Me-4-Br-Ph
1054	Me	$NHCH(Et)CH_2OMe$	2-Me-4-Br-Ph
1055	Me	$N(Pr)CH_2CH_2CN$	2-Me-4-Br-Ph
1056	Me	$OCH(Et)CH_2OMe$	2-Me-4-Br-Ph
1057	Me	$NHCH(CH_2OMe)_2$	2-Cl-4,6-Me_2-Ph
1058	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4,6-Me_2-Ph
1059	Me	$NHCH(CH_2OMe)_2$	4-Br-2,6-$(Me)_2$-Ph
1060	Me	$N(CH_2CH_2OMe)_2$	4-Br-2,6-$(Me)_2$-Ph
1061	Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
1062	Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
1063	Me	$NHCH(CH_2OMe)_2$	2-Br-4-CF_3-Ph
1064	Me	$N(CH_2CH_2OMe)_2$	2-Br-4-CF_3-Ph
1065	Me	$NHCH(CH_2OMe)_2$	2-Br-4,6-$(MeO)_2$-Ph
1066	Me	$N(CH_2CH_2OMe)_2$	2-Br-4,6-$(MeO)_2$-Ph
1067	Me	$NHCH(CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$-Ph
1068	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$-Ph
1069	Me	$NHCH(CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
1070	Me	$N(CH_2CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
1071	Me	$NHCH(CH_2OMe)_2$	4-(COMe)-2-Br-Ph
1072	Me	$N(CH_2CH_2OMe)_2$	4-(COMe)-2-Br-Ph
1073	Me	$NHCH(CH_2OMe)_2$	2,4,6-Me_3-pyrid-3-yl
1074	Me	$N(CH_2CH_2OMe)_2$	2,4,6-Me_3-pyrid-3-yl
1075	Me	$NHCH(CH_2OMe)_2$	2,4-$(Br)_2$-Ph
1076	Me	$N(CH_2CH_2OMe)_2$	2,4-$(Br)_2$-Ph
1077	Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
1078	Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SMe-Ph
1079	Me	$NHCH(CH_2OMe)_2$	4-i-Pr-2-SO_2Me-Ph
1080	Me	$N(CH_2CH_2OMe)_2$	4-i-Pr-2-SO_2Me-Ph
1081	Me	$NHCH(CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
1082	Me	$N(CH_2CH_2OMe)_2$	2,6-$(Me)_2$-4-SMe-Ph
1083	Me	$NHCH(CH_2OMe)_2$	2,6-(Me)2-4-SO_2Me-Ph
1084	Me	$N(CH_2CH_2OMe)_2$	2,6-(Me)2-4-SO_2Me-Ph
1085	Me	$NHCH(CH_2OMe)_2$	2-I-4-i-Pr-Ph
1086	Me	$N(CH_2CH_2OMe)_2$	2-I-4-i-Pr-Ph
1087	Me	$NHCH(CH_2OMe)_2$	2-Br-4-$N(Me)_2$-6-MeO-Ph

1088	Me	$N(CH_2CH_2OMe)_2$	2-Br-4-$N(Me)_2$-6-MeO-Ph
1089	Me	NEt_2	2-Br-4-MeO-Ph
1090	Me	NH-3-pentyl	2-Br-4-MeO-Ph
1091	Me	$NHCH(CH_2OMe)_2$	2-CN-4-Me-Ph
1092	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2,4,6-Me_3-Ph
1093	Me	$NHCH(CH_2CH_2OMe)CH_2OMe$	2-Me-4-Br-Ph
1094	Me	$NHCH(CH_2OMe)_2$	2,5-Me_2-4-MeO-Ph
1095	Me	$N(CH_2CH_2OMe)_2$	2,5-Me_2-4-MeO-Ph
1096	Me	NH-3-pentyl	2,5-Me_2-4-MeO-Ph
1097	Me	NEt_2	2,5-Me_2-4-MeO-Ph
1098	Me	$NHCH(CH_2OMe)_2$	2-Cl-4-MePh
1099	Me	$NCH(Et)CH_2OMe$	2-Cl-4-MePh
1100	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4-MePh
1101	Me	(S)-$NHCH(CH_2CH_2OMe)CH_2OMe$	2-Cl-4-MePh
1102	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2,5-Me_2-4-MeOPh
1103	Me	NEt_2	2-Me-4-MeOPh
1104	Me	OEt	2-Me-4-MeOPh
1105	Me	(S)-$NHCH(CH_2CH_2OMe)CH_2OMe$	2-Me-4-MeOPh
1106	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2-Me-4-MeOPh
1107	Me	$NHCH(CH_2CH_2OEt)_2$	2-Me-4-MeOPh
1108	Me	$N(c\text{-}C_3H_5)CH_2CH_2CN$	2,4-Cl_2-Ph
1109	Me	NEt_2	2-Me-4-ClPh
1110	Me	NH-3-pentyl	2-Me-4-ClPh
1111	Me	$N(CH_2CH_2OMe)_2$	2-Me-4-ClPh
1112	Me	$NHCH(CH_2OMe)_2$	2-Me-4-ClPh
1113	Me	NEt_2	2-Me-4-ClPh
1114	Me	NEt_2	2-Cl-4-MePh
1115	Me	NH-3-pentyl	2-Cl-4-MePh
1116	Me	$NHCH(CH_2OMe)_2$	2-Cl-4-MeOPh
1117	Me	$N(CH_2CH_2OMe)_2$	2-Cl-4-MeOPh
1118	Me	$NHCH(Et)CH_2OMe$	2-Cl-4-MeOPh
1119	Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-Cl-4-MeOPh
1120	Me	NEt_2	2-Cl-4-MeOPh
1121	Me	NH-3-pentyl	2-Cl-4-MeOPh
1123	Me	$NHCH(Et)CH_2CH_2OMe$	2-Cl-4-MeOPh
1124	Me	$NHCH(Me)CH_2CH_2OMe$	2-Cl-4-MeOPh

1125	Me	NHCH(Et)CH_2CH_2OMe	2-Br-4-MeOPh
1126	Me	NHCH(Me)CH_2CH_2OMe	2-Br-4-MeOPh
1127	Me	NHCH(Et)CH_2CH_2OMe	2-Me-4-MeOPh
1128	Me	NHCH(Me)CH_2CH_2OMe	2-Me-4-MeOPh
1129	Me	NHCH$(CH_2OMe)_2$	2-Cl-4,5-$(MeO)_2$Ph
1130	Me	N$(CH_2CH_2OMe)_2$	2-Cl-4,5-$(MeO)_2$Ph
1131	Me	NHCH(Et)CH_2OMe	2-Cl-4,5-$(MeO)_2$Ph
1132	Me	N(c-Pr)CH_2CH_2CN	2-Cl-4,5-$(MeO)_2$Ph
1133	Me	NEt_2	2-Cl-4,5-$(MeO)_2$Ph
1134	Me	NH-3-pentyl	2-Cl-4,5-$(MeO)_2$Ph
1135	Me	NHCH(Et)CH_2CH_2OMe	2-Cl-4,5-$(MeO)_2$Ph
1136	Me	NHCH(Me)CH_2CH_2OMe	2-Cl-4,5-$(MeO)_2$Ph
1137	Me	NHCH$(CH_2OMe)_2$	2-Br-4,5-$(MeO)_2$Ph
1138	Me	N$(CH_2CH_2OMe)_2$	2-Br-4,5-$(MeO)_2$Ph
1139	Me	NHCH(Et)CH_2OMe	2-Br-4,5-$(MeO)_2$Ph
1140	Me	N(c-Pr)CH_2CH_2CN	2-Br-4,5-$(MeO)_2$Ph
1141	Me	NEt_2	2-Br-4,5-$(MeO)_2$Ph
1142	Me	NH-3-pentyl	2-Br-4,5-$(MeO)_2$Ph
1143	Me	NHCH$(CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$Ph
1144	Me	N$(CH_2CH_2OMe)_2$	2-Cl-4,6-$(MeO)_2$Ph
1145	Me	NEt_2	2-Cl-4,6-$(MeO)_2$Ph
1146	Me	NH-3-pentyl	2-Cl-4,6-$(MeO)_2$Ph
1147	Me	NHCH$(CH_2OMe)_2$	2-Me-4,6-$(MeO)_2$Ph
1148	Me	N$(CH_2CH_2OMe)_2$	2-Me-4,6-$(MeO)_2$Ph
1149	Me	NHCH(Et)CH_2OMe	2-Me-4,6-$(MeO)_2$Ph
1150	Me	NEt_2	2-Me-4,6-$(MeO)_2$Ph
1151	Me	NH-3-pentyl	2-Me-4,6-$(MeO)_2$Ph
1152	Me	NHCH(Et)CH_2CH_2OMe	2-Me-4-MeOPh
1153	Me	NHCH(Me)CH_2CH_2OMe	2-Me-4-MeOPh
1154	Me	NHCH$(CH_2OMe)_2$	2-MeO-4-MePh
1155	Me	N$(CH_2CH_2OMe)_2$	2-MeO-4-MePh
1156	Me	NHCH(Et)CH_2OMe	2-MeO-4-MePh
1157	Me	N(c-Pr)CH_2CH_2CN	2-MeO-4-MePh
1158	Me	NEt_2	2-MeO-4-MePh
1159	Me	NH-3-pentyl	2-MeO-4-MePh
1160	Me	NHCH(Et)CH_2CH_2OMe	2-MeO-4-MePh

1161	Me	$NHCH(Me)CH_2CH_2OMe$	2-MeO-4-MePh
1162	Me	$NHCH(CH_2OMe)_2$	2-MeO-4-MePh
1163	Me	$N(CH_2CH_2OMe)_2$	2-MeO-4-MePh
1164	Me	$NHCH(Et)CH_2OMe$	2-MeO-4-MePh
1165	Me	$N(c\text{-}Pr)CH_2CH_2CN$	2-MeO-4-MePh
1166	Me	NEt_2	2-MeO-4-MePh
1167	Me	NH-3-pentyl	2-MeO-4-MePh
1168	Me	$NHCH(CH_2OMe)_2$	2-MeO-4-ClPh
1169	Me	$N(CH_2CH_2OMe)_2$	2-MeO-4-ClPh
1170	Me	$NHCH(Et)CH_2OMe$	2-MeO-4-ClPh
1171	Me	NEt_2	2-MeO-4-ClPh
1172	Me	NH-3-pentyl	2-MeO-4-ClPh

Utility

CRF-R1 Receptor Binding Assay for the Evaluation of Biological Activity

The following is a description of the isolation of cell membranes containing cloned human CRF-R1 receptors for use in the standard binding assay as well as a description of the assay itself.

Messenger RNA was isolated from human hippocampus. The mRNA was reverse transcribed using oligo (dt) 12-18 and the coding region was amplified by PCR from start to stop codons The resulting PCR fragment was cloned into the EcoRV site of pGEMV, from whence the insert was reclaimed using XhoI + XbaI and cloned into the XhoI + XbaI sites of vector pm3ar (which contains a CMV promoter, the SV40 't' splice and early poly A signals, an Epstein-Barr viral origin of replication, and a

hygromycin selectable marker). The resulting expression vector, called phchCRFR was transfected in 293EBNA cells and cells retaining the episome were selected in the presence of 400 μM hygromycin. Cells surviving 4 weeks of selection in hygromycin were pooled, adapted to growth in suspension and used to generate membranes for the binding assay described below. Individual aliquots containing approximately 1 x 10^8 of the suspended cells were then centrifuged to form a pellet and frozen.

For the binding assay a frozen pellet described above containing 293EBNA cells transfected with hCRFR1 receptors is homogenized in 10 ml of ice cold tissue buffer (50 mM HEPES buffer pH 7.0, containing 10 mM $MgCl_2$, 2 mM EGTA, 1 μg/l aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin). The homogenate is centrifuged at 40,000 x g for 12 min and the resulting pellet rehomogenized in 10 ml of tissue buffer. After another centrifugation at 40,000 x g for 12 min, the pellet is resuspended to a protein concentration of 360 μg/ml to be used in the assay.

Binding assays are performed in 96 well plates; each well having a 300 μl capacity. To each well is added 50 μl of test drug dilutions (final concentration of drugs range from 10^{-10} - 10^{-5} M), 100 μl of ^{125}I-ovine-CRF (^{125}I-o-CRF) (final concentration 150 pM) and 150 μl of the cell homogenate described above. Plates are then allowed to incubate at room temperature for 2 hours before filtering the incubate over GF/F filters (presoaked with 0.3% polyethyleneimine) using an appropriate cell harvester. Filters are rinsed 2 times with ice cold assay buffer before removing individual filters and assessing them for radioactivity on a gamma counter.

Curves of the inhibition of ^{125}I-o-CRF binding to cell membranes at various dilutions of test drug are analyzed by the iterative curve fitting program LIGAND

[P.J. Munson and D. Rodbard, *Anal. Biochem.* 107:220 (**1980**), which provides Ki values for inhibition which are then used to assess biological activity.

A compound is considered to be active if it has a K_i value of less than about 10000 nM for the inhibition of CRF.

Inhibition of CRF-Stimulated Adenylate Cyclase Activity

Inhibition of CRF-stimulated adenylate cyclase activity can be performed as described by G. Battaglia et al. *Synapse* **1**:572 (**1987**). Briefly, assays are carried out at 37° C for 10 min in 200 ml of buffer containing 100 mM Tris-HCl (pH 7.4 at 37° C), 10 mM $MgCl_2$, 0.4 mM EGTA, 0.1% BSA, 1 mM isobutylmethylxanthine (IBMX), 250 units/ml phosphocreatine kinase, 5 mM creatine phosphate, 100 mM guanosine 5'-triphosphate, 100 nM oCRF, antagonist peptides (concentration range 10^{-9} to 10^{-6m}) and 0.8 mg original wet weight tissue (approximately 40-60 mg protein). Reactions are initiated by the addition of 1 mM ATP/^{32}P]ATP (approximately 2-4 mCi/tube) and terminated by the addition of 100 ml of 50 mM Tris-HCL, 45 mM ATP and 2% sodium dodecyl sulfate. In order to monitor the recovery of cAMP, 1 µl of [^{3}H]cAMP (approximately 40,000 dpm) is added to each tube prior to separation. The separation of [^{32}P]cAMP from [^{32}P]ATP is performed by sequential elution over Dowex and alumina columns.

In vivo Biological Assay

The *in vivo* activity of the compounds of the present invention can be assessed using any one of the biological assays available and accepted within the art. Illustrative of these tests include the

Acoustic Startle Assay, the Stair Climbing Test, and the Chronic Administration Assay. These and other models useful for the testing of compounds of the present invention have been outlined in C.W. Berridge and A.J. Dunn *Brain Research Reviews* 15:71 (**1990**). Compounds may be tested in any species of rodent or small mammal.

Compounds of this invention have utility in the treatment of inbalances associated with abnormal levels of corticotropin releasing factor in patients suffering from depression, affective disorders, and/or anxiety.

Compounds of this invention can be administered to treat these abnormalities by means that produce contact of the active agent with the agent's site of action in the body of a mammal. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic agent or in combination of therapeutic agents. They can be administered alone, but will generally be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will vary depending on the use and known factors such as pharmacodynamic character of the particular agent, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and desired effect. For use in the treatment of said diseases or conditions, the compounds of this invention can be orally administered daily at a dosage of the active ingredient of 0.002 to 200 mg/kg of body weight. Ordinarily, a dose of 0.01 to 10

mg/kg in divided doses one to four times a day, or in sustained release formulation will be effective in obtaining the desired pharmacological effect.

Dosage forms (compositions) suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition.

The active ingredient can be administered orally is solid dosage forms, such as capsules, tablets and powders; or in liquid forms such as elixirs, syrups, and/or suspensions. The compounds of this invention can also be administered parenterally in sterile liquid dose formulations.

Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as but not limited to lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract.

Liquid dose forms for oral administration can contain coloring or flavoring agents to increase patient acceptance.

In general, water, pharmaceutically acceptable oils, saline, aqueous dextrose (glucose), and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for

parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, butter substances. Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Also used are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences", A. Osol, a standard reference in the field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules

A large number of units capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg lactose, 50 mg cellulose, and 6 mg magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestible oil such as soybean, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement was pumped into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules were washed and dried.

Tablets

A large number of tablets are prepared by conventional procedures so that the dosage unit was

100 mg active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg lactose. Appropriate coatings may be applied to increase palatability or delayed adsorption.


The compounds of this invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction, and disease.

Although the present invention has been described and exemplified in terms of certain preferred embodiments, other embodiments will be apparent to those skilled in the art. The invention is, therefore, not limited to the particular embodiments described and exemplified, but is capable of modification or variation without departing from the spirit of the invention, the full scope of which is delineated by the appended claims.


CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of Formulae (1) or (2):



(1)



(2)

and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and

pharmaceutically acceptable salt or pro-drug forms thereof, wherein:

A is N or CR;

Z is N or CR^2;

Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R^4 groups and each Ar is attached to an unsaturated carbon atom;

R is independently selected at each occurrence from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, halo, CN, C_1-C_4 haloalkyl;

R^1 is independently selected at each occurrence from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, halo, CN, C_1-C_4 haloalkyl, C_1-C_{12} hydroxyalkyl, C_2-C_{12} alkoxyalkyl, C_2-C_{10} cyanoalkyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl, NR^9R^{10}, C_1-C_4 alkyl-NR^9R^{10}, NR^9COR^{10}, OR^{11}, SH or $S(O)_nR^{12}$;

R^2 is selected from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl, C_1-C_4 hydroxyalkyl, halo, CN, $-NR^6R^7$, NR^9COR^{10}, $-NR^6S(O)_nR^7$, $S(O)_nNR^6R^7$, C_1-C_4 haloalkyl, $-OR^7$, SH or $-S(O)_nR^{12}$;

R^3 is selected from:

-H, OR^7, SH, $S(O)_nR^{13}$, COR^7, CO_2R^7, $OC(O)R^{13}$, NR^8COR^7, $N(COR^7)_2$, $NR^8CONR^6R^7$, $NR^8CO_2R^{13}$, NR^6R^7, $NR^{6a}R^{7a}$, $N(OR^7)R^6$, $CONR^6R^7$, aryl, heteroaryl and heterocyclyl, or

-C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_8 cycloalkyl, C_5-C_8 cycloalkenyl, C_4-C_{12} cycloalkylalkyl or C_6-C_{10} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl and heterocyclyl;

R^4 is independently selected at each occurrence from:

C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, NO_2, halo, CN, C_1-C_4 haloalkyl, NR^6R^7, NR^8COR^7, $NR^8CO_2R^7$, COR^7, OR^7, $CONR^6R^7$, $CO(NOR^9)R^7$, CO_2R^7, or $S(O)_nR^7$, where each such C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl and C_4-C_{12} cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_4 alkyl, NO_2, halo, CN, NR^6R^7, NR^8COR^7, $NR^8CO_2R^7$, COR^7 OR^7, $CONR^6R^7$, CO_2R^7, $CO(NOR^9)R^7$, or $S(O)_nR^7$;

R^6 and R^7, R^{6a} and R^{7a} are independently selected at each occurrence from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups;

R^8 is independently selected at each occurrence from H or C_1-C_4 alkyl;

R^9 and R^{10} are independently selected at each occurrence from H, C_1-C_4 alkyl, or C_3-C_6 cycloalkyl;

R^{11} is selected from H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_3-C_6 cycloalkyl;

R^{12} is C_1-C_4 alkyl or C_1-C_4 haloalkyl;

R^{13} is selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-

C_{12} cycloalkylalkyl, aryl, aryl(C_1-C_4 alkyl)-, heteroaryl or heteroaryl(C_1-C_4 alkyl)-;

R^{14} is selected from C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_3-C_8 cycloalkyl, or C_4-C_{12} cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, and C_1-C_6 alkylthio, C_1-C_6 alkylsulfinyl and C_1-C_6 alkylsulfonyl;

R^{15} and R^{16} are independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_4-C_{16} cycloalkylalkyl, except that for $S(O)_nR^{15}$, R^{15} cannot be H;

aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, and $CONR^{16}R^{15}$;

heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5

substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, and $CONR^{16}R^{15}$;


heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{15}R^{16}$, and $CONR^{16}R^{15}$;

n is independently at each occurrence 0, 1 or 2,


2. A method of claim 1 wherein, in the compound of Formulae (1) or (2), Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R^4 substituents.

3. A method of claim 1 wherein, in the compound of Formulae (1) or (2), A is N, Z is CR^2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R^1 and R^2 are CH_3, and R^3 is $NR^{6a}R^{7a}$.

4. A compound of Formulae (1) or (2):



(1)



(2)

and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein:

A is N or CR;

Z is N or CR^2;

Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R^4 groups and each Ar is attached to an unsaturated carbon atom;

R is independently selected at each occurrence from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, halo, CN, C_1-C_4 haloalkyl;

R^1 is independently selected at each occurrence from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl,

halo, CN, C_1-C_4 haloalkyl, C_1-C_{12} hydroxyalkyl, C_2-C_{12} alkoxyalkyl, C_2-C_{10} cyanoalkyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl, NR^9R^{10}, C_1-C_4 alkyl-NR^9R^{10}, NR^9COR^{10}, OR^{11}, SH or $S(O)_nR^{12}$;

R^2 is selected from H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl, C_1-C_4 hydroxyalkyl, halo, CN, $-NR^6R^7$, NR^9COR^{10}, $-NR^6S(O)_nR^7$, $S(O)_nNR^6R^7$, C_1-C_4 haloalkyl, $-OR^7$, SH or $-S(O)_nR^{12}$;

R^3 is selected from:

-H, OR^7, SH, $S(O)_nR^{13}$, COR^7, CO_2R^7, $OC(O)R^{13}$, NR^8COR^7, $N(COR^7)_2$, $NR^8CONR^6R^7$, $NR^8CO_2R^{13}$, NR^6R^7, $NR^{6a}R^{7a}$, $N(OR^7)R^6$, $CONR^6R^7$, aryl, heteroaryl and heterocyclyl, or

-C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_8 cycloalkyl, C_5-C_8 cycloalkenyl, C_4-C_{12} cycloalkylalkyl or C_6-C_{10} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl and heterocyclyl;

R^4 is independently selected at each occurrence from: C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, NO_2, halo, CN, C_1-C_4 haloalkyl, NR^6R^7, NR^8COR^7, $NR^8CO_2R^7$, COR^7, OR^7, $CONR^6R^7$, $CO(NOR^9)R^7$, CO_2R^7,

or $S(O)_nR^7$, where each such C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl and C_4-C_{12} cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_4 alkyl, NO_2, halo, CN, NR^6R^7, NR^8COR^7, $NR^8CO_2R^7$, COR^7 OR^7, $CONR^6R^7$, CO_2R^7, $CO(NOR^9)R^7$, or $S(O)_nR^7$;

R^6 and R^7, R^{6a} and R^{7a} are independently selected at each occurrence from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl),

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups;

R^8 is independently selected at each occurrence from H or C_1-C_4 alkyl;

R^9 and R^{10} are independently selected at each occurrence from H, C_1-C_4 alkyl, or C_3-C_6 cycloalkyl;

R^{11} is selected from H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_3-C_6 cycloalkyl;

R^{12} is C_1-C_4 alkyl or C_1-C_4 haloalkyl;

R^{13} is selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, aryl, aryl(C_1-C_4 alkyl)-, heteroaryl or heteroaryl(C_1-C_4 alkyl)-;

R^{14} is selected from C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_3-C_8 cycloalkyl, or C_4-C_{12} cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, and C_1-C_6 alkylthio, C_1-C_6 alkylsulfinyl and C_1-C_6 alkylsulfonyl;

R^{15} and R^{16} are independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_4-C_{16} cycloalkylalkyl, except that for $S(O)_nR^{15}$, R^{15} cannot be H;

aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano,

OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, and $CONR^{16}R^{15}$;

heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{16}R^{15}$, and $CONR^{16}R^{15}$;

heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{15}$, COR^{15}, CO_2R^{15}, $OC(O)R^{15}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{15}$, $NR^{15}R^{16}$, and $CONR^{16}R^{15}$;

n is independently at each occurrence 0, 1 or 2,

with the provisos that:

(1) when A is N, Z is CR^2, R^2 is H, R^3 is $-OR^7$ or $-OCOR^{13}$, and R^7 is H, then R^1 is not H, OH or SH;

(2) when A is N, Z is CR^2, R^1 is CH_3 or C_2H_5, R^2 is H, and R^3 is OH, H, CH_3, C_2H_5, C_6H_5, n-C_3H_7, i-C_3H_7, SH, SCH_3, NHC_4H_9, or $N(C_2H_5)_2$, then Ar is not phenyl or m-CH_3-phenyl;

(3) when A is N, Z is CR^2, R^2 is H, and Ar is pyridyl, pyrimidinyl or pyrazinyl, and R^3 is $NR^{6a}R^{7a}$, then R^{6a} and R^{7a} are not H or alkyl;

(4) when A is N, Z is CR^2, and R^2 is $SO_2NR^6R^7$, then R^3 is not OH or SH;

(5) when A is CR and Z is CR^2, then R^2 is not-$NR^6SO_2R^7$ or -$SO_2NR^6R^7$;

(6) when A is N, Z is CR^2 and R^2 is -$NR^6SO_2R^7$ or -$SO_2NR^6R^7$, then R^3 is not OH or SH;

(7) when A is N, Z is CR^2, R^1 is methyl or ethyl, R^2 is H, and R^3 is H, OH, CH_3, C_2H_5, C_6H_5, n-C_3H_7, iso-C_3H_7, SH, SCH_3, $NH(n\text{-}C_4H_9)$, or $N(C_2H_5)_2$, then Ar is not unsubstituted phenyl or m-methylphenyl;

(8) when A is CR, Z is CR^2, R^2 is H, phenyl or alkyl, R^3 is NR^8COR^7 and Ar is phenyl or phenyl substituted with phenylthio, then R^7 is not aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocycly(C_1-C_4 alkyl);

(9) when A is CR, Z is CR^2, R^2 is H or alkyl, Ar is phenyl, and R^3 is SR^{13} or $NR^{6a}R^{7a}$, then R^{13} is not aryl or heteroaryl and R^{6a} and R^{7a} are not H or aryl; or

(10) when A is CH, Z is CR^2, R^1 is OR^{11}, R^2 is H, R^3 is OR^7, and R^7 and R^{11} are both H, then Ar is not

phenyl, p-Br-phenyl, p-Cl-phenyl, p-$NHCOCH_3$-phenyl, p-CH_3-phenyl, pyridyl or naphthyl;

(11) when A is CH, Z is CR^2, R^2 is H, Ar is unsubstituted phenyl, and R^3 is CH_3, C_2H_5, CF_3 or C_6H_4F, then R_1 is not CF_3 or C_2F_5;

(12) when A is CR, R is H, Z is CR^2, R^2 is OH, and R^1 and R^3 are H, then Ar is not phenyl;

(13) when A is CR, R is H, Z is CR^2, R^2 is OH or NH_2, R^1 and R^3 are CH_3, then Ar is not 4-phenyl-3-cyano-2-aminopyrid-2-yl.

5. A compound of claim 4 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof with the additional provisos that: (1) when A is N, R^1 is H, C_1-C_4 alkyl, halo, CN, C_1-C_{12} hydroxyalkyl, C_1-C_4 alkoxyalkyl or $SO_2(C_1$-C_4 alkyl), R^3 is $NR^{6a}R^{7a}$ and R^{6a} is unsubstituted C_1-C_4 alkyl, then R^{7a} is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C_3-C_6 cycloalkyl; and (2) A is N, R^1 is H, C_1-C_4 alkyl, halo, CN, C_1-C_{12} hydroxyalkyl, C_1-C_4 alkoxyalkyl or $SO_2(C_1$-C_4 alkyl), R^3 is $NR^{6a}R^{7a}$ and R^{7a} is unsubstituted C_1-C_4 alkyl, then R^{6a} is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C_3-C_6 cycloalkyl.

6. A compound of claim 4 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically

acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R^4 substituents.

7. A compound of claim 6 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is N, Z is CR^2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R^1 and R^2 are CH_3, and R^3 is $NR^{6a}R^{7a}$.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 6.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 7.

11. A compound of claim 4 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is N.

12. A compound of Formula (2) of claim 11 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

13. A compound of claim 12 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R^4 substituents.

14. A compound of claim 12 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^3 is $NR^{6a}R^{7a}$ or OR^7.

15. A compound of claim 12 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents, and R^3 is $NR^{6a}R^{7a}$ or OR^7.

16. A compound of Formula (1) of claim 11 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR^2.

17. A compound of claim 16 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R^4 substituents.

18. A compound of claim 16 and isomers thereof, stereoisomeric forms thereof, or mixtures of

stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^3 is $NR^{6a}R^{7a}$ or OR^7.

19. A compound of claim 18 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is independently selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl)-, heteroaryl, heteroaryl(C_1-C_4 alkyl)-, heterocyclyl or heterocyclyl(C_1-C_4 alkyl)-; and

R^{7a} is independently selected at each occurrence from:

-H,

-C_5-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-

C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups.

20. A compound of claim 18 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are selected from:

-C_1-C_4 alkyl or C_3-C_6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, -COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl, and

-aryl or heteroaryl.

21. A compound of claim 18 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is selected from:

-C_1-C_4 alkyl and each such C_1-C_4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

22. A compound of claim 18 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R^{6a} and R^{7a} is selected from:

-C_3-C_6 cycloalkyl, each such C_3-C_6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15},

CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl,

-heteroaryl or

-heterocyclyl,

and the other of R^{6a} and R^{7a} is unsubstituted C_1-C_4 alkyl.

23. A compound of claim 18 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, each such C_1-C_{10} alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

24. A compound of claim 16 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents, and R^3 is $NR^{6a}R^{7a}$ or OR^7.

25. A compound of claim 24 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is independently selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl)-, heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is independently selected at each occurrence from:

-H,

-C_5-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl),

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups.

26. A compound of claim 24 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are selected from:

-C_1-C_4 alkyl or C_3-C_6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl, and

-aryl or heteroaryl.

27. A compound of claim 24 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are

-C_1-C_4 alkyl, each such C_1-C_4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

28. A compound of claim 24 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is:

-C_1-C_4 alkyl and each such C_1-C_4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

29. A compound of claim 24 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically

acceptable salt or pro-drug forms thereof wherein one of R^{6a} and R^{7a} is selected from:

-C_3-C_6 cycloalkyl, each such C_3-C_6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl,

-heteroaryl or

-heterocyclyl,

and the other of R^{6a} and R^{7a} is unsubstituted C_1-C_4 alkyl.

30. A compound of claim 24 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, each such C_1-C_{10} alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

31. A compound of claim 16 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein

-Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents,

-R^3 is $NR^{6a}R^{7a}$ or OR^7 and

-R^1 and R^2 are independently selected from H, C_1-C_4 alkyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl.

32. A compound of claim 31 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is independently selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl)-, heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is independently selected at each occurrence from:

-H,

-C_5-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each

occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl),

alternatively, NR^6R^7 and $NR^{6a}R^{7a}$ are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C_1-C_4 alkyl groups.

33. A compound of claim 31 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are selected from:

-C_1-C_4 alkyl or C_3-C_6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, -COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl, and

-aryl or heteroaryl.

34. A compound of claim 31 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are identical and are

-C_1-C_4 alkyl, each such C_1-C_4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, $-COR^{15}$, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

35. A compound of claim 31 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} is selected from:

-H,

-C_1-C_{10} alkyl, C_3-C_{10} alkenyl, C_3-C_{10} alkynyl, C_1-C_{10} haloalkyl with 1-10 halogens, C_2-C_8 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_{12} cycloalkylalkyl, C_5-C_{10} cycloalkenyl, or C_6-C_{14} cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl, aryl(C_1-C_4 alkyl), heteroaryl, heteroaryl(C_1-C_4 alkyl), heterocyclyl or heterocyclyl(C_1-C_4 alkyl);

R^{7a} is:

-C_1-C_4 alkyl and each such C_1-C_4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4

haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

36. A compound of claim 31 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R^{6a} and R^{7a} is selected from:

-C_3-C_6 cycloalkyl, each such C_3-C_6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $NR^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl,

-aryl,


-heteroaryl or

-heterocyclyl,

and the other of R^{6a} and R^{7a} is unsubstituted C_1-C_4 alkyl.

37. A compound of claim 31 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, each such C_1-C_{10} alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

38. A compound of claim 31 of Formula (50)



FORMULA (50)

and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, selected from the group consisting of:

a compound of Formula (50) wherein R^3 is -NHCH(n-Pr)$_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(Et)(n-Bu), R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -(n-Pr)(CH$_2$cPr), R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(CH$_2$CH$_2$OMe)$_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(Et)(n-Bu), R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OEt)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Me)(Ph)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(n\text{-}Pr)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(n\text{-}Pr)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -OEt, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CN)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Me)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-OCH(Et)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(n-Pr)(CH_2cPr), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Me)(CH_2N(Me)_2)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(cPr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(n-Pr)(CH_2CH_2CN), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(n-Bu)(CH_2CN), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OEt)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2CH_2OMe)(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is morpholino, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NH(c\text{-}Pr)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is CN, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is Me;

a compound of Formula (50) wherein R^3 is $-NCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)(CH_2CH_2OMe)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OMe)(CH_2CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is Me and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(c-Pr)(CH_2CH_2CN), R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is (*S*)-NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NH(CH_2OMe)(CH_2-iPr), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is H, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is NMe2, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)(n-Pr), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OEt)(Et), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is NMe2, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(Et)2, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(CH_2CH_2OMe)2, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)2, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(Et)2, R^{4a} is Me, R^{4b} is H, R^{4c} is Br, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(Et)2, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(Et)2, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(Et)2, R^{4a} is Me, R^{4b} is H, R^{4c} is NMe2, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is (*S*)-NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is (*S*)-NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -NHCH(CH_2OMe)(CH_2CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(c-Pr)(CH_2CH_2CN), R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NH(Et)(CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is Me, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)(CH_2CH_2OH)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is Me, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is Me, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2c\text{-}Pr)(n\text{-}Pr)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is Me, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(Et)(CH_2OMe)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is CN, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is -N(c-Pr)(CH_2CH_2CN), R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (50) wherein R^3 is $-NHCH(CH_2OH)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H; and

a compound of Formula (50) wherein R^3 is $N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H; and

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H.

39. A compound of claim 31 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein said compound is 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolo-1,3,5-triazine.

40. A compound of claim 31 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein said compound is 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2,5-dimethyl-4-methoxyphenyl)-[1,5-a]-pyrazolo-1,3,5-triazine.

41. A compound of claim 4 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically

acceptable salt or pro-drug forms thereof wherein A is CR.

42. A compound of Formula (2) of claim 41 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

43. A compound of claim 42 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R^4 substituents.

44. A compound of claim 42 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^3 is $NR^{6a}R^{7a}$ or OR^7.

45. A compound of claim 42 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents, and R^3 is $NR^{6a}R^{7a}$ or OR^7.

46. A compound of Formula (1) of claim 41 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR^2.

47. A compound of claim 46 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R^4 substituents.

48. A compound of claim 46 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^3 is $NR^{6a}R^{7a}$ or OR^7.

49. A compound of claim 46 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents, and R^3 is $NR^{6a}R^{7a}$ or OR^7.

50. A compound of claim 49 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, and each such C_1-C_{10} alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

51. A compound of claim 46 and isomers thereof, stereoisomeric forms thereof, or mixtures of

stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein


-Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^4 substituents,

-R^3 is $NR^{6a}R^{7a}$ or OR^7 and

-R^1 and R^2 are independently selected from H, C_1-C_4 alkyl, C_3-C_6 cycloalkyl, C_4-C_{10} cycloalkylalkyl.

52. A compound of claim 51 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^{6a} and R^{7a} are independently H or C_1-C_{10} alkyl, and each such C_1-C_{10} alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, C_1-C_4 haloalkyl, cyano, OR^{15}, SH, $S(O)_nR^{13}$, COR^{15}, CO_2R^{15}, $OC(O)R^{13}$, NR^8COR^{15}, $N(COR^{15})_2$, $R^8CONR^{16}R^{15}$, $NR^8CO_2R^{13}$, $NR^{16}R^{15}$, $CONR^{16}R^{15}$, aryl, heteroaryl or heterocyclyl.

53. A compound of claim 51 of Formula (51)



FORMULA (51)

and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof selected from the group consisting of:

a compound of Formula (51) wherein R^3 is $-NHCH(n\text{-}Pr)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(c\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(n\text{-}Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(n\text{-}Bu)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -NHCH(n-Pr)(CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is (*S*) $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -NH(Et), R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(n\text{-}Pr)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is (*S*) $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -N(n-Pr)(CH_2CH_2CN), R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is (*S*) $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NH(CH_2CH_2OMe)CH_2OMe$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -N(c-Pr)(CH_2CH_2CN), R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -N(c-Pr)(CH_2CH_2CN), R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -NHCH (n-Pr)(CH_2OMe), R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is -NHCH (n-Pr)(CH_2OMe), R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is OMe and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Br, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is OMe and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is OMe, R^{4d} is OMe and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(CH_2CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(CH_2OMe)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Pr)(CH_2CH_2CN)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-N(Bu)(Et)$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)CH_2OMe$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Cl, R^{4b} is H, R^{4c} is Me, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NHCH(Et)_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is Cl, R^{4d} is H and R^{4e} is H;

a compound of Formula (51) wherein R^3 is $-NEt_2$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H; and

a compound of Formula (51) wherein R^3 is $-N(Pr)(CH_2CH_2CN)$, R^{4a} is Me, R^{4b} is H, R^{4c} is OMe, R^{4d} is H and R^{4e} is H.

54. A compound of claim 51 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein said compound is 7-(3-pentylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolopyrimidine.

55. A compound of claim 51 and and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein said compound is 7-(Diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-[1,5-a]-pyrazolopyrimidine.

56. A compound of claim 51 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein said compound is 7-(N-(3-cyanopropyl)-N-propylamino)-2,5-dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine.

57. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4.

58. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 24.

59. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 38.

60. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 39.

61. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 40.

62. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 53.

63. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 54.

64. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 55.

65. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 56.

66. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility

SUBSTITUTE SHEET (RULE 26)

problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 4.

67. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 24.

68. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or

SUBSTITUTE SHEET (RULE 26)

alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 38.

69. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 39.

70. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's

SUBSTITUTE SHEET (RULE 26)

disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 40.

71. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 53.

72. A method of treating affective disorder, anxiety, depression, headache, irritable bowel

SUBSTITUTE SHEET (RULE 26)

syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 54.

73. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 55.

SUBSTITUTE SHEET (RULE 26)

74. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 56.

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

Inter nal Application No
PCT/US 97/13072

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D487/04 A61K31/505 //(C07D487/04,239:00,231:00), (C07D487/04,251:00,231:00),(C07D487/04,249:00,239:00), (C07D487/04,251:00,249:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 591 528 A (OTSUKA PHARMA CO LTD) 13 April 1994 cited in the application see the whole document ---	1-76
X	EP 0 531 901 A (FUJISAWA PHARMACEUTICAL CO) 17 March 1993 cited in the application see the whole document --- -/--	1-76

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
25 November 1997	23. 12. 97

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Steendijk, M

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inter. ...nal Application No
PCT/US 97/13072

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 68, no. 25, 17 June 1968 Columbus, Ohio, US; abstract no. 114635v, TAKAMIZAWA: "7-Haloacylaminopyrazolo(1,5-a)pyrimidines " XP002048048 & JP-A-6716314 see abstract ---	1-76
X	CHEMICAL ABSTRACTS, vol. 67, no. 23, 4 December 1967 Columbus, Ohio, US; abstract no. 108663r, TAKAMIZAWA: "7-Methylaminopyrazolo...." XP002048049 & JP-A-6711753 see abstract ---	1-76
X	CHEMICAL ABSTRACTS, vol. 74, no. 5, 1 February 1971 Columbus, Ohio, US; abstract no. 22872r, TAKAMIZAWA : "7-Aminoalkylaminopyrazolo..." XP002048050 & JP-A-7030335 see abstract ---	1-76
X	DATABASE WPI Section Ch, Week 9142 Derwent Publications Ltd., London, GB; Class B02, AN 91-306726 XP002048051 & JP 03 204 877 A (OTSUKA SEIYAKU KOGYO KK) , 6 September 1991 see abstract ---	1-76
X	US 3 920 652 A (SPRINGER ROBERT H ET AL) 18 November 1975 see the whole document ---	1-76
X	US 3 995 039 A (ROONEY CLARENCE STANLEY ET AL) 30 November 1976 cited in the application see the whole document ---	1-76
X	EP 0 714 898 A (OTSUKA PHARMA CO LTD) 5 June 1996 cited in the application see the whole document --- -/--	1-76

1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inter. ɔnal Application No
PCT/US 97/13072

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 503 099 A (OTSUKA PHARMA CO LTD) 16 September 1992 see the whole document	1-76
X	DATABASE WPI Section Ch, Week 8618 Derwent Publications Ltd., London, GB; Class B02, AN 86-116678 XP002048052 & JP 61 057 587 A (SHIONOGI & CO LTD) , 24 March 1986 see abstract	1-76
A	WO 94 13676 A (PFIZER ;CHEN YUHPYNG L (US)) 23 June 1994 see the whole document	1-76
P,A	WO 96 35689 A (NEUROGEN CORP ;YUAN JUN (US); HUTCHISON ALAN (US)) 14 November 1996 see the whole document	1-76
E	WO 97 29109 A (JANSSEN PHARMACEUTICA NV ;NEUROCRINE BIOSCIENCES INC (US); CHEN CH) 14 August 1997 see the whole document	1-76

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. onal Application No
PCT/US 97/13072

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0591528 A	13-04-94	AU 651986 B	11-08-94
		AU 8295891 A	17-11-92
		CA 2107479 A	23-10-92
		JP 5070353 A	23-03-93
		WO 9218504 A	29-10-92
EP 0531901 A	17-03-93	AU 2280592 A	11-03-93
		CA 2077732 A	10-03-93
		CN 1070404 A	31-03-93
		HU 65204 A	02-05-94
		JP 7252256 A	03-10-95
		JP 2057962 C	10-06-96
		JP 6287188 A	11-10-94
		JP 7088386 B	27-09-95
		MX 9205145 A	01-04-93
		US 5478827 A	26-12-95
		US 5624931 A	29-04-97
		US 5356897 A	18-10-94
		ZA 9206417 A	15-03-93
		CN 1075965 A	08-09-93
US 3920652 A	18-11-75	AR 193536 A	30-04-73
		AT 330780 B	26-07-76
		BE 786611 A	22-01-73
		BG 19806 A	10-10-75
		DD 99581 A	12-08-73
		DE 2236987 A	01-03-73
		FR 2150771 A	13-04-73
		GB 1359563 A	10-07-74
		LU 65892 A	15-01-73
		NL 7211011 A	20-02-73
		US 4021556 A	03-05-77
		AU 4488372 A	07-03-74
		ZA 7205139 A	25-04-73
US 3995039 A	30-11-76	NONE	
EP 0714898 A	05-06-96	AU 680370 B	24-07-97
		AU 2576595 A	15-01-96
		CA 2169719 A	28-12-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No
PCT/US 97/13072

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0714898 A		CN 1131948 A	25-09-96
		WO 9535298 A	28-12-95
		JP 8311068 A	26-11-96
		JP 8310951 A	26-11-96
EP 0503099 A	16-09-92	AU 653103 B	15-09-94
		AU 3877593 A	26-08-93
		AU 639615 B	29-07-93
		AU 8626191 A	28-04-92
		CN 1060844 A,B	06-05-92
		WO 9206096 A	16-04-92
		JP 5112571 A	07-05-93
		US 5420128 A	30-05-95
		JP 5000948 A	08-01-93
WO 9413676 A	23-06-94	AU 5666494 A	04-07-94
		CA 2150016 A	23-06-94
		CN 1097758 A	25-01-95
		CZ 9501584 A	17-01-96
		EP 0674641 A	04-10-95
		FI 935585 A	18-06-94
		HU 70505 A	30-10-95
		JP 7509726 T	26-10-95
		NO 952398 A	16-06-95
		NZ 258690 A	29-01-97
		PL 309357 A	02-10-95
		ZA 9309271 A	12-06-95
WO 9635689 A	14-11-96	US 5644057 A	01-07-97
		AU 5679096 A	29-11-96
		CA 2194756 A	14-11-96
		EP 0770080 A	02-05-97
WO 9729109 A	14-08-97	AU 1599197 A	28-08-97

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 3 784 233 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
05.06.2024 Bulletin 2024/23

(21) Application number: **19793181.9**

(22) Date of filing: **26.04.2019**

(51) International Patent Classification (IPC):
A61K 31/4162 *(2006.01)* ***A61K 31/505*** *(2006.01)*
A61K 31/519 *(2006.01)* ***C07D 231/54*** *(2006.01)*
C07D 233/70 *(2006.01)* ***C07D 247/02*** *(2006.01)*
A61K 9/20 *(2006.01)* ***A61P 35/00*** *(2006.01)*

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
A61K 31/519; A61K 31/5377; A61K 45/06; A61P 35/00; A61K 9/2004; A61K 9/4841 (Cont.)

(86) International application number:
PCT/US2019/029486

(87) International publication number:
WO 2019/210266 (31.10.2019 Gazette 2019/44)

(54) **METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS**

VERFAHREN ZUR BEHANDLUNG VON HODEN-UND EIERSTOCK-NEBENNIERENTUMOREN

MÉTHODES DE TRAITEMENT DE TUMEURS DES VERTIGES SURRÉNALIENS DES TESTICULES ET DES OVAIRES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **27.04.2018 US 201862663951 P**
23.03.2019 US 201962822815 P

(43) Date of publication of application:
03.03.2021 Bulletin 2021/09

(73) Proprietor: **Spruce Biosciences, Inc.**
South San Francisco, CA 94080 (US)

(72) Inventors:
- **HOWERTON, Alexis**
  San Francisco, California 94115 (US)
- **GERBER, Hal**
  Boca Raton, Florida 33432 (US)

(74) Representative: **Doherty, William et al**
Albright IP Limited
County House
Bayshill Road
Cheltenham, Glos. GL50 3BA (GB)

(56) References cited:
WO-A1-2008/036579
WO-A1-2015/112642
WO-A1-2019/036472
WO-A1-2019/036503
US-A1- 2010 196 389
US-A1- 2010 222 339
US-A1- 2017 020 877

- **CHEN HUA-DONG ET AL: "Ovarian Adrenal Rest Tumors Undetected by Imaging Studies and Identified at Surgery in Three Females with Congenital Adrenal Hyperplasia Unresponsive to Increased Hormone Therapy Dosage", ENDOCRINE PATHOLOGY, HUMANA PRESS, TOTOWA, NJ, US, vol. 28, no. 2, 28 December 2016 (2016-12-28), pages 146-151, XP036564071, ISSN: 1046-3976, DOI: 10.1007/S12022-016-9461-4 [retrieved on 2016-12-28]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets
A61K 31/5377, A61K 2300/00

Description

CROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62/663,951, filed April 27, 2018, and U.S. Provisional Patent Application No. 62/822,815, filed March 23, 2019.

BACKGROUND

[0002] Corticotropes are basophilic cells in the anterior pituitary that produce melanocyte-stimulating hormone, adrenocorticotropic hormone (ACTH) and lipotropin. The cells produce pro-opiomelanocortin (POMC) which undergoes cleavage to ACTH and β-lipotropin (β-LPH). These cells respond to corticotropin-releasing factor (CRF) and make up about 20% of the cells in the anterior pituitary. CRF is a releasing hormone that belongs to the corticotropin-releasing factor family and is the primary physiological regulator of proopiomelanocortin (POMC).

[0003] CRF is produced by parvocellular neuroendocrine cells within the paraventricular nucleus of the hypothalamus and is released at the median eminence from neurosecretory terminals of these neurons into the primary capillary plexus of the hypothalamo-hypophyseal portal system. The portal system carries the CRF to the anterior lobe of the pituitary, where it stimulates corticotropes to secrete ACTH and other biologically-active substances. ACTH, in turn, stimulates the synthesis of cortisol, glucocorticoids, mineralocorticoids and DHEA.

[0004] Testicular adrenal rest tumors (TART) and ovarian adrenal rest tumors (OART) are ACTH-responsive lesions of the testes and ovaries derived from adrenal tissue interchelated within these organs during embryogenesis. In response to high ACTH, hyperplasia of this tissue occurs, resulting in single or multiple lesions that may cause pain and infertility. The identification of compounds that modulate CRF function and downstream processes is an ongoing challenge. Currently, there are no non-steroidal, non-surgical solutions to control, shrink, or reduce TART. Disclosed herein, *inter alia*, are solutions to these and other problems in the art. Document CHEN HUA-DONG ET AL: "Ovarian Adrenal Rest Tumors Undetected by Imaging Studies and Identified at Surgery in Three Females with Congenital Adrenal Hyperplasia Unresponsive to Increased Hormone Therapy Dosage",ENDOCRINE PATHOLOGY, HUMANA PRESS, TOTOWA, NJ, US, vol. 28, no. 2, 28 December 2016 (2016-12-28), pages 146-151
discloses how patients with congenital adrenal hyperplasia have a predisposition for developing adrenal rest tumors. In contrast to testicular adrenal rest tumors, ovarian adrenal rest tumors are less common, and only a few cases have been reported in the literature. The preferred treatment for this type of tumors, which are also presently claimed, is said to be adrenal hormone replacement therapy.

SUMMARY


[0005] The references to methods of treatment in the summary and detailed description of the invention in this description are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy. Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a serious genetic disorder characterized by impaired adrenal synthesis of cortisol and consequent overproduction of adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17OHP), and adrenal androgens such as androstenedione (A4). CAH is an orphan condition with no FDA-approved therapy. To suppress androgen production, patients are often prescribed long-term supraphysiologic doses of glucocorticoid (GC), which has adverse effects and fail to suppress 17OHP and A4 in the majority of patients.

[0006] Compound 1 may be a potent, selective, nonsteroidal, oral corticotropin-releasing factor type-1 (CRF1) receptor antagonist that reduces excess ACTH, 17OHP, and A4 to improve clinical and biochemical sequelae of CAH. This may obviate the need for high dose steroids.

[0007] One aspect provided herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.

[0008] In some embodiments, the subject has congenital adrenal hyperplasia (CAH). In some embodiments, the size and/or number of the tumors is decreased or reduced.


[0009] One aspect provided herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a compound of structural Formula (I):



(I),

or a pharmaceutically acceptable salt thereof,
wherein:


R^1 and R^2 are independently ethyl or n-propyl;
R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and
R^4 is hydrogen, Br, R^aR^bN-, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,




; and

R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$-, $(CH_3)_3COC(O)NHCH_2CH_2$-, or $CH_3CH_2CH_2NHCH_2CH_2$-.


[0010] In some embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl. In some embodiments, R^3 is Cl, Br, or methyl. In some embodiments, R^4 is Br, R^aR^bN-, pyridin-4-yl, morpholin-4-yl, or



In some embodiments, R^4 is morpholin-4-yl or




[0011] In some embodiments, R^4 is hydrogen, Br, R^aR^bN- and R^a and R^b are independently C_1-C_3alkyl. In some embodiments, the compound is




or a pharmaceutically acceptable salt thereof.

[0012] In some embodiments, the compound is



, or a pharmaceutically acceptable salt thereof.

[0013] In some embodiments, the compound is



or a pharmaceutically acceptable salt thereof.

[0014] In some embodiments, the subject has congenital adrenal hyperplasia (CAH). In some embodiments, the size and/or number of the tumors is decreased or reduced.

[0015] In some embodiments, from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In some embodiments, from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In some embodiments, from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In some embodiments, from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.


[0016] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose from about 5 mg/day to about 25 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose from about 10 mg/day to about 400 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 100 mg/day to about 600 mg/day is administered to the subject.

[0017] In some embodiments, the compound is administered orally. In some embodiments, the compound is formulated as a capsule or tablet. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fed state. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fasted state.

[0018] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at least once per day. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at bedtime. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 4 hours before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 2 hours before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 30 minutes before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the evening. In some embodiments, the compound of Formula (I), or a pharmaceutically

acceptable salt thereof, is administered at about 10 pm at night.


[0019] One aspect described herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a pharmaceutical composition, comprising a compound of structural Formula (I) and a pharmaceutically acceptable excipient:



(I),


or a pharmaceutically acceptable salt thereof,
wherein:

R^1 and R^2 are independently ethyl or n-propyl;
R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and
R^4 is hydrogen, Br, R^aR^bN-, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,



; R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$-, $(CH_3)_3COC(O)NHCH_2CH_2$-, or $CH_3CH_2CH_2NHCH_2CH_2$-.

[0020] In some embodiments, the compound of Formula (I) has the structure:



,

or a pharmaceutically acceptable salt thereof.

[0021] In some embodiments, the pharmaceutical composition comprises from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0022] In some embodiments, the pharmaceutical composition comprises about 5 mg, about 10 mg, about 15 mg, about 20 mg, 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about

295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg about 500 mg, or about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.


[0023] In some embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 1000 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 25 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg/day to about 400 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 100 mg/day to about 600 mg/day.

[0024] In some embodiments, the pharmaceutical composition is administered orally. In some embodiments, the pharmaceutical composition is formulated as capsule or a tablet. In some embodiments, the pharmaceutical composition is administered in the fed state. In some embodiments, the pharmaceutical composition is administered in the fasted state. In some embodiments, the pharmaceutical composition is administered at least once per day.


[0025] In some embodiments, the pharmaceutical composition is administered at bedtime. In some embodiments, the pharmaceutical composition is administered less than about 4 hours before sleep. In some embodiments, the pharmaceutical composition is administered less than about 2 hours before sleep. In some embodiments, the pharmaceutical composition is administered less than about 30 minutes before sleep. In some embodiments, the pharmaceutical composition is administered in the evening. In some embodiments, the pharmaceutical composition is administered at about 10 pm at night.

[0026] In some embodiments, the method further comprises administering to the subject an additional chemotherapeutic agent. In some embodiments, the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen. In some embodiments, the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In some embodiments, the mineralocorticoid is fludrocortisone.

[0027] In some embodiments, the additional chemotherapeutic agent is another CRF_1 antagonist. In some embodiments, the CRF_1 antagonist is




S SR-126374,



or a pharmaceutically acceptable salt thereof.

[0028] In some embodiments, the CRF_1 antagonist is



or a pharmaceutically acceptable salt thereof.

[0029] In some embodiments, the method further comprises an additional treatment selected from surgical resection of the tumors and radiation therapy, or a combination thereof.

[0030] In some embodiments, the additional therapy is surgical resection and the surgical resection is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof.

[0031] In some embodiments, the surgical resection is prior to administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the surgical resection is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the surgical resection is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0032] In some embodiments, the additional treatment is radiation therapy and the radiation therapy is prior to, after, and/or concurrent with administration of the compound of structural

[0033] Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In some embodiments, the radiation therapy is prior to administration of the CRF_1 antagonist of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0034] In some embodiments, the radiation therapy is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the radiation therapy is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0035] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. Accordingly, the drawings and description are to be regarded as illustrative.

BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also "Figure" and "FIG." herein), of which:

FIG. 1A-1B. A schematic representation of intra-patient dose escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics **(A)**. A schematic representation of inhibition of CRF_1 with a CRF_1 antagonist (Compound 1) **(B)**.

FIG. 2. Graphic representation of pharmacokinetics (dose-proportional, adequate exposure at safe doses) in patients with CAH following 14-days of once daily dosing at each dose level with a CRF_1 antagonist (Compound 1).

FIG. 3. Graphic representation of pharmacokinetics (dose-proportional, adequate exposure at safe doses) in patients with CAH following 14-days of once daily dosing at each dose level with a CRF_1 antagonist (Compound 1).

FIG. 4. Graphic representation of patient-level response (measuring ACTH levels) to a CRF_1 antagonist (Compound 1).

FIG. 5A-5B. Graphic representation of patient-level response of sample responders (measuring ACTH levels) to a CRF_1 antagonist [Subject 003001 **(A)**; Subject 007002 **(B)**].

FIG. 6. Graphic representation of patient-level response (measuring 17-OHP levels) to a CRF_1 antagonist (Compound 1).

FIG. 7A-7B. Graphic representation of patient-level response of sample responders (measuring 17-OHP levels) to

a CRF_1 antagonist [Subject 003001 **(A)**; Subject 007002 **(B)**].

FIG. 8. Graphic representation of patient-level response (measuring androstenedione levels) to a CRF_1 antagonist (Compound 1).

FIG. 9A-9B. Graphic representation of patient-level response of sample responders (measuring androstenedione levels) to a CRF_1 antagonist (Compound 1) [Subject 003001 **(A)**; Subject 007002 **(B)**].

FIG. 10A-10B. Images of a patient with TART pre-treatment with a CRF_1 antagonist (Compound 1) **(A)** and 6-weeks post-treatment with a CRF_1 antagonist (Compound 1) **(B)**.

FIG. 11A-11B. Graphic representation of an *in vitro* binding assay of a CRF_1 antagonist (Compound 1); ^{125}I-sauvagine binding to rat cerebellar membranes one hour after oral administration of increasing Compound 1 doses **(A)** and *in vivo* inhibition of CRF-induced activity after treatment with a CRF_1 antagonist; Compound 1 (oral, 10 mg/kg) **(B)**.

FIG. 12A-12B. Graphic representation of ACTH levels **(A)** and 17-OHP levels **(B)** after treatment with a CRF_1 antagonist (Compound 1).

FIG. 13. Graphic representation of hormone responses after treatment with a CRF_1 antagonist (Compound 1).

FIG. 14 depicts the proof of concept and escalating QD dosing at 10 pm.

FIG. 15A-15D are graphic representations of changes in androstenedione seen in participants in Cohort A and Cohort B.

FIG. 16A-16D are graphic representations of changes in 17-hydroxyprogesterone seen in participants in Cohort A and Cohort B.

FIG. 17A-17D are graphic representations of changes in adrenocorticotropic hormone seen in participants in Cohort A and Cohort B.

DETAILED DESCRIPTION

[0037] While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only.

I. Definitions

[0038] The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.

[0039] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., $-CH_2O-$ is equivalent to $-OCH_2-$.

[0040] The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals, having the number of carbon atoms designated (i.e., C_1-C_{10} means one to ten carbons). Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-O-).

[0041] The term "alkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, $-CH_2CH_2CH_2CH_2-$. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. The term "alkenylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.

[0042] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: $-CH_2-CH_2-O-CH_3$, $-CH_2-CH_2-NH-CH_3$, $-CH_2-CH_2-N(CH_3)-CH_3$, $-CH_2-S-CH_2-CH_3$, $-CH_2-CH_2$, $-S(O)-CH_3$, $-CH_2-CH_2-S(O)_2-CH_3$, $-CH=CH-O-CH_3$, $-Si(CH_3)_3$, $-CH_2-CH=N-OCH_3$, $-CH=CH-N(CH_3)-CH_3$, $-O-CH_3$, $-O-CH_2-CH_3$, and -CN. Up to two or three heteroatoms may be

consecutive, such as, for example, $-CH_2-NH-OCH_3$ and $-CH_2-O-Si(CH_3)_3$. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P).

[0043] Similarly, the term "heteroalkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, $-CH_2-CH_2-S-CH_2-CH_2-$ and $-CH_2-S-CH_2-CH_2-NH-CH_2-$. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula $-C(O)_2R'-$ represents both $-C(O)_2R'-$ and $-R'C(O)_2-$. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as - C(O)R', -C(O)NR', -NR'R", -OR', -SR', and/or $-SO_2R'$. Where "heteroalkyl" is recited, followed by recitations of specific heteroalkyl groups, such as -NR'R" or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R" or the like.

[0044] The terms "cycloalkyl" and "heterocycloalkyl," by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl," respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A "cycloalkylene" and a "heterocycloalkylene," alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively. "Cycloalkyl" is also meant to refer to bicyclic and polycyclic hydrocarbon rings such as, for example, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc.

[0045] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C_1-C_4)alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0046] The term "acyl" means, unless otherwise stated, -C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0047] The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. The term "heteroaryl" refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term "heteroaryl" includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An "arylene" and a "heteroarylene," alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. A heteroaryl group substituent may be -O- bonded to a ring heteroatom nitrogen.


[0048] Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual

rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g. substituents for cycloalkyl or heterocycloalkyl rings). Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a spirocyclic ring system, substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.

[0049] The symbol "  " denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.

[0050] The term "oxo," as used herein, means an oxygen that is double bonded to a carbon atom.

[0051] The term "alkylarylene" as an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In embodiments, the alkylarylene group has the formula:



[0052] An alkylarylene moiety may be substituted (e.g. with a substituent group) on the alkylene moiety or the arylene linker (e.g. at carbons 2, 3, 4, or 6) with halogen, oxo, $-N_3$, $-CF_3$, $-CCl_3$, - CBr_3, $-CI_3$, -CN, -CHO, -OH, $-NH_2$, -COOH, $-CONH_2$, $-NO_2$, -SH, $-SO_2CH_3$ $-SO_3H$, $-OSO_3H$, - SO_2NH_2, $-NHNH_2$, $-ONH_2$, $-NHC(O)NHNH_2$, substituted or unsubstituted C_1-C_5 alkyl or substituted or unsubstituted 2 to 5 membered heteroalkyl). In embodiments, the alkylarylene is unsubstituted.

[0053] Each of the above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl," "heterocycloalkyl," "aryl," and "heteroaryl") includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0054] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R‴, -OC(O)R', - C(O)R', $-CO_2R'$, -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R‴, $-NR"C(O)_2R'$, - NR-C(NR'R"R‴)=NR"", -NR-C(NR'R")=NR‴, -S(O)R', $-S(O)_2R'$, $-S(O)_2NR'R"$, $-NRSO_2R'$, -NR'NR"R‴, -ONR'R", -NR'C(O)NR"NR‴R"", -CN, $-NO_2$, $-NR'SO_2R"$, -NR'C(O)R", - NR'C(O)-OR", -NR'OR", in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R, R', R", R‴, and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R‴, and R"" group when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., $-CF_3$ and $-CH_2CF_3$) and acyl (e.g., $-C(O)CH_3$, $-C(O)CF_3$, $-C(O)CH_2OCH_3$, and the like).

[0055] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: -OR', -NR'R", -SR', -halogen, - SiR'R"R‴, -OC(O)R', -C(O)R', $-CO_2R'$, -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R‴, $-NR"C(O)_2R'$, -NR-C(NR'R"R‴)=NR"", -NR-C(NR'R")=NR‴, -S(O)R', $-S(O)_2R'$, $-S(O)_2NR'R"$, $-NRSO_2R'$, -NR'NR"R‴, -ONR'R", -NR'C(O)NR"NR‴R"", -CN, $-NO_2$, -R', $-N_3$, $-CH(Ph)_2$, fluoro(C_1-C_4)alkoxy, and fluoro(C_1-C_4)alkyl, $-NR'SO_2R"$, -NR'C(O)R", -NR'C(O)-OR", -NR'OR", in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R", R‴, and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R‴, and R"" groups when more than one of these

groups is present.

[0056] Substituents for rings (e.g. cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent). In such a case, the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings). When a substituent is attached to a ring, but not a specific atom (a floating substituent), and a subscript for the substituent is an integer greater than one, the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different. Where a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent), the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency. Where a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms. Where the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.

[0057] Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.

[0058] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)-$(CRR')_q$-U-, wherein T and U are independently -NR-, -O-, - CRR'-, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-$(CH_2)_r$-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O) -, -$S(O)_2$-, -$S(O)_2$NR'-, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -$(CRR')_s$-X'- $(C"R"R'")_d$-, where s and d are independently integers of from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -$S(O)_2$-, or -$S(O)_2$NR'-. The substituents R, R', R", and R‴ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[0059] As used herein, the terms "heteroatom" or "ring heteroatom" are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0060] A "substituent group," as used herein, means a group selected from the following moieties:

(A) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, - SO_2NH_2, -$NHNH_2$, -ONH_2, -NHC=(O)$NHNH_2$, -NHC=(O) NH_2, -$NHSO_2H$, -NHC= (O)H, - NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from:

(i) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, - SO_2NH_2, -$NHNH_2$, -ONH_2, -NHC=(O)$NHNH_2$, -NHC=(O) NH_2, -$NHSO_2H$, -NHC= (O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from:

(a) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, - SO_2NH_2, -$NHNH_2$, -ONH_2, -NHC=(O)$NHNH_2$, -NHC=(O) NH_2, -$NHSO_2H$, -NHC= (O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, un-

substituted aryl, unsubstituted heteroaryl, and
(b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from: oxo,
halogen, $-CF_3$, -CN, -OH, $-NH_2$, -COOH, $-CONH_2$, $-NO_2$, -SH, $-SO_3H$, $-SO_4H$, $-SO_2NH_2$, $-NHNH_2$, $-ONH_2$, -NHC=(O)$NHNH_2$, -NHC=(O) NH_2, $-NHSO_2H$, -NHC= (O)H, - NHC(O)-OH, -NHOH, $-OCF_3$, $-OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl.

[0061] A "size-limited substituent" or " size-limited substituent group," as used herein, means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_{20} alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.

[0062] A "lower substituent" or " lower substituent group," as used herein, means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.

[0063] In some embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.

[0064] In other embodiments of the compounds herein, each substituted or unsubstituted alkyl may be a substituted or unsubstituted C_1-C_{20} alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl. In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C_1-C_{20} alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C_3-C_8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C_6-C_{10} arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.

[0065] In some embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl. In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted C_1-C_8 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C_3-C_7 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C_6-C_{10} arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene. In some embodiments, the compound is a chemical species set forth in the Examples section, figures, or tables below.

[0066] Certain compounds of the present invention possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present invention. The compounds of the present invention do not include those that are known in art to be too unstable to synthesize and/or isolate. The present invention is meant to

include compounds in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

[0067] As used herein, the term "isomers" refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.

[0068] The term "tautomer," as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.

[0069] It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention.

[0070] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.

[0071] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ^{13}C- or ^{14}C-enriched carbon are within the scope of this invention.

[0072] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^{3}H), iodine-125 (^{125}I), or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0073] It should be noted that throughout the application that alternatives are written in Markush groups, for example, each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.

[0074] "Analog" or "analogue" is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called "reference" compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.

[0075] The terms "a" or "an," as used in herein means one or more. In addition, the phrase "substituted with a[n]," as used herein, means the specified group may be substituted with one or more of any or all of the named substituents. For example, where a group, such as an alkyl or heteroaryl group, is "substituted with an unsubstituted C_1-C_{20} alkyl, or unsubstituted 2 to 20 membered heteroalkyl," the group may contain one or more unsubstituted C_1-C_{20} alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.

[0076] Moreover, where a moiety is substituted with an R substituent, the group may be referred to as "R-substituted." Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I)), a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R^{13} substituents are present, each R^{13} substituent may be distinguished as R^{13A}, R^{13B}, R^{13C}, R^{13D}, etc., wherein each of R^{13A}, R^{13B}, R^{13C}, R^{13D}, etc. is defined within the scope of the definition of R^{13} and optionally differently.

[0077] A "detectable moiety" as used herein refers to a moiety that can be covalently or noncovalently attached to a compound or biomolecule that can be detected for instance, using techniques known in the art. In embodiments, the detectable moiety is covalently attached. The detectable moiety may provide for imaging of the attached compound or biomolecule. The detectable moiety may indicate the contacting between two compounds. Exemplary detectable moieties are fluorophores, antibodies, reactive dies, radio-labeled moieties, magnetic contrast agents, and quantum dots. Exemplary fluorophores include fluorescein, rhodamine, GFP, coumarin, FITC, Alexa fluor, Cy3, Cy5, BODIPY, and cyanine dyes. Exemplary radionuclides include Fluorine-18, Gallium-68, and Copper-64. Exemplary magnetic contrast agents include gadolinium, iron oxide and iron platinum, and manganese.

[0078] Descriptions of compounds of the present invention are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.

[0079] The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds that are prepared

with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (*see,* for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0080] Thus, the compounds of the present invention may exist as salts, such as with pharmaceutically acceptable acids. The present invention includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, proprionates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g. methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art.

[0081] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents. In embodiments, compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compounds differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but, unless specifically indicated, the salts disclosed herein are equivalent to the parent form of the compound for the purposes of the present invention.

[0082] In addition to salt forms, the present invention provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Prodrugs of the compounds described herein may be converted *in vivo* after administration. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.

[0083] Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0084] "Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to a substance that aids the administration of a compound to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.

[0085] The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0086] A "CRF1 inhibitor" refers to a compound (e.g., compounds described herein) that reduces the activity of CRF1 when compared to a control, such as absence of the compound or a compound with known inactivity.

[0087] The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino

acid residues, wherein the polymer may optionally be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer. In embodiments, the terms "polypeptide," "peptide," and "protein", used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include genetically coded and non-genetically coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified polypeptide backbones. The terms include fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence; fusion proteins with heterologous and homologous leader sequences, with or without N-terminus methionine residues; immunologically tagged proteins; and the like.

[0088] A polypeptide, or a cell is "recombinant" when it is artificial or engineered, or derived from or contains an artificial or engineered protein or nucleic acid (*e.g.* non-natural or not wild type). For example, a polynucleotide that is inserted into a vector or any other heterologous location, *e.g.,* in a genome of a recombinant organism, such that it is not associated with nucleotide sequences that normally flank the polynucleotide as it is found in nature is a recombinant polynucleotide. A protein expressed *in vitro* or *in vivo* from a recombinant polynucleotide is an example of a recombinant polypeptide. Likewise, a polynucleotide sequence that does not appear in nature, for example a variant of a naturally occurring gene, is recombinant.

[0089] "Contacting" is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents that can be produced in the reaction mixture.

[0090] The term "contacting" may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway (e.g., MAP kinase pathway).

[0091] As defined herein, the term "activation", "activate", "activating" and the like in reference to a protein refers to conversion of a protein into a biologically active derivative from an initial inactive or deactivated state. The terms reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease.

[0092] The terms "agonist," "activator," "upregulator," etc. refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. The agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist. In embodiments, an agonist is a molecule that interacts with a target to cause or promote an increase in the activation of the target. In embodiments, activators are molecules that increase, activate, facilitate, enhance activation, sensitize, or up-regulate, e.g., a gene, protein, ligand, receptor, or cell.

[0093] As defined herein, the term "inhibition", "inhibit", "inhibiting" and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein target. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In embodiments, inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein). In embodiments, inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation).

[0094] The terms "inhibitor," "repressor" or "antagonist" or "downregulator" interchangeably refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist. An antagonist prevents, reduces, inhibits, or neutralizes the activity of an agonist, and an antagonist can also prevent, inhibit, or reduce constitutive activity of a target, e.g., a target receptor, even where there is no identified agonist. In embodiments, inhibitors are molecules that decrease, block, prevent, delay activation, inactivate, desensitize, or down-regulate, e.g., a gene, protein, ligand, receptor, or cell. An inhibitor may also be defined as a molecule that reduces, blocks, or inactivates a constitutive activity. An "antagonist" is a molecule that opposes the action(s) of an agonist.

[0095] The terms "corticotropin-releasing factor type-1," "CRF_1," "corticotropin-releasing hormone receptor 1," and

"CHHR1" refer to a protein (including homologs, isoforms, and functional fragments thereof) and is a receptor for corticotropin releasing-hormone. The terms include any recombinant or naturally-occurring form of CRF_1 variants thereof that maintain CRF_1 activity (e.g. within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% activity compared to wildtype CRF1). The terms include any mutant form of CRF_1 variants (e.g., frameshift mutations) thereof that maintain CRF_1 activity (e.g. within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% activity compared to wildtype CRF_1). In embodiments, the CRF_1 protein encoded by the *CRHR1* gene has the amino acid sequence set forth in or corresponding to Entrez 1233, UniProt P34998.

[0096] The term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (*e.g.*, ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, *etc.)*.

[0097] The terms "disease" or "condition" refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. The disease may be a malignant or benign tumor (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)). The disease may be cancer. In some further instances, "cancer" refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, adrenal, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphomas (*e.g.*, Burkitt's, Small Cell, and Large Cell lymphomas), Hodgkin's lymphoma, leukemia (including MDS, AML, ALL, ATLL and CML), or multiple myeloma.

[0098] As used herein, the term "cancer" refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemia, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound or method provided herein include adrenal cancer and tumors (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, cervical cancer, gastric cancer, ovarian cancer, lung cancer, and cancer of the head. Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, Medulloblastoma, colorectal cancer, pancreatic cancer. Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.

[0099] The term "congenital adrenal hyperplasia" or "CAH" are any of several autosomal recessive diseases resulting from mutations of genes for enzymes mediating the biochemical steps of production of mineralocorticoids, glucocorticoids or sex steroids from cholesterol by the adrenal glands (steroidogenesis). These conditions involve excessive or deficient production of sex steroids and can alter development of primary or secondary sex characteristics in some affected infants, children, or adults.

[0100] "Adrenal rest tumor" refers to a neoplasm of the testis (or ovaries) consisting of adrenal tissue. It may be secondary to hyperplasia of an adrenal gland.

[0101] "Testicular adrenal rest tumor(s)" or "TART" and/or ovarian adrenal rest tumor(s) are a complication of congenital adrenal hyperplasia (CAH), which may develop from ectopic remnants of intra-testicular adrenal tissue stimulated by adrenocorticotropic hormone (ACTH) hypersecretion. TART lesions are typically located within the rete testis and are bilateral, synchronous, nodular and multiple. TART can lead to testicular structural damage, spermatogenesis disorders, infertility and mass-forming lesions.

[0102] The term "leukemia" refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leuke-

mia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.

[0103] The term "sarcoma" generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectaltic sarcoma.

[0104] The term "melanoma" is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.

[0105] The term "carcinoma" refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with a compound or method provided herein include, for example, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatiniforni carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypernephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, or carcinoma villosum.

[0106] The terms "treating" or "treatment" refer to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. The term "treating" and conjugations thereof, may include prevention of an injury, pathology, condition, or disease. In embodiments, treating is preventing In embodiments, treating does not include preventing.

[0107] "Treating" or "treatment" as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical

results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (*i.e.*, not worsening) the state of disease, prevention of a disease's transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. In other words, "treatment" as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease's spread; relieve the disease's symptoms (*e.g.*, ocular pain, seeing halos around lights, red eye, very high intraocular pressure), fully or partially remove the disease's underlying cause, shorten a disease's duration, or do a combination of these things.

[0108] "Treating" and "treatment" as used herein include prophylactic treatment. Treatment methods include administering to a subject a therapeutically effective amount of a compound described herein. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of the compound, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.

[0109] The term "prevent" refers to a decrease in the occurrence of disease symptoms in a patient. As indicated above, the prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment. In embodiments, prevent refers to slowing the progression of the disease, disorder or condition or inhibiting progression thereof to a harmful or otherwise undesired state.

[0110] "Patient" or "subject in need thereof' refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.

[0111] An "effective amount" is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g., achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a "therapeutically effective amount." A "reduction" of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A "prophylactically effective amount" of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An "activity decreasing amount," as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A "function disrupting amount," as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (*see, e.g.*, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). The therapeutically effective amount can be ascertained by measuring relevant physiological effects, and it can be adjusted in connection with the dosing regimen and diagnostic analysis of the subject's condition, and the like. By way of example, measurement of the serum level of a CRF1 inhibitor (or, e.g., a metabolite thereof) at a particular time post-administration may be indicative of whether a therapeutically effective amount has been administered.

[0112] For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.

[0113] Therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan. Adjusting the dose to achieve maximal therapeutic window efficacy or toxicity in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.

[0114] The term "therapeutically effective amount," as used herein, refers to that amount of the therapeutic agent sufficient to ameliorate the disorder, as described above. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as "-fold" increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.

[0115] The terms "QD," "qd," and "q.d." refer to once a day, i.e., a drug or therapeutic agent is administered once a day for the duration of the therapeutic regimen.

[0116] The terms "BD," "bd," and "b.i.d." refer to twice a day, i.e., a drug or therapeutic agent is administered two times a day for the duration of the therapeutic regimen.

[0117] The terms "QID," "qid," and "q.i.d." refer to three times a day, i.e., a drug or therapeutic agent is administered three times a day for the duration of the therapeutic regimen.

[0118] Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.

[0119] As used herein, the term "administering" means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or the implantation of a slow-release device, *e.g.,* a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (*e.g.*, buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, *e.g.*, intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, *etc.* By "co-administer" it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies (e.g. anti-cancer agent, chemotherapeutic, or treatment for a neurodegenerative disease). The compound of the invention can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation). The compositions of the present invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. The compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The compositions of the present invention can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). In another embodiment, the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo. (See, *e.g.,* Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576-1587, 1989). The compositions of the present invention can also be delivered as nanoparticles.

[0120] By "co-administer" it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds of the invention can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). The compositions of the present invention can be delivered transdermally, by a topical route, or formulated as applicator sticks, solutions, suspensions,

emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

[0121] For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.

[0122] Utilizing the teachings provided herein, an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient. This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.

[0123] The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer (e.g. colon cancer), cardiovascular disease, metabolic disease, immune or inflammatory disease or disorder.

[0124] In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours, 2 days, 4 days, 1 week or 1 month of a second active agent. Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents may be linked or conjugated to one another. In some embodiments, the compounds described herein may be combined with treatments for cancer (e.g. colon cancer), cardiovascular disease, metabolic disease, immune or inflammatory disease or disorder.

[0125] The compounds described herein can be administered to treat a fertility disease or disorder and/or cancer. In this regard, the compounds disclosed herein may be administered either alone to treat such diseases or disorders or may be co-administered with another therapeutic agent to treat such diseases or disorders.

[0126] The compounds disclosed herein may be co-administered with an agonist or antagonist of CRF_1 function. The compounds described herein can be co-administered with conventional anti-cancer/chemotherapeutic.

[0127] "Anti-cancer agent" is used in accordance with its plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anti-cancer agent is a chemotherapeutic. In some embodiments, an anti-cancer agent is an agent identified herein having utility in methods of treating cancer. In some embodiments, an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI-1040, PD035901, selumetinib/ AZD6244, GSK1120212/ trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (*e.g.*, cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin), triazenes (decarbazine)), anti-metabolites (*e.g.*, 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), *etc.*), plant alkaloids (*e.g.*, vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, *etc.),* topoisomerase inhibitors (*e.g.,* irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, *etc.*), antitumor antibiotics (*e.g.,* doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, *etc.*), platinum-based compounds (*e.g.* cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g. U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins;

benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-aminotriazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bize-

lesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflomithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin I1 (including recombinant interleukin II, or rlL.sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon gamma-1b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate the formation or stability of microtubules, (e.g. Taxol.TM (i.e. paclitaxel), Taxotere.TM, compounds comprising the taxane skeleton, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS-10 and NSC-376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e. as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g. Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (i.e. LU-103793 and NSC-D-669356), Epothilones (e.g. Epothilone A, Epothilone B, Epothilone C (i.e. desoxyepothilone A or dEpoA), Epothilone D (i.e. KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e. BMS-310705), 21-hydroxyepothilone D (i.e. Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e. NSC-654663), Soblidotin (i.e. TZT-1027), LS-4559-P (Pharmacia, i.e. LS-4577), LS-4578 (Pharmacia, i.e. LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e. WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e. ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e. LY-355703), AC-7739 (Ajinomoto, i.e. AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, i.e. AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-106969), T-138067 (Tularik, i.e. T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, i.e. DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (i.e. BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e. SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, Inanocine (i.e. NSC-698666), 3-IAABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, i.e. T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (i.e. NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e. D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e. SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi)), steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette-Guérin (BCG), levam-

isole, interleukin-2, alpha-interferon, *etc.),* monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, *etc.*), radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to ^{111}In, ^{90}Y, or ^{131}I, *etc.*), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g. gefitinib (Iressa ™), erlotinib (Tarceva ™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, or the like.

[0128] "Chemotherapeutic" or "chemotherapeutic agent" is used in accordance with its plain ordinary meaning and refers to a chemical composition or compound having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.

[0129] The compounds disclosed herein may be co-administered with an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology, such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as vincristine, vinblastine, vindesine or vinorelbine, or a taxoid such as taxol or taxotere); or a topoisomerase inhibitor (for example an epipodophyllotoxin such as etoposide, teniposide, amsacrine, topotecan or a camptothecin); (ii) a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leuprorelin or buserelin), a progestogen (for example megestrol acetate), an aromatase inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of 5.alpha.-reductase such as finasteride; (iii) an agent which inhibits cancer cell invasion (for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function); (iv) an inhibitor of growth factor function, for example: a growth factor antibody (for example the anti-erbb2 antibody trastuzumab, or the anti-erbb1 antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoli- n-4-amine (gefitinib, AZD 1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) or 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazoli- n-4-amine (CI 1033)), an inhibitor of the platelet-derived growth factor family, or an inhibitor of the hepatocyte growth factor family; (v) an anti angiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin .alpha.v.beta.3 function or an angiostatin); (vi) a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213; (vii) an agent used in antisense therapy, for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense; (viii) an agent used in a gene therapy approach, for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme prodrug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or (ix) an agent used in an immunotherapeutic approach, for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

[0130] In embodiments, the compounds disclosed herein can be co-administered with an antibody, such as a monoclonal antibody targeting B-Lymphocytes (such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax 11-15) or antibody modulating Ig function such as anti-IgE (for example omalizumab).

[0131] In embodiments, treatment of cancer includes administration of an effective amount of at least two of the following: a CRF1 inhibitor, an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an agonistic antibody of CD137 (4-1BB). In some embodiments, the method may comprise the use of two or more combinations.

[0132] In a further embodiment, the compounds described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as ^{47}Sc, ^{64}Cu, ^{67}Cu, ^{89}Sr, ^{86}Y, ^{87}Y, ^{90}Y, ^{105}Rh, ^{111}Ag,

^{111}In, ^{117m}Sn, ^{149}Pm, ^{153}Sm, ^{166}Ho, ^{177}Lu, ^{186}Re, ^{188}Re, ^{211}At, and ^{212}Bi, optionally conjugated to antibodies directed against tumor antigens.

[0133] In addition, a CRF_1 inhibitor may be combined with the therapeutic administration of immune cells, sometimes referred to as adoptive cell transfer. These cells may be cells from the patient, a genetically related or unrelated donor, they may be genetically modified (e.g. CAR-T cells, NK cells, etc), cell lines, genetically modified cell lines and live or dead versions of the above. CRF1 inhibitors may also be combined with vaccines of any kind (e.g. protein/peptide, viral, bacterial, cellular) to stimulate immune responses to cancer.

[0134] The CRF_1 inhibitors/CRF_1 antagonists disclosed herein can be administered by any acceptable route, such oral, intraadiposal, intraarterial, intraarticular, intracranial, intradermal, intralesional, intramusculay, intranasal, intraocularal, intrapericardial, intraperitoneal, intrapleural, intraprostatical, intrarectal, intrathecal, intratracheal, intratumoral, intraumbilical, intravaginal, intravenousl, intravesicullar, intravitreal, liposomal, local, mucosal, parenteral, rectal, subconjunctival, subcutaneous, sublingual, topical, transbuccal, transdermal, vaginal, in cremes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, via localized perfusion, bathing target cells directly, or any combination thereof.

[0135] The CRF_1 inhibitors/CRF, antagonists disclosed herein can be administered by any acceptable route, such oral, intraadiposal, intraarterial, intraarticular, intracranial, intradermal, intralesional, intramusculay, intranasal, intraocularal, intrapericardial, intraperitoneal, intrapleural, intraprostatical, intrarectal, intrathecal, intratracheal, intratumoral, intraumbilical, intravaginal, intravenousl, intravesicullar, intravitreal, liposomal, local, mucosal, parenteral, rectal, subconjunctival, subcutaneous, sublingual, topical, transbuccal, transdermal, vaginal, in cremes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, via localized perfusion, bathing target cells directly, or any combination thereof.

[0136] The CRF_1 inhibitors/CRF, antagonists disclosed herein may be administered once daily until study reached endpoint. The CRF_1 inhibitors/CRF_1 antagonists disclosed herein may be administered at least three times but in some studies four or more times depending on the length of the study and/or the design of the study.

[0137] The compositions disclosed herein may be used in combination with additional cancer therapy. In some embodiments, the distinct cancer therapy comprises surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy or gene therapy. In some embodiments, the cancer is a chemotherapy-resistant or radio-resistant cancer.

[0138] A "cell" as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaroytic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.

[0139] "Control" or "control experiment" is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity of a protein in the absence of a compound as described herein (including embodiments and examples).

[0140] The term "modulator" refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule. In some embodiments, a CRF_1 associated disease modulator is a compound that reduces the severity of one or more symptoms of a disease associated with CRF_1 (e.g. an endocrine disorder, a cancer including but not limited to TART or OART). A CRF_1 modulator is a compound that increases or decreases the activity or function or level of activity or level of function of CRF_1. A modulator may act alone, or it may use a cofactor, e.g., a protein, metal ion, or small molecule. Examples of modulators include small molecule compounds and other bioorganic molecules. Numerous libraries of small molecule compounds (e.g., combinatorial libraries) are commercially available and can serve as a starting point for identifying a modulator. The skilled artisan is able to develop one or more assays (e.g., biochemical or cell-based assays) in which such compound libraries can be screened in order to identify one or more compounds having the desired properties; thereafter, the skilled medicinal chemist is able to optimize such one or more compounds by, for example, synthesizing and evaluating analogs and derivatives thereof. Synthetic and/or molecular modeling studies can also be utilized in the identification of an activator.

[0141] The term "modulate" is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. "Modulation" refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule. In embodiments, the terms "modulate", "modulation" and the like refer to the ability of a molecule (e.g., an activator or an inhibitor) to increase or decrease the function or activity of CRF_1, either directly or indirectly, relative to the absence of the molecule.

[0142] The term "associated" or "associated with" in the context of a substance or substance activity or function

associated with a disease (e.g. a protein associated disease, an endocrine disorder, a disease associated with CRF_1 activity, a CRF_1 associated disease (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) means that the disease (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function. For example, an endocrine disorder associated with CRF_1 activity or function may be an endocrine disorder that results (entirely or partially) from aberrant CRF_1 function (e.g. enzyme activity, protein-protein interaction, signaling pathway) or an endocrine disorder wherein a particular symptom of the disease is caused (entirely or partially) by aberrant CRF_1 activity or function. As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease. For example, an endocrine disorder associated with CRF_1 activity or function or a CRF_1 associated disease (e.g., an endocrine disorder including but not limited to TART or OART), may be treated with a compound described herein (e.g., CRF_1 modulator, CRF_1 inhibitor, or CRF_1 antagonist), in the instance where increased CRF_1 activity or function (e.g. signaling pathway activity) causes the disease (e.g., an endocrine disorder such as TART or OART). For example, an endocrine disorder associated with CRF_1 activity or function or a CRF_1 associated endocrine disorder, may be treated with an CRF_1 modulator or CRF_1 inhibitor, in the instance where increased CRF_1 activity or function (e.g. signaling pathway activity) causes the disease.

[0143] The term "aberrant" as used herein refers to different from normal. When used to describe enzymatic activity or protein function, aberrant refers to activity or function that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non-disease-associated amount (e.g. by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.

[0144] The term "signaling pathway" as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propogated to other signaling pathway components. For example, binding of a CRF_1 with a compound as described herein may reduce the level of a product of the CRF_1 catalyzed reaction or the level of a downstream derivative of the product or binding may reduce the interactions between the CRF_1 or a reaction product and downstream effectors or signaling pathway components (e.g., MAP kinase pathway), resulting in changes in cell growth, proliferation, or survival.

[0145] As used herein, the terms "corticotropin-releasing factor type-1," "CRF_1," "corticotropin-releasing hormone receptor 1," and "CHHR1" and all other related art-accepted terms, many of which are set forth below, refer to a compound capable of modulating, either directly or indirectly, the CRF_1 receptor in an *in vitro* assay, an *in vivo* model, and/or other means indicative of therapeutic efficacy. The terms also refer to a compound that exhibits at least some therapeutic benefit in a human subject.

[0146] The phrase "in a sufficient amount to effect a change" means that there is a detectable difference between a level of an indicator measured before (e.g., a baseline level) and after administration of a particular therapy. Indicators include any objective parameter (e.g., serum concentration) or subjective parameter (e.g., a subject's feeling of well-being).

[0147] The "activity" of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor; to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity; to the modulation of activities of other molecules; and the like. The term "proliferative activity" encompasses an activity that promotes, that is necessary for, or that is specifically associated with, for example, normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis.

[0148] "Substantially pure" indicates that a component makes up greater than about 50% of the total content of the composition, and typically greater than about 60% of the total polypeptide content. More typically, "substantially pure" refers to compositions in which at least 75%, at least 85%, at least 90% or more of the total composition is the component of interest. In some cases, the polypeptide will make up greater than about 90%, or greater than about 95% of the total content of the composition (percentage in a weight per weight basis).

[0149] The terms "specifically binds" and "selectively binds," when referring to a ligand/receptor, antibody/antigen, or other binding pair, indicates a binding reaction which is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated conditions, a specified ligand binds to a particular receptor and does not bind in a significant amount to other proteins present in the sample. The antibody, or binding composition derived from the antigen-binding site of an antibody, of the contemplated method binds to its antigen, or a variant or mutein thereof, with an affinity that is at least two-fold greater, at least 10-times greater, at least 20-times greater, or at least 100-times greater than the affinity with any other antibody, or binding composition derived therefrom. In embodiments, the antibody will have an affinity that is greater than about 10^9 liters/mol, as determined by, e.g., Scatchard analysis (Munsen, et al. (1980) Analyt. Biochem. 107:220-239).

[0150] The terms "DNA," "nucleic acid," "nucleic acid molecule," "polynucleotide" and the like are used interchangeably herein to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include linear and circular nucleic acids, messenger RNA (mRNA),


complementary DNA (cDNA), recombinant polynucleotides, vectors, probes, primers and the like.

[0151] As used herein, the terms "variants" and "homologs" are used interchangeably to refer to amino acid or nucleic acid sequences that are similar to reference amino acid or nucleic acid sequences, respectively. The term encompasses naturally-occurring variants and non-naturally-occurring variants. Naturally-occurring variants include homologs (polypeptides and nucleic acids that differ in amino acid or nucleotide sequence, respectively, from one species to another), and allelic variants (polypeptides and nucleic acids that differ in amino acid or nucleotide sequence, respectively, from one individual to another within a species). Thus, variants and homologs encompass naturally occurring amino acid and nucleic acid sequences encoded thereby and their isoforms, as well as splice variants of a protein or gene. The terms also encompass nucleic acid sequences that vary in one or more bases from a naturally-occurring nucleic acid sequence but still translate into an amino acid sequence that corresponds to the naturally-occurring protein due to degeneracy of the genetic code. Non-naturally-occurring variants and homologs include polypeptides and nucleic acids that comprise a change in amino acid or nucleotide sequence, respectively, where the change in sequence is artificially introduced (e.g., muteins); for example, the change is generated in the laboratory by human intervention ("hand of man"). Therefore, non-naturally occurring variants and homologs may also refer to those that differ from the naturally-occurring sequences by one or more conservative substitutions and/or tags and/or conjugates.


[0152] The term "muteins" as used herein refers broadly to mutated recombinant proteins. These proteins usually carry single or multiple amino acid substitutions and are frequently derived from cloned genes that have been subjected to site-directed or random mutagenesis, or from completely synthetic genes.


II. Compounds

[0153] In an aspect provided herein, is a compound of Formula (I):



or a pharmaceutically acceptable salt thereof. R^1 and R^2 are independently ethyl or n-propyl. R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy. R^4 is hydrogen, Br, R^aR^bN-, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,






R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$-, $(CH_3)_3COC(O)NHCH_2CH_2$-, or $CH_3CH_2CH_2NHCH_2CH_2$-In embodiments, the inhibitor forms an irreversible bond with the amino acid residue. In embodiments, the bond is a covalent bond.


[0154] In certain embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl.

[0155] In certain embodiments, R^3 is Cl, Br, or methyl.

[0156] In certain embodiments, R^4 is Br, R^aR^bN-, pyridin-4-yl, morpholin-4-yl, or




[0157] In certain embodiments, R^4 is morpholin-4-yl or




[0158] In certain embodiments, R^4 is hydrogen, Br, R^aR^bN- and R^a and R^b are independently C_1-C_3alkyl.

[0159] In certain embodiments, the compound is




or a pharmaceutically acceptable salt thereof.

[0160] In certain embodiments, the compound is



or a pharmaceutically acceptable salt thereof.

[0161] In certain embodiments, the compound is



or a pharmaceutically acceptable salt thereof.

[0162] The invention is defined by the claims. Any subject-matter falling outside the scope of the claims is provided for information purposes only. The following paragraphs are part of the disclosure but are not claimed.

[0163] In one aspect described herein, there is a method of treating a subject in need thereof comprising administering an astressin or a pharmaceutically acceptable salt or solvate thereof. An astressin generally refers to a nonselective corticotropin releasing hormone antagonist that reduces the synthesis of ACTH and cortisol.

[0164] In one aspect described herein, there is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, the method comprising: (i) measuring a hormone level in the subject in need thereof; (ii) administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof; and repeating steps (i) and (ii) until the hormone level reaches a pre-determined range followed by a maintenance therapy of a daily dosing of said astressin.

[0165] In one aspect described herein, there is a method of improving hyperandrogenic symptoms in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of treating menstrual irregularity, ovulatory dysfunction or infertility, in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of improving metabolic symptoms in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto; or a pharmaceutically acceptable salt or solvate thereof.

[0166] In one aspect described herein, there is a method of improving quality of life in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof.

III. Pharmaceutical Compositions

[0167] In an aspect, there is provided a pharmaceutical composition, for the claimed use, including a compound as described herein, including embodiments, or the structural Formula (I), and a pharmaceutically acceptable excipient.

[0168] The compounds (e.g., CRF_1 inhibitors/antagonists) of the present disclosure may be in the form of compositions suitable for administration to a subject. In general, such compositions are "pharmaceutical compositions" comprising a compound (e.g., CRF_1 inhibitor(s)/ antagonist(s)) and one or more pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients. In certain embodiments, the compound (e.g., CRF_1 inhibitor/antagonist) are present in a therapeutically acceptable amount. The pharmaceutical compositions may be used in the methods of the present disclosure; thus, for example, the pharmaceutical compositions can be administered *ex vivo* or *in vivo* to a subject in order to practice the therapeutic and prophylactic methods and uses described herein.

[0169] In one aspect described herein, there is a pharmaceutical composition in the form of a capsule comprising an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a pharmaceutical composition in the form of a tablet comprising an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof.

[0170] The pharmaceutical compositions of the present disclosure can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein.

[0171] The pharmaceutical compositions containing the active ingredient (e.g., an inhibitor of CRF_1 function) may be in a form suitable for oral use, for example, as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microbeads or elixirs. Pharmaceutical compositions intended for oral use may be prepared for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents such as, for example, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets, capsules and the like contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture thereof. These excipients may be, for example, diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.

[0172] The tablets, capsules and the like suitable for oral administration may be uncoated or coated to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for controlled release. Additional agents include biodegradable or biocompatible particles or a polymeric substance such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, polyanhydrides, polyglycolic acid, ethylene-vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers, polylactide/glycolide copolymers, or ethylenevinylacetate copolymers in order to control delivery of an administered compo-

sition. For example, the oral agent can be entrapped in microcapsules prepared by coacervation techniques or by interfacial polymerization, by the use of hydroxymethylcellulose or gelatin-microcapsules or poly(methylmethacrolate) microcapsules, respectively, or in a colloid drug delivery system. Colloidal dispersion systems include macromolecule complexes, nano-capsules, microspheres, microbeads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Methods for the preparation of the above-mentioned formulations will be apparent to those skilled in the art.

[0173] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, kaolin or microcrystalline cellulose, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

[0174] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture thereof. Such excipients can be suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example a naturally-occurring phosphatide (e.g., lecithin), or condensation products of an alkylene oxide with fatty acids (e.g., polyoxy-ethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., for heptadecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol (e.g., polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives.

[0175] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.

[0176] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, and optionally one or more suspending agents and/or preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified herein.

[0177] The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin, or mixtures of these. Suitable emulsifying agents may be naturally occurring gums, for example, gum acacia or gum tragacanth; naturally occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids; hexitol anhydrides, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.

[0178] The pharmaceutical compositions typically comprise a therapeutically effective amount of a CRF_1 inhibitor/antagonist contemplated by the present disclosure and one or more pharmaceutically and physiologically acceptable formulation agents. Suitable pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients include, but are not limited to, antioxidants (e.g., ascorbic acid and sodium bisulfate), preservatives (e.g., benzyl alcohol, methyl parabens, ethyl or n-propyl, p-hydroxybenzoate), emulsifying agents, suspending agents, dispersing agents, solvents, fillers, bulking agents, detergents, buffers, vehicles, diluents, and/or adjuvants. For example, a suitable vehicle may be physiological saline solution or citrate-buffered saline, possibly supplemented with other materials common in pharmaceutical compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Those skilled in the art will readily recognize a variety of buffers that can be used in the pharmaceutical compositions and dosage forms contemplated herein. Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. As an example, the buffer components can be water soluble materials such as phosphoric acid, tartaric acids, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof. Acceptable buffering agents include, for example, a Tris buffer; N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES); 2-(N-Morpholino)ethanesulfonic acid (MES); 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES); 3-(N-Morpholino)propanesulfonic acid (MOPS); and N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS).

[0179] After a pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form, a lyophilized form requiring reconstitution prior to use, a liquid form requiring dilution prior to use, or other acceptable form. In some embodiments, the pharmaceutical composition is provided in a single-use container (e.g., a single-use vial, ampule, syringe, or autoinjector (similar to, e.g., an EpiPen®)), whereas a multi-use container (e.g., a multi-use vial) is provided in other embodiments.

[0180] Formulations can also include carriers to protect the composition against rapid degradation or elimination from the body, such as a controlled release formulation, including liposomes, hydrogels, prodrugs and microencapsulated delivery systems. For example, a time-delay material such as glyceryl monostearate or glyceryl stearate alone, or in combination with a wax, may be employed. Any drug delivery apparatus may be used to deliver a CRF_1 inhibitor/antag-

onist, including implants (e.g., implantable pumps) and catheter systems, slow injection pumps and devices, all of which are well known to the skilled artisan.

[0181] Depot injections, which are generally administered subcutaneously or intramuscularly, may also be utilized to release the compound (e.g., CRF_1 inhibitor/antagonist) disclosed herein over a defined period of time. Depot injections are usually either solid- or oil-based and generally comprise at least one of the formulation components set forth herein. One of ordinary skill in the art is familiar with possible formulations and uses of depot injections.

[0182] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Acceptable diluents, solvents and dispersion media that may be employed include water, Ringer's solution, isotonic sodium chloride solution, Cremophor® EL (BASF, Parsippany, NJ) or phosphate buffered saline (PBS), ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium; for this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. Moreover, fatty acids, such as oleic acid, find use in the preparation of injectables. Prolonged absorption of particular injectable formulations can be achieved by including an agent that delays absorption (e.g., aluminum monostearate or gelatin).

[0183] The present disclosure contemplates the administration of the compound (e.g., CRF_1 inhibitor/antagonist) in the form of suppositories for rectal administration. The suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter and polyethylene glycols.

[0184] The compound (e.g., CRF_1 inhibitor/antagonist) contemplated by the present disclosure may be in the form of any other suitable pharmaceutical composition (e.g., sprays for nasal or inhalation use) currently known or developed in the future.

IV. Methods

[0185] In certain embodiments, provided herein are methods for treating or preventing a disease comprising administering an effective amount of a compound of Formula (I), or an isotopic variant thereof or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0186] In one embodiment, provided herein are methods for treating or preventing a tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing a benign tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing a malignant tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing an adrenal tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing an adrenal rest tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0187] In one embodiment, provided herein are methods for treating or preventing infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing male infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm count, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm motility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm morphology, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing female infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0188] In one embodiment, provided herein are methods for treating or preventing a proliferative or hyperproliferative disease or disorder according to the claims, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, thereof. In certain embodiments, the proliferative disease is cancer. In certain embodiments, the proliferative disease is a cancer of the breast, skin, prostate, cervix, uterus, ovary,

testes, bladder, lung, liver, larynx, oral cavity, colon and gastrointestinal tract (e.g., esophagus, stomach, pancreas), brain, thyroid, blood, and lymphatic system.

[0189] In certain embodiments, the cancer treatable with the methods provided herein includes, but is not limited to, (1) leukemias, including, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome or a symptom thereof (such as anemia, thrombocytopenia, neutropenia, bicytopenia or pancytopenia), refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in transformation (RAEB-T), preleukemia, and chronic myelomonocytic leukemia (CMML), (2) chronic leukemias, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, and hairy cell leukemia; (3) polycythemia vera; (4) lymphomas, including, but not limited to, Hodgkin's disease and non-Hodgkin's disease; (5) multiple myelomas, including, but not limited to, smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; (6) Waldenstrom's macroglobulinernia; (7) monoclonal gammopathy of undetermined significance; (8) benign monoclonal gammopathy; (9) heavy chain disease; (10) bone and connective tissue sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, metastatic cancers, neurilemmoma, rhabdomyosarcoma, and synovial sarcoma; (11) brain tumors, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, aligodendroglionna, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, and primary brain lymphoma; (12) breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mutinous breast cancer, tubular breast cancer, papillary breast cancer, primary cancers, Paget's disease, and inflammatory breast cancer; (13) adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; (14) thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; (15) pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; (16) pituitary cancer, including, but limited to, Cushing's disease, prol actin-secreting tumor, acromegaly, and diabetes insipius; (17) eye cancer, including, but not limited, to ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; (18) vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; (19) vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; (20) cervical cancers, including, but not limited to, squamous cell carcinoma, and adenocarcinoma; (21) uterine cancer, including, but not limited to, endometrial carcinoma and uterine sarcoma; (22) ovarian cancer, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; (23) esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; (24) stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; (25) colon cancer; (26) rectal cancer; (27) liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma; (28) gallbladder cancer, including, but not limited to, adenocarcinoma; (29) cholangiocarcinomas, including, but not limited to, pappillary, nodular, and diffuse; (30) lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma, and small-cell lung cancer; (31) testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); (32) prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; (33) penal cancer; (34) oral cancer, including, but not limited to, squamous cell carcinoma; (35) basal cancer; (36) salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; (37) pharynx cancer, including, but not limited to, squamous cell cancer and verrucous; (38) skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; (39) kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and/or uterer); (40) Wilms' tumor; (41) bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, and carcinosarcoma; and other cancer, including, not limited to, myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangio-endotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinomas (*See* Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin, Penguin Books U.S.A., Inc., United States of America).

[0190] Depending on the disorder, disease, or condition to be treated, and the subject's condition, the compounds or pharmaceutical compositions provided herein can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal,

intravenous, ICV, intracistemal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration and can be formulated, alone or together, in suitable dosage unit with pharmaceutically acceptable excipients, carriers, adjuvants, and vehicles appropriate for each route of administration as described elsewhere herein.

[0191] The suitability of a particular route of administration employed for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally without decomposing prior to entering the blood stream) and the disease being treated. Recommended routes of administration for the second active agents are known to those of ordinary skill in the art. See, e.g., Physicians' Desk Reference, 1755-1760 (56th ed., 2002).


[0192] In one embodiment, provided herein are methods for treating or preventing testicular adrenal rest tumors (TART) in a subject, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the subject has congenital adrenal hyperplasia (CAH).

[0193] In one embodiment, provided herein are methods for treating or preventing ovarian adrenal rest tumors (OART) in a subject, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the subject has congenital adrenal hyperplasia (CAH).


[0194] In an aspect provided herein, is a method of treating or preventing testicular adrenal rest tumors (TART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.


[0195] In an aspect provided herein, is a method of treating or preventing ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.

[0196] In an aspect provided herein, is a method of treating or preventing testicular adrenal rest tumors (TART), comprising administering to a subject in need thereof a compound of structural Formula (I):




or a pharmaceutically acceptable salt thereof. R^1 and R^2 are independently ethyl or n-propyl. R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy. R^4 is hydrogen, Br, R^aR^bN-, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,






R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$-, $(CH_3)_3COC(O)NHCH_2CH_2$-, or $CH_3CH_2CH_2NHCH_2CH_2$-.

[0197] In an aspect provided herein, is a method of treating or preventing ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a compound of structural Formula (I):



or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments.


[0198] In an aspect provided herein, is a method of decreasing or reducing adrenocorticotropic hormone (ACTH) levels in a subject in need thereof, comprising administering to the subject contacting the ACTH with a compound of structural Formula (I):



or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in ACTH.In certain embodiments, at least about 60% of the subjects demonstrate reduction in ACTH.In certain embodiments, at least about 70% of the subjects demonstrate reduction in ACTH. In certain embodiments, at least about 80% of the subjects demonstrate reduction in ACTH. In embodiments, at least about 10% of subjects were in the standard or normal range for ACTH after treatment.

[0199] In embodiments, at least about 20% of subjects were in the standard or normal range for ACTH after treatment. In embodiments, at least about 30% of subjects were in the standard or normal range for ACTH after treatment. In certain embodiments, ACTH levels are decreased or reduced within about 30 minutes post dosing. In certain embodiments, ACTH levels are decreased or reduced within about 1 hour post dosing. In certain embodiments, ACTH levels are decreased or reduced within about 90 minutes post dosing. In certain embodiments, ACTH levels are decreased or reduced within about 2 hours post dosing.


[0200] In an aspect provided herein, is a method of decreasing or reducing 17α-hydroxyprogesterone (17-OHP) levels in a subject in need thereof, comprising administering to the subject a compound of structural Formula (I):



or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 60% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 70% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 80% of the subjects demonstrate reduction in 17-OHP. In embodiments, at least

about 30% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 40% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 50% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 60% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 30% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 40% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 50% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 60% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment.

[0201] In an aspect provided herein, is a method of decreasing or reducing androstenedione levels in a subject in need thereof, comprising administering to the subject a compound of structural Formula (I):




or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in androstenedione.In certain embodiments, at least about 60% of the subjects demonstrate reduction in androstenedione.In certain embodiments, at least about 70% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least about 80% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least about 90% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least 100% of the subjects demonstrate reduction in androstenedione. In embodiments, at least about 30% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 40% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 50% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least 60% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 30% of subjects were in the standard or normal range for androstenedione after treatment. In embodiments, at least about 40% of subjects were in the standard or normal range for androstenedione after treatment. In embodiments, at least about 50% of subjects were in the standard or normal range for androstenedione after treatment.


[0202] In certain embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl.

[0203] In certain embodiments, R^3 is Cl, Br, or methyl.

[0204] In certain embodiments, R^4 is Br, R^aR^bN-, pyridin-4-yl, morpholin-4-yl, or




[0205] In certain embodiments, R^4 is morpholin-4-yl or




[0206] In certain embodiments, R^4 is hydrogen, Br, R^aR^bN- and R^a and R^b are independently C_1-C_3alkyl.

[0207] In certain embodiments, the compound is




or a pharmaceutically acceptable salt thereof.

[0208] In certain embodiments, the compound is



or a pharmaceutically acceptable salt thereof.

[0209] In certain embodiments, the compound is



or a pharmaceutically acceptable salt thereof.

[0210] In certain embodiments, a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate thereof is cyclically administered to a patient. Cycling therapy involves the administration of an active agent or a combination of active agents for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment. Prodrugs of the present compounds are not part of the claimed invention.

[0211] In certain embodiments, in the treatment, prevention, or amelioration of one or more symptoms of the disorders, diseases, or conditions described herein (e.g., treatment or prevention of testicular adrenal rest tumors (TART) or treatment or prevention of ovarian adrenal rest tumors (OART)), an appropriate dosage level of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof generally is ranging from about 1 mg to 3000 mg, from about 1 mg to 2000 mg, from about 1 mg to 1000 mg, from about 1 mg to about 500 mg, from about 5 mg to about 500 mg, from about 5 mg to about 400 mg, from about 5 mg to about 300 mg, from about 5 mg to about 250 mg, from about 5 mg to about 200 mg, from about 50 mg to about 200 mg, from about 10 mg to about 400 mg, from about 5 mg to about 25 mg, from about 10 mg to about 25 mg, or from about 25 to about 200 mg, which can be administered in single or multiple doses. In certain embodiments, the compound of Formula (I),

or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg/day.

[0212] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg.

In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg.

[0213] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, or about 1000 mg.

[0214] For oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing from about 1.0 mg to about 1,000 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about

680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 990 mg, about 990 mg, or about 1000 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for the symptomatic adjustment of the dosage to the patient to be treated. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 50 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 200 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.The pharmaceutical compositions can be administered on a regimen of one (1) to four (4) times per day, including once, twice, three times, and four times per day. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered once per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 990 mg, about 990 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered once per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered twice per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about

305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered three times per day.

[0215] In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate thereof is administered for a period of one day. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of two days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of three days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of four days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of five days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of six days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of seven days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of eight days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of nine days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of ten days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 11 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 12 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 13 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 14 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered for a period of 15 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 16 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 17 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 18 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 19 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 20 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 21 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 22 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 23 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 24 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 25 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate,

hydrate, or prodrug thereof is administered over a period of 26 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 27 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 28 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 29 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered for a period of 30 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 31 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 32 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 33 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 34 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 35 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 36 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 37 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 38 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 39 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 40 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 41 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 42 days or more.

[0216] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 14 days.

[0217] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or

prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 140 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 14 days.

[0218] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or

prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 140 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to

at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 14 days.

[0219] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 28 days. In

certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 28 days.

[0220] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a phar-

maceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 28 days.

[0221] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 255 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or

a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 420 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily

for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 42 days.

[0222] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 420 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of

Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 42 days.

[0223] In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, or about 400 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered twice per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, or about 800 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered at least once per day.

[0224] In certain embodiments, from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subj ect.

[0225] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally.

[0226] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is formu-

lated as a capsule or tablet.

[0227] In certain embodiments, from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.


[0228] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 25 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 25 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 10 mg/day to about 400 mg/day is administered to the subject.In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 100 mg/day to about 600 mg/day.

[0229] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fed state. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fasted state. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at least once per day.

[0230] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at bedtime. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 6 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 5 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 4 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 3 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 2 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 1 hour before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 30 minutes before sleep.

[0231] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the evening. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at about 10 pm at night.

[0232] In another aspect is provided a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a pharmaceutical composition, comprising a compound of structural Formula (I): and a pharmaceutically acceptable excipientcomprising with a compound as described herein, including embodiments, or the structural Formulae (I) and a pharmaceutically acceptable excipient:



or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3, and R^4 are as described herein, including embodiments.

[0233] In certain embodiments, the pharmaceutical composition comprises from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0234] In certain embodiments, the pharmaceutical composition comprises about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about

270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg about 500 mg, or about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0235] In certain embodiments, the pharmaceutical composition is administered orally.

[0236] In certain embodiments, the pharmaceutical composition is formulated as a capsule or tablet. In certain embodiments, the capsule or tablet comprises about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, or about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the capsule or tablet comprises about 50 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the capsule or tablet comprises about 200 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0237] In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subj ect.

[0238] In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 25 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 25 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg/day to about 400 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 100 mg/day to about 600 mg/day.

[0239] In certain embodiments, the pharmaceutical composition is administered in the fed state. In certain embodiments, the pharmaceutical composition is administered in the fasted state. In certain embodiments, the pharmaceutical composition is administered at least once per day.

[0240] In certain embodiments, the pharmaceutical composition is administered at bedtime. In certain embodiments, the pharmaceutical composition is administered less than about 6 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 5 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 4 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 3 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 2 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 1 hour before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 30 minutes before sleep.


[0241] In certain embodiments, the pharmaceutical composition is administered in the evening. In certain embodiments, the pharmaceutical composition is administered at about 10 pm at night.

[0242] In certain embodiments, the subject has congenital adrenal hyperplasia (CAH).


[0243] In certain embodiments, the size and/or number of the tumors is decreased or reduced. In certain embodiments, the size of the tumors is decreased or reduced. In certain embodiments, the size of the tumors is decreased or reduced.

[0244] In certain embodiments of the methods disclosed herein, the method further comprises administering to the subject an additional chemotherapeutic agent.


[0245] In certain embodiments, the the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen. In certain embodiments, the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In certain embodiments, the mineralocorticoid is fludrocortisone. In certain embodiments, the additional chemotherapeutic agent is another CRF_1 antagonist. In certain embodiments, the CRF_1 antagonist is:



S SR-126374,



or a pharmaceutically acceptable salt thereof. In certain embodiments, the CRF_1 antagonist is



or a pharmaceutically acceptable salt thereof.

[0246] In certain embodiments of the methods disclosed herein, the method further comprises an additional treatment selected from surgical resection of the tumors and radiation therapy, or a combination thereof. In certain embodiments, the additional therapy is surgical resection and the surgical resection is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In certain embodiments, the surgical resection is prior to administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the surgical resection is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the surgical resection is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0247] In certain embodiments, the additional treatment is radiation therapy and the radiation therapy is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In certain embodiments, the radiation therapy

is prior to administration of the CRF_1 antagonist of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the radiation therapy is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the radiation therapy is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0248] In one embodiment, the pharmaceutical compositions are provided in a dosage form for oral administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers. The pharmaceutical compositions provided herein that are formulated for oral administration may be in tablet, capsule, powder, or liquid form. In some embodiments, a tablet comprises a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil, or synthetic oil. Physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol may be included. In some embodiments, a capsule comprises a solid carrier such as gelatin.

[0249] In another embodiment, the pharmaceutical compositions are provided in a dosage form for parenteral administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers. Where pharmaceutical compositions may be formulated for intravenous, cutaneous or subcutaneous injection, the active ingredient will be in the form of a parenterally acceptable aqueous solution, which is pyrogen-free and has a suitable pH, isotonicity, and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles, such as Sodium Chloride injection, Ringer's injection, or Lactated Ringer's injection. In some embodiments, preservatives, stabilisers, buffers, antioxidants, and/or other additives are included as required.

[0250] In yet another embodiment, the pharmaceutical compositions are provided in a dosage form for topical administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers.

[0251] The pharmaceutical compositions can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-, and programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (*see, Remington: The Science and Practice of Pharmacy,* supra; Modified-Release Drug Delivery Technology, 2nd Edition, Rathbone et al., Eds., Marcel Dekker, Inc.: New York, NY, 2008).

[0252] The pharmaceutical compositions provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete a unit suitable for administration to a human and animal subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carriers or excipients. Examples of a unit-dosage form include an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dosage form. Examples of a multiple-dosage form include a vial, bottle of tablets or capsules, or bottle of pints or gallons.

[0253] The pharmaceutical compositions provided herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.

[0254] In certain embodiments, the pharmaceutical compositions provided herein further comprise one or more chemotherapeutic agents as defined herein.

A. Oral Administration

[0255] The pharmaceutical compositions provided herein for oral administration can be provided in solid, semisolid, or liquid dosage forms for oral administration. As used herein, oral administration also includes buccal, lingual, and sublingual administration. Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.

[0256] Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression.

Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); microcrystalline celluloses, such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corp., Marcus Hook, PA); and mixtures thereof. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The amount of a binder or filler in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.

[0257] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets. The amount of a diluent in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.

[0258] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.

[0259] Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W.R. Grace Co., Baltimore, MD) and CAB-O-SIL® (Cabot Co. of Boston, MA); and mixtures thereof. The pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.

[0260] Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, MA), and asbestos-free talc. Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate. Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol. Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup. Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil. Suitable organic acids include, but are not limited to, citric and tartaric acid. Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.

[0261] It should be understood that many carriers and excipients may serve several functions, even within the same formulation.

[0262] The pharmaceutical compositions provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that

resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach. Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.

[0263] The tablet dosage forms can be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.

[0264] The pharmaceutical compositions provided herein for oral administration can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule (DFC), consists of two sections, one slipping over the other, thus completely enclosing the active ingredient. The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a preservative to prevent the growth of microorganisms. Suitable preservatives are those as described herein, including methyl- and propyl-parabens, and sorbic acid. The liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. The capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient.

[0265] Coloring and flavoring agents can be used in all of the above dosage forms.

[0266] The pharmaceutical compositions provided herein for oral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

B. Parenteral Administration

[0267] The pharmaceutical compositions provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration. Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.

[0268] The pharmaceutical compositions provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (*see, Remington: The Science and Practice of Pharmacy,* supra).

[0269] The pharmaceutical compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.

[0270] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection. Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Suitable water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, *N*'-methy1-2-pyrrolidone, *N,N*-dimethylacetamide, and dimethyl sulfoxide.

[0271] Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl-and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate.

Suitable antioxidants are those as described herein, including bisulfite and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifying agents are those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and sulfobutylether 7-β-cyclodextrin (CAPTISOL®, CyDex, Lenexa, KS).

[0272] When the pharmaceutical compositions provided herein are formulated for multiple dosage administration, the multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungi static concentrations. All parenteral formulations must be sterile, as known and practiced in the art.

[0273] In one embodiment, the pharmaceutical compositions for parenteral administration are provided as ready-to-use sterile solutions. In another embodiment, the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use. In yet another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile suspensions. In yet another embodiment, the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile emulsions.

[0274] The pharmaceutical compositions provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

[0275] The pharmaceutical compositions provided herein for parenteral administration can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot. In one embodiment, the pharmaceutical compositions provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient in the pharmaceutical compositions diffuse through.

[0276] Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutyl-methacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers, such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.

[0277] Suitable outer polymeric membranes include but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.

V. Examples

[0278] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only.


Example 1. A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Compound 1 in Subjects with Testicular Adrenal Rest Tumors

[0279] Testicular adrenal rest tumors (TART) is a common complication in congenital adrenal hyperplasia (CAH) that is caused by adrenocorticotropin hormone (ACTH)-driven overstimulation of aberrant adrenal cells within the testes and results in impaired spermatogenesis and infertility. TARTS can be found anywhere on the testes, though a typical (very common) location is within the mediastinum. This is a particularly problematic location. Because of the central location of TARTs being in the mediastinum, compression of the nearby seminiferous tubules is common and can lead to obstructive azoospermia, irreversible damage to surrounding tissue, and permanent infertility in males.

[0280] Current treatment for TART consists of chronic high-dose glucocorticoids, a problematic therapy with significant side effects and a narrow therapeutic window. Given the serious nature of TART and the limitations and risks of chronic steroid therapy, new treatment modalities are needed for patients with TART. Compound 1, a high-affinity and selective small-molecule antagonist of the corticotropin-releasing factor type-1 (CRF_1) receptor, may be effective in blocking ACTH synthesis, thereby reducing the size of testicular lesions in TART and reducing the need for chronic supraphysiologic doses of glucocorticoids. This mechanism of action has been validated in a previous proof-of-concept study using a

similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-hydroxyprogesterone (17-OHP) in subjects with CAH. Compound 1 has been shown to have an acceptable safety and tolerability profile in nonclinical toxicology studies and in 2 completed Phase 1 clinical studies in healthy volunteers. These promising results provide a rationale for investigating the use of Compound 1 in the treatment of TART, in combination with replacement glucocorticoids and mineralocorticoids.

[0281] The structure of Compound 1 is:



[0282] Building upon the 2 completed Phase 1 studies of Compound 1 in healthy volunteers and the ongoing Phase 2 proof-of-concept study of Compound 1 in subjects with CAH, this Phase 2 will study Compound 1 specifically in male CAH subjects with TART for the first time. A sample size of approximately 12 subjects was selected to provide sufficient data for an initial evaluation of efficacy and safety in subjects with TART while maintaining feasible subject recruitment goals for this rare condition. Given the rarity of the disease and thus the small sample size that can be recruited, this study will be open label, and all enrolled subjects will receive active study drug. Subjects will serve as their own controls in that their outcome measures after 12 weeks of study drug dosing will be compared to their baseline measures.

[0283] The schedule of study visits (every 2 weeks through Week 4, then every 4 weeks for the remainder of the study) provides an appropriate balance between minimizing subject burden and closely monitoring subject safety and response to therapy. The 4-week post-treatment washout period will allow for adequate safety follow-up and analysis of any HPA axis rebound after the last dose of study drug.

[0284] The specification of study drug dosing at 10pm and after consumption of a snack is based on information from the Phase 1 studies in healthy volunteers. The plasma C_{max} (maximum concentration) for Compound 1 in the Phase 1 studies occurred approximately 5 hours after dosing. Therefore, Compound 1 will be dosed daily at 10pm in this study in order to achieve peak plasma study drug concentration at the time of day when most adrenal androgens are produced. Subjects will consume a standardized snack before taking study drug because the Phase 1 studies showed minimal study drug absorption when subjects were dosed in a fasted state. Specific dose reduction criteria, strict individual treatment stopping criteria, and appropriate laboratory and medical assessments have been established to ensure subject safety. **(FIGS. 1A-1B)**

Objectives	Endpoints
Primary	
• To assess the efficacy of Compound 1 in subjects with TART	• Reduction in the size/volume of TART on testicular ultrasound from screening to Week 12
Secondary	
• To evaluate the safety of Compound 1 in subjects with TART	• Adverse events (AEs), serious adverse events (SAEs), AEs leading to withdrawal, AEs of special interest (AESIs) • Physical examination findings • Vital signs • Changes in electrocardiogram (ECG) • Changes in clinical laboratory values
• To assess the pharmacodynamic (PD) biomarker effects of Compound 1	• Changes in plasma concentrations of key PD biomarkers, including ACTH, 17-OHP, testosterone, androstenedione, luteinizing hormone (LH),

(continued)

Secondary	
	follicle-stimulating hormone (FSH), inhibin B, sex hormone-binding globulin (SHBG), renin, and aldosterone from baseline to Week 12
• To assess changes on semen analysis	• Changes in sperm count, morphology, and motility from baseline to Week 12
• To assess changes in metabolism	• Changes in metabolic parameters, including fasting glucose, HbA1c, insulin sensitivity, and lipid profile (including LDL cholesterol, HDL cholesterol, and triglycerides), from baseline to Week 12
	• Changes in body weight, body mass index (BMI), waist circumference, and blood pressure
• To evaluate changes in quality of life (QoL) and mood	• Changes in QoL measured using the Short Form 36 (SF-36)
	• Changes in mood measured using the Hospital Anxiety and Depression Scale (HADS)

Study Population

[0285] Approximately 12 male subjects with TART will be enrolled at approximately 6 investigative sites in the United States, United Kingdom, and possibly other countries. Up to 12 additional subjects may be added to further evaluate specific safety, PD, or efficacy findings.

Eligibility Criteria

Inclusion Criteria

[0286]

- Adult male subjects aged 18 to 30, inclusive
- Documented historical diagnosis of CAH based on documented genetic mutation or historical documentation of elevated 17-OHP
- Diagnosis of TART via testicular ultrasound and/or magnetic resonance imaging (MRI) at screening with ≥1 lesion(s) measuring ≥2 cm in diameter
- On a stable regimen of GC replacement for ≥30 days before baseline
- Agree to follow contraception guidelines and refrain from donating sperm throughout the treatment period and for 90 days after the last dose of study drug
- Subject is able to understand all study procedures and risks involved and provides written informed consent indicating willingness to comply with all aspects of the protocol Exclusion Criteria
- Any clinically significant unstable medical condition, medically significant illness, or chronic disease within 30 days of screening, including but not limited to:
    - o A malignancy or <3 years of remission history from any malignancy, other than successfully treated localized skin cancer
    - o Presence of clinically significant renal disease, as evidenced by an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m^2
    - o Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
    - o Confirmed positive test at screening for active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
- Any clinically significant psychiatric disorders, including any current major depressive episode, bipolar disorder, schizophrenia, schizoaffective disorder, major depressive disorder with psychotic features, or any other psychotic disorder within the preceding 6 months

- HADS score >12 for either depression or anxiety
- At increased risk of suicide on the basis of the Investigator's judgment or the results of the Columbia-Suicide Severity Rating Scale (C-SSRS) conducted at screening and baseline (eg, C-SSRS Type 3, 4, or 5 ideation during the preceding 6 months or any suicidal behavior within the past 12 months)
- Clinically significant and abnormal clinical or laboratory assessments must be discussed with the Medical Monitor to determine eligibility for this study. Abnormal assessments that must be reviewed to determine eligibility include but are not limited to:

    o Clinically meaningful abnormal ECG results, in the opinion of the Investigator
    o Fridericia-corrected QT interval (QTcF) >450 msec
    o Alanine aminotransferase (ALT) >2x upper limit of normal (ULN)
    o Bilirubin >1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)

- A history that includes bilateral adrenalectomy or hypopituitarism
- Use of any other investigational drug within 30 days or 5 half-lives, whichever is longer, before initial screening
- Require use of prohibited concomitant medications, including strong inhibitors and/or inducers of CYP3A4 (with the exception of glucocorticoids, hydrocortisone, and dexamethasone) within 30 days or 5 half-lives (whichever is longer) of first dose of study drug. Medications that are sensitive substrates or substrates with narrow therapeutic ranges (metabolized by CYP3A4, 2C8, 2C9, or 2C19) should be discussed on a case-by-case basis with the Medical Monitor to determine whether the medication should be discontinued or may be continued with caution. If washout is feasible, then the medication should be withdrawn at least 30 days or 5 half-lives (whichever is longer) before the first dose of study drug.
- Donation of blood within 60 days before first dose of study drug, or donation of platelets, white blood cells, or plasma within 15 days before first dose of study drug.

Study Duration

[0287] The expected duration of study participation for each subject is up to approximately 20 weeks. This includes a screening period of ≤4 weeks, a treatment period of 12 weeks, and a safety follow-up period of 4 weeks.

Study Design

[0288] This is a Phase 2, open-label efficacy and safety study of Compound 1 for the treatment of TART. All subjects will receive a daily oral dose of Compound 1 for 12 weeks.In-clinic study visits will occur for screening and at Day 1 (baseline) and Weeks 2, 4, 8, 12 (end of treatment), and 16 (follow-up).

Dose, Route, Regimen

[0289] All subjects will receive a daily oral dose of Compound 1 for 12 weeks. Subjects will receive 600 mg/day during the first 2 weeks and 1000 mg/day during the remaining 10 weeks of the treatment period. Study drug will be taken daily at 10pm (or bedtime, if earlier), 5 to 15 minutes after consumption of a standardized snack.

[0290] On mornings of study visits with 8am blood draws for laboratory assessments, subjects should take their morning glucocorticoid replacement after the blood draws. For all other days during the study, subjects may take their morning glucocorticoid replacement at their usual time (generally between 6am and 8am).

[0291] If a subject experiences a Grade 3 or higher TEAE considered at least possibly related to study drug, the Investigator may reduce the subject's daily dose of Compound 1 down in increments of 200 mg. Study drug will be discontinued in subjects who experience clinically significant liver chemistry, QTcF, or other individual treatment stopping criteria.

Investigational Drug

[0292] Compound 1 is a small-molecule CRF_1 receptor antagonist and will be supplied as 200-mg, size 1, white, hard gelatin capsules.

Example 2.

[0293] Since elevated ACTH is the primary driver for TART growth, blocking ACTH synthesis using Compound 1, a

small-molecule antagonist of the CRF_1 receptor, may be effective in reducing ACTH levels, thereby reducing the size of testicular lesions in TART and reducing the need for chronic supraphysiologic doses of GCs. In CAH, this mechanism of action has been validated in a previous proof-of-concept study using a similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-OHP in subjects with CAH. The safety profile of Compound 1 has been established in nonclinical toxicology studies and in 2 completed Phase 1 clinical studies in healthy volunteers. A Phase 2 study in subjects with CAH is currently ongoing.

Nonclinical Toxicology of Compound 1

[0294] The nonclinical safety profile of Compound 1 has been evaluated in repeat-dose range-finding and definitive toxicology studies of up to 91 days in duration in rats and dogs using the clinically relevant route (oral) and schedule of administration (once daily). In rats and beagle dogs administered oral Compound 1 once daily for 91 consecutive days at doses up to 2000 mg/kg/day, toxicologic findings were all mild and limited to the male reproductive tract, and all Compound 1-related findings were reversible following a 6-week treatment-free recovery period.

[0295] Additionally, a fertility toxicology study was conducted in rats. In this study, male rats were administered oral Compound 1 once daily at 0, 5, 20, or 1000 mg/kg for 85 to 87 days (70 days before mating, during mating, and ≤4 days between mating and necropsy). Male reproductive performance (mean day of mating, mating and fertility indices, and conception rates) was unaffected by Compound 1 treatment. Untreated females mated with the Compound 1-treated males had no ovarian and uterine effects.

[0296] In addition, a complete battery of standard genotoxicity tests consisting of in vitro bacterial reverse mutation and chromosome aberration assays and an in vivo (rat) bone marrow micronucleus assay has been conducted. Exploratory and definitive embryo-fetal development studies in rabbits and a bovine corneal opacity and permeability assay have also been conducted.

Clinical Experience with Compound 1

[0297] To date, a total of 53 subjects, all healthy adults aged 21 to 65 years, have been treated with at least 1 dose of Compound 1 in 2 Phase 1 studies. The first-in-human study of Compound 1 (Study I3C-FW-BLAA) evaluated single ascending doses of 2 mg to 800 mg. In this study, a small number of subjects experienced diarrhea and headache of mild or moderate severity. A subsequent study (Study I3C-FW-BLAB) evaluated repeat doses of 50 mg, 100 mg, or 200 mg Compound 1 once daily for 14 consecutive days. A small number of subjects in the repeat-dose study experienced dyspnea, rhinorrhea, palpitations, and headache. The Phase 1 studies showed no clinically significant alterations in safety laboratory values, vital signs, or electrocardiograms (ECGs). Compound 1 has been well tolerated in healthy human subjects, with no SAEs, AEs leading to discontinuation, or dose-limiting toxicities (DLTs). A maximum tolerated dose has not been reached in humans.

[0298] An ongoing Phase 2 open-label study (Study Compound 2) is currently evaluating the safety and efficacy of Compound 1 dosed once daily for 6 weeks in adults with classic CAH. In the initial Cohort A of this study, all subjects are dosed starting at 200 mg/day for 14 days, escalating for each subject to 600 mg/day for 14 days, then 1000 mg/day for 14 days if the subject experiences no DLTs at the previous dose level. (FIGS. 2-3).

Known Potential Risks

[0299] Because the reversible testicular effects (degeneration/atrophy) observed in rats and dogs treated with high-dose Compound 1 (2,000 mg/kg/day) are likely associated with on-target (mechanism-driven) effects, these effects are likely to be relevant to human risk. However, male reproductive studies in rodents showed no impairment in fertility at the highest dose tested (1,000 mg/kg/day). Additionally, there were no effects on clinical laboratory markers of testicular function (LH and FSH) when Compound 1 was administered to healthy male volunteers at doses up to 200 mg per day for 14 consecutive days. Clinical laboratory measures of testicular function (LH, FSH, inhibin B, and SHBG) will be assessed throughout this study to monitor the risk of testicular injury. Testicular ultrasounds and semen analysis will also be performed at screening/baseline and the end of the treatment period.

[0300] Laboratory abnormalities in liver function tests (LFTs) have been observed at significantly higher doses in nonclinical studies. However, these events were not observed in the Phase 1 clinical studies. Clinical laboratory measures of liver chemistry will be assessed throughout this study, and strict individual treatment stopping criteria for liver chemistry findings are in place.

[0301] Compound 1-induced effects on the thyroid gland were noted in dogs after 91 days of high-dose (2,000 mg/kg/day) treatment but not in any other nonclinical studies. Clinical pathology parameters of thyroid function (eg, T4, T3, thyroid-stimulating hormone [TSH]) were not evaluated in the Phase 1 studies but will be monitored throughout this study.

Known Potential Benefits

[0302] Early clinical studies suggests that Compound 1 is effective as a CRF_1 receptor antagonist, a mechanism of action that supports the clinical investigation of Compound 1 for treatment of TART. In CAH, this mechanism of action has been validated in a previous proof-of-concept study using a similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-OHP in subjects with CAH.

Assessment of Potential Risks and Benefits

[0303] The mild and reversible toxicologic effects of Compound 1 on the male reproductive tract in nonclinical studies occurred in the context of animals with normal, rather than elevated, baseline hormone function. As a CRF_1 receptor antagonist, Compound 1 is intended to reduce abnormally elevated ACTH levels, which in TART drives overstimulation of aberrant adrenal cells within the testes. In nonclinical models where baseline hormone levels are within normal ranges, clinical benefits are not expected, and indeed, toxicities may be expected as a result of androgen reduction outside of the normal range. In TART, where baseline ACTH and androgen levels are pathologically elevated, androgen reduction would be considered a positive, therapeutic effect.

[0304] Given the serious nature of TART and the limitations (and risks) of chronic steroid therapy, new treatment modalities are needed for patients with TART. Given the acceptable safety and tolerability profile of Compound 1 in healthy volunteers from the Phase 1 program, the low probability of demonstrating meaningful PD marker changes in healthy subjects, and the lack of any clear benefit to exposing more healthy subjects to study drug, the Sponsor believes the benefit-to-risk profile favors the entry of Compound 1 into Phase 2 in subjects with TART.

Example 3. Congenital Andrenal Hyperplasia (CAH)

[0305] CAH results from a genetic defect in the 21-hydroxylase enzyme. CAH patients are thus unable to produce cortisol. Without cortisol to provide negative feedback, patients over-produce ACTH. High ACTH promotes the overproduction of potent androgens (male sex hormones). Without wishing to be bound by theory, Compound 1 blocks CRF_1 receptor to prevent ACTH release by the pituitary and associated drive on the hypothalamic-pituitary-adrenal axis. Replacement of cortisol to physiological levels will correct cortisol deficiency, however, will not lower ACTH, resulting in hyperplasia of adrenal gland and associated overproduction of adrenal androgens.

[0306] As shown in **FIGS. *4*** and **5A-5B,** the attenuation of ACTH demonstrates target engagement and functional CRF_1 receptor antagonism. 80% of subjects demonstrated reduction in ACTH. 70% of subjects demonstrated > 25% reduction in ACTH. 30% of subjects were in the normal range (*) after treatment with a CRF_1 receptor antagonist.

[0307] **FIGS. *6*** and **7A-7B** demonstrate "control" of disease based on standard guidelines, which would then allow steroid taper. 80% of subjects demonstrated reduction in 17-OHP. 50% of subjects demonstrated > 25% reduction in ACTH. 50% of subjects were in the guideline range (*; 1200 ng/dL) after treatment with a CRF_1 receptor antagonist.

[0308] **FIGS. *8*** and **9A-9B** demonstrate attenuation of morning rise in A4 upon treatment with a CRF1 antagonist, indicative of its ability to control excess andreogen production and associated symptoms. 100% of subjects demonstrated reduction in androstenedione (at various doses). 60% of subjects demonstrated > 25% reduction in androstenedione. 50% of subjects were within the normal reference range after treatment with a CRF_1 receptor antagonist.

[0309] ***FIGS. 10A-10B*** show approximately 25% shrinkage in TART in a 25 year old male with classic congenital adrenal hyperplasia following 6 weeks treatment with a CRF_1 receptor antagonist.

[0310] ***FIGS. 11A-11B*** demonstrate Compound 1 is a potent, selective, and functional CRF_1 receptor antagonist. In in vitro and ex vivo studies, Compound 1 was determined to be a potent and selective CRF_1 receptor antagonist with high affinity and selective for the $hCRF_1$ receptor. Compound 1 was found to have functional potency to inhibit adenylate cyclase activity (CRF_1 receptor-mediated downstream cascade), demonstrating in vitro efficacy as a CRF_1 receptor antagonist. Compound 1 was found to significantly inhibit CRF-induced locomotor behavior in response to i.c.v. administration of CRF (**FIG. 11B**).

[0311] ***FIGS. 12A-12B*** demonstrate single pill of CRF_1 receptor antagonist improves ACTH and 17-OHP in CAH patients.

[0312] ***FIG. 13*** shows the subject level hormone changes (ACTH, 17-OHP, and androstenedione) by dose of a CRF_1 receptor antagonist.

Example 4. Assess reduction in excess ACTH and adrenal steroid production

[0313] The objectives of the study are: to assess the ability of Compound 1 to reduce excess ACTH and adrenal steroid production in participants with classic CAH on a stable gluococorticoid regimen; to evaluate the safety and tolerability of tildacerfont in participants with classic CAH; and to evaluate the pharmacokinetics (PK) of tildacerfont.

ELIGIBILITY CRITERIA

[0314] Inclusion Criteria:

- Adult males and females 18 years or older
- Diagnosis of classic CAH due to 21-hydroxylase deficiency
- Morning 17OHP ≥800 ng/dL, before taking any morning GC dose
- On a stable regimen of gluococorticoid replacement for ≥30 days before enrollment

[0315] Exclusion Criteria:

- Clinically significant unstable medical condition, illness, or chronic disease within 30 days of screening
- Clinically significant psychiatric disorder
- History of bilateral adrenalectomy or hypopituitarism

STUDY DESIGN

[0316] FIG. 14 depicts the proof of concept and escalating QD dosing at 10 PM for Cohort A and the single dose level and BID dosing at 10 AM and 10 pm for Cohort B.

BASELINE CHARACTERISTICS

[0317] Table 1 provides a description of the baseline characteristics displayed by Cohort A and Cohort B. In Cohort A, 10 partcipants were enrolled and received at least 1 dose of Compound 1. One participant withdrew early because of an occupation-related scheduling conflict. In Cohort B, 9 participants were enrolled and received at least one dose of Compound 1. One participant was withdrawn upon discovery of a major protocol violation at Baseline and did not have postbaseline efficacy/PK data. Thus, baseline characteristics are calculated for n=8 in Cohort B. One participant in Cohort B was taking both HC and prednisone.

Table - 1 Baseline characteristics of each cohort

Parameter		Cohort A (n=10)	Cohort B (n=8)
Demographics			
	Age (years), mean (range)	39.3 (24-66)	36.8 (19-66)
	Sex	5M, 5F	1M, 7F
	Bmi (kg/m^2), mean ± SD	31.5 ± 12.0	31.1 ± 6.7
Daily GC dose (mg HC equivalents), mean range		28 (13-40)	35 (20-50)
Types of GCs		4 JC, 3 pred, 3 dex	2HC, 4 pred, 3 dex
17OHP at screening[a] (ng/dl), mean ± SD		5,985 ± 6,347	4,592 ±4,624
Abbreviations: 17OHP: 17-hydroxyprogesterone; BMI: body mass index; dex: dexamethasone; F: female; GC: glucocorticoid; HC: hydrocortisone; M: male; pred: prednisone; SD: standard deviation a 17OHP reference ranges: 27-199 ng/dL males, 15-290 ng/dL females.			

SAFETY

[0318] Across both cohorts, Compound 1 was generally well tolerated. The most common type of adverse event (AE) was gastrointestinal disorders There were no serious AEs and no AEs leading to withdrawal.

PHARMACOKINETICS

[0319] Over a wide range of doses (200 to 1000 mg QD), Compound 1 exhibited a predictable, dose-dependent PK profile.

EFFICACY

[0320] ***FIG.*** **15A-15D** show the changes in levels of Androstenedione (A4) across both cohorts. Levels of A4 improved at ≥1 dose level for 10 out of 10 participants in Cohort A and 6 out of 8 participants in Cohort B. Excess A4 is associated with clinical sequelae in CAH. Attenuation of A4 demonstrates control of adrenal androgen.

[0321] **FIG. 16A-16D** show the changes in levels of 17-hydroxyprogesterone (17-OHP) across both cohorts. Levels of 17OHP improved at ≥1 dose level for 8 out of 10 participants in Cohort A and 6 out of 7 participants in Cohort B. 17OHP is a critical hormone in CAH diagnosis and management. Attenuation of 17OHP demonstrates control of adrenal steroid production.

[0322] **FIG. 17A-17D** show the changes in levels of adrenocorticotropic hormone (ACTH) across both cohorts. Levels of ACTH improved at ≥1 dose level for 8 out of 10 participants in Cohort A and 5 out of 7 participants in Cohort B. Attenuation of ACTH demonstrates target engagement and fucntional CRF_1 receptor antagonism.

Table 2 - Percentage change from baseline in ACTH, 17OHP *and A4.*

	Cohort A			Cohort B
	200 mg QD (Week 2)	600 mg QD (Week 4)	1000 mg QD (Week 6)	200 mg BID (Weed 2)
ACTH	-25.7 (±51.6)	-60.1 (±37.5)	-32.7 (±47.0)	-36.5 (±58.0)
17OHP	+22.2 (±172.3)	-23.7 (±64.2)	-13.8 (±74.7)	-47.8 (±63.3)
A4	-12.1 (±47.4)	-33.2 (±36.5)	-28.6 (±44.6)	-16.0 (±81.4)

CONCLUSIONS

[0323] Compound 1, a potent and selective CRF_1 receptor antagonist, offers a novel nonsteroidal oral treatment approach for CAH. Compound 1 was well tolerated and efficacious in reducing excess ACTH, 17OHP, and androstenedione in patients with classic CAH. Compound 1 exhibited a predictable, dose-dependent PK profile suitable for the target population.


Claims

1. A corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART) in a subject in need thereof.

2. The CRF_1 antagonist for use according to claim 1, wherein the subject has congenital adrenal hyperplasia (CAH).

3. The CRF_1 antagonist for use according to claim 1, wherein the treatment is a reduction in the size and/or the number of the tumors.


4. The CRF_1 antagonist for use according to claim 1, wherein the CRF_1 antagonist comprises a compound having structural Formula (I):



(I),

or a pharmaceutically acceptable salt thereof,
wherein:


R^1 and R^2 are independently ethyl or n-propyl;
R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and
R^4 is hydrogen, Br, R^aR^bN-, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,




R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$-, $(CH_3)_3COC(O)NHCH_2CH_2$-, or $CH_3CH_2CH_2NHCH_2CH_2$-.

5. The CRF_1 antagonist for use according to claim 4, wherein R^3 is Cl, Br, or methyl.

6. The CRF_1 antagonist for use according to claim 4, wherein R^4 is Br, R^aR^bN-, pyridin-4-yl, morpholin-4-yl, or




7. The CRF_1 antagonist for use according to claim 4, wherein R^4 is morpholin-4-yl or



8. The CRF_1 antagonist for use according to claim 4, wherein R^4 is hydrogen, Br, R^aR^bN- and R^a and R^b are independently C_1-C_3alkyl.

9. The CRF_1 antagonist for use according to claim 4, wherein the compound is



or a pharmaceutically acceptable salt thereof.

10. The CRF_1 antagonist for use according to claim 1, wherein a dosage regime of the CRF_1 antagonist, or a pharmaceutically acceptable salt thereof, is about 5 mg/day to about 400 mg/day to the subject.

11. The CRF_1 antagonist or a pharmaceutically acceptable salt thereof for use according to claim 1, for use in oral administration.

12. The CRF_1 antagonist for use according to claim 1, wherein the CRF_1 antagonist, or a pharmaceutically acceptable salt thereof, is formulated as a capsule or tablet.

13. The CRF_1 antagonist of claim 1 and an additional chemotherapeutic agent, for use in the treatment or prevention of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART) in a subject in need thereof, wherein

the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen.

14. The CRF_1 antagonist and the additional chemotherapeutic agent for use according to claim 13, wherein the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone.

15. The CRF_1 antagonist for use according to claim 4, wherein R^3 is Cl, Br, methyl, or trifluoromethyl.


Patentansprüche

1. Corticotropin-releasing-Faktor-Typ-1 (CRF_1)-Antagonist oder ein pharmazeutisch verträgliches Salz davon zur Verwendung bei der Behandlung oder Vorbeugung von testikulären adrenalen Resttumoren (TART) oder ovariellen adrenalen Resttumoren (OART) bei einem Subjekt, das dessen bedarf.

2. CRF_1-Antagonist zur Verwendung nach Anspruch 1, wobei der Patient eine kongenitale Nebennierenhyperplasie (CAH) hat.

3. CRF_1-Antagonist zur Verwendung nach Anspruch 1, wobei die Behandlung in einer Verringerung der Größe und/oder der Anzahl der Tumore besteht.


4. CRF_1-Antagonist zur Verwendung nach Anspruch 1, wobei der CRF_1-Antagonist eine Verbindung 10 mit der Strukturformel (I) umfasst:



(I)

oder ein pharmazeutisch verträgliches Salz davon, wobei:

R^1 und R^2 unabhängig voneinander Ethyl oder n-Propyl sind;
R^3 Wasserstoff, Cl, Br, Methyl, Trifluormethyl oder Methoxy ist; und
R^4 Wasserstoff, Br, R^aR^bN-, Methoxymethyl, n-Butyl, Acetamido, Pyridin-4-yl, Morpholin-4-yl,




oder ;


ist
R^a und R^b unabhängig voneinander Wasserstoff, C_1-C_3-Alkyl, $H_2NCH_2CH_2$-, $(CH_3)_3COC(O)NHCH_2CH_2$- oder $CH_3CH_2CH_2NHCH_2CH_2$- sind.

5. CRF_1-Antagonist zur Verwendung nach Anspruch 4, wobei R^3 Cl, Br oder Methyl ist.

6. CRF_1-Antagonist zur Verwendung nach Anspruch 4, wobei R^4 Br, R^aR^bN-, Pyridin-4-yl, Morpholin-4-yl oder Folgendes ist:




7. CRF_1-Antagonist zur Verwendung nach Anspruch 4, wobei R^4 Morpholin-4-yl oder Folgendes ist:



8. CRF_1-Antagonist zur Verwendung nach Anspruch 4, wobei R^4 Wasserstoff, Br, R^aR^bN-ist und R^a und R^b unabhängig voneinander C_1-C_3-Alkyl sind.

9. CRF_1-Antagonist zur Verwendung nach Anspruch 4, wobei die Verbindung



oder ein pharmazeutisch verträgliches Salz davon ist.

10. CRF_1-Antagonist zur Verwendung nach Anspruch 1, wobei das Dosierungsschema des CRF_1-Antagonisten oder eines pharmazeutisch verträglichen Salzes davon etwa 5 mg/Tag bis etwa 400 mg/Tag für das Subjekt beträgt.

11. CRF_1-Antagonist oder ein pharmazeutisch verträgliches Salz davon zur Verwendung nach Anspruch 1 zur Verwendung bei oraler Verabreichung.

12. CRF_1-Antagonist zur Verwendung nach Anspruch 1, wobei der CRF_1-Antagonist oder ein pharmazeutisch verträgliches Salz davon als Kapsel oder Tablette formuliert ist.

13. CRF_1-Antagonist nach Anspruch 1 und zusätzliches chemotherapeutisches Mittel zur Verwendung bei der Behandlung oder Vorbeugung von testikulären adrenalen Resttumoren (TART) oder ovariellen adrenalen Resttumoren (OART) bei einem Subjekt, das dessen bedarf, wobei das zusätzliche chemotherapeutische Mittel ein Glucocorticoid, ein Mineralocorticoid, ein ACAT 1-Inhibitor oder ein Antiandrogen ist.

14. CRF_1-Antagonist und zusätzliches chemotherapeutisches Mittel zur Verwendung nach Anspruch 13, wobei das Glucocorticoid Beclomethason, Betamethason, Budesonid, Cortison, Dexamethason, Hydrocortison, Methylprednisolon, Prednisolon, Prednison oder Triamcinolon ist.

15. CRF_1-Antagonist zur Verwendung nach Anspruch 4, wobei R^3 Cl, Br, Methyl oder Trifluormethyl ist.

Revendications


1. Un antagoniste du facteur de libération de corticotropine de type 1 (CRF_1) ou un sel pharmaceutiquement acceptable de celui-ci, destiné à être utilisé dans le traitement ou la prévention des tumeurs surrénaliennes testiculaires au repos (TART) ou des tumeurs surrénaliennes ovariennes au repos (OART) chez un sujet qui le nécessite

2. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 1, dans lequel le sujet présente une hyperplasie

congénitale des surrénales (CAH).

3. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 1, dans lequel le traitement consiste en une réduction de la taille et/ou du nombre des tumeurs.


4. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 1, **caractérisé en ce que** l'antagoniste du CRF_1 comprend un composé 10 répondant à la formule structurale (I) :



(I),

ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel :

R^1 et R^2 représentent indépendamment un éthyle ou un n-propyle ;
R^3 représente un hydrogène, Cl, Br, méthyle, trifluorométhyle ou méthoxy ; et
R^4 représente un hydrogène, Br, R^aR^bN-, méthoxyméthyle, n-butyle, acétamido, pyridine-4-yle, morpholine-4-yle,




ou ;


R^a et R^b représentent indépendamment un hydrogène, un alkyle en C_1-C_3, $H_2NCH_2CH_2$-, $(CH_3)_3COC(O)NHCH_2CH_2$-, ou $CH_3CH_2CH_2NHCH_2CH_2$-.

5. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 4, dans lequel R^3 représente un Cl, Br ou méthyle.

6. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 4, dans lequel R^4 représente un Br, R^aR^bN-, pyridine-4-yle, morpholine-4-yle, ou




7. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 4, dans lequel R^4 est un morpholine-4-yle ou



8. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 4, dans lequel R^4 représente un hydrogène, Br, R^aR^bN- et R^a ainsi que R^b sont indépendamment un alkyle en C_1-C_3.

9. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 4, dans lequel le composé est



ou un sel pharmaceutiquement acceptable de celui-ci.

10. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 1, dans lequel un schéma posologique de l'antagoniste du CRF_1, ou d'un sel pharmaceutiquement acceptable de celui-ci, est d'environ 5 à 400 mg/jour pour le sujet.

11. L'antagoniste du CRF_1 ou un sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé selon la revendication 1, pour une utilisation en administration orale

12. L'antagoniste du CRF_1 destiné à être utilisé selon la revendication 1, dans lequel l'antagoniste du CRF_1, ou un sel pharmaceutiquement acceptable de celui-ci, est formulé sous forme de capsule ou de comprimé.

13. L'antagoniste du CRF_1 de la revendication 1 et un agent chimiothérapeutique supplémentaire, destinés à être utilisés dans le traitement ou la prévention des tumeurs surrénaliennes testiculaires au repos (TART) ou des tumeurs surrénaliennes ovariennes au repos (OART) chez un sujet le nécessitant, l'agent chimiothérapeutique supplémentaire étant un glucocorticoïde, un minéralocorticoïde, un inhibiteur de l'ACAT1 ou un antiandrogène.

14. L'antagoniste du CRF_1 et l'agent chimiothérapeutique supplémentaire destinés à être utilisés selon la revendication 13, dans lesquels le glucocorticoïde est la béclométhasone, la bétaméthasone, le budésonide, la cortisone, la dexaméthasone, l'hydrocortisone, la méthylprednisolone, la prednisone ou la triamcinolone

15. L'antagoniste du CRF1 destiné à être utilisé selon la revendication 4, dans lequel R^3 représente un Cl, Br, méthyle ou trifluorométhyle.



Baseline (AM) & PK/PD (Overnight)
PK/PD (Overnight)
PK/PD (Overnight)
PK/PD (Overnight)
Washout / Follow-Up (AM)
Cohort A: Open Label
Strength 1
Strength 2
Strength 3
14 Days
14 Days
14 Days
30 days

FIG. 1A



SPR001
Inhibits CRF1 receptor to reduce ACTH
ACTH
17 OHP
21 Hydroxylase Deficiency
Aldosterone
Cortisol
Androgens

FIG. 1B



Treatment
200 mg single-dose, Day 1
200 mg Q24h Day 14
600 mg Q24h Day 28
1000 mg Q24h Day 42
Mean SPR001 Concentration (ng/mL)
0
300
600
900
0
2
4
6
8
10
Time from Dose (hr)

FIG. 2



Concentration (ng/mL)
300
200
100
0
0
2
4
6
8
10
12
14
Time after first dose (days)
100 mg bid
200 mg bid
300 mg bid
200 mg qd
600 mg qd

FIG. 3



ACTH
% Change from Baseline
100
50
0
-50
-100
004-001
006-003
005-003
005-002
007-001
005-001
004-004
007-002
006-004
003-001

FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B

In Vitro Binding Assay




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13

ACTH: 7.2-63.3 pg/mL 17-OHP: <1200 ng/dL A4: 41-262 ng/dL (M) 27-152 ng/dL (F)




FIG. 13 (Cont.)

ACTH: 7.2-63.3 pg/mL 17-OHP: <1200 ng/dL A4: 41-262 ng/dL (M) 27-152 ng/dL (F)



Cohort A: Proof of concept, escalating QD dosing at 10 PM
(n=10 enrolled)
Baseline PD (Overnight);
Day 1 PK/PD (Overnight)
Week 2 PK/PD
(Overnight)
Week 4 PK/PD
(Overnight)
Week 6 PK/PD
(Overnight)
Follow-up
(Outpatient)
200 mg QD
600 mg QD
1000 mg QD
14 days
14 days
14 days
30 days
Cohort B: Single dose level, BID dosing at 10 AM and 10 PM
(n=9 enrolled)
Baseline PD
(Overnight)
Outpatient
Week 2 PK/PD
(Overnight)
Follow-up
(Outpatient)
200 mg BID
14 days
30 days

FIG. 14




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 62663951 **[0001]**
- US 62822815 **[0001]**
- US 4911920 A **[0119]**
- US 5403841 A **[0119]**
- US 5212162 A **[0119]**
- US 4861760 A **[0119]**
- WO 9722596 A **[0129]**
- WO 9730035 A **[0129]**
- WO 9732856 A **[0129]**
- WO 9813354 A **[0129]**
- WO 9902166 A **[0129]**
- WO 0040529 A **[0129]**
- WO 0041669 A **[0129]**
- WO 0192224 A **[0129]**
- WO 0204434 A **[0129]**
- WO 0208213 A **[0129]**
- US 4328245 A **[0264]**
- US 4409239 A **[0264]**
- US 4410545 A **[0264]**

Non-patent literature cited in the description

- Ovarian Adrenal Rest Tumors Undetected by Imaging Studies and Identified at Surgery in Three Females with Congenital Adrenal Hyperplasia Unresponsive to Increased Hormone Therapy Dosage. **CHEN HUA-DONG et al.** ENDOCRINE PATHOLOGY. HUMANA PRESS, 28 December 2016, vol. 28, 146-151 **[0004]**
- **BERGE et al.** Pharmaceutical Salts. *Journal of Pharmaceutical Science,* 1977, vol. 66, 1-19 **[0079]**
- **LIEBERMAN.** *Pharmaceutical Dosage Forms,* 1992, vol. 1-3 **[0111]**
- **LLOYD.** *The Art, Science and Technology of Pharmaceutical Compounding,* 1999 **[0111]**
- **PICKAR.** *Dosage Calculations,* 1999 **[0111]**
- Remington: The Science and Practice of Pharmacy. Lippincott, Williams & Wilkins, 2003 **[0111]**
- **RAO.** *J. Biomater Sci. Polym. Ed.,* 1995, vol. 7, 623-645 **[0119]**
- *Gao Pharm. Res.,* 1995, vol. 12, 857-863 **[0119]**
- **EYLES.** *J. Pharm. Pharmacol.,* 1997, vol. 49, 669-674 **[0119]**
- **AL-MUHAMMED.** *J. Microencapsul.,* 1996, vol. 13, 293-306 **[0119]**
- **CHONN.** *Curr. Opin. Biotechnol.,* 1995, vol. 6, 698-708 **[0119]**
- **OSTRO.** *Am. J. Hosp. Pharm.,* 1989, vol. 46, 1576-1587 **[0119]**
- **MUNSEN et al.** *Analyt. Biochem.,* 1980, vol. 107, 220-239 **[0149]**
- **FISHMAN et al.** Medicine. J.B. Lippincott Co, 1985 **[0189]**
- **PHILADELPHIA ; MURPHY et al.** Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery. Viking Penguin, Penguin Books U.S.A., Inc, 1997 **[0189]**
- Physicians' Desk Reference. 2002, 1755-1760 **[0191]**
- Modified-Release Drug Delivery Technology. Marcel Dekker, Inc, 2008 **[0251]**

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 487/04, A61K 31/495 | A1

(11) International Publication Number: **WO 97/29109**

(43) International Publication Date: 14 August 1997 (14.08.97)

(21) International Application Number: PCT/EP97/00459

(22) International Filing Date: 30 January 1997 (30.01.97)

(30) Priority Data:

60/011,279	7 February 1996 (07.02.96)	US
60/027,688	8 October 1996 (08.10.96)	US

(71) Applicants *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). NEUROCRINE BIOSCIENCES INC. [US/US]; 3050 Science Park Road, San Diego, CA 92121-1102 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: CHEN, Chen [CN/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US). WEBB, Thomas, R. [US/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US). McCARTHY, James, R. [US/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US). MORAN, Terence, J. [US/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US). WILCOXEN, Keith, M. [US/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US).


(74) Agent: WANTE, Dirk; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS

(57) Abstract



(I)

This invention concerns compounds of formula (I), including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R^1 is NR^4R^5 or OR^5; R^2 is C_{1-6}alkyl, C_{1-6}alkyloxy or C_{1-6}alkylthio; R^3 is hydrogen, C_{1-6}alkyl, C_{1-6}alkylsulfonyl, C_{1-6}alkylsulfoxy or C_{1-6}alkylthio; R^4 is hydrogen, C_{1-6}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, C_{3-6}cycloalkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl; R^5 is C_{1-8}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, Ar^1CH_2, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{3-6}alkenyl, thienylmethyl, furanylmethyl, C_{1-6}alkylthioC_{1-6}alkyl, morpholinyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylC_{1-6}alkyl, C_{1-6}alkyl substituted with imidazolyl; or a radical of the formula -Alk-O-CO-Ar^1; or R^4 and R^5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	**GB**	United Kingdom	**MW**	Malawi
AT	Austria	**GE**	Georgia	**MX**	Mexico
AU	Australia	**GN**	Guinea	**NE**	Niger
BB	Barbados	**GR**	Greece	**NL**	Netherlands
BE	Belgium	**HU**	Hungary	**NO**	Norway
BF	Burkina Faso	**IE**	Ireland	**NZ**	New Zealand
BG	Bulgaria	**IT**	Italy	**PL**	Poland
BJ	Benin	**JP**	Japan	**PT**	Portugal
BR	Brazil	**KE**	Kenya	**RO**	Romania
BY	Belarus	**KG**	Kyrgystan	**RU**	Russian Federation
CA	Canada	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CF	Central African Republic			**SE**	Sweden
CG	Congo	**KR**	Republic of Korea	**SG**	Singapore
CH	Switzerland	**KZ**	Kazakhstan	**SI**	Slovenia
CI	Côte d'Ivoire	**LI**	Liechtenstein	**SK**	Slovakia
CM	Cameroon	**LK**	Sri Lanka	**SN**	Senegal
CN	China	**LR**	Liberia	**SZ**	Swaziland
CS	Czechoslovakia	**LT**	Lithuania	**TD**	Chad
CZ	Czech Republic	**LU**	Luxembourg	**TG**	Togo
DE	Germany	**LV**	Latvia	**TJ**	Tajikistan
DK	Denmark	**MC**	Monaco	**TT**	Trinidad and Tobago
EE	Estonia	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**UG**	Uganda
FI	Finland	**ML**	Mali	**US**	United States of America
FR	France	**MN**	Mongolia	**UZ**	Uzbekistan
GA	Gabon	**MR**	Mauritania	**VN**	Viet Nam

PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS

Background of the invention

This invention relates to pyrazolopyrimidines which possess CRF receptor antagonistic properties, to pharmaceutical compositions containing these compounds as active ingredient, and the use thereof in the treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders in general.

The first corticotropin-releasing factor (CRF) was isolated from ovine hypothalmi and identified as a 41-amino acid peptide (Vale et al., *Science* 213:1394-1397, 1981). Subsequently, sequences of human and rat CRF were isolated and determined to be identical, but different from ovine CRF in 7 of the 41 amino acid residues (Rivier et al., *Proc. Natl. Acad. Sci. USA* 80:4851, 1983; Shibahara et al., *EMBO J.* 2:775, 1983). CRF has been found to produce profound alterations in endocrine, nervous and immune system functions. CRF is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotropic hormone ("ACTH"), β-endorphin, and other pro-opiomelanocortin ("POMC")-derived peptides from the anterior pituitary (Vale et al., *Science* 213:1394-1397, 1981). Briefly, CRF is believed to initiate its biological effects by binding to a plasma membrane receptor which has been found to be distributed throughout the brain (DeSouza et al., *Science* 221:1449-1451, 1984), pituitary (DeSouza et al., *Methods Enzymol. 124:560,* 1986; Wynn et al., *Biochem. Biophys. Res. Comm. 110:602-608,* 1983). adrenals (Udelsman et al., *Nature* 319:147-150, 1986) and spleen (Webster, E.L., and E.B. DeSouza, *Endocrinology* 122:609-617, 1988). The CRF receptor is coupled to a GTP-binding protein (Perrin et al., *Endocrinology* 118: 1171- 1179, 1986) which mediates CRF-stimulated increase in intracellular production of cAMP (Bilezikjian, L.M., and W.W. Vale, *Endocrinology 113:657-662,* 1983).

In addition to its role in stimulating the production of ACTH and POMC, CRF is also believed to coordinate many of the endocrine autonomic, and behavioral responses to stress, and may be involved in the pathophysiology of affective disorders. Moreover, CRF is believed to be a key intermediary in communication between the immune, central nervous, endocrine and cardiovascular systems (Crofford et al., J. *Clin. Invest.* 90:2555-2564, 1992; Sapolsky et al., *Science* 238:522-524, 1987; Tilders et al., *Regul. Peptides* 5:77-84, 1982). Overall, CRF appears to be one of the pivotal central nervous system neurotransmitters and plays a crucial role in integrating the body's overall response to stress.

Administration of CRF directly to the brain elicits behavioral, physiological, and endocrine responses identical to those observed for an animal exposed to a stressful environment. For example, intracerebroventricular injection of CRF results in behavioral activation (Sutton et al., *Nature* 297:331, 1982), persistent activation of the electroencephalogram (Ehlers et al., *Brain Res.* 2/8332, 1983), stimulation of the sympathoadrenomedullary pathway (Brown et al., *Endocrinology 110:928,* 1982), an increase of heart rate and blood pressure (Fisher et al., *Endocrinology 110:2222,* 1982), an increase in oxygen consumption (Brown et al., *Life Sciences* 30:207, 1982), alteration of gastrointestinal activity (Williams et al., *Am. J. Physiol.* 253:G582, 1987), suppression of food consumption (Levine et al., *Neuropharmacology* 22:337, 1983), modification of sexual behavior (Sirinathsinghji et al., *Nature* 305:232, 1983), and immune function compromise (Irwin et al., *Am. J. Physiol.* 255:R744, 1988). Furthermore, clinical data suggest that CRF may be hypersecreted in the brain in depression, anxiety-related disorders, and anorexia nervosa. (DeSouza, *Ann. Reports in Med. Chem.* 25:215-223, 1990).


Accordingly, clinical data suggest that CRF receptor antagonists may represent novel antidepressant and/or anxiolytic drugs that may be useful in the treatment of the neuropsychiatric disorders manifesting hypersecretion of CRF.

CRF receptor antagonists have been reported in for example, U.S. Patent No. 5,063,245 disclosing substituted 4-thio-5-oxo-3-pyrazoline derivatives and Australian Patent No. AU-A-41399/93, disclosing substituted 2-aminothiazole derivatives. WO-92/18504 and JP-32/04877 disclose pyrazolo[1,5-a]pyrimidines as antiinflammatory agents. Also, WO-94/13676, WO-94/13677 and WO-95/33750 disclose pyrrolopyrimidines, pyrazolo[3,4-d]pyrimidines and substituted purines as CRF receptor antagonists. Arylpyrazolo[1,5-a]pyrimidines have been described as xanthine oxidase inhibitors (Robins et al., *J. Heterocyclic Chem.* 22:601-634, 1985). JP-42/011,753 discloses 7-methylamino-pyrazolo[1,5-a]pyrimidine derivatives useful as sedative and antiphlogistic agents. And JP-61/057,587 discloses pyrazolo[1,5-a]pyrimidine derivatives useful as antiulcer agents.

Due to the physiological significance of CRF, the development of further biologically active small molecules having significant CRF receptor binding activity and which are capable of antagonizing the CRF receptor remains a desirable goal. Such CRF receptor antagonists would be useful in the treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders in general.

Description of the invention

This invention concerns CRF antagonistic compounds of formula (I)



(I),

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein

R^1 is NR^4R^5 or OR^5;

R^2 is C_{1-6}alkyl, C_{1-6}alkyloxy or C_{1-6}alkylthio;

R^3 is hydrogen, C_{1-6}alkyl, C_{1-6}alkylsulfonyl, C_{1-6}alkylsulfoxy or C_{1-6}alkylthio;

R^4 is hydrogen, C_{1-6}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, C_{3-6}cycloalkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl;

R^5 is C_{1-8}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, Ar^1CH_2, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{3-6}alkenyl, thienylmethyl, furanylmethyl, C_{1-6}alkylthioC_{1-6}alkyl, morpholinyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylC_{1-6}alkyl, C_{1-6}alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar^1;

or R^4 and R^5 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl; and

Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6}alkyl, trifluoromethyl, hydroxy, cyano, C_{1-6}alkyloxy, benzyloxy, C_{1-6}alkylthio, nitro, amino and mono- or di(C_{1-6}alkyl)amino; pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6}alkyl, trifluoromethyl, hydroxy, cyano, C_{1-6}alkyloxy, benzyloxy, C_{1-6}alkylthio, nitro, amino, mono- or di(C_{1-6}alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;

Ar^1 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C_{1-6}alkyl, C_{1-6}alkyloxy, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, trifluoromethyl and C_{1-6}alkyl substituted with morpholinyl; or pyridinyl; and

Alk is C_{1-6}alkanediyl.

In a further aspect the invention concerns novel compounds of formula (I) as defined above, with the proviso that 5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine are not included

The proviso is intended to exclude compounds disclosed in JP-61/057,587 and JP-42/011,753.

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C_{1-6}alkanediyl defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms, such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof; C_{1-2}alkyl defines straight saturated hydrocarbon radicals having from 1 to 2 carbon atoms such as methyl and ethyl; C_{2-4}alkyl defines straight and branched chain saturated hydrocarbon radicals having from 2 to 4 carbon atoms such as ethyl, propyl, butyl, 1-methylethyl and the like; C_{3-4}alkyl defines straight and branched chain saturated hydrocarbon radicals having from 3 to 4 carbon atoms such as propyl, butyl, 1-methylethyl and the like; C_{1-6}alkyl includes C_{1-2}alkyl and C_{3-4}alkyl radicals as defined hereinbefore and the higher homologs thereof having from 5 to 6 carbon atoms such as, pentyl, the pentyl isomers, hexyl and the hexyl isomers; C_{1-8}alkyl includes C_{1-6}alkyl and the higher homologues thereof having from 7 to 8 carbon atoms such as, for example, heptyl, octyl and the like; C_{3-6}alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 3 to 6 carbon atoms such as, for example, 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, and the like; and where said C_{3-6}alkenyl is linked to a nitrogen or oxygen, the carbon atom making the link preferably is saturated. C_{3-6}cycloalkyl comprises cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. HydroxyC_{1-6}alkyl refers to C_{1-6}alkyl substituted with a hydroxyl-group. Homopiperidinyl refers to a 7 membered saturated ring containing one nitrogen atom.

Depending on the nature of some of the substituents, the compounds of formula (I) may contain one or more asymmetric centers which may be designated with the generally used R and S nomenclature.

The compounds of the present invention contain basic nitrogen atoms and, as such, can be present as the free base or in the form of acid addition salts, both being part of this invention. Acid addition salts may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids.

Particular groups of compounds within the invention are those compounds of formula (I) wherein one or more of the following restrictions apply :

a) R^1 is NR^4R^5 wherein R^4 is hydrogen, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl or C_{3-6}alkenyl; in particular C_{2-4}alkyl, hydroxyC_{1-2}alkyl, C_{3-4}alkenyl or C_{1-2}alkylcarbonyloxyC_{2-4}alkyl; and R^5 is C_{1-8}alkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, phenylmethyl or C_{3-6}cycloalkylmethyl; in particular C_{2-4}alkyl, C_{3-4}alkenyl, hydroxyC_{2-4}alkyl or cyclopropylmethyl;

b) R^1 is OR^5 wherein R^5 is C_{1-6}alkyl; in particular C_{2-4}alkyl;

c) R^2 is C_{1-6}alkyl; in particular C_{1-2}alkyl;

d) R^3 is hydrogen, C_{1-6}alkyl or C_{1-6}alkylthio; in particular hydrogen, C_{1-2}alkyl or C_{1-2}alkylthio;

e) Ar is a phenyl substituted with 1, 2 or 3 substituents each independently selected from C_{1-6}alkyl, C_{1-6}alkyloxy or halo; wherein the phenyl moiety is preferably substituted in the 3-, 4-, 6-, 2,4- or 2,4,6-positions; or Ar is a pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, amino, nitro, trifluoromethyl, mono- or di(C_{1-6}alkyl)amino, piperidinyl or C_{1-6}alkyl; wherein the pyridinyl moiety preferably is connected via the 2- or 3-position to the remainder of the molecule.

Another particular group of compounds are those compounds of formula (I) wherein R^1 is NR^4R^5 and R^4 and R^5 are taken together with the nitrogen atom to which they are attached to form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl.


Preferred compounds are those compounds of formula (I) wherein R^1 is NR^4R^5 and R^4 is C_{3-4}alkyl or allyl, preferably propyl; R^5 is C_{2-4}alkyl, allyl or cyclopropylmethyl, preferably propyl; R^2 is methyl; R^3 is hydrogen, methyl or methylthio, preferably

propyl; and Ar is a phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, methyl or methoxy; and Ar in particular is pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, methyl or dimethylamino.

More preferably Ar is 3-pyridinyl substituted in the 4- and/or 6-position with methyl or dimethylamino.

Most preferred are those compounds selected from
3-(2,4-dichlorophenyl)-5-methyl-7-(*N*-propyl-*N*-cyclopropanemethylamino)-pyrazolo[2,3-a]pyrimidine;
3-(2,4-dichlorophenyl)-5-methyl-7-(*N*-allyl-*N*-cyclopropanemethylamino)-pyrazolo[2,3-a]pyrimidine;
2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(*N*,*N*-diallylamino)-pyrazolo[2,3-a]pyrimidine;
2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(*N*-butyl-*N*-cyclopropanemethyl-amino)pyrazolo[2,3-a]pyrimidine;
2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(*N*-propyl-*N*-cyclopropanemethyl-amino)pyrazolo[2,3-a]pyrimidine;
2-methyl-3-(4-chlorophenyl)-5-methyl-7-(*N*,*N*-dipropylamino)-pyrazolo[2,3-a]pyrimidine;
3-[6-(dimethylamino)-3-pyridinyl]-2,5-dimethyl-*N*,*N*-dipropylpyrazolo[2,3-a]pyrimidin-7-amine; or
3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-*N*,*N*-dipropyl-pyrazolo[2,3-a]pyrimidine-7-amine; or
3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-(*N*-propyl-*N*-methyloxyethylamino)-pyrazolo[2,3-a]pyrimidine;
the stereoisomeric forms and the pharmaceutically acceptable acid addition salts thereof.


The compounds of the present invention can generally be prepared by alkylating a pyrazolopyrimidine of formula (II) with an intermediate of formula (III). In intermediate (II), W is an appropriate leaving group such as halo, e.g. chloro, bromo, or a sulfonyloxy group, e.g. a mesyloxy or a tosyloxy group.



(II) (III) (I)

The above reaction is typically conducted in a suitable solvent, e.g. an aprotic solvent such as DMF or acetonitrile, an ether, e.g. tetrahydrofuran, preferably at an elevated temperature and, when the intermediates of formula (III) are volatile amines, in a sealed reaction vial.


Also, compounds of formula (I) wherein R^1 is OR^5 , said compounds being represented by formula (I-a), may be prepared by *O*-alkylating an intermediate of formula (VI) with an intermediate of formula (VII), wherein W is as defined above.



(VI) (VII) (I-a)

Said reaction for preparing compounds of formula (I-a) can be performed in a reaction-inert solvent such as, for example, *N*,*N*-dimethylformamide, and in the presence of a suitable base such as, for example, sodium hydride, preferably at a temperature ranging between room temperature and reflux temperature.

The compounds of formula (I) wherein R^1 is NR^4R^5, represented by formula (I-c), can be prepared from either compounds of formula (VIII) or (IX) by suitable *N*-alkylation reactions as depicted herebelow, wherein W is as previously defined. These *N*-alkylations are conducted in a reaction-inert solvent such as, for example, an ether e.g. tetrahydofuran and preferably in the presence of a strong base, e.g. NaH.



(VIII) (IX) (I-c)

In certain instances, this reaction can give rise to side products wherein R^2 is alkylated by (R^4 or R^5)–W, in particular where R^2 is methyl and R^4 or R^5 is C_{1-6}alkyl.

As outlined below, compounds of formula (I) may be converted into each other following art-known transformation procedures.


The compounds of formula (I) wherein R^3 is C_{1-6}alkylthio can be converted into compounds of formula (I) wherein R^3 is C_{1-6}alkylsulfonyl or C_{1-6}alkylsulfoxy by an oxidation reaction, e.g. treatment with a peroxide such as 3-chloroperbenzoic acid in a reaction-inert solvent, e.g. dichloromethane. By controlling the amount of oxidant and other reaction parameters, either compounds of formula (I) wherein R^3 is C_{1-6}alkylsulfonyl or C_{1-6}alkylsulfoxy can be obtained, or a mixture of both, which subsequently can be separated by conventional methods, e.g. column chromatography.

The compounds of formula (I) may also be converted into each other via art-known reactions or functional group transformations. For instance, compounds of formula (I) bearing a hydroxyC_{1-6}alkyl group may be converted into compounds of formula (I) bearing a C_{1-6}alkylcarbonyloxyC_{1-6}alkyl group, e.g. by treatment with an acid anhydride in an reaction-inert solvent such as, e.g. dichloromethane, and optionally in the presence of a base such as, e.g. pyridine.

Compounds of formula (I) bearing a nitro group may be converted to compounds of formula (I) bearing an amino group and subsequently to compounds of formula (I) having a mono- or di(C_{1-6}alkyl)amino group. Also, the amino group may be converted using a diazotization reaction to a halo.

Further, the Ar group of compounds of formula (I) can be halogenated using a halogenating agent such as, e.g. chlorine or bromine, in a suitable solvent, e.g. acetic acid, and optionally the reaction may be performed at a temperature ranging between room temperature and the reflux temperature of the reaction mixture.


Intermediates of formula (II) can be prepared according to the procedure as described in Robins et al., *J. Heterocyclic Chem.* 22:601-634, 1985.



Aminopyrazole derivatives (IV) are reacted with a β-keto ester (V), preferably under reflux conditions and in a suitable reaction-inert solvent such as an ether, e.g. THF, yielding hydroxypyrazolopyrimidines (VI) which are converted into intermediates of formula (II) by converting the hydroxy group of intermediate (VI) into leaving group W, e.g. by treating (VI) with methanesulfonyloxy chloride or a halogenating reagent such as, e.g. $POCl_3$.

Intermediates of formula (VIII) are prepared by treating intermediates of formula (II) with ammonia.

In an embodiment, this invention also provides for intermediates of formula (II'), wherein W' represents hydroxy, halo, mesyloxy or tosyloxy; with the proviso that Ar is other than phenyl.



Said intermediates of formula (II') may be prepared according to procedures used to prepare intermediates of formula (II), thereby thereby yielding compounds of formula (II'-a), defined as compounds of formula (II') wherein W' is hydroxy; and optionally converting compounds of formula (II'-a) into compounds of formula (II'-b), defined as compounds of formula (II') wherein W' is other than hydroxy.

Stereoisomers may be prepared by separation of the end products of formula (I) following art-known procedures, e.g. by treatment with an optically active acid and separating the thus-formed diastereoisomeric salts by selective crystallization or column chromatography. Or, stereoisomers may be prepared by using stereoisomeric starting materials in any of the above reaction schemes or in the preparation of intermediates described hereinafter.

The effectiveness of a compound as a CRF receptor antagonist may be determined by various assay methods. Suitable CRF antagonists of this invention are capable of inhibiting the specific binding of CRF to its receptor and antagonizing activities associated with CRF. A compound of structure (I) may be assessed for activity as a CRF antagonist by one or more generally accepted assays for this purpose, including (but not limited to) the assays disclosed by DeSouza et al. (*J. Neuroscience* 7:88, 1987) and Battaglia et al. (*Synapse* I:572, 1987). As mentioned above, suitable CRF antagonists include compounds which demonstrate CRF receptor affinity. CRF receptor affinity may be determined by binding studies that measure the ability of a compound to inhibit the binding of a radiolabeled CRF (*e.g.* [^{125}I]tyrosine CFR) to receptor (*e.g.*, receptors prepared from rat cerebral cortex membranes). The radioligand binding assay described by DeSouza et al. (*supra,* 1987) provides an assay for determining a compound's affinity for the CRF receptor. Such activity is typically calculated from the IC_{50} as the concentration of a compound necessary to displace 50% of the radiolabeled ligand from the receptor, and is reported as a "K_i" value calculated by the following equation :

$$K_i = \frac{IC_{50}}{1 + L/K_D}$$

where L = radioligand and K_D= affinity of radioligand for receptor (Cheng and Prusoff, *Biochem. Pharmacol.* 22:3099, 1973).

In addition to inhibiting CRF receptor binding, a compound's CRF receptor antagonist activity may be established by the ability of the compound to antagonize an activity associated with CRF. For example, CRF is known to stimulate various biochemical processes, including adenylate cyclase activity. Therefore, compounds may be evaluated as CRF antagonists by their ability to antagonize CRF-stimulated adenylate cyclase activity by, for example, measuring cAMP levels. The CRF-stimulated adenylate cyclase activity assay described by Battaglia et al. (*supra,* 1987) provides an assay for determining a compound's ability to antagonize CRF activity. Accordingly, CRF receptor antagonist activity may be determined by assay techniques which generally include an initial binding assay (such as disclosed by DeSouza (*supra,* 1987)) followed by a cAMP screening protocol (such as disclosed by Battaglia (supra, 1987)). With reference to CRF receptor binding affinities, CRF receptor antagonists of this invention have a K_i of less than 10 μM. In a preferred embodiment of this invention, a

CRF receptor antagonist has a K_i of less than 1 μM, and more preferably less than 0.25 μM *(i.e.,* 250 nM).

The CRF receptor antagonists of the present invention demonstrate activity at the CRF receptor site, and may be used as therapeutic agents for the treatment of a wide range of disorders or illnesses including endocrine, psychiatric, and neurologic disorders or illnesses. More specifically, the CRF receptor antagonists of the present invention may be useful in treating physiological conditions or disorders arising from the hypersecretion of CRF. Because CRF is believed to be a pivotal neurotransmitter that activates and coordinates the endocrine, behavioral and automatic responses to stress, the CRF receptor antagonists of the present invention can be used to treat neuropsychiatric disorders. Neuropsychiatric disorders which may be treatable by the CRF receptor antagonists of this invention include affective disorders such as depression; anxiety-related disorders such as generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, abnormal aggression, cardiovascular abnormalities such as unstable angina and reactive hypertension; and feeding disorders such as anorexia nervosa, bulimia, and irritable bowel syndrome. CRF antagonists may also be useful in treating stress-induced immune suppression associated with various diseases states, as well as stroke. Other uses of the CRF antagonists of this invention include treatment of inflammatory conditions (such as rheumatoid arthritis, uveitis, asthma, inflammatory bowel disease and G.I. motility), Cushing's disease, infantile spasms, epilepsy and other seizures in both infants and adults, and various substance abuse and withdrawal (including alcoholism).

In another embodiment of the invention, pharmaceutical compositions containing one or more CRF receptor antagonists are disclosed. For the purposes of administration, the compounds of the present invention may be formulated as pharmaceutical compositions. Pharmaceutical compositions of the present invention comprise a CRF receptor antagonist of the present invention *(i.e.,* a compound of structure (I)) and a pharmaceutically acceptable carrier and/or diluent. The CRF receptor antagonist is present in the composition in an amount which is effective to treat a particular disorder, that is, in an amount sufficient to achieve CRF receptor antagonist activity, and preferably with acceptable toxicity to the patient. Preferably, the pharmaceutical compositions of the present invention may include a CRF receptor antagonist in an amount from 0.1 mg to 250 mg per dosage depending upon the route of administration, and more preferably from 1 mg to 60 mg. Appropriate concentrations and dosages can be readily determined by one skilled in the art.

Pharmaceutically acceptable carrier and/or diluents are familiar to those skilled in the art. For compositions formulated as liquid solutions, acceptable carriers and/or diluents include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives. The compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a CRF receptor antagonist, diluents, dispersing and surface active agents, binders, and lubricants. One skilled in this art may further formulate the CRF receptor antagonist in an appropriate manner, and in accordance with accepted practices, such as those disclosed in *Remington's Pharmaceutical Sciences*, Gennaro, Ed., Mack Publishing Co., Easton, USA, 1990.

In another embodiment, the present invention provides a method for treating a variety of disorders or illnesses, including endocrine, psychiatric and neurologic disorders or illnesses. Such methods include administering of a compound of the present invention to a warm-blooded animal in an amount sufficient to treat the disorder or illness. Such methods include systemic administration of a CRF receptor antagonist of this invention, preferably in the form of a pharmaceutical composition. As used herein, systemic administration includes oral and parenteral methods of administration. For oral administration, suitable pharmaceutical compositions of CRF receptor antagonists include powders, granules, pills, tablets, and capsules as well as liquids, syrups, suspensions, and emulsions. These compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents, and other pharmaceutically acceptable additives. For parental administration, the compounds of the present invention can be prepared in aqueous injection solutions which may contain, in addition to the CRF receptor antagonist, buffers, antioxidants, bacteriostats, and other additives commonly employed in such solutions.

As mentioned above, administration of a compound of the present invention can be used to treat a wide variety of disorders or illnesses. In particular, the compounds of the present invention may be administered to a warm-blooded animal for the treatment of depression, anxiety disorder, panic disorder, obsessive-compulsive disorder, abnormal aggression, unstable angina, reactive hypertension, anorexia nervosa, bulimia, irritable bowel syndrome, stress-induced immune suppression, stroke, inflammation, Cushing's disease, infantile spasms, epilepsy, and substance abuse or withdrawal.

Hence, this invention provides the use of compounds of formula (I) for the manufacture of a medicine for treating physiological conditions or disorders arising from the hypersecretion of corticotropin-releasing factor (CRF); and in a further embodiment the use of novel compounds of formula (I) as a medicine is provided.

The following examples are provided for purposes of illustration, not limition.

Experimental part

Hereinafter "THF" means tetrahydrofuran and "DCM" means dichloromethane.

A. Preparation of the intermediates.

Example A.1

a) 3-Amino-4-(2,4-dichlorophenyl)pyrazole and ethyl acetoacetate (2 equivalents) were dissolved in dioxane and heated under reflux overnight. The mixture was concentrated *in vacuo* and diluted with ethyl acetate. An off-white solid formed after 2 days standing was collected by vacuum filtration, yielding 3-(2,4-dichlorophenyl)-5-methyl-7-hydroxypyrazolo[2,3-a]pyrimidine (intermediate 1).

b) Intermediate 1 (300 mg) was mixed with $POCl_3$ (1.5 ml) and heated to reflux for 1 hour. The resultant purple solution was carefully transferred into ice-water. The product was extracted with ethyl acetate, washed with saturated sodium bicarbonate and brine, dried over $MgSO_4$ and concentrated *in vacuo* to give 3-(2,4-dichlorophenyl-5-methyl-7-chloropyrazolo[2,3-a]pyrimidine (intermediate 2) as a brown solid (260 mg, 82%).

Example A.2

a) To a stirred solution of sodium hydride (60%, 25 mmol) in THF (10 ml) 6-(dimethylamino)-3-pyridineacetonitrile was added dropwise (10 mmol) in THF (10 ml). The solution was allowed to stir for 10 minutes before ethyl acetate (30 mmol) was added slowly. The resulting suspension was stirred at room temperature for another hour. The reaction mixture was concentrated under vacuum and dissolved in ethyl acetate/methanol (1:1) and filtered through silica. The filtrate was concentrated, yielding (intermediate 7).


b) A mixture of intermediate 7 and hydrazine hydrobromide (100 mmol) was dissolved in ethanol/water (9:1, total 100 ml) and refluxed for 1 hour. The reaction mixture was concentrated and the residue was partitioned between ethyl acetate and sodium bicarbonate solution. The combined extracts were dried over sodium sulfate, filtered and concentrated to dryness. The residue was dissolved in 1,4-dioxane (200 ml) and

refluxed for 16 hours in the presence of ethyl acetoacetate. The reaction mixture was cooled and an off-white solid precipitated out. Diethyl ether was added to aid in crystallization and the precipitate was filtered off and dried, yielding 3-[2-(dimethyl-amino)-5-pyridinyl]-2,5-dimethyl-7-hydroxypyrazolo[2,3-a]pyrimidine (intermediate 8).

c) Intermediate 8 was dissolved in $POCl_3$ (2 ml) and refluxed for 2 hours. The reaction mixture was cooled and poured onto ice. The solution was made basic (pH = 9) by addition of solid sodium carbonate and extracted with diethyl ether. The combined organic layers were dried over sodium sulfate, filtered and concentrated, yielding 3-[6-(dimethylamino)-3-pyridinyl]-2,5-dimethyl-7-chloro-pyrazolo[2,3-a]pyrimidine (intermediate 9).

Table 1 lists the intermediates that were prepared according to one of the above Examples.

Table 1 :



Interm. No.	Ex. No.	R^3	Ar
2	A.1	H	2,4-dichlorophenyl
3	A.1	CH_3S	2,4-dichlorophenyl
4	A.1	CH_3	2,4-dichlorophenyl
5	A.1	H	4-chlorophenyl
6	A.1	H	2,6-dichlorophenyl
13	A.1	CH_3	4-chlorophenyl
14	A.1	CH_3	3-methoxyphenyl
15	A.1	CH_3	4-methoxyphenyl
16	A.1	CH_3	2,4-dimethoxyphenyl
17	A.1	CH_3CH_2	3,4-dimethoxyphenyl
18	A.1	H	2,4,6-trimethoxyphenyl
9	A.2	CH_3	6-dimethylamino-3-pyridinyl
10	A.2	CH_3	6-dimethylamino-4-methyl-3-pyridinyl
11	A.2	CH_3	6-methyl-5-nitro-2-pyridinyl
12	A.2	CH_3	5-chloro-2-pyridinyl

Interm. No.	Ex. No.	R^3	Ar
19	A.1	CH_3	6-methyl-3-pyridinyl
20	A.1	CH_3	3-methyl-5-nitro-2-pyridinyl

B. Preparation of the final products.

Example B.1

A mixture of intermediate 2 (21 mg) and *N*-propyl-*N*-cyclopropanemethylamine (75 mg) was heated in a sealed reaction vial at 100°C overnight. Chromatography on a preparative TLC plate with 1:5 ethyl acetate-hexanes gave 3-(2,4-dichlorophenyl)-5-methyl-7-(*N*-propyl-*N*-cyclopropanemethylamino)-pyrazolo[2,3-a]pyrimidine (compound 17) (17.4 mg) and 3-(2,4-dichlorophenyl)-5-methyl-7-(*N*-cyclopropane-methylamino)-pyrazolo[2,3-a]pyrimidine (compound 8) (1 mg).

In a similar way, starting from intermediate 2 and (S)-(-)-leucinol respectively (R)-(+)-leucinol, (S)-2[[3-(2,4-dichlorophenyl)-5-methyl-7-pyrazolo[2,3-a]pyrimidinyl]amino]-4-methyl-1-pentanol (compound 11) and its R-analog (compound 12) were prepared.

Example B.2

A solution of intermediate 10 (8 g) and di-n-propylamine (13 g) in acetonitrile (50 ml) was heated at reflux for 3 hours. The mixture was filtrated through a short silica gel plug with ethyl acetate and the filtrate was concentrated *in vacuo* to provide a light yellow solid which was recrystallized from ether-hexanes, yielding 8.9 g (93%) of 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-*N*,*N*-dipropylpyrazolo[2,3-a]-pyrimidin-7-amine (compound 53).

Compound 53 was also converted to its hydrochloric acid addition salt by dissolving compound 53 (8.1 g) in a mixture of diethyl ether (150 ml) and DCM (50 ml) and treating said mixture with HCl in diethyl ether (1 M, 21.3 ml) dropwise with stirring. The resulting off-white solid was collected by filtration, yielding 8.7 g (98%) of 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-*N*,*N*-dipropyl-pyrazolo[2,3-a]pyrimidin-7-amine monohydrochloride.

Example B.3

Intermediate 3 (15 mg) was dissolved in ethanol (0.5 ml) and stirred in the presence of sodium ethoxide (12 mg) for 1 hour. Chromatography on silica gel gave 3-(2,4-dichlorophenyl)-7-(ethoxy)-5-methyl-2-methylthio-pyrazolo[2,3-a]pyrimidine (compound 50).

Example B.4

A solution of compound 6 (14 mg) in THF (3 ml) was treated with sodium hydride (60 mg, excess) at room temperature for 5 minutes, followed by iodopropane (0.3 ml). The reaction was stirred at room temperature overnight and quenched with methanol (0.5 ml). The resultant mixture was loaded onto a preparative TLC plate and developed with 1:5 ethyl acetate-hexanes to give 3-(2,4-dichlorophenyl)-5-methyl-7-[*N*-(3-methoxypropyl)-*N*-propylamino]-pyrazolo[2,3-a]pyrimidine (compound 45) (5.7 mg) as a colorless oil, 3-(2,4-dichlorophenyl)-5-butyl-7-[*N*-(3-methoxypropyl)-*N*-propylamino]-pyrazolo[2,3-a]pyrimidine (compound 46) (4 mg) and 3-(2,4-dichlorophenyl)-5-butyl-7-[3-methoxy-propylamino]-pyrazolo[2,3-a]pyrimidine (compound 47) (3.5 mg).

Example B.5

Compound 26 (8 mg) was dissolved in DCM (1 ml) and treated with acetic anhydride (0.1 ml) and pyridine (0.1 ml). The mixture was stirred at room temperature overnight and concentrated in vacuo. The residue was diluted with ethyl acetate and filtrated through a short silica gel column. Concentration of the filtrate gave 3-(2,4-dichlorophenyl)-5-methyl-7-[*N*-(2-acetoxyethyl)-*N*-benzylamino]-pyrazolo[2,3-a]-pyrimidine (compound 27) (8.6 mg) as a colorless oil.

Example B.6

A solution of compound 40 (20 mg) in DCM (3 ml) was treated with 3-chloroperbenzoic acid (19 mg). The solution was stirred at room temperature for 1 hour. Chromatography on a silica gel plate with ethyl acetate-hexanes (1:1) yielded compound 43 and compound 44.

Example B.7

A mixture of compound 55, palladium on activated carbon (100 mg) in dry ethanol (100 ml) was put on the hydrogenation unit and hydrogenation was carried out at 2.7 10^5 Pa (40 psi) for 2 hours. The reaction mixture was filtered and concentrated. The residue was dissolved in diethyl ether and concentrated, yielding 1.49 g of 3-(5-amino-3-methyl-2-pyridinyl)-2,5-dimethyl-*N*,*N*-dipropyl-pyrazolo[2,3-a]pyrimidine-7-amine (compound 56).

Example B.8

To a stirring solution of compound 56 (1.39 g) and aqueous formaldehyde (6.4 g) in ACN (20 ml) was added sodium cyanoborohydride (743 mg) at 0°C. Glacial acetic

acid (1 ml) was added and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The organic layer was washed with brine, dried over sodium sulfate, filtered, concentrated to dryness and purified by flash column chromatography on silica gel ($CH_2Cl_2/CH_3OH/NH_4OH$ 150:10:1). The desired fraction was isolated, yielding 1.30 g of 3-[5-(dimethylamino)-3-methyl-2-pyridinyl]-2,5-dimethyl-*N*,*N*-dipropyl-pyrazolo[2,3-a]pyrimidine-7-amine (compound 57).

Example B.9


To a solution of compound 56 (100 mg) in a mixture of concentrated HCl (1 ml) and water (1 ml), cooled in an ice bath, was added a solution of sodium nitrite (21 mg) in water (1 ml). The solution was added to a mixture of copper(I)chloride (281 mg) in concentrated HCl with stirring in an ice bath. A solid separated and the mixture was heated to 60°C and a clear solution was obtained. The reaction mixture was basified with NaOH, extracted with ethyl acetate, washed with brine and concentrated. Purification by preparative TLC yielded 16 mg of compound 98.




Example B.10

Compound 56 (100 mg) was added to a solution of fluoroboric acid (48% wt in water, 2 ml), cooled in an ice bath, followed by addition of a solution of sodium nitrite (20 mg) in water (1 ml). The temperature was kept under 10°C. The solid was collected by filtration, dried and partitioned between an aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was washed with brine, concentrated and the residue was purified by preparative TLC yielding 20 mg of compound 100.

Tables 2 to 5 list the compounds that were prepared according to one of the above Examples and tables 6 and 7 list the analytical data for these compounds.


Table 2 :



Co. No.	Ex. No.	R^4	R^5	Ar
1	B.1	hydrogen	n-propyl	2,4-dichlorophenyl
2	B.1	hydrogen	2-methylpropyl	2,4-dichlorophenyl
3	B.1	hydrogen	1,1-dimethylethyl	2,4-dichlorophenyl
4	B.1	hydrogen	3-hydroxypropyl	2,4-dichlorophenyl
5	B.1	hydrogen	3-pentyl	2,4-dichlorophenyl
6	B.1	hydrogen	$CH_3O(CH_2)_3$-	2,4-dichlorophenyl
7	B.1	hydrogen	$(CH_3)_2CHO(CH_2)_3$-	2,4-dichlorophenyl
8	B.1	hydrogen	cyclopropylmethyl	2,4-dichlorophenyl
9	B.1	hydrogen	3-methyl-2-butyl	2,4-dichlorophenyl
10	B.1	hydrogen	4-methyl-2-pentyl	2,4-dichlorophenyl
11	B.1	hydrogen	 (S)	2,4-dichlorophenyl
12	B.1	hydrogen	 (R)	2,4-dichlorophenyl
13	B.1	hydrogen	 (S)	2,4-dichlorophenyl
14	B.3	methyl	cyclopropylmethyl	2,4-dichlorophenyl
15	B.1	ethyl	n-butyl	2,4-dichlorophenyl
16	B.2	n-propyl	n-propyl	2,4-dichlorophenyl
17	B.1	n-propyl	cyclopropylmethyl	2,4-dichlorophenyl
18	B.1	n-propyl	$HOCH_2CH_2$-	2,4-dichlorophenyl
19	B.1	n-propyl	$CH_3O(CH_2)_2$-	2,4-dichlorophenyl
20	B.2	n-propyl	n-propyl	4-chlorophenyl
21	B.1	n-propyl	cyclopropyl	2,6-dichlorophenyl
22	B.1	n-propyl	$CH_3O(CH_2)_2$	2,6-dichlorophenyl
23	B.4	n-butyl	cyclopropylmethyl	2,4-dichlorophenyl
24	B.1	2-methylpropyl	cyclopropylmethyl	2,4-dichlorophenyl
25	B.1	3-methyl-2-butyl	cyclopropylmethyl	2,4-dichlorophenyl

Co. No.	Ex. No.	R^4	R^5	Ar
26	B.1	$HOCH_2CH_2$-	phenylmethyl	2,4-dichlorophenyl
27	B.5	$CH_3COO(CH_2)_2$-	phenylmethyl	2,4-dichlorophenyl
28	B.5	$CH_3COO(CH_2)_2$-	n-propyl	2,4-dichlorophenyl
29	B.4	allyl	cyclopropylmethyl	2,4-dichlorophenyl
45	B.4	n-propyl	$CH_3O(CH_2)_3$	2,4-dichlorophenyl
58	B.1	$CH_3O(CH_2)_2$-	$CH_3O(CH_2)_2$-	2,4-dichlorophenyl
59	B.1	hydrogen	$CH_3OCH_2CH(CH_3)$-	2,4-dichlorophenyl
60	B.1	hydrogen	1-hydroxy-2-hexyl	2,4-dichlorophenyl
61	B.1	hydrogen	1-hydroxy-2-pentyl	2,4-dichlorophenyl
62	B.2	n-propyl	n-propyl	6-dimethylamino-2,4-dimethyl-3-pyridinyl
63	B.1	ethyl	n-butyl	6-dimethylamino-2,4-dimethyl-3-pyridinyl
64	B.1	n-propyl	cyclopropylmethyl	6-dimethylamino-2,4-dimethyl-3-pyridinyl
65	B.1	n-propyl	cyclopropylmethyl	6-methyl-3-pyridinyl
66	B.1	n-butyl	n-butyl	6-methyl-3-pyridinyl
67	B.1	n-propyl	cyclopropylmethyl	2,4-dimethoxyphenyl
68	B.2	n-propyl	n-propyl	2,4,6-trimethoxyphenyl
69	B.1	n-propyl	$CH_3O(CH_2)_2$-	2,4,6-trimethoxyphenyl
70	B.1	n-propyl	cyclopropylmethyl	2,4,6-trimethoxyphenyl
71	B.1	ethyl	n-butyl	2,4,6-trimethoxyphenyl
72	B.1	ethyl	ethyl	2,4,6-trimethoxyphenyl


Table 3 :




Co. No.	Ex. No.	R^3	R^4	R^5	Ar
30	B.1	CH_3S	hydrogen	n-propyl	2,4-dichlorophenyl
31	B.1	CH_3S	hydrogen	2-propyl	2,4-dichlorophenyl

Co. No.	Ex. No.	R^3	R^4	R^5	Ar
32	B.1	CH_3S	hydrogen	3-heptyl	2,4-dichlorophenyl
34	B.1	CH_3S	hydrogen	2-methoxyphenylmethyl	2,4-dichlorophenyl
35	B.1	CH_3S	methyl	methyl	2,4-dichlorophenyl
36	B.1	CH_3S	ethyl	ethyl	2,4-dichlorophenyl
37	B.2	CH_3S	n-propyl	n-propyl	2,4-dichlorophenyl
38	B.1	CH_3S	n-propyl	cyclopropylmethyl	2,4-dichlorophenyl
39	B.1	CH_3S	2-propyl	2-propyl	2,4-dichlorophenyl
40	B.1	CH_3S	n-butyl	n-butyl	2,4-dichlorophenyl
41	B.1	CH_3S	n-butyl	cyclopropylmethyl	2,4-dichlorophenyl
42	B.1	CH_3S	allyl	allyl	2,4-dichlorophenyl
43	B.6	CH_3SO	n-propyl	cyclopropylmethyl	2,4-dichlorophenyl
44	B.6	CH_3SO_2	n-propyl	cyclopropylmethyl	2,4-dichlorophenyl
73	B.2	CH_3CH_2	n-propyl	n-propyl	3,4-dimethoxy-phenyl

Table 4 :



Co. No.	Ex. No.	R^4	R^5	Ar
48	B.2	n-propyl	n-propyl	4-chlorophenyl
49	B.1	n-propyl	cyclopropylmethyl	2,4-dichlorophenyl
51	B.1	n-propyl	$CH_3O(CH_2)_2$-	2,4-dimethoxyphenyl
52	B.2	n-propyl	n-propyl	6-dimethylamino-3-pyridinyl
53	B.2	n-propyl	n-propyl	6-dimethylamino-4-methyl-3-pyridinyl
54	B.2	n-propyl	n-propyl	5-chloro-2-pyridinyl
55	B.2	n-propyl	n-propyl	3-methyl-5-nitro-2-pyridinyl
56	B.7	n-propyl	n-propyl	5-amino-3-methyl-2-pyridinyl
57	B.8	n-propyl	n-propyl	5-dimethylamino-3-methyl-2-pyridinyl
74	B.1	$CH_3O(CH_2)_2$-	$CH_3O(CH_2)_2$-	4-chlorophenyl
75	B.1	$HOCH_2CH_2$-	phenylmethyl	4-chlorophenyl

Co. No.	Ex. No.	R^4	R^5	Ar
76	B.1	hydrogen	1-hydroxy-2-hexyl	4-chlorophenyl
77	B.1	hydrogen	1-hydroxy-2-pentyl	4-chlorophenyl
78	B.1	hydrogen	$CH_3S(CH_2)_2$-	4-chlorophenyl
79	B.1	hydrogen	 (S)	4-chlorophenyl
80	B.1	hydrogen	1-hydroxy-2-hexyl	6-dimethylamino-4-methyl-3-pyridinyl
81	B.1	ethyl	n-butyl	6-dimethylamino-4-methyl-3-pyridinyl
82	B.1	n-propyl	cyclopropylmethyl	6-dimethylamino-4-methyl-3-pyridinyl
83	B.1	n-propyl	phenylmethyl	6-dimethylamino-4-methyl-3-pyridinyl
84	B.1	allyl	allyl	6-dimethylamino-4-methyl-3-pyridinyl
85	B.1	n-butyl	n-butyl	6-dimethylamino-4-methyl-3-pyridinyl
86	B.1	hydrogen	3-pentyl	6-dimethylamino-4-methyl-3-pyridinyl
87	B.1	hydrogen	2-propyl	6-dimethylamino-4-methyl-3-pyridinyl
88	B.1	hydrogen	4-methyl-2-pentyl	6-dimethylamino-4-methyl-3-pyridinyl
89	B.1	methyl	n-butyl	6-dimethylamino-4-methyl-3-pyridinyl
90	B.2	n-propyl	n-propyl	6-dimethylamino-2-methyl-3-pyridinyl
91	B.1	n-propyl	cyclopropylmethyl	6-dimethylamino-2-methyl-3-pyridinyl
92	B.1	ethyl	n-butyl	6-dimethylamino-2-methyl-3-pyridinyl
93	B.1	n-butyl	n-butyl	6-dimethylamino-2-methyl-3-pyridinyl
94	B.1	n-propyl	n-propyl	4,6-dimethyl-3-pyridinyl
95	B.1	n-propyl	cyclopropylmethyl	4,6-dimethyl-3-pyridinyl
96	B.2	n-propyl	n-propyl	6-dimethylamino-2,4-dimethyl-3-pyridinyl
97	B.1	n-propyl	cyclopropylmethyl	6-dimethylamino-2,4-dimethyl-3-pyridinyl

Co. No.	Ex. No.	R^4	R^5	Ar
98	B.9	n-propyl	n-propyl	5-chloro-3-methyl-2-pyridinyl
99	B.9	n-propyl	n-propyl	5-iodo-3-methyl-2-pyridinyl
100	B.10	n-propyl	n-propyl	5-fluoro-3-methyl-2-pyridinyl
101	B.2	n-propyl	n-propyl	3-chloro-5-trifluoromethyl-2-pyridinyl
102	B.1	$CH_3O(CH_2)_2$-	$CH_3O(CH_2)_2$-	3-chloro-5-trifluoromethyl-2-pyridinyl
103	B.2	n-propyl	n-propyl	3,5-dichloro-2-pyridinyl
104	B.1	n-propyl	$CH_3O(CH_2)_2$-	3,5-dichloro-2-pyridinyl
105	B.1	n-propyl	cyclopropylmethyl	3,5-dichloro-2-pyridinyl
106	B.2	n-propyl	n-propyl	3-methyl-5-methoxy-2-pyridinyl
107	B.8	n-propyl	n-propyl	5-diethylamino-3-methyl-2-pyridinyl
33	B.8	n-propyl	n-propyl	6-diethylamino-4-methyl-3-pyridinyl
108	B.8	n-propyl	n-propyl	5-*N*-piperidinyl-3-methyl-2-pyridinyl
109	B.2	n-propyl	n-propyl	5-methyl-3-nitro-2-pyridinyl
110	B.2	n-propyl	n-propyl	3-amino-5-methyl-2-pyridinyl
111	B.9	n-propyl	n-propyl	3-chloro-5-methyl-2-pyridinyl
112	B.2	n-propyl	n-propyl	3-methylamino-5-methyl-2-pyridinyl
113	B.2	n-propyl	n-propyl	3-dimethylamino-5-methyl-2-pyridinyl
114	B.2	n-propyl	n-propyl	2-methyl-5-pyridinyl
115	B.1	n-propyl	cyclopropylmethyl	4-isopropylphenyl
116	B.2	n-propyl	n-propyl	3,4-dimethoxyphenyl
117	B.1	n-propyl	$CH_3O(CH_2)_2$-	3,4-dimethoxyphenyl
118	B.1	n-propyl	cyclopropyl	2,4-dimethoxyphenyl
119	B.1	hydrogen	$CH_3O(CH_2)_2$-	2,4-dimethoxyphenyl
120	B.1	n-propyl	$HO(CH_2)_2$-	2,4-dimethoxyphenyl
121	B.8	n-propyl	n-propyl	5-methylamino-3-methyl-2-pyridinyl
122	B.2	n-propyl	n-propyl	2,4-dimethoxyphenyl
123	B.1	ethyl	n-butyl	2,4-dimethoxyphenyl
124	B.1	n-propyl	2-hydroxypropyl	2,4-dimethoxyphenyl
125	B.2	n-propyl	n-propyl	4-methoxyphenyl
126	B.2	n-propyl	n-propyl	3-methoxyphenyl
127	B.1	n-propyl	cyclopropylmethyl	3-methoxyphenyl






Co. No.	Ex. No.	R^4 and R^5 taken together	Ar
128	B.1		4-chlorophenyl
129	B.1		4-chlorophenyl
130	B.1		6-dimethylamino-4-methyl-3-pyridinyl
131	B.1		6-dimethylamino-4-methyl-3-pyridinyl

Table 5 :





Co. No.	Ex. No.	R^1	R^2	R^3	Ar
46	B.4		n-C_4H_9	H	2,4-dichlorophenyl
47	B.4		n-C_4H_9	H	2,4-dichlorophenyl
50	B.3	CH_3CH_2O-	CH_3	CH_3-S-	2,4-dichlorophenyl

Table 6 : Analytical data

Co. No.	^{1}H NMR data ($CDCl_3$)	MS M + 1
1	δ 0.45 (m,2H), 0.78 (m,2H), 1.20 (m,1H), 2.84 (s,3H), 3.40 (d,2H), 5.98 (s,1H), 7.41 (dd,1H), 7.52 (d,1H), 7.76 (d,1H), 8.32 (s,1H)	335
2	δ 0.88 (d,3H), 1.05 (d,3H), 1.74 (m,1H), 2.52 (s,3H), 3.20 (t,2H), 5.87 (s,1H), 6.40 (t,1H), 7.30 (dd,1H), 7.47 (d,1H), 7.99 (d,1H), 8.42 (s,1H)	349

Co. No.	^{1}H NMR data ($CDCl_3$)	MS M + 1
3	δ 1.57 (s,9H), 2.54 (s,3H), 6.05 (s,1H), 6.48 (s,1H), 7.31 (d,1H), 7.47 (s,1H), 7.99 (d,1H), 8.39 (s,1H)	349
4	δ 1.97 (m,2H), 2.43 (s,3H), 3.62 (m,2H), 3.75 (t,3H), 4,00 (brs, 1H), 6.18 (s,1H), 7.39 (dd,1H), 7.52 (d,1H), 8.19 (d,1H), 8.43 (s,1H)	351
5	δ 1.03 (t,6H), 1.60-1.85 (m,4H), 2.56 (s,3H), 3.49 (m,1H), 5.92 (s,1H), 6.19 (d,1H), 7.35 (dd,1H), 7.50 (dd,1H), 8.01 (d,1H), 8.44 (s,1H)	363
6	δ 2.02 (m,2H), 2.51 (s,3H), 3.40 (s,3H), 3.51 (m,4H), 5.91 (s,1H), 6.71 (t,1H), 7.31 (dd,1H), 7.47 (d,1H), 7.99 (d,1H), 8.42 (s,1H)	365
7	δ 1.23 (d,6H), 2.00 (m,2H), 2.52 (s,1H), 3.51 (dd,2H), 3.59 (m,2H), 5.90 (s,1H), 6.92 (t,1H), 7.31 (dd, 1H), 7.46 (d,1H), 8.00 (d,1H), 8.41 (s,1H)	393
8	δ 0.35 (m,2H), 0.68 (m,2H), 1.25 (m,1H), 2.52 (s,3H), 3.23 (dd,2H), 5.88 (s,1H), 6.40 (t,1H), 7.32 (d,1H), 7.48 (s,1H), 7.99 (s,1H), 8.43 (s,1H)	347
9	δ 1.03 (d,3H), 1.06 (d,3H), 1.31 (d,3H), 1.95 (m,1H), 2.52 (s,3H), 3.54 (m,1H), 5.88 (s,1H), 6.23 (d,1H), 7.32 (d,1H), 7.47 (s,1H), 7.98 (d,1H), 8.41 (s,1H)	363
10	δ 0.95 (d,3H), 0.97 (d,3H), 1.40-1.80 (m,3H), 2.53 (s,3H), 3.76 (m,1H), 5.89 (s,1H), 6.12 (d,1H), 7.32 (d,1H), 7.47 (s,1H), 7.97 (d,1H), 8.40 (s,1H)	377
11	δ 0.94 (d,3H), 0.99 (d,3H), 1.53 (m,1H), 1.76 (m,1H), 2.50 (s,3H), 2.93 (brs,1H), 3.48 (m,1H), 3.76 (m,1H), 5.97 (s,1H), 6.22 (d,1H), 7.35 (dd, 1H), 7.51 (d,1H), 7.95 (d,1H), 8.36 (s,	393
12	δ 0.92 (d,3H), 0.97 (d,3H), 1.52 (m,2H), 1.72 (m,1H), 2.47 (s,3H), 3.02 (brs,1H), 3.42 (m,1H), 3.72 (m,2H), 5.94 (s,1H), 6.20 (d,1H), 7.33 (d,1H), 7.49 (s,1H), 7.92 (d,1H), 8.33 (s,	393
13	δ 0.99 (d,6H), 1.98 (m,1H), 2.44 (s,3H), 3.22 (brs, 1H), 3.46 (m,2H), 3.73 (m,1H), 5.88 (s,1H), 6.31 (d,1H), 7.32 (d,1H), 7.48 (s,1H), 7.92 (d,1H), 8.32 (s, 1H)	379
14	δ 0.21 (m,2H), 0.54 (m,2H), 1.10 (m,1H), 2.53 (s,3H), 3.28 (s,3H), 3.91 (d,2H), 5.99 (s,1H), 7.32 (d,1H), 7.48 (s,1H), 7.97 (d,1H), 8.43 (s,1H)	379

Co. No.	^{1}H NMR data ($CDCl_3$)	MS M + 1
15	δ 0.96 (t,3H), 1.31 (t,3H), 1.38 (m,2H), 1.71 (m,2H), 2.49 (s,3H), 3.74 (t,2H), 3.65 (q,2H), 5.90 (s,1H), 7.30 (dd,1H), 7.46 (d,1H), 7.97 (d,1H), 8.40 (s,1H)	377
16	δ 0.96 (t,6H), 1.73 (m,4H), 2.49 (s,3H), 3.73 (t,4H), 5.88 (s,1H), 7.33 (dd,1H), 7.46 (d,1H), 7.98 (d,1H), 8.40 (s,1H)	377
17	δ 0.26 (m,2H), 0.58 (m,2H), 0.98 (t,3H), 1.18 (m,1H), 1.76 (m,2H), 2.53 (s,3H), 3.76 (d,2H), 3.81 (t,2H), 6.02 (s,1H), 7.34 (dd,1H), 7.49 (dd,1H), 8.44 (s,1H)	389
18	δ 1.04 (t,3H), 1.77 (m,2H), 2.53 (s,3H), 3.47 (t,2H), 3.98 (m,2H), 4.06 (m,2H), 5.52 (brs, 1H), 6.03 (s,1H), 7.33 (d,1H), 7.48 (s,1H), 7.93 (d, 1H), 8.39 (s, 1H)	379
19	δ 0.98 (t,3H), 1.76 (m,2H), 2.50 (s,3H), 3.35 (s,3H), 3.67 (t,2H), 3.72 (m,2H), 4.14 (m,2H), 5.95 (s,3H), 7.29 (d,1H), 7.47 (s,1H), 7.97 (d,1H), 8.39 (s,1H)	393
20	δ 0.96 (t,6H), 1.73 (m,4H), 2.55 (s,3H), 3.74 (t,4H), 5.90 (s,1H), 7.40 (d,2H), 8.04 (d,2H), 8.25 (s,1H)	343
21	δ 0.26 (m,2H), 0.51 (m,2H), 0.92 (t,3H), 1.10 (m,1H), 1.69 (m,2H), 2.72 (s,3H), 3.41 (d,2H), 3.47 (t,2H), 6.17 (s,1H), 7.18 (t,1H), 7.43 (d,2H), 7.99 (s,1H)	389
22	δ 0.93 (t,3H), 1.67 (m,2H), 2.71 (s,3H), 3.32 (s,3H), 3.44 (t,2H), 3.61 (m,2H), 3.68 (m,2H), 6.16 (s,1H), 7.17 (t,1H), 7.41 (d,2H), 7.99 (s,1H)	393
23	δ 0.24 (m,2H), 0.55 (m,2H), 0.95 (t,3H), 1.38 (m,2H), 1.69 (m,2H), 2.51 (s,3H), 3.74 (d,2H), 3.82 (t,2H), 6.00 (s,1H), 7.31 (dd,1H), 7.48 (dd,1H), 7.98 (d,1H), 8.42 (s,1H)	403
24	δ 0.28 (m,2H), 0.50 (m,2H), 0.94 (d,6H), 1.10 (m,1H), 2.05 (m,1H), 2.52 (s,3H), 3.62 (d,2H), 3.82 (d,2H), 6.03 (s,1H), 7.32 (d,1H), 7.47 (s,1H), 7.99 (d,1H), 8.43 (s,1H)	403
25	δ 0.17 (m,2H), 0.47 (m,2H), 0.97 (t,6H), 1.05 (m,1H), 1.67 (m,4H), 2.52 (s,3H), 2.43 (d,2H), 4.71 (m,1H), 6.13 (s,1H), 7.32 (dd,1H), 7.47 (d,1H), 8.02 (d,1H), 8.43 (s,1H)	417
26	δ 2.41 (s,3H), 4.01 (m,2H), 4.15 (m,2H), 4.79 (s,2H), 5.62 (brs, 1H), 6.02 (s,1H), 7.35 (m,6H), 7.48 (s,1H), 7.91 (d,1H), 8.41 (s,1H)	427
27	δ 1.91 (s,3H), 2.47 (s,3H), 4.20 (t,2H), 4.43 (t,2H), 4.96 (s,2H), 6.03 (s,1H), 7.34 (m,6H), 7.49 (s,1H), 7.94 (d,1H), 8.44 (s,1H)	469

28	δ 0.98 (t,3H), 1.74 (m,2H), 1.93 (s,3H), 2.49 (s,3H), 3.59 (m,2H), 4.84 (m,2H), 4.39 (m,2H), 5.95 (s,1H), 7.30 (dd,1H), 7.46 (d,1H), 7.92 (d,1H), 8.38 (s,1H)	421
29	δ 0.28 (m,2H), 0.60 (m,2H), 1.20 (m,1H), 2.51 (s,3H), 3.70 (d,2H), 4.50 (d,2H), 5.29 (d,1H), 5.30 (d,1H), 5.96 (m,1H), 6.05 (s,1H), 7.32 (dd,1H), 7.48 (d,1H), 7.96 (d,1H), 8.44 (s,1H)	387
30	δ 1.07 (t,3H), 1.80 (m,2H), 2.46 (s,3H), 2.55 (s,3H), 3.36 (dt,2H), 5.82 (s,1H), 6.29 (t,1H), 7.29 (d,1H), 7.38 (d,1H), 7.51 (s,1H)	381
31	δ 1.41 (d,6H), 2.46 (s,3H), 2.55 (s,3H), 3.85 (m,1H), 5.82 (s,1H), 6.08 (d,1H), 7.29 (d,1H), 7.39 (d,1H), 7.51 (s,1H)	381
32	δ 0.92 (t,3H), 1.01 (t,3H), 1.25-1.80 (m,8H), 2.45 (s,3H), 2.54 (s,3H), 3.48 (m,1H), 5.79 (s,1H), 6.02 (d,1H), 7.27 (d,1H), 7.39 (d,1H), 7.50 (s,1H)	437
33	δ 0.96 (t,3H), 1.20 (t,6H), 1.74 (m, 4H), 2.15 (s,3H), 2.34 (s,3H), 2.41 (s, 3H), 3.56 (t,4H), 3.79 (t,4H), 5.77 (s,1H), 6.41 (s,1H), 7.54 (s,1H)	-
34	δ 2.45 (s,3H), 2.56 (s,3H), 3.93 (s,3H), 4.60 (d,2H), 5.90 (s,1H), 6.70 (t,1H), 6.99 (t,2H), 7.27-7.41 (m,4H), 7.52 (s,1H)	459
35	δ 2.44 (s,3H), 2.60 (s,3H), 3.35 (s,6H), 5.00 (brs,1H), 5.84 (s,1H), 7.29 (d,1H), 7.38 (d,1H), 7.51 (s,1H)	367
36	δ 1.36 (s,6H), 2.42 (s,3H), 2.59 (s,3H), 3.80 (m,4H), 5.80 (s,1H), 7.29 (d,1H), 7.38 (d,1H), 7.51 (s,1H)	395
37	δ 0.98 (t,6H), 1.78 (m,4H), 2.40 (s,3H), 2.59 (s,3H), 3.69 (m,4H), 5.74 (s,1H), 7.28 (d,1H), 7.48 (d,1H)	423
38	δ 0.30 (m,2H), 0.62 (m,2H), 0.99 (t,3H), 1.20 (m,1H), 1.81 (m,2H), 2.49 (s,3H), 2.59 (s,3H), 3.65-3.90 (m,4H), 5.87 (s,1H), 7.29 (d,1H), 7.39 (d,1H), 7.51 (s,1H)	435
39	δ 1.05 (d,3H), 1.38 (d,3H), 2.45 (s,3H), 2.56 (s,3H), 3.40 (m,1H), 5.80 (s,1H), 7.30 (d,1H), 7.37 (d,1H), 7.51 (s,1H)	423
40	δ 0.98 (t,6H), 1.40 (m,4H), 1.75 (m,4H), 2.42 (s,3H), 2.59 (s,3H), 3.71 (m,4H), 5.76 (s,1H), 7.29 (d,1H), 7.39 (d,1H), 7.51 (s,1H)	451
41	δ 0.29 (m,2H), 0.61 (m,2H), 0.93 (t,3H), 1.20-1.56 (m,3H), 1.75 (m,2H), 2.43 (s,3H), 2.59 (s,3H), 3.65-3.90 (m,4H), 5.88 (s,1H), 7.30 (d,1H), 7.39 (d,1H), 7.51 (s,1H)	449
42	δ 2.42 (s,3H), 2.59 (s,3H), 4.34 (d,4H), 5.30 (m,4H), 5.87 (s,1H), 6.05 (m,2H), 7.29 (d,1H), 7.39 (d,1H), 7.51 (s,1H)	419

Co. No.	^{1}H NMR data ($CDCl_3$)	MS M + 1
43	δ 0.31 (m,2H), 0.62 (m,2H), 1.00 (t,3H), 1.23 (m,1H), 1.81 (m,1H), 2.49 (s,3H), 3.05 (brs,3H), 3.42-3.95 (m,4H), 6.04 (s,1H), 7.33 (d,1H), 7.50 (s,1H), 7.51 (d,1H)	451
44	δ 0.13 (m,2H), 0.48 (m,2H), 0.90 (t,3H), 1.05 (m,1H), 1.60 (m,2H), 2.64 (s,3H), 3.05 (brs,3H), 3.48 (d,2H), 3.71 (m,2H), 6.04 (s,1H), 7.37 (d,1H), 7.54 (s,1H), 7.60 (d,1H)	485 (+H_2O)
45	δ 0.95 (t,3H), 1.42 (m,2H), 1.98 (m,2H), 2.49 (s,3H), 3.33 (s,3H), 3.56 (m,2H), 3.75 (m,2H), 5.93 (m,1H), 7.31 (d,1H), 7.46 (s,1H), 7.96 (d,1H), 8.40 (s,1H)	407
46	δ 0.91 (t,3H), 0.95 (t,3H), 1.35-2.05 (m,8H), 2.70 (t,2H), 3.33 (s,3H), 3.40 (m,6H), 5.92 (s,1H), 7.30 (d,1H), 7.46 (s,1H), 8.02 (d,1H), 8.41 (s,1H)	449
47	δ 0.87 (t,3H), 1.25 (m,2H), 1.70 (m,2H), 2.04 (m,2H), 2.68 (m,2H), 3.41 (s,3H), 3.56 (m,4H), 5.86 (s,1H), 6.60 (t,1H), 7.31 (d,1H), 7.46 (s,1H), 8.14 (d,1H), 8.50 (s,1H)	407
48	δ 0.95 (t,6H), 1.71 (m,4H), 2.47 (s,3H), 2.55 (s,3H), 3.71 (t,4H), 5.82 (s,1H), 7.39 (d,2H), 7.70 (d,2H)	357
49	δ 0.24 (m,2H), 0.54 (m,2H), 0.96 (t,3H), 1.12 (m,1H), 1.74 (m,2H), 2.35 (s,3H), 2.44 (s,3H), 3.73 (d,2H), 3.76 (t,2H), 5.93 (s,1H), 7.29 (d,1H), 7.35 (d,1H), 7.51 (s,1H)	403
50	δ 1.64 (t,3H), 2.52 (s,3H), 2.60 (s,3H), 4.56 (q,2H), 6.02 (s,3H), 7.30 (d,1H), 7.37 (d,1H), 7.51 (s,1H)	368
52	δ 0.9 (t, 6H), 1.68 (m, 4H), 2.13 (s, 3H), 2.30 (s, 3H), 2.37 (s, 3H), 3.05 (s, 6H), 3.65 (m, 4H), 5.74 (s, 1H), 6.44 (s, 1H), 8.01 (s, 1H)	M^+ = 366
53	δ 0.9 (t, 6H), 1.70 (m, 4H), 2.35 (s, 3H), 2.45 (s, 3H), 3.05 (s, 6H), 3.65 (m, 4H), 5.74 (s, 1H), 6.44 (s, 1H), 8.01 (s, 1H)	M^+ = 380
54	δ 0.95 (t, 6H), 1.73 (m, 4H), 2.52 (s, 3H), 2.76 (s, 3H), 3.73 (t, 4H), 5.85 (s, 1H), 7.68 (dd, 1H), 8.45 (d, 1H), 8.57 (d, 1H)	-
55	δ 0.96 (t, 6H), 1.70 - 1.78 (m, 4H), 2.44 (s, 3H), 2.47 (s, 3H), 2.50 (s, 3H), 3.73 (t, 4H), 5.48 (s, 1H), 8.36 (d, 1H), 9.32 (d, 1H)	383
56	δ 0.93 (t, 6H), 1.66 - 1.73 (m, 4H), 2.19 (s, 3H), 2.36 (s, 3H), 2.42 (s, 3H), 3.71 (t, 4H), 5.79 (s, 1H), 6.39 (d, 1H), 8.05 (d, 1H)	353
57	δ 0.96 (t, 6H), 1.62 - 1.70 (m, 4H), 2.2 (s, 3H), 2.36 (s, 3H), 2.40 (s, 3H), 2.96 (s, 6H), 3.68 (t, 4H), 5.76 (s, 1H), 6.91 (d, 1H), 8.08 (d,1H)	381

Table 7 : Analytical data

Co. No.	Mass spectral data	Co. No.	Mass spectral data
58	409 [M+]	95	364 [MH+]
59	365 [M+]	96	395 [MH+]
60	394 [MH+]	97	407 [MH+]
61	380 [MH+]	98	372 [MH+] (Cl^{35})
62	381 [MH+]	99	464 [MH+]
63	381 [MH+]	100	356 [MH+]
64	393 [MH+]	101	426 [MH+] (Cl^{35})
65	350 [MH+]	102	458 [MH+] (Cl^{35})
66	366 [MH+]	103	392 [MH+] (Cl^{35})
67	381 [MH+]	104	408 [MH+] (Cl^{35})
68	399 [MH+]	105	404 [MH+] (Cl^{35})
69	415 [MH+]	106	368 [MH+]
70	411 [MH+]	107	409 [MH+]
71	399 [MH+]	108	421 [MH+]
72	371 [MH+]	109	383 [MH+]
73	397 [MH+]	110	353 [MH+]
74	388 [M+]	111	372 [MH+] (Cl^{35})
75	407 [MH+]	112	366 [MH+]
76	373 [MH+]	113	381 [MH+]
77	359 [MH+]	114	338 [MH+]
78	346 [M+]	115	377 [MH+]
79	373 [MH+]	116	383 [MH+]
80	397 [MH+]	117	399 [MH+]
81	381 [MH+]	118	395 [MH+]
82	393 [MH+]	119	415 [MH+]
83	429 [MH+]	120	385 [MH+]
84	377 [MH+]	121	367 [MH+]
85	409 [MH+]	122	383 [MH+]
86	367 [MH+]	123	383 [MH+]
87	339 [MH+]	124	399 [MH+]
88	381 [MH+]	125	338 [MH+]
89	367 [MH+]	126	353 [MH+]
90	381 [MH+]	127	365 [MH+]
91	393 [MH+]	128	370 [M+]

Co. No.	Mass spectral data	Co. No.	Mass spectral data
92	381 [MH+]	129	368 [M+]
93	409 [MH+]	130	393 [MH+]
94	352 [MH+]	131	379 [MH+]

C. Pharmacological examples

Example C.1

REPRESENTATIVE COMPOUNDS HAVING CRF RECEPTOR BINDING ACTIVITY

Compounds were evaluated for binding activity to the CRF receptor by a standard radioligand binding assay as generally described by DeSouza et al. (*J. Neurosci.* 7:88-100, 1987). By utilizing various radiolabeled CRF ligands, the assay may be used to evaluate the binding activity of the compounds of the present invention with any CRF receptor subtype. Briefly, the binding assay involves the displacement of a radiolabeled CRF ligand from the CRF receptor.

More specifically, the binding assay was performed in 1.5 ml Eppendorf tubes using approximately 1 x 10^6 cells per tube stably transfected with human CRF receptors. Each tube received about 0.1 ml of assay buffer *(e.g.,* Dulbecco's phosphate buffered saline, 10 mM magnesium chloride, 20 µM bacitracin) with or without unlabeled sauvagine, urotensin I or CRF (final concentration, 1 µM) to determine nonspecific binding, 0.1 ml of [^{125}I] tyrosine - ovine CRF (final concentration ~200 pM or approximately the K_D as determined by Scatchard analysis) and 0.1 ml of a membrane suspension of cells containing the CRF receptor. The mixture was incubated for 2 hours at 22°C followed by the separation of the bound and free radioligand by centrifugation. Following two washes of the pellets, the tubes were cut just above the pellet and monitored in a gamma counter for radioactivity at approximately 80% efficiency. All radioligand binding data was analyzed using a non-linear least-square curve-fitting program.

Binding activity corresponds to the concentration (nM) of the compound necessary to displace 50% of the radiolabeled ligand from the receptor. The following compounds have a $K_i \leq 250$ nM : 5, 10, 12, 15 - 17, 19, 23, 24, 26, 27, 29, 31 - 33, 36 - 43, 48, 49, 51 - 54 and 57 - 130 as listed in Tables 2 - 5. Compounds 17, 29, 38, 41, 42, 48, 49, 51 - 54, 57, 58, 70, 71, 81 - 85, 90 - 92, 101, 103 - 105, 115, 118, 121 - 123 and 125 were found to show the best score in this test.

Example C.2

CRF STIMULATED ADENYLATE CYCLASE ACTIVITY

The compounds of the present invention may also be evaluated by various functional testing. For example, the compounds of the present invention may be screened for CRF-stimulated adenylate cyclase activity. An assay for the determination of CRF-stimulated adenylate cyclase activity may be performed as generally described by Battaglia et al. *(Synapse* 1:572, 1987), with modifications to adapt the assay to whole cell preparations.

More specifically, the standard assay mixture may contain the following in a final volume of 0.5 ml: 2 mM L-glutamine, 20 mM HEPES, and 1 mM IMBX in DMEM buffer. In stimulation studies, whole cells with the transfected CRF receptors are plated in 24-well plates and incubated for 1 hour at 37°C with various concentrations of CRF-related and unrelated peptides in order to establish the pharmacological rank-order profile of the particular receptor subtype. Following the incubation, the medium is aspirated, the wells rinsed once gently with fresh medium, and the medium aspirated. To determine the amount of intracellular cAMP, 300 µl of a solution of 95% ethanol and 20 mM aqueous hydrochloric acid is added to each well and the resulting suspensions are incubated at -20°C for 16 to 18 hours. The solution is removed into 1.5 ml Eppendorf tubes and the wells washed with an additional 200 µl of ethanol/aqueous hydrochloric acid and pooled with the first fraction. The samples are lyophilized and then resuspended with 500 µl sodium acetate buffer. The measurement of cAMP in the samples is performed using a single antibody kit. For the functional assessment of the compounds, a single concentration of CRF or related peptides causing 80% stimulation of cAMP production is incubated along with various concentrations of competing compounds (10^{-12} to 10^{-6}M).

Example C.3

The plus-maze and defensive withdrawal paradigms are correlated measures of exploratory activity sensitive to anxiogenic and anxiolytic effects of experimental treatments. These animal models are employed to examine anxiolytic and anti-stress actions of compounds of the present invention.

Example C.3-a : The Elevated Plus-Maze Paradigm

This test predicts how animals respond to an approach-avoidance situation involving a bright lighted space versus a dark "safe" area. Both spaces are elevated off the ground and constitute two runways intersecting in the form of plus sign. This type of

approach-avoidance situation is a classical test of "emotionality" and reactivity and is very sensitive to treatments that produce disinhibition (such an sedative/hypnotic drugs) and stress. No motivational constraints are necessary and the animal is free to remain in the dark or venture out on the open arms. The plus-maze apparatus has four arms (10 x 50 cm) at right angles to each other and is elevated from the floor (50 cm). Two of the arms are enclosed with walls (40 cm high) and two arms have no walls (open arms). Subjects are placed individually onto the center of the maze and allowed free access to all four arms for 5 minutes. Subjects are observed through a window in the door and via an on-line display of the rat's location on a computer monitor. Time spent in each arm is recorded automatically by photocell beams and a computer program. The maze is wiped clean with a damp cloth between each trial. The measure of anxiogenic-like behavior in this task is a decrease in time spent on open arms while the measure of anti-stress efficacy is a complementary increase in time spent on open arms.

Validation of the Plus-Maze Using CRF Peptides :
Central administration of CRF and exposure to any of several experimental stressors suppresses exploration in the elevated plus maze model of anxiety. When measuring the behavioral response to social defeat, central administration of the alpha-helical CRF (9-41) antagonist either post-stress [25 µg ICV] or pre-stress [1 µg ICV] reverses the anxiogenic effect of social defeat. This anti-stress action of the CFR antagonist is also exerted following intracerebral administration into the central nucleus of amygdala [250 ng IC].

Rats were administered the test compounds orally one hour prior to the five minute test. Some groups were placed in a water-filled pool for ninety seconds immediately prior to placement on the Plus-Maze (Stress group) while control subjects were removed directly from the home cage (Non-Stress group). In the non-treated animal group a significant reduction of the percentage of the average time spent in the open arms was observed (from about 36 to about 16 %). Upon administration of 2.5 or 20 mg/kg of compound 53, the % time in the open arms returned to a level equal, within the error range, to the untreated group.

Example C.3-b : The defensive Withdrawal Paradigm

Testing takes place in a plexiglas open field (106 x 92 x 77 cm) containing a cylindrical galvanized steel chamber measuring 17.1 cm deep and 10.2 cm in diameter. The chamber is open at one end and is located along the wall of the open field aligned

lengthwise and 15.0 cm away from a corner of the open field. The open end faces the corner. The open field is illuminated by fluorescent ceiling lighting. For testing, the animals are introduced into the unfamiliar test environment by placing them into the small chamber. Tests take 5 minutes in duration and the apparatus is cleaned with a mild acetic acid solution after each test. The test compound is administered orally one hour before the 5 minutes test. The behavior of the animals is monitored and recorded by video camera. The latency to leave the chamber will be measured and defined as the placement of all four paws in the open field. Also measured is the number of passages made between the chamber and the open field and the average length of time in the chamber per entry. The measure of anxiolytic efficacy is a decrease in mean time spent within the enclosed chamber. Compound 53 reduced the mean time in the chamber from about 80 seconds to about 20 to 40 seconds when administered at doses of 0.63, 2.5 and 20 mg/kg p.o. to rats.

Validation of Defensive Withdrawal using CRF peptides

When injected ICV, both alpha-helical CFR (9-41) and CRF modify behavior in the defensive withdrawal paradigm. In particular, ICV administration of CRF in animals previously familiarized with the apparatus increases both the latency to emerge from the small chamber and mean time spent in the chamber over the fifteen minute session. Similarly, infusion of CRF into the locus ceruleus produced similar changes in defensive withdrawal behavior suggesting that the interaction of CRF with noradrenergic neurons is involved in defensive withdrawal behavior in rats. Conversely, ICV administration of alpha-helical CRF (9-14) or d-Phe CRF (12-41), competitive CRF receptor antagonists, reverses the CRF-like effect of a restraint stressor in familiar environment condition and significantly decreases latency to emerge and mean time in chamber measures in animals unfamiliar with the apparatus.

D. Composition examples

The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic or topical administration to warm-blooded animals in accordance with the present invention.

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I), a *N*-oxide form, a pharmaceutically acceptable acid or base addition salt or a stereochemically isomeric form thereof.

Example D.1 : Oral solutions

9 g of methyl 4-hydroxybenzoate and 1 g of propyl 4-hydroxybenzoate are dissolved in 4 l of boiling purified water. In 3 l of this solution are dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 20 g of the A.I. The latter solution is combined with the remaining part of the former solution and 12 l of 1,2,3-propanetriol and 3 l of sorbitol 70% solution are added thereto. 40 g of sodium saccharin are dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of gooseberry essence are added. The latter solution is combined with the former, water is added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the A.I. per teaspoonful (5 ml). The resulting solution is filled in suitable containers.

Example D.2 : Capsules

20 g of the A.I., 6 g sodium lauryl sulfate, 56 g starch, 56 g lactose, 0.8 g colloidal silicon dioxide, and 1.2 g magnesium stearate are vigorously stirred together. The resulting mixture is subsequently filled into 1000 suitable hardened gelatin capsules, each comprising 20 mg of the A.I..

Example D.3 : Film-coated tablets

Preparation of tablet core

A mixture of 100 g of the A.I., 570 g lactose and 200 g starch is mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinyl-pyrrolidone in about 200 ml of water. The wet powder mixture is sieved, dried and sieved again. Then there are added 100 g microcrystalline cellulose and 15 g hydrogenated vegetable oil. The whole is mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

Coating

To a solution of 10 g methyl cellulose in 75 ml of denaturated ethanol there is added a solution of 5 g of ethyl cellulose in 150 ml of dichloromethane. Then there are added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol is molten and dissolved in 75 ml of dichloromethane. The latter solution is added to the former and then there are added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpyrrolidone and 30 ml of concentrated colour suspension and the whole is homogenated. The tablet cores are coated with the thus obtained mixture in a coating apparatus.

Example D.4 : Injectable solution


1.8 g methyl 4-hydroxybenzoate and 0.2 g propyl 4-hydroxybenzoate were dissolved in about 0.5 l of boiling water for injection. After cooling to about 50°C there were added while stirring 4 g lactic acid, 0.05 g propylene glycol and 4 g of the A.I. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 l volume, giving a solution of 4 mg/ml of A.I. The solution was sterilized by filtration and filled in sterile containers.

Example D.5 : Suppositories

3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 Grams surfactant and 300 grams triglycerides were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37 to 38°C to form 100 suppositories each containing 30 mg/ml of the A.I.

Claims

1. A compound of formula



(I),

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein

R^1 is NR^4R^5 or OR^5;

R^2 is C_{1-6}alkyl, C_{1-6}alkyloxy or C_{1-6}alkylthio;

R^3 is hydrogen, C_{1-6}alkyl, C_{1-6}alkylsulfonyl, C_{1-6}alkylsulfoxy or C_{1-6}alkylthio;

R^4 is hydrogen, C_{1-6}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, C_{3-6}cycloalkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl;

R^5 is C_{1-8}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, Ar^1CH_2, C_{3-6}alkenyl, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl, thienylmethyl, furanylmethyl, C_{1-6}alkylthioC_{1-6}alkyl, morpholinyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylC_{1-6}alkyl, C_{1-6}alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar^1;

or R^4 and R^5 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl; and

Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6}alkyl, trifluoromethyl, hydroxy, cyano, C_{1-6}alkyloxy, benzyloxy, C_{1-6}alkylthio, nitro, amino and mono- or di(C_{1-6}alkyl)amino; pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6}alkyl, trifluoromethyl, hydroxy, cyano, C_{1-6}alkyloxy, benzyloxy, C_{1-6}alkylthio, nitro, amino, mono- or di(C_{1-6}alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;

Ar^1 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C_{1-6}alkyl, C_{1-6}alkyloxy, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, trifluoromethyl and C_{1-6}alkyl substituted with morpholinyl; or pyridinyl; and

Alk is C_{1-6}alkanediyl;

with the proviso that 5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine are not included.

2. A compound according to claim 1 wherein R^1 is OR^5 and R^5 is C_{1-6}alkyl; or R^1 is NR^4R^5 and R^4 is hydrogen, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxy-C_{1-6}alkyl or C_{3-6}alkenyl, R^5 is C_{1-8}alkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, phenylmethyl or C_{3-6}cycloalkylmethyl; or R^4 and R^5 are taken together with the nitrogen atom to which they are attached to form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl; R^2 is C_{1-6}alkyl; R^3 is hydrogen, C_{1-6}alkyl or C_{1-6}alkylthio; and Ar is a phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C_{1-6}alkyl or C_{1-6}alkyloxy; or Ar is a pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, amino, nitro, trifluoromethyl, mono- or di(C_{1-6}alkyl)amino, piperidinyl or C_{1-6}alkyl.

3. A compound according to any of claims 1 to 2 wherein R^1 is NR^4R^5 and R^4 is C_{2-4}alkyl, hydroxyC_{1-2}alkyl, C_{3-4}alkenyl or C_{1-2}alkylcarbonyloxyC_{2-4}alkyl; R^5 is C_{2-4}alkyl, C_{3-4}alkenyl, hydroxyC_{2-4}alkyl or cyclopropylmethyl; R^2 is C_{1-2}alkyl; R^3 is hydrogen, C_{1-2}alkyl or C_{1-2}alkylthio.

4. A compound according to any of claims 1 to 3 wherein R^1 is NR^4R^5 and R^4 is C_{3-4}alkyl or allyl; R^5 is C_{2-4}alkyl, allyl or cyclopropylmethyl; R^2 is methyl; R^3 is methyl; and Ar is phenyl substituted in the 3-, 4-, 6-, 2,4- or 2,4,6-positions with halo, C_{1-6}alkyl or C_{1-6}alkyloxy.

5. A compound according to any of claims 1 to 3 wherein R^1 is NR^4R^5 and R^4 is C_{3-4}alkyl or allyl; R^5 is C_{3-4}alkyl, allyl or cyclopropylmethyl; R^2 is methyl; R^3 is methyl; and Ar is 3-pyridinyl substituted on the 4- and/or 6-position with methyl or dimethylamino.

6. A compound according to claim 1 wherein the compound is 3-[6-(dimethylamino)-3-pyridinyl]-2,5-dimethyl-*N*,*N*-dipropylpyrazolo[2,3-a]pyrimidin-7-amine, or 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-*N*,*N*-dipropylpyrazolo[2,3-a]pyrimidin-7-amine;


the stereochemically isomeric forms, or the pharmaceutically acceptable acid addition salts thereof.

7. A composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6.

8. A process for preparing a composition as claimed in claim 7 characterized in that a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6 is intimately mixed with a pharmaceutically acceptable carrier.

9. A compound according to any one of claims 1 to 6 for use as a medicine.


10. The use of compounds of formula



(I),

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R^1, R^2, R^3 and Ar are as defined in claim 1, including the compounds 5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine, for the manufacture of a medicament for treating physiological conditions or disorders arising from the hypersecretion of corticotropin-releasing factor (CRF).


11. A compound of formula (II') wherein the radicals R^2, R^3 and Ar are as defined in any of claims 1 to 5 and radical W' is hydroxy, halo, mesyloxy or tosyloxy; a stereoisomeric form or an acid addition salt form thereof, with the proviso that compounds wherein Ar is unsubstituted phenyl are not included.



(II')


12. A process of preparing a compound as claimed in claim 1, characterized by

a) reacting an intermediate of formula (II) with an intermediate of formula (III) in a reaction-inert solvent,



(II) (III) (I)

b) *O*-alkylating an intermediate of formula (VI) with an intermediate of formula (VII) in a reaction-inert solvent and in the presence of a suitable base, yielding compounds of formula (I-a), defined as compounds of formula (I) wherein R^1 is OR^5,




(VI) (VII) (I-a)

wherein in the above reaction schemes the radicals R^1, R^2, R^3, R^5 and Ar are as defined in claim 1 and W is an appropriate leaving group;

or, if desired, converting compounds of formula (I) into each other following art-known transformation reactions; and further, if desired, converting the compounds of formula (I), into an acid addition salt by treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

13. A process of preparing a compound of formula (II') as claimed in claim 10 characterized by

reacting an intermediate of formula (IV) with a β-keto ester (V) in a reaction-inert solvent, thereby yielding compounds of formula (II'-a), defined as compounds of formula (II') wherein W' is hydroxy;



and optionally converting compounds of formula (II'-a) into compounds of formula (II'-b), defined as compounds of formula (II') wherein W' is other than hydroxy;

wherein in the above reaction schemes the radicals R^2, R^3 and Ar are as defined in claim 1 and W' is hydroxy, halo, mesyloxy or tosyloxy;

or, if desired, converting compounds of formula (II') into each other following art-known transformation reactions; and further, if desired, converting the compounds of formula (II'), into an acid addition salt by treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/EP 97/00459

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D487/04 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 61 057 587 A (SHIONOGI AND CO., LTD., JAPAN) 1986 cited in the application & CHEMICAL ABSTRACTS, vol. 105, no. 25, 22 December 1986 Columbus, Ohio, US; abstract no. 226617e, see abstract ---	1
X	JP 42 011 753 A (SHIONOGI AND CO., LTD.) 1967 cited in the application see the whole document & CHEMICAL ABSTRACTS, vol. 67, no. 23, 4 December 1967 Columbus, Ohio, US; abstract no. 108663r, see abstract --- -/--	1

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

4

Date of the actual completion of the international search	Date of mailing of the international search report
15 May 1997	29. 05. 97

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	De Jong, B

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Intern. al Application No
PCT/EP 97/00459

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. MED. CHEM. (1976), 19(4), 512-16 CODEN: JMCMAR, 1976, XP002030876 NOVINSON, THOMAS ET AL: "Novel heterocyclic nitrofurfural hydrazones. In vivo antitrypanosomal activity" see page 516, compounds 7a, 7b ---	11
X	J. MED. CHEM. (1981), 24(5), 610-13 CODEN: JMCMAR;ISSN: 0022-2623, 1981, XP002030877 SENGA, KEITARO ET AL: "Synthesis and antischistosomal activity of certain pyrazolo[1,5-a]pyrimidines" see Table II, no. 33,35 ---	11
A	WO 94 13677 A (PFIZER ;CHEN YUHPYNG LIANG (US)) 23 June 1994 cited in the application see claims -----	1-13

4

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. al Application No
PCT/EP 97/00459

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 61057587 A	24-03-86	NONE	
JP 42011753 A		NONE	
WO 9413677 A	23-06-94	AU 5728194 A	04-07-94
		CA 2150709 A	23-06-94
		CN 1094048 A,B	26-10-94
		CZ 9501586 A	15-11-95
		EP 0674642 A	04-10-95
		FI 935675 A	18-06-94
		HU 70426 A	30-10-95
		JP 7509728 T	26-10-95
		NO 952399 A	16-08-95
		NZ 259114 A	24-03-97
		PL 309359 A	02-10-95
		ZA 9309405 A	15-06-95

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C07D 487/04, A61K 31/505, C07D 207/34 // (C07D 487/04, 239:00, 209:00)

A1

(11) International Publication Number: WO 94/13676

(43) International Publication Date: 23 June 1994 (23.06.94)

(21) International Application Number: PCT/US93/10715

(22) International Filing Date: 12 November 1993 (12.11.93)

(30) Priority Data:
07/991,764 17 December 1992 (17.12.92) US

(60) Parent Application or Grant
(63) Related by Continuation
US 07/991,764 (CIP)
Filed on 17 December 1992 (17.12.92)

(71) Applicant *(for all designated States except US)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: CHEN, Yuhpyng, L. [US/US]; 8 Waterview Drive, Waterford, CT 06385 (US).

(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).


(81) Designated States: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: PYRROLOPYRIMIDINES AS CRF ANTAGONISTS

(57) Abstract

The compounds of formula (I), wherein B, R_3, R_4, R_5 and R_6 are as defined herein, are useful in the treatment of stress-related and other diseases. These compounds have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of depression and anxiety related, and other disorders.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	**GB**	United Kingdom	**MR**	Mauritania
AU	Australia	**GE**	Georgia	**MW**	Malawi
BB	Barbados	**GN**	Guinea	**NE**	Niger
BE	Belgium	**GR**	Greece	**NL**	Netherlands
BF	Burkina Faso	**HU**	Hungary	**NO**	Norway
BG	Bulgaria	**IE**	Ireland	**NZ**	New Zealand
BJ	Benin	**IT**	Italy	**PL**	Poland
BR	Brazil	**JP**	Japan	**PT**	Portugal
BY	Belarus	**KE**	Kenya	**RO**	Romania
CA	Canada	**KG**	Kyrgystan	**RU**	Russian Federation
CF	Central African Republic	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CG	Congo			**SE**	Sweden
CH	Switzerland	**KR**	Republic of Korea	**SI**	Slovenia
CI	Côte d'Ivoire	**KZ**	Kazakhstan	**SK**	Slovakia
CM	Cameroon	**LI**	Liechtenstein	**SN**	Senegal
CN	China	**LK**	Sri Lanka	**TD**	Chad
CS	Czechoslovakia	**LU**	Luxembourg	**TG**	Togo
CZ	Czech Republic	**LV**	Latvia	**TJ**	Tajikistan
DE	Germany	**MC**	Monaco	**TT**	Trinidad and Tobago
DK	Denmark	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**US**	United States of America
FI	Finland	**ML**	Mali	**UZ**	Uzbekistan
FR	France	**MN**	Mongolia	**VN**	Viet Nam
GA	Gabon				


PYRROLOPYRIMIDINES AS CRF ANTAGONISTS

This invention relates to pyrrolopyrimidines, pharmaceutical compositions containing them, and their use in the treatment of stress-related and other diseases. The compounds have corticotropin-releasing factor (CRF) antagonist activity.

CRF antagonists are mentioned in U.S. Patents 4,605,642 and 5,063,245 referring to peptides and pyrazolinones, respectively. The importance of CRF antagonists is set out in the literature, e.g. as discussed in U.S. Patent 5,063,245, which is incorporated herein by reference. A recent outline of the different activities possessed by CRF antagonists is found in M.J. Owens et al., Pharm. Rev., Vol. 43, pages 425 to 473 (1991), also incorporated herein by reference. Based on the research described in these two and other references, CRF antagonists are considered effective in the treatment of a wide range of diseases including stress-related illnesses, such as stress-induced depression, anxiety, and headache; abdominal bowel syndrome; irritable colon syndrome; spastic colon; irritable colon; inflammatory diseases; immune suppression; human immunodeficiency virus (HIV) infections; Alzheimer's disease; gastrointestinal diseases; anorexia nervosa; hemorrhagic stress; drug and alcohol withdrawal symptoms; drug addiction, and fertility problems.

Certain substituted pyrrolopyrimidines have been described in the prior art. U.S. Patent 4,229,453 describes 4-amino substituted pyrrolopyrimidines for treating CNS illnesses or inflammations. Robins, Can. J. Chem., 55, 1251 (1977) describes the antibiotic tubercidin having a 7-ribofuranosyl group attached to 4-aminopyrrolopyrimidine. German Patent Publication 3145287 refers to three 7-bromophenyl-5,6-dimethyl-pyrrolopyrimidines as having analgesic, sedative, anti-convulsant and anti-inflammatory activity.

The present invention relates to a compound of the formula



I

and the pharmaceutically acceptable acid addition salts thereof, wherein

B is NR_1R_2, $CR_1R_2R_{11}$, $C(=CR_2R_{12})R_1$, $NHCR_1R_2R_{11}$, $OCR_1R_2R_{11}$, $SCR_1R_2R_{11}$, $NHNR_1R_2$, $CR_2R_{11}NHR_1$, $CR_2R_{11}OR_1$, $CR_2R_{11}SR_1$, or $C(O)R_2$;

R_1 is hydrogen, or C_1-C_6 alkyl which may be substituted by one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C_1-C_8 alkoxy, O-C -(C_1-C_6 alkyl), O-C NH(C_1-C_4 alkyl), O-C -N(C_1-C_4 alkyl)(C_1-C_2 alkyl), amino, NH(C_1-C_4 alkyl), N(C_1-C_2 alkyl)(C_1-C_4 alkyl), S(C_1-C_6 alkyl), N(C_1-C_4 alkyl)C (C_1-C_4 alkyl), NHC (C_1-C_4 alkyl), COOH, C O(C_1-C_4 alkyl), C NH(C_1-C_4 alkyl), C N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SH, CN, NO_2, SO(C_1-C_4 alkyl), SO_2(C_1-C_4 alkyl), SO_2NH(C_1-C_4 alkyl), SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), and said C_1-C_6 alkyl may contain one or two double or triple bonds;

R_2 is C_1-C_{12} alkyl, aryl or (C_1-C_{10} alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C_1-C_6 alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, benzyl or C_1-C_4 alkanoyl, wherein R_2 may be substituted independently by from one to three of chloro, fluoro, or C_1-C_4 alkyl, or one of hydroxy, bromo, iodo, C_1-C_6 alkoxy, O-C -(C_1-C_6 alkyl), O-C -N(C_1-C_4 alkyl)(C_1-C_2 alkyl), S(C_1-C_6 alkyl), NH_2, NH(C_1-C_2 alkyl), N(C_1-C_2 alkyl) (C_1-C_4 alkyl), N(C_1-C_4 alkyl)-C (C_1-C_4 alkyl), NHC (C_1-C_4 alkyl), COOH, C O(C_1-C_4 alkyl), C NH(C_1-C_4 alkyl), C N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SH, CN, NO_2, SO(C_1-C_4 alkyl), SO_2(C_1-C_4 alkyl), SO_2NH(C_1-C_4 alkyl), SO_2N(C_1-C_4 alkyl)(C_1-

C_2 alkyl), and wherein said C_1-C_{12} alkyl or C_1-C_{10} alkylene may contain one to three double or triple bonds; or

NR_1R_2 or $CR_1R_2R_{11}$ then R_1 and R_2 taken together with the atom to which they are attached may form a saturated 3- to 8-membered ring of which the 5- to 8-membered ring may contain one or two double bonds or one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, C_1-C_4 alkanoyl or benzyl;

R_3 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, $O(C_1$-C_6 alkyl), $NH(C_1$-C_6 alkyl), $N(C_1$-C_4 alkyl)$(C_1$-C_2 alkyl), SH, $S(C_1$-C_4 alkyl), $SO(C_1$-C_4 alkyl), or $SO_2(C_1$-C_4 alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may contain one double or triple bond and may be substituted by from 1 to 3 substituents R_8 independently selected from the group consisting of hydroxy, C_1-C_3 alkoxy, fluoro, chloro or C_1-C_3 thioalkyl;

R_4 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, formyl, $NH(C_1$-C_6 alkyl), $N(C_1$-C_6 alkyl$)(C_1$-C_2 alkyl), $SO_n(C_1$-C_6 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C_1-C_6 alkyls may be substituted by one hydroxy, trifluoromethyl, amino, carboxy, amido, $NHC(=O)(C_1$-C_4 alkyl), $NH(C_1$-C_4 alkyl), $N(C_1$-C_4 alkyl$)(C_1$-C_2 alkyl), $C(=O)O(C_1$-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, C_1-C_4 alkanoyl, phenyl or benzyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, formyl, C_1-C_6 alkyl, C_1-C_6 alkoxy or trifluoromethyl, or one of hydroxy, iodo, cyano, nitro, amino, $NH(C_1$-C_4 alkyl), $N(C_1$-C_4 alkyl$)(C_1$-C_2 alkyl), $COO(C_1$-C_4 alkyl), $CO(C_1$-C_4 alkyl), $SO_2NH(C_1$-C_4 alkyl), $SO_2N(C_1$-C_4 alkyl$)(C_1$-C_2 alkyl), SO_2NH_2, $NHSO_2(C_1$-C_4 alkyl), $S(C_1$-C_6 alkyl), $SO_2(C_1$-C_6 alkyl), wherein said C_1-C_4 alkyl

and C_1-C_6 alkyl may be substituted by one or two of fluoro, chloro, hydroxy, C_1-C_4 alkoxy, amino, methylamino, dimethylamino or acetyl wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may contain one double or triple bond; with the proviso that R_5 is not unsubstituted phenyl;

R_6 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, formyl, amino, $NH(C_1$-C_6 alkyl), $N(C_1$-C_6 alkyl)(C_1-C_2 alkyl), $SO_n(C_1$-C_6 alkyl), wherein n is 0, 1 or 2, cyano, carboxy, or amido, wherein said C_1-C_6 alkyls may be substituted by one hydroxy, trifluoromethyl, amino, carboxy, amido, NHC(C_1-C_4 alkyl), $NH(C_1$-C_4 alkyl), $N(C_1$-C_4 alkyl)(C_1-C_2 alkyl), C(=O)O(C_1-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_{11} is hydrogen, hydroxy, fluoro, chloro, $COO(C_1$-C_2 alkyl), cyano, or $CO(C_1$-C_2 alkyl); and

R_{12} is hydrogen or C_1-C_4 alkyl; with the proviso that (1) B is not straight chain alkyl, (2) when R_5 is unsubstituted cycloalkyl, R_3 and R_4 are hydrogen, and R_6 is hydrogen or methyl, then B is not NHR_2 wherein R_2 is benzyl or thienylmethyl, and (3) when R_5 is p-bromophenyl, and R_3, R_4 and R_6 are methyl, then B is not methylamino or hydroxyethylamino.

Preferred compounds of the formula I of the invention are those wherein B is NR_1R_2, $NHCHR_1R_2$, or $OCHR_1R_2$, wherein R_1 is C_1-C_6 alkyl, which may be substituted by one of hydroxy, fluoro or C_1-C_2 alkoxy, and may contain one double or triple bond; those wherein R_2 is benzyl or C_1-C_6 alkyl which may contain one double or triple bond, wherein said C_1-C_6 alkyl or the phenyl in said benzyl may be substituted by fluoro, C_1-C_6 alkyl, or C_1-C_6 alkoxy; those wherein R_3 is methyl, ethyl, fluoro, chloro or methoxy; those wherein R_4 and R_6 are independently hydrogen, methyl, or ethyl; and those wherein R_5 is phenyl substituted by two or three substituents, said substituent being independently fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethyl, C_1-C_6 alkyl which may be substituted by one of hydroxy, C_1-C_4 alkoxy or fluoro and may have one double or triple bond, -(C_1-C_4 alkylene)O(C_1-C_2 alkyl), C_1-C_3 hydroxyalkyl, hydroxy, formyl, $COO(C_1$-C_2 alkyl), -(C_1-C_2 alkylene)amino, or -C(O)(C_1-C_4 alkyl).

Specific preferred compounds include:

n-butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

di-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

ethyl-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

diethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

n-butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

2-{N-n-butyl-N-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-ethanol;

4-(1-ethyl-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine;

n-butyl-ethyl-[2,5-dimethyl-7-(2,4-dimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidyl-4-yl]-(1-ethyl-propyl)amine;

2-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-butan-1-ol;

2-(S)-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-butan-1-ol;

4-(1-ethyl-propoxy)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine;

4-(1-methoxymethyl-propoxy)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine;

4-(1-ethyl-butyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo-[2,3-d]pyrimidine;

[7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-(1-methoxymethyl-propyl)-amine;

2-[7-(2-bromo-4,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-butan-1-ol;

2-[7-(4-ethyl-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-butan-1-ol;

2-[7-(2-ethyl-4,6-dimethylphenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-butan-1-ol; and


2-[7-(2-fluoromethyl-4,6-dimethylphenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-butan-1-ol.

The invention also relates to a pharmaceutical composition for the treatment of illnesses induced or facilitated by corticotropin releasing factor which comprises a compound of the formula I as defined above in an amount effective in the treatment of said illnesses, and a pharmaceutically acceptable carrier, and a pharmaceutical composition for the treatment of inflammatory disorders, such as arthritis, asthma and allergies; anxiety; depression; fatigue syndrome; headache; pain; cancer; irritable bowel syndrome, including Crohn's disease, spastic colon and irritable colon; immune dysfunction; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease; gastrointestinal diseases; eating disorders such as anorexia nervosa; hemorrhagic stress; drug and alcohol withdrawal symptoms; drug addiction; stress-induced psychotic episodes; and fertility problems, which comprises a compound of the formula I as defined above in an amount effective in the treatment of said disorders, and a pharmaceutically acceptable carrier. Preferred compositions of the invention are those containing preferred compounds of formula I as described above.

The invention further relates to a method for the treatment of illnesses induced or facilitated by corticotropin releasing factor by administering to a subject in need of such treatment a compound of formula I as defined above in an amount effective in such treatment, and a method for the treatment of inflammatory disorders, such as arthritis, asthma and allergies; anxiety; depression; fatigue syndrome; headache; pain; cancer; irritable bowel syndrome, including Crohn's disease, spastic colon and irritable colon; immune dysfunction; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease; gastrointestinal diseases; eating disorders such as anorexia nervosa; hemorrhagic stress; drug and alcohol withdrawal symptoms; drug addiction; stress-induced psychotic episodes; and fertility problems, particularly depression and anxiety, by administering to a subject in need of such treatment a compound of formula I as defined above in an amount effective in

such treatment. Preferred methods of the invention are those administering a preferred compound of the formula I as described above.

The invention also relates to an intermediate compound of the formula



I I


wherein

D is hydroxy, chloro, or cyano,

R_4 and R_6 are each independently hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, $SO_n(C_1$-C_6 alkyl), wherein n is 0, 1 or 2, or cyano, wherein said C_1-C_6 alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, $NHC(=O)(C_1$-C_4 alkyl), $NH(C_1$-C_4 alkyl), $N(C_1$-C_4 alkyl)$(C_1$-C_2 alkyl), $C(=O)O(C_1$-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperdinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, C_1-C_4 alkanoyl, phenyl or phenylmethyl, wherein each of the above groups may be substituted independently by from one to three of fluoro, chloro, C_1-C_6 alkyl, C_1-C_6 alkoxy or trifluoromethyl, or one of bromo, iodo, cyano, nitro, amino, $NH(C_1$-C_4 alkyl), $N(C_1$-$C_4)(C_1$-C_2 alkyl), $COO(C_1$-C_4 alkyl), $CO(C_1$-C_4 alkyl), $SO_2NH(C_1$-C_4 alkyl), $SO_2N(C_1$-C_4 alkyl)$(C_1$-C_2 alkyl), SO_2NH_2, $NHSO_2(C_1$-$C_4)$, $S(C_1$-C_6 alkyl), $SO_2(C_1$-C_6 alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R_5 is not unsubstituted phenyl; and

R_9 is hydrogen, C_1-C_6 alkyl or chloro; with the proviso that when (a) R_4 and R_6 are methyl, R_9 is hydrogen and D is hydroxy, then R_5 is not phenyl (1) substituted by one of halogen, nitro, C_1-C_6 alkyl, C_1-C_6 alkoxy, or trifluoromethyl, and optionally in addition substituted by one or two of halogen, C_1-C_6 alkyl or C_1-C_6 alkoxy, or (2) di-or trisubstituted by one of nitro or trifluoromethyl and one or two of halogen, C_1-C_6 alkyl or C_1-C_6 alkoxy, and (b) when D is chloro, R_4 and R_9 are hydrogen, and R_6 is C_1-C_6 alkyl, then R_5 is not unsubstituted cyclohexyl; and a compound of the formula



VII

wherein

Q is $C(O)CHR_1R_2$ or cyano;

R_1 is hydrogen, or C_1-C_6 alkyl which may be substituted by one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C_1-C_8 alkoxy, $S(C_1$-C_6 alkyl), or nitro, and said C_1-C_8 alkyl may contain one or two double or triple bonds;

R_2 is C_1-C_{12} alkyl, aryl or (C_1-C_{10} alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C_1-C_6 alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, benzyl or C_1-C_4 alkanoyl, wherein R_2 may be substituted independently by from one to three of chloro, fluoro, or C_1-C_4 alkyl, or one of hydroxy, bromo, iodo, C_1-C_6 alkoxy, $S(C_1$-C_6 alkyl), or nitro, and wherein said C_1-C_{12} alkyl or C_1-C_{10} alkylene may contain one to three double or triple bonds; or

R_4 and R_6 are each independently hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, amino, $SO_n(C_1$-C_6 alkyl), wherein n is 0, 1 or 2, cyano, wherein said

C_1-C_6 alkyl may be substituted by one C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, C_1-C_4 alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, C_1-C_6 alkyl, C_1-C_6 alkoxy or trifluoromethyl, or one of bromo, iodo, cyano, nitro, amino. $NH(C_1$-C_4 alkyl), $N(C_1$-$C_4)(C_1$-C_2 alkyl), $COO(C_1$-C_4 alkyl), $CO(C_1$-C_4 alkyl), $SO_2NH(C_1$-C_4 alkyl), $SO_2N(C_1$-C_4 alkyl)$(C_1$-C_2 alkyl), SO_2NH_2, $NHSO_2(C_1$-C_4 alkyl), $S(C_1$-C_6 alkyl), $SO_2(C_1$-C_6 alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R_5 is not unsubstituted phenyl; and R_{16} is hydrogen or $C(O)C_1$-C_6 alkyl; with the proviso that when Q is cyano, R_4 and R_6 are not both methyl.

Whenever reference is made to alkyl, this includes both straight and branched chain alkyl.


Whenever reference is made herein to 3-to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl containing one to three of O, S or N-Z, it is understood that the oxygen and sulfur ring atoms are not adjacent to each other. The three membered cycloalkyl has just one O, S or N-Z. An example of a six-membered cycloalkyl having O and N is morpholinyl.

Whenever R_2 or R_5 is a heterocyclic group, the attachment of the group is through a carbon atom.

Whenever reference is made herein to C_1-C_4 alkyl or C_1-C_6 alkyl which "may contain one or two double or triple bonds" in the definitions of R_1, R_2 and R_3, it is understood that at least two carbons are present in the alkyl for one double or triple bond, and at least four carbons for two double and triple bonds.

Whenever an alkoxy group, e.g. in the definitions of R_1 and R_2, may have a double or triple bond, it is understood that such double or triple bond is not directly attached to the oxygen.

The compounds of formula I wherein B is NR_1R_2, $NHCR_1R_2R_{11}$, $OCR_1R_2R_{11}$, $SCR_1R_2R_{11}$, or $NHNR_1R_2$, and R_3 is hydrogen, C_1-C_6 alkyl or chloro (hereafter R_9) may be prepared by reaction of a compound of the formula



II

wherein D is Cl, and R_4, R_5 and R_6 are as defined above with reference to formula I, with a compound of the formula BH wherein B is as defined immediately above. The reaction is carried out in a solvent in the presence of a base at a temperature of between about 0° to about 150°C. Suitable solvents are organic solvents such as acetonitrile, dimethylsulfoxide, acetone, C_2-C_{15} alkyl alcohol, tetrahydrofuran, chloroform, benzene, xylene or toluene, preferably acetontrile or dimethylsulfoxide.


When B is NR_1R_2, $NHNR_1R_2$, or $NHCR_1R_2R_{11}$, an excess of BH is used. Other bases such as potassium carbonate or tri-(C_1-C_6)alkyl amine may be used instead. The reaction is carried out at a temperature of about 75° to 150°C. When the reaction is carried out in the presence of a base, such as sodium hydride or potassium C_1-C_4 alkoxide, a molar equivalent of the amine is used. When B is $OCR_1R_2R_{11}$ or $SCR_1R_2R_{11}$, a base which is capable of deprotonation of BH may be used, such as an alkali metal hydride such as sodium or potassium hydride, or an organometallic base such as sodium diisopropylamide, sodium bis(trimethylsily)amide, lithium diisopropylamide, lithium bis(trimethylsily)amide, sodium C_1-C_4 alkoxide or n-butylithium. The solvent used is dry tetrahydrofuran, dimethylsulfoxide, methylene chloride, or toluene, and the reaction temperature is between about -78°C and the reflux temperature of the reaction mixture, preferably 0°C to 80°C.

The compounds of formula I wherein R_3 is the groups other than R_9 (hereafter R_{10}) may be prepared by reacting a compound of the formula I wherein R_3 is chloro with a nucleophile of the formula $R_{10}H$ with or without an organic or inorganic base. Suitable bases include sodium, sodium hydride, and alkali metal hydroxide such as potassium hydroxide, and weaker bases such as potassium carbonate or triethylamine.

The latter are generally used when $R_{10}H$ is alkanol, C_1-C_6 alkanethiol, an amine, e.g. NH(C_1-C_6 alkyl), or tetrahydrobutyl ammonium fluoride. Suitable solvents are dimethylsulfoxide, acetonitrile, C_1-C_5 alkyl alcohol, tetrahydrofuran, benzene, toluene or methylene chloride.

The compounds of formula II wherein D is chloro may be prepared by reacting the corresponding 4-hydroxy compound of formula III (not shown) with an excess of phosphorus oxychloride or thionyl chloride at temperatures between about 60 to 140°C, conveniently at the reflux temperature of the reaction mixture. When the reaction is carried out in a solvent, suitable solvents are halogenated alkanes, such as methylene chloride or chloroform. The reaction may be in the presence of a base such as N,N-diethylaniline, trimethylamine or potassium carbonate.

The compounds of formula III wherein R_9 is hydrogen may be prepared by reaction of a compound of the formula



IV

wherein R_4, R_5, and R_6 are as defined with reference to formula I with formic acid at a temperature between about 60 to 140°C, preferably at the reflux temperature of the reaction mixture.


The compounds of formula III wherein R_9 is C_1-C_6 alkyl (hereafter R_{13}) may be prepared by reacting a compound of formula IV with $R_{13}COOCOR_{13}$ in $R_{13}COOH$ or $R_{13}CO(OC_1$-C_2 alkyl)$_3$ in acetic acid or an appropriate organic solvent such as ethyl acetate or toluene, at a temperature between 25° to 120°C, preferably at the reflux temperature of the reaction mixture. The compounds of formula III wherein R_9 is hydroxy may be prepared by reacting a compound of formula IV with chlorosulfonyl isocyanate in an appropriate solvent at temperature between -78°C to 100°C, preferably at -20°C to 60°C, followed by acid hydrolysis. The appropriate solvents include methylene chloride, dimethyl formamide, tetrahydrofuran, and toluene.

preferably dimethyl formamide or methylene chloride. The above formed compounds wherein R_9 is hydrogen, C_1-C_6 alkyl or hydroxy may be heated in aqueous acid to give the compounds of formula III. The appropriate aqueous acids are 85% phosphoric acid, hydrochloric acid, sulfuric acid, or acetic acid, preferably 85% phosphoric acid. The reaction is generally carried out at about 25 to 150°C, preferably 80 to 130°C. Alternatively, the formed compounds may be heated with phosphorous pentoxide and N,N-dimethylcyclohexanamine at about 150 to 200°C.

The compounds of formula IV may be prepared by conventional methods.

The compounds of formula I wherein B is $CR_1R_2R_{11}$ and R_3 is hydrogen, C_1-C_6 alkyl, or hydroxy (hereafter R_{14}) may be prepared, as depicted in Scheme 1, by heating a compound of the formula VI, wherein R_{14} is hydrogen, C_1-C_6 alkyl or amino, R_1, R_2, R_{11}, R_4, R_5, and R_6 are as defined above, and Y is $CR_1R_2R_{11}$, with ammonium chloride and $R_{14}CONH_2$ at reflux temperatures.

Scheme 1



V VI I-A

The compounds of formula I wherein B is $CR_1R_2R_{11}$ as defined above with reference to formula I and R_3 is as defined above with reference to formula I, other than hydrogen, C_1-C_6 alkyl, or hydroxy, may be prepared by reacting the 2-chloro derivatives of formula I wherein R_3 is chloro (formula I-B, not shown) with a nucleophile of formula $R_{15}H$ with or without an organic or inorganic base by the method described previously for the reaction with $R_{10}H$, wherein R_{15} is R_3 other than hydrogen, C_1-C_6 alkyl, hydroxy, and chloro. The compounds of formula I-B may be prepared by a method analogous to that for the conversion of compounds III to compounds II wherein D is chloro.


The compounds of formula VI may be prepared, as shown in Scheme I, starting from compounds of the formula V by methods analogous to those for the conversion of compounds IV to compounds III.

The compounds of formula V may be prepared by methods analogous to the conventional methods used for the preparation of compounds of formula IV by using $YCOCH_2CN$ instead of malonitrile, wherein Y is $CR_1R_2R_{11}$.

The compounds of formula I wherein B is $C(O)R_2$ may be prepared by reacting a compound of formula II wherein D is cyano with a Grignard reagent containing group R_2, e.g. R_2MgCl, or R_2MgBr.

The compounds of formula I wherein B is $CR_1R_2R_{11}$, $C(C=CR_2R_{12})R_1$, $CR_2R_{11}NHR_1$, $CR_2R_{11}OR_1$, $CR_2R_{11}SR_1$ or $C(O)R_2$, and R_3 is R_9 as defined above with reference to formula II, may be prepared as depicted in Scheme 2.

Scheme 2



The compounds of formula II wherein D is cyano and R_4, R_5, R_6 and R_9 are as defined above, prepared by reacting the corresponding compound wherein D is chloro with potassium cyanide in dimethylsulfoxide, are reacted with a Grignard reagent containing group R_1 as defined above to form the compound of formula VII. Further reaction of the compound of formula VII with a Grignard reagent containing group R_2 as defined above provides the compound of formula IC. Corresponding compounds of formula ID wherein B is $CR_1R_2R_{11}$ or $C(=CR_1R_{12})R_1$ may be prepared by conventional methods. Thus, reaction of IC with an acid, such as concentrated sulfuric acid or hydrochloric acid, gives a compound of formula I wherein B is $C(=CR_2R_{12})R_1$. Hydrogenation of a compound wherein B is $C(=CR_2R_{12})R_1$ using Pd/C or platinum oxide catalyst gives a compound I wherein B is CHR_1R_2. Reaction of a compound I wherein B is CR_1R_2OH with diethylamino sulfur trifluoride or triphenylphosphine carbontetrachloride affords a compound I wherein B is CR_1R_2F or CR_1R_2Cl, respectively.

When the compounds of the invention contain one or more chiral centers, it is understood that the invention includes the racemic mixture and the individual diastereomers and enantiomers of such compounds.

The acid addition salts of the compounds of formula I are prepared in a conventional manner by treating a solution or suspension of the free base of formula I with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques are employed in isolating the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p-toluenesulfonic, mandelic, di-p-toluoyl-L-tartaric and related acids.

The novel compound of the invention of formula I may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple, e.g. up to three, doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

For parenteral administration, solutions of the novel compound of formula I in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular

aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

Additionally, it is possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may be done by way of creams, jellies, gels, pastes and ointments in accordance with standard pharmaceutical practice.

The effective dosage for the compound of formula I depends on the intended route of administration and other factors such as age and weight of the patient, as generally known to a physician. The dosage also depends on the illness to be treated. The daily dosage will generally range from about 0.1 to 50 mg/kg of the body weight of the patient to be treated. For treatment of inflammatory diseases about 0.1 to about 100 mg/kg will be needed, for Alzheimer's disease, about 0.1 to about 50 mg/kg, as well as for gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, etc.

The methods for testing the compounds for formula I for their CRF antagonist activity are according to the procedures of Endocrinology, 116, 1653-1659 (1985) and Peptides, 10, 179-188 (1985) which determine the binding affinity of a test compound for a CRF receptor. The binding affinities for the compounds of formula I. expressed as IC_{50} values, generally range from about 0.2 nanomolar to about 10 micromolar.

The following Examples illustrate the invention. The following abbreviations are used: Ph=phenyl, Me=methyl, Bu=butyl, Et=ethyl, Pr=propyl.

Example 1

A. 2-amino-4-methyl-1-(2,4,6-trimethylphenyl)pyrrole-3-carbonitrile

A mixture 2-(2-bromo-1-methyl-ethylidene)-malononitrile and 2,4,6-trimethylaniline (17.330 g, 91.24 mmol) in 40 mL of isopropanol was stirred at room temperature for 15 hours. The reaction mixture was concentrated to dryness and diluted with chloroform and water. The chloroform layer was neutralized with dilute sodium hydroxide and washed with brine, separated, dried and concentrated to give 33.000 g of brown oily solid. The solid was purified through silica gel column chromatography to give 9.35 g (47.5%) of the title compound as an orange-yellow solid. ^1H NMR ($CDCl_3$) δ 2.0(s.6H). 2.15(s,3H), 2.35(s,3H), 3.75(brs.2H). 5.8(s.1H), 6.95(s,2H) ppm.

B. N-[3-cyano-4-methyl-1-(2,4,6-trimethylphenyl)-1H-pyrrol-2-yl]-acetamide

A mixture of the purified compound of step A (3.000 g, 12.54 mmol) and acetic anhydride (1.410 g, 1.31 ml, 13.82 mmol) in 3 ml of acetic acid was refluxed for 45 minutes, cooled and poured onto crushed ice and extracted with ethyl acetate. The organic layer was neutralized, dried and concentrated to give 3.71 g (105%) of dark-pink glass foam. ^{1}H NMR ($CDCl_3$) δ 1.95(s,6H), 2.2(s,3H), 2.32 (s,3H), 6.2(s,1H), 6.8(brs, 1H, NH), 6.9(s,2H) ppm.

C. 2,5-dimethyl-7-(2,4,6-trimethylphenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

A suspension of the compound of step B (3.200 g, 11.38 mmol) in 3 ml of 85% phosphoric acid was immersed in an oil bath preheated to 130°C for 30 minutes. The reaction mixtures was cooled and poured onto crushed ice and stirred until solid formed and ice melted. The solid was filtered, washed with water to give a tannished solid, the title compound, which was purified through silica gel column chromatography to give a tan solid. ^{1}H NMR ($CDCl_3$) δ 1.92(s,6H), 2.32(s,3H), 2.41(s,3H), 2.45(s,3H), 2.46(s,3H), 6.42(d,1H), 6.95(s,2H) ppm.

D. 4-chloro-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo-[2,3-d]pyrimidine

A mixture of the compound of step C (1.030 g, 3.67 mmol) and $POCl_3$ (3 ml) was heated at reflux for 2.5 hours and cooled. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with dilute sodium bicarbonate and brine, dried over anhydrous sodium sulfate, and concentrated to dryness to give the title compound as a tan solid which was purified through silica gel to give an off-white solid. ^{1}H NMR ($CDCl_3$) δ 1.90(s,6H), 2.35(s,3H), 2.50(s,3H), 2.65(s,3H), 6.78(s,1H), 7.00(s,2H) ppm.

EXAMPLE 2

A. 2-amino-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrole-3-carbonitrile

A mixture of 3-hydroxy-2-butanone (100.000 g, 1.135 mol), 2,4,6-trimethylaniline (153.225 g, 1.135 mol) and p-toluenesulfonic acid (0.670 g) in 500 ml of benzene was refluxed using a Dean-Stark trap to remove water. After 2 hours,malononitrile (75.000 g, 1.135 mol) was added and the mixture was refluxed for an additional 10 hours until all the staring material was consumed. The reaction mixture was cooled and precipitate formed and filtered. The solid was washed with a minimum amount of ethanol. The

solid was diluted with 500 ml of benzene and product was dissolved. Some undesired product was insoluble and was filtered off. The filtrate was concentrated to give a tan solid which was recrystallized from ethanol to give 130.260 g of off-white crystals. ^{1}H NMR ($CDCl_3$) δ 1.68(s,3H), 1.93(s,6H), 2.05(s,3H), 2.31(s,3H), 3.62(brs,2H), 6.95(s,2H) ppm.

B. N-[3-cyano-4,5-dimethyl-1-(2,4,6-trimethyphenyl)-1H-pyrrol-2-yl]-acetamide

The title compound was prepared as a tan solid by the procedure analogous to that of Example 1A starting with the compound of step A and acetic anahydride in acetic acid. The crude material was pure and used directly for the next cyclization step. ^{1}H NMR ($CDCl_3$) δ 1.75(s,3H), 1.80(s,6H), 1.95(s,3H), 2.18(s,3H), 2.30(s,3H), 6.60(brs, 1H), 6.93(s,2H) ppm.

C. 2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-3,7-dihydro-pyrrol[2,3-d]pyrimidin-4-one

A mixture of the compound of step B(157.600 g, 0.53 mol) and 100 ml of 85% phosphoric acid was heated for 0.5 hours in an oil bath at a temperature of 130°C. All the starting material was consumed and the desired product formed. The mixture was cooled, poured into 1200 ml of ice-water, and stirred. Precipitate formed and was filtered. The solid was washed with water, dried overnight to give 113.220 g of the title compound as brick-pink solid. ^{1}H NMR ($CDCl_3$) δ 1.85(s,6H), 1.87(s,3H), 2.34(s,3H), 2,41(s,3H), 2.44(s,3H), 7.00(s,2H) ppm.

EXAMPLE 3

A. 2-amino-4,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrole-3-carbonitrile

The crude material of the title compound was prepared as an oil by the procedure analogous to that of Example 2A starting with 4-hydroxy-3-hexanone. The crude material was used directly for the next acetylation step without further purification.

B. N-[3-cyano-4,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrol-2-yl]-acetamide

The title compound was prepared as an oil by the procedure of Example 1A starting with the compound of above step A and acetic anhydride in acetic acid. The crude material was purified through silica gel column chromatography using chloroform as eluent to give the title compound as an oil. ^{1}H NMR ($CDCl_3$) δ 0.85(t,3H), 1.26(t,3H), 1.92(s,6H), 2.19(s,3H), 2.23(q,2H), 2.33(s,3H), 2.59(q,2H), 6.95(s,2H) ppm.

C. 2-methyl-5,6-diethyl-7-(2,4,6-trimethylphenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

The title compound was prepared as a brown solid by the procedure of Example 2C starting with the compound of above step B and 85% phosphoric acid. The crude material was used directly for the next chlorination reaction without further purification.

EXAMPLE 4

The following compounds were prepared according to the method of Example 1 starting from the corresponding 2,5,6-trialkyl-7-(2,4,6-trimethylphenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one.

4-chloro-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine - a tan solid. ^{1}H NMR ($CDCl_3$) δ 1.81(s,6H), 1.99(s,3H), 2.35(s,3H), 2.46(s,3H), 2.59(s,3H), 7.01(s,2H) ppm.

4-chloro-2-methyl-5,6-diethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin - a tan solid. ^{1}H NMR ($CDCl_3$) δ 0.96(t,3H), 1.31(t,3H), 1.85(s,6H), 2.38(s,3H), 2.46(q,2H), 2.62(s,3H), 2.62(s,2H), 2.92(q,2H), 7.02(s,2H) ppm.


EXAMPLE 5

Butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine


A mixture of 4-chloro-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine (1.000 g, 3.36 mmol) and N-ethylbutylamine (3.400 g, 33.60 mmol) in 5 ml of dimethylsulfoxide was heated to reflux for 1.5 hours. The mixture was cooled and treated with water and a few drops of 2 N HCl to pH 6.5 and extracted with ethyl acetate. The organic layer was separated, washed with dilute sodium bicarbonate, brine, and dried over sodium sulfate anhydrous and concentrated to dryness. The residue was purified through silica gel column chromatography to give 995 mg (81% yield) of the title compound as an oil. ^{1}H NMR ($CDCl_3$) δ 0.90 (t,3H), 1.23(t,3H), 1.35(m,2H), 1.60-1.70(m,2H), 1.92(s,6H), 2.30(s,3H), 2.40(s,3H), 2.46(s,3H), 3.58(t,2H), 3.66(q,2H), 6.55(s,1H), 6.95(s,2H) ppm. The corresponding hydrogen chloride salt was prepared as a white crystals after recrystallization from ethyl acetate. ^{1}H NMR (D_2O) δ 0.90(t,3H), 1.34(m,5H), 1.75(m,2H), 1.90(s,6H), 2.37(s,3H), 2.48(s,3H), 2.55(s,3H), 3.80-3.94(m,4H), 7.09(s,2H) ppm.

EXAMPLE 6

The following compounds were prepared starting with the appropriate amine and the appropriate 4-chloro-2,5,6-trialkyl-7-(substituted phenyl)-7H-pyrrolo[2,3-d]pyrimidine and employing the general procedure of Example 5.



B	R_3	R_4	R_6	^{1}H NMR ($CDCl_3$) δ (ppm)
NMe_2	Me	Me	Me	1.82(s,6H), 2.00(s,3H) 2.38(s,3H) 2.40(s,3H), 2.90(s,3H), 3.58(s,6H), 7.03(s,2H)
NEt_2	Me	Me	Me	1.22(t,6H), 1.84(s,6H), 1.94(s,3H), 2.35(s,3H), 2.38(s,3H), 2.55(s,3H), 3.60(q,4H), 6.98(s,2H)
$N(n\text{-}Pr)_2$	Me	Me	Me	0.90(t,6H), 1.68(q,4H), 1.85(s,6H), 1.95(s,3H), 2.35(s,3H), 2.39(s,3H), 2.48(s,3H), 3.53(q,4H), 6.99(s,2H)
$N\text{-}(n\text{-}Bu)_2$	Me	Me	Me	0.88(t,6H), 1.30(m,4H), 1.61(m,4H), 1.82(s,6H), 1.92(s,3H), 2.30(s,3H), 2.34(s,3H), 2.47(s,3H), 3.50(t,4H), 6.95(s,2H)
EtN(n-Pr)	Me	Me	Me	0.92(t,3H), 1.20(t,3H), 1.64(m,2H), 1.85(s,6H), 1.94(s,3H), 2.35(s,3H), 2.38(s,3H), 2.47(s,3H), 3.49(t,2H), 3.59(q,2H), 6.99(s,2H)
EtN(n-Bu)	Me	Me	Me	0.90(t,3H), 1.19(t,3H), 1.33(m,2H), 1.60(m,2H), 1.83(s,6H), 1.92(s,3H), 2.33(s,3H), 2.35(s,3H), 2.45(s,3H), 3.51(t,2H), 3.58(q,2H), 6.96(s,2H)


B	R_3	R_4	R_6	^{1}H NMR ($CDCl_3$) δ (ppm)
$EtN(CH_2)_2OH$	Me	Me	Me	1.25(t,3H), 1.78(s,6H), 1.90(s,3H), 2.30(s,3H), 2.36(s,3H), 2.40(s,3H), 3.64(q,2H), 3.75(m,2H), 3.86(t,2H), 6.96(s,2H)
$(n\text{-}Bu)N(CH_2)_2OH$	Me	Me	Me	0.95(t,3H), 1.35(m,2H), 1.71(m,2H), 1.81(s,6H), 1.92(s,3H), 2.31(s,3H), 2.37(s,3H), 2.44(s,3H), 3.55(dd,2H), 3.72(t,2H), 3.87(t,2H), 6.95(s,2H)
$MeN(CH_2CHMe_2)$	Me	Me	Me	0.89(s,3H), 0.91(s,3H), 1.81(s,6H), 1.91(s,3H), 1.96-2.10(m,1H), 2.32(s,3H), 2.35(s,3H), 2.43(s,3H), 3.11(s,3H), 3.32(d,2H), 6.95(s,2H)
	Me	Me	Me	0.35(dd,2H), 0.47(m,2H), 0.90(t,3H), 1.10(m,1H), 1.67(m,2H), 1.83(s,6H), 1.93(s,3H), 2.33(s,3H), 2.37(s,3H), 2.45(s,3H), 3.41(d,2H), 3.62(t,2H), 6.97(s,2H)
$N(CH_2CH{=}CH)_2$	Me	Me	Me	1.85(s,6H), 1.96(s,3H), 2.36(s,3H), 2.39(s,3H), 2.49(s,3H), 4.18(d,4H), 5.20-5.32(m,4H), 5.90-6.10(m,2H), 7.00(s,2H)
MeN-CHMe(Et)	Me	Me	Me	0.87(t,3H), 1.29(d,3H), 1.4.-1.8(m,3H), 1.82(s,3H), 1.86(s,3H), 1.95(s,3H), 2.35(s,3H), 2.37(s,3H), 2.47(s,3H), 3.02(s,3H), 4.34(m,1H), 6.99(s,2H)
$N(CH_2CH_2OH)_2$	Me	Me	Me	1.59(brs,2H), 1.81(s,6H), 1.94(s,3H), 2.34(s,3H), 2.39(s,3H), 3.80-3.95(m,8H), 6.98(s,2H)
$HO(CH_2)_3N(CH_2)_2OH$	Me	Me	Me	1.80(s,6H), 1.93(s,3H), 1.90-2.00(m,2H), 2.33(s,3H), 2.39(s,3H), 2.43(s,3H), 3.65(t,2H), 3.70-3.85(m,2H), 3.89(m,2H), 6.98(s,2H)
$(n\text{-}Bu)N(CH_2CH_2OMe)$	Me	Me	H	0.91(t,3H), 1.31(m,2H), 1.67(m,2H), 1.90(s,6H), 2.32(s,3H), 2.41(s,3H), 2.42(s,3H), 3.36(s,3H), 3.60-3.70(m,4H), 3.82(t,2H), 6.56(s,1H), 6.95(s,2H)

B	R_3	R_4	R_6	^{1}H NMR ($CDCl_3$) δ (ppm)
p-Me-Ph$CH_2N(CH_2)_3OH$	Me	Me	H	1.80(m,2H), 1.90(s,6H), 2.20(s,3H), 2.30(s,3H), 2.34(s,3H), 2.49(s,3H), 3.54(t,2H), 3.82(t,2H), 4.90(s,2H), 6.58(s,1H), 6.95(s,2H), 7.10-7.25(m,4H)
EtN(n-Pr)	Me	Et	Et	0.93(t,6H), 1.1-1.3(m,6H), 1.68(m,2H), 1.88(s,6H), 2.36(s,3H), 2.42(q,2H), 2.49(s,3H), 2.80(q,2H), 3.49(t,2H), 3.58(q,2H), 6.99(s,2H)
EtN(n-Bu)	H	Me	Me	0.91(t,3H), 1.23(t,3H), 1.30(m,2H), 1.62(m,2H), 1.89(s,6H), 2.30(s,3H), 2.44(s,3H), 3.58(t,2H), 3.65(q,2H), 6.67(s,1H), 6.95(s,2H), 8.29(s,1H)
EtN(n-Pr) (HCl salt)	Me	Me	H	0.93(t,3H), 1.25(t,3H), 1.70(m,2H), 1.91(s,6H), 2.33(s,3H), 2.42(s,3H), 3.55(m,2H), 3.69(m,2H), 6.58(s,1H), 6.96(s,2H)
$N(n\text{-}Pr)_2$	Me	Me	H	0.90(t,6H), 1.65(m,4H), 1.90(s,3H), 2.30(s,3H), 2.40(s,3H), 2.45(s,3H), 3.5-3.6(m,4H), 6.55(s,1H), 6.93(s,2H)
$N(CH_2CH{=}CH_2)_2$	Me	Me	H	1.90(s,6H), 2.30(s,3H), 2.40(s,3H), 2.48(s,3H), 4.20(d,4H), 5.15-5.30(m,4H), 5.09-6.10(m,2H), 6.55(s,1H), 6.95(s,2H)
$EtN(CH_2CH(CH_3)_2)$	Me	Me	H	0.95(t,3H), 1.23(t,3H), 1.95(s,6H), 2.11(m,1H), 2.35(s,3H), 2.46(s,3H), 2.50(s,3H), 3.44(d,2H), 3.68(q,2H), 6.59(s,1H), 6.98(s,2H)
$EtN(CH_2C(Me){=}CH_2)$	Me	Me	H	1.21(t,3H), 1.73(d,3H), 1.93(s,6H), 2.34(s,3H), 2.42(s,3H), 2.48(s,3H), 3.63(q,2H), 4.18(s,2H), 4.95(s,1H), 5.05(s,1H), 6.58(s,1H), 6.97(s,2H)
$EtN(CH_2)_2N(CH_3)_2$	Me	Me	H	1.26(t,3H), 1.88(s,6H), 2.31(s,3H), 2.34(s,6H), 2.41(s,3H), 2.43(s,3H), 2.62(m,2H), 3.64(q,2H), 3.74(m,2H), 6.55(s,1H), 6.94(s,2H)
$EtN(CH_2C(Me)_2)$	Me	Me	Me	0.91(d,6H), 1.17(t,3H), 1.84(s,6H), 1.95(s,3H), 2.05(m,1H), 2.35(s,3H), 2.38(s,3H), 2.47(s,3H), 3.36(d,2H), 3.61(q,2H), 6.98(s,2H)

B	R_3	R_4	R_6	^{1}H NMR ($CDCl_3$) δ (ppm)
NH-$CHEt_2$	Me	Me	Me	0.96(t,6H), 1.5-1.8(m,4H), 1.82(s,6H), 1.87(s,3H), 2.3(s,3H), 2.39(s,3H), 2.40(s,3H), 4.30(m,1H), 4.76(d,1H,NH), 6.94(s,2H)
NH-$CHEt_2$	Me	Me	H	0.98(t,6H), 1.5-1.8(m,4H), 1.92(s,6H), 2.32(s,3H), 2.45(s,3H), 2.46(s,3H), 4.32(m,1H), 4.82(d,1H,NH), 6.44(s,1H), 6.95(s,2H)
NHCH(n-$Pr)_2$	Me	Me	Me	0.94(s,6H), 1.3-1.7(m,4H), 1.84(s,6H), 1.89(s,3H), 2.32(s,3H), 2.39(s,3H), 2.41(s,3H), 4.46(s,1H), 4.73(s,1H,NH), 6.96(s,2H)
NHCH(Me)(n-Bu)	Me	Me	Me	0.92(t,3H), 1.27(d,3H), 1.37(m,4H), 1.5-1.7(m,2H), 1.83(s,6H), 1.84(s,3H), 1.89(s,3H), 2.33(s,3H), 2.40(s,3H), 2.43(s,3H), 4.41(m,1H), 4.77(d,1H,NH), 6.96(s,2H)
NH(n-Bu)	Me	Me	H	0.98(t,3H), 1.35-1.45(m,2H), 1.5-1.7(m,2H), 1.90(s,6H), 2.30(s,3H), 2.43(s,3H), 2.44(s,3H), 3.57(q,2H), 4.90(m,t,1H, NH), 6.38(s,1H), 6.93(s,2H)
NHEt	Me	Me	H	1.30(t,3H), 1.90(s,6H), 2.30(s,3H), 2.44(s,3H), 2.46(s,3H), 3.62(m,2H), 4.90(t,1H,NH), 6.40(s,1H), 6.93(s,2H)
NH-cyclopropyl	Me	Me	Me	0.57(m,2H), 0,85(m,2H), 1.81(s,6H), 1.87(s,3H), 2.31(s,3H), 2.34(s,3H), 2.48(s,3H), 3.00(m,1H), 5.17(s,1H), 6.95(s,2H)
NH-(R)-CH(Et)(CH_2OH)	Me	Me	Me	1.05(t,3H), 1.5-1.8(m,2H), 1.80(s,6H), 1.89(s,3H), 2.31(s,3H), 2.40(s,6H), 3.84(2sets of ABq, 2H), 3.96(m,1H), 5.14(d,1H,NH), 6.95(s,2H), 7.04(s,1H)
NHCH(Me)(Et)	Me	Me	Me	0.99(t,3H), 1.25(d,3H), 1.57(m,2H), 1.82(s,6H), 1.88(s,3H), 2.31(s,3H), 2.39(s,3H), 2.41(s,3H), 4.35(m,1H), 4.78(d,1H,NH), 6.94(s,2H)

B	R_3	R_4	R_6	^{1}H NMR ($CDCl_3$) δ (ppm)
NH-(S)-CH(Et)(CH_2OH)	Me	Me	Me	1.05(t,3H), 1.5-1.8(m,2H), 1.80(s,6H), 1.89(s,3H), 2.31(s,3H), 2.40(s,6H), 3.84(2sets of ABq, 2H), 3.96(m,1H), 5.14(d,1H,NH), 6.95(s,2H), 7.04(s,1H)
NH-cyclopentyl	Me	Me	Me	1.49(m,2H), 1.67(m,2H), 1.81(s,6H), 1.87(s,3H), 2.13(m,2H), 2.31(s,3H), 2.37(s,3H), 2.42(s,3H), 4.58(m,1H), 4.93(d,1H,NH), 6.94(S,2H)
NH-(S)-CH(Et)(CH_2OH)	Me	Me	H	1.08(t,3H), 1.5-1.8(m,2H), 1.89(s,6H), 2.30(s,3H), 2.43(s,3H), 2.448(s,3H), 2.453(s,3H), 3.86(2sts of ABq,2H), 3.98(m,1H), 5.17(d,1H,NH), 6.48(s,1H), 6.81(s,1H), 6.94(s,1H)
NH-(S)-CH(Et)(CH_2OMe)	Me	Me	H	0.98(t,3H), 1.6-1.8(m,2H), 1.90(s,3H), 1.91(s,3H), 2.30(s,3H), 2.42(s,3H), 2.44(s,3H), 3.39(s,3H), 3.53(2 sets of ABq,2H), 4.46(m,1H), 5.24(d,1H,NH), 6.42(s,1H), 6.92(s,2H)
NHCH(Me)(Et)	Me	Me	H	0.99(t,3H), 1.26(d,3H), 1.5-1.7(m,2H), 1.91(s,6H), 2.30(s,3H), 2.44(s,6H), 4.34(m,1H), 4.79(d,1H,NH), 6.42(s,1H), 6.93(s,2H)
NH-(R)-CH(Et)(CH_2OMe)	Me	Me	Me	1.00(t,3H), 1.55-1.8(m,2H), 1.82(s,6H), 1.87(s,3H), 2.31(s,3H), 2.38(s,3H), 2.39(s,3H), 3.39(s,3H), 3.54(m,2H), 4.45(m,1H), 5.25(d,1H,NH), 6.94(s,2H)
NH-(S)-CH(Et)(CH_2OMe)	Me	Me	Me	1.00(t,3H), 1.55-1.8(m,2H), 1.82(s,6H), 1.87(s,3H), 2.31(s,3H), 2.38(s,3H), 2.39(s,3H), 3.39(s,3H), 3.54(m,2H), 4.45(m,1H), 5.25(d,1H,NH), 6.94(s,2H)

B	R_3	R_4	R_6	^{1}H NMR ($CDCl_3$) δ (ppm)
NH-CH_2CH(Me)(Et)	Me	Me	Me	0.96(t,3H), 1.00(d,3H), 1.1-1.3(m,2H), 1.4-1.6(m,2H), 1.6-1.8(m,1H), 1.82(s,6H), 1.88(s,3H), 2.31(s,3H), 2.39(s,3H), 2.42(s,3H), 3.40(m,1H), 3.54(m,1H), 5.00(t,1H,NH), 6.94(s,2H)
NH-(S)-CH(CH_2Ph)(CH_2OH)	Me	Me	Me	1.77(s,3H), 1.78(s,3H), 1.82(s,3H), 1.99(s,3H), 2.30(s,3H), 2.41(s,3H), 2.84(m,1H), 3.12(m,1H), 3.75(m,1H), 3.93(m,1H), 4.27(m,1H), 5.15(d,1H,NH), 6.94(s,2H), 7.2-7.4(m,5H)
NH-(R)-CH(CH_2Ph)(CH_2OH)	Me	Me	Me	1.77(s,3H), 1.78(s,3H), 1.82(s,3H), 1.99(s,3H), 2.30(s,3H), 2.41(s,3H), 2.84(m,1H), 3.12(m,1H), 3.75(m,1H), 3.93(m,1H), 4.27(m,1H), 5.15(d,1H,NH), 6.94(s,2H), 7.2-7.4(m,5H)
NH-(S)-CH(CH_2Ph)(CH_2OMe)	Me	Me	Me	1.80(s,3H), 1.83(s,3H), 1.88(s,3H), 2.31(s,3H), 2.33(s,3H), 2.44(s,3H), 2.90(m,1H), 3.13(m,1H), 3.40(s,3H), 3.44(m,2H), 4.70(m,1H), 5.35(d,1H,NH), 6.95(s,2H), 7.2-7.4(m,5H)
NH-(R)-CH(CH_2Ph)(CH_2OMe)	Me	Me	Me	1.80(s,3H), 1.83(s,3H), 1.88(s,3H), 2.31(s,3H), 2.33(s,3H), 2.44(s,3H), 2.90(m,1H), 3.13(m,1H), 3.40(s,3H), 3.44(m,2H), 4.70(m,1H), 5.35(d,1H,NH), 6.95(s,2H), 7.2-7.4(m,5H)
NH-(S)-CH(Et)(CH_2OEt)	Me	Me	H	1.00(t,3H), 1.20(t,3H), 1.6-1.8(m,2H0, 1.90(s,3H), 1.91(s,3H), 2.30(s,3H), 2.42(s,3H), 2.43(s,3H), 3.4-3.6(m,2H), 4.41(m,1H), 5.34(d,1H,NH), 6.42(s,1H), 6.93(s,2H)
NHCH_2CH(n-Bu)(Et)	Me	Me	Me	0.89(t,3H), 0.95(t.3H), 1.2-1.4(m,7H), 1.54-1.62(m.1H), 1.82(s,6H), 1.88(s.3H), 2.31(s,3H), 2.39(s,3H), 2.42(s.3H), 3.53(m.2H), 4.90(m.1H), 6.95(s.2H)



NR_1R_2	R_4	R_6	R_5
	^{1}H-NMR($CDCl_3$) δ (ppm)		
EtN(n-Bu)	Me	Me	2,4-dimethylphenyl
	0.89(t,3H), 1.15(t,3H), 1.30(m,2H), 1.2-1.4(m,2H), 1.87(s,3H), 1.97(s,3H), 2.33(s,3H), 2.37(s,3H), 2.44(s,3H), 3.49(t,2H), 3.55(q,2H), 6.9-7.2(m,3H)		
$N(n\text{-}Pr)_2$	Me	Me	2,4-dimethylphenyl
	0.86(t,6H), 1.62(m,4H), 1.87(s,3H), 1.97(s,3H), 2.34(s,3H), 2.37(s,3H), 3.48(m,4H), 6.95-7.20(m,3H)		
EtN(n-Bu)	Me	Me	2,6-dimethylphenyl
	0.89(t,3H), 1.31(t,3H), 1.31(m,2H), 1.62(m,2H), 1.86(s,3H), 1.90(s,3H), 2.35(s,3H), 2.43(s,3H), 3.50(t,2H), 3.56(q,2H), 7.1-7.2(m,3H)		
EtN(n-Pr)	Me	Me	2,4-dimethylphenyl
	0.89(t,3H), 1.18(t,3H), 1.66(m,2H), 1.86(s,6H), 1.91(s,3H), 2.35(s,3H), 2.43(s,3H), 3.43(m,2H), 3.56(m,2H), 7.0-7.2(m,3H)		
EtN(n-Bu)	Me	H	2,5-dimethylphenyl
	0.93(t,3H),1.22(t,3H), 1.25-1.45(m,2H), 1.6-1.8(m,2H), 2.04(s,6H), 2.33(s,3H), 2.41(s,3H), 2.42(s,3H), 3.58(t,2H), 3.64(q,2H), 6.70(s,1H), 7.06(s,1H), 7.1-7.25(m,2H)		
EtN(n-Bu)	Me	H	3-methyl-4-chlorophenyl
	0.94(t,3H), 1.23(t,3H), 1.23-1.45(m,2H), 1.4-1.6(m,2H), 2.43(s,3H), 2.44(s,3H), 2.58(s,3H), 3.4-3.75(m,4H), 6.94(s,1H), 7.4-7.65(m,3H)		
EtN(n-Bu)	Me	H	2,6-dimethyl-4-bromophenyl

NR_1R_2	R_4	R_5	R_5
	^{1}H-NMR($CDCl_3$) δ (ppm)		
	0.92(t,3H), 1.22(t,3H), 1.25-1.40(m,2H), 1.55-1.60(m,2H), 1.91(s,6H), 2.40(s,3H), 2.43(s,3H), 3.57(m,2H), 3.64(q,2H), 6.50(s,1H), 7.27(s,2H)		
EtN(n-Bu)	Me	H	2,4-dimethyl-6-bromophenyl
	0.98(t,3H), 1.28(T,3H), 1.3-1.5(m,2H), 1.6-1.8(M,2H), 2.00(s,3H), 2.36(s,3H), 2.48(s,3H), 2.53(s,3H), 3.64(t,2H), 3.71(q,2H), 6.63(s,1H), 7.09(d,1H), 7.38(d,1H)		
$NHCH(Et)_2$	Me	H	2,6-dimethyl-4-bromophenyl
	0.98(t,6H), 1.5-1.8(m,4H), 1.94(s,6H), 2.44(s,3H), 2.45(s,3H), 4.30(M,1H), 4.80(d,1H,NH), 6.39(S,1H), 7.28(s,2H)		
$NHCH(Et)(CH_2OH)$ (S)-isomer	Me	H	2,6-dimethyl-4-bromophenyl
	1.07(t,3H), 1.5-1.8(m,2H), 1.90(s,6H), 2.42(s,3H), 2.44(s,3H), 3.5-3.8(m,2H), 3.87(m,1H), 5.18(d,1H,NH), 6.45(s,1H), 6.56(s,1H), 7.27(s,2H)		
$NHCH(Et)(CH_2OMe)$	Me	H	2,6-dimethyl-4-bromophenyl
	1.00(t,3H), 1.55-1.75(m,2H), 1.92(s,6H), 2.42(s,3H), 2.43(s,3H), 3.39(s,3H), 3.55(2 sets of ABq,2H), 4.46(m,1H), 5.28(d,1H,NH), 6.38(s,1H), 7.26(s,2H)		
$NHCH(Et)(CH_2OH)$	Me	H	2,6-dimethyl-4-chlorophenyl
	1.07(t,3H), 1.55-1.80(m,2H), 1.91(s,6H), 2.42(s,3H), 2.45(s,3H), 3.74(2 sets of ABq,2H), 4.00(m,1H), 5.18(d,1H,NH), 6.46(s,1H), 6.60(brs,1H), 7.11(s,2H)		
$NH\text{-}CH(Et)(CH_2OH)$ (R)-isomer	Me	H	2,6-dimethyl-4-bromophenyl
	1.07(t,3H), 1.55-1.75(m,2H), 1.90(s,6H), 2.42(s,3H), 2.44(s,3H), 3.75(2 sets of ABq,2H), 4.00(m,1H), 5.14(d,1H,NH), 6.45(s,1H), 6.50(brs,1H), 7.27(s,2H)		

EXAMPLE 7

A. 1-[2-Amino-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrol-3-yl]-2-ethyl-butan-1-one

A mixture of 3-hydroxy-2-butanone (0.637 g, 7.23 mmol), 2,4,6-trimethylaniline (0.973 g, 7.19 mmol) and p-toluenesulfonic acid (0.012 g, 0.06 mmol) in 15 ml of

benzene was refluxed using a Dean-Stark trap to remove water. After 3 hours, 4-ethyl-3-oxo-hexanenitrile (1.008 g, 0.724 mmol) was added and the mixture was refluxed for an additional 15 hours until all the starting material was consumed. The mixture was cooled to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was dried and concentrated to give 1.679 g of brown oil which was purified by silica gel column chromatography to give 368 mg of the title compound as a brown oil and 732 mg of undesired 2-(2-ethyl-butyl)-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrole-3-carbonitrile as a yellow solid. ^{1}H-NMR ($CDCl_3$) (the title compound) δ 0.94(t,6H), 1.4-1.8(m,4H), 1.73(s,3H), 1.98(s,6H), 2.25(s,3H). 2.34(s,3H), 3.00(m,1H), 5.80(brs,2H), 6.99(s,2H) ppm. ^{1}H-NMR ($CDCl_3$) (2-(2-ethyl-butyl)-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrole-3-carbonitrile)δ0.85(t,6H),1.5-1.85(m,4H), 1.71(s,3H), 1.88(s,6H), 1.95-2.10(m,1H), 2.14(s,3H), 2.34(s,3H), 6.96(s,2H) ppm.

B. N-[3-(2-ethyl-butyryl)-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrol-2-yl]-acetamide

A mixture of 1-[2-amino-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrol-3-yl]-2-ethyl-butan-1-one (326 mg, 1 mmol) and acetic anhydride (108 mg, 1.05 mmol) in 3 ml of acetic acid was heated to reflux for 2 hours. The mixture was cooled, quenched with water, neutralized with saturated potassium carbonate, and extracted with ethyl acetate. The organic layer was washed with brine, dried, and concentrated to give the title compound as a dark oil. The oil was purified through silica gel column chromatography to give 107 mg of the title compound as a brown oil. ^{1}H-NMR ($CDCl_3$) δ 0.88(t,6H), 1.4-1.8(m,4H), 1.76(s,3H), 1.88(s,3H), 1.93(s,6H), 2.25(s,3H). 2.28(s,3H), 2.98(m,1H), 6.89(s,2H) ppm.

C. 4-(1-Ethyl-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine

A mixture of N-[3-(2-ethyl-butyl)-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrol-2-yl]-acetamide (100 mg, 0.27 mmol), ammonium chloride (290 mg, 5.42 mmol), and acetamide (1.635 g) was heated to reflux for 2 hours. The mixture was cooled, quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 56 mg of the title compound as a dark oil. The oil was purified through silica gel column chromatography to give the title compound as a yellow oil. ^{1}H-NMR ($CDCl_3$) δ 0.85(t,6H), 1.70-2.0(m,4H), 1.83(s,6H), 1.99(s,3H), 2.36(s,3H), 2.44(s,3H), 2.61(s,3H), 3.26(m,1H), 7.00(s,2H) ppm.

EXAMPLE 8

Butyl-ethyl-[2,5-dimethyl-7-(2,6-dimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-4-yl]amine and 4-[4-(butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethyl-benzoic acid

A solution of 7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4-yl]-butyl-ethyl-amine (0.700 g, 1.63 mmol) in 5 ml of dry tetrahydrofuran (THF) was added to a cooled solution of n-butyl lithium (n-BuLi) (2.5 M in hexane, 1.79 mmol) in 5 ml of dry THF at -78°C and stirred at that temperature for 20 minutes.

A part (1 mL) was taken from the reaction mixture and was quenched with an excess of water and extracted with ethyl acetate, dried and concentrated to give butyl-ethyl-[2,5-dimethyl-7-(2,6-dimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-4-yl]amine as a clear oil. The oil was treated with 1 N HCl in methanol and concentrated to dryness. The residue was recrystallized from ethyl acetate to give the corresponding HCl salt as white crystals, mp 148-150°C.

The rest of the reaction mixture was quenched with an excess of dry ice at -78°C and the -78°C bath was removed. After 30 minutes, tlc showed that no starting material was left, and the mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give an off-white solid (0.550 g). The solid was recrystallized from 2-propanol to give the second title compound as white crystals, mp 228-230°C.

EXAMPLE 9

4-[4-(Butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethyl-benzoic acid methyl ester

A mixture of 4-[4-(butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethyl-benzoic acid (0.230g, 0.583 mmol) in 40 ml of 1 N HCl and methanol was heated at reflux for 3 hours (tlc showed that all starting materials were consumed). The mixture was concentrated to dryness. The residue was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate. brine, dried and concentrated to give the title compound as a light brown oil. The oil was purified through silica gel column chromatography using 5% ethyl acetate in hexane as an eluent to give a golden oil. The corresponding HCl salt was prepared as an off-white solid, mp 58-60°C.

EXAMPLE 10

[4-(Butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethylphenyl}-methanol

A solution of 4-[4-(butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethyl-benzaldehyde (0.100 g, 0.264 mmol) in 1 ml MeOH was treated with sodium borohydride (0.030 g, 0.793 mmol) and stirred at room temperature for 20 minutes. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to dryness to give a clear oil. The oil was purified through silica gel column chromatography to give the title compound (0.092 g, 92% yield) as a white solid, mp 93-95°C.

EXAMPLE 11

Butyl-ethyl-[7-(4-fluoromethyl-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine

A solution of {4-[4-(butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethylphenyl}-methanol (0.071 g, 0.186 mmol) in 2 ml anhydrous methylene chloride was cooled to -78°C and treated with dimethylaminosulfur trifluoride (0.063g, 0.390 mmol) and stirred at room temperature for 1 hour. The mixture was quenched with water and extracted with chloroform. The organic layer was washed with brine, dried, and concentrated to give an oil which was purified through silica gel using 2% methanol/chloroform as eluent to give the title compound as an off-white solid, mp 163-165°C.

EXAMPLE 12

Butyl-ethyl-[7-(4-methoxymethyl-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine

A solution of {4-[4-(butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethylphenyl}-methanol (0.100 g, 0.263 mmol) in 1 ml of dry tetrahydrofuran was treated with sodium hydride (0.0116 g, 0.289 mmol, 60% in oil). After stirring for 10 minutes, an excess of methyl iodide was added. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give an oil. The oil was purified through silica gel column using 10% ethyl acetate in hexane as eluent to give 0.081 g (78%) of the title compound as a white glass form.

EXAMPLE 13

[7-(4-aminomethyl-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-butyl-ethyl-amine

A solution of 4-[4-(butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethyl-benzaldehyde (0.200 g, 0.528 mmol) in 2 ml of methanol was treated with sodium cyanoborohydride (0.023 g, 0.37 mmol), ammonium acetate (0.407 g, 5.28 mmol) and sodium sulfate. After stirring for 1 hour, the mixture was concentrated to remove methanol and the residue was dissolved in water, saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give an oil. The oil was purified through silica gel column using 10% methanol in chloroform as eluent to give the title compound as a clear oil. The corresponding di-HCl salt was prepared as a white solid, mp 158-160°C.


EXAMPLE 14

Butyl-ethyl-[7-(4-methoxyethyl-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine

The title compound was prepared starting from the 1-{4-[4-(butyl-ethyl-amino)-2,5-dimethyl-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethyl-phenyl}-ethanol,sodiumhydride and methyl iodide and employing the procedure of Example 12.

The ^{1}H NMR data of the compounds prepared by the methods of Examples 8 to 15 as well as other compounds prepared by these methods are listed in the following Table.


Table I



A

Example	R2'	R4'	^{1}H NMR ($CDCl_3$) δ (ppm)
8	Me	H	0.93(t,3H), 1.23(t,3H), 1.25-1.40(m,2H), 1.55-1.60(m,2H), 1.95(s,6H), 2.42(s,3H), 2.45(s,3H), 3.58(m,2H), 3.64(q,2H), 6.56(s,1H), 7.05-7.20(M,3H)
8	Me	COOH	0.95(t,3H), 1.27(t,3H), 1.3-1.45(m,2H), 1.6-1.8(m,2H), 1.96(s,6H), 2.43(s,3H), 2.56(s,3H), 3.65(t,2H), 3.72(q,2H), 6.61(s,1H), 7.52(s,2H)
	Me	CHO	0.92(t,3H), 1.23(t,3H), 1.25-1.40(m,2H), 1.55-1.70(m,2H), 2.03(s,6H), 2.42(s,3H), 2.43(s,3H), 3.58(m,2H), 3.64(q,2H), 6.54(s,1H), 7.65(s,2H), 9.99(s,1H)
10	Me	CH_2OH	0.92(t,3H), 1.22(t,3H), 1.25-1.40(m,2H), 1.55-1.70(m,2H), 1.94(s,6H), 2.41(s,3H), 2.45(s,3H), 3.58(t,2H), 3.65(q,2H), 4.55(s,2H), 6.54(s,1H), 7.09(s,2H)
	Me	CH(Me)(OH)	0.91(t,3H), 1.21(t,3H), 1.2-1.4(m,2H), 1.44(d,3H), 1.5-1.7(m,2H), 1.91(s,6H), 2.39(s,3H), 2.42(s,3H), 3.57(t,2H), 3.64(q,2H), 4.75(q,1H), 6.53(s,1H), 7.11(s,1H), 7.13(s,1H)
9	Me	COOMe	0.92(t,3H), 1.23(t,3H), 1.25-1.30(m,2H), 1.5-1.7(m,2H), 1.99(s,6H), 2.41(s,3H), 2.43(s,3H), 3.58(t,2H), 3.64(q,2H), 3.91(s,3H), 6.53(s,1H), 7.81(s,2H)
11	Me	CH_2F	0.90(t,3H), 1.20(t,3H), 1.24-1.40(m,2H), 1.5-1.7(m,2H), 1.95(s,6H), 2.38(s,3H), 2.42(s,3H), 3.54(t,2H), 3.62(q,2H). 4.30(d, 2H), 6.50(s,1H), 7.10(s,2H)
13	Me	CH_2NH_2	0.90(t,3H), 1.20(t,3H), 1.2-1.4(m,2H), 1.5-1.7(m,2H), 1.93(s,6H), 2.40(s,3H), 2.42(s,3H), 3.54(t,2H), 3.62(q,2H), 3.82(s,2H), 6.52(s,1H), 7.10(s,2H)
	Me	CONHMe	0.94(t,3H), 1.2-1.4(m,5H), 1.4-1.6(m,2H), 1.96(s,6H), 2.43(s,3H), 2.75(s,1.5H), 2.82(s,1.5H), 3.24(s,1H), 3.5-3.8(m.4H), 6.53(s,1H), 7.22(s,1H), 7.48(s,1H)
	Me	OH	0.89(t,3H), 1.20(t,3H), 1.2-1.4(m,2H), 1.5-1.7(m,2H), 1.76(s,6H), 2.379s,3H), 2.52(s,3H), 3.58(t,2H), 3.65(q,2H), 6.26(s,2H), 6.50(s,1H)

Example	R2'	R4'	^{1}H NMR ($CDCl_3$) δ (ppm)
	Me	I	0.92(t,3H), 1.22(t,3H), 1.2-1.35(m,2H), 1.5-1.7(m,2H), 1.89(s,6H), 2.40(s,3H), 2.44(s,3H), 3.57(t,2H), 3.64(q,2H), 6.50(s,1H), 7.48(s,2H)
	Me	Et	0.93(t,3H), 1.25(m,6H), 1.2-1.4(m,2H), 1.55-1.60(m,2H), 1.92(s,6H), 2.41(s,3H), 2.46(s,3H), 2.63(q,2H), 3.57(t,2H), 3.64(q,2H), 6.55(s,1H), 6.96(S,2H)
14	Me	CH(Me)(OMe)	0.88(t,3H), 1.18(t,3H), 1.2-1.4(m,2H), 1.38(d,3H), 1.5-1.7(m,2H), 1.90(s,6H), 2.36(s,3H), 2.40(s,3H), 3.24(s,3H), 3.4-3.65(m,4H), 4.20(q,1H), 6.50(s,1H), 7.00(s,2H)
12	Me	CH_2OMe	0.92(t,3H), 1.22(t,3H), 1.2-1.4(m,2H), 1.5-1.65(m,2H), 1.94(s6H), 2.41(s,3H), 2.44(s,3H), 3.42(s,3H), 3.45-3.52(m,4H), 4.42(s,2H), 6.53(s,1H), 7.10(s,2H)
	Me	$C(Me)_2(OH)$	0.92(t,3H), 1.22(t,3H), 1.25-1.40(m,2H), 1.5-1.7(m,2H), 1.58(s,6H), 1.95(s,6H), 2.40(s,3H), 2.45(s,3H), 3.5-3.7(m,4H), 6.54(s,1H), 7.23(s,2H)



NR_1R2	R2'	$R_{4'}$	^{1}H NMR ($CDCl_3$) δ (ppm)
$NHCH(Et)_2$	Me	H	0.98(t,6H), 1.5-1.8(m,4H), 1.97(s,6H), 2.44(s,3H), 2.46(s,3H), 4.34(m,1H), 4.81(d,1H), 6.44(s,1H), 7.1-7.2(m,3H)

$NHCH(Et)_2$	Me	CHO	0.98(t,6H), 1.5-1.8(m,4H), 2.06(s,6H), 2.43(s,3H), 2.46(s,3H), 4.31(m,1H), 4.83(d,1H), 6.43(s,1H), 7.66(s,1H), 9.99(s,1H)
$NHCH(Et)(CH_2OMe)$	Me	H	1.01(t,3H), 1.4-1.6(m,2H), 1.95(s,6H), 2.42(s,3H), 2.44(s,3H), 3.40(s,3H), 3.55(2 sets of ABq,2H), 4.48(m,1H), 5.26(d,1H,NH), 6.43(s,1H), 7.0-7.2(m,3H)

EXAMPLE 15


The following compounds of above formula A (Example 14) were prepared by procedures analogous to those in Examples 8 to 13.

R2'	R4'	^1H NMR ($CDCl_3$) δ (ppm)
H	Me	0.95(t,3H), 1.23(t,3H), 1.2-1.4(m,2H), 1.55-1.77(m,2H), 2.08(s,3H), 2.38(s,3H), 2.44(s,3H), 2.50(s,3H)3.59(t,2H), 3.66(q,2H), 6.71(ws,1H), 7.0-7.2(m,3H)
CHO	Me	0.95(t,3H), 1.26(t,3H), 1.25-1.45(m,2H), 1.6-1.8(m,2H), 2.05(s,3H), 2.438(s,3H), 2.443(s,3H), 2.448(s,3H), 3.5-3.8(m,4H), 6.7(s,1H), 7.39(d,1H), 7.68((d,1H), 9.33(s,1H)
CH_2OH	Me	0.96(t,3H), 1.27(t,3H), 1.25-1.45(m,2H), 1.6-1.75(m,2H), 1.95(s,3H), 2.41(s,3H), 2.43(s,3H), 2.44(s,3H), 3.5-3.8(m,4H), 4.15(m,2H), 6.6(s,1H), 7.11(s,1H), 7.26(s,1H)
CH_2F	Me	0.96(t,3H), 1.28(t,3H), 1.25-1.45(m,2H), 1.6-1.8(m,2H), 1.95(s,3H), 2.41(s,3H), 2.43(s,3H), 2.46(s,3H), 3.5-3.8(m,4H), 5.01(2 sets of ABq,2H), 6.63(s,1H), 7.15(s,1H), 7.25(s,1H)
CH(Me)(OH)	Me	0.96(t,3H), 1.27(t,3H), 1.25-1.409m,2H), 1.43(d,3H), 1.6-1.8(m,2H), 1.93(s,3H), 2.42(s,6H), 2.45(s,3H), 3.4-3.8(m,4H), 4.37(q,2H), 5.10(s,1H), 6.62(s,1H), 7.09(s,1H), 7.35(s,1H)

R2'	R4'	^{1}H NMR ($CDCl_3$) δ (ppm)
I	Me	0.96(t,3H), 1.27(t,3H), 1.25-1.45(m,2H), 1.6-1.8(m,2H), 1.97(s,3H), 2.34(s,3H), 2.46(s,3H), 2.50(s,3H), 3.5-3.8(m,4H), 6.58(s,1H), 7.10(S,1H), 7.62(s,1H)
Cl	Me	0.95(t,3H), 1.25(t,3H), 1.25-1.45(m,2H), 1.6-1.8(m,2H), 1.97(s,3H), 2.36(s,3H), 2.44(s,3H), 2.48(s,3H), 3.5-3.8(m,4H), 6.61(s,1H), 7.04(s,1H), 7.19(s,1H)
$C(Me)_2(OH)$	Me	0.94(t,3H), 1.18(s,3H), 1.25(t,3H), 1.25-1.5(m,2H), 1.55(s,3H), 1.6-1.8(m,2H), 1.69(s,3H), 2.38(s,3H), 2.42(s,3H), 2.43(s,3H), 3.5-3.8(m,4H), 4.13(brs,1H), 6.57(s,1H), 7.04(s,1H), 7.39(s,1H)
CH_2NH_2	Me	0.96(t,3H), 1.26(t,3H), 1.3-1.5(m,2H), 1.6-1.8(M,2H), 1.85(s,3H), 2.28(S<3H), 2.38(s,6H), 3.28(q,2H), 3.5-3.8(m,4H), 6.58(s,1H), 6.93(s,1H), 6.99(s,1H)
CH_2OMe	Me	0.96(t,3H), 1.26(t,3H), 1.25-1.45(m,2H), 1.6-1.8(m,2H), 1.92(s,3H), 2.38(s,3H), 2.44(s,3H), 2.46(s,3H), 3.25(s,3H), 3.61(t,2H), 3.68(q,2H), 4.04(ABq,2H), 6.62(s,1H), 7.06(s,1H), 7.22(s,1H)
Et	Me	0.95(t,3H), 1.04(t,3H), 1.26(t,3H), 1.25-1.45(m,2H), 1.90(s,3H), 2.15-2.35(m,2H), 2.37(s,3H), 2.44(s,3H), 2.47(s,3H), 3.63(m,2H), 3.67(q,2H), 6.57(s,1H), 6.98(s,1H), 7.01(s,1H)
CH(Me)(OMe)	Me	0.96(t,3H), 1.2-1.4(m,6H), 1.25-1.45(m,2H), 1.6-1.8(m,2H), 1.91(s,3H), 2.41(s,3H), 2.43(s,3H), 2.44(s,3H), 3.14(s,3H), 3.5-3.75(m,4H), 3.81(q,1H), 6.54(s,1H), 7.06(s,1H), 7.25(s,1H)

Example 16


A. The following compounds were prepared by the procedures analogous to those in Examples 8 to 13 starting from n-BuLi with 4-chloro-2,5-dimethyl-7-(2,6-dimethyl-4-bromo- or 2,4-dimethyl-6-bromo-phenyl)-7H-pyrrolo-[2,3-d]pyrimidine, followed by quenching with an appropriate electrophile compound.



$R^{2'}$	$R^{4'}$	^1H NMR ($CDCl_3$) δ (ppm)
Me	Et	1.25(t,3H), 1.89(s,6H), 2.50(s.3H). 2.63(s,3H), 2.62(m,2H), 6.78(s,1H). 6.99(s,2H)
Me	OH	1.79(s,6H), 2.50(s,3H), 2.74(s.3H). 6.36(s,2H), 6.80(s,1H), 8.60(s.1H)
Me	$C(Me_2)(OH)$	1.60(s,6H), 1.93(s,6H), 2.50(s,3H), 2.63(s,3H), 6.78(s,1H), 7.23(s.1H)
CH_2F	Me	1.92(s,3H), 2.43(s,3H), 2.52(s,3H). 2.53(s,3H), 4.87(ABq,1H), 5.11(ABq,1H), 6.87(s,1H), 7.26(s,1H), 7.27(s,1H)
Et	Me	1.01(t,3H), 1.87(s,3H), 2.20(q,2H), 2.38(s,3H), 2.53(s,3H), 2.65(s,3H). 6.81(s,1H), 7.01(s,1H), 7.04(s,1H)
$C(Me_2)(OH)$	Me	1.26(s,3H), 1.43(s,3H), 1.66(s.3H). 2.40(s,3H), 2.52(s,3H), 2.62(s.3H). 6.83(s,1H), 7.07(s,1H), 7.45(s.1H)
H	Me	2.04(s,3H), 2.40(s,3H), 2.51(s.3H). 2.67(s.3H), 6.92(s.1H). 7.13(s.2H). 7.18(s,1H)

$R^{2'}$	$R^{4'}$	^{1}H NMR ($CDCl_3$) δ (ppm)
CHO	Me	2.00(s,3H), 2.47(s,3H), 2.54(s,3H), 2.63(s,3H), 6.92(s,1H), 7.45(m,1H), 7.70(m,1H), 9.39(s,1H)
CH_2OH	Me	1.88(s,3H), 2.36(s,3H), 2.50(s,3H), 2.57(s,3H), 3.56(brs,1H), 4.05-4.25(m,2H), 6.84(s,1H), 7.08(s,1H), 7.25(s,1H)

B. The following compounds were prepared starting with the appropriate amine and the appropriate 4-chloro-2,5-dimethyl-7-(substituted phenyl)-7H-pyrrolo[2,3-d]pyrimidine (compounds listed in the table above under 16A or other related compounds) in DMSO and employing the general procedure of Example 5.



NR_1R_2	R_2'	R_4'	^{1}H NMR ($CDCl_3$) δ (ppm)
NH-(S)-CH(Et)(CH_2OH)	Me	Et	1.07(t,3H), 1.23(t,3H), 1.45-1.56(m,2H), 1.90(s,3H), 1.91(s,3H), 2.43(s,3H), 2.45(s,3H), 2.60(q,2H), 3.65(m,1H), 3.83(m,1H), 4.00(m,1H), 5.17(d,1H), 6.49(s,1H), 6.95(s,2H)
NH-(S)-CH(Et)(CH_2OH)	Et	Me	1.00(t,3H), 1.07(t,3H), 1.6-1.85(m,2H), 1.88(s,3H), 2.15-2.30(m,2H), 2.32(s,3H), 2.42(s,3H), 2.48(s,3H), 3.6-3.9(m,2H), 3.92-4.10(m,1H),5.25(d,1H), 6.5(s,1H), 6.94(s,1H), 7.0(s,1H)

NR_1R_2	R_2'	R_4'	^1H NMR ($CDCl_3$) δ (ppm)
NH-(S)-CH(Et)(CH_2OH)	Me	CMe_2OH	1.08(t,3H), 1.58(s,6H), 1.6-1.9(m,2H), 1.94(s,3H), 1.95(s,3H), 2.46(s,3H), 2.50(s,3H), 3.5-3.95(m,2H), 4.2(brs,1H), 5.28(brs,1H), 6.53(s,1H), 7.24(s,2H)
NH-(S)-CH(Et)(CH_2OH)	C(OH)(Me_2)	Me	1.11(t,3H), 1.24(s,3H), 1.5-1.9(m,2H), 1.50(s,0.5x3H), 1.53(0.5x3H), 1.71(s,3H), 2.39(s,3H), 2.43(s,3H), 2.48(s,3H), 3.16(brs,0.5H), 3.29(brs,0.5H), 3.6-3.95(m,2H), 3.95-4.10(m,1H), 5.2-5.3(m,1H), 6.54(s,1H), 7.05(s,1H), 7.40(s,0.5H), 7.43(s,0.5H)
NH-(S)-CH(Et)(CH_2OH)	H	Me	1.10(t,3H), 1.5-1.9(m,2H), 2.05(s,3H), 2.37(s,3H), 2.48(s,6H), 3.6-3.9(m,2H), 3.9-4.1(m,1H), 5.23(d,1H), 6.64(s,1H), 7.0-7.2(m,2H)
NH-(S)-CH(Et)(CH_2OH)	CHO	Me	1.09(t,3H), 1.55-1.90(m,2H), 2.02(s,3H), 2.42(s,6H), 2.47(s,3H), 3.6-3.9(m,2H), 4.0-4.15(m,1H), 5.27(t,1H), 6.62(s,1H), 7.39(s,1H), 7.65(s,1H), 9.36(s,1H)
NH-(S)-CH(Et)(CH_2OH)	CH_2OH	Me	both diastereoisomers were separated by column chromatography and showed identical spectra. 1.11(t,3H), 1.55-1.90(m,2H), 1.95(s,3H), 2.40(s,3H), 2.43(s,3H), 2.49(s,3H), 3.6-3.95(m,2H), 4.0-4.3(m,2H), 4.4(brs,1H), 5.30(d,1H), 6.57(s,1H), 7.11(s,1H), 7.27(s,1H)
NH-(S)-CH(Et)(CH_2OH)	CH_2F	Me	1.11(t,3H), 1.5-1.85(m,2H), 1.94(s,3H), 2.41(s,3H), 2.45(s,3H), 2.47(s,3H), 3.6-3.9(m,2H), 4.0-4.2(m,1H), 4.75-5.25(m,2H), 5.24(m,1H), 6.58(s,1H), 7.16(s,1H), 7.24(s,1H)

Example 17

The following compounds were prepared by the procedures analogous to those in Examples 8 to 13 starting from an excess of n-BuLi with 4-substituted amino-2,5-dimethyl-7-(2,4,6-tri-substituted-phenyl)-7H-pyrrolo-[2.3-d]pyrimidine, followed by quenching with an appropriate electrophile.

NR_1R_2	R_2'	R_4'	^1H NMR ($CDCl_3$) δ
NH-(S)-CH(Et)(CH_2OH)	CH_2CH_2OH	Me	1.11(t,3H), 1.5-1.9(m,2H), 1.84(s,3H), 2.37(s,3H), 2.45(s,3H), 2.48(s,3H), 2.45-2.65(m,2H), 3.6-3.95(m,4H), 4.15(m,1H), 5.28(d,1H), 6.54(s,1H), 7.02(s,1H), 7.09(s,1H)
NH-(S)-CH(Et)(CH_2OH)	Me	CHO	1.08(t,3H), 1.5-1.8(m,2H), 2.02(s,6H), 2.42(s,3H), 2.46(s,3H), 3.6-3.9(m,2H), 4.0(brs,1H), 5.20(d,1H), 6.49(s,1H), 7.65(s,2H), 9.98(s,1H)
NH-(S)-CH(Et)(CH_2OH)	Me	I	1.06(t,3H), 1.6-1.9(m,2H), 1.88(s,6H), 2.42(s,3H), 2.44(s,3H), 3.6-3.9(m,2H), 4.08(brs,1H), 5.20(d,1H), 6.45(s,1H), 7.48(s,2H)
NH-(S)-CH(Et)(CH_2OH)	Me	CH_2OH	1.08(t,3H), 1.6-1.85(m,2H), 1.93(s,6H), 2.45(s,6H), 3.6-3.95(m,2H), 4.10(brs,1H), 4.60(s,2H), 5.24(brs,1H), 6.50(s,1H), 7.11(s,2H)
NH-(S)-CH(Et)(CH_2OH)	Me	C(Me)-($C=CH_2$)	1.08(t,3H), 1.5-1.8(m,2H), 1.94(s,6H), 2.13(s,3H), 2.44(s,3H), 2.45(s,3H), 3.55-3.90(m,2H), 4.00(brs,1H), 5.07(s,1H), 5.20(d,1H), 5.35(s,1H), 6.50(s,1H), 7.21(s,2H)


EXAMPLE 18

4-sec-Butoxy-1-(2,5,6-trimethylphenyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidine

Sodium hydride (0.114g, 4.77mmol, 60% in oil) was washed with hexane, then treated with 2-butanol (1.18g, 15.90 mmol). After 20 minutes, a mixture of 4-chloro-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine(0.500g,1.59mmol) in 5 ml of anhydrous tetrahydrofuran was added to the reaction mixture and stirred for 2 hours. The mixture was concentrated to dryness, dissolved in ethyl acetate and water. The organic layer was separated, washed with brine, dried, and concentrated to give a clear oil. The oil residue was purified through silica gel column chromatography using 20% ethyl acetate in hexane as eluent to give a clear oil which crystallized under high vacuo to give 0.450 g (80.5%) of an off-white solid. The solid was recrystallized from i-propanol to give gold crystals, mp 178-180°C.

EXAMPLE 19

The following compounds were prepared starting with the appropriate alcohol or thiol and 4-chloro-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine or 4-chloro-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine and employing the general procedure of Example 18.



B	R_4'	R_4	R_6	^{1}H NMR ($CDCl_3$) δ (ppm)
$OCHEt_2$	Me	Me	Me	0.99(t,6H), 1.74(m,4H), 1.84(s,6H), 1.92(s,3H), 2.34(s,3H), 2.37(s,3H), 2.48(s,3H), 5.34(m,1H), 6.98(s,2H)
$OCHMe_2$	Me	Me	Me	1.41(d,6H), 1.82(s,6H), 1.91(s,3H), 2.33(s,3H), 2.36(s,3H), 2.48(s,3H), 5.55(m,1H), 6.98(s,2H)
OCH(Me)(Et)	Me	Me	Me	1.02(t,3H), 1.28(d,3H), 1.65-1.80(m,2H), 1.83(s,6H), 1.92(s,3H), 2.33(s,3H), 2.37(s,3H), 2.48(s,3H), 5.38(m,1H), 6.98(s,2H)
OCH(Et)(n-Pr)	Me	Me	Me	0.94(t,3H), 0.97(t,3H), 1.38-1.60(m,2H), 1.6-1.8(m,4H), 1.82(s,6H), 1.90(s,3H), 2.32(s,3H), 2.35(S,3H), 2.46(s,3H), 6.96(s,2H)
OCH(Et)(n-Bu)	Me	Me	Me	0.90(t,3H), 0.99(t,3H), 1.3-1.5(m,4H), 1.6-1.8(m,4H), 1.832(s,3H), 1.837(s,3H), 1.92(s,3H), 2.34(s,3H), 2.36(s,3H), 2.48(s,3H), 5.39(m,1H), 6.98(s,2H)

B	R_4'	R_4	R_6	^{1}H NMR ($CDCl_3$) δ (ppm)
OCH(Et)(n-pentyl)	Me	Me	Me	0.88(t,3H), 0.98(t,3H), 1.4-1.6(m,6H), 1.6-1.8(m,4H), 1.82(s,6H), 1.90(s,3H), 2.32(s,3H), 2.36(s,3H), 2.47(s,3H), 5.40(m,1H), 6.96(s,2H)
OCH(Et)(n-hexyl)	Me	Me	Me	0.85(t,3H), 0.97(t,3H), 1.20-1.50(m,8H), 1.6-1.8(m,4H), 1.82(s,6H), 1.90(s,3H), 2.32(s,3H), 2.35(s,3H), 2.46(s,3H), 5.37(m,1H), 6.96(s,2H)
$OCH(n\text{-}Pr)_3$	Me	Me	Me	0.94(t,3H), 1.4-1.6(m,4H), 1.6-1.8(m,4H), 1.83(s,6H), 1.91(s,3H), 2.33(s,3H), 2.36(S,3H), 2.48(s,3H), 5.50(m,1H), 6.97(s,2H)
$OCH(Et)(CH_2OMe)$	Me	Me	Me	1.03(t,3H), 1.82(s,3H), 1.83(s,3H), 1.91(s,3H), 2.33(s,3H), 2.37(s,3H), 2.47(s,3H), 3.43(s,3H), 3.68(m,2H), 5.55(m,1H), 6.97(s,2H)
$OCHEt_2$	Me	Me	H	0.99(t,6H), 1.63(m,4H), 1.92(s,6H), 2.32(s,3H), 2.41(s,3H), 2.50(s,3H), 5.35(m,1H), 6.52(s,1H), 6.96(s,2H)
$OCH(Et)(CH_2OMe)$	Me	Me	H	1.00(t,3H), 1.6-1.8(m.2H), 1.86(s,3H), 1.87(s,3H), 2.28(s,3H), 2.40(s,3H), 2.489s,3H), 3.40(s,3H), 3.62(m,2H), 5.51(m,1H), 6.48(s,1H), 6.92(s,2H)
OCH_2-(S)-$CH(NH_2)(Et)$	Br	Me	H	1.03(t,3H), 1.3-1.5(m,2H), 1.91(s,6H), 2.42(s,3H), 2.51(s,3H), 4.13(m,1H), 4.26(m,1H), 4.44(m,1H), 6.52(s,1H), 7.29(s,2H)
S-CH(Me)-CH(OH)(Me)	Br	Me	H	1.25(d,3H), 1.41(d,3H), 1.87(s,3H), 1.89(s,3H), 2.50(s,3H), 2.55(s,3H), 4.1-4.3(m,2H), 6.63(s,1H), 6.65(brs,1H), 7.30(s,2H)

EXAMPLE 20

A. 2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile

A mixture of 4-chloro-2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidine (10.000 g, 31.90 mmol) and potassium cyanide (20.75 g, 319 mmol) in 100

ml dimethylsulfoxide was heated at 130°C oil bath over weekend. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and concentrated to give 9.61 g (99%) of brown soild. The solid was recrystallized from i-propanol to give 6.34 g (65%) of the title compound as light golden crystals, mp 188-190°C. ^{1}H NMR ($CDCl_3$) δ 1.8(s,6H), 2.07(s,3H), 2.36(s,3H), 2.50(s,3H), 2.65(s,3H), 7.00(s,2H).

B. 2-Methyl-1-[2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-butan-1-one

To a solution of sec-butyl magnesium chloride (1.5 ml, 3.0 mmol, 2 M in diethyl ether) in 24 ml of dry tetrahydrofuran was added 2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile (0.814 g, 2.67 mmol) at room temperature and stirred for 5 hours. The mixture was quenched with 5 ml of 2N HCl, neutralized with saturated sodium bicarbonate, extracted with ethyl acetate. The organic layer was dried and concentrated to give a yellow solid. The solid was purified through silica gel column chromatography using chloroform as eluent to give 0.884 g (90%) of the title compound as yellow crystals, mp 133-135°C.

EXAMPLE 21

[2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propan-1-one and 1-[2,5,6-Trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-pentan-1-one were prepared starting from 2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile, and ethyl magnesium chloride and n-BuLi. respectively, employing the general procedure of Example 20B.

EXAMPLE 22

[2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propan-1-ol

A solution of 2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propan-1-one (0.300 g, 0.89 mmol) in 10 ml of methanol was treated with sodium borohydride ($NaBH_4$) (0.169 g, 4.47 mmol) at room temperature and stirred for 15 minutes. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried, and concentrated to give 0.291 g (96%) of the title compound as light yellow crystals. The crystals were recrystallized from i-propanol to give light yellow crystals, mp 143-144°C.

EXAMPLE 23

The following compounds were prepared by reduction of the corresponding ketone derivative with $NaBH_4$ by the procedure described in the Example 22:

1-[2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-pentan1-ol; and

2-Methyl-1-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-butan-ol.

EXAMPLE 24

The following compounds were prepared by reaction of the corresponding alcohol derivative with NaH, followed by reacting with alkyl iodide using the procedure analogous to that described in Example 12:

4-(1-Methoxy-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine;

4-(1-Ethoxy-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine; and

4-(1-Methoxy-2-methyl-butyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine.

EXAMPLE 25

[2,5,6-Trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-pentan-3-ol

A solution of 1-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propan-1-one (0.220 g, 0.656 mmol) in 10 ml of dry THF was treated with ethyl magnesium bromide (0.787 mmol, 0.39 ml, 2.0 m in THF) at 0°C and stirred at room temperature for 1 hour. The mixture was quenched with diluted HCl, neutralized with aqueous NaOH and extracted with ethyl acetate. The organic layer was dried and concentrated to give a yellow solid. The solid was redcrystallized from ethyl ether/ethyl acetate to give off-white crystals, mp 164-166.5°C.

EXAMPLE 26

[2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-hexan-3-ol

The title compound was prepared by reacting 1-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propan-1-one with n-propyl magnesium chloride using the procedure described in Example 25.

EXAMPLE 27

(1-Ethyl-1-fluoro-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine

The title compound was prepared by reacting of 3-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-pentan-3-ol with dimethylaminosulfur trifluoride using the procedure described in Example 11.

EXAMPLE 28

(1-Ethyl-propenyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine

A mixture of 3-[2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-pentan-3-ol (0.041 g, 0.122 mmol), concentrated sulfuric acid (0.055 g, 0.56 mmol) and acetic acid (0.136 g, 2.27 mmol) was heated to reflux for 1 hour, cooled, diluted with water, basified to pH 10 with 2 N NaOH and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to dryness to give 43 mg of the title compound as a clear oil. The oil was purified through silica gel column chromatography to give 40 mg of the title compound as a white solid, mp 59-61°C.

EXAMPLE 29

Compounds listed in the following Table II in which B is CH(OAc)(CHMeEt) and a mixture of two isomers 4-(1-ethyl-butenyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine and 4-(1-n-propyl-propenyl)-2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidine [see Table II in which B is C(=CHEt)(Et) and C(=CHMe)(n-Pr)] were prepared by a procedure analogous to that described in Example 28.

EXAMPLE 30

(1-Ethyl-butyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine

A mixture of two isomers, 4-(1-ethyl-butenyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine and 4-(1-n-propyl-propenyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine (67 mg, 0.185 mmol) in ethyl acetate (18 ml) and 10% Pd/C (38 mg) was hydrogenated at 50 psi for 15 hours. The mixture was filtered through celite. The filtrated was washed with brine, dried and concentrated to give 119 mg of oil. The oil was purified through silica gel column

chromatography using 7% ethyl acetate in hexane as eluent to give 31 mg (46%) of the title compound as off-white crystals, mp 100-102°C.

EXAMPLE 31

[-2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propan-1-one oxime

A mixture of 1-[-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propan-1-one (0.598 g, 1.783 mmol), hydroxylamino hydrochloride (0.370 g, 5.35 mmol), sodium acetate (0.439 g, 5.35 mmol) in MeOH (30 ml) was stirred at room temperature for 24 hours. The mixture was concentrated to dryness. The residue was diluted with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 0.657 g of a white glass form. The glass form was purified through silica gel column chromatography to separated both E (white crystals, mp 162-164°C, confirmed by X-ray structural analysis) and Z (white crystals, mp 84-87°C) isomers and a mixture of E and Z isomers (mp-150-190°C).

EXAMPLE 32

1-[2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propylamine

Hydrogenation of 1-[-2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propan-1-one oxime with 10% Pd/C in MeOH using the general procedure described in Example 28 resulted in the title compound.

EXAMPLE 33

[2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylmethyl]-formamide

A mixture of 2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile (1.000 g, 3.29 mmol), 1:1 Al/Ni alloy (1.0 g) in 70% aqueous formic acid (10 ml) was stirred at room temperature for 1 hour. The mixture was filtered through Celite, washed with 100 ml of water and 100 ml of ethyl acetate. The organic layer was separated, dried and concentrated to give a light green oil. The oil was purified through silica gel column chromatography using 2% methanol in chloroform as eluent to give 0.960 g (86.5%) of the title compound as an off-white soild. The solid was recrystallized from ethyl acetate to give a light yellow crystals, mp 202-204°C.

EXAMPLE 34


N-[2,5,6-Trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylmethyl]-acetamide

A mixture of 2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile (0.500 g, 1.64 mmol) and 10% Pd/C (0.500 g) in ethanol was hydrogenated at 55 psi for 5 hours. The mixture was filtered through celite and the filtrate was concentrated to give 0.500g (98.8%) of N-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylmethyl]-amine.

A mixture of N-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylmethyl]-amine (0.200 g, 0.648 mmol), acetic anhydride (0.132 g, 1.30 mmol), triethylamine (0.132 g, 1.30 mmol) in anhydrous methylene chloride (1 ml) was stirred at room temperature for 1 hour. The mixture was quenched with water and extracted with methylene chloride. The organic layer was separated, dried and concentrated to give 0.217 g (95.6%) of the title compound as a light tan solid. The solid was purified through silica gel column chromatography using 5% methanol in chloroform as eluent to give 0.200 g (88.1%) of the title compound as golden crystals, mp 140-143°C.

The ^{1}H NMR data of the compounds which are described in the Examples 20 to 34 are listed in the following Table.

Table II



B	^{1}H NMR ($CDCl_3$) δ (ppm)
CO-(n-Bu)	1.00(t,3H), 1.4-1.6(m,2H), 1.7-1.9(m,2H), 1.83(s,6H), 2.06(s,3H), 2.34(s,3H), 2.35(s,3H), 2.38(s,3H), 3.27(t,2H), 7.03(s,2H)
COEt	1.26(t,3H), 1.81(s,6H), 2.04(s,3H), 2.32(s,3H), 2.36(s,3H), 2.68(s,3H), 3.27(q,2H), 7.00(s,2H)
CO-CH(Me)(Et)	0.99(t,3H), 1.24(d,3H), 1.45-1.65(m,1H), 1.7-1.9(m,1H), 1.83(s,6H), 2.05(s,3H), 2.30(s,3H), 2.37(s,3H), 2.68(s,3H), 3.91(m,1H0, 7.03(s,2H)
CH(OH)(n-Bu)	0.95(t,3H), 1.2-1.8(m,6H), 1.77(s,3H), 1.87(s,3H), 2.00(s,3H), 2.37(s,3H), 2.39(s,3H), 2.63(s,3H), 5.20(dd,1H), 7.02(s,2H)
CH(OH)(Et)	1.12(t,3H), 1.6-2.0(m,2H), 1.77(s,3H), 1.87(s,3H), 2.00(s,3H), 2.37(s,3H), 2.39(s,3H), 2.63(s,3H), 4.97(d,1H), 5.15(m,1H), 7.02(s,2H)
CH(OMe)(Et)	1.02(t,3H), 1.82(s,3H), 1.83(s,3H), 2.01(s,3H), 1.8-2.1(m,2H), 2.36(s,3H), 2.45(s,3H), 2.669s,3H), 3.359s,3H0, 4.68(t,1H), 7.01(s,2H)
CH(OEt)(Et)	1.02(t,3H), 1.22(t,3H), 1.82(s,3H), 1.83(s,3H), 1.7-2.1(m,2H), 2.36(s,3H), 2.46(s,3H), 2.65(s,3H), 3.49(m,2H), 4.75(t,1H), 7.01(s,2H)
CH(OMe)(CHMeEt)	0.68(d,1.8H), 0.83(t,1.2H), 0.95(t,1.8H), 1.10(d,1.2H), 1.1-1.5(m,2H), 1.9-2.2(m,1H). 1.8(3 sets of s,6H), 2.0(s,3H), 2.359s,3H0. 2.53(s,3H0, 2.65(s,3H), 3.25(s,1.8H), 3.30(s,1.2H), 4.42(d,0.6H), 4.5(d,0.4H), 7.0(s,2H)
CH(OAc)(CHMeEt)	0.7(d,1.5H), 0.85(t,1.5H), 0.94(t,1.5H), 1.1(d,1.5H), 1.1-1.5(m,2H), 1.81(s,1.5H), 1.83(s,3H), 1.869s,1.5H), 2.0(s,3H), 2.22(s,1.5H), 2.24(s,1.5H), 2.2-2.4(m,0.5H), 2.32(s,3H), 2.49(s,1.5H), 2.51(s,1.5H), 2.60(s,3H), 3.0-3.2(m,0.5H), 6.12(m,1H), 7.0(s,2H)
$CFEt_2$	0.90(t,6H), 1.83(s,6H), 2.03(s,3H), 2.0-2.4(m,4H), 2.38(s,6H), 2.59(s,3H), 7.02(s,2H)
$CEt_2(OH)$	071(t,6H), 1.79(s,6H), 2.02(s,3H), 2.0-2.4(m,4H), 2.36(s,3H), 2.47(s,3H), 2.61(s,3H). 7.01(s,2H)

B	^{1}H NMR ($CDCl_3$) δ (ppm)
C(Et)(n-Pr)(OH)	0.71(t,3H), 0.84(t,3H), 1.4-1.6(m,2H), 1.80(s,3H), 1.81(s,3H), 2.04(s,3H), 1.9-2.2(m,4H), 2.38(s,3H), 2.49(s,3H), 2.63(s,3H), 6.83(s,1H), 7.03(s,2H)
CH(Et)(NH-n-Pr)	0.87(t,3H), 0.90(t,3H), 1.5-1.7(m,2H), 1.80(s,3H), 1.83(s,3H), 2.00(s,3H), 1.9-2.2(m,2H), 2.36(s,3H), 2.41(s,3H), 2.42(s,3H), 2.3-2.5(m,1H), 2.7-2.9(m,1H), 4.48(m,1H), 7.019s,2H), 7.15(s,1H),
=NOH)(Et)	1.0-1.2(m,3H), 1.79(s,1.5H), 1.80(s,1.5H), 1.99(s,1,.5H), 2.00(s,1.5H), 2.22(s,3H0, 2.35(s,3H), 2.65(s,1.5H), 2.68(s,1.5H), 2.7(q,1H), 2.99(q,1H), 6.93(s,2H), 9.05(brs,1H)
CH(Et)(NH2)	1.04(t,3H), 1.79(s,3H), 1.85(s,3H), 1.7-2.0(m,2H), 1.99(s,3H), 2.36(s,3H), 2.42(s,3H), 2.62(s,3H), 4.52(m,1H), 7.01(s,2H)
=CHMe)(Et)	1.00(t,2.1H), 1.1(t,0.9H), 1.47(d,0.9H), 1.82(s,6H), 1.9(d,2.1H), 2.02(s,3H), 2.25(s,3H), 2.4-2.8(m,5H), 5.6-5.8(m,1H), 7.0(s,2H)
=CHEt)(Et) + C(=CHMe)(n-Pr)	(m,5.4H), 1.82(s,6H), 1.869d,1.8H), 2.0(s,3H), 2.20(s,.1.2H), 2.21(s,1.8H), 2.359s,3H), 2.60(s,1.8H), 2.61(s,1.2H), 2.3-2.8(m,2.8H),5.4-5.8(m,1H), 6.959s,2H)
CH(n-Bu)(Et)	0.83(t,3H), 0.88(t,3H), 1.1-1.49(m,2H), 1.6-2.2(m,4H), 1.82(s,3H), 1.83(s,3H), 1.98(s,3H), 2.35(s,3H), 2.43(s,3H), 2.61(s,3H), 3.33(m,1H), 7.00(s,2H)
CH2NHCHO	1.79(s,6H), 2.00(s,3H), 2.35(s,3H), 2.48(s,3H), 2.62(s,3H), 4.98(d,2H), 7.01(s,2H), 8.05(brs,1H), 8.38(s,1H)
CH2NHCOCH3	1.79(s,6H), 1.97(s,3H), 2.12(s,3H), 2.34(s,3H), 2.43(s,3H), 2.61(s,3H), 4.90(d,2H), 6.99(s,2H), 7.46(brs,1H)

Example 35

A. 1-[2-Amino-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrol-3-yl]-2-ethyl-butan-1-one

A mixture of 3-hydroxy-2-butanone (0.637 g, 7.23 mmol), 2,4,6-trimethylaniline (0.973 g, 0.719 mmol) and p-toluene sulfonic acid (0.012 g) in 15 ml of benzene was heated at reflux under Dean-Stark trap for 3 hours. A solution of $(Et)_2CHCOCH_2CN$ (1.008 g, 7.24 mmol) was added to the reaction mixture and heated at reflux overnight. The mixture was cooled and diluted with ethyl acetate and water. The organic layer was separated and washed with water, aqueous sodium carbonate, and then brine; dried and concentrated to give a brown oil which contains the desired compound. 0.368 g of the desired compound was isolated after silica gel column chromatography using chloroform as eluent. ^1H NMR ($CDCl_3$) δ 0.94 (t,6H), 1.5-1.8 (m,4H), 1.73 (s,3H), 1.98 (s,6H), 2.26 (s,3H), 2.34 (s,3H), 3.00 (m,1H), 5.78 (brs,2H), 6.99 (s,2H) ppm.

B. N-[3-(2-Ethyl-butyryl)-4,5-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrol-2-yl]-acetamide

A mixture of the title compound from Example 35A (0.326 g, 1 mmol) and acetic anhydride (0.108 g, 1.05 mmol) in acetic acid (3 ml) was heated at reflux for 2 hours. The mixture was concentrated to dryness, diluted with water and extracted with ethyl acetate. The organic layer was washed with aqueous sodium carbonate and brine, dried and concentrated to give a dark oil. The oil was purified by silica gel column chromatography to give 107 mg of the title compound as a brown oil. ^1H NMR ($CDCl_3$) δ 0.88 (t,6H), 1.6-1.8 (m,4H), 1.76 (s,3H), 1.88 (s,3H), 1.93 (s,6H), 2.25 (s,3H), 2.28 (s,3H), 2.90-3.00 (m,1H), 6.89 (s,2H) ppm.


C. 4-(1-Ethylpropyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine

A mixture of the title compound of Example 35B (100 mg, 0.27 mmol) and ammonium chloride in 1.6 g of acetamide was heated at reflux for 2 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give the desired product which was purified by silica gel column chromatography to give the title compound as a yellow oil. ^1H NMR ($CDCl_3$) δ 0.85 (t,6H), 1.7-2.0 (m,4H), 1.83 (s,6H), 1.99 (s,3H), 2.35 (s,3H), 2.44 (s,3H), 2.61 (s,3H), 3.25-3.35 (m,1H), 7.00 (s,2H) ppm.

The following Preparations illustrate the synthesis of intermediates.

Preparation 1


The following compounds were prepared starting from the appropriate aniline and employing the general procedure of Example 1A.



R_5	^{1}H-NMR($CDCl_3$) δ (ppm)
3,5-ditrifluoromethylphenyl	2.2(s,3H), 4.0(s,2H), 6.15(s,1H), 7.9(s,2H)
2,5-dimethylphenyl	2.04(s,3H), 2.12(s,3H), 2.35(s,3H), 3.85(s,2H), 5.90(s,1H), 7.0(s,1H), 7.10-7.25(m,2H)
2-methyl-4-iodophenyl	2.05(s,3H), 2.10(s,3H), 3.80(s,2H), 5.85(s,1H), 6.92(d,1H), 7.60(dd,1H), 7.70(d,1H)
3-methyl-4-chlorophenyl	2.10(s,3H), 2.40(s,3H), 4.03(s,2H), 6.03(s,1H), 7.10(dd,1H), 7.21(d,1H), 7.45(d,1H)
4-bromo-2,6-dimethylphenyl	2.01(s,6H), 2.10(s,3H), 3.70(brs,2H), 5.72(s,1H), 7.30(s,2H)
2-bromo-4,6-dimethylphenyl	2.06(s,3H), 2.13(s,3H), 2.35(s,3H), 3.83(brs,2H), 5.81(s,1H), 7.08(s,1H), 7.35(s,3H)
4-chloro-2,6-dimethylphenyl	2.01(s,6H), 2.10(s,3H), 3.75(brs,2H), 5.75(s,1H), 7.14(s,2H)

Preparation 2


The following compounds were prepared starting from 3-hydroxy-2-butanone or 4-hydroxy-3-hexanone and the appropriate aniline and employing the general procedure of Example 2A.



R_4 and R_6	R_5	^{1}H-NMR($CDCl_3$) δ (ppm)
Me	2,4-dimethylphenyl	1.70(s,3H), 1.95(s,3H), 2.05(s,3H), 2.38(s,3H), 3.7(s,2H), 6.95-7.20(m,3H)
Me	2,6-dimethylphenyl	1.67(s,3H), 1.98(s,6H), 2.05(s,3H), 2.90(brs,2H), 7.05-7.21(m,3H)
Et	2,4,6-trimethylphenyl	No purification, the material was used directly for the next reaction step

Preparation 3

The following compounds were prepared starting from the corresponding compounds of preparations 1 and 2 and employing the general procedures of Examples 1B and 1C.




R_4=Me, R_6=H	^{1}H-NMR (solvent) δ (ppm)
R_5=3,5-ditrifluoromethylphenyl	(DMSO-d6) 2.32(s,3H), 7.50(s,1H), 8.05(s,1H), 8.55(s,1H), 12.10(s,1H)
R_5=2,5-dimethylphenyl	($CDCl_3$) 2.04(s,3H), 2.35(s,3H), 2.467(s,3H), 2.470(s,3H), 6.57(s,1H), 7.0-7.3(m,3H), 12.08(s,3H)

R_5=3-methyl-4-chlorophenyl	(DMSO-d_6) 2.29(s,3H), 2.31(s.3H), 2.38(s,3H), 7.12(s,1H), 7.55(m.2H), 7.67(d,1H), 11.90(s,1H)
R_5=4-bromo-2,6-dimethylphenyl	($CDCl_3$) 1.94(s,6H), 2.40(s,3H), 2.45(s,3H), 6.39(s,1H), 7.29(s,2H)
R_5=2-bromo-4,6-dimethylphenyl	(DMSO-d_6) 1.91(s,3H), 2.20(s.3H), 2.32(s,3H), 2.34(s,3H), 6.68(s,1H), 7.21(s,1H), 7.44(s,1H),11.80(s,1H)
R_5 = 4-chloro-2,6-dimethylphenyl	($CDCl_3$) 1.91(s,6H), 2.38(s,3H), 2.40(s,3H), 6.34(s,1H), 7.08(s.2H)
R_4 & R_6 = Me	^{1}H-NMR (solvent) δ (ppm)
R_5=2,4,6-trimethylphenyl	($CDCl_3$) 1.85(s,6H), 1.87(s,3H), 2.34(s,3H), 2.41(s,3H), 2.44(s.3H), 7.00(s,2H), 12.2(s,1H)
R_5=2,4-dimethylphenyl	($CDCl_3$) 1.90(s,3H), 1.93(s,3H), 2.38(s,3H), 2.42(s,6H), 7.0-7.2(m,3H), 12.25(s,1H)
R_5=2,6-dimethylphenyl	($CDCl_3$) 1.80-1.90(m,9H), 2.39(s,3H), 2.49(s,3H), 7.04-7.20(m,3H), 12.2(s,1H)

Preparation 4

The following compounds were prepared starting from the corresponding compounds of Preparation 3 and employing the general procedure in Example 1D.




R_4=Me, R_6=H	^{1}H-NMR ($CDCl_3$) δ (ppm)
R_5=3,5-ditrifluoromethylphenyl	2.53(s,3H), 2.74(s,3H), 7.27(s.1H), 7.82(s,1H), 8.29(s,2H)

R_5=2,5-dimethylphenyl	2.01(s,3H), 2.35(s,3H), 2.50(s,3H), 2.66(s,3H), 6.91(s,1H), 7.05(s,1H), 7.10-7.30(m2H)
R_5=3-methyl-4-chlorophenyl	2.46(s,3H), 2.51(s,3H), 2.74(s,3H), 7.15(s,1H), 7.47(s,2H), 7.55(s,1H)
R_5=4-bromo-2,6-dimethylphenyl	1.89(s,6H), 2.49(s,3H), 2.62(s,3H), 6.75(s,1H), 7.32(s,2H)
R_5 = 2-bromo-4,6-dimethylphenyl	1.96(s,3H), 2.37(s,3H), 2.52(s,3H), 2.65(s,3H), 6.82(s,1H), 7.11(s,1H), 7.38(s,1H)
R_4 and R_6 = Me	^{1}H-NMR ($CDCl_3$) δ (ppm)
R_5=2,4,6-trimethylphenyl	1.81(s,6H), 1.99(s,3H), 2.35(s,3H), 2.46(s,3H), 2.59(s,3H), 7.01(s,2H)
R_5=2,4-dimethylphenyl	1.84(s,3H), 2.03(s,3H), 2.39(s,3H), 2.44(s,3H), 2.59(s,3H), 6.90-7.15(m,3H)
R_5=2,6-dimethylphenyl	1.83(s,6H), 1.98(s,3H), 2.45(s,3H), 2.58(s,3H), 7.10-7.30(m,3H)
R_5=4-chloro-2,6-dimethylphenyl	1.91(s,6H), 2.51(s,3H), 2.64(s,3H), 6.77(s,1H), 7.17(s,2H)
R_4 and R_6 = Et	^{1}H-NMR ($CDCl_3$) δ (ppm)
R_5=2,4,6-trimethylphenyl	0.96(t,3H), 1.31(t,3H), 1.85(s,6H), 2.38(s,6H), 2.46(q,2H), 2.62(s,3H), 2.92(q,2H), 7.02(s,2H)

CLAIMS

1. A compound of the formula



I

and the pharmaceutically acceptable acid addition salts thereof, wherein

B is NR_1R_2, $CR_1R_2R_{11}$, $C(=CR_2R_{12})R_1$, $NHCR_1R_2R_{11}$, $OCR_1R_2R_{11}$, $SCR_1R_2R_{11}$, $NHNR_1R_2$, $CR_2R_{11}NHR_1$, $CR_2R_{11}OR_1$, $CR_2R_{11}SR_1$, or $C(O)R_2$;

R_1 is hydrogen, or C_1-C_6 alkyl which may be substituted by one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C_1-C_8 alkoxy, O-C -(C_1-C_6 alkyl), O-C NH(C_1-C_4 alkyl), O-C -N(C_1-C_4 alkyl)(C_1-C_2 alkyl), amino, NH(C_1-C_4 alkyl), N(C_1-C_2 alkyl)(C_1-C_4 alkyl), S(C_1-C_6 alkyl), N(C_1-C_4alkyl)C (C_1-C_4 alkyl), NHC (C_1-C_4 alkyl), COOH, C O(C_1-C_4 alkyl), C NH(C_1-C_4 alkyl), C N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SH, CN, NO_2, SO(C_1-C_4 alkyl), SO_2(C_1-C_4 alkyl), SO_2NH(C_1-C_4 alkyl), SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), and said C_1-C_6 alkyl may contain one or two double or triple bonds;

R_2 is C_1-C_{12} alkyl, aryl or (C_1-C_{10} alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C_1-C_6 alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, benzyl or C_1-C_4 alkanoyl, wherein R_2 may be substituted independently by from one to three of chloro, fluoro, or C_1-C_4 alkyl, or one of hydroxy, bromo, iodo, C.-

C_6 alkoxy, O-C(=O)-(C_1-C_6 alkyl), O-C(=O)-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), S(C_1-C_6 alkyl), NH_2, $NH(C_1$-C_2 alkyl), $N(C_1$-C_2 alkyl) (C_1-C_4 alkyl), $N(C_1$-C_4 alkyl)-C(=O)(C_1-C_4 alkyl), NHC(=O)(C_1-C_4 alkyl), COOH, C(=O)O(C_1-C_4 alkyl), C(=O)NH(C_1-C_4 alkyl), C(=O)N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SH, CN, NO_2, SO(C_1-C_4 alkyl), SO_2(C_1-C_4 alkyl), SO_2NH(C_1-C_4 alkyl), SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), and wherein said C_1-C_{12} alkyl or C_1-C_{10} alkylene may contain one to three double or triple bonds; or

NR_1R_2 or $CR_1R_2R_{11}$ may form a saturated 3- to 8-membered carbocyclic ring of which the 5- to 8-membered ring may contain one or two double bonds or one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, benzyl or C_1-C_4 alkanoyl;

R_3 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C_1-C_6 alkyl), NH(C_1-C_6 alkyl), N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SH, S(C_1-C_4 alkyl), SO(C_1-C_4 alkyl), or SO_2(C_1-C_4 alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may contain one double or triple bond and may be substituted by from 1 to 3 substituents R_5 independently selected from the group consisting of hydroxy, C_1-C_3 alkoxy, fluoro, chloro or C_1-C_3 thioalkyl;

R_4 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, amino, $NH(C_1$-C_6 alkyl), N(C_1-C_6 alkyl)(C_1-C_2 alkyl), SO_n(C_1-C_6 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C_1-C_6 alkyls may be substituted by one hydroxy, trifluoromethyl, amino, carboxy, amido, NHC(=O)(C_1-C_4 alkyl), $NH(C_1$-C_4 alkyl), $N(C_1$-C_4 alkyl)(C_1-C_2 alkyl), C(=O)O(C_1-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl,

piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, C_1-C_4 alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, formyl, C_1-C_6 alkyl, C_1-C_6 alkoxy or trifluoromethyl, or one of hydroxy, iodo, cyano, nitro, amino, $NH(C_1$-C_4 alkyl), $N(C_1$-$C_4)(C_1$-C_2 alkyl), $COO(C_1$-C_4 alkyl), $CO(C_1$-C_4 alkyl), $SO_2NH(C_1$-C_4 alkyl), $SO_2N(C_1$-C_4 alkyl)$(C_1$-C_2 alkyl), SO_2NH_2, $NHSO_2(C_1$-C_4 alkyl), $S(C_1$-C_6 alkyl), $SO_2(C_1$-C_6 alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may be substituted by one or two of fluoro, chloro, hydroxy, C_1-C_4 alkoxy, amino, methylamino, dimethylamino or acetyl wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may contain one double or triple bond; with the proviso that R_5 is not unsubstituted phenyl;

R_6 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, formyl, amino, $NH(C_1$-C_6 alkyl), $N(C_1$-C_6 alkyl$)(C_1$-C_2 alkyl), $SO_n(C_1$-C_6 alkyl), wherein n is 0, 1 or 2, cyano, carboxy, or amido, wherein said C_1-C_6 alkyls may be substituted by one hydroxy, trifluoromethyl, amino, carboxy, amido, $NHC(=O)(C_1$-C_4 alkyl), $NH(C_1$-C_4 alkyl), $N(C_1$-C_4 alkyl$)(C_1$-C_2 alkyl), $C(=O)O(C_1$-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_{11} is hydrogen, hydroxy, fluoro, chloro, $COO(C_1$-C_2 alkyl), cyano, or $CO(C_1$-C_2 alkyl); and

R_{12} is hydrogen or C_1-C_4 alkyl; with the proviso that (1) B is not straight chain C_1-C_{12} alkyl, (2) when R_5 is unsubstituted cycloakyl, R_3 and R_4 are hydrogen, and R_6 is hydrogen or methyl, then B is not NHR_2 wherein R_2 is benzyl or thienylmethyl, and (3) when R_5 is p-bromophenyl, and R_3, R_4 and R_6 are methyl, then B not methylamino or hydroxyethylamino.

2. A compound according to claim 1 wherein B is NR_1R_2, $NHCHR_1R_2$, or $OCHR_1R_2$, wherein R_1 is C_1-C_6 alkyl, which may be substituted by one of hydroxy, fluoro or C_1-C_2 alkoxy, and may contain one double or triple bond, and R_2 is benzyl or C_1-C_5 alkyl which may contain one double or triple bond, wherein said C_1-C_5 alkyl or the phenyl in said benzyl may be substituted by fluoro, C_1-C_5 alkyl, or C_1-C_5 alkoxy

3. A compound according to claim 1 wherein B is $CR_1R_2R_{11}$, wherein R_1 is C_1-C_6 alkyl which may be substituted by one C_1-C_6 alkoxy or hydroxy, R_2 is benzyl or C_1-C_6 alkyl wherein said C_1-C_6 alkyl or the phenyl in said benzyl may be substituted by one C_1-C_6 alkyl, C_1-C_6 alkoxy, fluoro, chloro or bromo, and R_{11} is hydrogen or fluoro.

4. A compound according to claim 1 wherein B is as defined in claim 1 and R_2 is C_1-C_6 alkyl which may be substituted by fluoro, C_1-C_6 alkyl or C_1-C_6 alkoxy and may contain one double or triple bond.

5. A compound according to claim 1 wherein B is as defined in claim 1 and R_2 is benzyl or methylthienyl, the phenyl or thienyl of which may be substituted by fluoro, chloro, C_1-C_4 alkyl or C_1-C_4 alkoxy.

6. A compound according to any one of claims 1 to 5 wherein R_3 is methyl, ethyl, fluoro, chloro, or methoxy.

7. A compound according to any one of claims 1 to 6 wherein R_4 and R_6 are hydrogen, methyl or ethyl.

8. A compound according to any one of claims 1 to 7 wherein R_5 is phenyl substituted by two or three substituents.

9. A compound according to claim 8 wherein said substituent is independently fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethyl, C_1-C_6 alkyl which may be substituted by one of hydroxy, C_1-C_4 alkoxy or fluoro and may have one double or triple bond, -(C_1-C_4 alkylene)O(C_1-C_2 alkyl), C_1-C_3 hydroxyalkyl, hydroxy, formyl, COO(C_1-C_2 alkyl), -(C_1-C_2 alkylene)amino, or -C(O)(C_1-C_4 alkyl).

10. A compound according to claim 1 wherein said compound is

n-butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

di-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

ethyl-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

diethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

n-butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

2-{N-n-butyl-N-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-ethanol;


4-(1-ethyl-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine;

n-butyl-ethyl-[2,5-dimethyl-7-(2,4-dimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;

2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidyl-4-yl]-(1-ethyl-propyl)amine; or

2-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-butan-1-ol.

11. A pharmaceutical composition for the treatment of (a) illnesses induced or facilitated by corticotropin releasing factor or (b) inflammatory disorders such as arthritis, asthma and allergies; anxiety; depression; fatigue syndrome; headache; pain; cancer; irritable bowel syndrome, including Crohn's disease, spastic colon and irritable colon; immune dysfunction; human immunodeficiency virus (HIV) infections; neurogenerative diseases such as Alzheimer's disease; gastrointestinal diseases; eating disorders such as anorexia nervosa; hemorrhagic stress; drug and alcohol withdrawal symptoms; drug addiction; stress-induced psychotic episodes; and fertility problems, which comprises a compound of the formula



I

and the pharmaceutically acceptable acid addition salts thereof, wherein

B is NR_1R_2, $CR_1R_2R_{11}$, $C(=CR_2R_{12})R_1$, $NHCR_1R_2R_{11}$, OCR_1R_2R... SCR_1R_2R... $NHNR_1R_2$, $CR_2R_{11}NHR_1$, $CR_2R_{11}OR_1$, $CR_2R_{11}SR_1$, or $C(O)R_2$;

R_1 is hydrogen, or C_1-C_5 alkyl which may be substituted by one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C_1-C_8 alkoxy, O-C -(C_1-C_5 alkyl), O-C NH(C_1-C_4 alkyl), O-C -N(C_1-C_2

O O O

alkyl)(C_1-C_2 alkyl), amino, NH(C_1-C_4 alkyl), N(C_1-C_2 alkyl)(C_1-C_4 alkyl), S(C_1-C_6 alkyl), N(C_1-C_4alkyl)C (C_1-C_4 alkyl), NHC (C_1-C_4 alkyl), COOH, C O(C_1-C_4 alkyl), C NH(C_1-C_4 alkyl), C N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SH, CN, NO_2, SO(C_1-C_4 alkyl), SO_2(C_1-C_4 alkyl), SO_2NH(C_1-C_4 alkyl), SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), and said C_1-C_6 alkyl may contain one or two double or triple bonds;

R_2 is C_1-C_{12} alkyl, aryl or (C_1-C_{10} alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C_1-C_6 alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, benzyl or C_1-C_4 alkanoyl, wherein R_2 may be substituted independently by from one to three of chloro, fluoro, or C_1-C_4 alkyl, or one of hydroxy, bromo, iodo, C_1-C_6 alkoxy, O-C -(C_1-C_6 alkyl), O-C -N(C_1-C_4 alkyl)(C_1-C_2 alkyl), S(C_1-C_6 alkyl), NH_2, NH(C_1-C_2 alkyl), N(C_1-C_2 alkyl) (C_1-C_4 alkyl), N(C_1-C_4 alkyl)-C (C_1-C_4 alkyl), NHC (C_1-C_4 alkyl), COOH, C O(C_1-C_4 alkyl), C NH(C_1-C_4 alkyl), C N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SH, CN, NO_2, SO(C_1-C_4 alkyl), SO_2(C_1-C_4 alkyl), SO_2NH(C_1-C_4 alkyl), SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), and wherein said C_1-C_{12} alkyl or C_1-C_{10} alkylene may contain one to three double or triple bonds; or

NR_1R_2 or $CR_1R_2R_{11}$ may form a saturated 3- to 8-membered carbocyclic ring, the 5- to 8-membered rings of which may contain one or two double bonds or one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, benzyl or C_1-C_4 alkanoyl;

R_3 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C_1-C_6 alkyl), NH(C_1-C_6 alkyl), N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SH, S(C_1-C_4 alkyl), SO(C_1-C_4 alkyl), or SO_2(C_1-C_4 alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may contain one

double or triple bond and may be substituted by from 1 to 3 substituents R_6 independently selected from the group consisting of hydroxy, C_1-C_3 alkoxy, fluoro, chloro or C_1-C_3 thioalkyl;

R_4 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, formyl, $NH(C_1$-C_6 alkyl), $N(C_1$-C_6 alkyl)$(C_1$-C_2 alkyl), $SO_n(C_1$-C_6 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C_1-C_6 alkyls may be substituted by one hydroxy, trifluoromethyl, amino, carboxy, amido, NHC (C_1-C_4 alkyl), $NH(C_1$-C_4 alkyl), $N(C_1$-C_4 alkyl)$(C_1$-C_2 alkyl), C O(C_1-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one or two of O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, C_1-C_4 alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, formyl, C_1-C_6 alkyl, C_1-C_6 alkoxy or trifluoromethyl, or one of hydroxy, iodo, cyano, nitro, amino, $NH(C_1$-C_4 alkyl), $N(C_1$-$C_4)(C_1$-C_2 alkyl), $COO(C_1$-C_4 alkyl), $CO(C_1$-C_4 alkyl), $SO_2NH(C_1$-C_4 alkyl), $SO_2N(C_1$-C_4 alkyl)$(C_1$-C_2 alkyl), SO_2NH_2, $NHSO_2(C_1$-C_4 alkyl), $S(C_1$-C_6 alkyl), $SO_2(C_1$-C_6 alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may be substituted by one or two of fluoro, chloro, hydroxy, C_1-C_4 alkoxy, amino, methylamino, dimethylamino or acetyl wherein said C_1-C_4 alkyl and said C_1-C_6 alkyl may contain one double or triple bond; with the proviso that R_5 is not unsubtituted phenyl;


R_6 is hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, formyl, amino, $NH(C_1$-C_6 alkyl), $N(C_1$-C_6 alkyl)$(C_1$-C_2 alkyl), $SO_n(C_1$-C_6 alkyl), wherein n is 0, 1 or 2, cyano, carboxy, or amido, wherein said C_1-C_6 alkyls may be substituted by one hydroxy, trifluoromethyl, amino, carboxy, amido, NHC (C_1-C_4 alkyl), $NH(C_1$-C_4 alkyl).

$N(C_1\text{-}C_4$ alkyl)$(C_1\text{-}C_2$ alkyl), $\overset{\overset{O}{\|}}{C}O(C_1\text{-}C_4$ alkyl), $C_1\text{-}C_3$ alkoxy, $C_1\text{-}C_3$ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_{11} is hydrogen, hydroxy, fluoro, chloro, $COO(C_1\text{-}C_2$ alkyl), cyano, or $CO(C_1\text{-}C_2$ alkyl); and

R_{12} is hydrogen or $C_1\text{-}C_4$ alkyl, in an amount effective in the treatment of said illnesses, and a pharmaceutically acceptable carrier.

12. A compound of the formula



II

wherein

D is hydroxy, chloro, or cyano;


R_4 and R_6 are each independently hydrogen, $C_1\text{-}C_6$ alkyl, fluoro, chloro, bromo, iodo, $C_1\text{-}C_6$ alkoxy, $SO_n(C_1\text{-}C_6$ alkyl), wherein n is 0, 1 or 2, or cyano, wherein said $C_1\text{-}C_6$ alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, $NHC(O)(C_1\text{-}C_4$ alkyl), $NH(C_1\text{-}C_4$ alkyl), $N(C_1\text{-}C_4$ alkyl)$(C_1\text{-}C_2$ alkyl), $C(O)O(C_1\text{-}C_4$ alkyl), $C_1\text{-}C_3$ alkoxy, $C_1\text{-}C_3$ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperdinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen, $C_1\text{-}C_4$ alkyl, $C_1\text{-}C_4$ alkanoyl, phenyl or benzyl, wherein each of the above groups may be substituted independently by from one to three of fluoro, chloro, $C_1\text{-}C_6$ alkyl, $C_1\text{-}C_6$ alkoxy or trifluoromethyl, or one of hydroxy, bromo, iodo, cyano, nitro, amino, $NH(C_1\text{-}C_4$ alkyl), $N(C_1\text{-}C_4)(C_1\text{-}C_2$ alkyl), $COO(C_1\text{-}C_4$ alkyl), $CO(C_1\text{-}C_4$ alkyl),

$SO_2NH(C_1\text{-}C_4$ alkyl), $SO_2N(C_1\text{-}C_4$ alkyl)$(C_1\text{-}C_2$ alkyl), SO_2NH_2, $NHSO_2(C_1\text{-}C_4)$, $S(C_1\text{-}C_6$ alkyl), $SO_2(C_1\text{-}C_6$ alkyl), wherein said $C_1\text{-}C_4$ alkyl and $C_1\text{-}C_6$ alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R_5 is not unsubstituted phenyl; and

R_9 is hydrogen, $C_1\text{-}C_6$ alkyl or chloro; with the proviso that when (a) R_4 and R_6 are methyl, R_9 is hydrogen and D is hydroxy, then R_5 is not phenyl (1) substituted by one of halogen, nitro, $C_1\text{-}C_6$ alkyl, $C_1\text{-}C_6$ alkoxy, or trifluoromethyl, and optionally in addition substituted by one or two of halogen, $C_1\text{-}C_6$ alkyl or $C_1\text{-}C_6$ alkoxy, or (2) di-or trisubstituted by one of nitro or trifluoromethyl and one or two of halogen, $C_1\text{-}C_6$ alkyl or $C_1\text{-}C_6$ alkoxy, and (b) when D is chloro, R_4 and R_9 are hydrogen, and R_6 is $C_1\text{-}C_6$ alkyl, then R_5 is not unsubstituted cyclohexyl.

13. A compound of the formula



VII

wherein

Q is $C(O)CHR_1R_2$ or cyano;

R_1 is hydrogen, or $C_1\text{-}C_6$ alkyl which may be substituted by one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, $C_1\text{-}C_8$ alkoxy, or nitro, and said $C_1\text{-}C_6$ alkyl may contain one or two double or triple bonds;

R_2 is $C_1\text{-}C_{12}$ alkyl, aryl or $(C_1\text{-}C_{10}$ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or $(C_1\text{-}C_6$ alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-Z wherein Z is hydrogen, $C_1\text{-}C_4$ alkyl, benzyl or $C_1\text{-}C_4$ alkanoyl, wherein R_2 may be substituted independently by

from one to three of chloro, fluoro, or C_1-C_4 alkyl, or one of hydroxy, bromo, iodo, C_1-C_6 alkoxy, nitro, SO(C_1-C_4 alkyl), SO_2(C_1-C_4 alkyl), SO_2NH(C_1-C_4 alkyl), SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), and wherein said C_1-C_{12} alkyl or C_1-C_{10} alkylene may contain one to three double or triple bonds;

R_4 and R_6 are each independently hydrogen, C_1-C_6 alkyl, fluoro, chloro, bromo, iodo, C_1-C_6 alkoxy, amino, or SO_n(C_1-C_6 alkyl), wherein n is 0, 1 or 2, or cyano, wherein said C_1-C_6 alkyl may be substituted by one C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one or two O, S or N-Z wherein Z is hydrogen, C_1-C_4 alkyl, C_1-C_4 alkanoyl, phenyl or benzyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, C_1-C_6 alkyl, C_1-C_6 alkoxy or trifluoromethyl, or one of hydroxy, bromo, iodo, cyano, nitro, amino, NH(C_1-C_4 alkyl), N(C_1-C_4)(C_1-C_2 alkyl), COO(C_1-C_4 alkyl), CO(C_1-C_4 alkyl), SO_2NH(C_1-C_4 alkyl), SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), SO_2NH_2, $NHSO_2$(C_1-C_4 alkyl), S(C_1-C_6 alkyl), SO_2(C_1-C_6 alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R_5 is not unsubstituted phenyl; and

R_{16} is hydrogen or C(O)C_1-C_6 alkyl; with the proviso that when Q is cyano, R_4 and R_6 are not both methyl.

INTERNATIONAL SEARCH REPORT

Interr nal Application No
PCT/US 93/10715

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D487/04 A61K31/505 C07D207/34 //(C07D487/04,239:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,31 45 287 (TROPONWERKE) 19 May 1983 cited in the application see page 4, line 1 - line 5; claim 1 ---	1,11
X	EP,A,0 475 411 (MARION MERRELL DOW) 18 March 1992 see claim 1 -----	12

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

'A' document defining the general state of the art which is not considered to be of particular relevance

'E' earlier document but published on or after the international filing date

'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

'O' document referring to an oral disclosure, use, exhibition or other means

'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'&' document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
9 March 1994	23. 03. 94

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Alfaro Faus, I

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter nal Application No
PCT/US 93/10715

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-3145287	19-05-83	NONE	
EP-A-0475411	18-03-92	AU-A- 8372991	19-03-92
		CA-A- 2051012	15-03-92
		CN-A- 1059909	01-04-92
		JP-A- 4270282	25-09-92
		NZ-A- 239750	25-02-94
		US-A- 5244896	14-09-93

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 487/04, 471/04, A61K 31/505, 31/435 // (C07D 487/04, 239:00, 231:00) (C07D 471/04, 249:00, 221:00) (C07D 487/04, 239:00, 209:00)

A1

(11) International Publication Number: **WO 98/08847**

(43) International Publication Date: 5 March 1998 (05.03.98)

(21) International Application Number: PCT/IB97/00922

(22) International Filing Date: 25 July 1997 (25.07.97)

(30) Priority Data:
60/025,039 28 August 1996 (28.08.96) US

(71) Applicant *(for all designated States except US)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: CHEN, Yuhpyng, Liang [US/US]; 8 Waterview Drive, Waterford, CT 06385 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES

(57) Abstract

This invention relates to compounds of formula (I), wherein the dashed lines represent optional double bonds; A is nitrogen or CR^7; B is $-NR^1R^2$, $-CR^1R^2R^{10}$-$C(=CR^2R^{11})R^1$, $-NHCR^1R^2R^{10}$, $-OCR^1R^2R^{10}$, $-SCR^1R^2R^{10}$, $-CR^2R^{10}NHR^1$, $-CR^2R^{10}OR^1$, $-CR^2R^{10}SR^1$ or $-COR^2$; J and K are each independently nitrogen or carbon and both J and K are not nitrogens; D and E are each selected, independently, from nitrogen, CR^4, C=O, C=S, sulfur, oxygen, CR^4R^6 and NR^8; G is nitrogen or carbon; and their use for the prevention or inhibition of a disorder that can be treated by antagonizing CRF.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

SUBSTITUTED 6,5- HETERO-BICYCLIC DERIVATIVES

Background of the invention

This invention relates to certain pharmaceutically active substituted 6,5-hetero-bicyclic derivatives, pharmaceutical compositions containing them and methods of administering them to subjects in need of their corticotropin releasing factor antagonist activity.

The substituted heterocyclic derivatives claimed in this case exhibit activity as corticotropin releasing factor (hormone) CRF (CRH) antagonists.

CRF antagonists are mentioned in U.S. Patents 4,605,642 and 5,063,245 referring to peptides and pyrazolinones, respectively. They are also referred to in the following: PCT Patent Application PCT/IB95/00439, which designates the United States and was filed on June 6, 1995 and published on December 14, 1995; PCT Patent Application PCT/IB95/00373, which designates the United States and was filed on May 18, 1995 and published on December 21, 1995; U.S. Patent Application 08/448,539, which was filed in the PCT on Nov. 12, 1993 and entered the U.S. national phase on June 14, 1995; PCT Patent Application WO 95/10506, which was filed on October 12, 1993 and published on April 20, 1995, and U.S. Patent Application 08/481,413, which was filed in the PCT on November 26, 1993 and entered the U.S. national phase on July 24, 1995; U.S. Patent Application 08/254,820, which was filed on April 19, 1995; Provisional U.S. Patent Application 60/008,396, which was filed on December 8, 1995; and Provisional U.S. Patent Application 60/006,333, which was filed on November 8, 1995. All the foregoing patent applications are incorporated herein by reference in their entireties.


The importance of CRF antagonists is set out in the literature, e.g., P. Black, Scientific American SCIENCE & MEDICINE,1995, p. 16-25; T. Lovenberg et al., Current Pharmaceutical Design, 1995, 1, 305-316; and United States Patent 5,063,245, which is referred to above. A recent outline of the different activities possessed by CRF antagonists is found in M. J. Owens et al., Pharm. Rev., Vol. 43, pages 425 to 473 (1991), also incorporated herein by reference. Based on the research described in these two and other references, CRF antagonists are effective in the treatment of a wide range of stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthemia, bipolar disorders and cyclothymia;

chronic fatigue syndrome; eating disorders such as anorexia and bulimia nervosa; generalized anxiety disorder; panic disorder; phobias; obsessive-compulsive disorder, post-traumatic stress disorder, pain perception such as fibromyalgia; headache; gastrointestinal diseases; hemorrhagic stress; ulcers; stress-induced psychotic episodes; fever; diarrhea; post-operative ileus, colonic hypersensitivity; irritable bowel syndrome; Crohn's disease; spastic colon; inflammatory disorders such as rheumatoid arthritis and osteoarthritis; pain; asthma; psoriasis; allergies; osteoporosis; premature birth; hypertension, congestive heart failure; sleep disorders; neurodegenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, multiinfarct dementia, Parkinson's disease, and Huntington's disease; head trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; stroke; spinal cord trauma; psychosocial dwarfism; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone; obesity; chemical dependencies and addictions; drug and alcohol withdrawal symptoms; infertility, cancer; infertility; muscular spasms; urinary incontinence; hypoglycemia and immune dysfunctions including stress induced immune dysfunctions, immune suppression and human immunodeficiency virus infections; and stress-induced infections in humans and animals.

The compounds of this invention are also believed to be inhibitors of CRH binding protein and therefore useful in the treatment of disorders the treatment of which can be effected or facilitated by inhibiting such protein. Examples of such disorders are Alzheimer's disease and obesity.

Summary of the Invention

The present invention relates to compounds of the formula



I

or a pharmaceutically acceptable salt thereof, wherein

the dashed lines represent optional double bonds;

A is nitrogen or CR^7;

B is $-NR^1R^2$, $-CR^1R^2R^{10}$, $-C(=CR^2R^{11})R^1$, $-NHCR^1R^2R^{10}$, $-OCR^1R^2R^{10}$, $-SCR^1R^2R^{10}$, $-CR^2R^{10}NHR^1$, $-CR^2R^{10}OR^1$, $-CR^2R^{10}SR^1$ or $-COR^2$;

J and K are each independently nitrogen or carbon and both J and K are not nitrogens ;

D and E are each selected, independently, from nitrogen, CR^4, C=O, C=S, sulfur, oxygen, CR^4R^6 and NR^8 ;

G is nitrogen or carbon;

the ring containing D, E, G, K, and J in formula I may be a saturated or unsaturated 5-membered ring and may optionally contain one or two double bonds and may optionally contain from one to three heteroatoms in the ring and may optionally have one or two C=O or C=S groups;

R^1 is C_1-C_6 alkyl optionally substituted with one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, -O-(C_1-C_4 alkyl), CF_3, -C(=O)O-(C_1-C_4alkyl), -OC(=O)(C_1-C_4 alkyl), -OC(=O)N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NHCO(C_1-C_4 alkyl), -COOH, -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_4 alkyl), -CN, $-NO_2$, -SO(C_1-C_4 alkyl), $-SO_2$(C_1-C_4 alkyl), $-SO_2$NH(C_1-C_4 alkyl) and $-SO_2$N(C_1-C_4 alkyl)(C_1-C_2 alkyl), wherein each of the C_1-C_4 alkyl groups in the foregoing R^1 groups may optionally contain one or two double or triple bonds;

R^2 is C_1-C_{12} alkyl which may optionally contain from one to three double or triple bonds, aryl or (C_1-C_4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C_1-C_4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C_3-C_8 cycloalkyl or (C_1-C_6 alkylene)(C_3-C_8 cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C_1-C_6 alkylene)(C_3-C_8 cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ^2 wherein Z^2 is selected from hydrogen, C_1-C_4 alkyl, benzyl and C_1-C_4 alkanoyl, and wherein each of the foregoing R^2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C_1-C_4 alkyl, or with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -OC(=O)(C_1-C_6 alkyl), -OC(=O)N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), amino, -NH(C_1-C_2 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)-CO-(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl),

-COOH, -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), -SH, -CN, -NO_2, -SO(C_1-C_4 alkyl), -SO_2(C_1-C_4 alkyl), -SO_2NH(C_1-C_4 alkyl) and -SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl);

-NR^1R^2 or -$CR^1R^2R^{10}$ may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ^3 wherein Z^3 is hydrogen, C_1-C_4 alkyl, benzyl or C_1-C_4 alkanoyl;

R^3 is hydrogen, C_1-C_4 alkyl, -O(C_1-C_4 alkyl), chloro, fluoro, bromo, iodo, (C_1-C_2 alkylene)-O-(C_1-C_2 alkyl), (C_1-C_2 alkylene)-OH, or -S(C_1-C_4 alkyl);

each R^4 is, independently, hydrogen, (C_1-C_6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C_1-C_2 alkylene)-OH, CF_3, CH_2SCH_3, nitro, -O(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), -C(=O)H or -C(=O)O(C_1-C_4alkyl);

R^6 is hydrogen, methyl or ethyl;

R^8 is hydrogen or C_1-C_4 alkyl;

R^5 is phenyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl and wherein each of the foregoing R^5 groups is substituted with from one to four substituents R^{13} wherein one to three of said substituents may be selected, independently, from fluoro, chloro, C_1-C_6 alkyl and -O(C_1-C_6 alkyl) and one of said substituents may be selected from bromo, iodo, formyl, OH, (C_1-C_4 alkylene)-OH, (C_1-C_4alkylene)-O-(C_1-C_2 alkyl), -CN, -CF_3, -NO_2, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_6 alkyl), -OCO(C_1-C_4 alkyl), (C_1-C_4 alkylene)-O-(C_1-C_4 alkyl), -S(C_1-C_6 alkyl), (C_1-C_4 alkylene)-S-(C_1-C_4 alkyl), -C(=O)O(C_1-C_4 alkyl), -C(=O)(C_1-C_4 alkyl), -COOH, -SO_2NH(C_1-C_4 alkyl), -SO_2N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -SO_2NH_2, -$NHSO_2$(C_1-C_4 alkyl), -S(C_1-C_6 alkyl) and -SO_2(C_1-C_6 alkyl), and wherein each of the C_1-C_4 alkyl and C_1-C_6 alkyl moieties in the foregoing R^5 groups may optionally have one or two double bonds;

R^7 is hydrogen, C_1-C_4 alkyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, -O(C_1-C_4 alkyl), -C(=O)(C_1-C_4 alkyl), -C(=O)O(C_1-C_4 alkyl), -OCF_3, -CF_3, -CH_2OH or -CH_2O(C_1-C_2 alkyl);

R^{10} is hydrogen, hydroxy, methoxy or fluoro;

R^{11} is hydrogen or C_1-C_4 alkyl; and

with the proviso that: a) when both J and K are carbon and D is CR^4 and E is nitrogen, then G can not be nitrogen; (b) when both J and K are carbons and D and G are nitrogens, then E can not be CR^4 or C=O or C=S; (c) when both J and K are carbons and D and E are carbons, then G can not be nitrogen; (d) when G is carbon, it must be double bonded to E; and (e) in the ring containing J, K, D, E and G, there can not be two double bonds adjacent to each other.


and the pharmaceutically acceptable salts of such compounds.

When the ring containing D, E, G, K and J is a 5-membered heteroaromatic ring, it may be, e.g., pyrazolo, imidazolo, thieno, furano, thiazolo, oxazolo, triazolo or thiadiazolo.


The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight branched or cyclic moieties or combinations thereof.

The term "alkoxy", as used herein, unless otherwise indicated, means -O-alkyl, where "alkyl" is defined as above.


Examples of more specific embodiments of formula I are the following, wherein $(R)_n$ represents from zero to two substituents, wherein such substitutents are as defined above in the definition of formula I.




I-A




I-B




I-E




I-J




I-K




I-C




I-D




I-G




I-H




I-L




I-M




I-N




I-O




I-R




I-S




I-V




I-W




I-P




I-Q




I-T




I-U




I-X




I-B′



I-Y



I-Z



I-A'

More specific embodiments of this invention include compounds of the above formula I wherein B is $-CHR^1R^2$, $-NR^1R^2$, $-NHCHR^1R^2$, $-OCHR^1R^2$ or $-SCHR^1R^2$, and R^1 is C_1-C_6 alkyl, which may optionally be substituted with one hydroxy, fluoro, CF_3 or C_1-C_4 alkoxy group and which may optionally contain one double or triple bond; and R^2 is benzyl or C_1-C_6 alkyl, which may optionally contain one double or triple bond, wherein said C_1-C_6 alkyl and the phenyl moiety of said benzyl may optionally be substituted with one fluoro, CF_3, C_1-C_2 alkyl, C_1-C_2 alkoxy or chloro group.

Other more specific embodiments of this invention include compounds of formula I wherein R^3 is methyl, ethyl, chloro or methoxy; R^4 and R^6 are selected from hydrogen, methyl and ethyl; R^5 is di- or tri-substituted phenyl, pyridyl, or pyrimidyl, in which the two or three substitutents on said phenyl, pyridyl or pyrimidyl are selected, independently, from C_1-C_4 alkyl, -O-(C_1-C_4 alkyl), (C_1-C_2 alkyl)-O-(C_1-C_4 alkyl), $-CF_3$, $-OCF_3$, -CHO, -(C_1-C_4 alkyl)-OH, cyano, chloro, fluoro, bromo and iodo, wherein each of the forgoing C_1-C_4 alkyl groups may optionally contain one double or triple bond;

Other more specific embodiments of this invention include compounds of the formula I wherein B is or contains an NR^1R^2 or $CR^1R^2R^{10}$ moiety which forms a saturated or unsaturated 5-membered carbocyclic ring wherein one of the ring carbons may optionally be replaced by a sulfur or oxygen atom.

Other more specific embodiments of this invention include compounds of the formula I wherein A is nitrogen or CR^7 and R^7 is hydrogen or methyl.

Other more specific embodiments of this invention include compounds of the formula I wherein B is $-CR^1R^2R^{10}$, $-C(=CR^2R^{11})R^1$, $-OCR^1R^2R^{10}$, $-SCR^1R^2R^{10}$, $-CR^2R^{10}NHR^1$, $CR^2R^{10}OR^1$, $-CR^2R^{10}SR^1$ or $-COR^2$.

Other more specific embodiments of this invention include compounds of the formula I wherein A is CH, J and K are carbon and D, E, and G are nitrogen;

Other more specific embodiments of this invention include compounds of the formula I wherein J and D are nitrogen, K and G are carbon, and E is CH, CCH_3, or CC_2H_5.

Other more specific embodiments of this invention include compounds of the formula I wherein B contains a $-NR^1R^2$ or $-CR^1R^2R^{10}$ moiety that is a saturated or unsaturated three to five membered ring.

Other more specific embodiments of this invention include compounds of the formula I wherein J and K are carbon, and D–E–G is O-C(CH_3)=C, O-CH=C,

S-C(CH_3)=C, S-CH=C, N(CH_3)-C(CH_3)=C, N(CH_3)-CH=C, O-N=C, S-N=C, N(CH_3)-N=C, O-CH_2N, S-CH_2N, or NH-C(C_1-C_2alkyl)=C.

Examples of preferred compounds of the formula I:

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;

[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;

7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;

[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-ethyl-propyl-amine;

[6-bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]-pyridin-7-yl]-(1-ethyl-propyl)-amine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]-pyridin-7-yl]-amine;

[6-bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-methyl-amine; and

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]-pyridine.

Other compounds of formula I include the following:

4-(1-ethyl-propoxy)-2,7-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]-pyrimidine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;

[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;

butyl-ethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;

3-(4-bromo-2,6-dimethyl-phenyl)-7-(1-ethyl-propoxy)-5-methyl-pyrazolo[1,5-a]-pyrimidine;

[2,7-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidin-4-yl]-diethyl-amine;

[2,7-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidin-4-yl]-ethyl-propyl-

amine;

[8-(4-chloro-2,6-dimethyl-phenyl)-2,7-dimethyl-pyrrolo[1,2-a]pyrimidin-4-yl]-ethyl-propyl-amine;

[8-(4-chloro-2,6-dimethyl-phenyl)-2,7-dimethyl-pyrrolo[1,2-a]pyrimidin-4-yl]-diethyl-amine;

[8-(4-chloro-2,6-dimethyl-phenyl)-2,6-dimethyl-pyrrolo[1,2-a]pyrimidin-4-yl]-diethyl-amine;

[2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidin-4-yl]-diethyl-amine;

[2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidin-4-yl]-ethyl-propyl-amine;

butyl-[2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidin-4-yl]-ethyl-amine;

[2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidin-4-yl]-(1-ethyl-propyl)-amine;

[8-(4-chloro-2,6-dimethyl-phenyl)-2,6-dimethyl-pyrrolo[1,2-a]pyrimidin-4-yl]-(1-ethyl-propyl)-amine;

8-(4-chloro-2,6-dimethyl-phenyl)-4-(1-ethyl-propoxy)-2,6-dimethyl-pyrrolo[1,2-a]-pyrimidine;

4-(1-ethyl-propoxy)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]-pyrimidine;

4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidine;

(1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidin-4-yl]-amine;

butyl-ethyl-[2-methyl-8-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-a]pyrimidin-4-yl]-amine;

butyl-ethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-2H-isothiazolo[2,3-a]-pyrimidin-7-yl]-amine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-2H-isothiazolo[2,3-a]-pyrimidin-7-yl]-amine;

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-2H-isothiazolo[2,3-a]-pyrimidine;

4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-imidazo[1,5-a]-

pyrimidine;

(1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-imidazo[1,5-a]pyrimidin-4-yl]-amine;

[2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-imidazo[1,5-a]pyrimidin-4-yl]-(1-ethyl-propyl)-amine;

4-(1-ethyl-propoxy)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-imidazo[1,5-a]-pyrimidine;

4-(1-ethyl-propoxy)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-6,7-dihydro-imidazo [1,5-a]pyrimidine;

4-(1-ethyl-propoxy)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-thiazolo[3,4-a]-pyrimidine;

4-(1-ethyl-propoxy)-2-methyl-7-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-b]pyridazine;

4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-b]-pyridazine;

4-(1-ethyl-propoxy)-2,6-dimethyl-7-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-b]; pyridazine;

4-(1-ethyl-propoxy)-2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-b]-pyridazine;

[2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-b]pyridazin-4-yl]-(1-ethyl-propyl)-amine;

(1-ethyl-propyl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-pyrrolo[1,2-b]pyridazin-4-yl]-amine;

[2,6-dimethyl-3-(2,4,6-trimethyl-phenyl)-imidazo[1,2-b]pyridazin-8-yl]-(1-ethyl-propyl)-amine;

8-(1-ethyl-propoxy)-2,6-dimethyl-3-(2,4,6-trimethyl-phenyl)-imidazo[1,2-b]-pyridazine;

8-(1-ethyl-propoxy)-6-methyl-3-(2,4,6-trimethyl-phenyl)-imidazo[1,2-b]pyridazine;

(1-ethyl-propyl)-[6-methyl-3-(2,4,6-trimethyl-phenyl)-imidazo[1,2-b]pyridazin-8-yl]-amine;

(1-ethyl-propyl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-imidazo[1,5-b]pyridazin-4-yl]-amine;

[2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-imidazo[1,5-b]pyridazin-4-yl]-(1-ethyl-propyl)-amine;

4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-imidazo[1,5-b]-pyridazine-b]pyridazine;

butyl-[2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-imidazo[1,5-b]pyridazin-4-yl]-ethyl-amine;

[2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-imidazo[1,5-b]pyridazin-4-yl]-ethyl-propyl-amine;

[2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-imidazo[1,5-b]pyridazin-4-yl]-diethyl-amine;

diethyl-[6-methyl-3-(2,4,6-trimethyl-phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]-amine;

ethyl-[6-methyl-3-(2,4,6-trimethyl-phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]-propyl-amine;

butyl-ethyl-[6-methyl-3-(2,4,6-trimethyl-phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]-amine;

(1-ethyl-propyl)-[6-methyl-3-(2,4,6-trimethyl-phenyl)-[1,2,4]triazolo[4,3-b]-pyridazin-8-yl]-amine;

8-(1-ethyl-propoxy)-6-methyl-3-(2,4,6-trimethyl-phenyl)-[1,2,4]triazolo[4,3-b]-pyridazine;

7-(1-ethyl-propoxy)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]-pyridine;

7-(1-ethyl-propoxy)-1,2,5-trimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]-pyridine;

(1-ethyl-propyl)-[1,2,5-trimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]-pyridin-7-yl]-amine;

[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;

butyl-[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]-ethyl-amine;

[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]-ethyl-propyl-amine;

[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]-diethyl-amine;

ethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-

propyl-amine;

butyl-ethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-amine;

diethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-amine;

[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;

[3-(4-chloro-2,6-dimethyl-phenyl)-5-methyl-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;

3-(4-chloro-2,6-dimethyl-phenyl)-7-(1-ethyl-propoxy)-5-methyl-3H-[1,2,3]triazolo[4,5-b]pyridine;

3-(4-bromo-2,6-dimethyl-phenyl)-7-(1-ethyl-propoxy)-5-methyl-3H-[1,2,3]triazolo[4,5-b]pyridine;

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-isothiazolo[4,5-b]pyridine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-isothiazolo[4,5-b]pyridin-7-yl]-amine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-isoxazolo[4,5-b]pyridin-7-yl]-amine;

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-isoxazolo[4,5-b]pyridine;

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b]pyridine;

7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b]pyridine;

[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-amine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-furo[3,2-b]pyridin-7-yl]-amine;

[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-furo[3,2-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;

7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-furo[3,2-b]pyridine;

7-(1-ethyl-propoxy)- 5-methyl-3-(2,4,6-trimethyl-phenyl)-furo[3,2-b]pyridine;

4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-6H-pyrrolo[3,4-b]-pyridine;

4-(1-ethyl-propoxy)-2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-6H-pyrrolo[3,4-b]-

pyridine;

(1-ethyl-propyl)-[2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-6H-pyrrolo[3,4-b]pyridin-4-yl]-amine;

[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-2-thia-4-aza-inden-7-yl]-(1-ethyl-propyl)-amine;

7-(1-ethyl-propoxy)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-2-thia-4-aza-indene;

4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-furo[3,4-b]pyridine;

[2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-furo[3,4-b]pyridin-4-yl]-(1-ethyl-propyl)-amine;

[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;

7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-2H-pyrazolo[4,3-b]-pyridine;

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-isothiazolo[4,3-b]pyridine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-isothiazolo[4,3-b]pyridin-7-yl]-amine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-d]-pyrimidin-7-yl]-amine;

diethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]-amine;

ethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]-propyl-amine;

butyl-ethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-d]-pyrimidin-7-yl]-amine;

[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-diethyl-amine;

butyl-[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-ethyl-amine;

butyl-ethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;

ethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;

diethyl-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;

[3-(4-chloro-2,6-dimethyl-phenyl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;

[3-(4-chloro-2,6-dimethyl-phenyl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;

3-(4-chloro-2,6-dimethyl-phenyl)-7-(1-ethyl-propoxy)-5-methyl-pyrazolo[1,5-a]-pyrimidine;

8-(4-chloro-2,6-dimethyl-phenyl)-4-(1-ethyl-propoxy)-2-methyl-pyrazolo[1,5-a]-[1,3,5]triazine;

(1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-amine;

4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a][1,3,5]-triazine;

4-(1-ethyl-propoxy)-2,7-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a][1,3,5]-triazine;

[2,7-dimethyl-8-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-(1-ethyl-propyl)-amine;

[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;

7-(1-ethyl-propoxy)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrazolo[4,3-b]-pyridine;

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-isothiazolo[4,5-b]-pyridine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-isothiazolo[4,5-b]pyridin-7-yl]-amine;

1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-7-(1-ethyl-propoxy)-1H-pyrrolo[3,2-b]pyridine;

1,5-dimethyl-3-(2,6-dimethyl-4-chloro-phenyl)-7-(1-ethyl-propoxy)-1H-pyrrolo[3,2-b]pyridine;

2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-7-(1-ethyl-propoxy)-1H-pyrrolo[3,2-b]pyridine;

2,5-dimethyl-3-(2,6-dimethyl-4-chloro-phenyl)-7-(1-ethyl-propoxy)-1H-pyrrolo[3,2-b]pyridine;

7-(1-cyclopropylmethyl-propoxy)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine;

7-(1-cyclopropylmethyl-propoxy)-1,5-dimethyl-3-(2,6-dimethyl-4-chloro-phenyl)-1H-pyrrolo[3,2-b]pyridine;

1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-7-(tetrahydro-furan-3-yloxy)-1H-pyrrolo[3,2-b]pyridine;

1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-7-(S)-(tetrahydro-furan-3-yloxy)-1H-pyrrolo[3,2-b]pyridine;

1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-7-(1-propyl-butoxy)-1H-pyrrolo[3,2-b]pyridine;

7-sec-butylsulfanyl-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine;

cyclopropylmethyl-[2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-b]pyrimidin-4-yl]-propyl-amine;

2-[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridin-7-ylamino]-butan-1-ol;

1,5-dimethyl-7-thiazolidin-3-yl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine;

[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]-ethyl-(2,2,2-trifluoro-ethyl)-amine;

cyclopropylmethyl-[1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]-propyl-amine;

(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-isoxazolo[4,5-b]pyridin-7-yl]-amine; and

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-isoxazolo[4,5-b]-pyridine.

This invention also relates to a pharmaceutical composition for the treatment, prevention or inhibition of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode

depression, recurrent depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions (e.g., dependencies on alcohol, nicotine, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfract dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; and hypoglycemia in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in the treatment of such disorder, and a pharmaceutically acceptable carrier.

The invention also relates to a method for the treatment, prevention or inhibition of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitator by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders;

cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome; Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions (e.g., dependencies on alcohol, nicotine, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; and hypoglycemia in a mammal, including a human, comprising administering to a subject in need of said treatment an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.

This invention also relates to a method of treating or preventing a disorder or condition, the treatment or prevention of which can be effected or facilitated by inhibiting CRH binding protein, in a mammal, including a human, comprising administering to said mammal a CRH binding protein inhibiting amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.


This invention also relates to a pharmaceutical composition for treating or preventing a disorder or conditon, the treatment or prevention of which can be effected or facilitated by inhibiting CRH binding protein in a mammal, including a human, comprising a CRH binding protein inhibiting amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

This invention includes all optical isomers and other stereoisomers of compounds of the formula I. When such compounds contain one or more chiral


centers, it is understood that the invention includes the racemic mixtures as well as all individual enantiomers and diastereomers of such compounds, and mixtures thereof.

Detailed Description of the Invention


The following compounds having the formulas II, III, IV and V are useful as intermediates in the synthesis of compounds of the formula I.




II



III



IV




V

wherein T is chloro, bromo, iodo or $-OSO_2CF_3$; W is cyano, formyl, or $-COO(C_0-C_4$ alkyl) and A, J, K, D, E, G, R^3, and R^5 are as defined above with reference to formula I.


Compounds of the formula I may be prepared as described below. In the reaction schemes and discussion that follow, A, B, D, E, G, J, K, R^3, R^5 and structural formulae I, II, III, IV, and V are defined as above.

SCHEME 1




VI-a IV-a

SCHEME 2




SCHEME 3




IV-c VI (W=CN, -COO(C_1-C_4 alkyl), -$CONH_2$) V-b

SCHEME 4




IX IV-d

SCHEME 5



X I-N

SCHEME 6




I-K, X=S or O, Y=O
I-U, X=S or O, Y=S


XI

I-L, X=S
I-M, X=O


SCHEME 7


B
D'H
A
R3
N
O
R5
XII
D' = NR8, O, S
NOH
XIII
NOR20
XIV
R20 = Acetate or CF3CO
D
I-V, D = NR8
I-W, D = O
I-X, D = S

SCHEME 8


XV
Hal = Br, Cl, I
XVI
XVII
XVIII
XIXa, R21 = H
XIXb, R21 = COOH
XIXc, R21 = C(OH)R4
I-G-a
I-6

SCHEME 9


NC
D
E
H_2N
R^5
XX
NH_2
ROOC
R^3
V-d
R=C_1-C_4 alkyl
T
II-d, T=Cl, Br, I
R^7
II-f
V-e
II-e
OH
IV-f

Compounds of the formula I wherein B is $-NR^1R^2$ or $-NHCR^1R^2R^{11}$ may be prepared by reacting a compound of the formula II wherein T is chloro, bromo, or iodo with a compound of the formula BH, in the presence of a base, with or without an organometallic compound such as Cu(I)X, wherein X is chloro, bromo or iodo, or an acid (such as p-TsOH (Ts=Tosyl) or another sterically hindered phenol) or an equivalent agent known to those of skill in the art. Suitable solvents for this reaction include DMSO, NMP, dimethylacetamide and THF. An excess of BH may be used as both the reagent and the base. Other bases such as potassium or sodium carbonate, a trialkylamine, a potassium or sodium (C_1-C_4 alkoxide) and sodium hydride may also be used. When R^7 is an electron withdrawing group such as $-COO(C_1$-C_4alkyl) or CN, the reaction generally is carried out at a temperature between about room temperature and about 100°C. When R^7 is a non-electron withdrawing group, the reaction temperature can generally range from about 50°C to about 270°C and the pressure can generally range from about 4 psi to about 300 psi. A pressure reactor may be used.

Alternatively, the compounds of formula I may be prepared by reacting a compound of the formula II wherein T is bromo or iodo with 1 equivalent or an excess of BH and a base such as sodium or potassium carbonate or a sodium or potassium (C_1-C_4 alkoxide), in the presence of a palladium (II) or a palladium (0) catalyst such as $Pd(OAc)_2$ or $Pd(PPh_3)_4$, together with a racemic or chiral phosphino agent such as 2,2-bis(diphenylphosphino)-1,1-binaphthyl (BINAP). Alternatively, premade Pd(II)(BINAP) may be used in an appropriate inert (i.e., inert with respect to the reaction at hand) solvent such as toluene, xylene, dioxane or sulfolane, at a temperature from about room temperature to about 180°C, preferably at about reflux temperature.

Compounds of the formula I wherein B is $-OCR^1R^2R^{11}$, $-SCR^1R^2R^{11}$, or $-NHCR^1R^2R^{11}$ may be prepared by reacting compounds in the formula II wherein T is chloro, bromo or iodo with a compound of the formula BH in the presence of a base which is capable of deprotonation of BH (e.g., sodium or potassium hydride, or an organometallic base such as sodium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, a sodium C_1-C_4 alkoxide or n-butyllithium), in an inert organic solvent such as tetrahydrofuran, acetonitrile, dimethylsulfoxide, acetone, a C_2-C_5 alcohol, chloroform, benzene, xylene, toluene, N,N-dimethylformamide (DMF), methylene chloride, 1-methyl-2-pyrrolidinone or a mixture of

two or more of the above solvents (e.g., DMSO and THF), at a temperature from about 0°C to about 180°C, preferably from about 50°C to about 180°C.

Compounds of the formula I wherein B is $-CR^1R^2R^{11}$, $-C(C=CR^2R^{12})R^1$, $-CR^2R^{11}NHR^1$, $-CR^2R^{11}OR^1$, $-CR^2R^{11}SR^1$, or $-C(O)R^2$ may be prepared from compounds of the formula III wherein W is cyano, formyl or carboxy, as described below.

Reacting compounds of formula III wherein W is cyano with a Grignard reagent containing the group R^2 in an inert solvent such as THF, glyme, ether or dioxane, will yield corresponding compounds of formula I wherein B is $-COR^2$. Further reaction of the compounds of formula I wherein B is COR^2 with a Grignard reagent containing R^1, using a solvent such as those referred to above, will yield the corresponding the compounds of formula I wherein B is $-CR^1R^2OH$. Reacting compounds of formula III wherein W is formyl with a Grignard reagent containing the group R^2, in an ethereal solvent such as those referred to above, will yield the corresponding compounds of formula I wherein B is $-CHR^2OH$.

Compounds of formula I wherein B is $-CR^1R^2R^{11}$ or $-C(C=CR^2R^{11})R^1$ may be prepared by conventional methods. Thus, reaction of a compound of the formula I wherein B is $-CR^{1'}R^{2'}OH$, (wherein $R^{1'}$ and $R^{2'}$ are defined as R^1 and R^2, respectively, except that $R^{1'}$ may not be R^1 and $R^{2'}$ may not be R^2), with an acid such as concentrated sulfuric acid in acetic acid, or a Burgess inner salt such as (carboxysulfamoyl)triethylammonium hydroxide methyl ester, will yield a compound of the formula I wherein B is $-C(=CR^2R^{11})R^1$. Hydrogenation of a compound of formula I wherein B is $-C(=CR^2R^{11})R^1$ using palladium on carbon (Pd/C) or a platinum dioxide catalyst in a (C_1-C_4)alkanol solvent will yield a compound of the formula I wherein B is $-CHR^1R^2$. Reaction of a compound of the formula I wherein B is $-CR^1R^2OH$ with diethylaminosulfur trifluoride or triphenylphosphine/carbon tetrachloride in an inert solvent such as carbon tetrachloride will afford a compound of the formula I wherein B is $-CR^1R^2F$ or $-CR^1R^2Cl$, respectively.

Reduction of a compound of formula I wherein B is $-COR^2$ with sodium borohydride, in an inert solvent such as a (C_1-C_4)alkanol, will yield a compound of the formula I wherein B is $-CHR^2OH$. Alkylation of a compound of the formula I wherein B is $-CHR^2OH$ with an alkyl halide (such as alkyl iodide) in the presence of a base such as sodium hydride (NaH) at room temperature, in an inert solvent such as toluene, THF,

dioxane or ether, will yield the corresponding compound of the formula I wherein B is $-CHR^2OR^1$.

Compounds of the formula I wherein B is $-CR^2R^{10}NHR^1$ may be prepared by conventional methods such as reductive amination of the corresponding compounds of the formula I wherein B is $-C(O)R^2$ with an appropriate amine and reducing agent (such as sodium cyanoborohydride, sodium triacetoxyborohydride, or lithium aluminum tetrahydride) in an appropriate inert solvent such as a C_1-C_4 alkanol or acetic acid.

Conversion of compounds in formula I wherein B is $-C(O)R^2$ into compounds in formula I wherein B is $-C(S)R^2$ can be accomplished using standard methods well known in the art (e.g., using Lawesson's Reagent or diphosphorus pentasulfide (P_2S_5)). Reduction of compounds of the formula I wherein B is $-C(S)R^2$ with a reducing agent such as sodium borohydride or lithium aluminum tetrahydride gives the corresponding compounds of the formula I wherein B is $-CHR^2SH$. Alkylation of compounds of the formula I wherein B is $-CHR^2SH$ with alkyl halide (such as alkyl iodide) in the presence of a base such as sodium hydride in an inert solvent such as THF, DMF or toluene at about room temperature will afford the corresponding compounds of the formula I wherein B is $-CHR^2SR^1$.

Compounds in formula II may be prepared from compounds of the formula IV or V as described below.

Compounds of formula II wherein T is chloro, bromo or iodo can be prepared by reacting compounds of the formula IV with from one equivalent to an excess of POT_3 (wherein T is chloro, bromo or iodo) in the presence or absence of a di(C_1-C_4 alkyl)aniline, preferably diethylaniline, with or without a solvent (such as dichloroethane, DMF, dimethylsulfoxide (DMSO) or acetamide), at a temperature from about room temperature to about 180°C, preferably from about 100°C to about 150°C. Alternatively, compounds of formula II wherein T is chloro, bromo or iodo can be prepared by reacting the corresponding compounds of formula II wherein T is $-O-SO_2CF_3$ with a sodium or potassium halide, in an appropriate inert solvent such as THF, sulfolane, DMSO, DMF or acetonitrile, at a temperature from about 60°C to about 180°C. Compounds of formula II wherein T is $-OSO_2CF_3$ can be prepared by reacting compounds of formula IV with Tf_2O in the presence of a base such as triethylamine or pyridine, in an appropriate inert solvent such as THF, methylene chloride, dioxane,

ether or toluene, at an temperature from about 0°C to about 50°C, preferably from about 0°C to about room temperature.

Alternatively, compounds of formula II wherein T is chloro, bromo or iodo may be prepared by reacting compounds of formula V with a (C_1-C_7 alkyl)-nitrite and Cu(I)T_2 (wherein T is chloro, bromo or iodo) in an appropriate inert solvent such as acetonitrile, acetone, methylene chloride, THF, dioxane, benzene, toluene, dichloroethane, DMF, DMSO or N-methylpyrrolidinone (NMP) at a temperature from about room temperature to about 150°C, preferably from about 40°C to about 100°C.

Compounds of the formula IV may be prepared by reacting the appropriate compounds of formula V with sodium nitrite ($NaNO_2$) in an aqueous acid such as sulfuric acid, acetic acid or phosporic acid, with or without an organic solvent, preferably in acetonitrite (CH_3CN) or acetone.

Compounds of formula III wherein W is cyano can be prepared by reacting the corresponding compounds of formula II wherein T is chloro, bromo or iodo with potassium cyanide, copper cyanide, sodium cyanide or a di(C_1-C_4alkyl)aluminum cyanide in an appropriate inert solvent such as dimethylsulfoxide, DMF, toluene or xylene, at temperature from about room temperature to about 180°C, preferably from about 60°C to about 150°C, with or without Pd(II)OAc or Pd(0)(PPh_3)$_4$.

Compounds of formula III wherein W is -CHO or -COOH may be prepared by reacting compounds in formula II wherein T is bromo or iodo with an organolithium reagent such as t-BuLi, s-BuLi, or n-BuLi in an appropriate inert solvent such as THF, dioxane, ether, benzene or methylene chloride, at temperature from about -120°C to about room temperature, preferably from about -110°C to about -60°C, followed by quenching with an appropriate electrophile such as DMF or CO_2 (gas or dry ice), to give compounds of formula III wherein W is -CHO and -COOH, respectively.

It is understood that the general organic chemistry knowledge can be applied to change the steps of the reaction sequences described herein depending on the feasibility of the reaction. For example, a protecting group may be used at any stage of the various syntheses described above at which it is workable, or an ester group may be reduced to the corresponding C_1-C_4 alkyl group at any convenient stage. Compounds of formulas I - XVIII, wherein R^3 is chloro, bromo, -COO(C_1-C_4 alkyl) or -COOH, can be converted to the corresponding compounds wherein R^3 is (C_1-C_4 alkyl), -O(C_1-C_4 alkyl), fluoro, -S(C_1-C_4 alkyl) at any convenient stage, as appropriate, in the

syntheses referred to above using methods described in the literature. Compounds of formula I - XVIII, wherein R^3 is -O(C_1-C_4 alkyl) or -S(C_1-C_4 alkyl) can be prepared by reacting the corresponding compounds wherein R^3 is chloro, bromo or iodo, with a nucleophile such as a C_1-C_4 alkanol or a C_1-C_4 alkanethiol, in the presence of an organic or inorganic base. Suitable bases for such a reaction include sodium and sodium hydride. Compounds of formulas I - XVIII wherein R^3 is fluoro can be prepared by reacting the corresponding compounds wherein R^3 is chloro with tetrabutylammonium fluoride in a suitable inert solvent such as DMSO, methylene chloride, or tetrahydrofuran. Tetrahydrofuran is preferred.

Reduction of an ester or carboxylic acid using lithium aluminum tetrahydride/aluminum trichloride ($LiAlH_4/AlCl_3$) in an appropriate inert solvent such as THF, ether, or dioxane, at temperature from about 100°C to about room temperature, will afford the corresponding compound wherein R^3 is CH_3. Conversion of compounds wherein B is -COOH to the corresponding compounds wherein B is -CO(C_1-C_3 alkyl) may be accomplished using standard alkylation methods well known in art. Reduction of compounds wherein B is -CO(C_1-C_3 alkyl) using standard methods well known in the art will afford the corresponding compounds wherein R^3 is one of various (C_1-C_4 alkyl) derivatives.

Compounds of the formula IV-a wherein A is CR^7 and G, J, and K are carbon may be prepared by heating compounds of formula VI-a with an appropriate compound of the formula $R^3C(O)CR^7COO(C_1$-C_4 alkyl) under acid or Lewis acid conditions with or without a solvent, as shown in Scheme 1. Examples of such reaction conditions are: a) heating in polyphosphoric acid; b) heating in toluene, benzene or xylene in the presence of acid catalyst (such as p-TsOH, sulfuric acid or HCl(g)) using a Dean-Stark trap; or c) heating in an appropriate solvent such as dichloroethane, diphenylether (Ph_2O) or Dowtherm A in the presence of a Lewis acid such as $SnCl_4$, $ZnCl_2$/HCl or $AlCl_3$.

Compounds of formula VI-a may be prepared using methods described in the scientific literature. (See Gazz. Chim. Ital.; 111, p167-172(1981); Chem. Pharm. Bull.; 24, 3001-3010 (1976); J. Org. Chem., 38, 1777-1780 (1973); Chem. Abstr. 68, 68982f (1968); Aust. J. Chem.; 22, 563-572(1969); J. Chem. Soc. Perkin Trans.2, p1954, p1957 (1972); J. Heterocycl. Chem.; FR, 19, 443-445(1982); J. Heterocycl. Chem., 22,

1496-1502 (1985); Tetrahedron, 47, 4639-4644 (1991); J. Heterocycl. Chem., 28, 2053-2055 (1991); J. Heterocycl. Chem., 29, 251-153 (1992).

Compounds of formula V-a and IV-a', wherein R is C_1-C_4alkyl can be prepared by heating compounds of formula VI wherein W is -CN and -COO(C_1-C_4 alkyl), respectively, with an appropriate $R^3C(O)CH_2COO(C_1$-C_4 alkyl) in the presence of a Lewis acid such as $SnCl_4$, $AlCl_3$, $TiCl_3$ or $ZnCl_2$, in a inert solvent such as dichloroethane, at about the reflux temperature, as shown in Scheme 2. Base hydrolysis of a compound of the formula V-a or IV-a' with sodium hydroxide in H_2O/(C_1-C_4 alcohol) at reflux, or with lithium hydroxide in water/THF or water/dioxane at temperature from about room temperature to about the reflux temperature, followed by decarboxylation by heating in a oil bath at a temperature from about 140-180°C will give a compound of formula V-b or IV-b, respectively. Compounds of the formulas V-a and IV-a' may be converted into compounds of the formula II-a, and compounds of the formulas V-b and IV-b may be converted into compounds of the formula II-b by the procedures described above. The conversion of compounds of the formula II-a into those of the formula II-c can be accomplished using procedures analogous to those described above for converting compounds wherein R^3 is -COO(C_1-C_4 alkyl) into those wherein R^3 is C_1-C_4 alkyl.

Compounds of formula VI may be prepared using methods described in the literature. (See Liebigs Ann Chem., 1534-1546, 1979; Gazz. Chim. Ital., 97, 25-33, 1967; Gazz. Chim. Ital., 120, 725-730, 1990; Eur. J. Med. Chem. Chim. Ther., 26, 143-158, 1991; J. Heterocycl. Che., Fr. 19, 443-445, 1982; J. Heterocycl. Chem., 22, 1496-1502, 1985; J. Heterocycl. Chem., 31, 305-312, 1994; J. Heterocycl. Chem., 24, 243-245, 1987; J. Org. Chem. 57, 3713-3716, 1992; Liebigs Ann Chem., 1702-1710, 1984; Chem. Pharm. Bull., 34, 701-702, 1986; Pharmazie, 48, 849-853, 1993; Bull. Soc. Chim. Belg., 103, 181-184, 1994; and Indian. J. Chem. Sect. B, 33, 436-440, 1994).

Compounds of formula IV-c wherein A is N and G, J, and K are carbon may be prepared, as shown in Scheme 3, by reacting compounds of formula VI with $(R^3CO)_2O$, R^3COOH or $R^3CO(OC_1$-C_2 alkyl)$_3$, in acetic acid or an appropriate inert organic solvent such as toluene, dioxane, acetonitrile, methylene chloride or chloroform, at a temperature from about 25°C to about 150°C, preferably at about the reflux temperature, followed by heating in 85% phosphoric acid or an aqueous acid such as acetic acid, hydrochloric acid or sulfuric acid, preferably in 50-85% phosphoric acid. Compounds of formula V-b may be prepared, as shown in Scheme 3, by heating the

corresponding compounds of formula VI with excess of the appropriate compound of the formula R^3CONH_2.

Compounds of formula IV-d may be prepared, as shown in Scheme 4, by reacting compounds of formula IX with an appropriate reagent having the formula $R^3C(O)CHR^7COO(C_1\text{-}C_4alkyl)$ in an R^3COOH solvent at temperature from about 60°C to about 180°C, preferably at about the reflux temperature.

Compounds of formula I-N may be prepared, as shown in Scheme 5, by reacting the corresponding compounds of formula X with a ($C_1\text{-}C_7$ alkyl)nitrite, with or without $CuBr_2$, $CuCl_2$, or CuI_2, in an appropriate inert solvent such as acetonitrile, acetone, methylene chloride, chloroform, benzene or toluene, preferably acetonitrile at a temperature from about 25°C to about 150°C, preferably from about 60°C to 100°C.

Compounds of formula I-L and I-M may be prepared, as shown in Scheme 6, by reacting compounds of formula XI wherein X is S or O with a compound of the formula R^4CHO or $R^4CH(OC_1\text{-}C_2$ alkyl)$_2$ and an acid catalyst such as p-TsOH, HCl, HBr, H_2SO_4, or HCl, in toluene, xylene or benzene, preferably toluene, with from one to ten equivalents of water, at temperature from about 70°C to about 160°C, using a Dean-Stark trap or in the presence of anhydrous sodium sulfate.

Compounds of formula I-K and I-U may be prepared by reacting the corresponding compounds of formula XI with triphosgene and thiophosgene, respectively, and a base such as triethylamine or pyridine in an appropriate inert solvent such as methylene chloride, THF, dioxane, ether, benzene or chloroform, preferably methylene chloride or dry THF, at temperature from about 0°C to about 25°C.

Compounds of formula I-V, I-W, and I-X may be prepared, as illustrated in Scheme 7, starting from compounds of formula XII. Compounds of formula XIII may be prepared by reacting the corresponding compounds of formula XII with hydroxylamine in acidic (e.g., in trifluoroacetic acid) or basic (e.g., in NaOAc or NaOH and hydroxylamine hydrochloride in a $C_1\text{-}C_4$ alcohol/water mixture) conditions at temperatures from about 25°C to about 150°C, preferably at about the reflux temperature. Compounds of formula XIV can be prepared by heating the corresponding compounds of formula XIII in acetic anhydride, trifluoroacetic anhydride or Tf_2O, with or without a solvent such as acetic acid or methylene chloride, in the presence of an appropriate amine base such as triethylamine or pyridine. Compounds of formula I-V, I-W and I-X may be prepared by heating the corresponding compounds

of formula XIV and pyridine in an inert solvent such as DMF, DMSO, NMP, sulfolane or acetamide at a temperature from about 80°C to about 180°C.

Compounds of formula I-G may be prepared, as illustrated in Scheme 8, by reducing the corresponding compounds of formula XVII. This reduction can be performed using standard methods known in literature for reduction of a nitro group to an amino group. Such methods include hydrogenation or reduction by iron in acetic acid. Cyclization may occur upon reduction or heating in an appropriate solvent such as a C_1-C_4 alcohol, acetonitrile, toluene, THF, methylene chloride or acetic acid.

The conversion of compounds of formula XVI into those of formula XVII can be accomplished using methods analogous to those described above for the conversion of compounds of formula V wherein W is cyano into compounds of formula I wherein B is a group having a carbon atom directly attached to the bicyclic ring. The best method for conversion of a cyano group to a -COOH group is acid hydrolysis, for example, heating the cyano compound in 50-85% phosphoric acid or 50-90% acetic acid, preferably phosphoric acid. The best method for converting a cyano group into a -CO(C_1-C_4 alkyl) is reacting the cyano compound with a Grignard reagent at a temperature from about 0°C to about 25°C in ether, THF or dioxane. The best method for converting a cyano group into a -CHO group is a diisobutylaluminum hydride reduction in THF, dioxane, or ether at a temperature from about -78°C to about 25°C, preferably from about -78°C to about -40°C.

Compounds of the formula XVI may be prepared by reacting compounds of formula XV, wherein Hal is chloro, bromo or iodo, with a sodium, potassium, or lithium salt of R^5CH_2CN in an appropriate inert solvent such as toluene, benzene, a C_1-C_5 alcohol, THF, DMSO, dioxane, or pyridine, with or without a Pd(II) or Pd(0) catalyst, at a temperature from about -78°C to about 130°C.

Alternatively, compounds of formula XVII may be prepared by subjecting compounds of the formula XV to halogen-metal exchange (e.g., using an organo lithium agent such as tBuLi, s-BuLi or BuLi at -78°C in ether, THF, or dioxane), followed by quenching with an electorphile such as R^5CHO, to give compounds of formula XVIII. Compounds of formula XIX-a may be prepared by reacting the corresponding compounds of formula XVIII with thionyl chloride, followed by reduction. Reacting compounds of formula XIX-a with a base (such as organolithium agent (e.g., lithium diisopropylamide or BuLi), followed by quenching with an electrophile (such as carbon

dioxide) will yield the corresponding compounds of formula XIX-b wherein R^{21} is -COOH. Compounds of formula XIX-c wherein R^{21} is -C(OH)R^4 may be prepared in a similar fashion by quenching the appropriate compound of formula XIX-a with an electrophile of the formula C_1-C_3 alkyl-CHO. Compounds of formula XVII can be prepared by reacting compounds of formula XIX-c with PCC (pyridinium chlorochromate) using standard PCC oxidation methods that are well known in the art.

Compounds of formula II-d, II-e and II-f, wherein T is chloro, bromo or iodo and D, E, R^3, R^5 and R^7 are as defined to those in formula I may be prepared, as shown in Scheme 9, by methods analogous to those described in Scheme 2. Alternatively, Compounds of formula II-d to II-f may be prepared using procedures analogous to those described in the literature (See: Pharm. Bull, 5, 229-231, 1957; Monatsh Chem, 100, 671-678, 1969; J. Heterocycl. Chem., 3, 218-220, 1966, Chem. Pharm. Bull,. 23, 2891-2895, 1975; J. Heterocycl. Chem., 8, 1-6, 1971; Justus Liebigs Ann. Chem, 735, 35-44, 1970; Tetrahedron Lett, 1479, 1968; and Chem. Abstr., 1939, 4988.)

The acid addition salts of compounds of the formula can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques can be employed to isolate the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p-toluenesulfonic, and related acids.

The compounds of formula I and their pharmaceutically acceptable salts (hereinafter referred to, collectively, as "the active compounds of this invention") may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, oils (e.g., sesame oil, peanut oil) and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I and pharmaceutically acceptable carriers can then be readily administered in a variety of dosage forms such as tablets, oil gel, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients

such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

For parenteral administration, solutions containing an active compound of this invention or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

The effective dosages for the active compounds of this invention will depend on the intended route of administration and factors such as the age and weight of the patient, as generally known to a physician. The dosages will also depend on the particular illness to be treated. For instance, the daily dosage for stress-induced illnesses, inflammatory disorders, Alzheimer's disease, gastro-intestinal diseases, anorexia nervosa, hemorrhagic stress and drug and alcohol withdrawal symptoms will generally range from about 0.1 to about 50 mg/kg body weight of the patient to be treated.

Methods that may be used to determine the CRF antagonist activity of the active compounds of this invention and their pharmaceutically acceptable salts are described in Endocrinology, 116, 1653-1659 (1985) and Peptides, 10, 179-188 (1985). The binding activities for compounds of the formula I, expressed as IC_{50} values, generally range from about 0.5 nanomolar to about 10 micromolar. Methods that can be used

to determine the CRF binding protein inhibiting activity of compounds of the formula I are described in Brain Research, (1997), 745 (1,2),248-255.

The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these examples. Melting points are uncorrected. Proton nuclear magnetic resonance spectra (^{1}H NMR) and C^{13} nuclear magnetic resonance spectra (C^{13} NMR) were measured for solutions in deuterochloroform ($CDCl_3$) and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane (TMS). The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad.

The following abbreviations are used in the Examples: Ph=phenyl; iPr=isopropyl.

EXAMPLE 1

7-(1-Ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine

A solution of 3-pentanol (140 mg, 1.5 mmol) in 1 ml of dry THF was treated with 60% sodium hydride in oil (28 mg, 0.7 mmol) and stirred at room temperature for 10 min. A solution of 7-chloro-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine (75 mg, 0.262 mmol) in 1 ml of dry THF was added and the resulting mixture was heated at reflux for 5 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give the crude material. The residue was purified through silica gel column chromatography using 3:7 chcloroform:hexane as eluent to give 75mg (88%) of the title compound. ^{1}H NMR ($CDCl_3$) δ 7.97(s,1H), 6.97(s,2H), 6.03(s,1H), 4.56(m,1H), 2.53(s,3H), 2.32(s,3H), 2.13(s,6H), 2.10(m,4H), 1.09(t,6H) ppm.

EXAMPLE 2

[2,5-Dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine

A mixture of 7-Chloro-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a] pyrimidine (60 mg, 0.2 mmol) and 1-ethylpropylamine (4 ml) in 1ml of N-methylpyrrolidinone was heated at 125°C oil bath for 15 hrs. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated and purified through silica gel column chromatography using 20% ethyl acetate in hexane as eluent to give 35 mg of the title compound as a yellow solid. ^{1}H NMR ($CDCl_3$) δ

6.96(s,2H), 6.00(d,1H), 5.77(s,1H), 3.47 (m,1H), 2.43(s,3H), 2.32(s,3H), 2.22(s,3H), 2.05(s,6H), 1.5-1.9(m,4H), 1.04(t,6H) ppm.

EXAMPLE 3

(1-Ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine

A mixture of 7-chloro-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a] pyrimidine (190 mg, 0.63 mmol) and 1-ethylpropylamine (4 ml) in 1ml of N-methylpyrrolidinone was heated at 125°C oil bath for 15 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated and purified through silica gel column chromatography using chloroform to 2% methanol in chloroform as eluent to give 195 mg (87%) of the title compound as a green solid. ^{1}H NMR ($CDCl_3$) δ 7.87(s,1H), 6.97(s,2H), 6.12(d,1H), 5.85(s,1H), 3.52(m,1H), 2.48(s,3H), 2.09(s,3H), 2.16(s,6H), 1.6-1.9(m,4H), 1.05(t,6H)ppm.

EXAMPLE 4

7-(1-Ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo [1,5-a]pyrimidine

To a suspension of 60% Sodium hydride in oil (160 mg) in 4 ml of DMSO was added 3-pentanol (853 mg), and then 7-chloro-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl) -pyrazolo[1,5-a]pyrimidine (580 mg) at room temperature. The mixture was heated at 88°C overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated and purified through silica gel column chromatography using 10% hexane in chloroform as eluent to give the title compound as an orange oil. ^{1}H NMR ($CDCl_3$) δ 6.96(s,2H), 5.95(s,1H), 4.52(m,1H), 2.48(s,3H), 2.33(s,3H), 2.27(s,3H), 2.03(s,6H), 1.75-2.00(m,4H), 1.08(t,6H)ppm.

EXAMPLE 5

[2,5-Dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-ethyl-propyl-amine

A mixture of 7-chloro-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a] pyrimidine (200 mg, 0.66 mmol) and N-propylethylamine (2 ml) in 1ml of N-methylpyrrolidinone was heated at 135°C oil bath for 4 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated and purified through silica gel column chromatography using hexane to 10% ethyl acetate in hexane as eluent to give 150 mg of the title compound as a clear

green oil. ^{1}H NMR ($CDCl_3$) δ 6.95(s,2H), 5.80(s,1H), 3.85(q,2H), 3.67(dd,2H), 2.41(s,3H), 2.32(s,3H), 2.21(s,3H), 2.03(s,6H), 1.76(m,2H), 1.29(t,3H), 0.98(t,3H) ppm.

EXAMPLE 6

[6-Bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b] pyridin-7-yl]-(1-ethyl-propyl)-amine

To a solution of butyl nitrite (119 mg, 1.15 mmol) and CuBr2 (205 mg, 0.919 mmol) in 16 ml of acetonitrile was added N4-(1-ethyl-propyl)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine (250 mg, 0.766 mmol). The resulting mixture was heated at 65°C for 1.5 hrs. The mixture was cooled to room temperature and 2N HCl (16 ml) was added. The mixture was neutralized with 2N NaOH and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give a brown oil. The oil residue was purified through silica gel column chromatography using 1:1 hexane :ethyl acetate as eluent to give 61mg of [6-bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b] pyridin-7-yl]-(1-ethyl-propyl)-amine as white crystals. Mp 123-125°C. ^{1}H NMR ($CDCl_3$) δ 7.06(s,2H), 5.53(d,1H), 5.22(m,1H), 4.67(s,2H), 2.39(s,3H), 1.96(s,6H), 1.6-1.9(m,4H), 1.06(t,6H)ppm and 103 mg of [6-bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-amine as white solid. Mp 115-117°C. ^{1}H NMR ($CDCl_3$) δ 7.04(s,2H), 5.36(d,1H), 5.21(m,1H), 2.64(s,3H), 2.38(s,3H), 1.95(s,6H), 1.6-1.9(m,4H), 1.05(t,6H)ppm.

EXAMPLE 7

(1-Ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b] pyridin-7-yl]-amine

A mixture of butyl nitrite (119 mg, 1.15 mmol) and N4-(1-ethyl-propyl)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine (250 mg, 0.766 mmol) in anhydrous acetonitrile (16 ml) was heated at 65°C for 2 hours. The mixture was cooled to room temperature and 2N HCl (16 ml) was added. The mixture was neutralized with 2N NaOH and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give 250 mg of the crude product as a brown oil. The oil residue was purified through silica gel column using chloroform as eluent to give 201 mg of the title compound as golden yellow solid. Mp 131-133°C. ^{1}H NMR ($CDCl_3$) δ 7.022(s,2H), 6.20(s,1H), 5.44(d,1H), 3.65(m,1H), 2.50(s,3H), 2.36(s,3H), 1.96(s,6H), 1.5-1.8(m,4H), 1.03(t,6H)ppm.

EXAMPLE 8

[6-Bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-methyl-amine

To a solution of [6-bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo [4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-amine (50 mg, 0.12 mmol) in dry THF)1.5 ml) was added 2.5 M n-BuLi in hexane (0.14 ml) at -78°C. After stirring at -78°C for 10 min, 0.5 ml of methyl iodide was added at that temperature then allowed to warmed to room temperature and stirred for 15 min for 2 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give 46 mg of brown oil. The residue was purified through silica gel coliumn chromatography using 1:1 chloroform:hexane as eluent to give the title compound as a golden oil. ^{1}H NMR ($CDCl_3$) δ 7.04(s,2H), 4.35(m,1H), 3.32(s,3H), 2.70(s,3H), 2.38(s,3H), 1.94(s,6H), 1.7-2.0(m,4H), 1.01(t,6H)ppm.

EXAMPLE 9

7-(1-Ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3] triazolo[4,5-b]pyridine

A mixture of 4-(1-Ethyl-propoxy)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3-diamine (50 mg, 0.153 mmol) and butyl nitrite (24 mg, 0.229 mmol) in 4 ml acetonitrile was heated at 65°C for 2 hours. An additional 0.13 ml of butyl nitrite was added and the resulting mixture was heated at 65°C for 2 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 58 mg of brown oil. The oil was purified through silica gel column chromatography using 5% ethyl acetate in hexane as eluent to give 46 mg (88%) of the title compound as a light yellow oil. ^{1}H NMR ($CDCl_3$) δ 7.04(s,2H), 6.60(s,1H), 5.26(m,1H), 2.57(s,3H), 2.38(s,3H), 1.94(s,6H), 1.8-2.0(m, 4H), 1.07(t,6H) ppm.

EXAMPLE 10

4-(1-Ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine

To a solution of 3-pentanol (0.09 ml, 0.883 mmol) in dry THF was added 60% NaH in oil (20 mg, 0.500 mmol) and stirred for 5 min. A solution of 4-chloro-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine (50 mg, 0.166 mmol) in dry THF was added to the reaction mixture and the resulting mixture was heated at reflux for 2 hr. The mixture was quenched with water, extracted with ethyl acetate. The

organic layer was washed with brine, separated, dried and concentrated to dryness to give the title compound as a white solid. ^{1}H NMR ($CDCl_3$) δ 6.92(s,3H), 5.43(m,1H), 4.02(s,3H), 2.56(s,3H), 2.29(s,3H), 2.08(s,6H), 1.80(m,4H), 0.99(t,6H).

The title compounds of Examples 11-14 were prepared by the method analogous to that described in Example 10 starting from of 4-chloro-2-methyl-5-substituted-7-(substituted-phenyl)-5H-pyrrolo[3,2-d]pyrimidine or 7-chloro-5-methyl-1-substituted-3-(substituted-phenyl)-1H-pyrrolo[3,2-b]pyridine and an appropriate alcohol or thiol and a base.

EXAMPLE 11

(+)-2,5-Dimethyl-4-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine.

^{1}H NMR ($CDCl_3$) δ 6.95(s,1H), 6.92(s,2H), 5.88(m,1H), 3.9-4.08(m,4H), 4.01(s,3H), 2.56(s,3H), 2.29(s,3H), 2.2-2.4(m,2H), 2.07(s,6H) ppm.

EXAMPLE 12

2,5-Dimethyl-4-(S)-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine.

^{1}H NMR ($CDCl_3$) δ 6.95(s,1H), 6.92(s,2H), 5.88(m,1H), 3.9-4.08(m,4H), 4.01(s,3H), 2.56(s,3H), 2.29(s,3H), 2.2-2.4(m,2H), 2.07(s,6H) ppm.

EXAMPLE 13

2,5-Dimethyl-4-(1-propyl-butoxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine.

^{1}H NMR ($CDCl_3$) δ 6.93(s,2H), 6.92(s,1H), 5.58(m,1H), 4.02(s,3H), 2.56(s,3H), 2.29(s,3H), 2.09(s,6H), 1.6-1.8(m,4H), 1.4-1.6(m,4H), 0.96(t,6H)ppm.

EXAMPLE 14

4-sec-Butylsulfanyl-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine.

^{1}H NMR ($CDCl_3$) δ 6.97(s,1H), 6.94(s,2H), 4.34(m,1H), 4.13(s,3H), 2.63(s,3H), 2.30(s,3H), 2.07(s,6H), 1.7-1.9(m,2H), 1.48(d,3H), 1.09(t,3H) ppm.

The title compounds of Examples 15-18 were prepared using the following procedure.

PROCEDURE FOR EXAMPLES. 15 - 18

A mixture of 4-chloro-2-methyl-5-substituted-7-(substituted-phenyl)-5H-pyrrolo[3,2-d]pyrimidine or 7-bromo-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-

pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester (1 mmol) and an appropriate amine in DMSO (2 ml) was heated in 130°C oil bath until all the starting material was consumed. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness to give the corresponding 4-alkylamino-2-methyl-5-substituted-7-(substituted-phenyl)-5H-pyrrolo[3,2-d]pyrimidineor 7-alkylamino-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester derivative. Silica gel column chromatography may be used for purification.

EXAMPLE 15

[2,5-Dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl]-(1-ethyl-propyl)-amine

^{1}H NMR ($CDCl_3$) δ 6.91(s,2H), 6.76(s,1H), 4.61(d,1H,NH), 4.33(m,1H), 4.04(s,3H), 2.49(s,3H), 2.28(s,3H), 2.09(s,6H), 1.72(m,2H), 1.60(m,2H), 0.98(t,6H)ppm.

EXAMPLE 16

Butyl-[2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl]-ethyl-amine

^{1}H NMR ($CDCl_3$) δ 6.96(s,1H), 6.92(s,2H), 3.93(s,3H), 3.44(q,2H), 3.40(m,2H), 2.57(s,3H), 2.29(s,3H), 2.09(s,6H), 1.57(m,2H), 1.30(m,2H), 1.14(t,3H), 0.88(t,3H)ppm.

EXAMPLE 17

2,5-Dimethyl-4-thiazolidin-3-yl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine

^{1}H NMR ($CDCl_3$) δ 7.03(s,1H), 6.92(s,2H), 4.78(s,2H), 4.02(s,3H), 3.96(m,2H), 3.18(m,2H), 2.56(s,3H), 2.29(,3H), 2.06(s,6H) ppm.

EXAMPLE 18

7-(1-Ethyl-propylamino)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester

^{1}H NMR ($CDCl_3$) δ 6.98(s,1H), 6.93(s,2H), 5.40(d,1H), 3.97(s,3H), 3.91(s,3H), 3.35(m,1H), 2.57(s,3H), 2.30(s,3H), 2.09(s,6H), 1.52(m,4H), 0.87(t,6H) ppm.

EXAMPLE 19

7-(1-Ethyl-propylamino)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]-pyridine-6-carboxylic acid

A mixture of 7-(1-ethyl-propylamino)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester and NaOH in a 1:1 mixture of

MeOH/water was heated at reflux over night. The resulting mixture was acidified with 2N HCl to a pH of 4-5, and extracted with chloroform. The organic layer was dried and concentrated to give the title compound.

^{1}H NMR ($CDCl_3$) δ 7.02(s,1H), 6.82(s,2H), 3.98(s,3H), 3.78(m,1H), 2.59(s,3H), 2.07(s,3H), 2.00(s,6H), 1.64(m,4H), 0.90(t,6H) ppm.

EXAMPLE 20

[1,5-Dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]-(1-ethyl-propyl)-amine

A mixture of 7-(1-ethyl-propylamino)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid was heated in 150-160°C oil bath until all the starting material was consumed. ^{1}H NMR ($CDCl_3$) δ 6.94(s,2H), 6.87(s,1H), 6.15(s,1H), 6.10(d,1H), 4.24(s,3H), 3.50(m,1H), 2.64(s,3H), 2.30(s,3H), 2.05(s,6H), 1.77(m,4H), 1.02(t,6H)ppm.

PREPARATION A

4-(2,4,6-Trimethyl-phenyl)-2H-pyrazol-3-ylamine

A mixture of 3-oxo-2-(2,4,6-trimethyl-phenyl)-propionitrile (2.300 g, 12.3 mmol), hydrazine hydrate (0.93 g) and glacial acetic acid (1.55 ml) in 20 ml benzene was heated at reflux for 4.5 hours. Reaction mixture was cooled to room temperature and 50 ml of 18.5% HCl in water was added. The benzene layer was separated and reextracted with 18.5% HCl. The aqueous layer were combined and neutralized with ammonium hydroxide and stirred at rt. overnight. Precipitate formed and was filtered to yield the title compound (0.256 g) as a yellow solid. The benzene layer was concentrated and purified through silica gel column using 5% methanol in chloroform as eluent to give an additional 1.450 g of the title compound; ^{1}H NMR ($CDCl_3$) δ 7.24(s,1H), 6.95(s,2H), 4.75(brs,2H), 2.32(s,3H),2.13(s,6H) ppm.

PREPARATION B

5-Methyl-4-(2,4,6-trimethyl-phenyl)-2H-pyrazol-3-ylamine

The title compound was prepared as white solid by the method analogous to that described in preparation A starting from 3-oxo-2-(2,4,6-trimethyl-phenyl)-butyronitrile. ^{1}H NMR ($CDCl_3$) δ 7.7(brs,1H), 6.96(s,2H), 2.32(s,3H), 2.13(s,3H), 2.06(s,6H) ppm.

PREPARATION C

2,5-Dimethyl-3-(2,4,6-trimethyl-phenyl)-4H-pyrazolo[1,5-a]pyrimidin-7-one

Methyl acetoacetate (0.38 ml) was added to a solution of 5-methyl-4-(2,4,6-trimethyl-phenyl)-2H-pyrazol-3-ylamine (641 mg, 2.98 mmol) in 4 ml of acetic acid. The reaction mixture was heated at reflux for overnight. The mixture was concentrated to dryness and the residue was purified through silica gel column chromatography using 5% methanol in chloroform as eluent to give 560 mg (65.5%) of the title compound as a white solid; ^{1}H NMR (DMSO-d_6) δ 11.7(s,1H), 6.98(s,2H), 5.52(s,1H), 2.29(s,3H), 2.20(s,3H), 1.97(s,3H), 1.95(s,6H) ppm.

PREPARATION D

5-Methyl-3-(2,4,6-trimethyl-phenyl)-4H-pyrazolo[1,5-a]pyrimidin-7-one

Methyl acetoacetate (0.7 ml) was added to a solution of 4-(2,4,6-Trimethyl-phenyl)-2H-pyrazol-3-ylamine (1.120 g, 5.57 mmol) in 5 ml of acetic acid and the resulting mixture was heated at reflux for two days. Reaction mixture cooled and a white solid formed. Ethanol (6 ml) was added and stirred at room temperature overnight, filtered to give white solid which was recrystallized from ethanol to give 673 mg(45.2%) of the title compound as white crystals. ^{1}H NMR (DMSO-d_6) δ 11.9(s,1H), 7.7(s,1H), 6.95(s,2H), 5.55(s,1H), 2.25(s,3H), 2.20(s,3H), 2.0(s,6H)ppm.

PREPARATION E

7-Chloro-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine

A suspension of 5-methyl-3-(2,4,6-trimethyl-phenyl)-4H-pyrazolo[1,5-a]pyrimidin -7-one (590 mg, 2.2 mmol) in 9 ml of $POCl_3$ was treated with diethylaniline (0.7 ml) and the resulting mixture was stirred at reflux for 15 hours. The reaction mixture was concentrated to dryness. The residue was treated with ice water and stirred for 20 min, then extracted with chloroform. The organic layer was dried and concentrated to yield an orange oil which crystallized upon standing. The material was purified through silica gel column chromatography using chloroform as eluent to give 590 mg (94%) of the title compound as a yellow solid; ^{1}H NMR ($CDCl_3$) δ 8.08(s,1H), 6.98(s,2H), 6.86(s,1H), 2.56(s,3H), 2.33(s,3H), 2.09(s,6H) ppm.

PREPARATION F

7-Chloro-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine

The title compound was prepared as an oil by the method analogous to that described in preparation E starting from 2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-4H-pyrazolo[1,5-a]pyrimidin-7-one. ^{1}H NMR ($CDCl_3$) δ 6.98(s,2H), 6.77(s,1H), 2.51(s,3H), 2.33(s,3H), 2.31(s,3H), 1.99(s,6H) ppm.

PREPARATION G

2,5-Dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol

A mixture of 3-amino-1-methyl-4-(2,4,6-trimethylphenyl)-1H-pyrrole-2-carbonitrile (0.4 mmol) and acetic anhydride (0.043 ml) in acetic acid (0.01 ml) was heated at reflux untill all the starting material was consumed. The reaction mixture was concentrated to dryness. The residue was quenched with water and extracted with ethyl acetate. The organic extracts was washed with brine and concentrated to dryness. The residue was suspended in 0.5 ml of 85% phosphoric acid and heated at 130°C for 1 hour. The mixture was cooled and poured into ice-water, stirred until solid formed. The solid was filtered to give 2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol. The alternative way for the work up is via extraction technique. The ice water was extracted with chloroform. The organic layer was dried and concentrated to dryness to give the desired product.

^{1}H NMR δ ($CDCl_3$) 6.92(s,2H), 6.88(s,1H), 4.14(s,3H), 2.43(s,3H), 2.29(s,3H), 2.09(s,6H).

The following compounds can be prepared in a similar manner:

2,5-Dimethyl-7-(2,6-dimethyl-4-chloro-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol;

2,5-Dimethyl-7-(2,6-dimethyl-4-bromo-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol;

2-Methyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol;

2-Methyl-7-(2,6-dimethyl-4-chloro-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol;

2-Methyl-7-(2, 6-drimethyl-4-bromo-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol; and

2-Methyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol;

PREPARATION H

4-Chloro-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine

A mixture of 2, 5-dimethyl-7-(2,4,6-trimethylphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol (1 mmol) in $POCl_3$ (1.3 ml) was heated at reflux until all the starting material were

consumed (about 1-3 hours). The mixture was concentrated to dryness. The residue was porued into ice-water and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness to give the title compound.

^{1}H NMR ($CDCl_3$) δ 7.18(s,1H), 6.95(s,2H), 4.16(s,3H), 2.69(s,3H), 2.31(s,3H), 2.05(s,6H) ppm.

PREPARATION I

7-Amino-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester

A mixture of 3-amino-1-methyl-4-(2,4,6-trimethylphenyl)-1H-pyrrole-2-carbonitrile (2 mmol), methyl acetoacetate (4 mmol) and $SnCl_4$ (4 mmol) in 1, 2-dichloroethane was heated at reflux for about six hours until all the starting material were consumed. The mixture was quenched with acetone, basified with saturated $NaHCO_3$, then filtered through Celite®. The filtrate was concentrated to dryness. The residue was quenched with water and extracted with chloroform. The chloroform layer was washed with brine, dried and concentrated to dryness to give 7-amino-1,5-dimethyl -3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester. The product may be purified by trituration.

^{1}H NMR ($CDCl_3$) δ 6.91(s,2H), 6.85(s,1H), 6.28(brs,2H), 4.10(s,3H), 3.89(s,3H), 2.62(s,3H), 2.28(s,3H), 2.09(s,6H) ppm.

PREPARATION J


7-Bromo-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester

A mixture 7-amino-1, 5-dimethyl-3-(2, 4, 6-trimethylphenyl)-1H-pyrrolo[3, 2-b]pyridine-6-carboxylic acid methyl ester (1 mmol), n-butylnitrite (BuONO) (1.5 mmol) and $CuBr_2$ in acetonitrile was heated at 60-70°C until all starting material was consumed. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness to give the title compound.

^{1}H NMR ($CDCl_3$) δ 7.09(s,1H), 6.94(s,2H), 4.16(s,3H), 3.98(s,3H), 2.52(s,3H), 2.30(s,3H), 2.04(s,6H) ppm. 2,7-dibromo-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl) -1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester was also produced as a minor component. ^{1}H NMR ($CDCl_3$) δ 7.00(s,2H), 4.45(s,3H), 4.03(s,3H), 2.51(s,3H), 2.34(s,3H), 2.12(s,6H) ppm.

CLAIMS

1. A compound of the formula



I

or a pharmaceutically acceptable salt thereof, wherein

the dashed lines represent optional double bonds;

A is nitrogen or CR^7;

B is $-NR^1R^2$, $-CR^1R^2R^{10}$ $-C(=CR^2R^{11})R^1$, $-NHCR^1R^2R^{10}$, $-OCR^1R^2R^{10}$, $-SCR^1R^2R^{10}$, $-CR^2R^{10}NHR^1$, $-CR^2R^{10}OR^1$, $-CR^2R^{10}SR^1$ or $-COR^2$;

J and K are each independently nitrogen or carbon and both J and K are not nitrogens ;

D and E are each selected, independently, from nitrogen, CR^4, C=O, C=S, sulfur, oxygen, CR^4R^6 and NR^8 ;

G is nitrogen or carbon;

the ring containing D, E, G, K, and J in formula I may be a saturated or unsaturated 5-membered ring and may optionally contain one or two double bonds and may optionally contain from one to three heteroatoms in the ring and may optionally have one or two C=O or C=S groups;

R^1 is C_1-C_6 alkyl optionally substituted with one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, -O-(C_1-C_4 alkyl), CF_3, -C(=O)O-(C_1-C_4alkyl), -OC(=O)(C_1-C_4 alkyl), -OC(=O)N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NHCO(C_1-C_4 alkyl), -COOH, -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_4 alkyl), -CN, $-NO_2$, -SO(C_1-C_4 alkyl), $-SO_2$(C_1-C_4 alkyl), $-SO_2$NH(C_1-C_4 alkyl) and $-SO_2$N(C_1-C_4 alkyl)(C_1-C_2 alkyl), wherein each of the C_1-C_4 alkyl groups in the foregoing R^1 groups may optionally contain one or two double or triple bonds;

R^2 is C_1-C_{12} alkyl which may optionally contain from one to three double or triple bonds, aryl or (C_1-C_4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C_1-C_4

alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C_3-C_8 cycloalkyl or (C_1-C_6 alkylene)(C_3-C_8 cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C_1-C_6 alkylene)(C_3-C_8 cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ^2 wherein Z^2 is selected from hydrogen, C_1-C_4 alkyl, benzyl and C_1-C_4 alkanoyl, and wherein each of the foregoing R^2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C_1-C_4 alkyl, or with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -OC(=O)(C_1-C_6 alkyl), -OC(=O)N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), amino, -NH(C_1-C_2 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)-CO-(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COOH, -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), -SH, -CN, -NO_2, -SO(C_1-C_4 alkyl), -SO_2(C_1-C_4 alkyl), -SO_2NH(C_1-C_4 alkyl) and -SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl);

-NR^1R^2 or $CR^1R^2R^{10}$ may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ^3 wherein Z^3 is hydrogen, C_1-C_4 alkyl, benzyl or C_1-C_4 alkanoyl;

R^3 is hydrogen, C_1-C_4 alkyl, -O(C_1-C_4 alkyl), chloro, fluoro, bromo, iodo, (C_1-C_2 alkylene)-O-(C_1-C_2 alkyl), (C_1-C_2 alkylene)-OH, or -S(C_1-C_4 alkyl);

each R^4 is, independently, hydrogen, (C_1-C_6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C_1-C_2 alkylene)-OH, CF_3, CH_2SCH_3, nitro, -O(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), -C(=O)H or -C(=O)O(C_1-C_4alkyl);

R^6 is hydrogen, methyl or ethyl;

R^8 is hydrogen or C_1-C_4 alkyl;

R^5 is phenyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl and wherein each of the foregoing R^5 groups is substituted with from one to four substituents R^{13} wherein one to three of said substituents may be selected, independently, from fluoro, chloro, C_1-C_6 alkyl and -O(C_1-C_6 alkyl) and one of said substituents may be selected from bromo, iodo, formyl, OH, (C_1-C_4 alkylene)-OH, (C_1-C_4alkylene)-O-(C_1-C_2 alkyl), -CN, -CF_3, -NO_2,

$-NH_2$, $-NH(C_1-C_4$ alkyl), $-N(C_1-C_2$ alkyl)$(C_1-C_6$ alkyl), $-OCO(C_1-C_4$ alkyl), (C_1-C_4 alkylene)-O-(C_1-C_4 alkyl), $-S(C_1-C_6$ alkyl), (C_1-C_4 alkylene)-S-(C_1-C_4 alkyl), $-C(=O)O(C_1-C_4$ alkyl), $-C(=O)(C_1-C_4$ alkyl), -COOH, $-SO_2NH(C_1-C_4$ alkyl), $-SO_2N(C_1-C_2$ alkyl)$(C_1-C_4$ alkyl), $-SO_2NH_2$, $-NHSO_2(C_1-C_4$ alkyl), $-S(C_1-C_6$ alkyl) and $-SO_2(C_1-C_6$ alkyl), and wherein each of the C_1-C_4 alkyl and C_1-C_6 alkyl moieties in the foregoing R^5 groups may optionally have one or two double bonds;

R^7 is hydrogen, C_1-C_4 alkyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, $-O(C_1-C_4$ alkyl), $-C(=O)(C_1-C_4$ alkyl), $-C(=O)O(C_1-C_4$ alkyl), $-OCF_3$, $-CF_3$, $-CH_2OH$ or $-CH_2O(C_1-C_2$ alkyl);

R^{10} is hydrogen, hydroxy, methoxy or fluoro;

R^{11} is hydrogen or C_1-C_4 alkyl; and

with the proviso that: a) when both J and K are carbons and D is CR^4 and E is nitrogen, then G can not be nitrogen; (b) when both J and K are carbons and D and G are nitrogens, then E can not be CR^4 or C=O or C=S; (c) when both J and K are carbons and D and E are carbons, then G can not be nitrogen; (d) when G is carbon, it must be double banded to E; and (e) in the ring containing J, K, D, E and G, there can not be two double bonds adjacent to each other;

and the pharmaceutically acceptable salts of such compounds.

2. Compounds according to claim 1 wherein B is $-NR^1R^2$, $-NHCHR^1R^2$, $-OCHR^1R^2$ and R^1 is C_1-C_6 alkyl, which may optionally be substituted with one fluoro, or C_1-C_4 alkoxy group and which may optionally contain one double or triple bond; and R^2 is C_1-C_4 alkyl or (C_1-C_2 alkyl)-CO-(C_1-C_2 alkyl) which may optionally contain one double or triple bond.

3. Compounds according to claim 1, wherein B is $-CHR^1R^2$, $-NR^1R^2$, $-NHCHR^1R^2$, $-OCHR^1R^2$, $-SCHR^1R^2$; and R^1 is C_1-C_6 alkyl, which may optionally be substituted with one hydroxy, fluoro, CF_3, cyclopropyl or C_1-C_4 alkoxy group and which may optionally contain one double or triple bond; and R^2 is benzyl or C_1-C_6 alkyl, which may optionally contain one double or triple bond, wherein said C_1-C_6 alkyl and the phenyl moiety of said benzyl may optionally be substituted with one fluoro, hydroxy, CF_3, cyclopropyl, C_1-C_2 alkyl, C_1-C_2 alkoxy or chloro group.

4. Compounds according to claim 1 wherein R^3 is methyl.

5. Compounds according to claim 1 wherein R^4, R^6, R^8, R^9, and R^{12} are hydrogen or methyl.

6. Compounds according to claim 1 wherein R^5 is di- or tri-substituted phenyl in which the two or three substitutents are independently selected from C_1-C_4 alkyl, O-(C_1-C_4 alkyl), (C_1-C_4 alkylene)-O-(C_1-C_4alkyl), CF_3, OCF_3, CHO, (C_1-C_4alkylene)-OH, cyano, chloro, fluoro, bromo and iodo, wherein each of the forgoing (C_1-C_4) alkyl groups may optionally contain one double or triple bond.

7. Compounds 1 wherein R^3 is methyl, ethyl, chloro or methoxy; and each of R^4, R^6, R^8, R^9, and R^{12} is, independently, hydrogen, methyl or ethyl.

8. Compounds wherein R^5 is di- or tri-substituted pyridyl, or pyrimidyl in which the two or three substitutents are independently selected from C_1-C_4 alkyl, O-(C_1-C_4 alkyl), (C_1-C_4 alkylene)-O-(C_1-C_4 alkyl), CF_3, OCF_3, CHO, (C_1-C_4 alkylene)-OH, cyano, chloro, fluoro, bromo and iodo, wherein each of the forgoing (C_1-C_4) alkyl groups may optionally contain one double or triple bond.

9. Compounds according to claim 1 wherein A is N, CH or CCH_3.

10. Compounds according to claim 1 wherein A is CH, J and K are carbon and D, E, and G are nitrogen.

11. Compounds according to claim 1 wherein J and D are nitrogen, and K and G are carbon, and E is CH, CCH_3 or CC_2H_5.

12. Compounds according to claim 1 wherein J and K are carbon, and D--EG is O-$C(CH_3)$=C, O-CH=C, S-$C(CH_3)$=C, S-CH=C, N(CH_3)-$C(CH_3)$=C, NH$C(CH_3)$=C, NH$C(CH_3CH_2)$=C, N(CH_3)-CH=C, O-N=C, S-N=C, N(CH_3)-N=C, O-CH_2N or S-CH_2N.

13. A compound according to claim 1 wherein B is -CHR^1R^2, -$NCHR^1R^2$ or -$OCHR^1R^2$, and the CHR^1R^2 group of B is a cyclopentane ring, a tetrahydrofuran ring or a tetrahydrothienyl ring.

14. A compound according to claim 1 wherein the NR^1R^2 group of B is a five membered saturated or unsaturated heterocyclic ring.

15. A compound according to claim 14 wherein the NR^1R^2 is a pyrrolo ring, a pyrrolidino ring, a thiazolidino ring or a morpholino ring.

16. A pharmaceutical composition for the treatment, prevention or inhibition of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic;

phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent, depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus; ulcer;diarrhea; stress-induced fever; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; and hypoglycemia in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of such disorder, and a pharmaceutically acceptable carrier.

17. A method for the treatment, prevention or inhibition of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent premenstrual syndrome, and

postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; and hypoglycemia in a mammal, comprising administering to a subject in need of said treatment an amount of a compound according to claim 1, that is effective in treating such disorder.

18. A method of treating or preventing a disorder or condition, the treatment or prevention of which can be effected or facilitated by inhibiting CRH binding protein in a mammal, comprising administering to said mammal a CRH binding protein inhibiting amount of a compound according to claim 1.


19. A pharmaceutical composition for treating or preventing a disorder or condition, the treatment or prevention of which can be effected or facilitated by inhibiting CRH binding protein in a mammal, comprising a CRH binding protein inhibiting amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.


20. A compound according to claim 11 or 12 wherein A is N or CH, R^3 is methyl and each R^4, R^6, R^8, R^9 and R^{12} is, independently, hydrogen or methyl.

21. A compound according to claim 20, wherein R^5 is di- or tri-substituted phenyl, wherein the two or three substitutents are independently selected from C_1-C_4


alkyl, O-(C_1-C_4 alkyl), (C_1-C_4 alkylene)-O-(C_1-C_4alkyl), CF_3, OCF_3, CHO, (C_1-C_4alkylene)-OH, cyano, chloro, fluoro, bromo and iodo, wherein each of the forgoing (C_1-C_4) alkyl groups may optionally contain one double or triple bond.

22. A compound of the formula





or



wherein $R^{3'}$ is C_1-C_4 alkyl, $R^{7'}$ is hydrogen, methyl, chloro, bromo, -COOH or -COO(C_1-C_4 alkyl), T is chloro, bromo, iodo or triflate, R^8 is hydrogen or C_1-C_4 alkyl and R^4 is hydrogen, (C_1-C_6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C_1-C_2 alkylene)-OH, CF_3, CH_2SCH_3, nitro, -O(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), -C(=O)H or -C(=O)O(C_1-C_4alkyl);

23. A compound according to claim 1 wherein said compound is:

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;

[2,5-Dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;

(1-Ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;

7-(1-Ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;

[2,5-Dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-ethyl-propyl-amine;

[6-Bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;

(1-Ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-amine;

[6-Bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-methyl-amine;

7-(1-Ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridine;

4-(1-Ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;

(±)-2,5-Dimethyl-4-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine;

2,5-Dimethyl-4-(S)-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine;

2,5-Dimethyl-4-(1-propyl-butoxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine; or

4-sec-Butylsulfanyl-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;

or a pharmaceutically acceptable salt of such compound.

INTERNATIONAL SEARCH REPORT

Intern. ial Application No
PCT/IB 97/00922

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D487/04 C07D471/04 A61K31/505 A61K31/435
//(C07D487/04,239:00,231:00),(C07D471/04,249:00,221:00),
(C07D487/04,239:00,209:00)
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 33750 A (PFIZER) 14 December 1995 see claims 1,13	1,16
P,X	WO 96 35689 A (NEUROGEN) 14 November 1996 see page 3, line 18 - line 25; claim 1; examples IE,II,ID	1,16,22

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
27 October 1997	04. 11. 97

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Alfaro Faus, I

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

In ational application No.
PCT/IB 97/00922

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 17 and 18 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr. ial Application No
PCT/IB 97/00922

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9533750 A	14-12-95	AU 2453095 A	04-01-96
		BR 9502708 A	30-04-96
		EP 0764166 A	26-03-97
		FI 964894 A	05-12-96
		HU 75774 A	28-05-97
		NO 965237 A	06-02-97
WO 9635689 A	14-11-96	US 5644057 A	01-07-97
		AU 5679096 A	29-11-96
		CA 2194756 A	14-11-96
		EP 0770080 A	02-05-97

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 October 2013 (31.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/160317 A2

(51) International Patent Classification:
A61K 31/4412 (2006.01)

(21) International Application Number:
PCT/EP2013/058413

(22) International Filing Date:
23 April 2013 (23.04.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1207102.3 23 April 2012 (23.04.2012) GB
12165231.7 23 April 2012 (23.04.2012) EP

(71) Applicant: **HOLSBOERMASCHMEYER NEUROCHEMIE GMBH** [DE/DE]; Maximilianstrasse 13, 80539 Munich (DE).

(72) Inventor: **HOLSBOER, Florian**; Rohmederstrasse 12, 80805 Munich (DE).

(74) Agent: **HUENGES, Martin**; Maiwald Patentanwalts GmbH, Postfach 33 05 23, 80065 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/160317 A2

(54) Title: CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY

(57) Abstract: The present invention relates to a corticotropin releasing hormone receptor type 1 (CRHRl) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a novel group of patients, i.e. patients having corticotropin releasing hormone (CRH) overactivity.

CRHR1 antagonists for use in the treatment of patients having CRH overactivity

Field of the Invention

The present invention relates to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having corticotropin releasing hormone (CRH) overactivity.

Background of the Invention

While current antidepressant drugs are effective treatments of depression and anxiety symptoms in a number of psychiatric disorders, a large fraction of patients only show partial remission of symptoms or do not respond at all (Trivedi *et al.*, Am J Psychiatry, 2006). This may be due to the fact that these drugs do not target the inherent pathophysiologic disturbances leading to clinical condition in these patients. A number of novel antidepressant strategies, derived from both animal studies and human studies have been tested, but so far with little success. One of these approaches is the use of corticotropin releasing hormone receptor type 1 (CRHR1) antagonists. A wealth of data ranging from molecular studies in experimental animals to open label studies in human patients indicate that CRHR1 antagonists are a promising novel approach in the treatment of depression and anxiety (Ising *et al.*, Exp Clin Psychopharmacol, 2007; Holsboer *et al.*, CNS Spectr, 2001; Paez-Pereda *et al.*, Expert Opin Invest Drugs, 2011). However, so far all randomized clinical trials have failed to demonstrate the superiority of this drug to placebo (Coric *et al.*, Depress Anxiety, 2010; Binneman *et al.*, Am J Psychiatry, 2008).


Hence, there is still a need for antidepressant drugs effective in the treatment of depression and/or anxiety symptoms in a number of psychiatric disorders.

It has now been found that despite the so far unsuccessful clinical trials, a specific group of patients, i.e. patients suffering from central corticotropin releasing hormone (CRH) overactivity, profits from the treatment with CRHR1 antagonists.

Summary of the Invention

One aspect of the invention relates to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having corticotropin releasing hormone (CRH) overactivity.

In an embodiment of the invention, the CRHR1 antagonist is a compound of formula (I)


(I)

or a pharmaceutically acceptable salt thereof, wherein

X_1 is $-CR_6$ or N;

X_2 is $-NR_1R_2$, $-CR_1R_2R_9$, $-C(=CR_2R_{10})R_1$, $-NHCHR_1R_2$, $-OCHR_1R_2$, $-SCHR_1R_2$, $-CHR_2OR_{10}$, $-CHR_2SR_{10}$, $-C(S)R_2$ or $-C(O)R_2$;

X_3 is NH, O, S, $-N(C_1\text{-}C_2$ alkyl) or $-C(R_{11}R_{12})$, wherein R_{11} and R_{12} are each, independently, hydrogen, trifluoromethyl or methyl, or one of R_{11} and R_{12} is cyano and the other is hydrogen or methyl, or
X_3 is N and X_3 and R_4 form a 5-membered ring substituted at X_3 with R_5;

R_1 is $C_1\text{-}C_6$ alkyl which may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, $C_3\text{-}C_8$ cycloalkyl, $C_1\text{-}C_4$ alkoxy, $-O\text{-}CO\text{-}(C_1\text{-}C_4$ alkyl), $-O\text{-}CO\text{-}NH(C_1\text{-}C_4$ alkyl), $-O\text{-}CO\text{-}N(C_1\text{-}C_4$ alkyl)$(C_1\text{-}C_2$ alkyl), $-NH(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}$

C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_6 alkyl and the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond;

R_2 is C_1-C_{12} alkyl, C_1-C_{12} alkoxyalkyl, aryl or -(C_1-C_4 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, oxadiazolyl or benzoxazolyl;

3- to 8-membered cycloalkyl or –(C_1-C_6 alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C_1-C_6 alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R_8 wherein R_8 is hydrogen or C_1-C_4 alkyl;

and wherein each of the foregoing R_2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl, or with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -O-CO-(C_1-C_6 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl), and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_{12} alkyl and/or the C_1-C_4 alkylene moiety of said -(C_1-C_4 alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR_1R_2 or –$CR_1R_2R_9$ may form a saturated 5- to 8-membered ring which may optionally contain one or two carbon-carbon double bonds and/or in which one or two of the ring carbons may optionally be replaced by an oxygen, nitrogen or sulfur atom and which may be substituted with at least one substituent;

R_3 is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF_3, methylthio, methylsulfonyl, CH_2OH, or CH_2OCH_3;

R_4 is hydrogen, C_1-C_4 alkyl, fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethoxy, -CH_2OCH_3, -$CH_2OCH_2CH_3$, -$CH_2CH_2OCH_3$, -CH_2OCF_3, CF_3,

amino, nitro, -NH(C_1-C_4 alkyl), -N(CH_3)$_2$, -NHCOCH$_3$ -NHCONHCH$_3$, -SO$_n$(C_1-C_4 alkyl) wherein n is 0, 1 or 2, hydroxy, -CO(C_1-C_4 alkyl), -CHO, cyano or -COO(C_1-C_4 alkyl) wherein said C_1-C_4 alkyl may optionally contain one double or triple bond and/or may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH$_3$, -NH(C_1-C_2 alkyl), -N(C_1-C_2 alkyl)$_2$, -COO(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, chloro, cyano and nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl,

wherein each of the above groups R_5 is substituted with from one to three substituents independently selected from fluoro, chloro, C_1-C_6 alkyl and C_1-C_6 alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, (C_1-C_6 alkyl)O(C_1-C_6)alkyl, -NHCH$_3$, -N(CH_3)$_2$, -COOH, -COO(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), -SO$_2$NH(C_1-C_4 alkyl), -SO$_2$N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -SO$_2$NH$_2$, -NHSO$_2$(C_1-C_4 alkyl), -S(C_1-C_6 alkyl) and SO$_2$(C_1-C_6 alkyl), and wherein the C_1-C_4 alkyl and the C_1-C_6 alkyl moieties of the foregoing R_5 groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

R_6 is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, -O(C_1-C_4 alkyl), -C(O)(C_1-C_4 alkyl), -C(O)O(C_1-C_4 alkyl), -OCF$_3$, CF$_3$, -CH$_2$OH, -CH$_2$OCH$_3$ or -CH$_2$OCH$_2$CH$_3$;

R_9 is hydrogen, hydroxy, fluoro, or methoxy;

R_{10} is hydrogen or C_1-C_4 alkyl.

Further, CRHR1 antagonists of the invention encompass compounds of formula (I) as defined above, wherein X_1 is –CR_6. Optionally, in the CRHR1 antagonists of the invention X_1 is -CR_6, wherein R_6 is hydrogen.

In a further embodiment of the CRHR1 antagonists of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ of the compound of formula (I) as defined above is substituted with at least one substituent selected from C_1-C_4 alkyl or with a 4-8 membered ring, which may be saturated or may contain one to three double bonds and in which one carbon atom may be replaced by CO or SO_2 and one to four carbon atoms may optionally be replaced by nitrogen.

In a specific embodiment of the CRHR1 antagonists of the invention, X_2 of the compound of formula (I) as defined above is $-NHCHR_1R_2$, $-OCHR_1R_2$ or $-NR_1R_2$.

Optionally, in the compounds of formula (I) as defined above $-NHCHR_1R_2$ is $-NHCH(CH_2OCH_3)_2$, $-NHCH(CH_2OCH_3)(CH_2CH_3)$, $-NHCH(CH_2CH_3)_2$,, $-NHCH(CH_2CH_2OCH_3)_2$ or $-NHCHR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl, or $-NR_1R_2$ is $-N(CH_2CH_3)(CH_3)$, $-N(CH_2CH_2CH_3)_2$, $-N(CH_2CH_2CH_3)(CH_2$-cyclopropyl), $-N(CH_2CH_3)(CH_2CH_2CH_2CH_3)$, $-N(CH_2CH_2OCH_3)_2$, or $-N(CH_2CH_2OCH_3)(CH_2CH_2CH_3)$, or $-OCHR_1R_2$ is $-OCH(CH_2CH_3)_2$, $-OCH(CH_2CH_3)CH_3$, $-OCH(CH_2CH_3)(CH_2CH_2CH_3)$, $-OCH(CH_2CH_3)(CH_2OCH_3)$.


In another embodiment of the CRHR1 antagonists of the invention, R_3 and R_4 of the compound of formula (I) as defined above are methyl.

In a further embodiment of the CRHR1 antagonists of the invention, X_3 of the compound of formula (I) as defined above is O.

Another embodiment of the invention relates to the CRHR1 antagonists of formula (I) as defined above, wherein R_5 is phenyl substituted with from one to three substituent(s) independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, CF_3.

A specific embodiment of the invention relates CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having

corticotropin releasing hormone (CRH) overactivity, wherein the CRHR1 antagonist is a compound of the formula (VI)



(VI)

or a pharmaceutically acceptable salt thereof, wherein
X_4 is O or NH.

In another specific embodiment, the CRHR1 antagonist of the invention is a class I or class II CRHR1 antagonist.

Another specific embodiment of the invention relates to a CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having corticotropin releasing hormone (CRH) overactivity, wherein the CRHR1 antagonist is selected from the group consisting of CP154,526, Antalarmin, CRA 5626, Emicerfont, DMP-696, DMP-904, DMP-695, SC-241, BMS-561388, Pexacerfont, R121919, NBI30545, PD-171729, Verucerfont, NBI34041, NBI35965, SN003, CRA0450, SSR125543A, CP-316,311, CP-376,395, NBI-27914, ONO-2333Ms, NBI-34101, PF-572778, GSK561579 and GSK586529.

In an exemplary embodiment of the present invention, the CRHR1 antagonist is DMP-696.

In an exemplary embodiment of the present invention, the CRHR1 antagonist is CP 316,311.

In an exemplary embodiment of the present invention, the CRHR1 antagonist is SSR125543A.

Brief Description of the Drawings

Figure 1: Graph of the phenotypic distribution of ln(AAUC) at in-patient admission. The X-axis shows the ln of the AUC of the ACTH response and the Y-axis the frequency in total N/bin. The dashed vertical indicates the cut-off for being classified as a low vs. high responder. AAUC is the area under the curve of the ACTH response.

Figure 2: Increased REMS activity in CRH-COE^{CNS} mice is suppressed by DMP696 (50mg/kg/d) application via drinking water. Treatment day one, light grey; treatment day 2, dark grey; treatment day three, black. Symbols indicate significant differences between baseline and treatment day one (+), two (#) or three (*). Light and dark bar on the x-axis indicate light and dark period, respectively.

Figure 3: Increased activity of REMS in CRH-COE^{CNS} is suppressed by application of the CRH-R1 antagonist SSR125543 (50mg/kg/d) via drinking water. Baseline day, white; treatment day two, dark grey; treatment day three, black. Symbols indicate significant differences between baseline and treatment day two (#) or three (*). Light and dark bar on the x-axis indicate light and dark period, respectively.

Figure 4: REMS activity in Cor26 CRH mice is suppressed by application of the CRH-R1 antagonist CP-316311 (50mg/kg/d) via drinking water. Baseline day, white; treatment day two, dark grey; treatment day three, black.

Definitions

Where the term "comprise" or "comprising" is used in the present description and claims, it does not exclude other elements or steps. For the purpose of the present invention, the term "consisting of" is considered to be an optional embodiment of the

term "comprising of". If hereinafter a group is defined to comprise at least a certain number of embodiments, this is also to be understood to disclose a group which optionally consists only of these embodiments.

Where an indefinite or a definite article is used when referring to a singular noun such as "a" or "an" or "the", this includes a plural form of that noun unless specifically stated. Vice versa, when the plural form of a noun is used it refers also to the singular form. For example, when SNPs are mentioned, this is also to be understood as a single SNP.

Furthermore, the terms first, second, third or (a), (b), (c) and the like in the description and in the claims are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.

The term "corticotropin releasing hormone receptor 1" of "CRHR1" of "CRF_1" refers to the receptor which binds to corticotropin-releasing hormone.

The term "CRHR1 antagonist" refers to a compound capable of binding directly or indirectly to a CRH receptor 1 so as to modulate the receptor mediated activity. CRHR1 antagonists are well known in the literature and are e.g. described in WO 94/13676, EP 0 773 023, WO 2004/047866, WO 2004/094420, WO 98/03510, WO 97/029109, WO 2006/044958, WO 2001/005776 and WO 95/033750. Exemplary CRHR1 antagonists comprise NBI30775/R121919 (Neurocrine), CP316.311 (Pfizer), CP154,526 (Pfizer), Emicerfont (Glaxo), ONO-2333Ms (Ono Pharmaceutical), Pexacerfont (Bristol-Myers-Squibb), SSR125543 (Sanofi-Aventis), NBI-34101 (Neurocrine) and TAI041 (Taisho).

Most of the non-peptidic CRHR1 antagonists can be described by or adhere to a pharmacophore model that comprises or features a lipophilic top group, a

heterocyclic core containing an invariable hydrogen bond acceptor, which is almost always a heterocyclic nitrogen, and a lipophilic, usually aromatic, bottom group.

Class I CRHR1 antagonists as used herein may be characterized in that the heterocyclic hydrogen bond acceptor and the bottom group are connected by a two-atom linker as exemplified by CRHR1 antagonists R-121919, NBI-30545, CP-154526, DMP696, pexacerfont (BMS-562086), emicerfont (GW876008), or verucerfont (GSK561679). Class II CRF1R antagonists as used herein may be characterized by a two-atom linker between hydrogen bond acceptor and the bottom group as present in CRHR1 antagonist SSR125543A.

"Downstream target" or "molecule which is downstream of the CRHR1 receptor" as used herein may denote a molecule such as an endogenous molecule (e.g. peptide, protein, lipid, nucleic acid or oligonucleotide) that is regulated by CRHR1 directly or indirectly. The direct or indirect regulation may comprise direct or indirect modulation of the activity and/or expression level and/or localization, degradation, stability of the downstream target.

The term "normal CRH activity" refers to a range of CRH activity which can be found in human beings who are not affected by a condition which is associated with an increase of CRH activity (such as depression). A value indicative for normal CRH activity is usually considered to be indicative or predictive for a patient not responding to a treatment with a CRHR1 antagonist.

Further definitions of the terms will be given below in the context of which the terms are used.

Detailed Description of the Invention

While so far all randomized clinical trials have failed to demonstrate the superiority of CRHR1 antagonist to placebo in the treatment of depression and anxiety, it has now been found that a certain patient group, i.e. patients with corticotropin releasing

hormone (CRH) overactivity, is responsive to the treatment with corticotropin releasing hormone receptor type 1 (CRHR1) antagonists.

Hence, the present invention relates to CRHR1 antagonists for use in the treatment of depressive symptoms and/or anxiety symptoms in said novel patient group, i.e. patients having CRH overactivity.

The terms “CRH overactivity”, “CRH system overactivity”, “CRH hyperactivity”, “CRH hyperdrive” or "central CRH hyperdrive" are used herein interchangeable. An indication for CRH overactivity may be an increase in activity or concentration of CRH or of one or several molecules downstream of the CRHR1 receptor, that are activated or whose concentration is increased based on the activation of CRHR1 receptor upon CRH binding. A further indication for CRH overactivity may be a decrease in activity or concentration of one or several molecules downstream of the CRHR1 receptor, that are inactivated or whose concentration is decreased based on the activation of CRHR1 receptor upon CRH binding. A value indicative for CRH overactivity is usually considered to be indicative or predictive for a patient responding to a treatment with a CRHR1 antagonist. CRH activity vs. CRH overactivity may be defined relatively to the whole group, e.g. by using a median split of the area under the curve of the ACTH response in the dex/CRH test. Responses in the upper median may be categorized as being predictive of CRH overactivity, while responses in the lower median are indicative of normal CRH activity.

A “value indicative for CRH activity”, a "value indicative for CRH overactivity" and/or a "value indicative for normal CRH activity" can be obtained by determining the concentration or activity of CRH and/or of a downstream target of the CRHR1 receptor. The analysis is usually set up in a way that it can be excluded that the modulation of activity or concentration of a downstream target of the CRHR1 receptor is due to another disturbance than CRH activity. For instance, the concentrations or activities of adrenocorticotrophin (ACTH) and/or cortisol are useful biomarkers for determining a value indicative for CRH overactivity.

Typically, the CRH overactivity in each patient may be determined by measuring the ACTH and/or cortisol level response to a combined dexamethasone suppression/CRH stimulation test as described in Heuser *et al.* (J Psychiatr Res., 1994).


The neuroendocrine response to the dex/CRH test may be analyzed using the total area under the curve (AUC) of the ACTH response. Patients suffering from depression normally show an increased release of cortisol and of adrenocorticotropic hormone (ACTH) in response to the combined treatment with dexamethasone and CRH as performed during the test, thus indicating a dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Patients with a high HPA axis dysregulation show AUC values of cortisol of between 3000 and 18000 AUC units (ng/ml x 75 min) and/or AUC values of ACTH of between 1000 and 6500 AUC units (pg/ml x 75 min). Patients having a low HPA axis dysregulation show AUC values of cortisol of between 300 and 2500 AUC units (ng/ml x 75 min) and/or AUC values of ACTH of between 250 and 1000 AUC units (pg/ml x 75 min) Various antidepressants lead to a reduction of these increased cortisol and ACTH levels in a combined dex/CRH test performed after the treatment with the antidepressants. Treatment response to antidepressants can thus be determined by performing a second dex/CRH test after treatment with the antidepressant and comparing the neuroendocrine response to the one shown in a combined dex/CRH test performed prior to treatment with the antidepressant.

In one embodiment of a combined dexamethasone suppression CRH stimulation test, subjects are pre-treated with dexamethasone and blood is drawn in certain intervals. Further, human CRH is administered after the first pretreatment with dexamethasone. Plasma ACTH and/or cortisol concentrations are then determined. The neuroendocrine response to the dex/CRH test may be analyzed using the total area under the curve (AUC) of the ACTH response. Details of an exemplary dex/CRH test are also described in Example 1 below.

Depressive symptoms comprise *inter alia* low mood, low self-esteem, loss of interest or pleasure, psychosis, poor concentration and memory, social isolation, psychomotor agitation/retardation, thoughts of death or suicide, significant weight change (loss/gain), fatigue, and feeling of worthlessness. The depressive disorders can last for weeks to lifelong disorder with periodic reoccurring depressive episodes. For the diagnosis of the depression mode (e.g. moderate or severe depression) the Hamilton Depression Rating Scale (HAM-D) (Hamilton, J Neurol Neurosurg Psychiatry, 1960) may be used. The depression mode may be also, in addition or alternatively, rated by alternative scales as the Beck Depression Inventory (BDI), the Montgomery-Åsberg Depression Scale (MADRS), the Geriatric Depression Scale (GDS), and/or the Zung Self-Rating Depression Scale (ZSRDS).

Anxiety symptoms comprise *inter alia* panic disorders, generalized anxiety disorder, phobias and posttraumatic stress disorder. Typical symptoms of anxiety are or include avoidance behavior which may lead to social isolation, physical ailments like tachycardia, dizziness and sweating, mental apprehension, stress and/or tensions. The strength of these symptoms ranges from nervousness and discomfort to panic and terror in humans or animals. Most anxiety disorders may last for weeks or even months, some of them even for years and worsen if not suitably treated. For measuring the severity of anxiety symptoms, the Hamilton Anxiety Rating Scale (HAM-A) and/or the State-Trait Anxiety Rating Scale (STAI) can be used.

A CRHR1 antagonist which may be used according to the invention in the treatment of depressive symptoms and/or anxiety symptoms in patients having CRH overactivity is a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, wherein

X_1 is -CR_6 or N;

X_2 is -NR_1R_2, -$CR_1R_2R_9$, -$C(=CR_2R_{10})R_1$, -$NHCHR_1R_2$, -$OCHR_1R_2$, -$SCHR_1R_2$, -CHR_2OR_{10}, -CHR_2SR_{10}, -$C(S)R_2$ or -$C(O)R_2$;

X_3 is NH, O, S, -N(C_1-C_2 alkyl) or -$C(R_{11}R_{12})$, wherein R_{11} and R_{12} are each, independently, hydrogen, trifluoromethyl or methyl, or one of R_{11} and R_{12} is cyano and the other is hydrogen or methyl, or
X_3 is N and X_3 and R_4 form a 5-membered ring substituted at X_3 with R_5;

R_1 is C_1-C_6 alkyl which may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_6 alkyl and the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond;

R_2 is C_1-C_{12} alkyl, C_1-C_{12} alkoxyalkyl, aryl or -(C_1-C_4 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, oxadiazolyl or benzoxazolyl;

3- to 8-membered cycloalkyl or –(C_1-C_6 alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and/or the cycloalkyl moiety of said -(C_1-C_6 alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R_8 wherein R_8 is hydrogen or C_1-C_4 alkyl;

and wherein each of the foregoing R_2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl, or with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -O-CO-(C_1-C_6 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), CN, NO_2,

-SO(C_1-C_4 alkyl), and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_{12} alkyl and/or the C_1-C_4 alkylene moiety of said -(C_1-C_4 alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR_1R_2 or –$CR_1R_2R_9$ may form a saturated 5- to 8-membered ring which may optionally contain one or two carbon-carbon double bonds and/or in which one or two of the ring carbons may optionally be replaced by an oxygen, nitrogen or sulfur atom and which may be substituted with at least one substituent;

R_3 is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF_3, methylthio, methylsulfonyl, CH_2OH, or CH_2OCH_3;

R_4 is hydrogen, C_1-C_4 alkyl, fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethoxy, -CH_2OCH_3, -$CH_2OCH_2CH_3$, -$CH_2CH_2OCH_3$, -CH_2OCF_3, CF_3, amino, nitro, -NH(C_1-C_4 alkyl), -$N(CH_3)_2$, -$NHCOCH_3$ -$NHCONHCH_3$, -SO_n(C_1-C_4 alkyl) wherein n is 0, 1 or 2, hydroxy, -CO(C_1-C_4 alkyl), -CHO, cyano or -COO(C_1-C_4 alkyl) wherein said C_1-C_4 alkyl may optionally contain one double or triple bond and/or may optionally be substituted with one substituent selected from hydroxy, amino, -$NHCOCH_3$, -NH(C_1-C_2 alkyl), -N(C_1-C_2 alkyl)$_2$, -COO(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, chloro, cyano and nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl,

wherein each of the above groups R_5 is substituted with from one to three substituents independently selected from fluoro, chloro, C_1-C_6 alkyl and C_1-C_6 alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, (C_1-C_6 alkyl)O(C_1-C_6)alkyl, -$NHCH_3$, -$N(CH_3)_2$, -COOH, -COO(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), -SO_2NH(C_1-C_4 alkyl), -SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -SO_2NH_2, -$NHSO_2$(C_1-C_4 alkyl), -S(C_1-C_6 alkyl) and SO_2(C_1-C_6 alkyl), and wherein the C_1-C_4 alkyl and the C_1-C_6 alkyl moieties of the foregoing R_5 groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

R_6 is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, -O(C_1-C_4 alkyl), -C(O)(C_1-C_4 alkyl), -C(O)O(C_1-C_4 alkyl), -OCF_3, CF_3, -CH_2OH, -CH_2OCH_3 or -$CH_2OCH_2CH_3$;

R_9 is hydrogen, hydroxy, fluoro, or methoxy;

R_{10} is hydrogen or C_1-C_4 alkyl.

In an embodiment of the invention, the CRHR1 antagonist of the present invention is a compound of formula (I) as defined above, wherein X_1 is –CR_6.

Alternatively, the CRHR1 antagonists of the invention encompass compound of formula (I) as defined above, wherein X_1 is N.


If X_1 is –CR_6, R_6 may be selected from the group consisting of hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, -O(C_1-C_4 alkyl), -C(O)(C_1-C_4 alkyl), -C(O)O(C_1-C_4 alkyl), -OCF_3, CF_3, -CH_2OH, -CH_2OCH_3 or -$CH_2OCH_2CH_3$. In a specific embodiment of the CRHR1 antagonists of the invention R_6 is hydrogen.

A further embodiment of the invention relates to a CRHR1 antagonist of formula (I) as defined above, wherein X_2 is selected from the group consisting of –$NHCHR_1R_2$, -$OCHR_1R_2$ or -NR_1R_2.

In a specific embodiment, X_2 is –$NHCHR_1R_2$. In another specific embodiment, X_2 is –$OCHR_1R_2$. In a further specific embodiment, X_2 is –NR_1R_2.

If X_2 is –$NHCHR_1R_2$, it is optionally selected from the group consisting of -$NHCH(CH_2OCH_3)_2$, -$NHCH(CH_2OCH_3)(CH_2CH_3)$, -$NHCH(CH_2CH_3)_2$, -$NHCH(CH_2CH_2OCH_3)_2$, -$NHCH(CH_3)(CH_2CH_3)$ or -$NHCHR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl, isopropyl, cyclopropyl, trifluoromethyl, or ethyl. More specifically X_2 is -$NHCH(CH_2CH_3)_2$. Alternatively, X_2 is -$NHCHR_1R_2$ wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl. Alternatively, X_2 is -$NHCH(CH_2CH_2OCH_3)_2$. Alternatively, X_2 is –

$NHCH(CH_2OCH_3)_2$. Alternatively, X_2 is $-NHCH(CH_3)(CH_2CH_3)$. More specifically, X_2 is



Alternatively, if X_2 is $-NR_1R_2$, it is optionally selected from the group consisting of -$N(CH_2CH_3)(CH_3)$, -$N(CH_2CH_2CH_3)_2$, -$N(CH_2CH_2CH_3)(CH_2$-cyclopropyl), -$N(CH_2CH_3)(CH_2CH_2CH_2CH_3)$, -$N(CH_2CH_2OCH_3)_2$, or-$N(CH_2CH_2OCH_3)(CH_2CH_2CH_3)$. Alternatively, X_2 is $-N(CH_2CH_2OCH_3)_2$.

If X_2 is -$OCHR_1R_2$, it is optionally selected from $-OCH(CH_2CH_3)_2$, -$OCH(CH_2CH_3)CH_3$, $-OCH(CH_2CH_3)(CH_2CH_2CH_3)$, $-OCH(CH_2CH_3)(CH_2OCH_3)$. More specifically, X_2 is $-OCH(CH_2CH_3)_2$.

Further CRHR1 antagonists for use according to the invention encompass compounds of formula (I) as defined above wherein R_1 is C_1-C_6 alkyl.

In another embodiment of the invention, R_1 of formula (I) is C_1 alkyl. In a further embodiment of the invention R_1 of formula (I) is C_2 alkyl. In a further embodiment of the invention, R_1 of formula (I) is C_3 alkyl. In a further embodiment of the invention, R_1 of formula (I) is C_4 alkyl. In a further embodiment, of the invention, R_1 of formula (I) is C_5 alkyl. In a further embodiment of the invention, R_1 of formula (I) is C_6 alkyl.

Any of the aforementioned R_1 groups may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl). Said C_1-C_6 alkyl and the

(C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond.

Specifically, R_1 is C_1-C_6 alkyl substituted with substituent R_7 selected from the group consisting of F, CF_3, C_1-C_4 alkoxy and C_3-C_8 cycloalkyl. More specifically, R_1 is selected from the group consisting of $–CH_2OCH_3$, $-CH_2CH_2OCH_3$ and $–CH_2$-cyclopropyl.

In another embodiment of the invention, R_2 of formula (I) is C_1-C_{12} alkyl. In another embodiment of the invention, R_2 of formula (I) is C_1-C_{12} alkoxyalkyl. In a further embodiment, R_2 is aryl. In another embodiment, R_2 is -(C_1-C_4 alkylene)aryl. In a further embodiment of the invention, R_2 is a 3- to 8-membered cycloalkyl. In another embodiment of the invention, R_2 is a –(C_1-C_6 alkylene)cycloalkyl.

Optionally, if the R_2 group is aryl or –(C_1-C_4 alkylene)alkyl said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, oxadiazolyl or benzoxazolyl. More specifically, R_2 is oxadiazolyl.

Optionally, if the R_2 group is a 3- to 8-membered cycloalkyl or a –(C_1-C_6 alkylene)cycloalkyl, one or two of the ring carbons of said cycloalkyl having at least 4 ring members and/or the cycloalkyl moiety of said -(C_1-C_6 alkylene)cycloalkyl having at least 4 ring members may be replaced by an oxygen or sulfur atom or by N-R_8 wherein R_8 is hydrogen or C_1-C_4 alkyl.

Each of the aforementioned R_2 groups may be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Alternatively, each of the aforementioned R_2 groups may be substituted with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -O-CO-(C_1-C_6 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl), and

-SO_2(C_1-C_4 alkyl). Optionally, said C_1-C_{12} alkyl and/or the C_1-C_4 alkylene moiety of said -(C_1-C_4 alkylene)aryl may contain one carbon-carbon double or triple bond.

In a specific embodiment of the invention, R_2 is aryl substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Optionally, R_2 is aryl substituted with one substituent selected from chloro, fluoro and C_1-C_4 alkyl. More specifically, R_2 is oxadiazolyl substituted with one substituent independently selected from chloro, fluoro, C_1-C_4 alkyl, CF_3 and cyclopropyl. Even more specifically, R_2 is oxadiazolyl substituted with methyl.

In another embodiment of the invention, X_2 is –$NHCHR_1R_2$, wherein R_1 is C_1-C_6 alkyl which may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_6 alkyl and the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond and R_2 is oxadiazolyl substituted with methyl. Optionally, X_2 is –$NHCR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl.


In another embodiment of the invention X_2 is -NR_1R_2 which forms a 5- to 8-membered ring. In a further embodiment of the invention X_2 is –$CR_1R_2R_9$ which forms a saturated 5- to 8-membered ring. The ring formed by -NR_1R_2 or –$CR_1R_2R_9$ optionally contains one or two carbon-carbon double bonds. Alternatively or additionally, one or two of the ring carbons may be replaced by an oxygen, nitrogen or sulfur atom.

In a specific embodiment, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by an oxygen, nitrogen or sulfur


atom. Optionally, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom. More specifically, the 5-membered ring formed by –NR_1R_2 is a pyrazol-1-yl. Alternatively, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a sulfur atom.

The above described 5- to 8-membered ring formed by –NR_1R_2 or –$CR_1R_2R_9$ may be substituted with at least one substituent. In one embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –$CR_1R_2R_9$ is substituted with one substituent selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –$CR_1R_2R_9$ is substituted with two substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –$CR_1R_2R_9$ is substituted with three substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –$CR_1R_2R_9$ is substituted with four substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring.

Said 4-8 membered ring may be saturated or may contain one to three double bonds. Optionally, the 4-8 membered ring is saturated. Additionally, one carbon atom of said 4-8 membered ring may be replaced by CO. Alternatively, one carbon atom of said 4-8 membered ring may be replaced by SO_2. Alternatively or additionally, one to four carbon atom(s) of the 4-8 membered ring may be replaced by nitrogen. Optionally, two carbon atoms are replaced by nitrogen. More specifically, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by CO. Alternatively, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by SO_2. In a specific embodiment of the invention, the above described 5- to 8-membered ring formed by –NR_1R_2 is substituted with



Optionally, X_2 is



In an alternative embodiment, the 4-8 membered ring contains one to three double bonds. Optionally, the 4-8 membered ring contains two double bonds. Additionally, one carbon atom of the 4-8 membered ring may be replaced by nitrogen and one carbon atom may be replaced by sulfur. Optionally, the above described ring is a 5 membered ring. In a specific embodiment of the invention, the above described 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with thiazol. Optionally, X_2 is a 5-membered ring formed by $-NR_1R_2$ containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom and wherein said 5-membered ring is substituted with thiazol.

In a specific embodiment of the invention, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with at least one C_1-C_4 alkyl. In another embodiment, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with two C_1-C_4 alkyl substituents. In another embodiment, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with three C_1-C_4 alkyl substituents. Optionally, X_2 is 3,5-dialkylpyrazol-1-yl, such as 3,5-diethylpyrazol-1-yl.

A further embodiment of the invention encompasses CRHR1 antagonists of formula (I) as defined above, wherein X_3 is NH, O, NCH_3, or N, whereby, if X_3 is N, X_3 and R_4 form a 5-membered ring substituted at X_3 with R_5. Specifically, X_3 of formula (I) as defined above is N and X_3 and R_4 form a 5-membered ring substituted at X_3 with

R_5. More specifically, X_3 of formula (I) as defined above is N and X_3 and R_4 form a 5-membered ring substituted at X_3 with R_5 wherein X_3 and R_4 form a group –N-CH_2CH_2-. Alternatively, X_3 is O or NH, more specifically X_3 is O.

The CRHR1 antagonist of the invention further encompasses a compound of formula (I) as defined above, wherein R_3 is methyl. In a further embodiment of the invention, R_4 of formula (I) as defined above is C_1-C_4 alkyl. Optionally R_4 of formula (I) as defined above is methyl. Alternatively, R_4 of formula (I) as defined above is ethyl. The present invention also encompasses CRHR1 antagonists wherein both R_3 and R_4 are methyl.

In another embodiment of the invention, the CRHR1 antagonist is a compound of formula (I) as defined above, wherein R_5 is phenyl substituted with from one to three substituents independently selected from fluoro, chloro, C_1-C_6 alkyl and C_1-C_6 alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, (C_1-C_6 alkyl)O(C_1-C_6)alkyl, -$NHCH_3$, -$N(CH_3)_2$, -COOH, -COO(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), -SO_2NH(C_1-C_4 alkyl), -SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -SO_2NH_2, -$NHSO_2$(C_1-C_4 alkyl), -S(C_1-C_6 alkyl) and SO_2(C_1-C_6 alkyl). The C_1-C_4 alkyl and the C_1-C_6 alkyl moieties of the foregoing R_5 groups may be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl.

In an embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (I) as defined above, wherein R_5 is phenyl substituted with from one to three substituent(s) independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, and CF_3. In a specific embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (I) as defined above, wherein R_5 is phenyl substituted with one substituent independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, and CF_3. In another embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (I) as defined above, wherein R_5 is phenyl substituted with two substituents independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, CF_3. In another embodiment of the invention,

the CRHR1 antagonist encompasses a compound of formula (I) as defined above, wherein R_5 is phenyl substituted with three substituents independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, and CF_3.


In a specific embodiment of the CRHR1 antagonist of the invention, R_5 is phenyl substituted with two substituents, wherein the two substituents are CH_3 and OCH_3.

In another specific embodiment of the CRHR1 antagonist of the invention, R_5 is phenyl substituted with three substituents, wherein the three substituents are CH_3.

In another specific embodiment of the CRHR1 antagonist of the invention, the three substituents of said phenyl are independently selected from CH_3 and Cl.

Specifically, R_5 is 2-chloro-4-methoxy-5-methyl-phenyl, 2,4,6-trimethyl-phenyl, 2,4,6-trichloro-phenyl, 4-methoxy-2-methyl-phenyl, 2,4-dichloro-phenyl, 4-chloro-2,6-dimethyl-phenyl, 2,4-dimethyl-phenyl, or 2,4-dimethoxy-phenyl. More specifically R_5 is 2,4,6-trimethyl-phenyl or 4-chloro-2,6-dimethyl-phenyl. Even more specifically, R_5 is 4-chloro-2,6-dimethyl-phenyl.

In a specific embodiment of the invention, the CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having CRH overactivity is a compound of formula (II)




(II),

wherein X_2, X_3, R_1, R_2 und R_5-R_{12} are as defined above for formula (I).

A further embodiment of the invention relates to a CRHR1 antagonist of formula (II) as defined above, wherein X_2 is selected from the group consisting of $-NHCHR_1R_2$, $-OCHR_1R_2$ or $-NR_1R_2$.

In a specific embodiment, X_2 is $-NHCHR_1R_2$. In another specific embodiment, X_2 is $-OCHR_1R_2$. In a further specific embodiment, X_2 is $-NR_1R_2$.

If X_2 is $-NHCHR_1R_2$, it is optionally selected from the group consisting of $-NHCH(CH_2OCH_3)_2$, $-NHCH(CH_2OCH_3)(CH_2CH_3)$, $-NHCH(CH_2CH_3)_2$, $-NHCH(CH_2CH_2OCH_3)_2$, $-NHCH(CH_3)(CH_2CH_3)$ or $-NHCHR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl, isopropyl, cyclopropyl, trifluoromethyl, or ethyl. More specifically, X_2 is $-NHCH(CH_2CH_3)_2$. Alternatively, X_2 is $-NHCHR_1R_2$ wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl. Alternatively, X_2 is $-NHCH(CH_2CH_2OCH_3)_2$. Alternatively, X_2 is $-NHCH(CH_2OCH_3)_2$. Alternatively, X_2 is $-NHCH(CH_3)(CH_2CH_3)$. More specifically, X_2 is



Alternatively, if X_2 is $-NR_1R_2$, it is optionally selected from the group consisting of $-N(CH_2CH_3)(CH_3)$, $-N(CH_2CH_2CH_3)_2$, $-N(CH_2CH_2CH_3)(CH_2$-cyclopropyl), $-N(CH_2CH_3)(CH_2CH_2CH_2CH_3)$, $-N(CH_2CH_2OCH_3)_2$, or $-N(CH_2CH_2OCH_3)(CH_2CH_2CH_3)$. Alternatively, X_2 is $-N(CH_2CH_2OCH_3)_2$.

If X_2 is $-OCHR_1R_2$, it is optionally selected from $-OCH(CH_2CH_3)_2$, $-OCH(CH_2CH_3)CH_3$, $-OCH(CH_2CH_3)(CH_2CH_2CH_3)$, $-OCH(CH_2CH_3)(CH_2OCH_3)$. More specifically, X_2 is $-OCH(CH_2CH_3)_2$.

Further CRHR1 antagonists for use according to the invention encompass compounds of formula (II) as defined above wherein R_1 is C_1-C_6 alkyl.

In another embodiment of the invention, R_1 of formula (II) is a C_1 alkyl. In a further embodiment of the invention, R_1 of formula (II) is a C_2 alkyl. In a further embodiment of the invention, R_1 of formula (II) is a C_3 alkyl. In a further embodiment of the invention, R_1 of formula (II) is a C_4 alkyl. In a further embodiment of the invention, R_1 of formula (II) is a C_5 alkyl. In a further embodiment of the invention, R_1 of formula (II) is a C_6 alkyl.

Any of the aforementioned R_1 groups may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl). Said C_1-C_6 alkyl and/or the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond.

Specifically, R_1 is C_1-C_6 alkyl substituted with substituent R_7 selected from the group consisting of F, CF_3, C_1-C_4 alkoxy and C_3-C_8 cycloalkyl. More specifically, R_1 is selected from the group consisting of –CH_2OCH_3, -$CH_2CH_2OCH_3$ and –CH_2-cyclopropyl.

In another embodiment of the invention, R_2 of formula (II) is C_1-C_{12} alkyl. In another embodiment of the invention, R_2 of formula (II) is C_1-C_{12} alkoxyalkyl. In a further embodiment, R_2 is aryl. In another embodiment, R_2 is -(C_1-C_4 alkylene)aryl. In a further embodiment of the invention, R_2 is a 3- to 8-membered cycloalkyl. In another embodiment of the invention, R_2 is a –(C_1-C_6 alkylene)cycloalkyl.

Optionally, if the R_2 group is aryl or –(C_1-C_4 alkylene)alkyl said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl,

benzimidazolyl, indolyl, oxadiazolyl or benzoxazolyl. More specifically, R_2 is oxadiazolyl.

Optionally, if the R_2 group is a 3- to 8-membered cycloalkyl or a –(C_1-C_6 alkylene)cycloalkyl, one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C_1-C_6 alkylene)cycloalkyl having at least 4 ring members may be replaced by an oxygen or sulfur atom or by N-R_8 wherein R_8 is hydrogen or C_1-C_4 alkyl.

Each of the aforementioned R_2 groups may be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Alternatively, each of the aforementioned R_2 groups may be substituted with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -O-CO-(C_1-C_6 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl), and -SO_2(C_1-C_4 alkyl). Optionally, said C_1-C_{12} alkyl and/or the C_1-C_4 alkylene moiety of said -(C_1-C_4 alkylene)aryl may contain one carbon-carbon double or triple bond.

In a specific embodiment of the invention, R_2 is aryl substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Optionally, R_2 is aryl substituted with one substituent selected from chloro, fluoro and C_1-C_4 alkyl. More specifically, R_2 is oxadiazolyl substituted with one substituent independently selected from chloro, fluoro, C_1-C_4 alkyl, CF_3 and cyclopropyl. Even more specifically, R_2 is oxadiazolyl substituted with methyl.

In another embodiment of the invention, X_2 is –NHCHR_1R_2, wherein R_1 is C_1-C_6 alkyl which may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_6 alkyl and the (C_1-


C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond and R_2 is oxadiazolyl substituted with methyl. Optionally, X_2 is $-NHCR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl.

In another embodiment of the invention, X_2 is $-NR_1R_2$ which forms a 5- to 8-membered ring. In a further embodiment of the invention, X_2 is $-CR_1R_2R_9$ which forms a saturated 5- to 8-membered ring. The ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ optionally contains one or two carbon-carbon double bonds. Alternatively or additionally, one or two of the ring carbons may be replaced by an oxygen, nitrogen or sulfur atom.


In a specific embodiment, $-NR_1R_2$ forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by an oxygen, nitrogen or sulfur atom. Optionally, $-NR_1R_2$ forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom. More specifically, the 5-membered ring formed by $-NR_1R_2$ is a pyrazol-1-yl. Alternatively, $-NR_1R_2$ forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a sulfur atom.

The above described 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ may be substituted with at least one substituent selected from C_1-C_4 alkyl or with a 4-8 membered ring. In one embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with one substituent selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with two substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with three substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with four substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring.

Said 4-8 membered ring may be saturated or may contain one to three double bonds. Optionally, the 4-8 membered ring is saturated. Additionally, one carbon atom of said 4-8 membered ring may be replaced by CO. Alternatively, one carbon atom of said 4-8 membered ring may be replaced by SO_2. Alternatively or additionally, one to four carbon atom(s) of the 4-8 membered ring may be replaced by nitrogen. Optionally, two carbon atoms are replaced by nitrogen. More specifically, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by CO. Alternatively, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by SO_2. In a specific embodiment of the invention, the above described 5- to 8-membered ring formed by $-NR_1R_2$ is substituted with



Optionally, X_2 is



In an alternative embodiment, the 4-8 membered ring contains one to three double bonds. Optionally, the 4-8 membered ring contains two double bonds. Additionally, one carbon atom of the 4-8 membered ring may be replaced by nitrogen and one carbon atom may be replaced by sulfur. Optionally, the above described ring is a 5-membered ring. In a specific embodiment of the invention, the above described 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with thiazol. Optionally, X_2 is a 5-membered ring formed by $-NR_1R_2$ containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom and wherein said 5-membered ring is substituted with thiazol.

In a specific embodiment of the invention, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with at least one C_1-C_4 alkyl. In another embodiment, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with two C_1-C_4 alkyl substituents. In another embodiment, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom is substituted with three C_1-C_4 alkyl substituents. Optionally, X_2 is 3,5-dialkylpyrazol-1-yl, such as 3,5-diethylpyrazol-1-yl.

A further embodiment of the invention encompasses CRHR1 antagonists of formula (II) as defined above, wherein X_3 is NH, O, NCH_3, or N, whereby if X_3 is N, X_3 and R_4 form a 5-membered ring substituted at X_3 with R_5. Specifically, X_3 of formula (II) as defined above is N and X_3 and R_4 form a 5-membered ring substituted at X_3 with R_5. More specifically, X_3 of formula (II) as defined above is N and X_3 and R_4 form a 5-membered ring substituted at X_3 with R_5, wherein X_3 and R_4 form a group –N-CH_2CH_2-. Alternatively, X_3 is O or NH, more specifically X_3 is O.

In another embodiment of the invention, the CRHR1 antagonist is a compound of formula (II) as defined above, wherein R_5 is phenyl substituted with from one to three substituents independently selected from fluoro, chloro, C_1-C_6 alkyl and C_1-C_6 alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, (C_1-C_6 alkyl)O(C_1-C_6)alkyl, -$NHCH_3$, -$N(CH_3)_2$, -COOH, -COO(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), -SO_2NH(C_1-C_4 alkyl), -SO_2N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -SO_2NH_2, -$NHSO_2$(C_1-C_4 alkyl), -S(C_1-C_6 alkyl) and SO_2(C_1-C_6 alkyl). The C_1-C_4 alkyl and the C_1-C_6 alkyl moieties of the foregoing R_5 groups may be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl.

In an embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (II) as defined above, wherein R_5 is phenyl substituted with from one to three substituent(s) independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl,

F, CF_3. In a specific embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (II) as defined above, wherein R_5 is phenyl substituted with one substituent independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, CF_3. In another embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (II) as defined above, wherein R_5 is phenyl substituted with two substituents independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, CF_3. In another embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (II) as defined above, wherein R_5 is phenyl substituted with three substituents independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, CF_3.


In a specific embodiment of the CRHR1 antagonist of the invention, R_5 is phenyl substituted with two substituents, wherein the two substituents are CH_3 and OCH_3.

In another specific embodiment of the CRHR1 antagonist of the invention, R_5 is phenyl substituted with three substituents, wherein the three substituents are CH_3.

In another specific embodiment of the CRHR1 antagonist of the invention, the three substituents of said phenyl are independently selected from CH_3 and Cl.

Specifically, R_5 is 2-chloro-4-methoxy-5-methyl-phenyl, 2,4,6-trimethyl-phenyl, 2,4,6-trichloro-phenyl, 4-methoxy-2-methyl-phenyl, 2,4-dichloro-phenyl, 4-chloro-2,6-dimethyl-phenyl, 2,4-dimethyl-phenyl, or 2,4-dimethoxy-phenyl. More specifically R_5 is 2,4,6-trimethyl-phenyl or 4-chloro-2,6-dimethyl-phenyl. Even more specifically, R_5 is 4-chloro-2,6-dimethyl-phenyl.

In another specific embodiment of the invention the CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having CRH overactivity is a compound of formula (III)



(III),

wherein X_2, R_1, R_2 und R_5-R_{10} are as defined for formulas (I) and (II) above.

A further embodiment of the invention relates to a CRHR1 antagonist of formula (III) as defined above, wherein X_2 is selected from the group consisting of –$NHCHR_1R_2$, $-OCHR_1R_2$ or $-NR_1R_2$.

In a specific embodiment, X_2 is $–NHCHR_1R_2$. In another specific embodiment, X_2 is $–OCHR_1R_2$. In a further specific embodiment, X_2 is $–NR_1R_2$.

If X_2 is $–NHCHR_1R_2$, it is optionally selected from the group consisting of -$NHCH(CH_2OCH_3)_2$, $-NHCH(CH_2OCH_3)(CH_2CH_3)$, $-NHCH(CH_2CH_3)_2$, -$NHCH(CH_2CH_2OCH_3)_2$, $-NHCH(CH_3)(CH_2CH_3)$ or $-NHCHR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl, isopropyl, cyclopropyl, trifluoromethyl, or ethyl. More specifically, X_2 is $-NHCH(CH_2CH_3)_2$. Alternatively, X_2 is $-NHCHR_1R_2$ wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl. Alternatively, X_2 is $–NHCH(CH_2CH_2OCH_3)_2$. Alternatively, X_2 is –$NHCH(CH_2OCH_3)_2$. Alternatively, X_2 is $–NHCH(CH_3)(CH_2CH_3)$. More specifically, X_2 is



Alternatively, if X_2 is $–NR_1R_2$, it is optionally selected from the group consisting of -$N(CH_2CH_3)(CH_3)$, $-N(CH_2CH_2CH_3)_2$, $-N(CH_2CH_2CH_3)(CH_2$-cyclopropyl), -$N(CH_2CH_3)(CH_2CH_2CH_2CH_3)$, $-N(CH_2CH_2OCH_3)_2$, or -$N(CH_2CH_2OCH_3)(CH_2CH_2CH_3)$. More specifically, X_2 is $–N(CH_2OCH_3)_2$. Alternatively, X_2 is $-N(CH_2CH_2OCH_3)_2$.

If X_2 is -$OCHR_1R_2$, it is optionally selected from –$OCH(CH_2CH_3)_2$, –$OCH(CH_2CH_3)CH_3$, –$OCH(CH_2CH_3)(CH_2CH_2CH_3)$, or –$OCH(CH_2CH_3)(CH_2OCH_3)$. More specifically, X_2 is –$OCH(CH_2CH_3)_2$.

Further CRHR1 antagonists for use according to the invention may encompass compounds of formula (III) as defined above wherein R_1 is C_1-C_6 alkyl.

In another embodiment of the invention, R_1 of formula (III) is a C_1 alkyl. In a further embodiment of the invention, R_1 of formula (III) is a C_2 alkyl. In a further embodiment of the invention, R_1 of formula (III) is a C_3 alkyl. In a further embodiment of the invention, R_1 of formula (III) is a C_4 alkyl. In a further embodiment of the invention, R_1 of formula (III) is a C_5 alkyl. In a further embodiment of the invention, R_1 of formula (III) is a C_6 alkyl.

Any of the aforementioned R_1 groups may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl). Said C_1-C_6 alkyl and the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond.

Specifically, R_1 is C_1-C_6 alkyl substituted with substituent R_7 selected from the group consisting of F, CF_3, C_1-C_4 alkoxy and C_3-C_8 cycloalkyl. More specifically, R_1 is selected from the group consisting of –CH_2OCH_3, -$CH_2CH_2OCH_3$ and –CH_2-cyclopropyl.

In another embodiment of the invention, R_2 of formula (III) is C_1-C_{12} alkyl. In another embodiment of the invention, R_2 of formula (III) is C_1-C_{12} alkoxyalkyl. In a further embodiment, R_2 is aryl. In another embodiment, R_2 is -(C_1-C_4 alkylene)aryl.

In a further embodiment of the invention, R_2 is a 3- to 8-membered cycloalkyl. In another embodiment of the invention, R_2 is a –(C_1-C_6 alkylene)cycloalkyl.

Optionally, if the R_2 group is aryl or –(C_1-C_4 alkylene)alkyl, said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, oxadiazolyl or benzoxazolyl. More specifically, R_2 is oxadiazolyl.

Optionally, if the R_2 group is a 3- to 8-membered cycloalkyl or a –(C_1-C_6 alkylene)cycloalkyl, one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C_1-C_6 alkylene)cycloalkyl having at least 4 ring members may be replaced by an oxygen or sulfur atom or by N-R_8 wherein R_8 is hydrogen or C_1-C_4 alkyl.

Each of the aforementioned R_2 groups may be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Alternatively, each of the aforementioned R_2 groups may be substituted with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -O-CO-(C_1-C_6 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl), and -SO_2(C_1-C_4 alkyl). Optionally, said C_1-C_{12} alkyl and/or the C_1-C_4 alkylene moiety of said -(C_1-C_4 alkylene)aryl may contain one carbon-carbon double or triple bond.

In a specific embodiment of the invention, R_2 is aryl substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Optionally, R_2 is aryl substituted with one substituent selected from chloro, fluoro and C_1-C_4 alkyl. More specifically, R_2 is oxadiazolyl substituted with one substituent independently selected from chloro, fluoro, C_1-C_4 alkyl, CF_3 and cyclopropyl. Even more specifically, R_2 is oxadiazolyl substituted with methyl.

In another embodiment of the invention, X_2 is –NHCHR_1R_2, wherein R_1 is C_1-C_6 alkyl which may optionally be substituted with one or two substituents R_7

independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_6 alkyl and the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond and R_2 is oxadiazolyl substituted with methyl. Optionally, X_2 is –NHCR_1R_2, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl.

In another embodiment of the invention, X_2 is -NR_1R_2 which forms a 5- to 8-membered ring. In a further embodiment of the invention, X_2 is –C$R_1R_2R_9$ which forms a saturated 5- to 8-membered ring. The ring formed by -NR_1R_2 or –C$R_1R_2R_9$ optionally contains one or two carbon-carbon double bonds. Alternatively or additionally, one or two of the ring carbons may be replaced by an oxygen, nitrogen or sulfur atom.


In a specific embodiment, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by an oxygen, nitrogen or sulfur atom. Optionally, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom. More specifically, the 5-membered ring formed by –NR_1R_2 is a pyrazol-1-yl. Alternatively, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a sulfur atom.

The above described 5- to 8-membered ring formed by –NR_1R_2 or –C$R_1R_2R_9$ may be substituted with at least one substituent selected from C_1-C_4 alkyl or with a 4-8 membered ring.

In one embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –C$R_1R_2R_9$ is substituted with one substituent selected from C_1-C_4 alkyl or a 4-8


membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with two substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with three substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with four substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring.

Said 4-8 membered ring may be saturated or may contain one to three double bonds. Optionally, the 4-8 membered ring is saturated. Additionally, one carbon atom of said 4-8 membered ring may be replaced by CO. Alternatively, one carbon atom of said 4-8 membered ring may be replaced by SO_2. Alternatively or additionally, one to four carbon atom(s) of the 4-8 membered ring may be replaced by nitrogen. Optionally, two carbon atoms are replaced by nitrogen. More specifically, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by CO. Alternatively, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by SO_2. In a specific embodiment of the invention, the above described 5- to 8-membered ring formed by $-NR_1R_2$ is substituted with



.

Optionally, X_2 is



.

In an alternative embodiment, the 4-8 membered ring contains one to three double bonds. Optionally, the 4-8 membered ring contains two double bonds. Additionally, one carbon atom of the 4-8 membered ring may be replaced by nitrogen and one

carbon atom may be replaced by sulfur. Optionally, the above described ring is a 5-membered ring. In a specific embodiment of the invention, the above described 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with thiazol. Optionally, X_2 is a 5-membered ring formed by $-NR_1R_2$ containing two double bonds, wherein one of the ring carbons is replaced by a nitrogen atom and wherein said 5-membered ring is substituted with thiazol.

In a specific embodiment of the invention, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with at least one C_1-C_4 alkyl. In another embodiment, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with two C_1-C_4 alkyl substituents. In another embodiment, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with three C_1-C_4 alkyl substituents. Optionally, X_2 is 3,5-dialkylpyrazol-1-yl, such as 3,5-diethylpyrazol-1-yl.

In another embodiment of the invention, the CRHR1 antagonist is a compound of formula (III) as defined above, wherein R_5 is phenyl substituted with from one to three substituents independently selected from fluoro, chloro, C_1-C_6 alkyl and C_1-C_6 alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, (C_1-C_6 alkyl)O(C_1-C_6)alkyl, $-NHCH_3$, $-N(CH_3)_2$, -COOH, -COO(C_1-C_4 alkyl), -CO(C_1-C_4 alkyl), $-SO_2NH$(C_1-C_4 alkyl), $-SO_2N$(C_1-C_4 alkyl)(C_1-C_2 alkyl), $-SO_2NH_2$, $-NHSO_2$(C_1-C_4 alkyl), -S(C_1-C_6 alkyl) and SO_2(C_1-C_6 alkyl). The C_1-C_4 alkyl and the C_1-C_6 alkyl moieties of the foregoing R_5 groups may be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl.

In an embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (III) as defined above, wherein R_5 is phenyl substituted with from one to three substituent(s) independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, and CF_3. In a specific embodiment of the invention, the CRHR1 antagonist

encompasses a compound of formula (III) as defined above, wherein R_5 is phenyl substituted with one substituent independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, and CF_3. In another embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (III) as defined above, wherein R_5 is phenyl substituted with two substituents independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, and CF_3. In another embodiment of the invention, the CRHR1 antagonist encompasses a compound of formula (III) as defined above, wherein R_5 is phenyl substituted with three substituents independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, and CF_3.


In a specific embodiment of the CRHR1 antagonist of the invention, R_5 is phenyl substituted with two substituents, wherein the two substituents are CH_3 and OCH_3.

In another specific embodiment of the CRHR1 antagonist of the invention, R_5 is phenyl substituted with three substituents, wherein the three substituents are CH_3.

In another specific embodiment of the CRHR1 antagonist of the invention, the three substituents of said phenyl are independently selected from CH_3 and Cl.

Specifically, R_5 is 2-chloro-4-methoxy-5-methyl-phenyl, 2,4,6-trimethyl-phenyl, 2,4,6-trichloro-phenyl, 4-methoxy-2-methyl-phenyl, 2,4-dichloro-phenyl, 4-chloro-2,6-dimethyl-phenyl, 2,4-dimethyl-phenyl or, 2,4-dimethoxy-phenyl. More specifically, R_5 is 2,4,6-trimethyl-phenyl or 4-chloro-2,6-dimethyl-phenyl. Even more specifically, R_5 is 4-chloro-2,6-dimethyl-phenyl.

Another specific embodiment of the invention relates to a CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having CRH overactivity, wherein the CRHR1 antagonist is a compound of formula (IV)




(IV),

wherein X_2, R_1, R_2, R_7, R_8, R_9 and R_{10} are as defined above for formulas (I) to (III).

A further embodiment of the invention relates to a CRHR1 antagonist of formula (IV) as defined above, wherein X_2 is selected from the group consisting of –$NHCHR_1R_2$, $-OCHR_1R_2$ or $-NR_1R_2$.

In a specific embodiment, X_2 is $–NHCHR_1R_2$. In another specific embodiment, X_2 is $–OCHR_1R_2$. In a further specific embodiment, X_2 is $–NR_1R_2$.

If X_2 is $–NHCHR_1R_2$, it is optionally selected from the group consisting of -$NHCH(CH_2OCH_3)_2$, $-NHCH(CH_2OCH_3)(CH_2CH_3)$, $-NHCH(CH_2CH_3)_2$, $NHCH(CH_2CH_2OCH_3)_2$, $-NHCH(CH)_3(CH_2CH_3)$ or $-NHCHR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl, isopropyl, cyclopropyl, trifluoromethyl, or ethyl. More specifically, X_2 is $-NHCH(CH_2CH_3)_2$. Alternatively, X_2 is $-NHCHR_1R_2$ wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl. Alternatively, X_2 is $-NHCH(CH_2CH_2OCH_3)_2$. Alternatively, X_2 is $-NHCH(CH_2OCH_3)_2$. Alternatively, X_2 is $–NHCH(CH_3)(CH_2CH_3)$. More specifically, X_2 is



Alternatively, if X_2 is $–NR_1R_2$, it is optionally selected from the group consisting of -$N(CH_2CH_3)(CH_3)$, $-N(CH_2CH_2CH_3)_2$, $-N(CH_2CH_2CH_3)(CH_2$-cyclopropyl), -

$N(CH_2CH_3)(CH_2CH_2CH_2CH_3)$, $-N(CH_2CH_2OCH_3)_2$, or $-N(CH_2CH_2OCH_3)(CH_2CH_2CH_3)$. Alternatively, X_2 is $-N(CH_2CH_2OCH_3)_2$.

If X_2 is $-OCHR_1R_2$, it is optionally selected from $-OCH(CH_2CH_3)_2$, $-OCH(CH_2CH_3)CH_3$, $-OCH(CH_2CH_3)(CH_2CH_2CH_3)$ or $-OCH(CH_2CH_3)(CH_2OCH_3)$. More specifically, X_2 is $-OCH(CH_2CH_3)_2$.

Further CRHR1 antagonists for use according to the invention encompass compounds of formula (IV) as defined above wherein R_1 is C_1-C_6 alkyl.

In another embodiment of the invention, R_1 of formula (IV) is a C_1 alkyl. In a further embodiment of the invention, R_1 of formula (IV) is a C_2 alkyl. In a further embodiment of the invention, R_1 of formula (IV) is a C_3 alkyl. In a further embodiment of the invention, R_1 of formula (IV) is a C_4 alkyl. In a further embodiment of the invention, R_1 of formula (IV) is a C_5 alkyl. In a further embodiment of the invention, R_1 of formula (IV) is a C_6 alkyl.

Any of the aforementioned R_1 groups may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl). Said C_1-C_6 alkyl and the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond.

Specifically, R_1 is C_1-C_6 alkyl substituted with substituent R_7 selected from the group consisting of F, CF_3, C_1-C_4 alkoxy and C_3-C_8 cycloalkyl. More specifically, R_1 is selected from the group consisting of $-CH_2OCH_3$, $-CH_2CH_2OCH_3$ and $-CH_2$-cyclopropyl.

In another embodiment of the invention, R_2 of formula (IV) is C_1-C_{12} alkyl. In another embodiment of the invention, R_2 of formula (IV) is C_1-C_{12} alkoxyalkyl. In a further embodiment, R_2 is aryl. In another embodiment, R_2 is -(C_1-C_4 alkylene)aryl. In a further embodiment of the invention, R_2 is a 3- to 8-membered cycloalkyl. In another embodiment of the invention, R_2 is a –(C_1-C_6 alkylene)cycloalkyl.

Optionally, if the R_2 group is aryl or –(C_1-C_4 alkylene)alkyl said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, oxadiazolyl or benzoxazolyl. More specifically, R_2 is oxadiazolyl.

Optionally, if the R_2 group is a 3- to 8-membered cycloalkyl or a –(C_1-C_6 alkylene)cycloalkyl, one or two of the ring carbons of said cycloalkyl having at least 4 ring members and/or the cycloalkyl moiety of said -(C_1-C_6 alkylene)cycloalkyl having at least 4 ring members may be replaced by an oxygen or sulfur atom or by N-R_8 wherein R_8 is hydrogen or C_1-C_4 alkyl.

Each of the aforementioned R_2 groups may be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Alternatively, each of the aforementioned R_2 groups may be substituted with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -O-CO-(C_1-C_6 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl), and -SO_2(C_1-C_4 alkyl). Optionally, said C_1-C_{12} alkyl and/or the C_1-C_4 alkylene moiety of said -(C_1-C_4 alkylene)aryl may contain one carbon-carbon double or triple bond.

In a specific embodiment of the invention, R_2 is aryl substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Optionally, R_2 is aryl substituted with one substituent selected from chloro, fluoro and C_1-C_4 alkyl. More specifically, R_2 is oxadiazolyl substituted with one substituent independently selected from chloro, fluoro, C_1-C_4 alkyl, CF_3 and cyclopropyl. Even more specifically, R_2 is oxadiazolyl substituted with methyl.

In another embodiment of the invention, X_2 is $-NHCHR_1R_2$, wherein R_1 is C_1-C_6 alkyl which may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_6 alkyl and/or the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond and R_2 is oxadiazolyl substituted with methyl. Optionally, X_2 is $-NHCR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl.


In another embodiment of the invention, X_2 is $-NR_1R_2$ which forms a 5- to 8-membered ring. In a further embodiment of the invention, X_2 is $-CR_1R_2R_9$ which forms a saturated 5- to 8-membered ring. The ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ optionally contains one or two carbon-carbon double bonds. Alternatively or additionally, one or two of the ring carbons may be replaced by an oxygen, nitrogen or sulfur atom.

In a specific embodiment, $-NR_1R_2$ forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by an oxygen, nitrogen or sulfur atom. Optionally, $-NR_1R_2$ forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom. More specifically, the 5-membered ring formed by $-NR_1R_2$ is a pyrazol-1-yl. Alternatively, $-NR_1R_2$ forms a 5-membered ring containing two double bonds, wherein one of the ring carbons is replaced by a sulfur atom.

The above described 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ may be substituted with at least one substituent selected from C_1-C_4 alkyl or with a 4-8 membered ring. In one embodiment of the invention, the 5- to 8-membered ring


formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with one substituent selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with two substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with three substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with four substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring.

Said 4-8 membered ring may be saturated or may contain one to three double bonds. Optionally, the 4-8 membered ring is saturated. Additionally, one carbon atom of said 4-8 membered ring may be replaced by CO. Alternatively, one carbon atom of said 4-8 membered ring may be replaced by SO_2. Alternatively or additionally, one to four carbon atom(s) of the 4-8 membered ring may be replaced by nitrogen. Optionally, two carbon atoms are replaced by nitrogen. More specifically, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by CO. Alternatively, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by SO_2. In a specific embodiment of the invention the above described 5- to 8-membered ring formed by $-NR_1R_2$ is substituted with



.

Optionally, X_2 is




.

In an alternative embodiment, the 4-8 membered ring contains one to three double bonds. Optionally, the 4-8 membered ring contains two double bonds. Additionally,

one carbon atom of the 4-8 membered ring may be replaced by nitrogen and one carbon atom may be replaced by sulfur. Optionally, the above described ring is a 5-membered ring. In a specific embodiment of the invention, the above described 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with thiazol. Optionally, X_2 is a 5-membered ring formed by $-NR_1R_2$ containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom and wherein said 5-membered ring is substituted with thiazol.

In a specific embodiment of the invention, the 5-membered ring formed by $-NR_1R_2$,containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with at least one C_1-C_4 alkyl. In another embodiment, the 5-membered ring formed by $-NR_1R_2$, containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom, is substituted with two C_1-C_4 alkyl substituents. In another embodiment, the 5-membered ring formed by $-NR_1R_2$,containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom is substituted with three C_1-C_4 alkyl substituents. Optionally, X_2 is 3,5-dialkylpyrazol-1-yl, such as 3,5-diethylpyrazol-1-yl.

In another specific embodiment of the invention, the CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having CRH overactivity is a compound of formula (V)




(V)

or a pharmaceutically acceptable salt thereof, wherein X_2, R_1, R_2, R_7, R_8, R_9 and R_{10} are as defined for formulas (I)-(IV) above.

A further embodiment of the invention relates to a CRHR1 antagonist of formula (V) as defined above, wherein X_2 is selected from the group consisting of $–NHCHR_1R_2$, $-OCHR_1R_2$ or $-NR_1R_2$.

In a specific embodiment, X_2 is $–NHCHR_1R_2$. In another specific embodiment, X_2 is $–OCHR_1R_2$. In a further specific embodiment, X_2 is $–NR_1R_2$.

If X_2 is $–NHCHR_1R_2$, it is optionally selected from the group consisting of $-NHCH(CH_2OCH_3)_2$, $-NHCH(CH_2OCH_3)(CH_2CH_3)$, $-NHCH(CH_2CH_3)_2$, $NHCH(CH_2CH_2OCH_3)_2$, $-NHCH(CH_3)(CH_2CH_3)$ or $-NHCHR_1R_2$ wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl, isopropyl, cyclopropyl, trifluoromethyl, or ethyl. More specifically, X_2 is $-NHCH(CH_2CH_3)_2$. Alternatively, X_2 is $-NHCHR_1R_2$ wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl. Alternatively, X_2 is $–NHCH(CH_2CH_2OCH_3)_2$. Alternatively, X_2 is $-NHCH(CH_2OCH_3)_2$. Alternatively, X_2 is $–NHCH(CH_3)(CH_2CH_3)$. More specifically, X_2 is



Alternatively, if X_2 is $–NR_1R_2$, it is optionally selected from the group consisting of $-N(CH_2CH_3)(CH_3)$, $-N(CH_2CH_2CH_3)_2$, $-N(CH_2CH_2CH_3)(CH_2$-cyclopropyl), $-N(CH_2CH_3)(CH_2CH_2CH_2CH_3)$, $-N(CH_2CH_2OCH_3)_2$, or $-N(CH_2CH_2OCH_3)(CH_2CH_2CH_3)$. Alternatively, X_2 is $–N(CH_2CH_2OCH_3)_2$.

If X_2 is $-OCHR_1R_2$, it is optionally selected from $–OCH(CH_2CH_3)_2$, $–OCH(CH_2CH_3)CH_3$, $–OCH(CH_2CH_3)(CH_2CH_2CH_3)$ or $–OCH(CH_2CH_3)(CH_2OCH_3)$. More specifically, X_2 is $–OCH(CH_2CH_3)_2$.

Further CRHR1 antagonists for use according to the invention encompass compounds of formula (V) as defined above wherein R_1 is C_1-C_6 alkyl.

In another embodiment of the invention, R_1 of formula (V) is a C_1 alkyl. In a further embodiment of the invention, R_1 of formula (V) is a C_2 alkyl. In a further embodiment of the invention, R_1 of formula (V) is a C_3 alkyl. In a further embodiment of the invention, R_1 of formula (V) is a C_4 alkyl. In a further embodiment of the invention, R_1 of formula (V) is a C_5 alkyl. In a further embodiment of the invention, R_1 of formula (V) is a C_6 alkyl.

Any of the aforementioned R_1 groups may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl). Said C_1-C_6 alkyl and the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond.

Specifically, R_1 is C_1-C_6 alkyl substituted with substituent R_7 selected from the group consisting of F, CF_3, C_1-C_4 alkoxy and C_3-C_8 cycloalkyl. More specifically, R_1 is selected from the group consisting of –CH_2OCH_3, -$CH_2CH_2OCH_3$ and –CH_2-cyclopropyl.

In another embodiment of the invention, R_2 of formula (V) is C_1-C_{12} alkyl. In another embodiment of the invention, R_2 of formula (V) is C_1-C_{12} alkoxyalkyl. In a further embodiment, R_2 is aryl. In another embodiment, R_2 is -(C_1-C_4 alkylene)aryl. In a further embodiment of the invention, R_2 is a 3- to 8-membered cycloalkyl. In another embodiment of the invention, R_2 is a –(C_1-C_6 alkylene)cycloalkyl.

Optionally, if the R_2 group is aryl or –(C_1-C_4 alkylene)alkyl, said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl,

benzimidazolyl, indolyl, oxadiazolyl or benzoxazolyl. More specifically, R_2 is oxadiazolyl.

Optionally, if the R_2 group is a 3- to 8-membered cycloalkyl or a –(C_1-C_6 alkylene)cycloalkyl, one or two of the ring carbons of said cycloalkyl having at least 4 ring members and/or the cycloalkyl moiety of said -(C_1-C_6 alkylene)cycloalkyl having at least 4 ring members may be replaced by an oxygen or sulfur atom or by N-R_8 wherein R_8 is hydrogen or C_1-C_4 alkyl.

Each of the aforementioned R_2 groups may be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Alternatively each of the aforementioned R_2 groups may be substituted with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -O-CO-(C_1-C_6 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl), and -SO_2(C_1-C_4 alkyl). Optionally, said C_1-C_{12} alkyl and/or the C_1-C_4 alkylene moiety of said -(C_1-C_4 alkylene)aryl may contain one carbon-carbon double or triple bond.

In a specific embodiment of the invention, R_2 is aryl substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl. Optionally, R_2 is aryl substituted with one substituent selected from chloro, fluoro and C_1-C_4 alkyl. More specifically, R_2 is oxadiazolyl substituted with one substituent independently selected from chloro, fluoro, C_1-C_4 alkyl, CF_3 and cyclopropyl. Even more specifically, R_2 is oxadiazolyl substituted with methyl.

In another embodiment of the invention, X_2 is –NHCHR_1R_2, wherein R_1 is C_1-C_6 alkyl which may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl), -COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl) and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_6 alkyl and/or the


(C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond and R_2 is oxadiazolyl substituted with methyl. Optionally, X_2 is –NHCHR_1R_2, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl.

In another embodiment of the invention, X_2 is -NR_1R_2 which forms a 5- to 8-membered ring. In a further embodiment of the invention, X_2 is –C$R_1R_2R_9$ which forms a saturated 5- to 8-membered ring. The ring formed by -NR_1R_2 or –C$R_1R_2R_9$ optionally contains one or two carbon-carbon double bonds. Alternatively or additionally, one or two of the ring carbons may be replaced by an oxygen, nitrogen or sulfur atom.


In a specific embodiment, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by an oxygen, nitrogen or sulfur atom. Optionally, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom. More specifically, the 5-membered ring formed by –NR_1R_2 is a pyrazol-1-yl. Alternatively, -NR_1R_2 forms a 5-membered ring containing two double bonds, wherein one of the rings carbons is replaced by a sulfur atom.

The above described 5- to 8-membered ring formed by –NR_1R_2 or –C$R_1R_2R_9$ may be substituted with at least one substituent selected from C_1-C_4 alkyl or with a 4-8 membered ring. In one embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –C$R_1R_2R_9$ is substituted with one substituent selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –C$R_1R_2R_9$ is substituted with two substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –C$R_1R_2R_9$ is substituted with three substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring. In another embodiment of the invention, the 5- to 8-membered ring formed by –NR_1R_2 or –C$R_1R_2R_9$ is substituted with four substituents independently selected from C_1-C_4 alkyl or a 4-8 membered ring.

Said 4-8 membered ring may be saturated or may contain one to three double bonds. Optionally, the 4-8 membered ring is saturated. Additionally, one carbon atom of said 4-8 membered ring may be replaced by CO. Alternatively, one carbon atom of said 4-8 membered ring may be replaced by SO_2. Alternatively or additionally, one to four carbon atom(s) of the 4-8 membered ring may be replaced by nitrogen. Optionally, two carbon atoms are replaced by nitrogen. More specifically, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by CO. Alternatively, two carbon atoms of the 4-8 membered ring are replaced by nitrogen and one carbon atom is replaced by SO_2. In a specific embodiment of the invention the above described 5- to 8-membered ring formed by $-NR_1R_2$ is substituted with




Optionally, X_2 is



In an alternative embodiment, the 4-8 membered ring contains one to three double bonds. Optionally, the 4-8 membered ring contains two double bonds. Additionally, one carbon atom of the 4-8 membered ring may be replaced by nitrogen and one carbon atom may be replaced by sulfur. Optionally, the above described ring is a 5 membered ring. In a specific embodiment of the invention, the above described 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with thiazol. Optionally, X_2 is a 5-membered ring formed by $-NR_1R_2$ containing two double bonds, wherein one of the rings carbons is replaced by a nitrogen atom and wherein said 5-membered ring is substituted with thiazol.

In a specific embodiment of the invention, the 5-membered ring formed by $-NR_1R_2$ containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom is substituted with at least one C_1-C_4 alkyl. In another embodiment, the 5-membered ring formed by $-NR_1R_2$ containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom is substituted with two C_1-C_4 alkyl substituents. In another embodiment, the 5-membered ring formed by $-NR_1R_2$ containing two double bonds and wherein one carbon atom is replaced by a nitrogen atom is substituted with three C_1-C_4 alkyl substituents. Optionally, X_2 is 3,5-Dialkylpyrazol-1-yl, more specifically 3,5-Diethylpyrazol-1-yl.

In another specific embodiment of the invention the CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having CRH overactivity is a compound of formula (VI)



(VI)

or a pharmaceutically acceptable salt thereof, wherein
X_4 is O or NH.

In another embodiment of the invention, the CRHR1 antagonist is selected from the group consisting of CP154,526, Antalarmin, CRA 5626, Emicerfont, DMP-696, DMP-904, DMP-695, SC-241, BMS-561388, Pexacerfont, R121919, NBI30545, PD-171729, Verucerfont, NBI34041, NBI35965, SN003, CRA0450, SSR125543A, CP-316,311, CP-376,395, NBI-27914, ONO-2333Ms, NBI-34101, PF-572778, GSK561579 and GSK586529.




In a particular embodiment of the invention, the CRHR1 antagonist is DMP-696.





In a particular embodiment of the invention, the CRHR1 antagonist is CP-316,311.





In a particular embodiment of the invention, the CRHR1 antagonist is SSR125543A





The corresponding structural formulas of some of the above-mentioned CRHR1 antagonists for use in the present invention are set out in Table 1 below:




Table 1



Structural formula	CRHR1 antagonist (name)
	R = H **CP154,526** R = CH_3 **Antalarmin**
	**CRA5626 / R317573 / JNJ19567470 / TAI-041**
	**GW876008 /Emicerfont**

Structural formula	CRHR1 antagonist (name)
	**DMP-696**
	**DMP-904**
	**DMP-695**
	**SC-241 / LWH-234**

Structural formula	CRHR1 antagonist (name)
	**BMS-561388**
	**BMS-562086 / Pexacerfont**
	**R121919 / NBI30775**
	**NBI30545**

Structural formula	CRHR1 antagonist (name)
	**PD-171729**
	**GSK561679 / NBI-77860 / Verucerfont**
	**SB-723620 / NBI34041**
	**NBI35965**

Structural formula	CRHR1 antagonist (name)
	**SN003**
	**CRA0450 / R278995**
	**SSR125543A**

Structural formula	CRHR1 antagonist (name)
	X = O **CP-316,311** X = NH **CP-376,395**
	**NBI-27914**

ONO-2333Ms, NBI 34101, PF-572778, GSK561579 and GSK586529 are described by Zorilla and Koob (Drug Discovery Today, 2010, 371-383) as corticotropin releasing factor receptor antagonists (corticotropin releasing factor is a synonym for CRHR1 antagonists) tested in clinical trials.

In another aspect of the invention, the above-described CRHR1 antagonists are for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having CRH overactivity, wherein CRH overactivity is detected by determining the status of a marker indicative for CRH overactivity.

In one embodiment, the marker indicative for CRH overactivity is selected from the group consisting of a biomarker, a set of biomarkers and a clinical marker.

The one or more biomarkers may be obtained by a genome-wide screening for single nucleotide polymorphisms in patients with depressive and/or anxiety symptoms.

For example, the biomarker or set of biomarkers constituting a marker for CRH activity may be selected from one or more biomarkers of the group comprising:

- SNP rs6437726,
- SNP rs1986684,
- SNP rs7380830,
- SNP rs3903768,
- SNP rs7325978,
- SNP rs13585,
- SNP rs9368373,
- SNP rs10935354,
- SNP rs8095703,
- SNP rs10206851,
- SNP rs9542977,
- SNP rs4942879,
- SNP rs9542954,
- SNP rs1593478,
- SNP rs9542951,
- SNP rs2188534,
- SNP rs12524124,
- SNP rs4352629,
- SNP rs7448716,
- SNP rs11873533,
- SNP rs10062658,
- SNP rs12547917,
- SNP rs1038268,
- SNP rs2375811,
- SNP rs1352671,
- SNP rs364331,
- SNP rs1924949,

- SNP rs11025990,
- SNP rs3758562,
- SNP rs10156056.

In particular, the biomarker or set of biomarkers constituting a marker for CRH activity may be selected from one or more biomarkers of the group comprising:

- SNP rs6437726 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 1, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs1986684 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 2, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs7380830 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 3, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs3903768 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 4, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs7325978 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 5, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs13585 which is represented by a single polymorphic change at position 185 of SEQ ID NO: 6, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9368373 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 7, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs10935354 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 8, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,

- SNP rs8095703 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 9, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs10206851 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 10, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9542977 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 11, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs4942879 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 12, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs9542954 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 13, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs1593478 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 14, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9542951which is represented by a single polymorphic change at position 201 of SEQ ID NO: 15, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs2188534 which is represented by a single polymorphic change at position 200 of SEQ ID NO: 16, wherein in one or two alleles the wild-type nucleotide G is replaced by indicator nucleotide T,
- SNP rs12524124 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 17, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs4352629 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 18, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,

- SNP rs7448716 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 19, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs11873533 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 20, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs10062658 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 21, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs12547917 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 22, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs1038268 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 23, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs2375811 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 24, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs1352671 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 25, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs364331 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 26, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs1924949 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 27, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs11025990 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 28, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,

- SNP rs3758562 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 29, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs10156056 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 30, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide G.

In a specific embodiment, the set of biomarkers comprises at least 15, at least 20, at least 25 or all of the following biomarkers:

- SNP rs6437726,
- SNP rs1986684,
- SNP rs7380830,
- SNP rs3903768,
- SNP rs7325978,
- SNP rs13585,
- SNP rs9368373,
- SNP rs10935354,
- SNP rs8095703,
- SNP rs10206851,
- SNP rs9542977,
- SNP rs4942879,
- SNP rs9542954,
- SNP rs1593478,
- SNP rs9542951,
- SNP rs2188534,
- SNP rs12524124,
- SNP rs4352629,
- SNP rs7448716,
- SNP rs11873533,
- SNP rs10062658,

- SNP rs12547917,
- SNP rs1038268,
- SNP rs2375811,
- SNP rs1352671,
- SNP rs364331,
- SNP rs1924949,
- SNP rs11025990,
- SNP rs3758562,
- SNP rs10156056.

In another specific embodiment, the set of biomarkers comprises at least 15, at least 20, at least 25 or all of the following biomarkers:

- SNP rs6437726 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 1, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs1986684 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 2, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs7380830 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 3, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs3903768 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 4, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs7325978 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 5, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs13585 which is represented by a single polymorphic change at position 185 of SEQ ID NO: 6, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,

- SNP rs9368373 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 7, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs10935354 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 8, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs8095703 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 9, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs10206851 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 10, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9542977 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 11, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs4942879 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 12, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs9542954 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 13, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs1593478 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 14, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9542951which is represented by a single polymorphic change at position 201 of SEQ ID NO: 15, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs2188534 which is represented by a single polymorphic change at position 200 of SEQ ID NO: 16, wherein in one or two alleles the wild-type nucleotide G is replaced by indicator nucleotide T,

- SNP rs12524124 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 17, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs4352629 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 18, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs7448716 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 19, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs11873533 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 20, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs10062658 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 21, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs12547917 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 22, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs1038268 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 23, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs2375811 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 24, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs1352671 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 25, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs364331 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 26, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,

- SNP rs1924949 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 27, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs11025990 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 28, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs3758562 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 29, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs10156056 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 30, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide G.

For example, the set of biomarkers consists of the following biomarkers:

- SNP rs6437726,
- SNP rs1986684,
- SNP rs7380830,
- SNP rs3903768,
- SNP rs7325978,
- SNP rs13585,
- SNP rs9368373,
- SNP rs10935354,
- SNP rs8095703,
- SNP rs10206851,
- SNP rs9542977,
- SNP rs4942879,
- SNP rs9542954,
- SNP rs1593478,
- SNP rs9542951,
- SNP rs2188534,

- SNP rs12524124,
- SNP rs4352629,
- SNP rs7448716,
- SNP rs11873533,
- SNP rs10062658,
- SNP rs12547917,
- SNP rs1038268,
- SNP rs2375811,
- SNP rs1352671,
- SNP rs364331,
- SNP rs1924949,
- SNP rs11025990,
- SNP rs3758562,
- SNP rs10156056.

In another example, the set of biomarkers consists of the following biomarkers:

- SNP rs6437726 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 1, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs1986684 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 2, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs7380830 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 3, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs3903768 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 4, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs7325978 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 5, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,

- SNP rs13585 which is represented by a single polymorphic change at position 185 of SEQ ID NO: 6, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9368373 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 7, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs10935354 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 8, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs8095703 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 9, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs10206851 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 10, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9542977 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 11, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs4942879 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 12, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs9542954 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 13, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs1593478 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 14, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9542951which is represented by a single polymorphic change at position 201 of SEQ ID NO: 15, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,

- SNP rs2188534 which is represented by a single polymorphic change at position 200 of SEQ ID NO: 16, wherein in one or two alleles the wild-type nucleotide G is replaced by indicator nucleotide T,
- SNP rs12524124 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 17, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs4352629 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 18, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs7448716 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 19, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs11873533 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 20, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs10062658 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 21, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs12547917 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 22, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs1038268 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 23, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs2375811 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 24, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs1352671 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 25, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,

- SNP rs364331 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 26, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs1924949 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 27, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs11025990 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 28, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs3758562 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 29, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs10156056 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 30, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide G.

The status of a marker indicative for CRH overactivity may be determined by a method comprising determining the status of a marker as defined herein in a nucleic acid isolated from a patient's sample, wherein the presence of indicator nucleotides as defined herein is indicative for CRH overactivity.

The term "biomarker", as used herein, relates to any nucleic acid sequence of any length, or a derivative thereof, which comprises a polymorphic variant as defined in:

- SNP rs6437726,
- SNP rs1986684,
- SNP rs7380830,
- SNP rs3903768,
- SNP rs7325978,
- SNP rs13585,
- SNP rs9368373,
- SNP rs10935354,
- SNP rs8095703,
- SNP rs10206851,
- SNP rs9542977,
- SNP rs4942879,
- SNP rs9542954,
- SNP rs1593478,
- SNP rs9542951,
- SNP rs2188534,
- SNP rs12524124,
- SNP rs4352629,
- SNP rs7448716,
- SNP rs11873533,
- SNP rs10062658,
- SNP rs12547917,
- SNP rs1038268,
- SNP rs2375811,
- SNP rs1352671,
- SNP rs364331,
- SNP rs1924949,

- SNP rs11025990,
- SNP rs3758562, and/or
- SNP rs10156056.

A biomarker may, for instance, be represented by a nucleic acid molecule of a length of e.g. 1 nt, 2 nt, 3 nt, 4 nt, 5 nt, 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 60 nt, 70 nt, 80 nt, 90 nt, 100 nt, 200 nt, 300 nt, 400 nt, 500 nt, 1000 nt, 2000 nt, or more or any length in between these lengths. The representing nucleic acid may be any suitable nucleic acid molecule, e.g. a DNA molecule, e.g. a genomic DNA molecule or a cDNA molecule, or a RNA molecule, or a derivative thereof. The biomarker may further be represented by translated forms of the nucleic acid, e.g. a peptide or protein as long as the polymorphic modification leads to a corresponding modification of the peptide or protein. Corresponding information may be readily available to the skilled person from databases such as the NCBI SNP repository and NCBI Genbank.

The SNPs as described herein may be present on the Watson or the Crick strand, with presence of the corresponding base. I.e. if, for example, a polymorphism is present on the Watson strand as A, it is present on the Crick strand as T, if the polymorphism is present on the Watson strand as T, it is present on the Crick strand as A, if the polymorphism is present on the Watson strand as G, it is present on the Crick strand as C, and if the polymorphism is present on the Watson strand as C, it is present on the Crick strand as G, and vice versa. Also the insertion or deletion of bases may be detected on the Watson and/or the Crick strand, with correspondence as defined above. For analytic purposes the strand identity may be defined, or fixed, or may be choose at will, e.g. in dependence on factors such the availability of binding elements, GC- content etc. Furthermore, for the sake of accuracy, the SNP may be defined on both strands (Crick and Watson) at the same time, and accordingly be analyzed.

A "polymorphic site" or “polymorphic variant” as used herein relates to the position of a polymorphism or SNP as described herein within the genome or portion of a

genome of a subject, or within a genetic element derived from the genome or portion of a genome of a subject.

The term "wildtype sequence" as used herein refers to the sequence of an allele, which does not show the CRH overactivity phenotype according to the present invention. The term may further refer to the sequence of the non phenotype-associated allele with the highest prevalence within a population, e.g. within a Caucasian population.

The term "indicator sequence" as used herein refers to the sequence of an allele, which shows an association with a CRH overactivity phenotype according to the present invention. The term "indicator nucleotide" as used herein refers to the identity of the nucleotide at the position of a SNP or polymorphic site as defined herein, associated with a CRH overactivity phenotype according to the present invention. The term may refer to a non-wildtype nucleotide at positions of SEQ ID NO: 1 to 30 as described below:

- SNP rs6437726 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 1, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs1986684 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 2, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs7380830 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 3, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs3903768 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 4, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,

- SNP rs7325978 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 5, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs13585 which is represented by a single polymorphic change at position 185 of SEQ ID NO: 6, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9368373 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 7, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs10935354 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 8, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs8095703 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 9, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs10206851 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 10, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs9542977 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 11, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs4942879 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 12, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs9542954 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 13, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs1593478 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 14, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,

- SNP rs9542951 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 15, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs2188534 which is represented by a single polymorphic change at position 200 of SEQ ID NO: 16, wherein in one or two alleles the wild-type nucleotide G is replaced by indicator nucleotide T,
- SNP rs12524124 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 17, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs4352629 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 18, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs7448716 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 19, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs11873533 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 20, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs10062658 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 21, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs12547917 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 22, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs1038268 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 23, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide T,
- SNP rs2375811 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 24, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,

- SNP rs1352671 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 25, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs364331 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 26, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide C,
- SNP rs1924949 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 27, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs11025990 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 28, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs3758562 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 29, wherein in one or two alleles the wild-type nucleotide A is replaced by indicator nucleotide G,
- SNP rs10156056 which is represented by a single polymorphic change at position 201 of SEQ ID NO: 30, wherein in one or two alleles the wild-type nucleotide C is replaced by indicator nucleotide G.

The term "determining the status of a biomarker" or determining the status of a marker" as used herein refers to any suitable method or technique of detecting the identity of an SNP, e.g. at the positions of the biomarkers described herein. The determination method may be a sequencing technique or a technique based on complementary nucleic acid binding. The context of the indicated positions, as well as the strand may differ, e.g. from patient to patient, or from sample to sample etc.

The term "allele" or "allelic sequence" as used herein refers to a particular form of a gene or a particular nucleotide, e.g. a DNA sequence at a specific chromosomal location or locus. In certain embodiments of the present invention a SNP as defined herein may be found at or on one of two alleles in the human genome of a single subject. In further, specific embodiments, a SNP as defined herein may also be found

at or on both alleles in the human genome of a single subject. The presence of an indicator nucleotide or an indicator triplet as defined herein on both alleles may have a higher predictive value than the presence of an indicator nucleotide or an indicator triplet on one allele only, the other allele comprising a wildtype genotype. The presence or absence of indicator nucleotides or indicator triplets on one or two alleles may be connected or linked with an algorithm for predicting the a treatment response to CRHR1 antagonists in patients with depressive symptoms and/or anxiety symptoms as described herein.

A person skilled in the art would be able to derive the exact position, nucleotide sequence, and indicator sequence from the above identified rs-nomenclature, e.g. from suitable database entries and associated information systems, e.g. the Single Nucleotide Polymorphism database (dbSNP) which is incorporated herein by reference. The information may also be retrievable in case of changes to the nomenclature, or to the surrounding sequence elements, e.g. based on history functions of a suitable database.

The term "isolated nucleic acid molecule" a used herein refers to a nucleic acid entity, e.g. DNA, RNA etc, wherein the entity is substantially free of other biological molecules, such as, proteins, lipids, carbohydrates, other nucleic acids or other material, such as cellular debris and growth media. Generally, the term "isolated" is not intended to refer to the complete absence of such material, or to the absence of water, buffers, or salts, unless they are present in amounts which substantially interfere with the methods of the present invention.

In another embodiment, the biomarker constituting a marker for CRH overactivity is REM density.

Such a marker or set of markers or combination of markers as described above may be used for predicting a treatment response to CRH antagonists in patients with depressive and/anxiety symptoms.

Exemplary embodiments for determining the status of a marker indicative for CRH overactivity are described below.

In particular, it has been found that a treatment response to CRH antagonists in patients with depressive symptoms and/or anxiety symptoms can be reliably predicted by using a machine-learning based prediction algorithm derived from the association of SNPs with values indicative for CRH overactivity.

The term "treatment response to CRHR1 antagonists in patients with depressive symptoms and/or anxiety symptoms" in the sense of the invention refers to a response in a patient with depressive symptoms and/or anxiety symptoms during and/or after the treatment with one or more CRHR1 antagonists compared to before the treatment. The response may range from a partial alleviation of the symptoms to a complete remission of the symptoms, indicated by the change of symptoms strength and/or frequency of relapse of individual symptoms and/or the mean change on a depression scale, e.g. as described herein. The response can occur shortly after treatment or after a certain time period. A decrease in symptom severity from pre-treatment of 25% or more is usually considered a partial alleviation of symptoms. Remission may be defined as achieving a value of 8 or less on the Hamilton Depression Rating Scale (HAM-D) or equivalent values on other rating scales named below.

A further aspect concerns the provision of an algorithm for predicting a treatment response to CRHR1 antagonists in patients with depressive symptoms and/or anxiety symptoms. The method may comprise the following steps:

(a) performing a single nucleotide polymorphism (SNP) genotyping analysis in a group of patients with depressive symptoms and/or anxiety symptoms;

(b) determining a value indicative for CRH activity in each patient of the group, wherein a value indicative for CRH overactivity is indicative or predictive for a patient responding to a treatment with a CRH1 antagonist;

(c) identifying at least one SNP associated with a value indicative for CRH overactivity as determined in step (b);

(d) determining the algorithm by machine-learning from the association of the at least one SNP identified in step (c) with the value indicative for CRH overactivity.

In a step (a), a single nucleotide polymorphism (SNP) genotyping analysis in a group of patients with depressive symptoms and/or anxiety symptoms is performed.

A "group of patients" as used herein comprises at least two patients, such as at least 10 patients, or at least 100 patients, or at least 150 patients. Patients included in the analysis of step (a) may exhibit at least a moderate to severe depressive mode. The group of patients may comprise patients with CRH overactivity and/or patients with normal CRH activity.

The term "polymorphism" as used herein refers to a variation in the genome of individuals, including, insertions, deletions, point mutations and translocations.

The term "single nucleotide polymorphism" is well understood by the skilled person and refers to a point mutation at a certain position in the nucleotide sequence. In other words, only one nucleotide differs in a certain region.

The nucleotide, that is present in the majority of the population, is also referred to as wild-type allele or major allele. As used herein, this state is defined as "absence of a SNP".

The specific nucleotide that is present in the minority of the population is also referred as the point mutation, mutated nucleotide or minor allele. As used herein this state is defined as "presence of a SNP".

In theory, the wild-type allele could be mutated to three different nucleotides. However, the event of a mutation to a first nucleotide in the reproductive cells of an individual that gets established in a population occurs very rarely. The event that the same position is mutated to a second nucleotide and established in the population virtually never occurs and can be therefore neglected. Therefore, as used herein, a

certain nucleotide position in the genome of an individual can have two states, the wild-type state (absence of a SNP) and the mutated state (presence of a SNP).

The term "single nucleotide polymorphism (SNP) genotyping analysis" as used herein refers to a test of determining in one or several patients the presence or absence of at least one SNP, typically several SNPs, and in some embodiments all (known) SNPs the human genome, including endogenous and exogenous regions. In particular, a SNP genotyping analysis as used herein may not be limited to the CRHR1 gene or to genes of the CRH pathway. In other words, an SNP genotyping analysis as used herein can be a genome-wide screening for SNPs.

SNP genotyping analysis can be performed by methods known in the art such as microarray analysis or sequencing analysis or PCR related methods or mass spectrometry or 5'-nuclease assays or allele specific hybridization or high-throughput variants of these techniques or combinations thereof. These and other methods are known in the art. See for example Rampal, DNA Arrays: Methods and Protocols (Methods in Molecular Biology) 2010; Graham & Hill, DNA Sequencing Protocols (Methods in Molecular Biology) 2001; Schuster, Nat. Methods, 2008 and Brenner, Nat. Biotech., 2000; Mardis, Annu Rev Genomics Hum Genet., 2008. Genomewide arrays can be purchased from different suppliers such as Illumia and Affymetix.

For example, the determination of the nucleotide sequence and/or molecular structure may be carried out through allele-specific oligonucleotide (ASO)-dot blot analysis, primer extension assays, iPLEX SNP genotyping, Dynamic allele-specific hybridization (DASH) genotyping, the use of molecular beacons, tetra primer ARMS PCR, a flap endonuclease invader assay, an oligonucleotide ligase assay, PCR-single strand conformation polymorphism (SSCP) analysis, quantitative real-time PCR assay, SNP microarray based analysis, restriction enzyme fragment length polymorphism (RFLP) analysis, targeted resequencing analysis and/or whole genome sequencing analysis.

In some embodiments, any of the methods described herein comprises the determination of the haplotype for two copies of the chromosome comprising the SNPs identified herein.

A "subject's sample" as used herein may be any sample derived from any suitable part or portion of a subject's body. In some embodiments, blood or saliva samples are used. The sample used in the context of the present invention should be collected in a clinically acceptable manner, in particular in a way that nucleic acids and/or proteins are preserved.

The term “primer” may denote an oligonucleotide that acts as an initiation point of nucleotide synthesis under conditions in which synthesis of a primer extension product complementary to a nucleic acid strand is induced.

The term “probe” may denote an oligonucleotide that selectively hybridizes to a target nucleic acid under suitable conditions.

The primers and probes may be generated such that they are able to discriminate between wild-type allele or mutated allele of the position of a SNP to be analyzed. Methods for the design of sequence specific primers and probes are known in the art (see e.g. William B. Coleman, Gregory J. Tsongalis, Molecular Diagnostics: For the Clinical Laboratorian, 2007; Weiner *et al.* Genetic Variation: A Laboratory Manual, 2010).

Typically, a SNP is considered in the genotyping analysis if it occurs in a certain percentage in the population, for example in at least 5 % or at least 10% of the population. In other words, the minor allele frequency (MAF) is larger than 0.05 or 0.10 (MAF > 0.05 or MAF > 0.10).

For the SNP genotyping analysis a nucleic acid or DNA sample from a subject or patient may be used. The nucleic acid or DNA sample can be a blood sample, a hair sample, a skin sample or a salvia sample of the patient. Any other sample obtainable

from the patient and containing patient nucleic acid or DNA can also be used. The sample can be collected from the patient by any method known in the art. For example, a blood sample can be taken from a patient by use of a sterile needle. The collection of salvia out of the mouth and throat of the patient can be performed by use of a sterile cotton bud or by flushing said area and collecting the flushing solution.

Usually, the nucleic acid or DNA is extracted or isolated or purified from the sample prior to SNP genotyping analysis. Any method known in the art may be used for DNA extraction or purification. Suitable methods comprise *inter alia* steps such as centrifugation steps, precipitation steps, chromatography steps, dialyzing steps, heating steps, cooling steps and/or denaturation steps. For some embodiments, a certain nucleic acid or DNA content in the sample may be reached. Nucleic acid or DNA content can be measured for example via UV spectrometry as described in the literature. However, in alternative embodiments SNP genotyping analysis may also be performed by using a non-extracted or non-purified sample.

DNA amplification may also be useful prior to the SNP analysis step. Any method known in the art can be used for DNA amplification. The sample can thus be provided in a concentration and solution appropriate for the SNP analysis.

The analyzed SNPs may be represented by values 0, 1 or 2. The value "0" may indicate that the SNP is present on none of the two homologous chromosomes. The value "1" may indicate that the SNP is present on one of the two homologous chromosomes. The value "2" may indicate that the SNP is present on both homologous chromosomes. Homologous chromosomes correspond to each other in terms of chromosome length, gene loci and staining pattern. One is inherited from the mother, the other is inherited from the father.

In a step (b) of the method for providing a prediction algorithm, a value indicative for CRH activity in each patient is determined.

Steps (c) and (d) of the method for providing a prediction algorithm may analyze the association of the analyzed SNPs with the value indicative for CRH overactivity and/or normal CRH activity and generate an algorithm for predicting the treatment response to CRHR1 antagonists.

In an exemplary embodiment, the group of patients may be split into two sets of similar size and similar values for descriptors such as demographic descriptors or clinical descriptors. These two sets are hereinafter also referred to as "training set" and "test set".

In step (c) of the method of this exemplary embodiment, at least one SNP associated with the value indicative for CRH overactivity as determined in step (b) is identified in the training set.

Further, there can be at least two alternatives for the result provided by the prediction algorithm. First, the result may be a categorical answer whether the patient responds to CRHR1 antagonist treatment or not. Second, the prediction algorithm may provide the answer to which degree the patient responds or does not respond to the treatment. Depending on the desired result provided by the prediction algorithm the way of determining the algorithm may differ.

In the alternative that the prediction algorithm will analyze whether a patient responds or does not respond to CRHR1 antagonist treatment, the values indicative for CRH activity may be provided as logic data variable (Boolean type; 0 vs. 1; true vs. false, high vs. low responder). Therefore, if the test performed to determine values indicative for CRH overactivity provides a data range, the patients may be dichotomized by a threshold into high vs. low responders.

In the alternative that the test will analyze to which degree the patient responds or does not respond to the CRHR1 antagonist treatment, the values indicative for CRH activity may be provided as numerical values.

Typically, SNPs that are modified in a significant percentage of the population are used in the method for providing a prediction algorithm. For example, only SNPs with a minor allele frequency (MAF) greater than 0.05 or 0.10 may be selected for further analysis. This means that only SNPs that are modified in at least 5 % or 10% of the population are selected for further analysis.

Association for all SNPs with the value indicative for CRH activity is tested by an association analysis testing the likelihood for a patient to be CRH overactive vs. CRH non-overactive in dependence of the genotype of said patient. Said association analysis may be conducted for example by an additive genetic model and/or by a logistic regression. A SNP is e.g. identified to be associated with a value indicative for CRH overactivity if the corresponding p-value is at least 1 x 10^{-3} or at least 1 x 10^{-4} or at least 1 x 10^{-5}. The lower the p-value the more the SNP is associated with a value indicative for CRH overactivity. Accordingly, a SNP is e.g. identified to be associated with a value indicative for normal CRH activity if the corresponding p-value is at least 1 x 10^{-3} or at least 1 x 10^{-4} or at least 1 x 10^{-5}.

In the step (d) of this exemplary embodiment, the algorithm for predicting a treatment response to CRHR1 antagonists may be determined by the use of SNPs in the test set by a machine learning method.

The term “algorithm for predicting” as used herein may refer to a classification function (also known as binary classification test).

The term “machine-learning” as used herein may refer to a method known to the person skilled in the art of machine learning. In particular, machine learning is concerned with the design and development of algorithms that allow computers to evolve behaviors based on empirical data, such as from sensor data or databases. It may be selected from the group consisting of artificial neural network learning, decision tree learning, support vector machine learning, Bayesian network learning, clustering, and regression analysis.

The term "reliable prediction of the treatment response to CRHR1 antagonists" as used herein may refer to a high performance of the prediction algorithm. The evaluation of the performance of the prediction algorithm may depend on the problem the algorithm is applied for. If the algorithm is used to identify patients that are likely to response to the treatment with CRHR1 antagonists the performance is usually expressed by a high accuracy and/or sensitivity and/or precision. If patients should be identified which are likely not to respond to the treatment with CRHR1 antagonists, specificity and/or negative predictive value are typical statistical measures to describe the performance of the prediction algorithm.

For optimizing the prediction performance of the algorithm, the step of determining the algorithm by a machine-learning method in a first subset of the test set and testing the prediction performance in an second independent subset of the test set may be repeated based on different numbers and groups of SNPs, until the desired prediction performance is reached.

Accuracy, sensitivity, precision, specificity and negative predictive value are exemplary statistical measure of the performance of the prediction algorithm. In the following, examples are given for determining the performance of the prediction algorithm.

As used herein, accuracy may be calculated as (number of true positives + number of true negatives) / (number of true positives + number of false positives + number of true negatives + number of false negatives), e.g. (number of patients correctly diagnosed as responding to CRHR1 antagonist + number of patients correctly diagnosed as not responding to CRHR1 antagonist) / (number of patients correctly diagnosed as responding to CRHR1 antagonist + number of patients wrongly diagnosed as responding to CRHR1 antagonist + number of patients correctly diagnosed as not responding to CRHR1 antagonist + number of patients wrongly diagnosed as not responding to CRHR1 antagonist). The accuracy of prediction may e.g. be at least 60%, at least 70%, at least 80% or at least 90%.

A used herein, sensitivity may be calculated as (true positives) / (true positives + false negatives), e.g.: (number of patients correctly diagnosed as responding to CRHR1 antagonist) / (number of patients correctly diagnosed as responding to CRHR1 antagonist + number of patients wrongly diagnosed as not responding to CRHR1 antagonist). The sensitivity of prediction may be at least 60%, at least 70%, at least 80% or at least 90%.

As used herein, precision (also referred to as positive predictive value) may be calculated as (true positives) / (true positives + false positives), e.g.: (number of patients correctly diagnosed as responding to CRHR1 antagonist) / (number of patients correctly diagnosed as responding to CRHR1 antagonist + number of patients wrongly diagnosed as responding to CRHR1 antagonist). The precision of prediction may be at least 60%, at least 70%, at least 80% or at least 90%.

As used herein, specificity is calculated as (true negatives) / (true negatives + false positives), e.g.: (number of patients correctly diagnosed as not responding to CRHR1 antagonist) / (number of patients correctly diagnosed as not responding to CRHR1 antagonist + number of patients wrongly diagnosed as responding to CRHR1 antagonist). The specificity of prediction may be at least 60%, at least 70%, at least 80% or at least 90%.

As used herein, negative predictive value is calculated as (true negatives) / (true negatives + false negatives), e.g.: (number of patients correctly diagnosed as not responding to CRHR1 antagonist) / (number of patients correctly diagnosed as not responding to CRHR1 antagonist + number of patients wrongly diagnosed as not responding to CRHR1 antagonist). The negative predictive value may be at least 60%, at least 70%, at least 80% or at least 90%.

Other statistical measures useful for describing the performance of the prediction algorithm are geometric mean of sensitivity and specificity, geometric mean of positive predictive value and negative predictive value, F-measure and area under ROC curve, and the positive and negative likelihood ratios, the false discovery rate

and Matthews correlation coefficient. These measures and method for their determination are well known in the art.

In general, a prediction algorithm with high sensitivity may have low specificity and vice versa. The decision to select an algorithm having certain statistical characteristics such as accuracy, sensitivity or specificity may also depend on the costs associated with a treatment with a CRHR1 antagonist should the prediction be positive and/or whether such a treatment is detrimental in cases where the result is a false positive.

For a prediction whether a patient likely responds to the treatment with CRHR1 antagonists the prediction algorithm may be based on a number of SNPs sufficient to achieve a prediction sensitivity and/or precision of at least 55%, optionally at least 80%.

For the prediction whether it is unlikely that a patient responds to the treatment with CRHR1 antagonists the prediction algorithm may be based on a number of SNPs sufficient to achieve a prediction specificity and/or negative predictive value of at least 55%, optionally at least 80%.

For a prediction whether a patient responds to a treatment with CRHR1 antagonists or not the prediction algorithm may be based on a number of SNPs sufficient to achieve sensitivity and/or precision and/or specificity and/or negative predictive value of at least 55%, optionally at least 80%.

In one embodiment, a number N of SNPs is associated with a value indicative for CRH overactivity or normal CRH activity in step (d) of the method for providing an algorithm and/or the presence or absence of a number N of SNPs is determined in step (a) of the method for predicting a treatment response, wherein N is sufficient to provide an accuracy of at least 80% and a sensitivity of at least 70% and a specificity of at least 70%. In another embodiment, a number N of SNPs is associated with a value indicative for CRH overactivity in step (d) of the method for providing an

algorithm and/or the presence or absence of a number N of SNPs is determined in step (a) of the method for predicting a treatment response, wherein N is sufficient to provide an accuracy of at least 85% and a sensitivity of at least 80% and a specificity of at least 80%.

Typically, at least 10, at least 20, at least 25 or at least 30 SNPs are used for determination of the algorithm in step (d) of the method for providing a prediction algorithm.

The skilled person in the art knows that the use of different machine-learning methods and adapting parameters used therein can be also used for improvement of the prediction reliability. The whole statistical work-flow can be automated by a computer.

Another aspect is a method for predicting a treatment response to CRHR1 antagonists in patients with depressive symptoms and/or anxiety symptoms, wherein the method may comprise the following steps:

(a) determining in a nucleic acid sample obtained from a patient the presence or absence of at least one single nucleotide polymorphism (SNP) associated with a value indicative for CRH overactivity;

(b) predicting the treatment response to CRHR1 antagonists by linking the prediction algorithm provided by the method described above with the presence or absence of the at least one SNP determined in step (a).

"Linking an algorithm for predicting a treatment response to CRHR1 antagonists in patients having depressive symptoms and/or anxiety symptoms with the presence or absence of the at least one SNP" as used herein may refer to using such an algorithm to predict the treatment response based on the determined presence or absence of the at least one SNP, e.g. by integrating the at least one SNP determined in step (a) of the above method by the algorithm.

In one embodiment the method comprises a further step of obtaining a nucleic acid

sample from a patient preceding the step of SNP determination.

In one embodiment of the method for predicting a treatment response to CRHR1 antagonists in patients with depressive symptoms and/or anxiety symptoms, step (a) comprises determining at least one of the SNPs, optionally all of the SNPs which were associated with a value indicative for CRH overactivity when determining the algorithm by machine-learning from this association.

Typically, a SNP is considered in the genotyping analysis of step (a) of the method of prediction if it occurs in a certain percentage in the population, for example in at least 5 % or at least 10% of the population. In other words, the minor allele frequency (MAF) is larger than 0.05 (MAF > 0.05) or 0.10 (MAF > 0.10).

For the SNP genotyping analysis of step (a) of the method of prediction, a nucleic acid or a DNA sample from a patient may be used. The nucleic acid or DNA sample can be a blood sample, a hair sample, a skin sample or a salvia sample of the patient. Any other sample of the patient containing nucleic acid or DNA can also be used. The sample can be collected from the patient by any method known in the art. For example, a blood sample can be taken from a patient by use of a sterile needle. The collection of salvia out of the mouth and throat of the patient can be performed by use of a sterile cotton bud or by flushing said area and collecting the flushing solution.

Usually, the nucleic acid or DNA is extracted or purified from the sample prior to SNP genotyping analysis. Any method known in the art may be used for DNA extraction or purification. Suitable methods comprise *inter alia* steps such as centrifugation steps, precipitation steps, chromatography steps, dialyzing steps, heating steps, cooling steps and/or denaturation steps. For some embodiments, a certain DNA content in the sample may be reached. Nucleic acid or DNA content can be measured for example via UV spectrometry as known in art. However, the SNP genotyping analysis may also be performed by using a non-extracted or non-purified sample.

Nucleic acid or DNA amplification may also be useful prior to the SNP analysis step. Any method known in the art can be used for DNA amplification. The sampled can thus be provided in a concentration and solution appropriate for the SNP analysis.

The analyzed SNPs may be represented by values 0, 1 or 2. The value "0" may indicate that the SNP is present on none of the two homologous chromosomes. The value "1" may indicate that the SNP is present on one of the two homologous chromosomes. The value "2" may indicate that the SNP is present on both homologous chromosomes. Homologous chromosomes correspond to each other in terms of chromosome length, gene loci and staining pattern. One is inherited from the mother, the other is inherited from the father.

In order to determine SNPs, SNP-specific primers and/or probes, a primer extension reaction, SNP microarrays, DNA-sequencing may be used. These reagents and methods are routinely used in the art (see for example Chen, PCR Cloning Protocols (Methods in Molecular Biology) 2002; Schuster, Nat. Methods, 2008, Rampal, DNA Arrays: Methods and Protocols (Methods in Molecular Biology) 2010; Brenner, Nat. Biotech., 2000; Mardis, Annu Rev Genomics Hum Genet., 2008). For example, MALDI-TOF (matrix-assisted laser desorption ionization time of flight) mass spectrometry on the Sequenom platform (San Diego, USA) may be used to genotype the selected variants. For primer selection, multiplexing and assay design, and the mass-extension for producing primer extension products the MassARRAY Assay Designer software may be used using the sequences presented in table 2 as input. The MassARRAY Typer 3.4 software may be used for genotype calling. Any other reagent or method known to the person skilled in the art may be used in order to detect the SNPs in an individual.

In one embodiment, at least one SNP determined in step (a) and used for the prediction algorithm of step (b) is a SNP selected from the group consisting of SNPs as shown in table 2 and an SNP in strong linkage disequilibrium with any of the SNPs shown in table 2.

Table 2: SNPs (together with flanking sequences) which may be used to predict the response to CRHR1 antagonists in patients with depressive symptoms and/or anxiety symptoms. The position of the SNP is indicated in bold as **[wild-type allele/mutated allele]**.

SNP_ID	SEQUENCE
RS6437726 SEQ ID NO. 1	CAAGAAAGAGAGTAATAAAAATAACCACAATGAGGGCTCTCATTAATACT GGATCTTATGGAAACCAATTGTTCAGTCCCTCAACAAAAGACCAGATGG GCAGGAAGCTAAATATACACCATGCACTAAACATTATGAGTATCATAGTT TACAAGTCAAAGGGGGCTCTATTGAAGATAGTTCTATTTTCCCTCTATAT T**[A/G]**TCTGCTAGACAATACCTGATAACATTATCCAAGTAAATGACAACTT GATAAATAGTAATTTCCAATGGTGAACAGAGGTGACATTTCCTCATTACA AAAATATTTTCTTTGGCAGATGAGATTAACTGAATAAGAAATCCACTGAC ACTGAAATCACAGAGCCAAATTCCCTATCACAGCACTTATCACATTGCGT TAGG
RS1986684 SEQ ID NO. 2	TTCCTTGTAGCGGGGAGAGAGACTCAGGGAAGGCAGGGTGATACCTGA GTTGGGGCTTAAAGCAAGGTAGGGTGTGTGTGGTGATGGCAAAATAGG TAGGAAGACAGCACGGGCAAAGTCCTGGAGGCAAGGACAGAAAGAGGA AGTGGCAGGAAGTGAGGCTGGGGAAATGAGTAGGGGTCAATCATGATG TTTCTGGT**[A/G]**TAGGGAAGAGTTTGGAATGCATCCTCTAGGCCATACGC CATTGGGGGCTTTTAAGAAAGACAGTGATGTTGGTTTGATTTGCATTTTA TATAGACTTTTCTGGCAGCTGAGAGGAAGGTGGTTTTGAGAATCACAAA GCTGCGGGAAGATCAGTCAGGAGGGTTCTAGAATAATCCAGGCAAGAG CTGATGGGGACTGAG
RS7380830 SEQ ID NO. 3	ACAGGGGTGGCTACTCTTTCTCCAGAAATAGGTGTCCTGTGGGGCATTT TGAAGTAGAATGTTGATAGTTGCTTTCAATTTTAGACTGGTAAATAAGAAT TGGGCATTTGAATTTCAATATACTCACTGTGTAACTGTTATTGAGTATGCT TTAAGTGACCTATAATACTGCTTCATTTAACTTTATTGTCCTAATAACT**[C/T]**TCTTAGAGTGACAATAACTTAGGTTAGCCACTTGCCTAGGGTTCTGAA ACCAAGTAAATGGTGGAGCTGGAATTGC**T**GTTCTTGTCAGTCATTAGACT AGATCGGTTTTCTTCTTCCTACAAATTTTATATACTAAAAAATTTTGAAAAA AGACATTT**T**TCTTTGGGAAAAATAGGGAATGTCAGATCCCTTTGGAGATG
RS3903768 SEQ ID NO. 4	CTCGCAGCAACCAAGCCTGCCCAAGCCGGGGAAACCTGGGGAGCAAAC CTTCACCTGCACTGTACATCAGAGACCAGTTGGCCCTATTTTGGCTCCT GTGGACAGGTAAGTATCCCTTTTGACTCATCCCCCAAATATCAGGTGAG CCAGGAAAATAAGGCCTTTGGCTTAGACAGTCAATTCAAAGTCTGCCAT AGCAT**[A/C]**CCTAATTACATCCCTATTGCCCCTTTTCTAGGTCGTTTCTCC TCTAACACGATTTTATTTTTCTGTCAGCCATTTTATTTTATTTCTCACCTTG AAATATATGTTTTCTTTGCAGTTTTTGCTTTGGCTTCCTGCTAACTCTATT TGGGCAATTGTTTAAGGCTGAACACTTGGTTATGAGAGGTACCCTGTTG TGTTGA
RS7325978 SEQ ID NO. 5	TCATCAAGTCTCCTTTTTCTCTAGGAAAAATAACATTGTCAAGGTTATTAA CAGTCAATAAGCTGTCATAGGCTCAGCATGGATGGGGATATTGGGTTTC CTTGTGCTTATATGAAAGATGGGAAAATCCGAAGTTCTTTTCACCCTGAT ATGGAAAATACCCAACATGAGGAGAAGCAGCAGCTATATGATTCTGAGC A**[C/T]**AGAATGGGAGTAAGAATAGGGTCATGCTGTACTGATTATCTGCTA ATAAAATGCAAAAGTGTTAGGTAATTTCATCAATATCCAGTTAATACTAAT ATAGTTAATATTTCATGACTGGGTAATATTTTATAATGATAAATATTTTTAT AGATCTTAGCTCTTTTTATTCTCATATCAACTGTATGAAATCAGTGATTGG T

SNP_ID	SEQUENCE
RS13585 SEQ ID NO. 6	CTGGGGACCTCAGGGAGAGGTACGCAGGTTGCCATGGCTGCGTCTGCA GTCCACCTGCCTTTCCACGCCAGGGAGTCAGTGATGTGGAGCCCCCTG GGCCCCAGTGGAAGCAGCGATCAGACTATGTGTCCTTGAAATAATGTTT ATTCCACGCTGTCCCGACAGCCCCCTCTGCAGGTCCCCT**[C/**T**]**GGTGTA CTCTGAGGTGGGAAACCCTCCCTGGGGGCGGTGAAGGGGAACTCGGG CCACCCCACCAGCCAGCAGATGCTCCAGCAGCCAGAGCCCCAGCCTGG AGCTGAGGCTCTTCCTGGGGCTCGCCGGGCCCCTGCAGGCTTTTCGGA CCCTCAGCCAGCCCGGCTTCCTCTGCTTTGGGCAGCAGCAAGCTGGCC CTT
RS9368373 SEQ ID NO. 7	TTCCTGTGCCTCAGCTCCTCTGTAGAATGGTGCTGGCAATACAGTTTGC CTCATTGGGCTCTTGTAAGCTTTAAATAGGTTATTATACATAAAGAGCTA ATAGTGATGCCTGTAGCCGTTGTCTAAGTGCTAGCTCTGATGATGGTGA CAAAGAAGTAATAGCAATCAGTGGTTTAGATTAAACCATTTTAGGCATAA AC**[C/**T**]**GTTCTGCTAGAATCCAAGGGGAGATTTTTTCCCATCAAGGAGAC ATAGCTTGTTGGGAAGATAAGACATACCCAATTGCAGAAGTAATTAATTA ATTCTTTTTTTTTTTTTTTTTTTTTTTTTTGCGATGGAGTTTCGCTCTTGTT GCCCAGGCTGGAGTGCAATAGCATGATCTCGGCTCACCACAACCTCTG CCTCCT
RS10935354 SEQ ID NO. 8	ATAGGCCCTATACAGCTCTCAATTTCTTTAATCAATCTTCCTAGCAGCCC GTGAGAAATATTACTGTCTTCAGCTTCCTAAAGGAGAAAACAGAGGCCT GGAGGGATTAAAAGACTTTTCTAAGATTTTAGAGGGCATGTTAGGGTTCA GGCCCAGGGCTGTCTAACCCAAGGCCTAATTCCTTCTATTACATCCATC AT**[A/G]**CATGAGTGAGCACTGGGCATGAGGATACGTCAGTGAAAGGGGC CCTGTAACATGGACCTTACATTTTGGCTGGGGGAGACAGGCAATGAATA CATAGGACCATGTTGGGAAGTGCTAAGTACTCTGATGATAACACAGCAG GGTGAGGTGACAGAGGTCTAGGGAGAGTGGTGTTCAGCAAAAACTTCT CTGGGGAGAGA
RS8095703 SEQ ID NO. 9	AAAATTTACCAGGTTTAAAAAAAAAAAAACTCAAATGATATTTCAGAAACC TACCCCTTTCAAAACAAGGAGGAGAAAAATCTTCTCCACAAAAGCACATA TTGAAAAAATATTTTGGGGGCAAGGCCTGAAAGGGTTGGCAGTGTGCAG TTCTGTTATTATTCCCGTGGCCATTTTATGGGCCTCAGCAAAACACTGGG **[A/G]**TCATTATCTGTCTTCTGGTTACTCCAGGAGAGCTAGCCATCACAAC CCAATGGAAGAGACTTCAGAGAAACCCACACAGGCACCAGAAGTCCTTC CCTTTCATCTGCCACTGTGGGGTTTTGTCCTCATCTATTACAATGTTGTC CAATCTCAGACTGCATTCAGAACAAAGGCTCTCAGACTGAGGATGAGTT CTTGGA
RS10206851 SEQ ID NO. 10	CCAAATAATTGTTATTGTTGTTTTAACATGGCAATCACGTTATTTGCCATA TGTGAAAAAGAATATTTAAAATGCTTTTTAAAACTATGTATGTAAAAGAAT GTTTAAATTGTTTTAAAAATATGTTATATCTACCTTGGCACCATCCTTGCT GTTGAGAAATGACTTTTACCTGCTTACTTAGAAGGAAATGTCAGAAG**[C/T]**AGAAGTACATTTGAATACGATTATTTGAAAGCTTCATCCATTTTTCAAAG AATGTATACAGTAACACTAAATAGAAAGCATAGTTTATCAACTCTTCACTA AGAACAGTCTAGCAAGTATATCAGAGTGGCTGTGGTTCCAGTTGGACTA ACCTAATCATTTATGAAAAGGTGATAATAAGCTTGGACCAAGAGCACCCA
RS9542977 SEQ ID NO. 11	CAGATGTTATGTGAAACTCTGGAGAAATAGTAGCAAGCAAGACTCACAT GCCTCCTGCCCTCACAGAGCTCCATGATCTGGTGAAAGTGCCAGATATT TAAACCCATGGATGTGTGCACACAAAATAACAATTCTCTCAAGCGTTGTG AAGAAAAGTCACAGAGCACTACAAAAGCATGTAAGAGTGAGGCAAAACC TAT**[C/T]**GTGTTAGGACAGGGAAGGCTTCTGTGAGCTAACCTGAAGGAT GAGTAGGGGTGAGCCAGATGAAAAGGCGAGAGAAAAACATTCTGAGCA GAGACTGCCACTGAGTGCATCCCAGTTTTCCCAACATCTTAACACTGTAT AATGACTACACTGGATTTTCTTCATCCTGGATCCATGGTTAGACATGTTA ATATGCCTTC

SNP_ID	SEQUENCE
RS4942879 SEQ ID NO. 12	CCCAGTCTGTGGTATTTTTTTATAGCAGCACAAACAGACTAACACAAGAG GTGGATAGGATTTGCGAGCATGGACCTTGGAGGTTTGTGGCCTCAATTT AAAGTGAGTACATTCACCCAGCTGGTGTTTTTCTCTTGCTGCTTGGGCA CAGAGATGGAGTAAATGGGTCTAATCAAGGATAAAGGGAGAGCCAAAGA GAT**[A/G]**GTAATATTTGAAAGGAAGTGTTTTTAATGATGTGCCATGTAATC TGAGCTGGGTCAGGAATGAAGTGAAAAACTAAGAGATGATGGATGATGA TAGGGGCTGTGAAAGGAAAACAAATCTTGGGGCCCCCAAATCACTAAGC TAAAGGAGAAAGTCAAGCTGGGAACTGTTTAGGGCAATCCTGCCTCCCA TTTTATTCA
RS9542954 SEQ ID NO. 13	TATTACTGCTGAGAAAACTGGGTTTGATAAACTAAAGATGCCCATGTATA TCAGTCATGCTCCTGGTGAGAACAGGTGGCTCACTGCATAATGAGAGGA ATATTCAATTAACTATTTACAAAGCTATGGATGACATGTAGGGAAGCCAC AGAGAGAGTACAGTATCTAGAGCTAGTAAGAGTAGAAGGCCATCACTGT CC**[A/C]**CAGGCCTAAAGGAGGTAGAGCAGTCAAAGGAAACAAGAGACAA GGGAGGCTGCGAGGACAGGGCCACCTGGCAGAGCCATAACCTTAAACT AGGTAGTCACTTCTTGGCAACTCTGCAGGTAGGGAGCCAACCTCACTTT TAACCCTCCCTCTGATGCCCAGCTGGTTTACCCCATTGGTGAAAATCAG TGGGTGAGGGA
RS1593478 SEQ ID NO. 14	CATGAAAAGATACTTAACATTGTAACATCTTTGCATTAGGGAACTGCAAA TCAAAATCATAACAAAATAGTACTGCATGCTCATTAGGATGACTATAATC CAAAAGAATAAAAAAGAAAATAACAGGTGTTGGTAGGGATACAGATATAG AGAAACTGGAGCTCTCATGCCTTGCTGGGGGGCATGTAAAATGATTCTG C**[C/T]**GCTTTGGAAAACAGTTTGGTGGTTCCTCAAAAAGTTAAACATATAA TCCAACAATTCCACCCAAAAGAATTGAAAGCAGGGTCTAGTACACCAAC GTTCATAGCAGCTTTATTCACATCAAGCCAAAGGTGGAAGCAGCCCAAA TGTCTACTGATGGATGAGTTGATACACAAAATGTGGTATATATATGCAAT GGAATA
RS9542951 SEQ ID NO. 15	GCCACTTGAATGCCCCAAAATGGAGAGATGGGCGTGGGAAGAGAAAGA CACCTCAGCAACACAGAGCTGAGAAAACACTGTGAGTTTTATTTAATTCC TACTTACCGTTATTTTGCATAGTAAACAAAAGGGATATTTTTGAAAATCCC TTTGGATAATTTCTGCCACCTAAAATTCTGAGCATTTTGACTCACTGCCTT **[A/G]**TAAAAAGAATCAATTAATTGAATAAGAGAAGGGATTCTCCCCTGAT CTTTTCAAGAATCCTTAAAAGGCACATTTCTCACTAAGGATCTTGAAAGT GTATTTCTAGCCAATCCCAGGAGTCACTGCTCAGAGATTTACATTTCACA AATGTAATCAACAGCCTAAGCAGAATATTGACGTTTGGACTGCAGAGCT CTGCT
RS2188534 SEQ ID NO. 16	AGGGTCCCCAAATATTTCCATTTGAGATGACAAAGTGCTCTTCAGTCATT TAGCTTACTCTTCAGTTCAGATGACTTATCATCTTGATTTCAGAGAGTTCA TATATGTCTGTTTTAAAAAACTGGTTCAAAAAGTCTGAAGTTACGAAACTA AACCAAATATGCATTACTCTCATGTCAAATTACAAGCTCTTAGCTGC**[G/T]** GGGATTTTTTCACATGCAGCCTGGAGCCCTTGAAAACCTCTGTTTTCTGT TAGACTCTCCAGGGTACACAGAAGTTGCCTCATTATTTTAGTTAATGGTG ACTGCAAATAAGCCCCCCAAGTCATTTAACTATGTGCTTACCACTGCTTT AAAAGAACCCCAAGTTAGGTCCTCATGTAGGTAAAGGAGCTCCCTTCAC A
RS12524124 SEQ ID NO. 17	ACTTGGGCCCAAAGGCATTCAACTAGAAAGCTGGTAATAATAACAGCGA CAGTTTATTGAGTCTTAGTGTTTCTGAGAACTTTTCTAAGTACTTTACACA TATTAAATTTTTAAATCTTCACATTAGTCCTGTGAGGAAGGTACTATTGTT ATGTCTGTATTACCCATGGGGATACTGACGCACAAAGAAGTCAAGTAAT**[A/G]**TATTTAAGATTCTAGTAAGTGCAGAGCCCAGGTGCATGCAGTGCCT GGGCTCTGCCACCCATGCAGTGCTGACTAGGGCTTCCACCCATGGATTT TTTTTTTTTTTTTTTTTTTTTGAGACAGAGTTTCGCTCTTGTTGCCCAGGC TGGAGTGCAATGGCATGATCTCGGCTCACCACAACCTCCGCCTCTCGG GTTCAA

SNP_ID	SEQUENCE
RS4352629 SEQ ID NO. 18	CCCATAATAATGAAGGATTGGACCTGATAATCTATCAGGTACATTTTAGC CTGAAATTTATTTGTACACACGCACAAACACAGACATGTGCACACACACA TACACATATATATATAACATTTATAAATTTTAAAACATAAAGCTATACTAGA AATGAAAGCTTATATATTGAACTGCCCCACCTTTCTATTTGCAGCCAG**[C/ T]**TACCACCCCAGTCTAATGTTTCACTTTATATAAATTCATTTATTCTTTTA CTCATTTCAAATATATGATGATGTAACTATAAAATCAACATTTAGTCACTC TGAATAACCCAAAATAGCAAATAATTTAAAAATCACTTCCACTTGACTTTA GAATCTATTACATGCATTGTTTTTCCAGAAAATTTACCTCATAATTAT
RS7448716 SEQ ID NO. 19	CTACTTATATGATTAGAGAACAAGAATACTAGGGGGAAAATCAGCATGCA TATAATCTAAGAAATTGTCATTATAATTTTAAAATCCTTTGCAAAATCAGTA AATATGAGTTTAACTTATATAATGATACACACACACACTGATATGATGCTT TATTGTCTAAACACTGGCTGCTTGTGGAGACGTATTCTGGTAACAAA**[A/G]**AATATAGCATCTTAAAATTGATGCTAGCATTGTATATCCAAATAGAGAGT AAATGCAACCAGAATATTTTTTATATGTTTAACATTGTAGTGTTGCTGACA TCATTATATATTTGGTTATGTTAATCTCAAAATGCACAATATAGCTGTATG ATCTGTATAATGCAAAAAAATGTAGAGCTTCATTTTGATATTTATTAT
RS11873533 SEQ ID NO. 20	CTGGAAGGGAACAATGGAAGAGGTGCATTAGTCACATTCCAAAATGCAG GAAGCAATAACATGTGGCACTATTGTCATTTATGTAGCACCCTAAATACT GGGACAAATGACATAGATGCCCTTCTGTGATTACTAAACTCCCCCACAG TGTCTCAGAAGGAAGAGCTTTTGACAGGAAATCATCAAGATCTGATGAC ATT**[A/C]**GAGAGCAATTAACATTCTCTTCAACCATGAACTAATTGCCTCAT TCACATTTTTCTAGCCATCCTAGGAAGCAGATAATAAGCAGCAATTGTCC TGCCCAGGAATTCTGACTTGTGTAATTTGTAAAGCTTTTCTTTGTATCTAT TTCTTTCCTGTGGCCATCTTTTTGTTTTTGGACTGTTTGGTAACAGTAAGT GGGT
RS10062658 SEQ ID NO. 21	ATCATTCAGTATTAAGAGAGAAATGAATACATTTTCAGATATACAAGAATT CAGTTTACCTCCCACAGAATCTCTGAAAAAAATATTAGATTACTATAGTTA AAAAGGAAAATAAAATAAGTCCTGTTAGAAATAATTGGTAAAAAAGCAAA GGTGATGAAAACTTATTGAAATATATTATTAAAGTAATTGTTAAAAAT**[A/G]** TACACTAAATCTAGAATATATAAATGTAGCAGTTGTTAAGGGGAAGGGGA AATAGAAGTGGAAGAAAATGAACATTAGAACAAATGTTTAGCAGTGGGAT TATTTTATTGGAAGTCTAATGTAAGAAGTATATTCTCCAGGGAGGTATTT CAAGGACATATGAATAGTAAAGGGATAATAAAACAACTCTATAAGGTAGT
RS12547917 SEQ ID NO. 22	CACACACAACGCTGGGCCCAGTAAATAAGTTTTGTTTTTTCCCAGGGAA AAGTTGAACAACAATGGTGAGACCAGGAAGGCTCTCCGTTCACAGGAAA TACTGTGTCACCGCTCGGCCGCAGGCTGTGTGAGGTCACGGGCGACGC TCGGGTCACGTGTGGCGGCTCCTGTTCACAGTGCCGTGTGTGATAAACT GGGAC**[C/T]**TTCTGGTGAGGGGAGACTGGCGGGGGGTGGGGAGGGCA AGGAGTGGGAAAGTCGCCTATAAATGTTTAACAAAAGATCCGCAATGGG AACAGGAACTTGCATTCTTTCTTTCAATGGACAAAGCTTCCACATCAAGA TACGCTTGTGTGCTGGGACCAAATGCCACAGTGCGGCGAAACTCGTGA GCACAAGTCCTGCGT
RS1038268 SEQ ID NO. 23	ACAACAGGGTATCCTAGCCCAGCAAAATTGACTCATAAATTTAATGATCA CGCAATTGGTAATTCTAAATCCAGTCAGAAGTCTACATTCTGTGTCCACA GTGTCATGTCTAGATGTTGGTCCAGTCTCCCATGGACTGTGCCTTGTTAT TTGTTTTCTCTTTGCTAAGCCACATCCCCTGAGGGCTCTGTTTATGCTCA**[C/T]**TGCAAAATCTTTGACTTTTTAACTTACTGGGCATATTGTCTTCCTACT TTTGTTCTCTTCTGTTATTTTATTTACTTGACTCTGACATGTCTCATTCCC

SNP_ID	SEQUENCE
RS2375811 SEQ ID NO. 24	TTTCAATGGGACTGGTTGGACAGTGGGTGCAGCCCATGAAGGGCAAGC CAAAGCAGGCCGGGGCATCACCTCACCCGGGAAGCACAAGGGGTCAG GCGATTTCTCTTTCCTAGTCAAGGGAAGCCATGGCAGACTGCACCTGGA AAAACGAGACACTTCCACCCAAATACTGCGTTTTTCGCAAGGTCTTAGCA ACTAAC**[A/G]**GACAAGGAGATTCTCTCCCGTGCCTGGCTCGGCTGGTCC CACACCCACGGTGACTTGTTCACTGCTAGCACAGCAGTTTGAGATCGAA CTACGAGGCAACAACCTGGCTAAGGGAGGGGCATCTGCCATTGCTGAG GCTTGAGTAGGTAAACAAAGTGGCCAGGAAGCTCGAACTGGGTGGAGC CCACTGCAGCTTAGCA
RS1352671 SEQ ID NO. 25	ACTTTAGGGACTTTGAGTGATGGACAACCCCCTATCAGATATCATCAGC CTGAAACATCCTTATCTTGGCATTAAATTAGAAGGAACCCCAGACCCTGC GTACCAGAATTGTTAGAATCACAGTCTCAGTAAAGAACCAACTCCTGATC ACTTCTCTAAAGGAAAGTTCTAGAAGTCTGCACACTCTGCAGTCACTTTC A**[A/C]**TTCTATCCAAGTGTACACTTAGAACTCTAGAAAACACTACGGACA GTCTTCAGCCAGGTAAAGCCTAAAACCAGCAAAGAACAGGGAGAGTGA GGGA
RS364331 SEQ ID NO. 26	CGGATTATCACAGTTCTCAAAAGAGGAGTATGCATTTGCTTGCTCCAATT CCTCTTCTTCTACACTCTCTTAAGCATTCCTCAACCAGTCTAATATCTCAT AGTTCCCCAAAACTGCTCTGTTCAAGACCATTAGTAAGATCTTTGATGTT AATCTGTGGACCGTATCTCTGTCCTTATTTTACTTGAAGCCCAACAGCA**[A/C]**ATAAAAAAGTTGTTCTCCTCTCCTCCCTGCTACACTTTCCTTATGTG GCTTGCTGGGCTCCTCAGTCCCCTGTGAAAAACTCTGACATGGAGATAC TGCAGACCAGTAGAAGGGCTGGGCAGACACTATACAGAAACAGTATGC CCTACATGCTCCTTGGCTAAATCTCTAGAATTTTTTTCAGAACTCATCCA CAAATT
RS1924949 SEQ ID NO. 27	ATTTTATCTCATTTACTTATTAAATCAAACCAATATTTTATGAAGTGATTCC AGTATTGGAATAAAAATGTAATTCTTTAATCATTAAAAAATCTTTATGAATA CCTTACATCAACTGTAGGGGACCAACCAGGGAAAAGCAGGGAGACTTG TAGAATCTACACCTCCAGAACAACCGACCTCCATCTTCTGGACAACTC**[A/ G]**TCTTCTAAAGTGCAGGACAGACTAGTTGGGGGAGAAAGGAGGAAATG AAAGAGATAGACTAAAAGGGAGGGAGAGAACAGATATTTTTTAAGTACC TGTTATGTTCTGGATACAGCACAGAGTACATTGTATCTATTATTATAAGG CATAAAGAAAGATTTCTCAGGTTTTTGGAGTCAGATTGCAATATAAAATA ATAG
RS11025990 SEQ ID NO. 28	TAACTTCAAATTGTTTTGCAAAATCTCTGTCATAAAAATGCTTACCAACAA ATACTGATACTAAATTTAGATGTGGGGGTATTAGTTATAATCCTGAAGTG GGAGGGGGAACTTCTTAATTCCAATTTAGTTCTAAGAGAAGGAAGAGTA TTTAGGCCCAGAGAAGGTTACGCTTAAAGGTCTGATAGTGTTTTCTTTGA **[A/G]**AAATATGTCTCAAACTAGAGAATAAAACTAATTATCTCATCTAAGTT ACCTAGAGACATTTATGCTCATCAGTTTGATAAAGGACTGCAAGTAGACA CAGAAGCTGTATTTTCAGTCTTGAACCCAGCAATAGTACATTAACAAGAT TGGGGCAAGGCAAAGGGACTTTTGTGGCACAAGATACAATATATGGATT GCGT
RS3758562 SEQ ID NO. 29	CTCTTCAAAGGCCTTTGCCCTTGGGTACCACAGGTTCTGAGACAAGAGG GCTATGGAGAGCCCCCATTATAGCTGGAGCCTCCTGCCCTGCCCAAAG GTGTGACTTGAAGGGTGGAATTTCAGGCAGCGTGGCTCGCCCCAGGGA GGCAAAGAGGCCAGGGGAATCTTCAAAGGCCCTGGGCTCATCCCAGCT AGGAGGC**[A/G]**GGCACAGTCATAACCCTAATCCAGTGAACTCAGCCCTC ATCCTGACTCTCATGGTATTCTGTCCCAGGGAGCCTCTTTCCAGCTTTCT TAGAAGCTTTAATGTCAGCACTTGCAGGGCCTTAGAAACTGCACGCTAC CTCTTCATTTCATACATGAGGAAACTGAGGCCCAGGGTGGACACAGGGC TGCCCAGCGAGTTA

SNP_ID	SEQUENCE
RS10156056 SEQ ID NO. 30	ATTATAAAGCAAAGCACTAACCTCATAGAATACCTGAGTCAAGTTCCCTG TGTTCTCATTTTCTAGCCTCTTCTACCAGACACTATGAAAAATAACAGCC CCATCTCTCCAGAAAATCTTAGGAGATATAGGCGTGCTGAATTTAAGGT GTCTGTGGCACATGCAAGTGGATCAGCCACTGGGCTGTCCAGAATGCA AGA**[C/G]**AGAACTCAGAGTTGGGGACATAAACTTGGCAGTCATCTGTGTA AAAGAGAAAAGGTAGGTAAAGTCCCACAAGGATGGGTTGGCCTACAGAA GGCACAGAGAGAAGAGAGCCTGGTTTAGCATGGGCTACGATCAGAGTC CCTGGGTTCAAATCTTGGCTCCACCCATTTCTATCTGGTTGCTCTAGGG CATGTTACCTA

Polymorphisms in linkage disequilibrium with a SNP of table 2 can be identified by by methods known in the art. For example, Develin and Risch (Genomics, 1995) provide guidance for determining the parameter delta (also referred to as the "r") as a standard measure of the disequilibrium. Gabriel *et al*. (Science, 2002) provides instructions for finding the maximal r^2 value in populations for disease gene mapping. Further, Carlson *et al.* (Am. J. Hum. Genet. (2003) disclose methods for selecting and analyzing polymorphisms based on linkage disequilibrium for disease gene association mapping. Stoyanovich and Pe'er (Bioinformatics, 2008) show that polymorphisms in linkage disequilibrium with indentified SNPs have virtually identical response profiles. Currently, several databases provide datasets that can be searched for polymorphisms in strong linkage disequilibrium, which can be accessed by the following addresses: http://1000.genomes.org, http://www.hapmap.org, http://www.broadinsitute.org/mpg/snap. An example workflow for determining SNPs linkage disequilibrium to a specific SNP is outlined in Uhr *et al*. (Neuron, 2008).

SNP in strong linkage disequilibrium as used herein means that the SNP is in linkage disequilibrium with an r^2 higher than 0.7 or higher than 0.8 in the tested population or an ethnically close reference population with the identified SNP.

In another embodiment, at least 20, optionally at least 25 or at least 30 SNPs selected from the group of table 2 are determined in step (a) and integrated by the prediction algorithm in step (b). For example, all intergenic SNPs of table 2 are determined in step (a) and integrated by the prediction algorithm in step (b). In another exemplary embodiment, all SNPs selected from the group of table 2 are determined in step (a)

and integrated by the prediction algorithm of step (b).

Typically, in step (a) of the method of predicting a treatment response to CRHR1 antagonists, the presence or absence of those SNPs is determined which were identified to be associated with values indicative for normal CRH activity or CRH overactivity and were thus considered when determining the prediction algorithm by machine-learning as described above.

In one embodiment of the method for predicting a treatment response to CRHR1 antagonists in patients with depressive symptoms and/or anxiety symptoms, the method as described above may be accompanied by analyzing the rapid-eye-movement (REM) sleep, e.g. during night sleep of a patient in a sleep EEG.

In other embodiments, an increase in REM sleep may serve as a biomarker to identify patients who would benefit from treatment with a CRHR1 antagonist.

REM sleep typically comprises a characteristic coincidence of nearly complete muscle atonia, a waking-like pattern of brain oscillations and rapid eye movements (REMs). The amount of REMs during consecutive REM sleep episodes is usually increasing throughout the night. Single and short REMs with low amplitude can be characteristic for initial parts of REM sleep. The amount of REMs, in particular within the first REM sleep episode, can be of clinical relevance. Recent clinical and animal data supports the correlation of REM density with an increased CRH activity. For example, Kimura et al. (Mol. Psychiatry, 2010) showed that mice overexpressing CRH in the forebrain exhibit constantly increased rapid eye movement (REM) sleep compared to wildtype mice. In addition, it could be shown that treatment with the CRHR1 antagonist DMP696 could reverse the REM enhancement.

Further, the SNP analysis and REM density analysis as described herein may be combined for predicting the response of patients with depressive symptoms and/or anxiety symptoms to treatment with a CRHR1 antagonist. The REM analysis may be carried out before, concomitant or after the SNP analysis. For example, the REM

density analysis may be carried out on persons that where identified by the SNP analysis as CRH hyperdrive patients.

The recording of a "sleep-EEG" (also referred to "polysomatic recordings") may comprise electroencephalography (EEG), vertical and horizontal elecrooculography (EOG), electromyography (EMG) and/or electrocardiography (ECG). In EOG, muscle activities of right and left eye may be recorded by electrooculograms (one or typically two channels) in order to visualize the phasic components of REM sleep.

"REM analysis" or "analyzing the rapid-eye-movement (REM)" may refer to a method comprising recoding of muscle activities of right and left eye by EOG and then analyzing the electrooculogram. The recognition of REM in the electrooculogram may be done manually (for example by standard guidelines Rechtschaffen and Kales, 1968, Bethesda, MD: National Institute of Neurological Diseases and Blindness).

The invention is further described in the following example which is solely for the purpose of illustrating specific embodiments of the invention, and is also not to be construed as limiting the scope of the invention in any way.

Example 1

Methods:

Patients:

Patients with unipolar or bipolar depression admitted as in-patients to the Max Planck Institute of Psychiatry (MPI), Munich, Germany, for treatment of a depressive episode were included in the study. Patients were diagnosed by psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria. Patients with bipolar disorder or depressive disorder due to a general medical or neurological condition were excluded, as were patients with a lifetime diagnosis of drug abuse and depressive symptoms secondary to alcohol or substance abuse or dependency. Ethnicity was recorded using a self-report sheet for

nationality, first language and ethnicity of the patient and of all four grandparents. All patients were Caucasian and part of the Munich-Antidepressant-Response-Signature (MARS) project (Hennings *et al.*, J Psychiatr Res., 2009) (www.mars-depression.de). They were treated with antidepressant medications according to doctor's choice. Severity of depressive symptoms was assessed at admission and at the time of the dex/CRH test by trained raters using the 17-item Hamilton Depression Rating Scale (HAM-D, Hamilton, J Neurol Neurosurg Psychiatry, 1960). 192 patients fulfilling the criteria for at least a moderate to severe depressive episode (HAM-D≥18) at both time points and who had been administered a dex/CRH test within 10 days of in-patients admission and had genome-wide SNP data were included in this analysis. The study was approved by the Ethics Committee of the Ludwig Maximilians University in Munich, Germany, and written informed consent was obtained from all subjects.

Dex/CRH test:

The dex/CRH test was administered as described in detail in Heuser *et al.* (J Psychiatr Res., 1994). In brief, subjects were pre-treated with 1.5 mg of dexamethasone per os at 11 pm. The following day, at 3 pm, 3.30 pm, 3.45 pm, 4 pm and 4.15 pm blood was drawn. An intravenous bolus of 100 µg of human CRH (Ferring, Kiel, Germany) was given at 3.02 pm. Plasma ACTH concentrations were assessed by an immunometric assay without extraction (Nichols Institute, San Juan Capistrano, California; USA). The neuroendocrine response to the dex/CRH test was analyzed using the total area under the curve (AUC) of the ACTH response.

SNP Genotyping:

After enrollment in the study 40 ml of EDTA blood was drawn from each patient. DNA was extracted from fresh blood using the Puregene® whole blood DNA-extraction kit (Gentra Systems Inc; MN). Genotyping was performed on Illumina Human 610k quad genotyping arrays (Illumina Inc., San Diego, USA) according to the manufacturer's standard protocols. The average call rate exceeded 99 %, with samples below 98 % being either retyped or excluded from the study. The reproducibility for samples genotyped twice was 99.99 % or better.

Data analysis:

To identify genetic predictors for the ACTH response to the dex/CRH test in patients with moderate to severe depression, the 192 patients were randomly split into a training (N = 96) and test set (N = 96). The demographic and clinical descriptors of these two samples are given in table 3.

Table 3:

Demographic and clinical description of the 192 patients in the trainings and test set.

	training set	test set	p-value
N	96	96	
% female	52,1	57,2	n.s.
% bipolar (1 or 2)	12,5	12,5	n.s.
% with psychotic symptoms	15,2	11,4	n.s.
age (mean years (SD))	47,2 (14,2)	51,3 (13,2)	0,038
BMI at admission (mean SD)	24,9 (4,1)	24,9 (4,3)	n.s.
age-on (mean years (SD))	34,72 (14,5)	36,6 (15,9)	n.s.
number of previous episodes (mean N (SD))	3,2 (4,0)	3,3 (4,7)	n.s.
depression severity at admission (mean HAMD-17 score (SD))	26,4 (4,4)	27,7 (4,8)	0,058
depression severity at dex-crh test (mean HAMD-17 score (SD))	26,9 (5,0)	28,5 (5,0)	0,029
Cortisol AUC (mean (SD))	3611,4 (3414)	3688,6 (3491)	n.s.
ACTH AUC (mean (SD))	1246 (910)	1482,8 (1319)	n.s.
days after admission when dex-CRH test was performed	6,1 (2,2)	5,9 (2,2)	n.s.

After natural log transformation of the AUC of the ACTH response in the dex/CRH test, patients were dichotomized into high vs. low responders. For the ACTH AUC the cut-off was ln ACTH AUC > 7.0. This placed 46.4% (89 out of a total of 192 individuals) in the high responder class. See the corresponding histogram in Figure 1.

Using an additive genetic model and a logistic regression with sex and age as covariates in PLINK (http://pngu.mgh.harvard.edu/purcell/plink/), the association of all SNPs with a MAF > 0.05 were tested on the 610k arrays with the dichotomized response for cortisol and ACTH in the dex/CRH test in the training set. The top 30 associated SNPs were then used to predict either ACTH or cortisol response status in the test set using a "Probabilistic Neural Network und General Regression Neural Network" approach (implementation DTREG 10.3.3 www.dtreg.com). All values were derived from a 20 fold cross validation.

Results:

The top 30 association with ACTH response status are given in table 4. Association p-values ranged from 5.0 e-5 to 2.3 e-4 for the ACTH response.

The genotypes for the 30 SNPs each were then used to predict ACTH response status in the second, independent test cohort (subgroup of the test set).

Table 4: List of 30 SNPs used to predict ACTH AUC in the second test cohort.

SNP	Chromosome	Coordinate_HG18	P-value training	GeneVariant	GeneName
rs6437726	chr3	108321446	5.037e-005	INTERGENIC	N/A
rs1986684	chr11	110629697	5.287e-005	UPSTREAM	N/A
rs7380830	chr5	66022641	5.459e-005	INTRONIC	ENSG0000019656
rs3903768	chr13	49294756	6.811e-005	INTERGENIC	N/A
rs7325978	chr13	71960761	8.206e-005	INTERGENIC	N/A
rs13585	chr22	45131843	0.0001016	REGULATORY_REGION,3PRIME_UTR	TRMU
rs9368373	chr6	22024631	0.0001063	INTERGENIC	N/A
rs10935354	chr3	141026326	0.0001073	INTERGENIC	N/A
rs8095703	chr18	11041081	0.0001183	INTERGENIC	N/A
rs10206851	chr2	5381477	0.0001267	INTERGENIC	N/A
rs9542977	chr13	71958236	0.0001499	INTERGENIC	N/A
rs4942879	chr13	49314940	0.0001537	INTERGENIC	N/A
rs9542954	chr13	71918308	0.0001643	INTERGENIC	N/A
rs1593478	chr18	2292023	0.0001663	INTERGENIC	N/A
rs9542951	chr13	71913959	0.0001664	INTERGENIC	N/A
rs2188534	chr7	111837550	0.0001823	INTERGENIC	N/A
rs12524124	chr6	22051921	0.000185	INTERGENIC	N/A
rs4352629	chr5	87792577	0.0001985	INTERGENIC	N/A
rs7448716	chr5	87788451	0.0001985	INTERGENIC	N/A
rs11873533	chr18	3732713	0.0002107	INTRONIC	DLGAP1
rs10062658	chr5	102881920	0.0002216	INTERGENIC	N/A
rs12547917	chr8	142306580	0.0002282	INTRONIC	SLC45A4
rs1038268	chr9	31967623	0.000229	INTERGENIC	N/A
rs2375811	chr9	31979998	0.000229	INTERGENIC	N/A
rs1352671	chr9	32033985	0.000229	INTERGENIC	N/A
rs364331	chr9	32039631	0.000229	INTERGENIC	N/A
rs1924949	chr13	71975473	0.0002323	INTERGENIC	N/A
rs11025990	chr11	21218608	0.0002323	INTRONIC	NELL1
rs3758562	chr10	72032086	0.0002369	INTRONIC	PRF1
rs10156056	chr7	22720613	0.0002394	INTERGENIC	N/A

The results of the prediction in the test set are summarized below:

For the prediction of the dichotomized ACTH response status in the dex/CRH the following prediction values were achieved:

ACTH:

Accuracy = 85.33%
Sensitivity = 87.18%
Specificity = 83.33%
Geometric mean of sensitivity and specificity = 85.23%
Positive Predictive Value (PPV) = 85.00%
Negative Predictive Value (NPV) = 85.71%
Geometric mean of PPV and NPV = 85.36%
Precision = 85.00%
Recall = 87.18%
F-Measure = 0.8608
Area under ROC curve (AUC) = 0.851852

Using genome-wide SNP association data for the ACTH response in the dex/CRH test, a subset of 30 SNPs could be identified that allowed an accurate, sensitive and specific prediction of these phenotypes in independent sets of patients. Increased ACTH secretion in this test has been linked to an increase in central CRH/CRHR1 function. Although environmental, pharmacological and disease state-dependent factors have previously been described to influence the endocrine response to this test in depressed patients (Ising *et al.*, Neuropsychopharmacol Biol Psychiatry, 2005; Heim *et al.* Biol Psychiatry, 2008; Kunzel *et al.* Neuropsychopharmacology, 2003), it has now been shown that genetic polymorphisms alone are strong predictors.

Patients with depression or anxiety disorders, classified into the high ACTH response group according to the genotypes of the presented 30 SNPs described in this example will be more likely to respond to CRHR1 antagonist treatment. This allows an

enrichment of such patients for CRHR1 antagonist treatment studies who will most likely respond to this specific treatment.

Example 2:

Sleep disturbances, such as decreased slow-wave sleep, increased sleep fragmentation and rapid-eye-movement sleep (REMS) disinhibition, are cardinal symptoms of major depression in humans. This study aims to identify those patients where a central CRH hyperdrive plays a causal role and which would therefore respond favourably to a CRHR1 antagonist. To test the relationship between a central CRH-overexpression and REM-disinhibition in particular, transgenic mouse models where CRH is overexpressed as a result of genetic engineering were employed.

Many animal models of depression share increases in REM-sleeps (REMS) as a common feature. Therefore, increased REMS in animals should reflect REMS-disinhibitions in humans. Mice with CNS-specific CRH-overexpression strikingly share the characteristic increases in REMS. As such, an increase in REMS indicates a central hypersecretion of CRH and may serve as a biomarker to identify those patients who would benefit from treatment with a CRHR1 antagonist.

Experiments were conducted with two different mouse lines of excessive central CRH secretion and their respective control littermates (CL). Mice of the CRH-COE^{CNS} line are characterised by CRH-overexpression within the whole CNS, whereas mice of the Cor26 CRH line display a CRH-overexpression specific to CRH-ergic neurons of the CNS. Three different CRHR1 antagonists were tested. While DMP-696 (bicyclic) and CP-316,311 (monocyclic) are class I CRH-R1 antagonists, SSR125543A (long off-rate, typical slow-tight binding inhibitor) belongs to class II CRH-R1 antagonists. DMP-696 and SSR125543A were applied to CRH-COE^{CNS} mice (n_{DMP696}= 6/6 COE/CL; $n_{SSR125543}$= 6/5 COE/CL), while CP-316,311 was tested in Cor26 CRH mice ($n_{CP316.311}$= 5/3 Cor26/CL). In all cases, animals were left to recover from EEG/EMG-electrode implantation for two weeks, after which two days of baseline recording were initiated. Treatment with CRH-R1

antagonist or respective vehicle control commenced thereafter for five consecutive days. Antagonists were applied through the drinking water at a daily dose of 50mg/kg body weight. EEG and EMG recordings were manually scored as wake, non-REMS (NREMS), and REMS in four second epochs by an experienced evaluator.

As previously shown, CRH-COE^{CNS} mice display significantly higher REMS activity under baseline condition as compared to controls. Chronic DMP-696 (50mg/kg/d DMP-696) treatment entails only a mild suppression of REMS in CL mice. However, DMP-696-treated CRH-COE^{CNS} mice show a significant decrease in REMS activity beginning with treatment day two ($P<0.05$). The strongest suppression of REMS activity in CRH-COE^{CNS} animals could be observed on treatment day three (Figure 2).

Comparable to DMP696 treatment, oral application of SSR125543A (50mg/kg/d) affected REMS levels in CRH-overexpressing mice. No effects of SSR125543 on REMS activity in control animals could be detected. In contrast, a significant suppression of REMS could be observed beginning with day two in CRH-overexpressing animals ($P\leq0.035$). Similar to DMP696 treatment, REMS suppression in CRH-COE^{CNS} mice never exceeded baseline REMS-levels of CL (Figure 3).

Application of CP-316,311 (Pfizer) in the Cor26 CRH mouse line showed no significant effect on REMS levels in CL animals (data not shown). Similarly, in CRH-overexpressing Cor26 CRH mice suppression in REMS apparently seemed weak. However, comparison of the area under the curve (AUC) within the light period of baseline and treatment day three showed a significant decrease ($P=0.006$) of REMS levels after CP-316,311 application (Figure 4).

CRH is one of the major drivers of the stress response in the brain. Hyperactivity of the CRH system seems to be responsible for cognitive impairments, emotional responses, and behavioural changes which are typical for depression. One of those


behavioural changes are sleep disturbances exemplified by REMS disinhibition. The link between CRH-overexpression and REMS level increases is evidenced by the mouse lines used in these experiments. Since CRH-overexpression in the Cor26 CRH mouse line is limited to CRH-ergic neurons, the net increase of CRH is lower when compared to the whole brain overexpression in CRH-COE^{CNS} mice. As a result, the phenotype of increased REMS levels was less profound in Cor26 CRH mice as compared to CRH-COE^{CNS} animals.

The main finding of this study is that the normalization of CRH-elicited sleep-EEG disturbances is striking when (1) different chemical classes of CRHR1 antagonists are used and (2) different animal models for CRH-induced sleep-EEG changes that are typical for human depression are employed. REMS disinhibition is indicative of a central CRH dysfuntion (i.e. hyperactivity) and as such may serve as a biomarker for the identification of depressed patients where depression is caused by central CRH-hyperdrive. Normalization of the sleep pattern by application of different CRHR1 antagonists could be shown in all of our experiments, employing different classes of CRHR1 receptors and different animal models overexpressing centrally CRH.

Claims

1. Corticotropin releasing hormone receptor type 1 (CRHR1) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients having corticotropin releasing hormone (CRH) overactivity.

2. CRHR1 antagonist for use according to claim 1, wherein the CRHR1 antagonist is a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, wherein

X_1 is $-CR_6$ or N;

X_2 is $-NR_1R_2$, $-CR_1R_2R_9$, $-C(=CR_2R_{10})R_1$, $-NHCHR_1R_2$, $-OCHR_1R_2$, $-SCHR_1R_2$, $-CHR_2OR_{10}$, $-CHR_2SR_{10}$, $-C(S)R_2$ or $-C(O)R_2$;

X_3 is NH, O, S, $-N(C_1\text{-}C_2$ alkyl) or $-C(R_{11}R_{12})$, wherein R_{11} and R_{12} are each, independently, hydrogen, trifluoromethyl or methyl, or one of R_{11} and R_{12} is cyano and the other is hydrogen or methyl, or

X_3 is N and X_3 and R_4 form a 5-membered ring substituted at X_3 with R_5;

R_1 is $C_1\text{-}C_6$ alkyl which may optionally be substituted with one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, $C_3\text{-}C_8$ cycloalkyl, $C_1\text{-}C_4$ alkoxy, $-O\text{-}CO\text{-}(C_1\text{-}C_4$ alkyl), $-O\text{-}CO\text{-}NH(C_1\text{-}C_4$ alkyl), $-O\text{-}CO\text{-}N(C_1\text{-}C_4$ alkyl)$(C_1\text{-}C_2$ alkyl), $-NH(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}C_2$ alkyl)$(C_1\text{-}C_4$ alkyl), $-S(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}C_4$ alkyl)$CO(C_1\text{-}C_4$ alkyl), $-NHCO(C_1\text{-}C_4$ alkyl), $-COO(C_1\text{-}C_4$ alkyl), $-CONH(C_1\text{-}C_4$ alkyl), $-CON(C_1\text{-}C_4$ alkyl)$(C_1\text{-}C_2$ alkyl), CN, NO_2, $-SO(C_1\text{-}C_4$ alkyl) and $-SO_2(C_1\text{-}C_4$ alkyl), and

wherein said C_1-C_6 alkyl and the (C_1-C_4) alkyl moieties in the foregoing R_7 groups may optionally contain one carbon-carbon double or triple bond;

R_2 is C_1-C_{12} alkyl, C_1-C_{12} alkoxyalkyl,
aryl or -(C_1-C_4 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, oxadiazolyl or benzoxazolyl;

3- to 8-membered cycloalkyl or –(C_1-C_6 alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C_1-C_6 alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R_8 wherein R_8 is hydrogen or C_1-C_4 alkyl;

and wherein each of the foregoing R_2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl, or with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, -O-CO-(C_1-C_6 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -S(C_1-C_6 alkyl), CN, NO_2, -SO(C_1-C_4 alkyl), and -SO_2(C_1-C_4 alkyl), and wherein said C_1-C_{12} alkyl and/or the C_1-C_4 alkylene moiety of said -(C_1-C_4 alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR_1R_2 or –$CR_1R_2R_9$ may form a saturated 5- to 8-membered ring which may optionally contain one or two carbon-carbon double bonds and/or in which one or two of the ring carbons may optionally be replaced by an oxygen, nitrogen or sulfur atom and which may be substituted with at least one substituent;

R_3 is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF_3, methylthio, methylsulfonyl, CH_2OH, or CH_2OCH_3;

R_4 is hydrogen, C_1-C_4 alkyl, fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethoxy,
-CH_2OCH_3, -$CH_2OCH_2CH_3$, -$CH_2CH_2OCH_3$, -CH_2OCF3, CF_3, amino, nitro, -NH(C_1-C_4 alkyl), -$N(CH_3)_2$, -$NHCOCH_3$ -$NHCONHCH_3$, -SO_n(C_1-C_4 alkyl) wherein n is 0, 1 or 2, hydroxy, -CO(C_1-C_4 alkyl), -CHO, cyano or -COO(C_1-C_4

alkyl) wherein said C_1-C_4 alkyl may optionally contain one double or triple bond and/or may optionally be substituted with one substituent selected from hydroxy, amino, -$NHCOCH_3$, -$NH(C_1$-C_2 alkyl), -$N(C_1$-C_2 alkyl$)_2$, -$COO(C_1$-C_4 alkyl), -$CO(C_1$-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, chloro, cyano and nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl,

wherein each of the above groups R_5 is substituted with from one to three substituents independently selected from fluoro, chloro, C_1-C_6 alkyl and C_1-C_6 alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, (C_1-C_6 alkyl)$O(C_1$-C_6)alkyl, -$NHCH_3$, -$N(CH_3)_2$, -COOH, -$COO(C_1$-C_4 alkyl), -$CO(C_1$-C_4 alkyl), -$SO_2NH(C_1$-C_4 alkyl), -$SO_2N(C_1$-C_4 alkyl)(C_1-C_2 alkyl), -SO_2NH_2, -$NHSO_2(C_1$-C_4 alkyl), -$S(C_1$-C_6 alkyl) and $SO_2(C_1$-C_6 alkyl), and wherein the C_1-C_4 alkyl and the C_1-C_6 alkyl moieties of the foregoing R_5 groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

R_6 is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, -$O(C_1$-C_4 alkyl), -$C(O)(C_1$-C_4 alkyl), -$C(O)O(C_1$-C_4 alkyl), -OCF_3, CF_3, -CH_2OH, -CH_2OCH_3 or -$CH_2OCH_2CH_3$;

R_9 is hydrogen, hydroxy, fluoro, or methoxy;

R_{10} is hydrogen or C_1-C_4 alkyl.

3. CRHR1 antagonist for use according to claim 2, wherein
X_1 is $-CR_6$.

4. CRHR1 antagonist for use according to claim 3, wherein X_1 is CH.

5. CRHR1 antagonist for use according to any of claims 2 to 4, wherein the 5- to 8-membered ring formed by $-NR_1R_2$ or $-CR_1R_2R_9$ is substituted with at least one substituent selected from C_1-C_4 alkyl or
with a 4-8 membered ring, which may be saturated or may contain one to three double bonds and in which one carbon atom may be replaced by CO or SO_2 and one to four carbon atoms may optionally be replaced by nitrogen.

6. CRHR1 antagonist for use according to any of claims 2 to 4, wherein
X_2 is $-NHCHR_1R_2$, $-OCHR_1R_2$ or $-NR_1R_2$.

7. CRHR1 antagonist for use according to claim 6, wherein
$-NHCHR_1R_2$ is $-NHCH(CH_2OCH_3)_2$, $-NHCH(CH_2OCH_3)(CH_2CH_3)$, $-NHCH(CH_2CH_3)_2$, $-NHCH(CH_2CH_2OCH_3)_2$, $-NHCH(CH_3)(CH_2CH_3)$ or $-NHCHR_1R_2$, wherein R_1 is ethyl and R_2 is oxadiazolyl substituted with methyl, isopropyl, cyclopropyl, trifluoromethyl, or ethyl,
or
$-NR_1R_2$ is $-N(CH_2CH_3)(CH_3)$, $-N(CH_2CH_2CH_3)_2$, $-N(CH_2CH_2CH_3)(CH_2$-cyclopropyl), $-N(CH_2CH_3)(CH_2CH_2CH_2CH_3)$, $-N(CH_2CH_2OCH_3)_2$, or $-N(CH_2CH_2OCH_3)(CH_2CH_2CH_3)$
or
$-OCHR_1R_2$ is $-OCH(CH_2CH_3)_2$, $-OCH(CH_2CH_3)CH_3$, $-OCH(CH_2CH_3)(CH_2CH_2CH_3)$, $-OCH(CH_2CH_3)(CH_2OCH_3)$.


8. CRHR1 antagonist for use according to any of claims 2 to 7, wherein
R_3 and R_4 are methyl.

9. CRHR1 antagonist for use according to any of claims 2 to 8, wherein

X_3 is O.

10. CRHR1 antagonist for use according to any of claims 2 to 9, wherein
R_5 is phenyl substituted with from one to three substituent(s) independently selected from the group CH_3, CH_2CH_3, OCH_3, Cl, F, CF_3.

11. CRHR1 antagonist for use according to any of claims 1 to 10, wherein the CRHR1 antagonist is a compound of the formula (VI)



(VI)

or a pharmaceutically acceptable salt thereof, wherein
X_4 is O or NH.

12. CRHR1 antagonist for use according to claim 1, wherein the CRHR1 antagonist is a class I CRHR1 antagonist.

13. CRHR1 antagonist for use according to claim 1, wherein the CRHR1 antagonist is a class II CRHR1 antagonist.

14. CRHR1 antagonist for use according to claim 1, wherein the CRHR1 antagonist is selected from the group consisting of CP154,526, Antalarmin, CRA 5626, Emicerfont, DMP-696, DMP-904, DMP-695, SC-241, BMS-561388, Pexacerfont, R121919, NBI30545, PD-171729, Verucerfont, NBI34041, NBI35965,